PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MACLEANHUNTER, S; MAKELA, TP; GRZESCHICZEK, A; ALITALO, K; MOROY, T				MACLEANHUNTER, S; MAKELA, TP; GRZESCHICZEK, A; ALITALO, K; MOROY, T			EXPRESSION OF A RLF L-MYC MINIGENE INHIBITS DIFFERENTIATION OF EMBRYONIC STEM-CELLS AND EMBROID BODY FORMATION	ONCOGENE			English	Article							C-MYC; DNA-BINDING; N-MYC; PROVIRAL INSERTION; MYELOID-LEUKEMIA; PROTEIN; GENE; GROWTH; ACTIVATION; APOPTOSIS	Rearrangements of the L-myc proto-oncogene with the cellular gene rlf occur in a subset of human small cell lung carcinoma (SCLC) resulting in the expression of a fusion protein. To investigate whether expression of such a rlf/L-myc fusion protein could contribute to the development of SCLC we constructed a chimeric minigene where the rlf first exon and the L-myc second and third exon are under the control of the rlf promoter thereby recapitulating the events of the rearrangement. Attempts to generate transgenic mice with this minigene showed that mouse embryos containing high copy numbers of the rlf/L-myc minigene fail to develop, suggesting that the expression of a rlf/L-myc fusion protein interferes with early differentiation processes. To investigate the nature of this potential embryonic lethality further, we transfected the rlf/L-myc construct stably into embryonic stem (ES) cells. Transfected ES lines that express the rlf/L-myc construct do not show a higher proliferation rate than the parental ES line but fail to properly develop embroid bodies. In addition, outgrowth and differentiation of cells from embroid bodies was severely impaired in ES cells expressing the rlf/L-myc construct when compared to normal ES cells, again suggesting an interference of rlf/L-myc expression with proper differentiation. Expression of a rlf/L-myc fusion may therefore be of critical importance in tumorigenesis by blocking differentiation and thereby allowing continued proliferation of cells and the aquisition of further mutations leading to a fully malignant tumor.	UNIV MARBURG, INST MOLEKULARBIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY; UNIV CAMBRIDGE, SCION HLTH LTD, CAMBRIDGE CB3 0JQ, ENGLAND; UNIV HELSINKI, DEPT PATHOL, MOLEC CANC BIOL LAB, SF-00014 HELSINKI, FINLAND	Philipps University Marburg; University of Cambridge; University of Helsinki			Alitalo, Kari K/J-5013-2014; Moroy, Tarik/D-9923-2011; makela, tomi/B-3734-2009	Alitalo, Kari K/0000-0002-7331-0902; makela, tomi/0000-0002-4869-8044				ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ASKEW DS, 1991, ONCOGENE, V6, P1915; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOLLER K, 1993, COLD SPRING HARBOR C, P39; BRULET P, 1980, P NATL ACAD SCI-BIOL, V77, P4113, DOI 10.1073/pnas.77.7.4113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DOLCETTI R, 1989, ONCOGENE, V4, P1009; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HARLOW E, 1988, ANTIBODIES LABORATOR; HOGAN B, 1986, MANIPULATION MOUSE E; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KOSKINEN PJ, 1993, SEMIN CANCER BIOL, V4, P3; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; MAKELA TP, 1992, ONCOGENE, V7, P405; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENBAUM H, 1989, EMBO J, V8, P748; Sambrook J, 1989, MOL CLONING LABORATO; SETOGUCHI M, 1989, MOL CELL BIOL, V9, P4515, DOI 10.1128/MCB.9.10.4515; SEWING A, 1993, J CELL SCI, V104, P545; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VASTRIK I, 1994, IN PRESS CRIT REV ON; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	35	10	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3509	3517						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970711				2022-12-28	WOS:A1994PT39200013
J	COX, LS; MIDGLEY, CA; LANE, DP				COX, LS; MIDGLEY, CA; LANE, DP			XENOPUS P53 IS BIOCHEMICALLY SIMILAR TO THE HUMAN TUMOR-SUPPRESSOR PROTEIN P53 AND IS INDUCED UPON DNA-DAMAGE IN SOMATIC-CELLS	ONCOGENE			English	Article							WILD-TYPE P53; CASEIN KINASE-II; LARGE T-ANTIGEN; PURIFIED DNA; FREE-EXTRACT; SV40-TRANSFORMED CELLS; REPLICATION OCCURS; GENE AMPLIFICATION; NUCLEAR-ENVELOPE; BINDING FUNCTION	Xenopus p53 cDNA, homologous to the human tumour suppressor p53, has previously been cloned from oocyte and gastrula libraries. In this report, we describe a polyclonal antibody 2674 raised against Xenopus p53 (Xp53) expressed in bacteria, that recognises proteins of approximately 52, 46 and 35 kDa present in Xenopus oocytes, parthenogenically activated eggs and in somatic tissue culture cells. We report here purification of Xp53 from insect cells infected with XpS3-baculovirus, and this protein is shown to be phosphorylated by casein kinase II but has low sequence-specific DNA binding activity. Using similar purification conditions, we have isolated endogenous Xp53, shelving that Xenopus eggs contain high levels of p53 protein. Xp53 from eggs binds to the p53-specific DNA-binding consensus sequence. Two dimensional gel analysis indicates that Xp53 from eggs may exist in various states of phosphorylation. u.v.-induced DNA damage of somatic Xenopus cells results in accumulation of Xp53. We suggest that the high levels of putative Xp53 detected in eggs may represent maternal stockpiles of a protein necessary to protect rapidly dividing cells from the effects of DNA damage.			COX, LS (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,CRC,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND.		Cox, Lynne/AAT-2047-2021; Lane, David P/C-4920-2008	Cox, Lynne/0000-0002-5306-285X; Lane, David/0000-0003-0551-3545				BACHVAROVA R, 1966, J EXP ZOOL, V163, P285, DOI 10.1002/jez.1401630307; BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1992, J CELL SCI, V101, P43; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; COX LS, 1990, J CELL SCI, V97, P177; Davidson E. H., 1986, GENE ACTIVITY EARLY; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARVEY M, 1993, ONCOGENE, V8, P2457; HOEVER M, 1994, ONCOGENE, V9, P109; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HUTCHISON C, 1989, J CELL SCI, V93, P605; HUTCHISON CJ, 1988, DEVELOPMENT, V103, P553; HUTCHISON CJ, 1987, EMBO J, V6, P2003, DOI 10.1002/j.1460-2075.1987.tb02464.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLS AD, 1989, J CELL SCI, V94, P471; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	58	23	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2951	2959						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084598				2022-12-28	WOS:A1994PG82200021
J	CROSS, MA; HEYWORTH, CM; MURRELL, AM; BOCKAMP, EO; DEXTER, TM; GREEN, AR				CROSS, MA; HEYWORTH, CM; MURRELL, AM; BOCKAMP, EO; DEXTER, TM; GREEN, AR			EXPRESSION OF LINEAGE RESTRICTED TRANSCRIPTION FACTORS PRECEDES LINEAGE-SPECIFIC DIFFERENTIATION IN A MULTIPOTENT HEMATOPOIETIC PROGENITOR-CELL LINE	ONCOGENE			English	Note							LOOP-HELIX GENE; ERYTHROID-DIFFERENTIATION; CHROMOSOMAL LOCALIZATION; ERYTHROLEUKEMIA CELLS; STEM-CELLS; SCL GENE; GATA-1; ONCOGENE; CLONING; GROWTH	Lineage commitment and differentiation are likely to be coordinated by the combined effects of multiple transcription factors acting on numerous different target genes. The mechanisms by which lineage-restricted patterns of transcription factor expression are established are therefore of particular relevance to our understanding of the role of transcription factors both in normal development and in oncogenesis. Here, we report that the genes for the lineage-restricted transcription factors SCL, GATA-1 and GATA-2 are expressed in all multipotent, IL-3-dependent, haemopoietic progenitor cell lines tested. Moreover, a liquid differentiation assay has been used to demonstrate down regulation of SCL, GATA-1, GATA-2 and PU-1 during differentiation into non-expressing lineages. These data support the concept that multiple lineage-restricted transcription factors are expressed prior to lineage commitment.	UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND	University of Cambridge	CROSS, MA (corresponding author), CHRISTIE HOSP NATL HLTH SERV TRUST,PATERSON INST CANC RES,CRC,DEPT EXPTL HAEMATOL,WILMSLOW RD,MANCHESTER M20 9BX,ENGLAND.			Bockamp, Ernesto/0000-0002-6181-1734; Green, Anthony/0000-0002-9795-0218; Cross, Michael/0000-0002-8815-7621	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; HARRISON PR, 1978, EXP CELL RES, V115, P395, DOI 10.1016/0014-4827(78)90293-8; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; KAN O, 1993, HAEMOPOIESIS PRACTIC, P123; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEONARD M, 1993, BLOOD, V82, P1071; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER J, 1991, ONCOGENE, V6, P187; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	30	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3013	3016						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084606				2022-12-28	WOS:A1994PG82200029
J	NATOLI, G; AVANTAGGIATI, ML; CHIRILLO, P; PURI, P; IANNI, A; BALSANO, C; LEVRERO, M				NATOLI, G; AVANTAGGIATI, ML; CHIRILLO, P; PURI, P; IANNI, A; BALSANO, C; LEVRERO, M			RAS-DEPENDENT AND RAF-DEPENDENT ACTIVATION OF C-JUN TRANSCRIPTIONAL ACTIVITY BY THE HEPATITIS-B VIRUS TRANSACTIVATOR PX	ONCOGENE			English	Article							X-GENE PRODUCT; PROTEIN-KINASE; HEPATOCELLULAR-CARCINOMA; CELLS; PHOSPHORYLATION; EXPRESSION; PROTOONCOGENE; PROMOTERS; SERINE-63; GROWTH	The mechanisms by which pX, the transactivator of the Hepatitis B Virus (HBV), exerts its effects on transcription of viral and cellular genes have not yet been fully clarified. While previous reports suggested the possibility of a direct interaction of pX, which lacks intrinsic DNA-binding activity, with components of the cellular transcription machinery, more recent investigations support the hypothesis that pX might activate cellular kinases involved in transcriptional regulation and growth control. We analysed the mechanisms of c-Jun transcription factor activation by pX and in particular the role of cellular proteins involved in the transduction of mitogenic signals (namely Ha-Ras and Raf-1). In both HeLa and undifferentiated F9 cells pX was able to increase the activity of exogenous transfected c-Jun but not of c-Jun proteins bearing mutations in the serine residues located in the amino-terminal transcriptional activation domain. We show by use of Ha-Ras and Raf-1 dominant negative mutants that both Ha-Ras and Raf-1 are required for pX-induced activation of c-Jun transcriptional activity. In addition we show that pX is able to cooperate with Raf-1 in c-Jun activation. Our results are consistent with the hypothesis that at least one site of action of pX is peripheral and is located upstream of the Ras genes products.	UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,FDN ANDREA CESALPINO,I-00161 ROME,ITALY; UNIV CAGLIARI,IST MED INTERNA,CAGLIARI,ITALY; UNIV LAQUILA,DIPARTIMENTO MED INTERNA,I-67100 LAQUILA,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; University of Cagliari; University of L'Aquila	NATOLI, G (corresponding author), UNIV ROMA LA SAPIENZA,IST CLIN MED 1,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018; Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Natoli, Gioacchino/0000-0003-0711-2411; Puri, Pier Lorenzo/0000-0003-4964-0095; Levrero, Massimo/0000-0002-4978-0875				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BALSANO C, 1994, IN PRESS J HEPATOL; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEASLEY RP, 1981, LANCET, V2, P1129; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHISAKA O, 1987, GENE, V60, P183; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FEITELSON MA, 1993, ONCOGENE, V8, P1109; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOIKE K, 1989, MOL BIOL MED, V6, P151; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEE TH, 1991, J VIROL, V65, P5939; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; LEVRERO M, 1990, VIROLOGY, V174, P299, DOI 10.1016/0042-6822(90)90079-7; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; SCHEK N, 1991, ONCOGENE, V6, P1735; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TAKADA S, 1994, ONCOGENE, V9, P341; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990	46	127	128	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2837	2843						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084589				2022-12-28	WOS:A1994PG82200009
J	CRIPPS, KJ; PURDIE, CA; CARDER, PJ; WHITE, S; KOMINE, K; BIRD, CC; WYLLIE, AH				CRIPPS, KJ; PURDIE, CA; CARDER, PJ; WHITE, S; KOMINE, K; BIRD, CC; WYLLIE, AH			A STUDY OF STABILIZATION OF P53 PROTEIN VERSUS POINT MUTATION IN COLORECTAL-CARCINOMA	ONCOGENE			English	Note							TUMOR SUPPRESSOR GENE; MONOCLONAL-ANTIBODIES; TISSUE-SECTIONS; BREAST-CANCER; WILD-TYPE; EXPRESSION; ANTIGEN	Abnormalities of the p53 tumour suppressor gene occur in many types of cancer including approximately 60% of colorectal carcinomas. This study investigates in 47 colorectal carcinomas the relationship between stabilised p53 protein detected by immunocytochemistry (ICC), and p53 mutation. 27 cases stained positively with the antibody PAb1801. Sequencing of exons 5-8 revealed 19 mutations in 18 of these cases (one tumour contained two different mutations). A rapid, non-radioactive method was developed to screen for mutations in this region of the gene involving Single Strand Conformational Polymorphism analysis (SSCP) and a MspI restriction digestion. This screen detected 17/19 (89%) of the sequenced mutations, and a further four mutations in 20 PAb1801 negative cases that were confirmed by sequencing. Reproducibility of ICC in detecting stabilised protein was assessed by restaining the 47 cases with the antibody DO7 after pre-treatment to optimise detection. Fewer cases were negative with DO7 although overall concordance with PAb1801 was good. A substantial proportion of carcinomas with stabilised p53 as detected by ICC do not contain mutations in exons 5-8, whilst some mutations (the majority in exon 6) are not associated with stabilisation.			CRIPPS, KJ (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.			Purdie, Colin/0000-0002-1258-4010				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1991, ONCOGENE, V6, P1699; BODNER SM, 1992, ONCOGENE, V7, P743; CARDER P, 1993, ONCOGENE, V8, P1397; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DUNN JM, 1993, BRIT J SURG, V80, P1410, DOI 10.1002/bjs.1800801118; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALL PA, 1993, ONCOGENE, V8, P203; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACQUEMIER J, 1994, BRIT J CANCER, V69, P846, DOI 10.1038/bjc.1994.164; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PURDIE CA, 1991, AM J PATHOL, V138, P807; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUEZ NR, 1990, P NATL ACAD SCI USA, V89, P12028; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SOUSSI T, 1990, ONCOGENE, V5, P945; TENERIELLO MG, 1993, CANCER RES, V53, P3101; TOMINAGA O, 1993, ONCOGENE, V8, P2653; VILLUENDAS R, 1993, BLOOD, V82, P3151; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOJTESEK B, 1993, BRIT J CANCER, V67, P1254, DOI 10.1038/bjc.1993.234; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402	35	94	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2739	2743						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058340				2022-12-28	WOS:A1994PC05400038
J	SEWING, A; MULLER, R				SEWING, A; MULLER, R			PROTEIN-KINASE-A PHOSPHORYLATES CYCLIN D1 AT 3 DISTINCT SITES WITHIN THE CYCLIN BOX AND AT THE C-TERMINUS	ONCOGENE			English	Note							RETINOBLASTOMA PROTEIN; NUCLEAR-PROTEIN; CELL-CYCLE; BINDING; ACTIVATION; SEQUENCES; PHASE; G(1)	Cyclin D1 is a nuclear phosphoprotein that is thought to play a major role in the control of G(0)/G(1)-->S progression. The fact that its expression is not tightly regulated during cell cycle progression suggests that its activity might be modulated by post-translational mechanisms. In the present study, we show that out of five serine-threonine kinases tested only protein kinase A (PKA) was able to phosphorylate cyclin D1 in vitro. In agreement with this observation, forskolin treatment, but not TPA stimulation, led to increased phosphorylation of cyclin D1 in vivo. Phosphoamino acid analysis and two-dimensional phosphopeptide mapping of wild-type and truncated cyclin D1 proteins showed that PKA phosphorylates three distinct serine residues in cyclin D1 at positions 90, 197 and 234. Serine-90 is located within the cyclin box, raising the possibility that phosphorylation of cyclin D1 might play a role in regulating the interaction with other proteins.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KATO J, 1993, GENE DEV, V7, P331; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SEWING A, 1994, J CELL SCI, V107, P581; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2733	2736						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058338				2022-12-28	WOS:A1994PC05400036
J	PRASAD, MVVSV; SHORE, SK; DHANASEKARAN, N				PRASAD, MVVSV; SHORE, SK; DHANASEKARAN, N			ACTIVATED MUTANT OF G-ALPHA(13) INDUCES EGR-1, C-FOS, AND TRANSFORMATION IN NIH 3T3 CELLS	ONCOGENE			English	Article							ALPHA-SUBUNIT; NIH-3T3 CELLS; PROTEIN; GROWTH; DIFFERENTIATION; STIMULATION; FIBROBLAST; MECHANISM; MUTATIONS; ENCODES	Expression of the constitutively activated mutant alpha-subunit of the heterotrimeric G protein G alpha(13) (alpha(13)Q226L) leads to the transformation of NIH-3T3 cells. An analysis of the mitogenic pathway mediated by alpha(13)Q226L indicated that the expression of the primary response genes, early growth response gene-1 (Egr-1, a nuclear transcription factor with zinc-finger moth) and c-fos (a leucine zipper transcription factor as well as a protooncogene) are constitutively activated in alpha(13)Q226L-transformants. While ras-transformed cells did not express Egr-1, cells transformed by the GTPase deficient mutant a-subunit of G alpha(12) (alpha(12)Q229L) exhibited a ''weak'' expression, suggesting that the induction of Egr-1 and c-fos is intrinsic to G alpha(13) signaling pathway and not a consequence of the transformed phenotype. Taken together, these results provide the first evidence that the G alpha(13) signaling pathway involves the activation of specific transcription factors and defines the expression of these nuclear transcription factors as a possible molecular mechanism in alpha(13)Q226L-mediated cell proliferation and transformation.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA 12227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILLER AD, 1984, CELL, V36, P51; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; SHORE SK, 1989, ONCOGENE, V4, P1411; SIFFERT W, 1988, TRENDS BIOCHEM SCI, V13, P148, DOI 10.1016/0968-0004(88)90074-6; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	25	64	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2425	2429						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036026				2022-12-28	WOS:A1994NX62900038
J	LEBWOHL, DE; MUISEHELMERICKS, R; SEPPLORENZINO, L; SERVE, S; TIMAUL, M; BOL, R; BORGEN, P; ROSEN, N				LEBWOHL, DE; MUISEHELMERICKS, R; SEPPLORENZINO, L; SERVE, S; TIMAUL, M; BOL, R; BORGEN, P; ROSEN, N			A TRUNCATED CYCLIN D1 GENE ENCODES A STABLE MESSENGER-RNA IN A HUMAN BREAST-CANCER CELL-LINE	ONCOGENE			English	Article							GROWTH-FACTORS; MESSENGER-RNA; MOLECULAR-CLONING; HUMAN-TUMORS; BCL-1 GENE; AMPLIFICATION; EXPRESSION; HST; CARCINOMAS; ONCOGENE	The G1 cyclin D1 is amplified in approximately 20% of human breast cancers and is frequently overexpressed as part of an amplicon in these tumors, suggesting a potential role for this gene in the pathogenesis of breast cancer. Although amplification of cyclin D1 occurs in human breast cancer, it is possible that another gene in the amplicon is the relevant oncogene in these cancers. We now report a truncation of the cyclin D1 gene in a human breast cancer cell line, associated with overexpression of a short cyclin D1 mRNA. In a survey of breast cancer cell lines and tumors by Southern blot hybridization, using a 1.2 kb human cyclin D1 cDNA, we observed that genomic DNA derived from the MDA MB-453 cell line contains an extra band in the Bg1II and BamHI digests, suggesting that one allele of gene is altered. Moreover, the altered allele is amplified three-fold relative to the normal allele, and contains a 3' deletion. On Northern analysis, the MDA MB-453 line has a marked increase in 1.1 to 1.3 kb transcripts, which are truncated at the 3' end, in contrast to the normally predominant 4.2 kb transcript. The 1.1 - 1.3 kb cyclin D1 mRNA has a longer half-life than the 4.2 kb mRNA, indicating that the 3' truncation may contribute an increased stability and therefore an elevated steady-state level of the short mRNA. These alterations in the cyclin D1 gene and mRNA suggest that altered expression of cyclin D1 may be important in the malignant transformation of this cell line, and support the identification of cyclin D1 as a dominant oncogene at 11q13 in human breast cancer.	MEM SLOAN KETTERING CANC CTR, DEPT SURG, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	LEBWOHL, DE (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, 1275 YORK AVE, NEW YORK, NY 10021 USA.		Rosen, Neal/ABF-2677-2020					ALI IU, 1989, ONCOGENE, V4, P89; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; CULLEN KJ, 1991, CANCER INVEST, V9, P443, DOI 10.3109/07357909109084643; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FAUST JB, 1992, CANCER RES, V52, P2460; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAMMIE GA, 1991, ONCOGENE, V6, P439; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; LISCIA DS, 1989, ONCOGENE, V4, P1219; Maniatis T., 1982, MOL CLONING; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHUURING E, 1992, ONCOGENE, V7, P355; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THEILLET C, 1989, ONCOGENE, V4, P915; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	29	101	101	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1925	1929						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208539				2022-12-28	WOS:A1994NR68500016
J	TIEMANN, F; DEPPERT, W				TIEMANN, F; DEPPERT, W			IMMORTALIZATION OF BALB/C MOUSE EMBRYO FIBROBLASTS ALTERS SV40 LARGE T-ANTIGEN INTERACTIONS WITH THE TUMOR-SUPPRESSOR P53 AND RESULTS IN A REDUCED SV40 TRANSFORMATION-EFFICIENCY	ONCOGENE			English	Article							ADENOVIRUS E1A PROTEINS; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODIES; WILD-TYPE; ONCOGENIC TRANSFORMATION; CELLULAR-TRANSFORMATION; BINDING-SITES; MUTANT P53; CELLS; COOPERATION	In order to analyse the immortalizing and transforming potential of simian virus 40 (SV40), we compared the transformation efficiencies of SV40 in primary and in established BALB/c mouse fibroblasts. Five independently isolated clones of freshly immortalized normal fibroblasts (FTE cells) were established from precrisis BALB/c mouse embryo fibroblasts (pMEF cells) according to the protocol for establishing 3T3 cells (Todaro & Green, 1963). These cells expressed a wild-type p53 and were indistinguishable in all parameters analysed from original 3T3 cells kept in our laboratory. Using abortive infection to control gene dosage, followed by selection of transformed cells by cloning in soft agar, SV40 was able to transform primary cells with a much higher efficiency than 3T3 or FTE cells. Analysis of this unexpected result revealed that the different transformation efficiencies of SV40 in primary and established cells correlated with an altered cellular response to SV40 infection regarding metabolic stabilization of p53 complexed to large T during abortive infection. Whereas p53 in pMEF cells became stabilized upon abortive infection with SV40, p53 in 3T3 and FTE cells remained unstable. Our results strongly favour the hypothesis that metabolic stabilization and the ensuing higher levels of p53 in abortively infected cells enhance the transforming competence of large T.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg								AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, ONCOGENE, V4, P1103; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DEPPERT W, 1989, NATO ASI SERIES; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ECKHART W, 1989, ONCOGENES MOL ORIGIN, P223; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUKUSAWA K, 1991, MOL CELL BIOL, V11, P3472; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MANFREDI JJ, 1993, J VIROL, V67, P4750, DOI 10.1128/JVI.67.8.4750-4759.1993; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MONTENARH M, 1985, EMBO J, V4, P2941, DOI 10.1002/j.1460-2075.1985.tb04027.x; OLSON DC, 1993, ONCOGENE, V8, P2353; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; PRIVES C, 1991, COLD SH Q B, V56, P227; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; REIHSAUS E, 1992, EXP CELL RES, V199, P10, DOI 10.1016/0014-4827(92)90456-I; RICHTER W, 1990, VIROLOGY, V174, P543, DOI 10.1016/0042-6822(90)90108-4; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMBECK R, 1987, J VIROL, V61, P3561, DOI 10.1128/JVI.61.11.3561-3569.1987; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WALSER A, 1986, EMBO J, V5, P883, DOI 10.1002/j.1460-2075.1986.tb04299.x; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZERRAHN J, 1992, ONCOGENE, V7, P1371; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	74	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1907	1915						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208537				2022-12-28	WOS:A1994NR68500014
J	ZHEN, Z; GIORDANO, S; LONGATI, P; MEDICO, E; CAMPIGLIO, M; COMOGLIO, PM				ZHEN, Z; GIORDANO, S; LONGATI, P; MEDICO, E; CAMPIGLIO, M; COMOGLIO, PM			STRUCTURAL AND FUNCTIONAL DOMAINS CRITICAL FOR CONSTITUTIVE ACTIVATION OF THE HGF-RECEPTOR (MET)	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; C-MET; TYROSINE KINASE; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; ONCOGENIC REARRANGEMENT; THYROID CARCINOMAS; TPR; PROTOONCOGENE	The MET gene, encoding the tyrosine kinase receptor for Hepatocyte Growth Factor, is a potentially harmful oncogene overexpressed ina significant fraction of human cancers. To study the molecular mechanisms responsible for oncogenic activation, the biochemical and biological properties of a number of MET constructs were analysed. The native heterodimeric receptor (alpha beta), the beta chain alone, as well as a kinase defective mutant did not transform rodent fibroblasts upon transfection. The cytoplasmic domain, truncated immediately below the transmembrane region, acquired constitutive tyrosine kinase activity in vivo, produced foci of transformation, and was tumorigenic in nude mice. Removal of the first 39 amino acids of the juxtamembrane domain resulted in loss of constitutive activation in vivo and transforming potential, without impairment of the in vitro kinase activity. Replacement of the juxtamembrane domain with 5' TPR sequences restored constitutive kinase activation and transforming properties. Site-directed mutagenesis of either of the two tyrosine residues involved in the positive regulation of the catalytic activity upon phosphorylation (Y-1234 or Y-1235 in the kinase domain of the HGF receptor), strongly impaired TPR-MET transforming potential. These data show that: (1) the truncated cytoplasmic HGF receptor has constitutive kinase activity and is oncogenic; (2) the first 39 amino acids of the juxtamembrane domain and (3) the regulatory tyrosines in the catalytic domain are required to unleash its transforming potential.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,TURIN,ITALY; NATL CANC INST,DEPT EXPTL ONCOL E,MILAN,ITALY	University of Turin; Fondazione IRCCS Istituto Nazionale Tumori Milan			Giordano, Silvia/J-9858-2018; Medico, Enzo/AAC-3185-2021	Giordano, Silvia/0000-0003-1854-1086; Medico, Enzo/0000-0002-3917-2438; Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; COCHET C, 1988, J BIOL CHEM, V263, P3290; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GRECO A, 1992, ONCOGENE, V7, P237; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KING HWS, 1988, ONCOGENE, V2, P617; LIU C, 1992, ONCOGENE, V7, P181; LONGATI P, 1994, ONCOGENE, V9, P49; MICHELIN S, 1993, ONCOGENE, V8, P1983; MITCHELL PJ, 1992, ONCOGENE, V7, P383; MITCHELL PJ, 1992, ONCOGENE, V7, P2329; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MORUZZI EV, 1993, J BIOL CHEM, V268, P18176; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, IN PRESS CELL; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; QUI F, 1988, EMBO J, V7, P1003; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	61	63	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1691	1697						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183564				2022-12-28	WOS:A1994NL81500021
J	DEB, SP; MUNOZ, RM; BROWN, DR; SUBLER, MA; DEB, S				DEB, SP; MUNOZ, RM; BROWN, DR; SUBLER, MA; DEB, S			WILD-TYPE HUMAN P53 ACTIVATES THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR PROMOTER	ONCOGENE			English	Review							HUMAN PAPILLOMAVIRUS TYPE-16; PROTO-ONCOGENE; GENE-EXPRESSION; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; RESPONSIVE ELEMENT; TRANSFORMED-CELLS; NUCLEAR-PROTEIN; BINDING PROTEIN; CARCINOMA-CELLS	We show that wild-type human p53 transactivates the human epidermal growth factor receptor (EGFR) promoter in vivo in a dose-dependent manner, implicating p53 in promotion of cell proliferation. This activation is sensitive to the expression of cellular oncoprotein MDM2 and human papillomavirus type 18 (HPV-18) E6 protein. The p53 response element is localized within -15 and -569 of the promoter. The EGFR promoter does not have a TATA box, and has low activity in Saos-2 cells in the absence of p53. Results from our in vivo transient transfection assays suggest that p53-binding sites, without any other known promoter element, can act as bidirectional promoters in the presence of wild-type p53. Gel retardation analyses suggest that p53 may serve to nucleate TBP on a promoter. We propose that p53 successfully nucleates the transcription complex, possibly via direct interaction with TFIID, and activates the EGFR promoter.	UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIAID NIH HHS [AI31498-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031498] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COLLINS VP, 1993, SEMIN CANCER BIOL, V4, P27; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V115, P185; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALEY J, 1987, ONCOGENE RES, V1, P375; HALEY JD, 1991, J BIOL CHEM, V266, P1746; HALL PA, 1993, ONCOGENE, V8, P203; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MENDELSOHN J, 1992, NATL CANCER I MONOGR, V13, P125; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5103; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEAL DE, 1992, UROL INT, V48, P365, DOI 10.1159/000282357; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P137; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SANTON JB, 1986, CANCER RES, V46, P4701; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIO Y, 1992, P NATL ACAD SCI USA, V89, P5206; SHOBAT O, 1987, ONCOGENE, V1, P277; STOSCHECK CM, 1986, CANCER RES, V46, P1030; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; THOMPSON KL, 1992, MOL ENDOCRINOL, V6, P627, DOI 10.1210/me.6.4.627; Tripathy D, 1992, Cancer Treat Res, V63, P15; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG WD, 1991, MOL CELL BIOL, V11, P4561, DOI 10.1128/MCB.11.9.4561; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225	113	110	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1341	1349						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152794				2022-12-28	WOS:A1994NH40100005
J	CHAPMAN, RM; CORCORAN, MM; GARDINER, A; HAWTHORN, LA; COWELL, JK; OSCIER, DG				CHAPMAN, RM; CORCORAN, MM; GARDINER, A; HAWTHORN, LA; COWELL, JK; OSCIER, DG			FREQUENT HOMOZYGOUS DELETIONS OF THE D13S25 LOCUS IN CHROMOSOME REGION 13Q14 DEFINES THE LOCATION OF A GENE CRITICAL IN LEUKEMOGENESIS IN CHRONIC B-CELL LYMPHOCYTIC-LEUKEMIA	ONCOGENE			English	Note							RETINOBLASTOMA GENE; LEUKEMIA; PROBES	Cytogenetic studies of B-cell chronic lymphocytic leukaemia show structural abnormalities involving the 13q14 chromosome region as the only karyotypic change in a significant proportion of tumours. This observation suggests the location of a gene important in leukaemogenesis. A series of 68 BCLL tumours have been analysed for allele loss using a series of probes from 13q14. Using intragenic polymorphic markers from the retinoblastoma predisposition gene LOH was observed in 25% of tumours including 3/6 showing cytogenetically obvious deletions of the 13q14 region and 3/6 showing translocations involving 13q14. However, three deletions with proximal breakpoints in 13q14 did not show allele loss, demonstrating that the breakpoint lay distal to RB1. Using the D13S25 locus, which lies 1.6 cM distal to RB1, allele loss was seen in 90% of tumours with structural rearrangements of 13q14 and 75% of tumours with an apparently normal karyotype. 50% of these tumours showed homozygous loss of D13S25, suggesting that a 'tumour suppressor gene' lies in this region. The more distal D13S31 locus, 1 cM distal to D13S25, was infrequently involved in allele loss demonstrating that the minimum region of overlap for homozygous deletions is aproximately 1 Mbp around the D13S25 locus.	ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL,CASTLE LANE E,BOURNEMOUTH BH7 7DW,ENGLAND; INST CHILD HLTH,ICRF,ONCOL GRP,LONDON WC1N 1EH,ENGLAND	University of London; University College London				Hawthorn, Lesleyann/0000-0001-8179-0937; Cowell, John/0000-0002-2079-5950				BOWCOCK AM, 1991, GENOMICS, V11, P517, DOI 10.1016/0888-7543(91)90058-M; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; EINHORN S, 1989, LEUKEMIA, V3, P871; HAWTHORN LA, 1993, ONCOGENE, V8, P1415; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JULIUSSON G, 1990, CANCER GENET CYTOGEN, V45, P143, DOI 10.1016/0165-4608(90)90079-P; KAY NE, 1993, BRIT J HAEMATOL, V84, P257, DOI 10.1111/j.1365-2141.1993.tb03061.x; LUI Y, 1992, GENE CHROMOSOME CANC, V4, P250; LUI Y, 1993, P NATL ACAD SCI USA, V90, P8697; MATUTES E, 1993, BRIT J HAEMATOL, V84, P13; MITCHELL CD, 1989, ONCOGENE, V4, P253; MORRIS CM, 1991, GENE CHROMOSOME CANC, V3, P455, DOI 10.1002/gcc.2870030607; ONADIM Z, 1992, BRIT J CANCER, V65, P711, DOI 10.1038/bjc.1992.150; ONADIM ZO, 1990, ARCH DIS CHILD-FETAL, V65, P651, DOI 10.1136/adc.65.7_Spec_No.651; OSCIER D, 1990, BLOOD, V76, P241; PETERSON LC, 1992, GENE CHROMOSOME CANC, V4, P273, DOI 10.1002/gcc.2870040402; STILGENBAUER S, 1993, BLOOD, V81, P2118; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305	20	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1289	1293						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134133				2022-12-28	WOS:A1994NC04800036
J	YAMITHEZI, A; PLAKSIN, D; EISENBACH, L				YAMITHEZI, A; PLAKSIN, D; EISENBACH, L			C-FOS AND C-JUN OVEREXPRESSION IN MALIGNANT-CELLS REDUCES THEIR TUMORIGENIC AND METASTATIC POTENTIAL, AND AFFECTS THEIR MHC CLASS-I GENE-EXPRESSION	ONCOGENE			English	Article							NF-KAPPA-B; EMBRYONAL CARCINOMA-CELLS; MAJOR HISTOCOMPATIBILITY GENE; TRANS-ACTING FACTOR; PROTO-ONCOGENE FOS; NEGATIVE REGULATION; TUMOR-CELLS; TRANSCRIPTION FACTORS; BINDING AFFINITIES; CANCER METASTASIS	Reduced co-expression of the c-fos and c-jun protooncogenes has been correlated with the down regulation of H-2K class I major histocompatibility antigens in high-metastatic cell lines from the Lewis lung carcinoma, B16 melanoma and the K1735 melanoma. Transfection of c-jun and c-fos genes into the high metastatic clones D122 (3LL) and F10.9 (B16 melanoma) resulted in activation of H-2 class I gene expression. D122 transfectants expressing high levels of c-jun and c-fos and F10.9 transfectants expressing high levels of c-fos exhibited markedly reduced tumorigenicity and were of low metastatic potential. In contrast, transfection of junB into the low metastatic, high H-2K(b), D(b) expressor clone A9 (3LL), reduced MHC class I gene expression, and converted the parental low, into high-metastatic cells. The data demonstrate the involvement of genes from the fos and jun family in regulation of MHC class I expression and consequently in regulation of immunogenicity and metastatic competence of tumor cells.	WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Eisenbach, Lea R/0000-0002-4816-1968	NATIONAL CANCER INSTITUTE [R01CA028139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BARZILAY J, 1987, LEUKEMIA, V1, P198; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; Eisenbach L, 1991, Semin Cancer Biol, V2, P179; EISENBACH L, 1984, INT J CANCER, V34, P567, DOI 10.1002/ijc.2910340421; Eisenbach L, 1983, Symp Fundam Cancer Res, V36, P101; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; FLANAGAN JR, 1991, P NATL ACAD SCI USA, V88, P3145, DOI 10.1073/pnas.88.8.3145; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KRALOVA J, 1992, EMBO J, V11, P4591, DOI 10.1002/j.1460-2075.1992.tb05561.x; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; KUSHTAI G, 1990, INT J CANCER, V45, P1131, DOI 10.1002/ijc.2910450624; KUSHTAI G, 1988, ONCOGENE, V2, P119; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4304, DOI 10.1073/pnas.88.10.4304; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; OZATO K, 1981, J IMMUNOL, V126, P317; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; PORGADOR A, 1993, INT J CANCER, V53, P471, DOI 10.1002/ijc.2910530320; PORGADOR A, 1992, CANCER RES, V52, P3679; PORGADOR A, 1993, J IMMUNOL, V150, P1458; PORGADOR A, 1991, INT J CANCER, P54; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, COLD SPRING HARB SYM, V53, P749, DOI 10.1101/SQB.1988.053.01.085; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; VERMA IM, 1990, CIBA F SYMP, V150, P128; VERMA IM, 1988, UCLA S MOL CELLULAR, V87; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	80	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1065	1079						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134110				2022-12-28	WOS:A1994NC04800009
J	BROWN, PH; CHEN, TK; BIRRER, MJ				BROWN, PH; CHEN, TK; BIRRER, MJ			MECHANISM OF ACTION OF A DOMINANT-NEGATIVE MUTANT OF C-JUN	ONCOGENE			English	Article							TRANSCRIPTIONAL ACTIVATION; MAMMALIAN-CELLS; PROTO-ONCOGENE; LEUCINE ZIPPER; FOS; PROTEINS; AP-1; TRANSFORMATION; DOMAIN; ONCOPROTEIN	The AP-1 transcriptional activating complex, made up of Jun and Fos proteins, is involved in controlling many cellular processes such as cell proliferation, differentiation and transformation. We have previously characterized a dominant-negative mutant of c-Jun called TAM-67 which forms dimers with c-Jun and c-Fos, and binds DNA as a homodimer or heterodimer with c-Jun or c-Fos. This dominant-negative mutant is a potent inhibitor of AP-1 mediated transactivation, as well as c-jun/ras and TPA/ras-induced transformation. The present report describes experiments designed to elucidate the exact molecular mechanism of this dominant-negative inhibitor. The DNA binding kinetics of both TAM-67:TAM-67 homodimers as well as TAM-67:Fos heterodimers were studied and compared to those of c-Jun and other transactivation-deficient mutants of c-Jun. These studies demonstrated that the TAM-67 proteins have similar DNA binding kinetics to c-Jun and other Jun mutant proteins. Thus, the deletion of the amino-terminal end of the Jun protein does not significantly alter the protein's affinity for DNA. In addition, to determine whether TAM-67 functions through the formation of homodimers, or through interactions with endogenous c-Jun or c-Fos, we constructed a pair of chimeric proteins made by replacing the leucine zipper of TAM-67 with the leucine zippers of GCN4 and c-Fos. These chimeric proteins, termed TAM/GCN4 and TAM/Fos, were then tested for their ability to bind DNA, inhibit c-Jun-induced transactivation, and inhibit TPA/ras-mediated transformation. The results of these studies show that while both chimeric proteins bind equally well to DNA, only the TAM/Fos protein, and not the TAM/GCN4 protein, inhibits AP-1-induced transactivation and TPA/ras-induced transformation. When compared to the TAM-67 protein, the TAM/Fos protein is an equally potent inhibitor of transactivation and transformation. These results suggest that TAM-67 inhibits AP-1-mediated processes through a 'quenching' mechanism by inhibiting the function of endogenous Jun and/or Fos proteins. The implications of these mechanistic findings on the development of potent inhibitors of signal transduction pathways are discussed.	NCI, DIV CANC PREVENT & CONTROL, BIOMARKERS & PREVENT RES BRANCH, ROCKVILLE, MD 20850 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA				Brown, Powel/0000-0002-3398-163X				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BROWN PH, 1993, ONCOGENE, V8, P877; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HIRAI SI, 1990, ONCOGENE, V5, P39; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN IM, 1992, ONCOGENE, V7, P1119; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2	30	212	217	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					791	799						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108121				2022-12-28	WOS:A1994MW55100014
J	FEO, S; DILIEGRO, C; JONES, T; READ, M; FRIED, M				FEO, S; DILIEGRO, C; JONES, T; READ, M; FRIED, M			THE DNA REGION AROUND THE C-MYC GENE AND ITS AMPLIFICATION IN HUMAN TUMOR-CELL LINES	ONCOGENE			English	Note							HUMAN-BREAST CARCINOMA; BURKITT-LYMPHOMA; CHROMOSOMAL TRANSLOCATIONS; N-MYC; ONCOGENE; EXPRESSION; SEQUENCES; CANCER; LOCUS; REARRANGEMENT	In order to study amplicons containing the c-myc locus in human tumour cells we have analysed the region around the human c-myc gene. Using pulsed field gel electrophoresis we have constructed a 1.8 Mb map of the c-myc locus using six rare-cutting endonucleases. In addition we have cloned 130 kb of continuous DNA around the c-myc gene which includes 65 kb of 5' sequence and 65 kb of 3' sequence. The first exon of the pvt-1 gene was located 59 kb 3' of the c-myc gene. Using nine neighbouring probes, covering a region of about 395 kb around the c-myc gene, we were able to determine the extent and composition of c-myc amplicons in the HL60, NCI-N417, Colo320HSR, SkBr3 and the Sk-N-MC human tumour cell lines. Furthermore we analysed the chromosomal location of amplified c-myc DNA in NCI-N417 and SkBr3 cells. Similarities and differences between the amplified DNA in the different cell lines are discussed.	IMPERIAL CANC RES FUND,EUKARYOT GENE ORG & EXPRESS LAB,LONDON WC2A 3PX,ENGLAND; CNR,IST BIOL SVILUPPO,I-90123 PALERMO,ITALY; DIPARTIMENTO BIOL CELLULARE & SVILUPPO,I-90123 PALERMO,ITALY; IMPERIAL CANC RES FUND,HUMAN CYTOGENET LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Consiglio Nazionale delle Ricerche (CNR); Cancer Research UK			Corbett-Jones, Tania A/E-4891-2013; Feo, Salvatore/C-1333-2012; Jones, Tania/C-8912-2011	Corbett-Jones, Tania A/0000-0002-0067-3382; Feo, Salvatore/0000-0003-3877-2906; Jones, Tania/0000-0002-0067-3382; Di Liegro, Carlo Maria/0000-0001-7362-7814				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FEO S, 1990, NUCLEIC ACIDS RES, V18, P4949, DOI 10.1093/nar/18.16.4949; FEO S, 1990, GENOMICS, V6, P192, DOI 10.1016/0888-7543(90)90467-9; FUKUMOTO M, 1993, SOMAT CELL MOLEC GEN, V19, P21, DOI 10.1007/BF01233951; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HEARD E, 1991, P NATL ACAD SCI USA, V88, P8242, DOI 10.1073/pnas.88.18.8242; JOOS S, 1992, CANCER RES, V52, P6547; KOZBOR D, 1984, CANCER RES, V44, P438; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LEHRACH H., 1990, GENOME ANAL, P39; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LITT M, 1985, P NATL ACAD SCI USA, V82, P6206, DOI 10.1073/pnas.82.18.6206; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; THEILLET C, 1989, ONCOGENE, V4, P915; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; WHANGPENG J, 1982, GENE AMPLIFICATION, P107; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	38	26	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					955	961						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108141				2022-12-28	WOS:A1994MW55100034
J	OHASHI, K; MIZUNO, K; KUMA, K; MIYATA, T; NAKAMURA, T				OHASHI, K; MIZUNO, K; KUMA, K; MIYATA, T; NAKAMURA, T			CLONING OF THE CDNA FOR A NOVEL RECEPTOR TYROSINE KINASE, SKY, PREDOMINANTLY EXPRESSED IN BRAIN	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; C-MET PROTOONCOGENE; SIGNAL TRANSDUCTION; LEUKEMIA-CELLS; PROTEIN; FAMILY; ONCOGENES; DOMAINS; GENE; PRODUCT	Based on homology to the tyrosine kinase domain of the chick erythroblastosis virus oncogene v-sea, we cloned a cDNA encoding a novel receptor tyrosine kinase from a human hepatoma HepG2 cDNA library. The encoded protein, which we termed 'Sky', contains an intracellular tyrosine kinase domain and a unique extracellular domain with two immunoglobulin (Ig)-like domains and two fibronectin type III (FN III) domains; The overall structure of Sky is homologous to the reported sequence of the oncogenic Axl/Ufo receptor tyrosine kinase. Phylogenetic analysis in the tyrosine kinase domain shows that Sky, Axl/Ufo, Ark, and v-Ryk form a subfamily distinct from other tyrosine kinases. Northern blot analysis revealed that sky mRNA is expressed predominantly in brain and faintly in tissues of other organs. As the combination of Ig-like and FN III domains is often observed in neural cell adhesion molecules and receptor protein tyrosine phosphatases, Sky may be involved in cell adhesion processes, particularly in the central nervous system.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,OSAKA 565,JAPAN	Kyushu University; Kyoto University; Osaka University			Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X				BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; FAUST M, 1992, ONCOGENE, V7, P1287; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMA K, 1993, MOL BIOL EVOL, V10, P539; Kuma K, 1991, CURR OPIN STRUC BIOL, V1, P384, DOI 10.1016/0959-440X(91)90036-S; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MIZUNO K, 1993, HEPATOCYTE GROWTH FA, P1; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	36	123	137	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					699	705						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108112				2022-12-28	WOS:A1994MW55100004
J	KOUHARA, H; KOGA, M; KASAYAMA, S; TANAKA, A; KISHIMOTO, T; SATO, B				KOUHARA, H; KOGA, M; KASAYAMA, S; TANAKA, A; KISHIMOTO, T; SATO, B			TRANSFORMING ACTIVITY OF A NEWLY CLONED ANDROGEN-INDUCED GROWTH-FACTOR	ONCOGENE			English	Article							FACTOR FGF RECEPTOR; SHIONOGI CARCINOMA-115 CELLS; EXPRESSION CDNA CLONING; BREAST-CANCER-CELLS; SERUM-FREE CULTURE; POINT MUTATION; FACTOR-ALPHA; BASIC FGF; FIBROBLAST; PROLIFERATION	Our previous study demonstrated that androgen-dependent growth of mouse mammary carcinoma cells (SC-3) was mediated through an induction of heparin-binding growth factor, termed as androgen-induced growth factor (AIGF). Here, we report that NIH3T3 cells stably transfected with AIGF expression vector exhibit the abilities of tumor formation in nude mice, focus formation in monolayer culture and colony formation in soft agar. Thus, this newly cloned growth factor can be categorized as an oncogene. In addition, androgen-induced enhancement of DNA synthesis in SC-3 cells can be blocked by simultaneous incubation with AIGF antisense oligonucleotides. The possibility is also addressed that AIGF exerts its biological activity through an interaction with fibroblast growth factor (FGF) receptor. Transfection of expression vector encoding a variant form of FGF receptor-1 cloned from SC-3 cells into FGF receptor-negative L6 cells results in AIGF-dependent inhibition of differentiation. These results demonstrate that the ability of androgen to elicit transformed phenotype of SC-3 cells is mediated through AIGF induction and its interaction with FGF receptor-1,	OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Kishimoto, Tadamitsu/C-8470-2009					ABLAHAM JA, 1986, EMBO J, V5, P2523; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE R, 1989, MOL ENDOCRINOL, V3, P372, DOI 10.1210/mend-3-2-372; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; HAGGINS C, 1952, CANCER RES, V12, P134; HARRIS SE, 1989, MOL ENDOCRINOL, V3, P1839, DOI 10.1210/mend-3-11-1839; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; KASAYAMA S, 1991, J CELL PHYSIOL, V148, P260, DOI 10.1002/jcp.1041480211; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOUHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P31, DOI 10.1016/0006-291X(91)90885-B; LU J, 1989, CANCER RES, V49, P4963; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MATSUO Y, 1987, CANCER RES, V47, P188; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NISHII K, 1991, CANCER RES, V51, P5573; NISHIZAWA Y, 1990, CANCER RES, V50, P3866; NOGUCHI S, 1987, CANCER RES, V47, P263; NONOMURA N, 1990, CANCER RES, V50, P2316; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAITO H, 1991, BIOCHEM BIOPH RES CO, V174, P136, DOI 10.1016/0006-291X(91)90496-T; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SATO B, 1988, PROGR ENDOCRINOLOGY, P99; STORY MT, 1987, BIOCHEM BIOPH RES CO, V142, P702, DOI 10.1016/0006-291X(87)91471-9; SUMITANI S, 1993, ENDOCRINOLOGY, V132, P1199, DOI 10.1210/en.132.3.1199; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	35	65	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					455	462						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290257				2022-12-28	WOS:A1994MW24800012
J	ALONIGRINSTEIN, R; ZANBAR, I; ALBOUM, I; GOLDFINGER, N; ROTTER, V				ALONIGRINSTEIN, R; ZANBAR, I; ALBOUM, I; GOLDFINGER, N; ROTTER, V			WILD-TYPE P53 FUNCTIONS AS A CONTROL PROTEIN IN THE DIFFERENTIATION PATHWAY OF THE B-CELL LINEAGE	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; MOUSE CELLS; TRANSCRIPTIONAL ACTIVATION; ATAXIA-TELANGIECTASIA; BURKITT-LYMPHOMA; CYCLE CONTROL; REGION GENES; MUTATIONS; EXPRESSION; MUTANT	An analysis of cell lines representing different stages of the B-cell differentiation pathway indicated that about 50% of the cell lines examined expressed exclusively wild type p53 protein. These lines therefore offer a convenient system to study the involvement of p53 in cell differentiation. When 70Z/3, a pre-B cell line which expresses wild type p53, was treated with the differentiation inducer lipopolysaccharide (LPS), it was seen that increased levels of p53 mRNA preceded specific changes in kappa (kappa) immunoglobulin expression. This increased expression of kappa specific mRNA, which was evaluated by specific PCR analysis, was blocked following transfection with mutant p53 coding plasmids. Treatment of 13A60, another cell line which endogenously expresses wild type p53, with LPS caused a secretion of IgA antibodies, also accompanied by increased p53 mRNA expression. The conclusion was that induction of B-cell differentiation involves the transcription of the p53 gene. This was further substantiated by experiments showing that differentiation of stable clones derived from the 70Z/3 cell line, harboring a p53-promoter-CAT plasmid, induced increased CAT activity. Furthermore, wild type p53 transactivated the promoter control sequences of the kappa light chain gene. Taken together, these results suggest that p53 is involved in B-cell differentiation, a pathway which involves DNA rearrangements that may be accompanied by generation of faulty DNA. The fact that wild type p53 was shown to function as a transcriptional factor, coupled with the notion that it is associated with DNA repair systems, may designate p53 as a control protein in the B-cell differentiation pathway.	TEL AVIV UNIV,SACKLER FAC MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	ROTTER, V (corresponding author), WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL.			Aloni-Grinstein, Ronit/0000-0003-1695-5576				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BOYD AW, 1981, J IMMUNOL, V126, P2461; CHENG J, 1992, CANCER RES, V52, P222; CORALIA IR, 1992, BLOOD, V79, P1982; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FENAUX P, 1992, LEUKEMIA, V6, P42; FENAUX P, 1992, BRIT J HAEMATOL, V80, P178, DOI 10.1111/j.1365-2141.1992.tb08897.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1990, ONCOGENE, V5, P1285; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KELMAN Z, 1989, BLOOD, V74, P2318; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7492; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEBOEUF RD, 1989, GENE, V82, P371, DOI 10.1016/0378-1119(89)90065-6; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5683; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PERRY RP, 1979, CELL, V18, P1333, DOI 10.1016/0092-8674(79)90243-5; PORAT Y, 1993, BIOCH BIOPHYSICAL RE, V194, P391; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; Rotter Varda, 1993, Trends in Cell Biology, V3, P46, DOI 10.1016/0962-8924(93)90151-P; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SANTO H, 1973, J EXP MED, V138, P593; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SORIANO P, 1991, CELL, V64, P639; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WIMAN KG, 1991, ONCOGENE, V6, P1633; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	76	83	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3297	3305						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247532				2022-12-28	WOS:A1993MG78200013
J	FUJIWARA, KT; KATAOKA, K; NISHIZAWA, M				FUJIWARA, KT; KATAOKA, K; NISHIZAWA, M			2 NEW MEMBERS OF THE MAF ONCOGENE FAMILY, MAFK AND MAFF, ENCODE NUCLEAR B-ZIP PROTEINS LACKING PUTATIVE TRANSACTIVATOR DOMAIN	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING PROTEIN; LEUCINE ZIPPER; C-JUN; FOS PROTEINS; V-JUN; GENE; C/EBP; TRANSFORMATION; RETROVIRUS	The v-maf oncogene of the avian musculoaponeurotic fibrosarcoma virus, AS42, encodes a nuclear protein which contains a characteristic b-Zip domain. By screening a chicken embryo fibroblast (CEF) cDNA library under moderately stringent hybridization conditions, we picked up a series of cDNA clones for a novel maf-related gene which we named mafK. We also identified another maf-related gene named mafF by screening a chicken genomic library using a mafK probe. Structural analyses suggested that the mafK and mafF genes consist of three exons. The exon-intron structures of the two genes resemble each other, but differ from that of the chicken c-maf gene. As compared to the c-Maf protein, the proteins encoded by the mafK and the mafF genes are rather small in size and lack the regions corresponding to the amino terminal acidic domain present in the c-Maf protein. On the other hand, the structures of the b-Zip domain are well conserved among these Maf-related proteins. When overexpressed by using an avian retroviral vector, the two maf-related genes did not induce morphological transformation of CEF cells but induced colony formation in soft agar with very low efficiencies. With a specific antibody, the MafK protein was detected predominantly in the nuclei of the cells infected with the virus which carries the mafK gene. Tissue distributions of these three maf-family genes are different from one another, probably reflecting their different functions in vivo.	JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research								BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1984, CELL, V36, P259; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KAWAI S, 1972, VIROLOGY, V48, P126, DOI 10.1016/0042-6822(72)90120-1; KAWAI S, 1970, JPN J EXP MED, V40, P243; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Marston F. A. O., 1987, DNA CLONING, P59; MITCHELL P, 1989, SCIENCE, V289, P371; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TABATA T, 1991, EMBO J, V10, P1459, DOI 10.1002/j.1460-2075.1991.tb07666.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1964, NATL CANCER I MONOGR, V17, P527; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	39	163	171	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2371	2380						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361754				2022-12-28	WOS:A1993LT36800007
J	SHIMIZU, E; COXON, A; OTTERSON, GA; STEINBERG, SM; KRATZKE, RA; KIM, YW; FEDORKO, J; OIE, H; JOHNSON, BE; MULSHINE, JL; MINNA, JD; GAZDAR, AF; KAYE, FJ				SHIMIZU, E; COXON, A; OTTERSON, GA; STEINBERG, SM; KRATZKE, RA; KIM, YW; FEDORKO, J; OIE, H; JOHNSON, BE; MULSHINE, JL; MINNA, JD; GAZDAR, AF; KAYE, FJ			RB PROTEIN STATUS AND CLINICAL CORRELATION FROM 171 CELL-LINES REPRESENTING LUNG-CANCER, EXTRAPULMONARY SMALL-CELL CARCINOMA, AND MESOTHELIOMA	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; ALTERED EXPRESSION; SUSCEPTIBILITY GENE; COLORIMETRIC ASSAY; BLADDER-CANCER; PHOSPHORYLATION; CYCLE; ABNORMALITIES; GROWTH; DNA	We have studied RB protein expression in 171 cell lines derived from patients with small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pulmonary carcinoid, mesothelioma, and extrapulmonary small cell cancer (EPSC) and have correlated this data with clinical outcome. We detected absent or aberrant RB protein expression in 66/75 SCLC, 12/80 NSCLC, 1/6 carcinoid, 0/5 mesothelioma, and 4/5 EPSC samples. In addition, we observed integration of human papilloma virus (HPV) DNA in the single EPSC cell line that retained wildtype RB protein. We did not detect integration of HPV, SV40 or adenoviral DNA in other tumor samples with wildtype RB status. We also noted a stable, hypophosphorylated mutant RB in 12 SCLC and 3 NSCLC samples which might have been falsely interpreted as wildtype by current immunohistochemical techniques. Analysis of the matched clinical data showed no associations between RB status and age, sex, extent of disease, performance status, smoking history, and previous treatment. In addition, retrospective analyses showed no consistent correlation of RB protein expression with either best clinical response, overall survival, or in vitro chemotherapeutic drug sensitivity. The stable expression of RB after gene transfection into RB(-) SCLC cells, however, resulted in a trend toward increased in vitro resistance to etoposide, cisplatin and doxorubicin.	NCI, NAVY ONCOL BRANCH, BETHESDA, MD 20889 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20889 USA; NCI, BIOSTAT SECT, BETHESDA, MD 20889 USA; DIV CANC PREVENT & CONTROL, BIOMARKERS SECT, GAITHERSBURG, MD 20850 USA; UNIV TEXAS, SW MED CTR, SIMMONS CANC CTR, DALLAS, TX 75235 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			kaye, frederic/E-2437-2011					BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CARMICHAEL J, 1987, CANCER RES, V47, P936; CARNEY DN, 1985, CANCER RES, V45, P2913; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUTREAL PA, 1991, ONCOGENE, V6, P1109; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kratzke R A, 1992, Cancer Treat Res, V63, P61; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OOKAWA K, 1993, ONCOGENE, V8, P2175; OTTERSON GA, 1993, ONCOGENE, V8, P949; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RYGAARD K, 1990, CANCER RES, V50, P5312; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SCHIFFMAN MH, 1991, J CLIN MICROBIOL, V29, P573, DOI 10.1128/JCM.29.3.573-577.1991; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STRONG LC, 1984, J NATL CANCER I, V73, P303, DOI 10.1093/jnci/73.2.303; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XU HJ, 1994, JNCI-J NATL CANCER I, V86, P695, DOI 10.1093/jnci/86.9.695; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, ONCOGENE, V6, P1139; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471	47	126	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2441	2448						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058306				2022-12-28	WOS:A1994PC05400002
J	XIA, Y; HWANG, L; COBB, MH; BAER, R				XIA, Y; HWANG, L; COBB, MH; BAER, R			PRODUCTS OF THE TAL2 ONCOGENE IN LEUKEMIC T-CELLS - BHLH PHOSPHOPROTEINS WITH DNA-BINDING ACTIVITY	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEIN; GLUTATHIONE-S-TRANSFERASE; CHROMOSOMAL TRANSLOCATION; ESCHERICHIA-COLI; ENHANCER-BINDING; GENE; MOTIF; PURIFICATION; MYOD	The TAL2 gene is activated as a result of the (7;9) (q34;q32) translocation, a chromosome defect found in the malignant cells of some patients with T-cell acute lymphoblastic leukemia (T-ALL). TAL2 potentially encodes a basic helix-loop-helix motif that is highly related to those specified by TAL1 and LYL1, distinct genes that have also been implicated in T-ALL. In this report we show that leukemic cells bearing the (7;9) (q34;q32) translocation express a TAL2 gene product of 108 amino acids. In leukemic cells this product exists in both a phosphorylated (pp13(TAL2)) and an unphosphorylated (p12(TAL2)) form. Serine residue 100 is the major site of TAL2 phosphorylation in vivo, and it serves as an effective in vitro substrate for mitogen-activated protein (MAP) kinases such as ERK1. TAL2 polypeptides interact in vivo with the E2A gene products (E47 and E12) to form bHLH heterodimers that bind DNA in a sequence-specific manner. The TAL2 polypeptides do not bind DNA by themselves, however, suggesting that their functional properties may be contingent upon association with other bHLH proteins. Taken together, the properties of TAL2 evaluated here broadly resemble those described previously for TAL1, and therefore support the idea that both proteins promote T-ALL by a common mechanism.	UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473	NCI NIH HHS [CA44016] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044016] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APLAN PD, 1992, BLOOD, V79, P1327; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BERNARD O, 1991, ONCOGENE, V6, P1477; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHAKRABORTY T, 1992, J BIOL CHEM, V267, P17498; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FINKEL T, 1993, J BIOL CHEM, V268, P5; FITZGERALD TJ, 1991, BLOOD, V78, P2686; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HSU HL, 1994, UNPUB; HSU HL, 1994, IN PRESS P NATL ACAD, V91; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JONSSON OG, 1991, J CLIN INVEST, V87, P2029, DOI 10.1172/JCI115232; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REYNOLDS TC, 1987, CELL, V50, P107, DOI 10.1016/0092-8674(87)90667-2; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1988, NATURE, V335, P559; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH SD, 1988, BLOOD, V71, P395; TYCKO B, 1989, J EXP MED, V169, P369, DOI 10.1084/jem.169.2.369; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WESTBROOK CA, 1987, P NATL ACAD SCI USA, V84, P251, DOI 10.1073/pnas.84.1.251; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; XIA Y, 1992, GENE CHROMOSOME CANC, V4, P211, DOI 10.1002/gcc.2870040304	54	31	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1437	1446						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152805				2022-12-28	WOS:A1994NH40100016
J	THOMPSON, J; CHOUDHURY, S; KASHANCHI, F; DONIGER, J; BERNEMAN, Z; FRENKEL, N; ROSENTHAL, LJ				THOMPSON, J; CHOUDHURY, S; KASHANCHI, F; DONIGER, J; BERNEMAN, Z; FRENKEL, N; ROSENTHAL, LJ			A TRANSFORMING FRAGMENT WITHIN THE DIRECT REPEAT REGION OF HUMAN HERPESVIRUS TYPE-6 THAT TRANSACTIVATES HIV-1	ONCOGENE			English	Article							HUMAN CYTOMEGALO-VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; EPSTEIN-BARR-VIRUS; LYMPHOCYTES-T; EXANTHEM-SUBITUM; READING FRAME; STRAIN AD169; B VIRUS; DNA; IDENTIFICATION	HHV-6 infection has been associated with several malignancies including non-Hodgkin's lymphoma and Hodgkin's disease by the presence of high antibody titer and/or the presence of HHV-6 DNA. To understand their oncogenic potential, SalI restriction fragments from HHV-6 strain U1102 were transfected into NIH3T3 cells to assess transforming ability. A 3.9-kbp SalI-L DNA fragment spanning the junction of the direct repeat left (DR(L)) and unique long segment (U(L)) regions of HHV-6 induced foci of morphologically altered cells. The SalI-L transformed NIH3T3 focal lines induced tumors in nude mice within 2 weeks. The retention of HHV-6 specific DNA observed in SalI-L transformed cells and their tumor-derived lines suggest a possible maintenance function. Since both HHV-6 infection as well as transforming fragments from other DNA viruses have been shown to transactivate the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR), SalI-L was examined for transactivation activity. SalI-L up-regulated HIV-1 LTR CAT 10-15 fold in both monkey CV-1 and human T Jurkat cells. The further study of the SalI-L transforming fragment exhibiting transactivation of HIV-1 LTR will elucidate whether these two activities are encoded by a single gene and will aid in the understanding of the interaction between HHV-6 and HIV-1 as it relates to progression of AIDS and/or AIDS-related malignancies.	GEORGETOWN UNIV, SCH MED, DEPT MICROBIOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, DEPT IMMUNOL, WASHINGTON, DC 20007 USA; TEL AVIV UNIV, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL; NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA	Georgetown University; Georgetown University; Tel Aviv University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [CA37259-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA037259, R01CA037259] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABLASHI D, 1993, ARCH VIROL, V129, P363, DOI 10.1007/BF01316913; ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERNEMAN ZN, 1992, HUMAN HERPESVIRUS, V6, P81; BERTRAM G, 1991, In Vivo (Attiki), V5, P271; BRADY J, 1983, CANCER CELL, V1, P105; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DONIGER J, 1987, J BIOL CHEM, V262, P3813; ELBEIK T, 1986, J VIROL, V60, P645, DOI 10.1128/JVI.60.2.645-652.1986; ELLINGER K, 1992, HUMAN HERPESVIRUS, V6, P209; ENSOLI B, 1989, EMBO J, V8, P3019, DOI 10.1002/j.1460-2075.1989.tb08452.x; FRENKEL N, 1990, P NATL ACAD SCI USA, V87, P748, DOI 10.1073/pnas.87.2.748; GENG YQ, 1992, J VIROL, V66, P1564, DOI 10.1128/JVI.66.3.1564-1570.1992; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HORVAT RT, 1991, J VIROL, V65, P2895, DOI 10.1128/JVI.65.6.2895-2902.1991; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; JAHAN N, 1989, J VIROL, V63, P2866, DOI 10.1128/JVI.63.6.2866-2869.1989; JARIWALLA RJ, 1980, P NATL ACAD SCI-BIOL, V77, P2279, DOI 10.1073/pnas.77.4.2279; JARRETT RF, 1988, LEUKEMIA, V2, P496; JOSEPHS SF, 1988, LEUKEMIA, V2, P132; JOSEPHS SF, 1986, SCIENCE, V234, P601, DOI 10.1126/science.3020691; JOSEPHS SF, 1988, J VIROL METHODS, V21, P179, DOI 10.1016/0166-0934(88)90064-X; KELLER JM, 1984, CELL, V36, P381, DOI 10.1016/0092-8674(84)90231-9; KISHI M, 1988, J VIROL, V62, P4824, DOI 10.1128/JVI.62.12.4824-4827.1988; KOUZARIDES T, 1988, VIROLOGY, V165, P151, DOI 10.1016/0042-6822(88)90668-X; LINDQUESTER GJ, 1991, VIROLOGY, V182, P102, DOI 10.1016/0042-6822(91)90653-S; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; MARTIN MED, 1991, J GEN VIROL, V72, P157, DOI 10.1099/0022-1317-72-1-157; MARTIN MED, 1991, J VIROL, V65, P5381, DOI 10.1128/JVI.65.10.5381-5390.1991; MOCARSKI ES, 1988, J GEN VIROL, V69, P2613, DOI 10.1099/0022-1317-69-10-2613; NELSON JA, 1982, J VIROL, V43, P83, DOI 10.1128/JVI.43.1.83-91.1982; NIEDERMAN JC, 1988, LANCET, V2, P817; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RAZZAQUE A, 1990, ONCOGENE, V5, P1365; RAZZAQUE A, 1988, P NATL ACAD SCI USA, V85, P5709, DOI 10.1073/pnas.85.15.5709; REYES GR, 1979, COLD SPRING HARB SYM, V44, P629; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMER EC, 1991, P NATL ACAD SCI USA, V88, P5922, DOI 10.1073/pnas.88.13.5922; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEEPER TA, 1990, AM J CLIN PATHOL, V93, P776, DOI 10.1093/ajcp/93.6.776; TAKAHASHI K, 1989, J VIROL, V63, P3161, DOI 10.1128/JVI.63.7.3161-3163.1989; TORELLI G, 1991, BLOOD, V77, P2251, DOI 10.1182/blood.V77.10.2251.2251; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WESTON K, 1986, J MOL BIOL, V192, P177, DOI 10.1016/0022-2836(86)90359-1; YAMANISHI K, 1988, LANCET, V1, P1065; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986	56	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1167	1175						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134119				2022-12-28	WOS:A1994NC04800020
J	CHEN, JM; ZONG, CS; WANG, LH				CHEN, JM; ZONG, CS; WANG, LH			TISSUE AND EPITHELIAL CELL-SPECIFIC EXPRESSION OF CHICKEN PROTOONCOGENE C-ROS IN SEVERAL ORGANS SUGGESTS THAT IT MAY PLAY ROLES IN THEIR DEVELOPMENT AND MATURE FUNCTIONS	ONCOGENE			English	Article							TYROSINE-KINASE RECEPTOR; HUMAN INSULIN-RECEPTOR; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; SEVENLESS PROTEIN; GENE; FAMILY; PROTOONCOGENE; PRODUCTS; MEMBERS	Proto-oncogene c-ros codes for a receptor-type protein tyrosine kinase (PTK) sharing high homology with the Drosophila sevenless protein. Recent studies of c-ros expression in mouse by in situ hybridization showed that c-ros was expressed specifically and transiently in the epithelial cells of late embryonic kidney collecting duct and intestine villi. Those investigators suggested that c-ros may play a role in the development of those organelles. In the present study, we have examined the expression profile of c-ros in chicken by RNAase protection and in situ hybridization with riboprobes. Our results showed that in addition to kidney and intestine, low levels of c-ros mRNA could also be detected in lung, testis, thymus and bursa. Expression of c-ros commences during middle to late embryonic stages in those organs and persists into the adult life. In situ hybridization revealed that expression of c-ros was restricted to the epithelial cells of all the tissues examined including kidney, intestine, bursa, thymus and testis. In kidney c-ros was detected in all the epithelial cells of the collecting ducts, in intestine it was detected in the epithelial cells of villi and the underneath crypts. Our finding of c-ros expression in chicken differs from those in mouse in (1) instead of transient expression during the embryonic stage, expression of c-ros in chicken kidney and intestine persists into the adult life and (2) expression of c-ros in renal collecting ducts is not restricted to its growing tips, instead it is expressed in the entire epithelial layer of the ducts. Our results suggest that c-ros may play a role not only in the initial induction events in the organogenesis, but also in the mature function of those organs.	MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA 29339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN GA, 1959, AM J ANAT, V104, P163, DOI 10.1002/aja.1001040202; BASLER K, 1988, CELL, V54, P299; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P1122; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; CHEN JM, 1991, ONCOGENE, V6, P257; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GILBERT SF, 1991, DEV BIOL, P582; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HART AC, 1993, NATURE, V361, P732, DOI 10.1038/361732a0; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Kratochwil K., 1983, P99; KRESS C, 1990, DEVELOPMENT, V109, P775; LEDOUARIN N, 1968, ANN EMBRYOL MORPHOG, V1, P29; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NORTON PA, 1990, CELL, V61, P15, DOI 10.1016/0092-8674(90)90209-W; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Rolnik V.V., 1970, BIRD EMBRYOLOGY; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; Sambrook J., 1989, MOL CLONING; SHARMA S, 1989, ONCOGENE RES, V5, P91; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; TIEDGE H, 1991, DNA CELL BIOL, V10, P143, DOI 10.1089/dna.1991.10.143; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LH, 1974, J VIROL, V14, P1515, DOI 10.1128/JVI.14.6.1515-1529.1974; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982	35	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					773	780						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108119				2022-12-28	WOS:A1994MW55100012
J	FELIX, CA; BROWN, DL; MITSUDOMI, T; IKAGAKI, N; WONG, A; WASSERMAN, R; WOMER, RB; BIEGEL, JA				FELIX, CA; BROWN, DL; MITSUDOMI, T; IKAGAKI, N; WONG, A; WASSERMAN, R; WOMER, RB; BIEGEL, JA			POLYMORPHISM AT CODON-36 OF THE P53 GENE	ONCOGENE			English	Note							CELL LUNG-CANCER; TP53; MUTATIONS; P53-GENE; REGION	A polymorphism at codon 36 in exon 4 of the p53 gene was identified by single strand conformation polymorphism (SSCP) analysis and direct sequencing of genomic DNA PCR products. The polymorphic allele, present in the heterozygous state in genomic DNAs of four of 100 individuals (4%), changes the codon 36 CCG to CCA, eliminates a FinI restriction site and creates a BccI site. Including this polymorphism there are four known polymorphisms in the p53 coding sequence.	CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV GENET,PHILADELPHIA,PA 19104; UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT SURG 2,KITAKYUSHU,FUKUOKA 807,JAPAN; THOMAS JEFFERSON UNIV,CANC RES CTR,PHILADELPHIA,PA 19107	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Occupational & Environmental Health - Japan; Jefferson University	FELIX, CA (corresponding author), CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV ONCOL,PHILADELPHIA,PA 19104, USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505	NATIONAL CANCER INSTITUTE [R01CA046274, P01CA047983] Funding Source: NIH RePORTER; NCI NIH HHS [P0-1 CA 47983, CA 46274] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA HG, 1990, ONCOGENE, V5, P1409; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; CARBONE D, 1991, ONCOGENE, V6, P1691; CHIBA I, 1990, ONCOGENE, V5, P1603; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P6969, DOI 10.1093/nar/19.24.6969-a; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELACALLE O, 1990, NUCLEIC ACIDS RES, V18, P206, DOI 10.1093/nar/18.1.206-a; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; FELIX CA, 1993, ONCOGENE, V8, P1203; FELIX CA, 1992, J CLIN INVEST, V90, P653, DOI 10.1172/JCI115907; FELIX CA, 1992, CANCER RES, V52, P2243; FELIX CA, 1992, J CLIN INVEST, V89, P649; MAZARS GR, 1992, ONCOGENE, V7, P781; MITSUDOMI T, 1992, ONCOGENE, V7, P171; PERILONGO G, 1993, LEUKEMIA, V7, P912; PROSSER J, 1991, NUCLEIC ACIDS RES, V19, P4799, DOI 10.1093/nar/19.17.4799-a; WILLEMS PMW, 1992, NUCLEIC ACIDS RES, V20, P1172, DOI 10.1093/nar/20.5.1172-a	17	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					327	328						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302598				2022-12-28	WOS:A1994MW24700041
J	SHAUGHNESSY, J; WIENER, F; HUPPI, K; MUSHINSKI, JF; POTTER, M				SHAUGHNESSY, J; WIENER, F; HUPPI, K; MUSHINSKI, JF; POTTER, M			A NOVEL C-MYC-ACTIVATING RECIPROCAL T(1215) CHROMOSOMAL TRANSLOCATION JUXTAPOSES S-ALPHA TO PVT-1 IN A MOUSE PLASMACYTOMA	ONCOGENE			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; DNA FRAGMENTS; NEOPLASTIC DEVELOPMENT; ATAXIA-TELANGIECTASIA; MURINE PLASMACYTOMAS; AGAROSE GELS; CELL-LINES; LOCUS; SEQUENCES; ONCOGENE	Oil-induced murine plasmacytomas typically carry c-myc-activating non-random reciprocal chromosomal translocations that take the form of either a T(12;15) that fuses the c-myc proto-oncogene to an immunoglobulin heavy chain switch region or a T(6;15) that juxtaposes the Pvt-l locus, located 220 kb 3' of c-myc, to the immunoglobulin light china locus, C-kappa. In this report we show that the plasmacytoma ABPC 60 harbors a novel c-myc-activating T(12;15) in which the chromosome 15 breakpoint occurs in the Pvt-1 region, resulting in the head-to-tail juxtaposition of the Pvt-1 major breakpoint cluster to the IgA switch region. Restriction mapping and nucleotide sequencing of this atypical translocation indicate that a paracentric inversion in chromosome 12 must have preceeded the translocation. This is the first example of a T(12;15) with a break 3' of the c-myc gene. The rearrangement places the 3' C alpha enhancer (3'alpha E) greater than 200 kb downstream of the c-myc promoters, however c-myc mRNA levels are similar to those observed in plasmacytomas with typical T(12;15)s that translocate 3'alpha E much closer (15-25 kb) and upstream of c-myc. The up regulation of c-myc that results from this rearrangement is thought to be brought about by the interaction of the c-myc promoters with the IgA enhancer element that has been strategically relocated into the Pvt-1 region.	NCI,GENET LAB,BETHESDA,MD 20892; KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM,SWEDEN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Karolinska Institutet								AXELSON H, 1991, ONCOGENE, V6, P2263; BAER R, 1985, CELL, V43, P705, DOI 10.1016/0092-8674(85)90243-0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CALVO CF, 1991, J IMMUNOL, V146, P1353; CITRI Y, 1987, J EXP MED, V165, P1188, DOI 10.1084/jem.165.4.1188; CLURMAN BE, 1988, CELLULAR ONCOGENE AC, P55; COCKERILL PN, 1990, NUCLEIC ACIDS RES, V18, P2643, DOI 10.1093/nar/18.9.2643; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; DAVIS MM, 1980, SCIENCE, V209, P1360, DOI 10.1126/science.6774415; DENNY CT, 1986, NATURE, V320, P549, DOI 10.1038/320549a0; EARLY PW, 1979, P NATL ACAD SCI USA, V76, P857, DOI 10.1073/pnas.76.2.857; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HUPPI K, 1993, INT J CANCER, V53, P493, DOI 10.1002/ijc.2910530323; HUPPI K, 1990, P NATL ACAD SCI USA, V87, P6964, DOI 10.1073/pnas.87.18.6964; HUPPI K, 1992, IMMUNOGENETICS, V37, P288; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LIEBERSON R, 1991, NUCLEIC ACIDS RES, V19, P933, DOI 10.1093/nar/19.4.933; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MOUNTZ JD, 1984, SCIENCE, V226, P1087, DOI 10.1126/science.6494925; MUSHINSKI JF, 1988, CELLULAR ONCOGENE AC, P181; NESBITT MN, 1973, CHROMOSOMA, V41, P145, DOI 10.1007/BF00319691; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; POTTER M, 1990, CARCINOGENESIS, V11, P1, DOI 10.1093/carcin/11.1.1; RADCLIFFE G, 1990, MOL CELL BIOL, V10, P382, DOI 10.1128/MCB.10.1.382; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MA, 1987, MOL CELL BIOL, V7, P4130, DOI 10.1128/MCB.7.11.4130; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STERN MH, 1989, BLOOD, V74, P2076; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANNESS BG, 1983, NATURE, V301, P425, DOI 10.1038/301425a0; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3; WILLIAMS BG, 1980, GENETIC ENG, P201; 1972, J HERED, V63, P69	49	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					247	253						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302586				2022-12-28	WOS:A1994MW24700030
J	TSUCHIYA, H; FUJII, M; TANAKA, Y; TOZAWA, H; SEIKI, M				TSUCHIYA, H; FUJII, M; TANAKA, Y; TOZAWA, H; SEIKI, M			2 DISTINCT REGIONS FORM A FUNCTIONAL ACTIVATION DOMAIN OF THE HTLV-1 TRANSACTIVATOR TAX1	ONCOGENE			English	Note							VIRUS TYPE-I; TRANSCRIPTIONAL ACTIVATION; ADENOVIRUS-E1A PROTEIN; BINDING; EXPRESSION; GENES; PROMOTERS; MECHANISM; SEQUENCES; ENHANCER	Taxi of human T-cell leukemia virus type 1 (HTLV-1) is an enigmatic viral transactivator that regulates expression of the viral gene and also several cellular genes normally controlled by various mitogenic signals. However, previous studies have failed to define the functional domains of Taxi for enhancer specificities and for transcriptional activation (95% of the protein portion was indispensable for the activation function). This complexity has hampered understanding of the molecular basis of Taxi action. In this study, we analysed the activation function of a Taxi fused to the heterologous DNA-binding domain of the yeast transcription factor GAL4 and dissected the domain required for the activation function by using derivatives of a Taxi mutant with an insertion between amino acids (a.a.) 170 and 171. Analysis of the derivatives of the mutant fusion protein having various partial overlaps encompassing the interrupted site suggested that two contiguous stretches, AD-I (2-255 a.a.) and AD-II (227-337 a.a.), should be both intact for the activation function of Taxi and that they form a functional activation domain.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC VIROL & ONCOL,KANAZAWA,ISHIKAWA 920,JAPAN; KITASATO UNIV,SCH HYG SCI,DEPT IMMUNOL,SAGAMIHARA,KANAGAWA 228,JAPAN	Kanazawa University; Kitasato University			Seiki, Motoharu/K-9443-2015					ALEXANDRE C, 1991, ONCOGENE, V6, P1851; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P2349; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HIRAI H, 1992, ONCOGENE, V7, P1737; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; KELLY K, 1992, ONCOGENE, V7, P1463; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SEMMES OJ, 1992, VIROLOGY, V188, P754, DOI 10.1016/0042-6822(92)90530-3; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	34	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					337	340						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302601				2022-12-28	WOS:A1994MW24700043
J	HAMELIN, R; JEGO, N; LAURENTPUIG, P; VIDAUD, M; THOMAS, G				HAMELIN, R; JEGO, N; LAURENTPUIG, P; VIDAUD, M; THOMAS, G			EFFICIENT SCREENING OF P53 MUTATIONS BY DENATURING GRADIENT GEL-ELECTROPHORESIS IN COLORECTAL TUMORS	ONCOGENE			English	Article							SINGLE BASE SUBSTITUTIONS; POLYMERASE CHAIN-REACTION; CANCER CELL-LINES; SUPPRESSOR GENE; BREAST-CANCER; DNA FRAGMENTS; LUNG-CANCER; GC-CLAMP; POINT MUTATIONS; KI-RAS	Alterations in exons 5-8 of the p53 gene have been found in the vast majority of human tumors. Although some specific codons have been revealed as preferential mutational sites in defined tumor types, mutations are generally so scattered within this region that various screening methods for their detection have been widely used. However, the capacity of these techniques to detect exhaustively all mutations has not been evaluated. In this report, conditions for analysing exons 5-8 of the p53 gene by denaturing gradient gel electrophoresis (DGGE) have been elaborated using the Melt87 and SQHTX computer programs. The procedure requires five different amplifications. The screening of 90 colorectal tumors revealed 56 amplification products demonstrating abnormal DGGE behavior. Direct sequencing of these amplification products after asymmetric polymerase chain reaction (PCR) showed, besides polymorphism, 49 somatically mutated DNA samples (54.4%) corresponding to 38 different p53 variants. Moreover, 25 additional p53 variants identified in other tumor types were also detectable with our conditions. Thus, altogether the procedure has been successfully used in the detection of 63 different p53 variants. The experimental differences in migration between the wild-type homoduplex DNA molecule and the heteroduplex(es) containing one mismatch were systematically compared with those calculated by the SQHTX program. The computer program was found to be reliably predictive. This DGGE procedure appears thus to be effective and reliable for detecting mutations in exons 5-8 of the p53 gene.	INST CURIE,GENET TUMEURS LAB,26 RUE ULM,F-75231 PARIS 05,FRANCE; FAC SCI PHARMACEUT & BIOL PARIS,BIOL MOLEC LAB,F-75006 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite			laurent-puig, pierre/B-2226-2013; Vidaud, Michel/O-7346-2017; Laurent-Puig, Pierre/K-3641-2019	laurent-puig, pierre/0000-0001-8475-5459; Laurent-Puig, Pierre/0000-0001-8475-5459				ABRAMS ES, 1990, GENOMICS, V7, P463, DOI 10.1016/0888-7543(90)90188-Z; BAKER SJ, 1990, CANCER RES, V50, P7717; BARTEK J, 1990, ONCOGENE, V5, P893; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CARBONE D, 1991, ONCOGENE, V6, P1691; CHIBA I, 1990, ONCOGENE, V5, P1603; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DAMICO D, 1992, ONCOGENE, V7, P339; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISHIOKA C, 1991, BIOCHEM BIOPH RES CO, V177, P901, DOI 10.1016/0006-291X(91)90623-F; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JEGO N, 1993, ONCOGENE, V8, P209; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KRAWCZAK M, 1991, HUM GENET, V86, P425; LAW JC, 1991, CANCER RES, V51, P6385; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LOTHE RA, 1992, J NATL CANCER I, V84, P1100, DOI 10.1093/jnci/84.14.1100; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MAZARS GR, 1992, ONCOGENE, V7, P781; MAZARS GR, 1992, ONCOGENE, V7, P1015; MAZARS R, 1992, CANCER RES, V52, P3918; MAZARS R, 1991, ONCOGENE, V6, P1685; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PORTIER M, 1992, ONCOGENE, V7, P2539; PROSSER J, 1990, ONCOGENE, V5, P1573; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sambrook J., 1989, MOL CLONING LABORATO, P31; SHAW P, 1991, ONCOGENE, V6, P2121; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHIRASAWA S, 1991, CANCER RES, V51, P2874; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THEOPHILUS BDM, 1989, NUCLEIC ACIDS RES, V17, P7707, DOI 10.1093/nar/17.19.7707; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; TOMNAGA O, 1993, IN PRESS ONCOGENE; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575	47	95	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2213	2220						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336944				2022-12-28	WOS:A1993LP17100022
J	RAO, VN; OHNO, T; PRASAD, DDK; BHATTACHARYA, G; REDDY, ESP				RAO, VN; OHNO, T; PRASAD, DDK; BHATTACHARYA, G; REDDY, ESP			ANALYSIS OF THE DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION FUNCTIONS OF HUMAN FLI-1 PROTEIN	ONCOGENE			English	Article							ETS-RELATED PROTEIN; PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; C-FOS; C-ETS-1 PROTOONCOGENE; DOMAIN PROTEIN; GENE FAMILY; ERG GENE; V-ETS	Three of the ets oncogene superfamily members v-ets, Spi-1/PU.1 and Fli-1, have been shown to he directly involved in retroviral-mediated acute erythroleukemias. The Fli-1 gene was found to be rearranged in 75% of the erythroleukemias induced by Friend murine leukemia virus (F-MuLV), suggesting that it could play a key role in cellular transformation. We have previously isolated and characterized the human Fli-1 gene and have found it to be highly homologous (80%) to the human erg-2 gene. Human Fli-1 was also shown to be rearranged in Ewing's sarcoma cases, in which the amino-terminal region of the Fli-1 gene was replaced with a novel coding region of a putative RNA-binding protein, EWS. In this report, we show that the recombinant Fli-1 protein expressed in bacteria binds to DNA in a sequence-specific manner. It appears that Fli-1 and erg proteins fall into the category of ets proteins that recognize limited ets target sequences, unlike c-ets-1, ets-2 and Elk-1. The Fli-1 gene was found to activate the transcription of the reporter gene that was linked to Fli-1 target sequences, suggesting that Fli-1 is a sequence-specific transcriptional activator. Deletion analysis revealed the presence of two autonomous transcriptional activation domains, one at the amino-terminal region (amino-terminal transcriptional activation domain, ATA) and the other at the carboxy-terminal region (carboxy-terminal transcriptional activation domain, CTA). Secondary structural analysis of ATA and CTA domains revealed the presence of helix-loop-helix (H-L-H) and/or turn-loop-turn (T-L-T) regions. From these results it appears that a portion of the Fli-1 ATA domain (H-L-H region) was replaced by the amino-terminal domain of EWS gene in Ewing's sarcoma cases. Therefore alteration in the transcriptional activation function of Fli-1 may be responsible for human malignancies such as sarcomas, leukemias and lymphomas in which this gene is rearranged.	JEFFERSON CANC INST,BLUMLE LIFE SCI BLDG,233 S 10 ST,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CA 51083, CA 57157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057157, P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PRASAD DDK, 1992, CANCER RES, V52, P5833; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1992, ONCOGENE, V11, P2335; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1992, GUIDE BOOK ONCOGENES; REDDY ESP, 1990, CANCER RES, V50, P5013; ROBERTSON M, 1988, NATURE, V336, P522, DOI 10.1038/336522a0; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SELLERI L, 1991, P NATL ACAD SCI USA, V88, P887, DOI 10.1073/pnas.88.3.887; SIDDIQUE H, 1993, ONCOGENE, V8; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TREIZENBERG SJ, 1988, GENE DEV, V2, P718; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6; [No title captured]	59	107	107	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2167	2173						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336942				2022-12-28	WOS:A1993LP17100017
J	CAIRNS, P; SHAW, ME; KNOWLES, MA				CAIRNS, P; SHAW, ME; KNOWLES, MA			INITIATION OF BLADDER-CANCER MAY INVOLVE DELETION OF A TUMOR-SUPPRESSOR GENE ON CHROMOSOME-9	ONCOGENE			English	Note							TRANSITIONAL CELL-CARCINOMA; INTERFERON GENES	Although many genetic lesions including suppressor gene inactivation have been identified in sporadic tumours, the identity of the common initiating or early genetic events in most cases remains obscure. We have analysed tumour and leucocyte DNA from a series of 252 primary human bladder tumours of all grades and stages for deletions of chromosome 9. Probes from four polymorphic loci were used to detect loss of heterozygosity (LOH) in tumour specimens. Fifty-nine per cent of tumours from patients informative at one or more of these loci showed LOH. A comparison of LOH for markers on 9p and 9q indicated that proximal 9p or 9q is the likely site for a candidate bladder tumour-suppressor gene. Most strikingly, LOH was observed not only in tumours of high grade or stage but also in > 50% of grade 1 and 2 superficial (pTa) tumours. This is the first change to be identified at significant frequency in such tumours. Inactivation of a tumour-suppressor gene on chromosome 9 may therefore be an early genetic event in the development of bladder cancer.			CAIRNS, P (corresponding author), MARIE CURIE SKLODOWSKA MEM INST,EPITHELIAL CARCINOGENESIS LAB,OXTED RHS 0TL,SURREY,ENGLAND.			Knowles, Margaret/0000-0002-9363-8657				BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BERGER MS, 1987, BRIT J CANCER, V56, P533, DOI 10.1038/bjc.1987.238; CAIRNS P, 1991, ONCOGENE, V6, P2305; COOK PJ, 1969, INT J CANCER, V4, P93, DOI 10.1002/ijc.2910040113; COOMBS LM, 1991, BRIT J CANCER, V63, P601, DOI 10.1038/bjc.1991.139; CZERNIAK B, 1990, BRIT J CANCER, V62, P762, DOI 10.1038/bjc.1990.374; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIBAS Z, 1984, CANCER RES, V44, P1257; JAMES CD, 1991, CANCER RES, V51, P1684; KAYE KW, 1982, J UROLOGY, V128, P31, DOI 10.1016/S0022-5347(17)52738-X; LATHROP GM, 1988, GENOMICS, V3, P361; MOSTOFI FK, 1988, DIAGNOSIS MANAGEMENT, P83; Mostofi FK, 1973, INT CLASSIFICATION T; OLUMI AF, 1990, CANCER RES, V50, P7081; PRESTI JC, 1991, CANCER RES, V51, P5405; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607; Sambrook J, 1989, MOL CLONING LABORATO; TRENT JM, 1982, P NATL ACAD SCI-BIOL, V79, P7809, DOI 10.1073/pnas.79.24.7809; TSAI YC, 1990, CANCER RES, V50, P44; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0; 1988, HMSO CANCER STATISTI; 1978, TNM CLASSIFICAITON M	24	200	204	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1083	1085						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8096074				2022-12-28	WOS:A1993KT22000034
J	LAROCCA, SA; CROUCH, DH; GILLESPIE, DAF				LAROCCA, SA; CROUCH, DH; GILLESPIE, DAF			C-MYC INHIBITS MYOGENIC DIFFERENTIATION AND MYOD EXPRESSION BY A MECHANISM WHICH CAN BE DISSOCIATED FROM CELL-TRANSFORMATION	ONCOGENE			English	Article							TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; TERMINAL DIFFERENTIATION; MUSCLE-CELLS; PROTEIN; GENE; MAX; PROLIFERATION; ONCOGENE; JUN	The c-Myc oncoprotein is a basic-helix-loop-helix-leucine zipper (b-HLH-LZ) transcription factor involved in regulating cell proliferation and differentiation. We have used retrovirus-mediated gene transfer to investigate the effect of ectopic c-Myc expression on the spontaneous differentiation of primary quail myoblasts in vitro. Unlike normal myoblasts, c-Myc-expressing myoblasts are unable to form myotubes or express muscle-specific genes, such as myosin, and show severely reduced expression of the myogenic regulatory factors myoD, myogenin, and myf5. The c-Myc leucine zipper (LZ) motif is essential for the differentiation block since myoblasts expressing a mutant with a partial deletion of this region, c-Myc Delta 7, differentiate and express myoD family regulators and muscle-specific genes normally. Remarkably, c-Myc Delta 7, like wild-type c-Myc, retains the capacity to transform the growth phenotype of myoblasts, and associates with the b-HLH-LZ Myc partner protein Max in transformed cells. We conclude that the block to myogenic differentiation induced by c-Myc can be dissociated from cell transformation per se, and that this attribute correlates more closely with down-regulation of myoD family gene expression. These findings are discussed in the light of current models of Myc function.	BEATSON INST CANC RES,WOLFSON LAB MOLEC PATHOL,CANC RES CAMPAIGN BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	Beatson Institute			la rocca, severina anna/D-8028-2011; Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CATLING AD, 1993, ONCOGENE, V8, P1875; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; CROUCH DH, 1990, ONCOGENE, V5, P683; CROUCH DH, 1993, ONCOGENE, V8, P1849; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ENRIETTO PJ, 1989, VIROLOGY, V168, P256, DOI 10.1016/0042-6822(89)90265-1; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GROSSI M, 1991, ONCOGENE, V6, P1767; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PATCHINSKY T, 1986, J VIROL, V59, P341; Penn L J, 1990, Semin Cancer Biol, V1, P69; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RAMSAY GM, 1990, P NATL ACAD SCI USA, V87, P2102, DOI 10.1073/pnas.87.6.2102; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SOLLENBERGER KG, 1994, ONCOGENE, V9, P661; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; SU HY, 1991, ONCOGENE, V6, P1759; TATO F, 1983, DIFFERENTIATION, V24, P131, DOI 10.1111/j.1432-0436.1983.tb01312.x; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	50	62	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3499	3508						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970710				2022-12-28	WOS:A1994PT39200012
J	RAPP, UR; TROPPMAIR, J; BECK, T; BIRRER, MJ				RAPP, UR; TROPPMAIR, J; BECK, T; BIRRER, MJ			TRANSFORMATION BY RAF AND OTHER ONCOGENES RENDERS CELLS DIFFERENTIALLY SENSITIVE TO GROWTH-INHIBITION BY A DOMINANT-NEGATIVE C-JUN MUTANT	ONCOGENE			English	Article							MAP KINASE-KINASE; PROTEIN-KINASE; V-RAF; SIGNAL TRANSDUCTION; EMBRYO CELLS; MYC PROTEIN; TRANSCRIPTION; EXPRESSION; ACTIVATION; PHOSPHORYLATION	In NIH3T3 cells expressing active Raf-1 protein serine/threonine kinase (PSK) c-jun expression is constitutive while c-fos expression is attenuated. This alteration prompted us to determine whether oncogene transformation would render cells differentially sensitive to growth inhibition by a dominant negative mutant of c-jun, TAM 67. Growth inhibition was observed in three types of assays: (1) transfection of TAM 67 into cells stably transformed by a variety of oncogenes, (2) cotransfection of TAM 67 with oncogene expression plasmids into NIH3T3 cells and (3) titration of oncogene-expressing retroviruses on cells stably expressing TAM 67. The results clearly demonstrate that Raf-1 dependent oncogenes, which include receptor protein tyrosine kinases (PTKs)-, intracellular PTKs- and Ras-derived genes share the Raf phenotype of constitutive c-jun expression, attenuated c-fos induction, and high sensitivity to growth suppression by TAM 67. Additionally, the intracellular PSK oncogene, mos and the nuclear oncogenes c-myc, c-fos, and SV40 T antigen were TAM 67-sensitive for transformation This universal pattern of altered growth regulation in oncogene transformed fibroblast cell lines highlights the potential usefulness of c-jun based inhibitors for control of tumor cell growth.	NCI, DIV CANC PREVENT & CONTROL, BIOMARKERS & PREVENT RES BRANCH, ROCKVILLE, MD 20850 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; UNIV WURZBURG, INST STRAHLEN & ZELLFORSCH, WURZBURG, GERMANY; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC, BCDP, FREDERICK, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Wurzburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Troppmair, Jakob/0000-0002-0611-3837				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEAN M, 1987, ONCOGENE RES, V1, P279; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GRUGEL S, UNPUB; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOLCH W, 1993, ONCOGENE, V8, P361; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MIYASHITA T, UNPUB; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PROPST F, 1993, MOL BASIS HUMAN CANC, P173; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rapp U R, 1987, Haematol Blood Transfus, V31, P450; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAPP UR, IN PRESS CELLULAR VI; RAPP UR, 1988, LUNG CANCER, V4, P162; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WANG HG, 1994, ONCOGENE, V9, P2751; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	52	60	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3493	3498						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970709				2022-12-28	WOS:A1994PT39200011
J	GALLOHENDRIKX, E; COPPS, J; PERCY, D; CROY, BA; WILDEMAN, AG				GALLOHENDRIKX, E; COPPS, J; PERCY, D; CROY, BA; WILDEMAN, AG			ENHANCEMENT OF PANCREATIC TUMOR-METASTASIS IN TRANSGENIC IMMUNODEFICIENT MICE	ONCOGENE			English	Article							NATURAL-KILLER-CELLS; T-ANTIGEN; ACINAR-CELLS; MOUSE MODEL; NUDE-MICE; SCID MICE; GROWTH; GENE; EXPRESSION; NK	Metastatic pancreatic cancer presents a bleak prognosis. Typically, human tumor development has been modelled in animals by generating transgenic mice carrying an oncogene, and metastasis studied by engrafting human tumor cells into immunodeficient mice. We derived mouse lines that spontaneously develop metastatic pancreatic cancer by crossing a transgenic line that develops primary pancreatic adenocarcinomas with lines that are deficient for different lymphocyte components of the immune system. We obtained transgenics carrying the SCID mutation resulting in loss of B and T cell function, those carrying the beige mutation resulting in impaired NK cell and macrophage activity, and those carrying both mutations. Although human graft studies indicated that the SCID mutation permits metastasis of different types of tumor cells, in our mice its effect on metastasis of the pancreatic tumor was minimal. In contrast, the beige mutation resulted in metastasis in almost 90% of the animals. The SCID and beige mutations synergistically resulted in faster growing tumors. Both primary tumors and metastases contained undifferentiated and differentiated cell types. The tissue distribution of metastases was similar to that recorded from human patients with pancreatic cancer, suggesting that mechanisms underlying metastasis in these mice could be similar to those involved in human disease.	UNIV GUELPH, DEPT MOLEC BIOL & GENET, GUELPH N1G 2W1, ON, CANADA; UNIV GUELPH, DEPT PATHOL, GUELPH N1G 2W1, ON, CANADA; UNIV GUELPH, DEPT BIOMED SCI, GUELPH N1G 2W1, ON, CANADA	University of Guelph; University of Guelph; University of Guelph								ALOSCO T, 1993, CANCER IMMUNOL IMMUN, V36, P364, DOI 10.1007/BF01742252; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BREUER M, 1991, RADIAT ENVIRON BIOPH, V30, P181, DOI 10.1007/BF01226614; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; CECI JD, 1991, ONCOGENE, V6, P323; CONNELLY CS, 1989, EXP CELL RES, V183, P257, DOI 10.1016/0014-4827(89)90387-X; CROY BA, 1990, J REPROD FERTIL, V88, P231, DOI 10.1530/jrf.0.0880231; CROY BA, 1982, J REPROD IMMUNOL, V4, P277; DECKHUT AM, 1992, J VIROL, V66, P440, DOI 10.1128/JVI.66.1.440-447.1992; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; FODSTAD O, 1984, CANCER RES, V44, P4403; FU XY, 1992, P NATL ACAD SCI USA, V89, P5645, DOI 10.1073/pnas.89.12.5645; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GARRIDO F, 1993, IMMUNOL TODAY, V14, P491, DOI 10.1016/0167-5699(93)90264-L; GLASNER S, 1992, AM J PATHOL, V140, P1237; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HENNING R, 1981, VIROLOGY, V108, P325, DOI 10.1016/0042-6822(81)90441-4; HILL LL, 1991, CANCER RES, V51, P4937; HOGAN B, 1986, MANIPULATING MOUSE E; HOWARD JM, 1977, CURR PROBL CANCER, V2, P1; INOHARA H, 1992, CARCINOGENESIS, V13, P845, DOI 10.1093/carcin/13.5.845; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KERBEL RS, 1991, CANCER METAST REV, V10, P201, DOI 10.1007/BF00050792; KIM YB, 1980, J IMMUNOL, V125, P755; LANIER LL, 1992, CURR OPIN IMMUNOL, V4, P38, DOI 10.1016/0952-7915(92)90121-T; LEE GH, 1990, CARCINOGENESIS, V11, P1145, DOI 10.1093/carcin/11.7.1145; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MUELLER BM, 1991, CANCER METAST REV, V10, P193, DOI 10.1007/BF00050791; NOMURA T, 1990, J RADIAT RES, V31, P288, DOI 10.1269/jrr.31.288; NOMURA T, 1991, JPN J CANCER RES, V82, P701, DOI 10.1111/j.1349-7006.1991.tb01906.x; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; PHILLIPS RA, 1989, CURR TOP MICROBIOL, V152, P259; PROSS HF, 1993, NAT IMMUN, V12, P279; QIAN JH, 1991, J IMMUNOL, V146, P3250; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; REDDY S, 1987, CANCER RES, V47, P2456; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; STUTMAN O, 1981, NATURE, V290, P254, DOI 10.1038/290254a0; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TANAKA Y, 1989, VIROLOGY, V171, P205, DOI 10.1016/0042-6822(89)90527-8; TEVETHIA SS, 1980, VIROLOGY, V107, P13, DOI 10.1016/0042-6822(80)90268-8; TEVETHIA SS, 1980, VIRAL ONCOLOGY, P581; WEINER LM, 1993, CANCER RES, V53, P94; WILLIAMS SS, 1993, LAB ANIM SCI, V43, P139; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	58	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2983	2990						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084602				2022-12-28	WOS:A1994PG82200025
J	STOLZENBERG, MC; BRUGIERES, L; GARDES, M; DESSARPSFREICHEY, F; CHOMPRET, A; BRESSAC, B; LENOIR, G; BONAITIPELLIE, C; LEMERLE, J; FEUNTEUN, J				STOLZENBERG, MC; BRUGIERES, L; GARDES, M; DESSARPSFREICHEY, F; CHOMPRET, A; BRESSAC, B; LENOIR, G; BONAITIPELLIE, C; LEMERLE, J; FEUNTEUN, J			GERM-LINE EXCLUSION OF A SINGLE P53 ALLELE BY PREMATURE TERMINATION OF TRANSLATION IN A LI-FRAUMENI SYNDROME FAMILY	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; MESSENGER-RNA; NONSENSE MUTATIONS; BREAST-CANCER; DEFICIENT; NEOPLASMS; CHILDREN; MICE	Germline p53 mutations have been detected in approximately half of the families affected by the Li-Fraumeni syndrome (LFS), in which they are believed to represent the genetic status predisposing to multiple cancers. Failure to detect mutations in the other half of LFS families suggests that sequence analysis, which has been limited to the p53 gene coding region, have overlooked other genetic events lying outside of this region or/and that alterations in other gene(s) than p53 may also lead to the syndrome. In this report, we present the evidence that a single base pair deletion in the p53 coding sequence, leading to premature signal termination of translation, generates a null allele by preventing transport of mutant allele mRNAs into the cytoplasm. This allelic exclusion which confers a status of unizygote vis-a-vis the wild-type p53 gene to individuals who carry the mutant allele, leads to predisposition to multiple cancers in a Li-Fraumeni family. Thus, the loss of the wild-type p53 allele appears as the rate limiting step in tumor induction.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT PEDIAT ONCOL,F-94805 VILLEJUIF,FRANCE; INSERM,U155,UNITE RECH EPIDEMIOL GENET,F-75016 PARIS,FRANCE; INST GUSTAVE ROUSSY,UNITE DIAGNOST MOLEC,F-94805 VILLEJUIF,FRANCE; INT AGCY RES CANC,F-69372 LYON 08,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; World Health Organization; International Agency for Research on Cancer (IARC)			Feunteun, Jean/AAZ-1267-2020; Paillerets, Brigitte Bressac-de/D-8954-2018; Stolzenberg, Marie-Claude/I-6281-2017	Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; Stolzenberg, Marie-Claude/0000-0001-8026-0360; Feunteun, Jean/0000-0003-1212-9189				BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; BIRCH JM, 1994, CANCER RES, V54, P1298; BORRESEN AL, 1992, CANCER RES, V52, P3234; BRUGIERES L, 1993, CANCER RES, V53, P452; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ENSSLE J, 1993, P NATL ACAD SCI USA, V90, P10091, DOI 10.1073/pnas.90.21.10091; FELIX CA, 1993, ONCOGENE, V8, P1203; FREBOURG T, 1992, CANCER RES, V52, P6976; FREBOURG T, 1994, CANCER RES, V54, P878; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HORIO Y, 1994, ONCOGENE, V9, P1231; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JOLLY KW, 1994, ONCOGENE, V9, P97; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LI FP, 1988, CANCER RES, V48, P5358; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MCINTOSH I, 1993, NAT GENET, V4, P219, DOI 10.1038/ng0793-219; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868	33	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2799	2804						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084585				2022-12-28	WOS:A1994PG82200005
J	YAGI, T; SHIGETANI, Y; FURUTA, Y; NADA, S; OKADO, N; IKAWA, Y; AIZAWA, S				YAGI, T; SHIGETANI, Y; FURUTA, Y; NADA, S; OKADO, N; IKAWA, Y; AIZAWA, S			FYN EXPRESSION DURING EARLY NEUROGENESIS IN MOUSE EMBRYOS	ONCOGENE			English	Article							SEGMENT-SPECIFIC EXPRESSION; ADHERENS-TYPE JUNCTIONS; PERIPHERAL T-CELLS; NEURAL-TUBE; MICE LACKING; MUTANT MICE; GENE; HINDBRAIN; PHOSPHORYLATION; KINASES	Fyn is a member of the Src family of tyrosine kinases which are thought to play important roles in cell to cell interactions during morphogenesis. The developmental profile of Fyn expression was examined using mutant mice in which lacZ gene was introduced into this locus. The expression was characteristic in the neural system, Though at low levels, it was detected in the headfold at embryonic day (E) 7.5 and in the luminal surface of neuroectoderm along the entire neural groove at E8.5. The expression appeared regional in rhombomeres at E8.5 and E9.5. Consistent expression was also found at a low level in the notochord. The expression was high in later stages of the neural tube which consists of three layers; it was in the marginal layer but not in the germinal layer. High expression was also found in developing dorsal root filaments of neural crest origin; Non-expression in dividing neuroepithelial cells and expression in developing neural fibers appeared ubiquitous features of Fyn expression throughout the entire brain.	INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC ONCOL LAB, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, INST BASIC MED SCI, DEPT ANAT, TSUKUBA, IBARAKI 305, JAPAN; OSAKA UNIV, INST PROT RES, DIV PROT METAB, SUITA, OSAKA 565, JAPAN	RIKEN; University of Tsukuba; Osaka University								ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BALLYCUIF L, 1993, DEVELOPMENT, V117, P543; BARE DJ, 1993, ONCOGENE, V8, P1429; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; COOPER JA, 1984, J BIOL CHEM, V259, P7835; EASTER SS, 1993, J NEUROSCI, V13, P285; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HIRSCH MR, 1991, FEBS LETT, V287, P197, DOI 10.1016/0014-5793(91)80050-D; HORAK ID, 1990, ONCOGENE, V5, P597; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KARFUNKEL P, 1972, J EXP ZOOL, V181, P289, DOI 10.1002/jez.1401810302; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LOWELL C, 1993, MOUSE MOL GENETICS, P70; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MANESS PF, 1986, DEV BIOL, V117, P83, DOI 10.1016/0012-1606(86)90350-7; MOASE CE, 1991, DEVELOPMENT, V113, P1049; MOLINA TJ, 1993, J IMMUNOL, V151, P699; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NOMURA S, 1989, DEVELOPMENT, V105, P575; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; Windle WF, 1936, J COMP NEUROL, V63, P431, DOI 10.1002/cne.900630304; Windle WF, 1936, J COMP NEUROL, V63, P173, DOI 10.1002/cne.900630202; YAGI T, 1993, ONCOGENE, V8, P3343; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAMANASHI Y, 1986, P NATL ACAD SCI USA, V83, P5459	45	41	41	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2433	2440						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058305				2022-12-28	WOS:A1994PC05400001
J	YAMANE, A; SEETHARAM, L; YAMAGUCHI, S; GOTOH, N; TAKAHASHI, T; NEUFELD, G; SHIBUYA, M				YAMANE, A; SEETHARAM, L; YAMAGUCHI, S; GOTOH, N; TAKAHASHI, T; NEUFELD, G; SHIBUYA, M			A NEW COMMUNICATION-SYSTEM BETWEEN HEPATOCYTES AND SINUSOIDAL ENDOTHELIAL-CELLS IN LIVER THROUGH VASCULAR ENDOTHELIAL GROWTH-FACTOR AND FLT TYROSINE KINASE RECEPTOR FAMILY (FLT-1 AND KDR/FLK-1)	ONCOGENE			English	Article							C-MET PROTOONCOGENE; MOLECULAR-CLONING; RAT-TISSUES; EXPRESSION; BINDING; GENE; IDENTIFICATION; PURIFICATION; SEQUENCE; MITOGEN	Hepatocyte Growth Factor (HGF)/Scatter Factor secreted from sinusoidal endothelial cells and Kupffer cells in liver activates the c-Met tyrosine kinase receptor expressed on hepatocytes. Here we report yet another possible communication system through a different ligand and tyrosine kinase receptor in an opposite direction. We isolated and determined the primary structure of the entire coding region of rat flt-1 (fms-like tyrosine kinase), a receptor for Vascular Endothelial Growth Factor (VEGF). Using rat flt-1 cDNA as a probe we found that the flt-1 mRNA was expressed at very high levels in sinusoidal endothelial cells in normal rat liver, but was hardly detectable in hepatocytes. The transcripts of another VEGF receptor KDR/Flk-1 structurally related to Flt-1 was also expressed specifically in sinusoidal endothelial cells. On the other hand, VEGF mRNA was expressed weakly in hepatocytes, but not in the nonparenchymal cell fraction. Furthermore, in an in vitro culture system, VEGF demonstrated a remarkably specific growth-stimulatory activity as well as maintenance activity on the sinusoidal endothelial cells. These results suggest that hepatocytes regulate the proliferation and survival of the sinusoidal endothelial cells in liver in a paracrine manner. Therefore two reciprocal communication systems, VEGF-Flt receptor family and HGF-Met receptor, may exist in hepatic tissue.	UNIV TOKYO, INST MED SCI, DEPT GENET, MINATO KU, TOKYO 108, JAPAN; TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL	University of Tokyo; Technion Israel Institute of Technology			GOTOH, Noriko/D-8430-2015; Neufeld, Gera/F-1524-2019					APRELIKOVA O, 1992, CANCER RES, V52, P746; ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ECIHMANN A, 1993, MECH DEVELOP, V42, P33; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FINNERTY H, 1993, ONCOGENE, V8, P2293; GALLAND F, 1993, ONCOGENE, V8, P1233; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P42, DOI 10.1016/S0006-291X(05)81018-6; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAMADORI G, 1992, BIOCHEM BIOPH RES CO, V183, P739, DOI 10.1016/0006-291X(92)90545-V; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHIMAOKA S, 1987, EXP CELL RES, V172, P228, DOI 10.1016/0014-4827(87)90109-1; TANAKA K, 1978, J BIOCHEM-TOKYO, V84, P937, DOI 10.1093/oxfordjournals.jbchem.a132207; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TERMAN BI, 1991, ONCOGENE, V6, P1677; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; YASMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	41	244	256	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2683	2690						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058332				2022-12-28	WOS:A1994PC05400029
J	BUSTELO, XR; SUEN, KL; LEFTHERIS, K; MEYERS, CA; BARBACID, M				BUSTELO, XR; SUEN, KL; LEFTHERIS, K; MEYERS, CA; BARBACID, M			VAV COOPERATES WITH RAS TO TRANSFORM RODENT FIBROBLASTS BUT IS NOT A RAS GDP/GTP EXCHANGE FACTOR	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; SACCHAROMYCES-CEREVISIAE; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; ESCHERICHIA-COLI; PROTO-ONCOGENE; ACTIVATION; KINASE	Vav is a proto-oncogene specifically expressed in cells of hematopoietic origin. Its gene product contains a series of structural motifs, including SH2 and SH3 domains, suggestive of a role in signal transduction. The Vav protein also possesses a Dbl-homology (DH) domain previously found in regulators of the Ras superfamily of small GTP-binding proteins. Recently, Vav has been reported to be the major Ras GDP/GTP exchange factor (GEF) in hematopoietic cells [Gulbins et al., Science 260, 822 (1993); J. Immunol. 152, 2123 (1994)]. The following observations are inconsistent with such a role: (i) Vav proteins do not exhibit Ras GEF activity in standard GDP/GTP exchange assays; (ii) Cells overexpressing Vav do not have increased levels of GTP-bound Ras proteins; (iii) Overexpression of Vav does not overcome the growth inhibitory activity of RasN17, a mutant that blocks Ras signaling by inhibiting Ras GEFs; (iv) Transformation of NIH3T3 cells by Vav oncoproteins is not inhibited by a farnesyl transferase inhibitor that completely blocks transformation by both Ras and its well characterized GEF, RasCDC25 and (v) The morphology of Vav-transformed NIH3T3 cells is dramatically different from that induced by Ras and RasCDC25. Whereas these observations make it unlikely that Vav functions either as a RasGEF or as an upstream regulatory element of Ras, we have observed that Vav can cooperate with normal Ras proteins to transform NIH3T3 cells. These results suggest that Vav and Ras may mediate signal transduction by distinct, but interactive mitogenic pathways.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT CHEM,PRINCETON,NJ 08543	Bristol-Myers Squibb; Bristol-Myers Squibb			Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; PUI L, 1992, CURR BIOL, V2, P275; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307	42	106	106	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2405	2413						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036025				2022-12-28	WOS:A1994NX62900036
J	EKSTRAND, AJ; LONGO, N; HAMID, ML; OLSON, JJ; COLLINS, VP; JAMES, CD; LIU, L				EKSTRAND, AJ; LONGO, N; HAMID, ML; OLSON, JJ; COLLINS, VP; JAMES, CD; LIU, L			FUNCTIONAL-CHARACTERIZATION OF AN EGF RECEPTOR WITH A TRUNCATED EXTRACELLULAR DOMAIN EXPRESSED IN GLIOBLASTOMAS WITH EGFR GENE AMPLIFICATION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMAS; HUMAN-BRAIN TUMORS; ENHANCED EXPRESSION; HUMAN GLIOMAS; FACTOR-ALPHA; LINES; OVEREXPRESSION; IDENTIFICATION; PROTEIN	The most common type of alteration of the epidermal growth factor receptor gene (EGFR) in human glioblastomas results in the synthesis of an aberrant mRNA lacking 801 bases that encode amino acids 6-273 of the receptor's extracellular domain. To study the effects of this mutation on receptor function, we have developed chinese hamster ovary cell transfectants which express the mutant EGF receptor. Comparison of wildtype and mutant receptor properties in this cell host indicates that the truncated receptor does not bind EGF or TGF-alpha and, consequently, DNA synthesis is not stimulated in cultures of mutant transfectants by either grown factor. However, levels of DNA synthesis determined for mutant transfectants in serum-free media are several-fold higher than those determined for corresponding cultures of wild-type transfectants. Western blot analysis with anti-phosphotyrosine antibody indicates that the mutant receptor is constitutively phosphorylated in CHO cells, and the same analysis applied to lysates of glioblastoma biopsies reveals the altered receptor is readily detectable as a phosphotyrosine protein in tumors for which there is evidence of corresponding EGFR gene and transcript alterations. In total, these results indicate that the aberrant EGF receptor synthesized in glioblastomas, and which lacks a portion of the extracellular domain necessary for ligand binding, is an activated tyrosine kinase.	EMORY UNIV,SCH MED,DEPT NEUROSURG,MOLEC NEUROONCOL LAB,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,DIV MED GENET,ATLANTA,GA 30322; KAROLINSKA HOSP,LUDWIG INST CANC RES,S-17671 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT PATHOL,S-17671 STOCKHOLM,SWEDEN	Emory University; Emory University; Karolinska Institutet; Karolinska University Hospital; Ludwig Institute for Cancer Research; Karolinska Institutet; Karolinska University Hospital			James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X	NCI NIH HHS [CA55728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGNER SH, 1990, CANCER RES, V50, P8017; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAFFANET M, 1992, EUR J CANCER, V28A, P11, DOI 10.1016/0959-8049(92)90374-B; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V131, P207, DOI 10.1016/0006-291X(85)91790-5; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HALEY J, 1987, ONCOGENE RES, V1, P375; HALEY JD, 1989, ONCOGENE, V4, P273; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; JAMES CD, 1988, CANCER RES, V48, P5546; LEONARD JH, 1991, INT J CANCER, V48, P511, DOI 10.1002/ijc.2910480406; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LONGO N, 1992, J BIOL CHEM, V267, P12416; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MALDEN LT, 1988, CANCER RES, V48, P2711; MASUI H, 1991, CANCER RES, V51, P6170; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; NISTER M, 1988, CANCER RES, V48, P3910; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1987, SCIENCE, V238, P1048; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMAMOTO T, 1986, CANCER RES, V46, P414; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816	32	224	232	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2313	2320						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036013				2022-12-28	WOS:A1994NX62900024
J	LUKAS, J; JADAYEL, D; BARTKOVA, J; NACHEVA, E; DYER, MJS; STRAUSS, M; BARTEK, J				LUKAS, J; JADAYEL, D; BARTKOVA, J; NACHEVA, E; DYER, MJS; STRAUSS, M; BARTEK, J			BCL-1 CYCLIN D1 ONCOPROTEIN OSCILLATES AND SUBVERTS THE G1 PHASE-CONTROL IN B-CELL NEOPLASMS CARRYING THE T(1114) TRANSLOCATION	ONCOGENE			English	Article							T(11-14) CHROMOSOME-TRANSLOCATION; CYCLIN GENE-EXPRESSION; RETINOBLASTOMA PROTEIN; CENTROCYTIC LYMPHOMA; NUCLEAR-PROTEIN; OVEREXPRESSION; REARRANGEMENT; BREAKPOINTS; LEUKEMIAS; ONCOGENE	In an effort to elucidate the biological role played by cyclin D1, a candidate BCL-1 oncogene, in human B-cell rumours carrying the t(11;14) translocation, we have studied the properties of this cyclin protein in a series of human lymphoid lines with rearrangements in the BCL-1 locus. The BCL-1/cyclin D1 protein was easily detectable in both immunocytochemistry and immunoblotting, its abundance grossly correlating with the mRNA levels. The cyclin D1 protein was localised predominantly to nuclei and there was a striking variation of staining intensity among the exponentially growing cells, reflecting the maximum level reached in mid/late G1 and the lowest level in S-phase. This characteristic mode of cell cycle-dependent oscillation was confirmed by three independent approaches, demonstrating that even upon rearrangement, the expression of cyclin D1 is regulated in a cyclical manner. Antibody-mediated and anti-sense oligonucleotide 'knockout' experiments revealed that the aberrantly expressed BCL-1/cyclin D1 protein is required for G1 phase progression of all four B-cell tumours with the BCL-1 rearrangement. Consistent with the proposed oncogenic role of this cyclin, our data demonstrate that the BCL-1 deregulation caused by chromosomal rearrangement leads to expression of a functionally active cyclin D1 protein which subverts the G1 phase control in the human B-cell tumours carrying the t(11;14) translocation.	DANISH CANC SOC, DIV CANC BIOL, DK-2100 COPENHAGEN O, DENMARK; ROYAL CANC HOSP, INST CANC RES, HADDOW LABS, SUTTON SM2 5NG, SURREY, ENGLAND; ADDENBROOKES HOSP, DEPT HAEMATOL, CAMBRIDGE CB2 2QQ, CAMBS, ENGLAND; MAX PLANCK GESELL, D-13122 BERLIN, GERMANY	Danish Cancer Society; University of London; Institute of Cancer Research - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Max Planck Society			Bartek, Jiri/G-5870-2014; Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236; Lukas, Jiri/0000-0001-9087-506X				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTEK J, 1993, STEM CELLS, V11, P51, DOI 10.1002/stem.5530110611; BARTEK J, 1992, ONCOGENE, V7, P101; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1991, CANCER RES, V51, P3602; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, IN PRESS J CELL BIOL; LUKAS J, 1994, IN PRESS J IMMUNOL M; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEEKER T, 1991, GENE CHROMOSOME CANC, V8, P80; MELO JV, 1988, CLIN EXP IMMUNOL, V73, P23; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NACHEVA E, 1990, BRIT J HAEMATOL, V74, P70, DOI 10.1111/j.1365-2141.1990.tb02540.x; PALMERO I, 1993, ONCOGENE, V8, P1049; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RABBITTS PH, 1988, ONCOGENE, V3, P99; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; RIMOKH R, 1993, BLOOD, V81, P3063; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SALTMAN DL, 1988, BLOOD, V72, P2026, DOI 10.1182/blood.V72.6.2026.2026; Sambrook J, 1989, MOL CLONING LABORATO; SETO M, 1992, ONCOGENE, V7, P1401; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	46	81	82	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2159	2167						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036001				2022-12-28	WOS:A1994NX62900006
J	OSWALD, F; LOVEC, H; MOROY, T; LIPP, M				OSWALD, F; LOVEC, H; MOROY, T; LIPP, M			E2F-DEPENDENT REGULATION OF HUMAN MYC - TRANSACTIVATION BY CYCLIN-D1 AND CYCLIN-A OVERRIDES TUMOR-SUPPRESSOR PROTEIN FUNCTIONS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; HUMAN BREAST-CANCER; CELL-CYCLE; C-MYC; MESSENGER-RNA; MOLECULAR-CLONING; BINDING PROTEIN; DNA-BINDING	Transcription of the human proto-oncogene MYC is repressed in quiescent or non-dividing cells. Upon mitogenic stimulation expression of MYC is rapidly and transiently induced, maintained throughout G(1), and declines to a basal level throughout further cell cycle transitions. Regulation of MYC promoter activity critically depends on the presence of a binding site for transcription factor E2F. Human E2F has been implicated also in the control of cell cycle progression through it association with the retinoblastoma suppressor gene product RB, and with multimeric protein complexes containing the G(1)-S- and S-phase cyclins E and A, respectively. Using CAT reporter co-transfection assays we show here that transcription from the MYC P2 promoter is induced efficiently by E2F-1, but repressed by RB. Furthermore, overexpression of cyclin A strongly activates the MYC promoter and this effect is further enhanced by coexpression of E2F-1 and cyclin A. We also find that expression of G(1)-phase cyclin D1 leads to an E2F binding site-dependent trans-activation of the MYC promoter and that this activation can be abrogated by overexpression of RB. The interaction of D-type G(1) cyclins with RB resembles that of the adenovirus E1A protein with RB in that it can disrupt inhibitory E2F-RB complexes. Our results support a model in which intervention of distinct cyclins and their respective associated kinases promotes transcriptional activation of MYC throughout the cell cycle either by conversion of E2F within multimeric complexes into an active transcription factor or by liberation of free functional E2F.	MAX DELBRUCK CTR MOLEC MED, D-13122 BERLIN, GERMANY; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY; UNIV MUNICH, INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Philipps University Marburg; University of Munich			Moroy, Tarik/D-9923-2011; Lipp, Martin/G-2235-2010; Oswald, Franz/AAO-9584-2020	Lipp, Martin/0000-0002-0087-2672				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DESTONE J, 1987, MOL CELL BIOL, V7, P1697; Dobner T, 1991, DNA Seq, V1, P409, DOI 10.3109/10425179109020799; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL FL, 1993, ONCOGENE, V8, P1377; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HARPER JW, 1993, CELL, V75, P805; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LOVEC H, 1994, ONCOGENE, V9, P323; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEEKER TC, 1989, BLOOD, V74, P1801; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROSENBERG CL, 1993, ONCOGENE, V8, P519; SCHUURING E, 1992, ONCOGENE, V7, P355; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SETO M, 1992, ONCOGENE, V7, P1401; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	74	109	111	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2029	2036						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208548				2022-12-28	WOS:A1994NR68500027
J	CROOK, T; FISHER, C; MASTERSON, PJ; VOUSDEN, KH				CROOK, T; FISHER, C; MASTERSON, PJ; VOUSDEN, KH			MODULATION OF TRANSCRIPTIONAL REGULATORY PROPERTIES OF P53 BY HPV-E6	ONCOGENE			English	Note							HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CARCINOMA CELL-LINES; CERVICAL-CARCINOMA; E6 ONCOPROTEIN; RETINOBLASTOMA GENES; BINDING PROTEIN; DEGRADATION; PROMOTERS; TRANSACTIVATION	The E6 protein encoded by human papillomavirus type 16 (HPV16), a genital virus with oncogenic potential, can target cellular p53 for rapid degradation following the formation of a complex including the two proteins. Some studies suggest that the E6 proteins encoded by HPV6 and 11, viral types which are normally limited to benign lesions, may also interact with p53, although the association is weaker than that seen with HPV16 E6. The present study demonstrates that E6 proteins from HPV16 and HPV6 can modulate the transcriptional regulatory functions of p53 in several cell types. A series of E6 mutants was used to show that association between E6 and p53 is necessary for this activity and that E6 proteins which retain the ability to associate with p53 but show no detectable degradation activity in vitro can, to some extent, abrogate p53 mediated transcriptional trans-regulation. This activity is augmented, however, by the ability of the E6 protein to target bound p53 for rapid degradation. These results suggest that some degree of modulation of p53 function is necessary in the normal viral life cycle but also demonstrate a correlation between the efficiency of this activity and oncogenic potential of the virus.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARK Y, 1993, EMBO J, V12, P461; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOO KB, 1993, VIROLOGY, V193, P1042; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUJITA M, 1992, CANCER RES, V52, P5323; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JACKSON P, 1993, ONCOGENE, V8, P589; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEGAWA K, 1993, ONCOGENE, V8, P543; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TUCK SP, 1989, ONCOGENE RES, V4, P81; VOUSDEN KH, 1991, SEMIN VIROL, V2, P307; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	51	63	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1225	1230						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134125				2022-12-28	WOS:A1994NC04800026
J	LEE, TC; ZHANG, Y; SCHWARTZ, RJ				LEE, TC; ZHANG, Y; SCHWARTZ, RJ			BIFUNCTIONAL TRANSCRIPTIONAL PROPERTIES OF YY1 IN REGULATING MUSCLE ACTIN AND C-MYC GENE-EXPRESSION DURING MYOGENESIS	ONCOGENE			English	Article							ADENOVIRUS E1A PROTEIN; BINDING COMPLEXES; MESSENGER-RNA; PROMOTER; DIFFERENTIATION; ELEMENTS; ACTIVATION; MYOBLASTS; CELLS; IDENTIFICATION	Oncogene expression is generally incompatible with terminal cell differentiation as in myogenesis. We present evidence that this incompatibility can be caused in part by the dual activity of a Kruppel-related zinc finger, YY1 (formerly F-ACT1), in differentially regulating oncogene and muscle-specific gene expression. The c-myc and skeletal alpha-actin gene promoters contain YY1 binding sites thought to act either as positive or negative cis-acting elements. Through manipulating the intracellular level of YY1 by treating primary myoblasts with bromo-deoxyuridine (BrdU), which inhibited myogenesis and increased the YY1 protein content, or by transfecting YY1 cDNA expression vector, we show that it can simultaneously inhibit and activate expression of the skeletal alpha-actin and c-myc genes, respectively. The transrepression activity of YY1 solely depends on its C-terminal zinc finger region (amino acids 297-407) while its transactivation function requires an additional N-terminal domain (amino acids 1-90) normally masked in the full-length protein. We propose that the high level of YY1 in proliferating myoblasts might serve to maintain c-myc expression and suppress muscle actin expression, which can then be gradually reversed by downregulating YY1 activity toward myogenesis.	BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030; SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	Baylor College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267, P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL42267, P01HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1992, NUCLEIC ACIDS RES, V20, P140, DOI 10.1093/nar/20.1.140; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEE TC, 1992, BIOTECHNIQUES, V12, P486; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MOBERG KH, 1992, ONCOGENE, V7, P411; MODAK SP, 1993, ONCOGENE, V8, P645; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; PLET A, 1992, ONCOGENE, V7, P1847; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SCHWARTZ RJ, 1981, BIOCHEMISTRY-US, V20, P4122, DOI 10.1021/bi00517a027; SEJERSEN T, 1985, J CELL PHYSIOL, V125, P465, DOI 10.1002/jcp.1041250315; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SPENCER CA, 1990, ADV CANCER RES, V56, P1; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEINTRAUB H, 1972, J MOL BIOL, V70, P337, DOI 10.1016/0022-2836(72)90543-8; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	38	110	117	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1047	1052						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134108				2022-12-28	WOS:A1994NC04800006
J	MARVEL, J; PERKINS, GR; RIVAS, AL; COLLINS, MKL				MARVEL, J; PERKINS, GR; RIVAS, AL; COLLINS, MKL			GROWTH-FACTOR STARVATION OF BCL-2 OVEREXPRESSING MURINE BONE-MARROW CELLS INDUCED REFRACTORINESS TO IL-3 STIMULATION OF PROLIFERATION	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; C-MYC; HEMATOPOIETIC-CELLS; CALCIUM IONOPHORES; GENE-EXPRESSION; GERMINAL CENTER; APOPTOSIS; DEATH; SURVIVAL	Murine bone-marrow derived BAF3 cells, overexpressing the human Bcl-2 gene product, showed considerably delayed onset of apoptosis when deprived of IL-3. Such Bcl-2-BAF3 cells arrested rapidly in the G1 phase of the cell cycle upon IL-3 removal, then became refractory to IL-3 re-stimulation. The delay in IL-3 induced proliferation of Bcl-2 over-expressing cells was due to down-regulation of a specific signalling pathway. In the refractory cells, IL-3 was able to stimulate protein tyrosine phosphorylation and c-myc mRNA accumulation, but not rapid Erk2 activation or cdc2 mRNA accumulation.	INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND; CSIC,INST LOPEZ NEYRA PARASITOL,GRANADA,SPAIN	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)			marvel, jacqueline/H-8638-2014; Lopez-Rivas, Abelardo/E-5115-2015	marvel, jacqueline/0000-0001-6241-459X; Lopez-Rivas, Abelardo/0000-0002-9351-9690				ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BARDON S, 1987, CANCER RES, V47, P1441; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS M, 1991, Current Biology, V1, P140, DOI 10.1016/0960-9822(91)90212-F; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAWAKAMI M, 1991, EXP CELL RES, V193, P120, DOI 10.1016/0014-4827(91)90545-6; LEEVERS S, 1992, EMBO J, V11, P568; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PEZZELLA F, 1990, AM J PATHOL, V137, P225; POPPEMA S, 1992, IMMUNOL REV, V126, P163, DOI 10.1111/j.1600-065X.1992.tb00636.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIGII SM, 1980, SELECTED METHODS CEL; STERN M, 1992, J IMMUNOL, V148, P3543; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	44	70	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1117	1122						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134114				2022-12-28	WOS:A1994NC04800014
J	YE, XH; KRALLI, A; GE, R; RICCIARDI, RP; KNOWLES, BB				YE, XH; KRALLI, A; GE, R; RICCIARDI, RP; KNOWLES, BB			DOWN-REGULATION OF MHC CLASS-I ANTIGEN IN INSULINOMA CELLS CONTROLLED BY THE R1 ELEMENT OF THE H-2 ENHANCER	ONCOGENE			English	Article							TRANSFORMED RAT-CELLS; PANCREATIC BETA-CELLS; GENE-EXPRESSION; NEGATIVE REGULATION; TRANSGENIC MICE; FACTOR BINDING; T-ANTIGEN; N-MYC; MOUSE; COMPLEX	Tumorigenesis in mice of the rat insulin promoter [RIP]-simian virus 40 tumor antigen [SV40 Tag] transgenic lineages, RIP1-Tag2 and RIP1-Tag4, is a process initiated by expression of SV40 Tag in pancreatic beta cells, evolution of islet cell hyperplasia and insulinoma appearance. Analysis of major histocompatibility complex [MHC] class I gene expression during this process revealed a normal level of MHC class I molecules at the surface of pancreatic islet cells of RIP1-Tag4 mice, while hyperplastic islets from the same mice contained cells expressing a normal level and cells expressing a low level of MHC class I antigen. Insulinomas themselves expressed very low levels or no MHC class I gene product. Thus, down-regulation of MHC class I gene appears to accompany tumor progression of SV40 Tag-transformed beta islet cells. MHC class I antigen expression in a series of clonally derived cell lines of beta cell origin from different SV40 Tag-induced insulinomas ranged from quite low to undetectable, although expression was inducible by interferon-gamma. Nuclear run-on and transient transfection analyses indicated that expression of the MHC class I gene in these cells is controlled at the transcriptional level, and that the decreased expression is paralleled by reduced binding of transcription factors to the R1 element of the H-2 enhancer.	WISTAR INST ANAT & BIOL, 36TH & SPRUCE ST, PHILADELPHIA, PA 19104 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; AMER CYANAMIDE, PEARL RIVER, NY 10965 USA; UNIV PENN, SCH DENT MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of California System; University of California San Francisco; University of Pennsylvania			Ge, Ruowen/D-8352-2012	Ge, Ruowen/0000-0002-0750-7336; Knowles, Barbara B./0000-0002-2597-5619	NATIONAL CANCER INSTITUTE [R01CA029797, P30CA010815, R01CA018470] Funding Source: NIH RePORTER; NCI NIH HHS [CA18470, CA10815, CA29797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKRILL AM, 1988, ONCOGENE, V3, P483; ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BLIEDEN TM, 1991, INT J CANCER, P82; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; CAMPBELL IL, 1985, DIABETES, V34, P1205, DOI 10.2337/diabetes.34.11.1205; CHEN E, 1986, MOL CELL BIOL, V6, P1698, DOI 10.1128/MCB.6.5.1698; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GE R, 1992, THESIS U PENNSYLVANI; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GILLIGAN A, 1989, DIABETES, V38, P1056, DOI 10.2337/diabetes.38.8.1056; GOODING LR, 1979, J IMMUNOL, V122, P1002; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HENSELING U, 1990, MOL CELL BIOL, V10, P4100, DOI 10.1128/MCB.10.8.4100; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JEFFERIES WA, 1988, EMBO J, V7, P3423, DOI 10.1002/j.1460-2075.1988.tb03216.x; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; JUULMADSEN HR, 1990, APMIS, V98, P624, DOI 10.1111/j.1699-0463.1990.tb04980.x; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KNOWLES BB, 1979, J IMMUNOL, V122, P1798; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; KRALLI A, 1991, THESIS U PENNSYLVANI; LENARDO M, 1989, EMBO J, V8, P3351, DOI 10.1002/j.1460-2075.1989.tb08497.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LEW AM, 1986, IMMUNOLOGY, V57, P3; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; OZATO K, 1985, P NATL ACAD SCI USA, V82, P2427, DOI 10.1073/pnas.82.8.2427; PAN S, 1982, J IMMUNOL, V128, P243; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; ROSA F, 1983, EMBO J, V2, P239, DOI 10.1002/j.1460-2075.1983.tb01412.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; SOONG TW, 1991, CANCER DETECT PREV, V15, P231; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; TEVETHIA SS, 1990, J VIROL, V64, P1192, DOI 10.1128/JVI.64.3.1192-1200.1990; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; YE X, 1994, IN PRESS P NATL ACAD; YE X, 1993, THESIS U PENNSYLVANI; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	56	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1195	1204						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134122				2022-12-28	WOS:A1994NC04800023
J	STEINMANN, KE; PEI, XF; STOPPLER, H; SCHLEGEL, R; SCHLEGEL, R				STEINMANN, KE; PEI, XF; STOPPLER, H; SCHLEGEL, R; SCHLEGEL, R			ELEVATED EXPRESSION AND ACTIVITY OF MITOTIC REGULATORY PROTEINS IN HUMAN PAPILLOMAVIRUS IMMORTALIZED KERATINOCYTES	ONCOGENE			English	Article							SV40 LARGE-T; CELL-CYCLE REGULATION; RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; OPEN READING FRAMES; FISSION YEAST; TYROSINE PHOSPHORYLATION; ALTERED DIFFERENTIATION; TRANSCRIPTION FACTOR; ACTIVATES P34CDC2	The E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 are expressed in cell lines derived from cervical cancers and can immortalize primary human keratinocytes. Since expression of E6/E7 has been shown to induce mitotic defects and karyotype instability in primary human cells, we investigated the effect of these viral oncoproteins on the expression and activity of mitotic regulatory proteins. Primary human keratinocytes immortalized by the entire genome or by only the E6/E7 genes of HPV types 16 and 18 displayed 5- to 20-fold increases in the abundance of p34(cdc2), cyclin B and cyclin A when compared with normal parental cells. Results obtained from normal and immortalized cells that were derived from identical single donors were similar to those from mixed donor cultures. Increased protein levels were achieved without corresponding increases in mRNA, indicating alterations in translational and/or post-translational control. The histone H1 kinase activities associated with these regulatory proteins were also elevated, but to a lesser extent than the protein levels. Because p34(cdc2), cyclin B and cyclin A regulate the entry into and exit from mitosis, increased expression and activity of these proteins could contribute to the mitotic defects and chromosomal aberrations associated with HPV-induced immortalization.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, BOSTON, MA 02115 USA; GEORGETOWN UNIV, SCH MED, DEPT PATHOL, WASHINGTON, DC 20007 USA	Harvard University; Harvard T.H. Chan School of Public Health; Georgetown University					NATIONAL CANCER INSTITUTE [R01CA053371, F32CA009235] Funding Source: NIH RePORTER; NCI NIH HHS [NCI 5RO1CA4979, NCI 1F32CA09235, NCI 1RO1CA53371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANKSSCHLEGEL SP, 1983, J CELL BIOL, V96, P330, DOI 10.1083/jcb.96.2.330; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUCHOU T, 1993, ONCOGENE, V8, P1765; CRUM CP, 1984, NEW ENGL J MED, V310, P880, DOI 10.1056/NEJM198404053101403; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DRAETTA G, 1988, ONCOGENE, V2, P553; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEIKRANTZ W, 1991, J CELL SCI, V98, P303; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NAGATA A, 1991, NEW BIOL, V3, P959; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OSHIMA J, 1993, ONCOGENE, V8, P2987; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RICE RH, 1993, MOL BIOL CELL, V4, P185, DOI 10.1091/mbc.4.2.185; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TAM SW, 1992, CELL GROWTH DIFFER, V3, P811; TOMMASINO M, 1993, ONCOGENE, V8, P195; TSAI LH, 1993, ONCOGENE, V8, P1593; VILLA LL, 1991, VIROLOGY, V181, P374; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	92	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					387	394						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290252				2022-12-28	WOS:A1994MW24800005
J	YAN, XQ; BRADY, G; ISCOVE, NN				YAN, XQ; BRADY, G; ISCOVE, NN			OVEREXPRESSION OF PDGF-B IN MURINE HEMATOPOIETIC-CELLS INDUCES A LETHAL MYELOPROLIFERATIVE SYNDROME IN-VIVO	ONCOGENE			English	Article							V-SIS GENE; COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR; RETROVIRUS VECTORS; GM-CSF; EXPRESSION; INTERLEUKIN-1; INVIVO; MICE	Although PDGF is not a primary hematopoietic cytokine, effects in hematopoietic cell cultures have been reported. We recently described responses of multilineage hematopoietic precursors to PDGF. The effects were shown to be neutralized by antibody to LL-1 beta and mediated by marrow macrophages that expressed PDGF receptor RNA and responded to PDGF by upregulation of IL-1 RNA. The present study was performed to determine whether constitutive expression of PDGF by hematopoietic cells would have hematopoetic consequences in vivo. Retroviral vectors containing a PDGF-B gene were constructed and infected into normal marrow cells. Irradiated mice reconstituted with infected cells consistently developed a lethal myeloproliferative syndrome with anemia, neutrophilia and monocytosis, declining hematopoiesis in marrow with shift to the spleen, and extensive infiltration of immature hematopoietic cells into the parenchymal organs and connective tissues. In addition to PDGF, the retroviral constructs expressed a nea resistance marker. Phenotypic expression patterns in fibroblasts and in hematopoietic colony-forming cells in vitro were consistent with a significant degree of interaction between the two expressed inserts. Moreover, selection of infected cells for G418 resistance significantly reduced not only the number of infected reconstituting cells but also the intensity of the evoked syndrome in vivo. The observations have important implications for projected gene therapy protocols, and identify a novel potential pathway to myeloproliferative disease.	UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO M4X 1K9, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto								BANCROFT JD, 1984, MANUAL HISTOLOGICAL, P52; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BOWENPOPE DF, 1984, BLOOD, V64, P458; BOWTELL DDL, 1988, J VIROL, V62, P2464, DOI 10.1128/JVI.62.7.2464-2473.1988; BRACH MA, 1990, BLOOD, V76, P1972; BRADY G, 1988, ONCOGENE, V3, P687; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; CHANG JM, 1989, J CLIN INVEST, V84, P1488, DOI 10.1172/JCI114324; CHANG JM, 1989, BLOOD, V73, P1487; DAINIAK N, 1983, J CLIN INVEST, V71, P1206, DOI 10.1172/JCI110869; DELWICHE F, 1985, J CLIN INVEST, V76, P137, DOI 10.1172/JCI111936; DICK JE, 1991, BLOOD, V78, P624, DOI 10.1182/blood.V78.3.624.bloodjournal783624; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ELIAS JA, 1990, J IMMUNOL, V145, P161; EMERMAN M, 1986, NUCLEIC ACIDS RES, V14, P9381, DOI 10.1093/nar/14.23.9381; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; FIBBE WE, 1988, BLOOD, V72, P860; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; HANNINK M, 1986, MOL CELL BIOL, V6, P1304, DOI 10.1128/MCB.6.4.1304; HARIHARAN IK, 1989, CURR TOP MICROBIOL, V149, P99; HARRISON DE, 1991, BLOOD, V78, P1237; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; ISCOVE NN, 1989, J IMMUNOL, V142, P2332; ISCOVE NN, 1990, J IMMUNOL, V145, P190; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JOHNSSON A, 1986, EMBO J, V5, P1535, DOI 10.1002/j.1460-2075.1986.tb04394.x; JOHNSSON A, 1985, P NATL ACAD SCI USA, V82, P1721, DOI 10.1073/pnas.82.6.1721; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; METCALF D, 1989, LEUKEMIA, V3, P847; MICHALEVICZ R, 1986, BRIT J HAEMATOL, V63, P591, DOI 10.1111/j.1365-2141.1986.tb07537.x; PAIGE CJ, 1986, J IMMUNOL METHODS, V93, P37, DOI 10.1016/0022-1759(86)90430-8; PANTAZIS P, 1990, EUR J HAEMATOL, V45, P127; QUESNIAUX VFJ, 1993, BLOOD, V81, P1497; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; Sambrook J, 1989, MOL CLONING; SIEFF CA, 1987, J CLIN INVEST, V79, P48, DOI 10.1172/JCI112806; VAUX DL, 1990, INT IMMUNOL, V2, P965, DOI 10.1093/intimm/2.10.965; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; YAN XQ, 1993, J IMMUNOL, V150, P2440; ZSEBO KM, 1988, BLOOD, V71, P99; [No title captured]	46	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					163	173						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302575				2022-12-28	WOS:A1994MW24700020
J	BOUSSET, K; HENRIKSSON, M; LUSCHERFIRZLAFF, JM; LITCHFIELD, DW; LUSCHER, B				BOUSSET, K; HENRIKSSON, M; LUSCHERFIRZLAFF, JM; LITCHFIELD, DW; LUSCHER, B			IDENTIFICATION OF CASEIN KINASE-II PHOSPHORYLATION SITES IN MAX - EFFECTS ON DNA-BINDING KINETICS OF MAX HOMODIMER AND MYC/MAX HETERODIMERS	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; C-MYC ONCOPROTEIN; PROTEIN-PHOSPHORYLATION; RAS COTRANSFORMATION; SEQUENCE; CELLS; TRANSCRIPTION; ACTIVATION; INCREASES; P34CDC2	Myc proteins have been implicated in the regulation of cell growth and differentiation. The identification of Max, a basic region/helix-loop-helix/leucine zipper protein, as a partner for Myc has provided insights into Myc's molecular function as a transcription factor. Recent evidence indicates that the relative abundance of Myc and Max is important to determine the level of specific gene transcription; In this report we have identified two major in vivo phosphorylation sites in Max (Ser-2 and -11) which can be modified in vitro by casein kinase II (CKII). Phosphorylation of these sites modulates DNA-binding by increasing both the on- and off-rates of Max homo- as well as Myc/Max heterodimers. In addition, our data indicate that the steady state binding of the shorter version of Max (p21) to DNA was similar yet its rate of dissociation faster than that of the longer version of Max (p22). These data argue that different Max complexes have different kinetic properties and that these can be modified by CKII phosphorylation. We propose this as an important biological mechanism by which different dimeric complexes can exchange with varying efficiencies on DNA, thereby responding to changes in cell growth conditions.	HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY; UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG R3E 0V9,MB,CANADA	Hannover Medical School; University of Manitoba			Henriksson, Marie Arsenian/F-5010-2015; Litchfield, David/E-4636-2015; Luscher, Bernhard/A-7330-2011	Litchfield, David/0000-0002-2425-6620; Luscher, Bernhard/0000-0002-9622-8709				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMATI B, 1993, CELL, V72, P235; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; HENRIKSSON M, 1993, IN PRESS ONCOGENE; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LITCHFIELD DW, 1993, IN PRESS MOL CHEM BI; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEEK DW, 1992, BIOCHEM J, V287, P1; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PINNA LA, 1981, BIOCHEM BIOPH RES CO, V100, P449, DOI 10.1016/S0006-291X(81)80117-9; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; VASTRIK I, 1993, ONCOGENE, V8, P503; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	46	86	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3211	3220						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247525				2022-12-28	WOS:A1993MG78200003
J	SRIVASTAVA, S; WANG, SW; TONG, YA; PIROLLO, K; CHANG, EH				SRIVASTAVA, S; WANG, SW; TONG, YA; PIROLLO, K; CHANG, EH			SEVERAL MUTANT P53 PROTEINS DETECTED IN CANCER-PRONE FAMILIES WITH LI-FRAUMENI SYNDROME EXHIBIT TRANSDOMINANT EFFECTS ON THE BIOCHEMICAL-PROPERTIES OF THE WILD-TYPE P53	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; GERM-LINE; TRANSFORMED-CELLS; SIMIAN VIRUS-40; BREAST-CANCER; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; T-ANTIGEN; MUTATIONS; EXPRESSION	The identification of germ-line mutations in the p53 gene has provided a situation where comparable amounts of wild-type and mutant p53 co-exist in constitutional cells of certain individuals who are cancer-prone. Here we report the biochemical characteristics of several Li-Fraumeni syndrome associated mutant p53 proteins in order to assess the influence of germ-line mutant p53 on the functions of the wild-type p53. Unlike 248W mutant p53 protein, which was previously shown to have no effect on the wild-type p53 conformation (Milner & Medcalf, 1991; Cell 65, 765-774), germ-line associated mutant p53 proteins with residue 133T, 245D or 258K, converted the wild-type p53 conformation into the mutant conformation. Furthermore, lysates containing cotranslated wild-type p53 and these mutant p53 proteins were significantly impaired for DNA and SV40 large T antigen binding. These observations suggest that at least some germ-line p53 mutants might exhibit dominant effects on wild-type p53 functions and, like other mutant p53 proteins, the phenotype of germ-line mt p53 proteins might be variable depending on the particular mutation.	UNIFORMED SERV UNIV HLTH SCI,DEPT SURG,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA	SRIVASTAVA, S (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814, USA.			Wang, Shouwen/0000-0001-8484-1795	NATIONAL CANCER INSTITUTE [R29CA046455, R01CA045158] Funding Source: NIH RePORTER; NCI NIH HHS [CA46455, CA45158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BORRESEN AL, 1992, CANCER RES, V52, P3234; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1990, ONCOGENE, V5, P845; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAW JC, 1991, CANCER RES, V51, P6385; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MILNER J, 1989, ONCOGENE, V4, P665; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, ONCOGENE, V7, P1673; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	53	52	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2449	2456						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361758				2022-12-28	WOS:A1993LT36800016
J	BARBACID, M				BARBACID, M			NERVE GROWTH-FACTOR - A TALE OF 2 RECEPTORS	ONCOGENE			English	Review							TYROSINE PROTEIN-KINASE; HIGH-AFFINITY RECEPTORS; TUMOR-NECROSIS-FACTOR; HUMAN NEUROTROPHIC FACTOR; HUMAN NGF RECEPTOR; MOLECULAR-CLONING; TRK PROTOONCOGENE; FACTOR FAMILY; NEURONAL DIFFERENTIATION; GENE-TRANSFER				BARBACID, M (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543, USA.							Barbacid Mariano, 1993, P123; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERND P, 1984, J BIOL CHEM, V259, P5509; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHESA PG, 1988, J HISTOCHEM CYTOCHEM, V36, P383, DOI 10.1177/36.4.2831267; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; HOSANG M, 1985, J BIOL CHEM, V260, P655; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, IN PRESS NEURON; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1990, FEBS LETT, V266, P187, DOI 10.1016/0014-5793(90)81536-W; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1991, NATURE, V350, P150; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MARSH HN, 1993, IN PRESS J NEUROSCI; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; RAKOWICZSZULCZYNSKA EM, 1988, CANCER RES, V48, P7200; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STEININGER TL, 1993, IN PRESS BRAIN RES; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; THOMSON TM, 1988, EXP CELL RES, V174, P533, DOI 10.1016/0014-4827(88)90323-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; YAN Q, 1989, J COMP NEUROL, V290, P585, DOI 10.1002/cne.902900411	79	228	235	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2033	2042						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336933				2022-12-28	WOS:A1993LP17100002
J	BRADBURY, JM; ARNO, J; EDWARDS, PAW				BRADBURY, JM; ARNO, J; EDWARDS, PAW			INDUCTION OF EPITHELIAL ABNORMALITIES THAT RESEMBLE HUMAN BREAST-LESIONS BY THE EXPRESSION OF THE NEU/ERBB-2 ONCOGENE IN RECONSTITUTED MOUSE MAMMARY-GLAND	ONCOGENE			English	Article							DUCTAL CARCINOMA INSITU; NEU ONCOGENE; PROTEIN OVEREXPRESSION; C-ERBB-2 PROTEIN; CELL-LINE; TUMORS; CANCER; RECEPTOR; GENE; PROTOONCOGENE	We have developed a transplantation system that allows us to introduce oncogenes into mouse mammary epithelial cells in culture and then to reconstitute an epithelial tree in vivo from the genetically altered cells. Introduction of the neu oncogene, a transforming homologue of the human proto-oncogene c-erbB-2, produced a variety of abnormal patterns of epithelial growth, many of which resembled lesions found in human breasts. In four of 43 oncogene-bearing glands, areas of ductal carcinoma in situ were found, an abnormality previously observed in transgenic neu-bearing mice. Six glands developed localized areas of dense stroma containing excess ductal structures comprised of mildly hyperplastic epithelium. These areas resembled the human breast lesion termed sclerosing adenosis. Other glands developed hyperplastic epithelium, sometimes with multilayering of the cells and/or atypical changes such as abnormally large nuclei. In human breasts such lesions would be termed mild or atypical hyperplasia. In all the abnormal areas examined, levels of neu protein above background level were detected by immunohistochemistry. Some staining was localized to membranes (as observed in ductal carcinoma in situ in humans) but cytoplasmic staining was also common in the lesions induced in mice by the neu oncogene. The range of abnormalities seen in the reconstituted glands carrying the neu oncogene suggests that the matching lesions in the human breast may be stages on one pathway to tumour development.			BRADBURY, JM (corresponding author), UNIV CAMBRIDGE, DEPT PATHOL, TENNIS COURT RD, CAMBRIDGE CB2 1QP, ENGLAND.		Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374				BANERJEE M R, 1976, TCA (Tissue Culture Association) Manual, V2, P457, DOI 10.1007/BF00918341; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARTKOVA J, 1990, HUM PATHOL, V21, P1164, DOI 10.1016/0046-8177(90)90154-W; BATTIFORA H, 1990, HISTOPATHOLOGY, V16, P105, DOI 10.1111/j.1365-2559.1990.tb01076.x; BERGER MS, 1988, CANCER RES, V48, P1238; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRADBURY JM, 1988, INT J CANCER, V42, P923, DOI 10.1002/ijc.2910420623; BRADBURY JM, 1991, INT J CANCER, V48, P908, DOI 10.1002/ijc.2910480619; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEOME KB, 1959, CANCER RES, V19, P515; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; EDWARDS PAW, 1988, ONCOGENE, V2, P407; EDWARDS PAW, 1993, IN PRESS CANCER SURV; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GULLICK WJ, 1990, INT J CANCER, P55; GUSTERSON BA, 1988, BRIT J CANCER, V58, P453, DOI 10.1038/bjc.1988.239; GUSTERSON BA, 1987, MOL CELL PROBE, V1, P383, DOI 10.1016/0890-8508(87)90019-3; GUSTERSON BA, 1988, INT J CANCER, V42, P842, DOI 10.1002/ijc.2910420608; HANNA W, 1990, MODERN PATHOL, V3, P455; LACROIX H, 1989, ONCOGENE, V4, P145; LEMOINE NR, 1990, ONCOGENE, V5, P237; LIU E, 1992, ONCOGENE, V7, P1027; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NIELSEN LL, 1991, CANCER RES, V51, P3762; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; PORTER PL, 1991, CANCER, V68, P331, DOI 10.1002/1097-0142(19910715)68:2<331::AID-CNCR2820680221>3.0.CO;2-X; PRESS MF, 1990, ONCOGENE, V5, P953; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; STRANGE R, 1992, DEVELOPMENT, V115, P49; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VATTEN LJ, 1992, EUR J CANCER, V28A, P1148, DOI 10.1016/0959-8049(92)90476-I; WANG BC, 1991, CANCER RES, V51, P5649; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	41	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1551	1558						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8099220				2022-12-28	WOS:A1993LE06400018
J	WOODS, C; LEFEUVRE, C; STEWART, N; BACCHETTI, S				WOODS, C; LEFEUVRE, C; STEWART, N; BACCHETTI, S			INDUCTION OF GENOMIC INSTABILITY IN SV40-TRANSFORMED HUMAN-CELLS - SUFFICIENCY OF THE N-TERMINAL-147 AMINO-ACIDS OF LARGE T-ANTIGEN AND ROLE OF PRB AND P53	ONCOGENE			English	Article							HUMAN-DIPLOID FIBROBLASTS; WILD-TYPE P53; MOUSE EMBRYO FIBROBLASTS; LARGE TUMOR-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; SIMIAN VIRUS-40; CYCLE CHECKPOINT; DNA-SYNTHESIS; CHROMOSOMAL-ABERRATIONS; MONOCLONAL-ANTIBODIES	Genomic instability is an early event in the transformation of human cells by SV40 and may contribute, as a mutagenic process, to the generation of the rare cells which survive crisis and yield immortal populations. We have previously reported that expression of large T antigen is responsible for induction of chromosome aberrations and aneuploidy. In the present study we have demonstrated that the amino terminal 147 amino acids of the protein are as proficient as full length T antigen for this destabilization of the cell genome. Analysis of mutants within this region indicated that T antigens defective for binding to pRB or lacking the first 127 amino acids are significantly reduced in their ability to induce aneuploidy and/or aberrations, whereas a cytoplasmic T antigen is less severely impaired. In addition, we have shown that binding of T antigen to p53 is dispensable for genome destabilization but may be required for continued proliferation of genetically aberrant cells.	MCMASTER UNIV,DEPT PATHOL,MOLEC VIROL & IMMUNOL PROGRAMME,HAMILTON L8N 3Z5,ON,CANADA	McMaster University								ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; ANDERSON RW, 1988, J VIROL, V62, P285, DOI 10.1128/JVI.62.1.285-296.1988; ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; BAUMANN EA, 1985, J VIROL, V54, P882, DOI 10.1128/JVI.54.3.882-885.1985; BOND JA, 1994, ONCOGENE, V9, P1885; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; CHANG PL, 1986, EXP CELL RES, V167, P407, DOI 10.1016/0014-4827(86)90181-3; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRIEDRICH TD, 1992, J VIROL, V66, P4576, DOI 10.1128/JVI.66.7.4576-4579.1992; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARNDEN DG, 1985, ISCN; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAYFLICK L, 1965, EXP CELL RES, V37, P617; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MACLEAN K, 1994, ONCOGENE, V9, P719; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; RASHEED D, 1974, CANCER, V33, P1033; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; RAY FA, 1993, CARCINOGENESIS, V14, P1511, DOI 10.1093/carcin/14.8.1511; SACK GH, 1981, IN VITRO CELL DEV B, V17, P1; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; SLADEK TL, 1992, J VIROL, V66, P1059, DOI 10.1128/JVI.66.2.1059-1065.1992; SMITH JR, 1992, AM J CLIN NUTR, V55, P1215; SOMPAYRAC L, 1994, VIROLOGY, V200, P849, DOI 10.1006/viro.1994.1255; SOMPAYRAC L, 1988, VIROLOGY, V163, P391, DOI 10.1016/0042-6822(88)90279-6; SOMPAYRAC L, 1992, VIROLOGY, V191, P439, DOI 10.1016/0042-6822(92)90206-5; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TJIAN R, 1978, P NATL ACAD SCI USA, V75, P1279, DOI 10.1073/pnas.75.3.1279; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	78	52	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2943	2950						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084597				2022-12-28	WOS:A1994PG82200020
J	BOND, JA; WYLLIE, FS; WYNFORDTHOMAS, D				BOND, JA; WYLLIE, FS; WYNFORDTHOMAS, D			ESCAPE FROM SENESCENCE IN HUMAN-DIPLOID FIBROBLASTS INDUCED DIRECTLY BY MUTANT P53	ONCOGENE			English	Article							EPITHELIAL-CELLS; P53-DEFICIENT MICE; TUMOR SUPPRESSION; CANCER SYNDROME; IMMORTALIZATION; TRANSFORMATION; ABNORMALITIES; MECHANISMS; RB	Cellular senescence is thought to be a key restraint on the progression of human tumours, escape from which involves loss of function of tumour suppressor genes. The number and nature of the genes involved however is uncertain, in particular the role of p53 mutation, which is commonly correlated with tumour progression. To address this question, we used the novel approach of directly assessing the effect of mutant p53 on 'pre-aged' human diploid fibroblasts (HDF), thereby avoiding the uncertainty of additional cooperating events, inherent in transgenic models. HDF were passaged till near-senescent and then infected with an amphotropic retroviral vector encoding an ala143 human mutant p53. The results show conclusively that p53 mutation alone is sufficient to extend the proliferative lifespan of normal fibroblasts by approximately 17 population doublings, but has no phenotypic effect on 'young' fibroblasts. We conclude that a key tumour-limiting function of wild-type p53 is to mediate growth arrest after a given number of cell divisions, in agreement with data implicating a p53-regulated gene, WAF-1/sdi-1, in cellular senescence. This may be reconciled with its 'guardian of the genome' role, if telomere erosion, a key change in senescence, is perceived by the cell as a form of DNA 'damage'.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL GRP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University								BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; NODA A, IN PRESS EXP CELL RE; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; TSUKADA T, 1993, ONCOGENE, V8, P3313; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q	18	175	184	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1885	1889						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208534				2022-12-28	WOS:A1994NR68500011
J	BORRELLO, MG; PELICCI, G; ARIGHI, E; DEFILIPPIS, L; GRECO, A; BONGARZONE, I; RIZZETTI, MG; PELICCI, PG; PIEROTTI, MA				BORRELLO, MG; PELICCI, G; ARIGHI, E; DEFILIPPIS, L; GRECO, A; BONGARZONE, I; RIZZETTI, MG; PELICCI, PG; PIEROTTI, MA			THE ONCOGENIC VERSIONS OF THE RET AND TRK TYROSINE KINASES BIND SHC AND GRB2 ADAPTER PROTEINS	ONCOGENE			English	Article							PAPILLARY THYROID CARCINOMAS; NERVE GROWTH-FACTOR; PROTO-ONCOGENE; NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; PROTOONCOGENE; RECEPTOR; RAS; PRODUCT; ACTIVATION	Proto-TRK and proto-RET genes encode receptor type tyrosine kinases. Oncogenic rearrangements of both proto-oncogenes have been detected with a significant frequency in human papillary thyroid carcinomas. Chimeric Ret and Trk oncoproteins, encoded by different rearrangements of proto-TRK and proto-RET genes, display a constitutive phosphorylation on tyrosine. Moreover, it has been shown that phosphorylated tyrosine receptors, activated by their ligands, form multiprotein complexes responsible for transducing mitogenic or differentiation signals. We have therefore begun to analyse in this study the signal transduction pathways triggered by different Ret and Trk oncoproteins. We have shown that the SH2 domain of the adaptor protein She coimmunoprecipitates with all the Ret and Trk oncoproteins as well as with NGF-activated proto-Trk receptor. Tyrosine phosphorylation of Trk proteins both normal and oncogenic is necessary for their binding to She. In addition, in cells containing either Ret or TrK oncoproteins, She proteins are constitutively phosphorylated on tyrosine and bound to Grb2. Only in in vitro experiments were Ret and Trk oncoproteins shown to bind the SH2 region of Grb2. Finally, when proto-Trk product is stimulated by NGF, She phosphorylation and association with Grb2 are induced. In conclusion, we have shown that Ret and Trk oncoproteins can form multiprotein complexes, however, the functional meaning of the described interactions has to be elucidated.	UNIV PERUGIA,IST CLIN MED 1,MONTELUCE POLICLIN,I-06100 PERUGIA,ITALY	University of Perugia	BORRELLO, MG (corresponding author), IST NAZL TUMORI,DIV EXPTL ONCOL E,VIA VENEZIAN 1,I-20133 MILAN,ITALY.		Borrello, Maria Grazia/C-3161-2017; Bongarzone, Italia/B-9544-2017; Pelicci, Giuliana/AAA-8921-2022; Greco, Angela/C-1953-2017; Pelicci, Pier Giuseppe/AAL-6572-2020; De Filippis, Lidia/H-3098-2017	Borrello, Maria Grazia/0000-0002-6854-2848; Bongarzone, Italia/0000-0003-2530-9170; Pelicci, Giuliana/0000-0003-0986-8255; Greco, Angela/0000-0003-2994-0349; De Filippis, Lidia/0000-0002-2196-9430; Pierotti, Marco Alessandro/0000-0002-7431-8332				BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRECO A, 1992, ONCOGENE, V7, P237; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZI C, 1992, ONCOGENE, V7, P2189; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIEROTTI MA, 1993, NATO ASI SER, P87; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1993, ONCOGENE, V8, P2105; SOZZI G, 1992, GENE CHROMOSOME CANC, V5, P212, DOI 10.1002/gcc.2870050307; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	36	109	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1661	1668						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183561				2022-12-28	WOS:A1994NL81500018
J	LEE, YY; WILCZYNSKI, SP; CHUMAKOV, A; CHIH, D; KOEFFLER, HP				LEE, YY; WILCZYNSKI, SP; CHUMAKOV, A; CHIH, D; KOEFFLER, HP			CARCINOMA OF THE VULVA - HPV AND P53 MUTATIONS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; POLYMERASE CHAIN-REACTION; SQUAMOUS-CELL CARCINOMA; CHRONIC MYELOCYTIC-LEUKEMIA; CERVICAL-CARCINOMA; INSITU HYBRIDIZATION; POINT MUTATIONS; BLAST CRISIS; N-RAS; GENE	Recent evidence suggests that squamous cell carcinoma of the vulva may have more than one etiology, with only some tumors associated with human papillomavirus (HPV). Cells infected with HPV produce a viral protein (E6) which binds to and causes rapid degradation of p53, possibly contributing to cellular transformation. In several human malignancies, point mutations of p53 alter activity of the p53 protein contributing to cellular transformation. We tested, for the first time, the possibility that HPV-negative tumors of the vulva may have a high incidence of inactivating mutations of p53; while HPV-containing vulvar tumors rarely would have p53 mutations. Twenty-one tumors of the vulva were evaluated for the presence of HPV sequences by amplication with the polymerase chain reaction (PCR) and Southern blotting. These were evaluated for p53 mutations by single strand conformation polymorphism and sequencing of PCR products. HPV DNA sequences were found in 12 of 21 (57%) cancers of the vulva; only one of these 12 (8%) HPV-positive samples had a missense mutation of p53. In contrast, four of nine (44%) HPV-negative vulvar tumors had point mutations of p53. The p53 mutations were found in only metastatic lesion and the only recurrent tumor samples suggesting that the acquisition of p53 mutations may be associated with neoplastic progression. In conclusion, alterations in p53 activity appear to be important in the development of carcinoma of the vulva.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90048; CITY HOPE NATL MED CTR,DEPT PATHOL,DUARTE,CA 91010	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; City of Hope			Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166	NATIONAL CANCER INSTITUTE [R29CA053005, P30CA042710, P01CA042710] Funding Source: NIH RePORTER; NCI NIH HHS [CA42710, CA53005] Funding Source: Medline; NIDDK NIH HHS [DK42702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ANDERSEN WA, 1991, AM J OBSTET GYNECOL, V165, P329, DOI 10.1016/0002-9378(91)90086-7; BISHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766; BLOSS JD, 1991, HUM PATHOL, V22, P711, DOI 10.1016/0046-8177(91)90294-Y; BORRESEN AL, 1992, LANCET, V339, P1350; BOSHART M, 1986, J VIROL, V58, P963, DOI 10.1128/JVI.58.3.963-966.1986; BUSBYEARLE RMC, 1992, LANCET, V339, P1350, DOI 10.1016/0140-6736(92)91993-I; BUSCEMA J, 1988, OBSTET GYNECOL, V71, P601; CARSON LF, 1988, OBSTET GYNECOL, V72, P63; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, ONCOGENE, V6, P873; CRUM CP, 1992, OBSTET GYNECOL, V79, P448, DOI 10.1097/00006250-199203000-00025; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FOTI A, 1991, BLOOD, V77, P2441; FUJITA M, 1992, CANCER RES, V52, P5323; FULTS D, 1992, CANCER RES, V52, P674; GUPTA J, 1987, AM J PATHOL, V127, P206; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUBBERT M, 1990, BLOOD, V75, P1163; MANOS MM, 1989, CANCER CEL, V7, P209; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; NUOVO GJ, 1988, OBSTET GYNECOL, V72, P770; NUOVO GJ, 1991, GYNECOL ONCOL, V43, P275, DOI 10.1016/0090-8258(91)90035-4; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PAQUETTE RL, 1993, CANCER-AM CANCER SOC, V72, P1272, DOI 10.1002/1097-0142(19930815)72:4<1272::AID-CNCR2820720420>3.0.CO;2-Q; PARK DJ, 1993, IN PRESS ONCOGENE; PFISTER H, 1987, ADV CANCER RES, V48, P113, DOI 10.1016/S0065-230X(08)60691-0; PILOTTI S, 1990, MODERN PATHOL, V3, P442; SAKASHITA A, 1992, BLOOD, V79, P477; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SOUSSI T, 1990, ONCOGENE, V5, P945; STRETCH JR, 1991, CANCER RES, V51, P5976; TAMURA G, 1991, CANCER RES, V51, P3056; TOKI T, 1991, INT J GYNECOL PATHOL, V10, P107, DOI 10.1097/00004347-199104000-00001; TWIGGS LB, 1988, INT J GYNECOL PATHOL, V7, P48, DOI 10.1097/00004347-198803000-00005; VENUTI A, 1989, J GEN VIROL, V70, P1587, DOI 10.1099/0022-1317-70-6-1587; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	42	100	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1655	1659						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183560				2022-12-28	WOS:A1994NL81500017
J	MARTI, A; JEHN, B; COSTELLO, E; KEON, N; KE, G; MARTIN, F; JAGGI, R				MARTI, A; JEHN, B; COSTELLO, E; KEON, N; KE, G; MARTIN, F; JAGGI, R			PROTEIN KINASE-A AND AP-1 (C-FOS/JUND) ARE INDUCED DURING APOPTOSIS OF MOUSE MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article							GENE-EXPRESSION; NUCLEAR FACTOR; BETA-CASEIN; TISSUE TRANSGLUTAMINASE; TRANSGENIC MICE; FOS EXPRESSION; ONCOGENE FOS; DEATH; JUN; INDUCTION	At weaning the mammary gland undergoes a reductive remodelling process (involution) which is associated with the cessation of milk protein gene expression and programmed cell death of milk-producing epithelial cells. Elevated nuclear protein kinase A (PKA) activity was observed from one day post-lactation, paralleled by increased c-fos, junB, junD and to a lesser extent c-jun mRNA levels. AP-1 DNA binding activity was transiently induced and the AP-1 complex was shown to consist principally of cFos/JunD. Oct-1 DNA binding activity and Oct-1 protein were gradually lost from the gland over the first 4 days of involution, whereas Oct-1 mRNA levels remained unchanged. Comparing nuclear extracts from normal mammary glands with nuclear extracts from glands which had been cleared of all epithelial cells 3 weeks after birth, revealed that PKA activation, AP-1 induction and Oct-1 inactivation all are dependent on the presence of the epithelial compartment. The increased Fos/Jun expression and the inactivation of Oct-1 may be consequences of the increased PKA activity. A similar induction of AP-1 (cFos/JunD) was also observed in the involuting rat ventral prostate pointing to a possible role for AP-1 in programmed cell death.	UNIV BERN,CLIN & EXPTL RES LAB,TIEFENAUSTR 120,CH-3004 BERN,SWITZERLAND; ISREC,CH-1066 EPALINGES,SWITZERLAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT PHARMACOL,DUBLIN 4,IRELAND	University of Bern; Swiss Institute Experimental Cancer Research; University College Dublin				Costello, Eithne/0000-0002-0104-8992				ABATE C, 1991, ONCOGENE, V6, P2179; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Angel P, 1992, Matrix Suppl, V1, P156; BANDYK MG, 1990, J UROLOGY, V143, P407, DOI 10.1016/S0022-5347(17)39975-5; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; DOWD DR, 1992, MOL CELL BIOL, V12, P3600, DOI 10.1128/MCB.12.8.3600; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GINZBURG I, 1980, NUCLEIC ACIDS RES, V8, P3553, DOI 10.1093/nar/8.16.3553; GONZALEZMARTIN C, 1992, DEV BRAIN RES, V68, P83, DOI 10.1016/0165-3806(92)90250-Z; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HENNIGHAUSEN LG, 1982, EUR J BIOCHEM, V125, P131, DOI 10.1111/j.1432-1033.1982.tb06660.x; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MEDINA D, 1978, BREAST CANCER PLENUM, P47; MELLSTROM B, 1991, ONCOGENE, V6, P1959; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STRANGE R, 1992, DEVELOPMENT, V115, P49; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; THOMPSON HJ, 1992, CANCER EPIDEM BIOMAR, V1, P597; TOURAY M, 1991, ONCOGENE, V6, P211; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	70	198	198	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1213	1223						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134124				2022-12-28	WOS:A1994NC04800025
J	KIESER, A; WELCH, HA; BRANDNER, G; MARME, D; KOLCH, W				KIESER, A; WELCH, HA; BRANDNER, G; MARME, D; KOLCH, W			MUTANT P53 POTENTIATES PROTEIN-KINASE-C INDUCTION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR EXPRESSION	ONCOGENE			English	Note							SWISS 3T3 CELLS; FACTOR GENE; TRANSFORMATION; INHIBITION; MUTATIONS; ONCOGENE; TUMORS; RAS; ANGIOGENESIS; MODULATION	Many tumor cells produce vascular endothelial growth factor (VEGF), which is thought to be a pivotal mediator of tumor neoangiogenesis. Expression of the VEGF gene can be induced by tumor promoting phorbol esters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA), which activate protein kinase C (PKC). Here we show that in transient transfection assays a mutated form of the murine p53 tumor suppressor gene (ala135-->val) induces expression of VEGF mRNA and potentiates TPA stimulated VEGF mRNA expression. In NM 3T3 cells which stably overexpress the temperature sensitive p53 (ala135-->val), displaying mutant phenotype at 37 degrees C and wildtype phenotype at 32.5 degrees C, induction of VEGF mRNA and protein by activated PKC is strongly synergistic with mutant, but not wildtype p53. Mutant p53 specifically increases TPA induction of VEGF without affecting the expression of other TPA inducible genes. TPA dependent VEGF expression is also enhanced by human p53 mutated at amino acid 175. Thus, our data link PKC and p53, the gene most frequently altered in human tumors, with the regulation of tumor angiogenesis.	GODECKE AG,UNIV FREIBURG,INST MOLEK ZELLBIOL,W-7800 FREIBURG,GERMANY; UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,W-7800 FREIBURG,GERMANY; GODECKE AG,BIOL RES & DEV,W-7800 FREIBURG,GERMANY	University of Freiburg; University of Freiburg			Kolch, Walter/ABF-2102-2021; Kieser, Arnd/M-4616-2014	Kieser, Arnd/0000-0003-0783-1950; Kolch, Walter/0000-0001-5777-5016				AKINAGA S, 1991, CANCER RES, V51, P4888; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; Folkman J, 1992, Semin Cancer Biol, V3, P65; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIM RW, 1987, ONCOGENE, V1, P263; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER CW, 1993, ONCOGENE, V8, P1815; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; WEINSTEIN IB, 1990, ADV 2ND MESSENGER PH, V26, P307; ZARLING JM, 1973, J NATL CANCER I, V50, P137, DOI 10.1093/jnci/50.1.137; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	39	410	428	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					963	969						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108142				2022-12-28	WOS:A1994MW55100035
J	JACOBSON, DR; MILLS, NE				JACOBSON, DR; MILLS, NE			A HIGHLY SENSITIVE ASSAY FOR MUTANT RAS GENES AND ITS APPLICATION TO THE STUDY OF PRESENTATION AND RELAPSE GENOTYPES IN ACUTE-LEUKEMIA	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; POLYMERASE CHAIN-REACTION; ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; N-RAS; MYELODYSPLASTIC SYNDROMES; ONCOGENE MUTATIONS; POINT MUTATIONS; MYELOPROLIFERATIVE DISORDERS; CHROMOSOME-ABERRATIONS	Most studies of ras oncogene activation use assays for ras mutations based on the polymerase chain reaction (PCR) of DNA segments containing ras exons 1 and 2, followed by allele-specific oligonucleotide (ASO) hybridization or direct sequencing, which require that to be detectable, a mutation must be present in at least 3-25% of ras alleles. Thus, studies of tissues in which only a fraction of cells contains a ras mutation risk false negative results. To minimize this risk, we have developed a highly sensitive, non-radioactive assay for uas mutations. Ras genes were PCR-amplified using mismatched primers, to introduce restriction sites into products derived from normal alleles. Repeated restriction digestion and PCR enriched for mutant alleles, visualized by agarose gel electrophoresis. Serially diluted DNA samples containing I as mutations demonstrated detection of 1 mutant/10(6) normal alleles (four orders of magnitude more sensitive than PCR/ASO hybridization). This assay was applied to DNA from four patients with relapsed acute leukemia in whom ras mutations present at diagnosis were not detectable by PCR/ASO hybridization at relapse. In one case, the mutation present at diagnosis was demonstrated at relapse. In the others, loss of the mutation was confirmed, at a greatly increased sensitivity. This method is widely applicable to detection of mutant ras alleles admired with larger numbers of normal alleles.	NEW YORK VET AFFAIRS MED CTR,MED SERV,NEW YORK,NY; NYU,MED CTR,DEPT MED,NEW YORK,NY; NYU,MED CTR,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY	New York University; New York University	JACOBSON, DR (corresponding author), NEW YORK VA MED CTR,RES SERV 151,423 E 23 ST,NEW YORK,NY 10010, USA.				NHLBI NIH HHS [T32HL07151] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUJA HG, 1990, BLOOD, V75, P1684; BALL ED, 1990, PROG CLIN BIOL RES, V333, P499; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BARELI M, 1989, BLOOD, V73, P281; BARTRAM CR, 1992, HEMATOL ONCOL CLIN N, V6, P557, DOI 10.1016/S0889-8588(18)30328-9; BARTRAM CR, 1989, LEUKEMIA, V3, P247; BASHEY A, 1992, BLOOD, V79, P981; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BROWETT PJ, 1989, ONCOGENE, V4, P1029; CHEN J, 1991, ANAL BIOCHEM, V195, P51, DOI 10.1016/0003-2697(91)90293-3; CHIN IYM, 1992, ACTA HAEMATOL-BASEL, V87, P107; COGSWELL PC, 1989, BLOOD, V74, P2629; COLLINS SJ, 1991, ONCOGENE RES, V3, P117; FARR C, 1991, BRIT J HAEMATOL, V77, P323, DOI 10.1111/j.1365-2141.1991.tb08578.x; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; GIRVITZ SC, 1980, ANAL BIOCHEM, V106, P492, DOI 10.1016/0003-2697(80)90553-9; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; HIRAI H, 1987, BIOCHEM BIOPH RES CO, V147, P108, DOI 10.1016/S0006-291X(87)80093-1; INOKUCHI K, 1991, ANN HEMATOL, V62, P211, DOI 10.1007/BF01729834; Jacobson D R, 1991, PCR Methods Appl, V1, P146; JACOBSON DR, 1992, HUM GENET, V89, P353; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KAHN SM, 1991, ONCOGENE, V6, P1079; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEVI S, 1991, CANCER RES, V51, P3497; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LIU ET, 1990, CLIN LAB MED, V10, P797; LUBBERT M, 1992, ONCOGENE, V7, P263; LYONS J, 1988, BLOOD, V71, P1707; MANE SM, 1990, GENE CHROMOSOME CANC, V2, P71, DOI 10.1002/gcc.2870020113; MANO H, 1993, JPN J CANCER RES, V80, P102; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MOSKOVITS T, 1992, AM J HEMATOL, V41, P302, DOI 10.1002/ajh.2830410422; NAKAGAWA T, 1992, ONCOLOGY, V49, P114; NAKAGAWA T, 1991, BRIT J HAEMATOL, V77, P250, DOI 10.1111/j.1365-2141.1991.tb07988.x; NEGRIN RS, 1991, BLOOD, V78, P255; PADUA RA, 1988, LEUKEMIA, V2, P503; PEDERSENBJERGAARD J, 1988, CANCER RES, V48, P1812; SAGLIO G, 1989, TUMORI, V75, P337, DOI 10.1177/030089168907500407; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SENN HP, 1988, INT J CANCER, V41, P59, DOI 10.1002/ijc.2910410112; SENN HP, 1988, BLOOD, V72, P931; SHEN WPV, 1987, ONCOGENE, V1, P157; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SMITH MT, 1992, J NATL CANCER I, V84, P1626; SYVANEN AC, 1992, INT J CANCER, V50, P713, DOI 10.1002/ijc.2910500508; TAYLOR JA, 1992, J NATL CANCER I, V84, P1626, DOI 10.1093/jnci/84.21.1626; TERADA N, 1990, BLOOD, V75, P453; TERADA N, 1991, LEUKEMIA RES, V15, P935, DOI 10.1016/0145-2126(91)90170-X; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TODD AV, 1991, LEUKEMIA, V5, P160; TODD AV, 1991, AM J HEMATOL, V38, P207, DOI 10.1002/ajh.2830380310; TOKSOZ D, 1987, ONCOGENE, V1, P409; URBANOISPIZUA A, 1992, LEUKEMIA, V6, P342; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; YUNIS JJ, 1989, ONCOGENE, V4, P609	58	64	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					553	563						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290266				2022-12-28	WOS:A1994MW24800023
J	TOKSOZ, D; WILLIAMS, DA				TOKSOZ, D; WILLIAMS, DA			NOVEL HUMAN ONCOGENE IBC DETECTED BY TRANSFECTION WITH DISTINCT HOMOLOGY REGIONS TO SIGNAL-TRANSDUCTION PRODUCTS	ONCOGENE			English	Article							MOLECULAR-CLONING; TRANSFORMING GENE; MYELOID-LEUKEMIA; TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; CDC24 GENE; CELL-CYCLE; SEQUENCE; DBL	In order to isolate transforming genes involved in leukemias, DNA from a CML acute phase sample was transfected into NIH-3T3 Cells and found to be tumorigenic in nude mice. Partial genomic cloning using human repeat sequence as probe followed by cDNA cloning of this oncogene, termed Ibc, was undertaken. The lbc cDNA sequence shows no identity to known proteins and codes for a predicted hydrophilic protein product of 47 kD, which contains several consensus kinase phosphorylation sites. The N-terminus encodes a consensus E-F hand motif followed by a region of homology to the transforming human oncogene dbl associated with regulatory activity for the ras superfamily of small G proteins, while the C-terminus contains homology with pleckstrin and rac protein kinase in a region which overlaps with the recently defined PH (pleckstrin homology) domain. Lbc expression is restricted to human hematopoietic cells and skeletal muscle, lung and heart. Transfection of 3T3 cells with an expression vector encoding lbc cDNA results in focus formation, demonstrating its biological activity. These data indicate that the lbc oncogene encodes a novel product implicated in distinct cellular signal transduction functions.	INDIANA UNIV, RILEY HOSP CHILDREN, SCH MED, HOWARD HUGHES MED RES INST, INDIANAPOLIS, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	TOKSOZ, D (corresponding author), HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT HEMATOL ONCOL, 320 LONGWOOD AVE, BOSTON, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [2PO1-HL32262] Funding Source: Medline; PHS HHS [U03634] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS JM, 1992, ONCOGENE, V7, P611; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKEBE Y, 1988, MOL CELL BIOL, V466, P1431; TOKSOZ D, 1987, ONCOGENE, V1, P409; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	42	107	112	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					621	628						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290273				2022-12-28	WOS:A1994MW24800030
J	FAVIER, D; GONDA, TJ				FAVIER, D; GONDA, TJ			DETECTION OF PROTEINS THAT BIND TO THE LEUCINE-ZIPPER MOTIF OF C-MYB	ONCOGENE			English	Note							PROTO-ONCOGENE PRODUCT; LEUKEMIA-CELL LINE; HEMATOPOIETIC-CELLS; MYELOID-LEUKEMIA; HOMEOBOX GENE; DNA-BINDING; V-MYB; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; EXPRESSION	The product of the c-myb proto-oncogene, c-Myb, binds DNA and can enhance transcription of genes bearing copies of the DNA sequence it recognises. Deletion or disruption of a negative regulatory domain (NRD) in the carboxyl portion of c-Myb results in enhanced transactivating capacity and in parallel, leads to activation of its ability to transform haemopoietic cells. Since mutational analysis has shown that one critical element within the NRD is a leucine zipper motif, we have sought to identify cellular proteins that can interact with the c-Myb leucine zipper. Using fusion proteins containing this region as an affinity reagent, we have identified two nuclear proteins, p67 and p160, that bind to the wildtype, but not to a mutated c-Myb leucine zipper. These two proteins were shown to be related by comparison of peptides generated by partial digestion. While p160 was found to be ubiquitous amongst different murine haemopoietic cell lines, and was also present in NIH3T3 fibroblasts, p67 was detected in a restricted set of immature myeloid cells. Intriguingly p160, but not p67, could also bind to the c-Jun leucine zipper.	INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA; INST MED & VET SCI,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia								ALEXANDER B, 1992, GENE CHROMOSOME CANC, V5, P286, DOI 10.1002/gcc.2870050404; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAUERLE PA, 1988, SCIENCE, V242, P540; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COOPER PC, 1982, LEUKEMIA RES, V6, P313, DOI 10.1016/0145-2126(82)90093-5; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GONDA TJ, 1991, SEMINARS VIROLOGY, V2, P351; GONDA TJ, 1993, IN PRESS BLOOD; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P308; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDO T, 1992, ONCOGENE, V7, P1999; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; ZOBEL A, 1991, ONCOGENE, V6, P1397	44	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					305	311						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302594				2022-12-28	WOS:A1994MW24700037
J	PEREZ, JL; SHEN, XY; FINKERNAGEL, S; SCIORRA, L; JENKINS, NA; GILBERT, DJ; COPELAND, NG; WONG, TW				PEREZ, JL; SHEN, XY; FINKERNAGEL, S; SCIORRA, L; JENKINS, NA; GILBERT, DJ; COPELAND, NG; WONG, TW			IDENTIFICATION AND CHROMOSOMAL MAPPING OF A RECEPTOR TYROSINE KINASE WITH A PUTATIVE PHOSPHOLIPID-BINDING SEQUENCE IN ITS ECTODOMAIN	ONCOGENE			English	Article							FACTOR-VIII; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; GENETIC-LINKAGE; DNA-SEQUENCES; FACTOR-V; C-KIT; FAMILY; MOUSE; ACID	We have cloned a novel receptor tyrosine kinase that has an unusual ectodomain. The extracellular sequence consists of 416 amino acids and has none of the structural motifs that have been found in other receptor tyrosine kinases. The 150 amino acids in the amino terminus of the receptor is homologous to a putative phospholipid-binding sequence that is found also in other cell adhesion molecules such as the neuronal A5 antigen and coagulation factors V and VIII. The kinase domain has a short cytoplasmic tail and contains a short insert between subdomains I and II. The structure of this receptor kinase suggests that it belongs to a new family of receptors involved in cell-cell interactions. The cell adhesion kinase (Cak) is expressed at low levels in most adult tissues and expression is highest in the brain and lung. Using fluorescence in situ hybridization and interspecific backcross mapping, the Cak gene was localized to human chromosome 6 and mouse chromosome 17.	ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854; ROBERT WOOD JOHNSON MED SCH,DEPT PEDIAT,PISCATAWAY,NJ 08854; NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; GOODWIN RH, UNPUB; Green EL, 1981, GENETICS PROBABILITY, P77; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JABS EW, 1987, AM J HUM GENET, V41, P374; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANE WH, 1988, BLOOD, V71, P539; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MUNOZDORADO J, 1991, CELL, V67, P995, DOI 10.1016/0092-8674(91)90372-6; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PAWSON T, 1990, TRENDS GENET, V6, P110; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RESCIGNO J, 1991, ONCOGENE, V6, P1909; ROSNET O, 1991, ONCOGENE, V6, P1641; RYDER LP, 1981, ANNU REV GENET, V15, P169, DOI 10.1146/annurev.ge.15.120181.001125; SHIER P, 1989, J BIOL CHEM, V264, P14605; SIRACUSA LD, 1991, GENETICS, V127, P169; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; ZHU H, 1993, APP CYTOGENET, V19, P33; ZIEGLER SF, 1993, ONCOGENE, V8, P663	43	41	45	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					211	219						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302582				2022-12-28	WOS:A1994MW24700026
J	BARKER, PE; SAVELYEVA, L; SCHWAB, M				BARKER, PE; SAVELYEVA, L; SCHWAB, M			TRANSLOCATION JUNCTIONS CLUSTER AT THE DISTAL SHORT ARM OF CHROMOSOME-1 (1P36.1-2) IN HUMAN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article							HUMAN NEURO-BLASTOMA; INSITU HYBRIDIZATION; LINKAGE MAP; HETEROZYGOSITY; DELETIONS; FEATURES; CANCER; LINES; DNA	Human neuroblastoma cells show at high frequency structural changes of the distal short arm of chromosome 1 (1p). The commonly altered region has been identified in previous loss-of-heterozygosity (LOH) studies to involve deletion of 1p36.1-2. These bands are also the site of constitutional alterations in patients with neuroblastoma. In an approach to define the 1p36.1-2 alterations in more detail we here employ four neuroblastoma cell lines to map translocation breaks involving 1p36.1-2 by fluorescence in situ hybridization (FISH). A chromosomal interval flanked by loci DIS96 and DIS98 contained translocation junctions in each of four lines. This analysis identifies in 1p a restricted genomic region as involved in chromosomal rearrangement in different neuroblastomas. The specificity of neuroblastoma translocation junctions at the molecular level implicates this genomic region in tumor development.	GERMAN CANC RES CTR,DEPT CYTOGENET,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; BARKER PE, 1993, HUMAN NEUROBLASTOMA, P209; BERTHOLD F, 1990, NEUROBLASTOMA TUMOR, P1; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; BUROKER N, 1987, HUM GENET, V77, P175, DOI 10.1007/BF00272388; COLLINS A, 1992, P NATL ACAD SCI USA, V2, P4589; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; HARNETT PR, 1991, CANCER GENET CYTOGEN, V54, P109, DOI 10.1016/0165-4608(91)90037-U; HEIM S, 1992, RECENT ADV HISTOPATH, V15, P37; LAMB J, 1989, CYTOGENET CELL GENET, V51, P1029; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; LICHTER P, 1991, GENET ANAL-BIOMOL E, V8, P24, DOI 10.1016/1050-3862(91)90005-C; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MOLEY JF, 1992, CANCER RES, V52, P770; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1991, ADV NEUROBLASTOMA RE, P1; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	33	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3353	3358						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247537				2022-12-28	WOS:A1993MG78200019
J	CUPP, C; TAYLOR, JP; KHALILI, K; AMINI, S				CUPP, C; TAYLOR, JP; KHALILI, K; AMINI, S			EVIDENCE FOR STIMULATION OF THE TRANSFORMING GROWTH-FACTOR-BETA-1 PROMOTER BY HIV-1 TAT IN CELLS DERIVED FROM CNS	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY-SYNDROME; NECROSIS-FACTOR-ALPHA; LONG-TERMINAL REPEAT; MONONUCLEAR PHAGOCYTES; AIDS PATIENTS; INDEPENDENT ACTIVATION; KAPOSIS-SARCOMA; BRAIN CULTURES; GLIAL-CELLS	Infection by human immunodeficiency virus type 1 (HIV-1), the etiologic agent of the acquired immunodeficiency syndrome (AIDS), is often complicated with a high incidence of neurologic disorders. It is believed that HIV-1, in addition to infecting both macroglial and microglial cells, may influence the expression of several strategic genes of uninfected neighboring or latently infected brain cells. It is suspected that the viral-encoded transregulatory protein, Tat, facilitates cross-communications between these cells. In support of this concept, earlier studies demonstrated that Tat is released from the infected cells, and has the capacity to be taken up by the uninfected cells and exert its biological activity on the responsive gene. Recent studies in several laboratories suggest the involvement of Tat in altering the expression of a limited number of cellular regulatory factors which, in turn, may mediate the altered physiology of the cells. In this communication, we demonstrate the ability of the HIV-1 Tat protein to increase expression of transforming growth factor beta1 (TGF-beta1), a cytokine with potent immunosuppressive activity, in human astrocytic glial cells. Implications of the Tat-mediated induction of TGF-beta1 expression and cytokine involvement in the regulation of immune response and central nervous system (CNS) pathology are discussed.	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,JEFFERSON INST MOLEC MED,MOLEC NEUROVIROL SECT,PHILADELPHIA,PA 19107	Jefferson University			Taylor, J. Paul/N-2482-2018	Taylor, J. Paul/0000-0002-5794-0349				BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BREEN EC, 1990, J IMMUNOL, V144, P480; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CHOWDHURY M, 1993, ONCOGENE, V8, P887; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HELLAND DE, 1991, J VIROL, V65, P4547, DOI 10.1128/JVI.65.8.4547-4549.1991; JEYAPAUL J, 1991, ONCOGENE, V6, P1507; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KEKOW J, 1990, P NATL ACAD SCI USA, V87, P8321, DOI 10.1073/pnas.87.21.8321; KHALILI K, 1986, J VIROL, V60, P935, DOI 10.1128/JVI.60.3.935-942.1986; KIM SJ, 1989, J BIOL CHEM, V264, P402; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LAZDINS JK, 1991, J IMMUNOL, V147, P1201; LAZDINS JK, 1991, RES VIROLOGY, V142, P239, DOI 10.1016/0923-2516(91)90063-9; LEPEZUNIGA JL, 1987, J CLIN MICROBIOL, V25, P1695, DOI 10.1128/JCM.25.9.1695-1700.1987; LOTZ M, 1990, FASEB J, V4, P1861; MARCUZZI A, 1992, J VIROL, V66, P4228, DOI 10.1128/JVI.66.7.4228-4232.1992; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WAHL SM, 1991, J EXP MED, V173, P981, DOI 10.1084/jem.173.4.981; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WRIGHT SC, 1988, J IMMUNOL, V141, P99	44	104	104	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2231	2236						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336945				2022-12-28	WOS:A1993LP17100024
J	LEE, EB; BEUG, H; HAYMAN, MJ				LEE, EB; BEUG, H; HAYMAN, MJ			MUTATIONAL ANALYSIS OF THE ROLE OF THE CARBOXY-TERMINAL REGION OF THE V-ERBB PROTEIN IN ERYTHROID CELL-TRANSFORMATION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; SINGLE POINT MUTATION; EGF RECEPTOR; TYROSINE KINASES; GENE-PRODUCT; C-ERBB; IDENTIFICATION; EXPRESSION; MUTANTS	The v-erbB protein encoded by the avian erythroblastosis virus AEV-H is responsible for the transformation of fibroblasts and erythroblasts by this virus. Deletion of amino acids 961-1102, which lie carboxy terminal to the kinase domain of the v-erbB protein, destroys the ability of the virus to transform erythroid cells without severely affecting fibroblast transformation. This region is termed the E-domain and has been postulated to contain a region important for erythroid cell transformation. In-frame deletions of approximately 23 amino acids were introduced throughout the E-domain in an attempt to locate a specific region that was essential for erythroid cell transformation. Several of the deletions gave rise to a partial transformed phenotype, although no single deletion that completely abolished erythroid cell transformation was found. Interestingly, deletion of amino acids 1031-1055 resulted in a superactivated v-erbB protein that was more active for erythroid cell transformation than the wild-type AEV-H v-erbB protein. This indicates that there is a negative regulatory region located within this region that normally partially suppresses the transforming activity of the v-erbB protein for erythroid cells. These data suggest that the E-domain contains both negative and positive regulatory regions that function in erythroid cells, and complete deletion of the region is necessary to abolish erythroid cell transformation.	SUNY STONY BROOK, DEPT IRON STEEL & OTHER MET, STONY BROOK, NY 11794 USA; INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NATIONAL CANCER INSTITUTE [R01CA042573, P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HAYMAN MJ, 1992, CANCER SURV, V15, P53; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JANSSON M, 1987, ONCOGENE, V1, P167; KAMPS MP, 1988, ONCOGENE, V2, P305; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSEN J, 1992, ONCOGENE, V7, P1903; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEE EB, 1990, ONCOGENE, V5, P1165; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; ROBINSON HL, 1992, ONCOGENE, V7, P2025; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROYERPOKORA B, 1979, NATURE, V282, P750, DOI 10.1038/282750a0; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; THEROUX SJ, 1992, IN PRESS J BIOL CHEM; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	43	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1317	1327						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8097581				2022-12-28	WOS:A1993KY32800025
J	ARCINAS, M; BOXER, LM				ARCINAS, M; BOXER, LM			DIFFERENTIAL PROTEIN-BINDING TO THE C-MYC PROMOTER DURING DIFFERENTIATION OF HEMATOPOIETIC-CELL LINES	ONCOGENE			English	Article							LIGATION-MEDIATED PCR; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ZINC-FINGER PROTEIN; BURKITT-LYMPHOMA; CHROMATIN STRUCTURE; INDUCIBLE PROTEIN; DNA INTERACTIONS; HEAT-SHOCK; 1ST EXON	In vivo footprinting has been used to examine protein binding sites in the c-myc promoter during differentiation cell lines. The c-myc gene is proliferating cells, but c-myc levels decrease dramatically during differentiation. A number of potential protein binding sites have been identified from in vitro studies of the c-myc promoter, but very little is known about occupancy of these sites in vivo. We have identified in vivo footprints at DNase hypersensitive sites II2 and III1 which disappear during differentiation, while a footprint at site IV is present only in differentiated cells. Footprints at DNase hypersensitive sites I and II1 do not change with differentiation. A protected region near DNase hypersensitive site III2 is present in both undifferentiated and differentiated cells, but it extends further 5' in undifferentiated cells. From the protected sequences we have been able to identify candidate transcription factors likely to be involved in the control of c-myc expression. By electrophoretic mobility shift assay we have demonstrated that a protein binds to the sequence at site IV. We have also examined the 3' end of the first exon and the 5' end of intron I and do not find any evidence for protein binding sites in this region that was thought to be important for the block to transcription elongation during differentiation.	VET ADM MED CTR, CTR MOLEC BIOL MED, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER; NCI NIH HHS [CA34233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BORNKAMM GW, 1988, C MYC DEGREGULATION; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; CONKLIN KF, 1984, DNA METHYLATION; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FIBACH E, 1983, CANCER RES, V43, P4136; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LANG JC, 1991, ONCOGENE, V6, P2067; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; MOBERG KH, 1992, ONCOGENE, V7, P411; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PLET A, 1992, ONCOGENE, V7, P1847; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SALUZ HP, 1987, LABORATORY GUIDE GEN; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WANG ZY, 1992, BIOCHEM BIOPH RES CO, V188, P433, DOI 10.1016/0006-291X(92)92403-K; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WIJNHOLDS J, 1991, NUCLEIC ACIDS RES, V19, P33, DOI 10.1093/nar/19.1.33; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	62	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2699	2706						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058334				2022-12-28	WOS:A1994PC05400031
J	FRANCASTEL, C; GROISMAN, R; PFARR, CM; ROBERTLEZENES, J				FRANCASTEL, C; GROISMAN, R; PFARR, CM; ROBERTLEZENES, J			ANTISENSE C-JUN OVERCOMES A DIFFERENTIATION BLOCK IN A MURINE ERYTHROLEUKEMIA CELL-LINE	ONCOGENE			English	Article							ERYTHROID-DIFFERENTIATION; HEMOGLOBIN-SYNTHESIS; DOWN-REGULATION; PORPHOBILINOGEN DEAMINASE; RECEPTOR ACTIVITY; MYELOID-LEUKEMIA; GENE-EXPRESSION; CONTROL REGION; FOS PROTEINS; GLOBIN	We have studied the expression of the c-jun gene during dimethyl-sulfoxide (DMSO) induced differentiation of Friend erythroleukemia (F-MEL) cells. No expression of c-jun was detected in a differentiation-competent F-MEL cell line (745A) either before or after treatment with DMSO. By contrast, c-jun expression was constitutive in a F-MEL cell line (TFP10) resistant to DMSO-induced differentiation and increased with DMSO. We have investigated the possible role of c-jun in conferring this resistance by stably transfecting either sense or antisense c-jun constructs into both differentiation-sensitive 745A and defective TFP10 cell lines. Inhibition of c-jun expression by antisense transcripts in the TFP10 cells restored their ability to undergo erythroid differentiation when exposed to DMSO while expression of junB or junD antisense vectors failed to do so. In addition, c-jun overexpression in the 745A cells resulted in decreased DMSO-induced differentiation. These results indicate a correlation between the level of c-jun expression and the ability of F-MEL cells to undergo DMSO-induced differentiation and suggest that c-jun may be an important negative regulator in this process.	HOP PAUL BROUSSE,INSERM,U268,ONCOGENESE APPL LAB,F-94800 VILLEJUIF,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,CNRS,UA 1644,F-75724 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)			Pfarr, Curt/HHD-1410-2022; Francastel, Claire/AAI-4798-2021	Groisman, Regina/0000-0003-3990-7622; Francastel, Claire/0000-0002-6353-4320				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLOCH A, 1984, CANCER TREAT REP, V68, P199; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHERN YJ, 1991, BLOOD, V78, P991, DOI 10.1182/blood.V78.4.991.bloodjournal784991; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGLIATI T, 1993, ONCOGENE, V8, P1263; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FRANCASTEL C, 1992, LEUKEMIA, V6, P935; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GRANDCHAMP B, 1985, J BIOL CHEM, V260, P9630; HOUSSET M, 1982, BRIT J HAEMATOL, V51, P125, DOI 10.1111/j.1365-2141.1982.tb07297.x; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JEANNESSON P, 1984, ANTICANCER RES, V4, P47; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MARKS PA, 1987, CANCER RES, V47, P657; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MECHTA F, 1989, New Biologist, V1, P297; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROCHOWNIK EV, 1990, BLOOD, V76, P1830; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; ROBERTLEZENES J, 1988, CANCER RES, V48, P3972; RYSECK RP, 1991, ONCOGENE, V6, P533; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SARTORELLI AC, 1985, BRIT J CANCER, V52, P293, DOI 10.1038/bjc.1985.193; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRENTESAUX C, 1993, LEUKEMIA, V7, P452; TSIFTSOGLOU AS, 1985, ANTICANCER RES, V5, P81; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2	50	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1957	1964						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208542				2022-12-28	WOS:A1994NR68500020
J	CARBONE, M; PASS, HI; RIZZO, P; MARINETTI, MR; DIMUZIO, M; MEW, DJY; LEVINE, AS; PROCOPIO, A				CARBONE, M; PASS, HI; RIZZO, P; MARINETTI, MR; DIMUZIO, M; MEW, DJY; LEVINE, AS; PROCOPIO, A			SIMIAN-VIRUS 40-LIKE DNA-SEQUENCES IN HUMAN PLEURAL MESOTHELIOMA	ONCOGENE			English	Article							T-DELETION MUTANTS; GROWTH FACTOR-I; MALIGNANT MESOTHELIOMA; PROTEIN PHOSPHATASE-2A; ASBESTOS EXPOSURE; MINERAL FIBERS; TUMOR-ANTIGEN; SV40; CELLS; MECHANISMS	Mesotheliomas are pleural, pericardial, or peritoneal neoplasms frequently associated with asbestos exposure, and it is estimated that over the next twenty years up to 80,000 new cases are expected in the USA alone. We found simian virus 40-like DNA sequences in 29 of 48 mesotheliomas studied (60%) and demonstrated simian virus large-T antigen expression in 13 of 16 specimens. The matching lung samples did not contain simian virus 40-like sequences; however, they contained asbestos. These findings are to our knowledge the first demonstration of a physical link between DNA viruslike sequences and human mesothelioma. We suggest that a simian virus 40-like virus may act independently or as a co-carcinogen with asbestos. Moreover, the selective large T antigen expression by mesothelioma and not by the surrounding pulmonary parenchyma may have both diagnostic and therapeutic implications.	NCI, SURG BRANCH, THORAC ONCOL SECT, BETHESDA, MD 20892 USA; UNIV G DANNUNZIO, FAC MED, IST PATOL UMANA & MED SOCIALE, FISIOPATOL MOLEC LAB, I-66013 CHIETI, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); G d'Annunzio University of Chieti-Pescara	CARBONE, M (corresponding author), NICHHD, DNA REPLICAT REPAIR & MUTAGENESIS SECT, BLDG 6, ROOM 1A11, BETHESDA, MD 20892 USA.		Procopio, Antonio Domenico/AAB-2451-2021	Procopio, Antonio Domenico/0000-0001-6897-8724; Pass, Harvey/0000-0003-3222-3471; rizzo, paola/0000-0001-7174-9674				ANTMAN KH, 1993, CANC PRINCIPLES PRAC, P1489; APPEL JD, 1988, P NATL ACAD SCI USA, V85, P7670, DOI 10.1073/pnas.85.20.7670; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BROWN P, 1975, AM J EPIDEMIOL, V93, P291; BROWN RC, 1990, MOL ASPECTS MED, V11, P325, DOI 10.1016/0098-2997(90)90002-J; BUCHMAN AR, 1981, DNA TUMOR VIRUSES 2, P799; CARBONE M, 1992, J VIROL, V66, P1804, DOI 10.1128/JVI.66.3.1804-1808.1992; CARBONE M, 1989, CANCER RES, V49, P1565; CHURG A, 1993, MODERN PATHOL, V6, P509; CICALA C, 1993, AM J PATHOL, V142, P1524; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; CICALA C, 1994, IN PRESS J VIROL; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DOUGHERTY RM, 1976, J GEN VIROL, V33, P61, DOI 10.1099/0022-1317-33-1-61; Dubes G. R., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P185; EDDY BE, 1961, P SOC EXP BIOL MED, V107, P191; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FISHER W, 1931, HDB SPEZIELLEN PATHO, V3, P509; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; GERBER P, 1962, VIROLOGY, V18, P582, DOI 10.1016/0042-6822(62)90061-2; GERBER P, 1967, P SOC EXP BIOL MED, V125, P1284, DOI 10.3181/00379727-125-32336; HENDERSON DW, 1992, CANCER SERIES, P183; Henderson DW, 1992, MALIGNANT MESOTHELIO, P69; JAURAND MC, 1987, J NATL CANCER I, V79, P797; KE Y, 1989, AM J PATHOL, V134, P979; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; LANPHEAR BP, 1992, J OCCUP ENVIRON MED, V34, P718; LEE TC, 1993, CANCER RES, V53, P2858; LEWIS AM, 1985, SCIENCE, V227, P15, DOI 10.1126/science.3843807; LEWIS AM, 1979, P NATL ACAD SCI USA, V76, P4299, DOI 10.1073/pnas.76.9.4299; LEWIS AM, 1973, BIOHAZARDS BIOL RES, P96; Mallory TB, 1947, NEW ENGL J MED, V236, P407; MARK EJ, 1991, ANN NY ACAD SCI, V643, P196, DOI 10.1111/j.1749-6632.1991.tb24463.x; MAYOL X, 1993, ONCOGENE, V8, P2561; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MEW D, 1993, CONT ONCOLOGY, V3, P50; MORRIS JA, 1961, P SOC EXP BIOL MED, V108, P56, DOI 10.3181/00379727-108-26843; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; MUSCAT JE, 1991, CANCER RES, V51, P2263; PASS HI, 1993, CURR PROB SURG, V30, P925; PETERSON JT, 1984, CANCER, V54, P951, DOI 10.1002/1097-0142(19840901)54:5<951::AID-CNCR2820540536>3.0.CO;2-A; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RABSON AS, 1962, J NATL CANCER I, V29, P1123; REDDEL RR, 1989, J NATL CANCER I, V81, P945, DOI 10.1093/jnci/81.12.945; RESNICOFF M, IN PRESS J CANCER RE; ROGGLI VL, 1992, PATHOLOGY ASBESTOS A, P383; ROGGLI VL, 1992, PATHOLOGY ASBESTOS A, P109; ROGGLI VL, 1992, CANC SERIES, P201; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SELIKOFF IJ, 1980, CANCER, V46, P2736, DOI 10.1002/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SHAH KV, 1972, J NATL CANCER I, V48, P557; SHAH KV, 1971, AM J EPIDEMIOL, V93, P291, DOI 10.1093/oxfordjournals.aje.a121260; SHEIN HM, 1962, P NATL ACAD SCI USA, V48, P1164, DOI 10.1073/pnas.48.7.1164; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; SWEET BH, 1960, P SOC EXP BIOL MED, V105, P420, DOI 10.3181/00379727-105-26128; Topp WC, 1981, DNA TUMOR VIRUSES 2, P205; WAGNER J C, 1960, Br J Ind Med, V17, P260; WALSH JW, 1982, NEUROSURGERY, V10, P643, DOI 10.1227/00006123-198205000-00018; Weissmann L B, 1989, Oncology (Williston Park), V3, P67; WEITZMAN SA, 1984, ARCH BIOCHEM BIOPHYS, V228, P373, DOI 10.1016/0003-9861(84)90078-X; Willis RA, 1938, J PATHOL BACTERIOL, V47, P35, DOI 10.1002/path.1700470105; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YEUNG RS, 1993, ONCOGENE, V8, P3465	68	382	384	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1781	1790						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183577				2022-12-28	WOS:A1994NL81500034
J	DELGADO, MD; HALLIER, M; MENECEUR, P; TAVITIAN, A; MOREAUGACHELIN, F				DELGADO, MD; HALLIER, M; MENECEUR, P; TAVITIAN, A; MOREAUGACHELIN, F			INHIBITION OF FRIEND-CELLS PROLIFERATION BY SPI-1 ANTISENSE OLIGODEOXYNUCLEOTIDES	ONCOGENE			English	Note							ETS GENE FAMILY; VIRUS-INDUCED ERYTHROLEUKEMIA; PUTATIVE ONCOGENE SPI-1; WILD-TYPE P53; TRANSCRIPTION FACTOR; C-MYB; ERYTHROPOIETIN RECEPTOR; OLIGOMER COMPLEMENTARY; TUMORIGENIC CELLS; LEUKEMIA-VIRUS	The spi-1 proto-oncogene encodes the transcription factor PU.1 which is normally expressed in all hematopoietic cell lineages except in T cell lines. During the murine acute erythroleukemia induced by the Friend retrovirus, SFFV, spi-1 deregulation by insertional mutagenesis results in the overexpression of Spi-1/PU.1 in the malignant proerythroblastic cell. To assess the Spi-1 role in the proliferation and the differentiation arrest of the Friend tumor cells we inhibited spi-1 gene expression in two Friend cell lines by using antisense oligodeoxyribonucleotides. Proliferation and cloning efficiency of both cell lines were significantly inhibited by spi1 antisense. This antiproliferative effect was not related to an apparent maturation of erythroleukemic cells demonstrating that repression of spi-1 expression is not sufficient per se to restore the ability of the proerythroblastic cells to spontaneously differentiate in mature erythroblasts. These data suggest that the spi-1 gene would be involved in the Friend leukemic process by promoting the proerythroblast to proliferate.	FAC MED PARIS,INSERM,U248,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Delgado, M. Dolores/K-9056-2014	Delgado, M. Dolores/0000-0003-4682-4040				ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOWARD JC, 1993, ONCOGENE, V8, P2721; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SHEN DW, 1983, P NATL ACAD SCI-BIOL, V80, P5919, DOI 10.1073/pnas.80.19.5919; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKESHITA K, 1993, P NATL ACAD SCI USA, V90, P3535, DOI 10.1073/pnas.90.8.3535; WANG YL, 1993, J VIROL, V67, P1322, DOI 10.1128/JVI.67.3.1322-1327.1993; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	43	45	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1723	1727						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183568				2022-12-28	WOS:A1994NL81500025
J	BEG, AA; BALDWIN, AS				BEG, AA; BALDWIN, AS			ACTIVATION OF MULTIPLE NF-KAPPA-B/REL DNA-BINDING COMPLEXES BY TUMOR-NECROSIS-FACTOR	ONCOGENE			English	Note							B P50; SUBUNIT; REL; TRANSCRIPTION; PRECURSOR; PRODUCT; GENE; P65	NF-kappa B is an inducible transcription factor that regulates the expression of numerous genes involved in immune and inflammation responses and in cellular growth control. Typically, NF-kappa B is localized in the cytoplasm complexed with members of the I kappa B family. The most well characterized form of NF-kappa B is comprised of a heterodimer of a 50 kD (p50/NFKB1) and a 65 kD (p65/RelA) protein. This heterodimeric protein was thought to be primarily responsible for transcriptional regulation of target genes. However, recent studies have led to the identification of other kappa B binding proteins such as c-Rel, RelB and p52 (NFKB2/lyt-10) although their role in gene regulation has been less clear. Here, using gel mobility shift assays as well as a highly sensitive DNA-protein crosslinking assay, we provide evidence for the existence of multiple tumor necrosis factor (TNF)inducible kappa B binding complexes containing various members of the NF-kappa B/Rel family, namely p50 and p65 as well as the c-Rel and p52 oncoproteins. Dimeric complexes containing various combinations of these proteins appear rapidly in nuclei of TNF-alpha-stimulated cells and include, along with a p50-p65 heterodimer, p50-c-Rel, p65-c-Rel, p52-c-Rel and p52-p65 complexes. The presence of multiple inducible complexes containing distinct combinations of NF-kappa B/Rel family members indicate that specific kappa B responsive genes may be regulated in an NF-kappa B subunit-dependent manner.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA52515] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SPRINGER TA, 1989, CURRENT PROTOCOLS MO, V2; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	25	58	63	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1487	1492						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152812				2022-12-28	WOS:A1994NH40100023
J	ZHU, GC; DECKER, SJ; MACLEAN, D; MCNAMARA, DJ; SINGH, J; SAWYER, TK; SALTIEL, AR				ZHU, GC; DECKER, SJ; MACLEAN, D; MCNAMARA, DJ; SINGH, J; SAWYER, TK; SALTIEL, AR			SEQUENCE SPECIFICITY IN THE RECOGNITION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR BY THE ABL SRC-HOMOLOGY-2 DOMAIN	ONCOGENE			English	Article							C-ABL; ONCOGENE PRODUCT; TYROSINE KINASES; PHOSPHOLIPASE-C; ABELSON VIRUS; CELL-LINE; PROTEINS; BINDING; SH2; TRANSFORMATION	The transforming activity of the abl gene product requires a functional src homology 2 (SH2) domain. An assay was developed to evaluate this function by examining binding of a bacterially-expressed abl SH2 domain to the activated EGF receptor, used as a surrogate tyrosine phosphorylated protein. The sequence specificity of this interaction has been explored with a series of point mutants of EGF receptor. Analysis of equilibrium binding reveals that substitution of Tyr(1086) for Phe in the EGF receptor produced a 10-fold reduced affinity for abl SH2 domain binding as compared to the wildtype receptor. Moreover, a phosphorylated peptide modeled on the sequences surrounding Tyr(1086) specifically inhibits abl SH2 binding, with an IC50 of approximately 10 mu M. Evaluation of a series of additional peptides, modeled on the Tyr(1086) sequence, revealed that the carboxy terminal residues directly next to the phosphotyrosine were particularly critical to this binding. Molecular modeling studies of the pTyr(1086) peptide revealed the potential hydrophobic, ionic and hydrogen bonding interactions involved in the functions of the abl SH2 domain.	WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT CHEM, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT MICROBIOL, ANN ARBOR, MI 48109 USA	Pfizer; Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HOLM L, 1992, PROTEINS, V14, P213, DOI 10.1002/prot.340140208; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATUDA M, 1990, SCIENCE, V248, P1537; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MITCHELL JBO, 1993, J CHEM SOC FARADAY T, V89, P2619, DOI 10.1039/ft9938902619; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; Saltiel A R, 1993, Curr Opin Neurobiol, V3, P352, DOI 10.1016/0959-4388(93)90128-L; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU G, 1993, J BIOL CHEM, V266, P12964; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	32	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1379	1385						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152798				2022-12-28	WOS:A1994NH40100009
J	FUJIMOTO, J; YAMAMOTO, T				FUJIMOTO, J; YAMAMOTO, T			BRT, A MOUSE GENE ENCODING A NOVEL RECEPTOR-TYPE PROTEIN-TYROSINE KINASE, IS PREFERENTIALLY EXPRESSED IN THE BRAIN	ONCOGENE			English	Article							MOLECULAR-CLONING; LEUKEMIA-CELLS; W-LOCUS; FAMILY; DOMAINS; ONCOGENE; SEQUENCE	Using polymerase chain reaction (PCI)-mediated cloning procedure, we have isolated a novel gene encoding protein-tyrosine kinase from fetal mouse brain. This gene, named brt (from brain tyrosine kinase), had an open reading frame that encoded 856 amino acids. The deduced amino acid sequence revealed that the gene product had all the hallmarks of a receptor-type protein-tyrosine kinase. The brt protein showed significant homology to the axl/ufo protein that has an oncogenic potential. Northern blot analysis showed that but was expressed preferentially in the brain of both embryo and adult. Thus, brt is a new member of the subfamily of receptor-type protein-tyrosine kinases and is suggested to play important roles in development and functions in the central nervous system.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,TOKYO 108,JAPAN	University of Tokyo								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BASLER K, 1988, TRENDS GENET, V4, P74, DOI 10.1016/0168-9525(88)90044-3; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAUST M, 1992, ONCOGENE, V7, P1287; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KELMANZ, 1993, ONCOGENE, V8, P37; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MARCELLE C, 1992, ONCOGENE, V7, P2479; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ AS, 1993, ONCOGENE, V8, P509; SHIBUYA M, 1990, ONCOGENE, V5, P519; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SUDOL M, 1993, ONCOGENE, V8, P823; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237	32	69	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					693	698						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108111				2022-12-28	WOS:A1994MW55100003
J	PARK, DJ; WILCZYNSKI, SP; PAQUETTE, RL; MILLER, CW; KOEFFLER, HP				PARK, DJ; WILCZYNSKI, SP; PAQUETTE, RL; MILLER, CW; KOEFFLER, HP			P53 MUTATIONS IN HPV-NEGATIVE CERVICAL-CARCINOMA	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; POLYMERASE CHAIN-REACTION; TUMOR SUPPRESSOR GENE; CELL LUNG-CANCER; DNA; ASSOCIATION; EXPRESSION; SEQUENCE; LINES; TRANSCRIPTION	Human papillomavirus (HPV) infection has been strongly linked to the development of cervical carcinoma. Two viral oncoproteins, E6 and E7, produced by HPV, have been shown to immortalize primary human genital epithelial cells by interacting with the protein products of cellular tumor suppressor genes p53 and Rb, respectively. E6 binds to the cellular p53 protein promoting p53 degradation and inactivity. This mechanism has been suggested to contribute to the oncogenesis of HPV-positive anogential cancers. In HPV-negative cervical carcinoma, p53 mutation is thought to be the possible mechanism of oncogenesis. We have studied 257 cervical carcinoma specimens for HPV infection by Southern blot analysis and polymerase chain reaction (PCR). Of 257 samples, 39 were HPV-negative. We have further studied 21 HPV-negative specimens for p53 mutations utilizing PCR amplification of genomic DNA followed by single-stranded conformation polymorphism (SSCP) analysis and DNA sequencing. We found only two missense point mutations of p53 gene. In summary, although inactivation of p53 mediated either by E6 or by mutations may be an important key step in the development of cervical carcinoma, our study suggests that other mechanisms may also be involved in development of cervical cancer.	CITY HOPE NATL MED CTR, DEPT PATHOL, DUARTE, CA 91010 USA	City of Hope	PARK, DJ (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, CEDARS SINAI MED CTR, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90048 USA.				NCI NIH HHS [CA42710, CA32737] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710, P30CA042710, P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKIN NB, 1989, CANCER GENET CYTOGEN, V37, P229, DOI 10.1016/0165-4608(89)90053-8; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLOSS JD, 1991, HUM PATHOL, V22, P711, DOI 10.1016/0046-8177(91)90294-Y; BORRESEN AL, 1992, LANCET, V339, P1350; BUSBYEARLE RMC, 1992, LANCET, V339, P1350, DOI 10.1016/0140-6736(92)91993-I; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, ONCOGENE, V6, P873; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUJITA M, 1992, CANCER RES, V52, P5323; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hayashi K, 1991, PCR Methods Appl, V1, P34; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLY EA, 1986, J NATL CANCER I, V76, P983; Hoskins WJ, 1989, CANC PRINCIPLES PRAC, P1099; HOWLEY PM, 1991, CANCER RES, V51, pS5019; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MANOS MM, 1989, CANCER CEL, V7, P209; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLER CW, 1992, CANCER RES, V52, P1695; MUNGER K, 1989, J VIROL, V63, P4417; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAQUETTE RL, 1993, CANCER-AM CANCER SOC, V72, P1272, DOI 10.1002/1097-0142(19930815)72:4<1272::AID-CNCR2820720420>3.0.CO;2-Q; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WERNESS BA, 1991, IMPORTANT ADV ONCOLO, P2; WILCZYNSKI SP, 1988, HUM PATHOL, V19, P697, DOI 10.1016/S0046-8177(88)80176-X; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	49	82	82	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					205	210						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302581				2022-12-28	WOS:A1994MW24700025
J	BOLEN, JB				BOLEN, JB			NONRECEPTOR TYROSINE PROTEIN-KINASES	ONCOGENE			English	Review							CELL ANTIGEN RECEPTOR; EXPRESS HIGH-LEVELS; C-ABL; SRC-FAMILY; SIGNAL TRANSDUCTION; TRANSFORMING PROTEIN; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; CATALYTIC DOMAINS; MOLECULAR-CLONING				BOLEN, JB (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA.							APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EISEMAN E, 1992, NATURE, V355, P78; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOWE C, 1993, IN PRESS P NATL ACAD; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MATHEYPREVOT B, 1982, CELL, V28, P897, DOI 10.1016/0092-8674(82)90069-1; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OVERDUIN M, 1992, P NATL ACAD SCI USA, V89, P11673, DOI 10.1073/pnas.89.24.11673; PARTANEN J, 1991, ONCOGENE, V6, P2013; PAWSON T, 1988, ONCOGENE, V3, P491; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RESH MD, 1990, ONCOGENE, V5, P1437; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SEFTON BM, 1991, ONCOGENE, V6, P683; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TOSHIHIKO T, 1992, BLOOD, V80, P617; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WILKS AF, 1988, ONCOGENE, V3, P289; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	101	217	378	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2025	2031						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336932				2022-12-28	WOS:A1993LP17100001
J	HERMANN, T; HOFFMANN, B; PIEDRAFITA, FJ; ZHANG, XK; PFAHL, M				HERMANN, T; HOFFMANN, B; PIEDRAFITA, FJ; ZHANG, XK; PFAHL, M			V-ERBA REQUIRES AUXILIARY PROTEINS FOR DOMINANT NEGATIVE ACTIVITY	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; ACID-RESPONSIVE ELEMENT; DNA-BINDING DOMAIN; RETINOIC-ACID; C-ERBA; CELL-TRANSFORMATION; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; ALPHA-MYOSIN	The avian v-erbA protein is an important example of a dominant negative oncogene. It has been identified as a highly mutated form of its cellular homolog, the thyroid hormone receptor alpha (TR-alpha), and its biological activity has been correlated with its repressor function on certain receptor-regulated genes. Although v-erbA has lost the hormone responsiveness of its cellular homolog, it has retained DNA-binding activity, and it has been implied that this function is required for repression and transformation. Here we demonstrate that v-erbA forms heterodimers with the retinoid X receptor (RXR-alpha). Only heteromeric v-erbA-RXR-alpha complexes show DNA-binding strong enough to account for its potent repressor function. In addition, v-erbA-RXR-alpha heterodimers specifically bind natural thyroid hormone-responsive elements (TREs) but not retinoic acid-responsive elements (RAREs). Repression of TRE-controlled gene expression by v-erbA requires the presence of RXR-alpha with the natural TREs tested. In contrast, natural RAREs investigated here do not bind the v-erbA-RXR-alpha heterodimer and also are not significantly repressed by v-erbA. Carboxy-terminal mutations that abolish verbA-RXR-alpha heterodimer formation also abolish v-erbA repressor activity. These data suggest that interaction of v-erbA with RXRs or similar auxiliary receptors is essential for the dominant negative activity of the v-erbA oncogene.	LA JOLLA CANC RES FDN, CANC RES CTR, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035083] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35083] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, J MOL ENDOCRINOL, V4, P1734; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; ROSEN ED, 1991, MOL CELL ENDOCRINOL, V78, pC83, DOI 10.1016/0303-7207(91)90175-R; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	76	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					55	65						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8093812				2022-12-28	WOS:A1993KN00500007
J	SCHULZE, A; ZERFASS, K; SPITKOVSKY, D; HENGLEIN, B; JANSENDURR, P				SCHULZE, A; ZERFASS, K; SPITKOVSKY, D; HENGLEIN, B; JANSENDURR, P			ACTIVATION OF THE E2F TRANSCRIPTION FACTOR BY CYCLIN D1 IS BLOCKED BY P16(INK4), THE PRODUCT OF THE PUTATIVE TUMOR-SUPPRESSOR GENE MTS1	ONCOGENE			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; FIBROBLASTS; G(1); SITE; IDENTIFICATION; OVEREXPRESSION; PROGRESSION; INHIBITION	The oncoprotein cyclin D1 binds to and activates cyclin-dependent kinase 4 (cdk4), whose activity is inhibited by p16(INK4), the product of the putative tumor suppressor gene MTS1. Cyclin D1 controls the timing of S phase onset in mammalian cells. We show that cyclin D1 acts as a positive regulator of the transcription factor E2F. In particular, cyclin D1 overexpression leads to the activation of the dihydrofolate reductase (DHFR) gene promoter. Activation depends on the E2F binding site in the DHFR promoter, known to mediate its activation at the G1/S transition in vivo. Cyclin D1 can also activate the adenovirus E2 promoter via E2F. Both promoters are repressed by p16(INK4) and this repression can be released by overexpression of cdk4. The data reported here support a direct role for cyclin D1 and its associated kinase in cell cycle regulation of E2F activity and S phase-specific gene expression. In addition, we show that both E2F sites bind complexes containing the retinoblastoma protein (pRB) and that in RB-deficient cell lines overexpression of cyclin D1 fails to activate E2F-dependent transcription, indicating that pRB may be involved in promoter activation.	DEUTSCH KREBSFORSCHUNGSZENTRUM, FORSCHUNGSSCHWERPUNKT ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY; CNRS, CTR GENET MOLEC, F-91190 GIF SUR YVETTE, FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Jansen-Dürr, Pidder/ABG-2466-2020; Schulze, Almut/AAX-8257-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Schulze, Almut/0000-0002-8199-6422				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; BOEUF H, 1990, ONCOGENE, V5, P691; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARPER JW, 1993, CELL, V75, P805; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LOVEC H, 1994, ONCOGENE, V9, P323; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1992, ONCOGENE, V7, P1681; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WIMMEL A, 1994, ONCOGENE, V9, P995; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	36	60	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3475	3482						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970707				2022-12-28	WOS:A1994PT39200009
J	ADACHI, M; MIYACHI, T; SEKIYA, M; HINODA, Y; YACHI, A; IMAI, K				ADACHI, M; MIYACHI, T; SEKIYA, M; HINODA, Y; YACHI, A; IMAI, K			STRUCTURE OF THE HUMAN LC-PTP (HEPTP) GENE - SIMILARITY IN GENOMIC ORGANIZATION WITHIN PROTEIN-TYROSINE-PHOSPHATASE GENES	ONCOGENE			English	Note							MOLECULAR-CLONING; PHOSPHOTYROSINE PHOSPHATASE; SEQUENCE SIMILARITY; MOTH-EATEN; EXPRESSION; MUTATIONS; DOMAINS; KINASES; FAMILY; EXONS	Recently, various cDNA sequences coding protein-tyrosine phosphatases (PTPs) have been reported and their extensive similarities in the catalytic domains clarified, but knowledge of the structures and organizations of their genes is still limited. In this study, a detailed structure and organization of the human intracellular LC-PTP (also called HePTP) gene is reported. The 13 to 18.5 kb genomic clones encoding human LC-PTP have been isolated. The LC-PTP gene is organized into 11 exons, including the 5'-noncoding first exon and the 3'-noncoding exon. Splicing sites for exons 4 to 10, which encode the conserved catalytic PTP domain, arise almost at the same position as for the CD45 gene. This elucidation of the LC-PTP gene structure provides insight into the domain evolution of intracellular LC-PTP and transmembrane CD45, which may be generated by gene duplications of an ancestral gene.			ADACHI, M (corresponding author), SAPPORO MED UNIV,SCH MED,DEPT INTERNAL MED 1,SAPPORO,JAPAN.							ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ADACHI M, 1992, CANCER RES, V52, P737; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; ADACHI M, 1994, FEBS LETT, V338, P47, DOI 10.1016/0014-5793(94)80114-2; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GOKKEL E, 1992, ONCOGENE, V7, P1423; HALL LR, 1988, J IMMUNOL, V141, P2781; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ISOBE M, 1994, ONCOGENE, V9, P1751; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAI C, 1994, ONCOGENE, V9, P877; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	31	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3031	3035						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084610				2022-12-28	WOS:A1994PG82200033
J	HUPPI, K; SIWARSKI, D; DOSIK, J; MICHIELI, P; CHEDID, M; REED, S; MOCK, B; GIVOL, D; MUSHINSKI, JF				HUPPI, K; SIWARSKI, D; DOSIK, J; MICHIELI, P; CHEDID, M; REED, S; MOCK, B; GIVOL, D; MUSHINSKI, JF			MOLECULAR-CLONING, SEQUENCING, CHROMOSOMAL LOCALIZATION AND EXPRESSION OF MOUSE P21 (WAF1)	ONCOGENE			English	Note							GENE; INHIBITOR; PROTEIN; KINASES	The recent discovery that expression of Waf1 (p21), an inhibitor of cyclin-dependent kinases, is induced by the tumor suppressor p53 provides an important linkage between growth suppression and the cell cycle. We report here the cloning and sequencing of a mouse p21 cDNA that contains the entire coding region. Hybridization of the mouse p21 probe in Southern blot analyses confirms that p21 is a single-copy gene and that the corresponding locus, Waf1, lies proximal to H-2 on mouse chromosome 17. In northern analyses, the expression of p21 is found in most normal mouse tissues, but a surprising lack of correlation is found. between mRNA levels of p21 and p53. In order to determine which regions of p21 are most evolutionarily conserved, we have compared the cDNA sequences for the entire p21 coding region in 13 different mouse strains or species and the human p21 sequence. We conclude that two regions (corresponding to human codons 21-60 and 130-164) are strongly conserved in p21 and that these regions may represent domains that are especially critical to a functional p21 protein.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HUPPI, K (corresponding author), NCI, GENET LAB, BLDG 37, BETHESDA, MD 20892 USA.		Mock, Beverly A/B-3110-2015; Michieli, Paolo/A-2588-2011	Mock, Beverly A/0000-0003-2479-4549; Michieli, Paolo/0000-0002-3093-8871				CHEDID M, 1994, ONCOGENE, V9, P3021; DIETRICH W, 1992, GENETICS, V131, P423; DOSIK JK, IN PRESS MAMMALIAN G; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HARPER JW, 1993, CELL, V75, P805; HIMMELBAUER H, 1993, MAMM GENOME, V4, pS230, DOI 10.1007/BF00360843; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUPPI K, 1993, INT J CANCER, V53, P493, DOI 10.1002/ijc.2910530323; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; MOCK BA, 1993, MAMM GENOME, V4, P461, DOI 10.1007/BF00296823; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUSSI T, 1990, ONCOGENE, V5, P945; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	18	93	95	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3017	3020						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084607				2022-12-28	WOS:A1994PG82200030
J	METTUS, RV; LITVIN, J; WALI, A; TOSCANI, A; LATHAM, K; HATTON, K; REDDY, EP				METTUS, RV; LITVIN, J; WALI, A; TOSCANI, A; LATHAM, K; HATTON, K; REDDY, EP			MURINE A-MYB - EVIDENCE FOR DIFFERENTIAL SPLICING AND TISSUE-SPECIFIC EXPRESSION	ONCOGENE			English	Article							DNA-BINDING DOMAIN; C-MYB; B-MYB; NUCLEOTIDE-SEQUENCE; ONCOGENE ACTIVATION; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; CELL-DIFFERENTIATION; FUNCTIONAL DOMAINS; MYELOID-LEUKEMIA	The myb gene family consists of three members, A-myb, B-myb and c-myb. The proteins encoded by these genes bind DNA in a sequence-specific manner and regulate transcription of target genes. In this communication, we report the nucleotide sequence of murine A-myb cDNA. This gene encodes a protein of 751 amino acids with an estimated molecular weight of 83 kDa. cDNA sequence analysis of multiple independent cDNA clones reveals the presence of alternatively spliced mRNAs that encode smaller proteins. Northern blot analysis of adult mouse tissue RNAs reveals A-myb expression predominantly in the testis, with very low levels of expression in the ovaries, spleen and brain. In situ hybridization analysis of adult mouse testis shows that this gene is expressed at high levels in type A spermatogonia (stem cells), and preleptotene and pachytene spermatocytes, with concomitant downregulation of expression upon terminal differentiation of these cells into mature spermatozoa. This pattern of expression suggests that A-myb is involved in the control of proliferation and differentiation of spermatogonia. This potential function of A-myb in spermatogenesis is reminiscent of the role of c-myb in hematopoiesis.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [5-P30-CA12227, CA-52009] Funding Source: Medline; NIGMS NIH HHS [GM49489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009, P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AUER KH, 1987, EMBO J, V6, P2719; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BIDENKAPP H, 1988, NATURE, V355, P835; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1994, ONCOGENE, V9, P2469; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; LAM EWF, 1992, ONCOGENE, V7, P1885; MCMAHON J, 1988, ONCOGENE, V3, P717; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PAULES RS, 1988, ONCOGENE, V3, P59; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; Russel D. L., 1990, HISTOLOGICAL HISTOPA; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILLIAMS DL, 1987, BIOTECHNIQUES, V5, P718; ZAKERI ZF, 1988, DEV BIOL, V125, P417, DOI 10.1016/0012-1606(88)90222-9	43	73	75	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3077	3086						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084617				2022-12-28	WOS:A1994PG82200041
J	DALY, RJ; BINDER, MD; SUTHERLAND, RL				DALY, RJ; BINDER, MD; SUTHERLAND, RL			OVEREXPRESSION OF THE GRB2 GENE IN HUMAN BREAST-CANCER CELL-LINES	ONCOGENE			English	Note							EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; MITOGENIC SIGNAL TRANSDUCTION; RETINOIC ACID RECEPTOR; PHOSPHOLIPASE-C; ADAPTER PROTEIN; TRANSGENIC MICE; EGF RECEPTOR; NUCLEOTIDE EXCHANGE; EXPRESSION CLONING	A receptor blotting technique was used to detect SH2 domain containing epidermal growth factor receptor (EGFR) substrates that exhibited differential expression either between normal breast epithelial cells and breast cancer cells or between different human breast cancer cell lines. This identified a 25 kD protein, subsequently identified as Grb2, which was markedly overexpressed in three breast cancer cell lines (MCF-7, MDA-MB-361 and -453) relative to both normal breast epithelial cells and the majority of breast cancer cell lines. Northern blot analysis revealed that 7/19 breast cancer cell lines exhibited more than twofold overexpression of Grb2 mRNA, with overexpression correlating with high expression of erbB receptors. In MCF-7, MDA-MB-361 and -453 cells the overexpression of Grb2 mRNA and protein was accompanied by a small amplification of the Grb2 gene locus. Overexpression of Grb2 correlated with increased complex formation between Grb2 and the hSos-1 Ras GDP-GTP exchange protein. This upregulation of the Ras signalling pathway might modulate the growth factor sensitivity of human breast cancer cells and therefore play a role in tumour progression.			DALY, RJ (corresponding author), ST VINCENTS HOSP,GARVAN INST MED RES,DIV CANC BIOL,DARLINGHURST,NSW 2010,AUSTRALIA.		Sutherland, Robert L/A-8378-2008; Daly, Roger J/C-8179-2009	Binder, Michele/0000-0002-4494-6717; Daly, Roger/0000-0002-5739-8027				ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BOS JL, 1989, CANCER RES, V49, P4682; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUCKLEY MF, 1993, ONCOGENE, V8, P5127; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DICKSON RB, 1988, GROWTH FACTORS ONCOG, P119; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FRIEDMAN E, 1993, NAT GENET, V5, P242, DOI 10.1038/ng1193-242; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; HARLOW E, 1988, ANTIBODIES LABORATOR; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KOGA M, 1990, CANCER RES, V50, P4849; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAINSBURY JRC, 1987, LANCET, V1, P1398; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500	47	92	98	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2723	2727						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058337				2022-12-28	WOS:A1994PC05400034
J	HICKMAN, ES; PICKSLEY, SM; VOUSDEN, KH				HICKMAN, ES; PICKSLEY, SM; VOUSDEN, KH			CELLS EXPRESSING HPV16 E7 CONTINUE CELL-CYCLE PROGRESSION FOLLOWING DNA-DAMAGE INDUCED P53 ACTIVATION	ONCOGENE			English	Article							WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; SUSCEPTIBILITY GENE; DEPENDENT KINASES; ADENOVIRUS E1A; TUMOR-ANTIGEN; GROWTH ARREST; BINDING-SITE; PROTEIN	Stabilisation and activation of p53 contributes to the G1 arrest exhibited by many cells in response to DNA damage. One function of p53 is the transcriptional activation of an inhibitor of cyclin dependent kinases; enzymes which phosphorylate and inactivate the growth inhibitory function of the pRB tumour suppressor protein. In this study we show that expression of either of the human papillomavirus encoded E6 and E7 oncoproteins allows cell cycle progression following DNA damage. This suggests that both viral proteins can function in the same pathway; E6 by directly targeting p53 for degradation and E7 through the interaction with pRB, one of the potential downstream effecters of p53.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CRC,CELL TRANSFORMAT GRP,DUNDEE DD1 4HN,SCOTLAND	Imperial College London; Ludwig Institute for Cancer Research; University of Dundee								BANKS L, 1990, ONCOGENE, V5, P1383; BARTEK J, 1992, ONCOGENE, V7, P101; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CASEY G, 1991, ONCOGENE, V6, P1791; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON N, 1994, IN PRESS ONCOGENE; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRIS JDH, 1993, ONCOGENE, V8, P892; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1994, IN PRESS ONCOGENE; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TOMMASINO M, 1993, ONCOGENE, V8, P195; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILKINSON D, 1988, J EXP MED, V167, P1442, DOI 10.1084/jem.167.4.1442; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	58	102	105	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2177	2181						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036003				2022-12-28	WOS:A1994NX62900008
J	GUJULUVA, CN; BAEK, JH; SHIN, KH; CHERRICK, HM; PARK, NH				GUJULUVA, CN; BAEK, JH; SHIN, KH; CHERRICK, HM; PARK, NH			EFFECT OF UV-IRRADIATION ON CELL-CYCLE, VIABILITY AND THE EXPRESSION OF P53, GADD153 AND GADD45 GENES IN NORMAL AND HPV-IMMORTALIZED HUMAN ORAL KERATINOCYTES	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENES; DNA-DAMAGING AGENTS; WILD-TYPE P53; HUMAN PAPILLOMAVIRUS; GROWTH ARREST; PROTEIN; CARCINOGENESIS; TRANSFORMATION; PARTICIPATION; INITIATION	We previously demonstrated neoplastic conversion of HPV-immortalized human oral keratinocytes by exposing cells to chemical carcinogens, but failed to transform normal human oral keratinocytes with same chemical carcinogens in vitro. Though the reason for different responses of normal and HPV-immortalized oral keratinocytes to chemical carcinogens remains speculative, the difference may be due to the capacity of normal cells and incapacity of HPV-immortalized cells for repairing damaged DNA induced by carcinogens, Since (1) the repair of damaged DNA takes place in G(1)/G(2) phases of cell cycle, (2) wild type p53 plays major role in the induction of transient G(1) and/or G(2) arrests, and (3) the expression of gadd45 and gadd153 is also associated with the cell cycle arrest and DNA damage, we investigated transient cell cycle arrest and the expression of p53, gadd45 and gadd153 in normal human oral keratinocytes, HPV-immortalized oral keratinocytes, and an oral cancer cell line expressing mutant p53 after exposing cells to UV light. Normal cells demonstrated transient G(1) arrest after exposure to UV light, but other tested cells did not. While UV-irradiation significantly increased the level of intranuclear wild type p53 protein in normal cells, it did not alter p53 protein levels in HPV-immortalized and oral cancer cells. The level of gadd45 transcripts was enhanced in all tested cells, but normal cells demonstrated higher increase in the level of gadd45 after UV-exposure compared to other tested cells. The level of gadd153 gene transcripts was only increased in normal oral keratinocytes after UV-irradiation. These data indicate that UV-induced transient G(1) arrest in normal oral keratinocytes may be associated with both enhanced levels of intranuclear wild type p53 protein and gadd45 and gadd153 transcripts.	UNIV CALIF LOS ANGELES,SCH DENT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010049] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE 10049] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDIERY WS, 1993, CELL, V75, P817; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIM MS, 1993, ANTICANCER RES, V13, P1405; KIM MS, 1993, CANCER RES, V53, P4811; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI SL, 1992, CARCINOGENESIS, V13, P1981, DOI 10.1093/carcin/13.11.1981; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MIN BM, 1994, IN PRESS ORAL ONCOL; MULLAART E, 1990, MUTAT RES, V237, P189, DOI 10.1016/0921-8734(90)90001-8; NAGANO T, 1993, ARCH DERMATOL, V129, P1157, DOI 10.1001/archderm.129.9.1157; NAQUI A, 1986, ANNU REV BIOCHEM, V55, P137, DOI 10.1146/annurev.biochem.55.1.137; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SAKAI E, 1992, ONCOGENE, V7, P927; SCHAFFNER M, 1990, CELL, V63, P1129; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	40	99	103	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1819	1827						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208528				2022-12-28	WOS:A1994NR68500003
J	FENG, GS; SHEN, R; HENG, HHQ; TSUI, LC; KAZLAUSKAS, A; PAWSON, T				FENG, GS; SHEN, R; HENG, HHQ; TSUI, LC; KAZLAUSKAS, A; PAWSON, T			RECEPTOR-BINDING, TYROSINE PHOSPHORYLATION AND CHROMOSOME LOCALIZATION OF THE MOUSE SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE SYP	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; HEMATOPOIETIC-CELL PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; MOTH-EATEN MICE; SH2 DOMAIN; AUTOPHOSPHORYLATION SITES; SEQUENCE SIMILARITY; SIGNAL TRANSDUCTION	The murine phosphotyrosine phosphatase, Syp, is a widely-expressed cytoplasmic enzyme that contains two SH2 domains. Syp is physically associated with activated receptors for epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), apparently through its SH2 domains. This phosphatase is rapidly phosphorylated in cells treated with PDGF or EGF, and is constitutively phosphorylated in v-src transformed cells. Here we report that either the N-terminal or C-terminal Syp SH2 domain alone bound to the activated beta PDGF receptor or EGF-receptor in vitro, and that the two SH2 domains linked together exhibited synergistic binding. Substitution of the Tyr1009 autophosphorylation site in the C-terminal tail of activated beta PDGFR with Phe abolished the in vitro binding of either SH2 domain to the activated receptor. A 9 amino acid phosphopeptide corresponding to the Tyr1009 autophosphorylation site of the beta PDGFR inhibited association of the Syp SH2 domains with the receptor. These results indicate that the Syp SH2 domains have an intrinsic specificity for the Tyr1009 autophosphorylation site of the beta PDGFR that dictates binding of the intact Syp phosphatase, and suggest that both SH2 domains have a related binding specificity. Phosphoamino acid analysis of Syp from PDGF-stimulated cells indicated that PDGF primarily induces Syp phosphorylation on tyrosine residues. The mouse Syp gene has been mapped to chromosome 5F region by the fluorescence in situ hybridization. These findings suggest specific functions for Syp in signal transduction downstream of receptor tyrosine kinases.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON, CANADA; HOSP SICK CHILDREN, DEPT GENET, TORONTO M5G 1X8, ON, CANADA; NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO 80206 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); National Jewish Health			Pawson, Tony J/E-4578-2013; Tsui, Lap-chee/A-1081-2010					ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, IN PRESS METHODS MOL; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LAROSE L, 1993, ONCOGENE, V8, P2493; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J, 1989, MOL CLONING LABORATO; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Shultz L D, 1991, Semin Immunol, V3, P397; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	71	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1545	1550						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183548				2022-12-28	WOS:A1994NL81500004
J	WONG, WT; KRAUS, MH; CARLOMAGNO, F; ZELANO, A; DRUCK, T; CROCE, CM; HUEBNER, K; DIFIORE, PP				WONG, WT; KRAUS, MH; CARLOMAGNO, F; ZELANO, A; DRUCK, T; CROCE, CM; HUEBNER, K; DIFIORE, PP			THE HUMAN EPS15 GENE, ENCODING A TYROSINE KINASE SUBSTRATE, IS CONSERVED IN EVOLUTION AND MAPS TO 1P31-P-32	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; FACTOR RECEPTOR KINASE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; SH3 DOMAINS; RAS; GRB2; CLONING; SOS	Employing an expression cloning approach for tyrosine kinase substrates, we have previously isolated the coding sequence for a novel putative EGFR substrate, eps15, from NIH3T3 fibroblasts. Eps15 displayed a receptor-specific pattern of tyrosine phosphorylation in vivo and was able to transform NIH3T3 cells upon overexpression. To gain understanding of eps15 function as well as its role in normal and neoplastic proliferation, we cloned the human eps15 coding sequence and studied expression of the human RNA and protein, evolutionary conservation, and chromosomal location. The close structural similarity of human eps15 with the murine homologue is indicated by 89% and 90% identity of nucleotide and predicted amino acid sequences, respectively. Using the human eps15 coding sequence as probe, we demonstrate that eps15 is member of a gene family that is highly conserved during evolution. An essential function of eps15 in cell growth regulation is underscored by our observation of ubiquitous expression at the transcript and the protein level in normal and malignant human cells. The human EPS15 locus maps to chromosome 1p31-p32, a region involved in deletion in neuroblastoma, translocations in acute lymphoblastic leukemia, and exhibiting a fragile site.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, PHILADELPHIA, PA 19107 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University			Di Fiore, Pier Paolo/K-2130-2012; Young, Richard A/F-6495-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [CA51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BRUNS GA, 1993, CHROMOSOME COORDINAT, V1, P143; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CIMINO G, 1991, CANCER RES, V51, P6712; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1991, METHOD ENZYMOL, V196, P65; HALUSKA FG, 1988, P NATL ACAD SCI USA, V85, P2215, DOI 10.1073/pnas.85.7.2215; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUEBNER K, 1991, AM J HUM GENET, V48, P726; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Katz Wendy S., 1992, Current Opinion in Cell Biology, V4, P939, DOI 10.1016/0955-0674(92)90122-S; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LI N, 1993, NATURE, V363, P86; LINNENBACH AJ, 1993, MOL CELL BIOL, V13, P1507, DOI 10.1128/MCB.13.3.1507; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MITELMAN F, 1993, CHROMOSOME COORDINAT, V1, P700; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MORRIS SW, 1993, GENOMICS, V15, P677, DOI 10.1006/geno.1993.1124; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFF JS, 1993, SCIENCE, V261, P1733; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHILO BZ, 1992, FASEB J, V6, P2915, DOI 10.1096/fasebj.6.11.1322852; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TWEARDY DJ, 1992, BLOOD, V79, P1148, DOI 10.1182/blood.V79.5.1148.bloodjournal7951148; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	49	45	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1591	1597						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183552				2022-12-28	WOS:A1994NL81500009
J	MONTANO, X; SHAMSHER, M; WHITEHEAD, P; DAWSON, K; NEWTON, J				MONTANO, X; SHAMSHER, M; WHITEHEAD, P; DAWSON, K; NEWTON, J			ANALYSIS OF P53 IN HUMAN CUTANEOUS MELANOMA CELL-LINES	ONCOGENE			English	Note							MALIGNANT-MELANOMA; SV40-TRANSFORMED CELLS; MELANOCYTIC LESIONS; METASTATIC CAPACITY; DYSPLASTIC NEVUS; EXPRESSION; PROTEIN; MUTATIONS; GENE; SUPPRESSOR	Mutations in the p53 tumour suppressor gene have been detected in a variety of human malignancies. Mutations have been found predominantly in conserved regions two to five. Our aim was to analyse p53 at the protein and DNA level in seven melanoma cell lines of cutaneous origin (HMB-2, DX3, LT5.1, MJM, SK23, A375P and A375M), including two parental/metastatic derivatives (A375P and A375M; DX3 and LT5.1). By immunohistochemical staining with three mouse monoclonal antibodies and a rabbit polyclonal serum, it was possible to observe differential nuclear expression of p53. The quantitation of p53 protein levels by ELISA correlated with the nuclear staining pattern. Western blotting showed an intact p53 protein in all cell lines; p53 was polymorphic in three cell lines (MJM, A375P and A375M). DNA sequencing studies showed that all cell lines had wild type p53. These results suggest that p53 is unlikely to play a significant role in the genesis of cutaneous melanoma.	LONDON HOSP,COLL MED,DEPT EXPTL DERMATOL,LONDON E1 2BL,ENGLAND	University of London; Queen Mary University London	MONTANO, X (corresponding author), LONDON HOSP,COLL MED,IMPERIAL CANC RES FUND,SKIN TUMOUR LAB,56 ASHFIELD ST,LONDON E1 2BL,ENGLAND.							ALBINO AP, 1991, J CUTAN PATHOL, V18, P273, DOI 10.1111/j.1600-0560.1991.tb01235.x; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BEENKEN SW, 1991, NUCLEIC ACIDS RES, V19, P4747, DOI 10.1093/nar/19.17.4747; BERGMAN W, 1986, ANN HUM GENET, V50, P249, DOI 10.1111/j.1469-1809.1986.tb01046.x; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BURNS PA, 1991, ONCOGENE, V6, P2363; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CARBONE D, 1991, ONCOGENE, V6, P1691; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAM NJ, 1993, CANCER RES, V53, P2235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARSHALL JF, 1991, INT J CANCER, V49, P924, DOI 10.1002/ijc.2910490621; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MOLES JP, 1993, ONCOGENE, V8, P583; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, ONCOGENE, V7, P1673; MUKAI S, 1986, CANCER GENET CYTOGEN, V22, P45, DOI 10.1016/0165-4608(86)90136-6; NEWTON JA, 1992, DIAGNOSIS MANAGEMENT, P53; ORMEROD EJ, 1986, CANCER RES, V46, P884; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RADDY P, 1992, CANCER RES, V52, P3804; SANGER F, 1973, P NATL ACAD SCI USA, V70, P1209, DOI 10.1073/pnas.70.4.1209; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; STRETCH JR, 1991, CANCER RES, V51, P5976; TOBAL K, 1992, BRIT J CANCER, V66, P900, DOI 10.1038/bjc.1992.382; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	46	61	62	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1455	1459						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152807				2022-12-28	WOS:A1994NH40100018
J	SCHWARTEWALDHOFF, I; MARTIN, W; WILLECKE, K; SCHAFER, R				SCHWARTEWALDHOFF, I; MARTIN, W; WILLECKE, K; SCHAFER, R			FUNCTIONAL IDENTIFICATION AND MOLECULAR-CLONING OF A RAT GENE MEDIATING GROWTH-INHIBITION AND PROGRAMMED CELL-DEATH IN NORMAL AND TRANSFORMED RAT-CELL LINES	ONCOGENE			English	Article							WILD-TYPE P53; TUMOR SUPPRESSOR GENES; HIGHER EUKARYOTIC CELLS; C-MYC EXPRESSION; RB GENE; EMBRYONIC FIBROBLASTS; ONCOGENE EXPRESSION; EPITHELIAL-CELLS; CARCINOMA-CELLS; HAMSTER-CELLS	We wished to identify DNA sequences conferring suppression of proliferation and transformed phenotypes. Thus, we have transfected DNA from normal rat cells, covalently linked to neo DNA coding for neomycin resistance into a tumorigenic, HRAS transformed rat cell line. Phenotypic revertants were selected after the first cycle of transfection by enrichment procedures that served to eliminate transformed cells. The revertant clones continued to express the HRAS oncogene, but exhibited a lower tumorigenicity, loss of anchorage-independent proliferation, flat morphology, and retardation of growth in monolayer culture. The reverted phenotype could be transferred in a second cycle of transfection into the HRAS transformed rat cells. Neo DNA ligated to genomic donor DNA was used as a tagging sequence to molecularly clone the transferred DNA sequence in a recombinant phage. Fragments of the cloned DNA detect a 2.5 kb transcript in parental cells and revertants. Thus, the recombinant phage harbors a putative growth inhibitory gene, designated trg, that is expressed at a higher level in rat embryo fibroblasts and in the REF52 cell line. Introduction of recombinant phage DNA into established 208F and Rat-2 cells and into HRAS-, v-fgr-, v-fms- and v-raf-transformed rat cell lines resulted in inhibition of growth and induction of programmed cell death.	UNIV ZURICH,DEPT PATHOL,DIV CANC RES,CH-8091 ZURICH,SWITZERLAND	University of Zurich	SCHWARTEWALDHOFF, I (corresponding author), UNIV BONN,INST GENET,DIV MOLEC GENET,MOLEK GENET ABT,ROMERSTR 164,D-53117 BONN,GERMANY.		Schäfer, Reinhold/AAB-5110-2021					ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKER RF, 1983, P NATL ACAD SCI-BIOL, V80, P1174, DOI 10.1073/pnas.80.5.1174; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BASSIN RH, 1984, CANCER CELL, V2, P463; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADY G, 1985, EMBO J, V4, P2583, DOI 10.1002/j.1460-2075.1985.tb03974.x; BRADY G, 1984, GENE, V27, P223, DOI 10.1016/0378-1119(84)90143-4; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EIDEN MV, 1991, MOL CELL BIOL, V11, P5321, DOI 10.1128/MCB.11.10.5321; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GEISER A G, 1989, Critical Reviews in Oncogenesis, V1, P261; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HARRIS H, 1988, CANCER RES, V48, P3302; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KLINGER HP, 1983, JNCI-J NATL CANCER I, V71, P559; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTIN W, 1992, EXP CELL RES, V200, P41, DOI 10.1016/S0014-4827(05)80069-2; MERCER WE, 1990, ONCOGENE, V5, P973; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; NAGY A, 1987, J CELL SCI, V87, P651; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PADMANABHAN R, 1987, MOL CELL BIOL, V7, P1894, DOI 10.1128/MCB.7.5.1894; PHILIPSON L, 1991, J CELL BIOCHEM, V46, P95, DOI 10.1002/jcb.240460202; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAGER R, 1986, CANCER RES, V46, P1573; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1983, CANCER RES, V43, P2240; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; Smith J R, 1990, Adv Cancer Res, V54, P63, DOI 10.1016/S0065-230X(08)60808-8; SORRENTINO V, 1989, ANTICANCER RES, V9, P1925; SORRENTINO V, 1989, ONCOGENE, V4, P569; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEINBERG B, 1978, CELL, V13, P300; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	78	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					899	909						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108134				2022-12-28	WOS:A1994MW55100027
J	BARBEAU, D; CHARBONNEAU, R; WHALEN, SG; BAYLEY, ST; BRANTON, PE				BARBEAU, D; CHARBONNEAU, R; WHALEN, SG; BAYLEY, ST; BRANTON, PE			FUNCTIONAL INTERACTIONS WITHIN ADENOVIRUS E1A PROTEIN COMPLEXES	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; HUMAN CYCLIN-A; EARLY REGION-1A POLYPEPTIDES; LARGE T-ANTIGENS; SV40 LARGE-T; CELL-CYCLE; PHOSPHORYLATION SITES; DNA-SYNTHESIS; 1A PROTEINS	The transforming potential of adenovirus E1A oncogene products derives largely from the formation of complexes with cellular proteins, including the p105(Rb) tumor suppressor and a related p107 species, p130 and p300 proteins, and cyclin A (p60(cycA)). Extensive quantitative analyses using E1A deletion mutants identified unique binding patterns for each of these polypeptides within the amino terminus and conserved regions 1 and 2 (CR1 and CR2) of E1A proteins. A novel protein, termed p400, was found by peptide mapping to be related to p300, and, like p300, to require the E1A amino terminus and a portion of CR1 for binding. p130 was shown to be related to p107, and like p107, to associate with p60(cycA). p107, p130 and p105(Rb) all interacted primarily with CR2, however, sequences within CR1 and the amino terminus were capable of weak interactions and appeared to function cooperatively with CR2 to bind these proteins. Protein kinase activity present in E1A complexes probably derives at least in part from p60(cycA)-linked p33(cdk2) associated with p107 and p130. In vitro phosphorylation of complexes purified by immunoprecipitation resulted in labeling of several proteins. p60(cycA) was phosphorylated to about the same extent in cyclin A complexes prepared from either AD5- or mock-infected KB cells, however, that of p130 and p107 was dramatically higher in p60(cycA) complexes from infected cells. p300 was also phosphorylated in complexes prepared using E1A-specific antibodies. Thus one role of E1A proteins in signal transduction and regulation of the cell cycle may be to control the biological activity of p107, p130 and p300 by enhancing their phosphorylation through complex formation.	DEPT BIOCHEM, MONTREAL H3G 1Y6, PQ, CANADA; MCMASTER UNIV, DEPT BIOL, HAMILTON L8S 4K1, ON, CANADA	McMaster University								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; BELLETT AJD, 1989, J VIROL, V63, P303, DOI 10.1128/JVI.63.1.303-310.1989; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUMONT DJ, 1993, J GEN VIROL, V74, P583, DOI 10.1099/0022-1317-74-4-583; DUMONT DJ, 1992, VIROLOGY, V189, P111, DOI 10.1016/0042-6822(92)90686-J; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HALL FL, 1993, ONCOGENE, V8, P1377; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NAKAJIMA T, 1987, MOL CELL BIOL, V7, P3846, DOI 10.1128/MCB.7.10.3846; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROWE DT, 1983, VIROLOGY, V127, P253, DOI 10.1016/0042-6822(83)90142-3; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TREMBLAY ML, 1989, VIROLOGY, V169, P397, DOI 10.1016/0042-6822(89)90165-7; TREMBLAY ML, 1988, J BIOL CHEM, V263, P6375; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	94	116	117	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					359	373						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290250				2022-12-28	WOS:A1994MW24800003
J	CAMPBELL, CE; HUANG, A; GURNEY, AL; KESSLER, PM; HEWITT, JA; WILLIAMS, BRG				CAMPBELL, CE; HUANG, A; GURNEY, AL; KESSLER, PM; HEWITT, JA; WILLIAMS, BRG			ANTISENSE TRANSCRIPTS AND PROTEIN-BINDING MOTIFS WITHIN THE WILMS-TUMOR (WT1) LOCUS	ONCOGENE			English	Article							DENYS-DRASH SYNDROME; ZINC-FINGER GENE; FAMILIAL PREDISPOSITION; HOMOZYGOUS DELETION; FUNCTIONAL-ANALYSIS; N-MYC; EXPRESSION; 11P13; PROMOTER; REGION	Transcription of the WT1 locus is restricted, both temporally and spatially, to a subset of epithelial cells in mammalian kidneys and gonads. WT1, one of the two divergent transcripts mapping to this locus encodes a zinc finger protein that is likely a transcriptional regulator. The other transcript, WIT1, encodes a product of unknown function that is subject to alternate splicing in the region immediately 5' of the WT1 gene. Analysis of the 5' end of this locus further revealed the presence of multiple transcriptional start sites for both genes, such that some of the WIT1 transcripts are encoded by the antisense strand of the first exon of WT1. The genomic region surrounding the transcriptional start sites appears to constitute part of a bi-directional promoter based on the ability of a DNA fragment derived from this region to direct expression of a chimeric CAT gene construct in transient transfection assays. Discrete sequences within the region are capable of interaction in vitro with nuclear extracts derived from a variety of rat and mouse tissues, Interestingly, recombinant WT1, representing the product of zinc finger region of the most abundant of the four alternatively spliced transcripts, is also capable of binding to sequences within this region.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON,CANADA	University of Toronto	CAMPBELL, CE (corresponding author), CLEVELAND CLIN FDN,DEPT CANC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; COPPES MJ, 1992, CANCER RES, V52, P6125; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; COWELL JK, 1991, ONCOGENE, V6, P595; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GERALD WL, 1992, AM J PATHOL, V140, P1031; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1991, AM J HUM GENET, V48, P997; KIKUCHI H, 1992, AM J PATHOL, V140, P781; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KNOX JJ, 1991, MOL CELL BIOL, V11, P2946, DOI 10.1128/MCB.11.6.2946; KOUFOS A, 1989, AM J HUM GENET, V44, P711; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MAW MA, 1992, CANCER RES, V52, P3094; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TADOKORO K, 1992, ONCOGENE, V7, P1215; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; WANG ZY, 1992, J BIOL CHEM, V267, P21999; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	50	57	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					583	595						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290269				2022-12-28	WOS:A1994MW24800026
J	CROWE, AJ; MCGLADE, J; PAWSON, T; HAYMAN, MJ				CROWE, AJ; MCGLADE, J; PAWSON, T; HAYMAN, MJ			PHOSPHORYLATION OF THE SHC PROTEINS ON TYROSINE CORRELATES WITH THE TRANSFORMATION OF FIBROBLASTS AND ERYTHROBLASTS BY THE V-SEA TYROSINE KINASE	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTORS; VIRUS; GAP; SRC; DOMAINS; S13; IDENTIFICATION; RETROVIRUS; EXPRESSION	The S13 avian erythroblastosis viral genome encodes an oncogenic tyrosine kinase, termed env-sea, that is capable of transforming fibroblasts and erythroblasts, Although the tyrosine kinase activity of the env-sea protein has been shown to be necessary for transformation, no substrates for this enzyme have been detected in vivo. Here we demonstrate that the recently described she proteins are phosphorylated on tyrosine residues in both S13 transformed fibroblasts and erythroblasts. Furthermore, using an S13 temperature sensitive mutant, we show that the phosphorylation of the she proteins occurs concomitantly with the activation of the tyrosine kinase activity of the env-sea protein. These observations make the phosphorylation of the she proteins a good candidate for being involved in oncogenic signaling by the env-sea oncoprotein.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013		NCI NIH HHS [CA42573, CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042573, P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; CROWE AJ, 1993, ONCOGENE, V8, P181; CROWE AJ, 1993, CELL GROWTH DIFFER, V4, P403; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; HAYMAN MJ, 1987, PATHOL IMMUNOPATH R, V6, P390, DOI 10.1159/000157065; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAMPS MP, 1988, ONCOGENE, V2, P305; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KNIGHT J, 1990, VIROLOGY, V178, P232, DOI 10.1016/0042-6822(90)90398-B; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kowenz E, 1987, Haematol Blood Transfus, V31, P199; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, ELL, V70, P359; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	28	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					537	544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290264				2022-12-28	WOS:A1994MW24800021
J	PURDIE, CA; HARRISON, DJ; PETER, A; DOBBIE, L; WHITE, S; HOWIE, SEM; SALTER, DM; BIRD, CC; WYLLIE, AH; HOOPER, ML; CLARKE, AR				PURDIE, CA; HARRISON, DJ; PETER, A; DOBBIE, L; WHITE, S; HOWIE, SEM; SALTER, DM; BIRD, CC; WYLLIE, AH; HOOPER, ML; CLARKE, AR			TUMOR-INCIDENCE, SPECTRUM AND PLOIDY IN MICE WITH A LARGE DELETION IN THE P53 GENE	ONCOGENE			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; CANCER; EXPRESSION; MUTATIONS; ANTIGEN; AMPLIFICATION; PROTEIN; LINE; IRRADIATION	In human tumourigenesis the tumour suppressor gene most commonly affected by mutation, inactivation or allele loss is p53. Loss of p53 function is associated both with failure to maintain a normal diploid status and inability to delete cells by apoptosis following DNA damage. To investigate further the role of p53 we have generated mice carrying a large deletion within the gene. All animals homozygous for this deletion develop spontaneous tumours, predominantly lymphomas, by the age of 6 months. 10% of heterozygotes develop a range of neoplasms, with a lower predisposition towards lymphoma, by 9 months. Both tumour incidence and spectrum in heterozygotes differ from those previously reported in another p53 mutant stock, suggesting either difference in exposure to carcinogens between the two stocks, or a role for modulating genes within different genetic backgrounds. Tumours showed frequent loss of diploid status, and the majority of those arising in heterozygotes showed loss of the wild type allele. These findings are consistent with the concept that p53 acts as a tumour suppressor by preventing the propagation of DNA damage to daughter cells.	UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	rose, lorraine/0000-0001-5135-8262; Clarke, Alan/0000-0002-4281-426X; Purdie, Colin/0000-0002-1258-4010				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BODNER SM, 1992, ONCOGENE, V7, P743; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FYFE L, 1993, IMMUNOL LETT, V35, P45, DOI 10.1016/0165-2478(93)90146-S; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALL PA, 1993, ONCOGENE, V8, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KASTAN MB, 1991, CANCER RES, V51, P6304; Kerr J.F.R., 1987, P93; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PURDIE CA, 1991, AM J PATHOL, V138, P807; QUIRKE P, 1985, BRIT J CANCER, V51, P99, DOI 10.1038/bjc.1985.14; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; RUIZ JC, 1990, MOL CELL BIOL, V10, P3056, DOI 10.1128/MCB.10.6.3056; SAID JW, 1992, AM J PATHOL, V141, P1343; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMID P, 1991, DEVELOPMENT, V113, P857; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SYMONDS H, 1991, J VIROL, V65, P5417, DOI 10.1128/JVI.65.10.5417-5424.1991; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	46	307	313	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					603	609						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290271				2022-12-28	WOS:A1994MW24800028
J	SOLLENBERGER, KG; KAO, TL; TAPAROWSKY, EJ				SOLLENBERGER, KG; KAO, TL; TAPAROWSKY, EJ			STRUCTURAL-ANALYSIS OF THE CHICKEN MAX GENE	ONCOGENE			English	Note							DNA-BINDING; C-MYC; RAS COTRANSFORMATION; ENHANCERS; PROTEIN; DOMAINS; FORMS	The recent identification of Max, a nuclear phosphoprotein that dimerizes with members of the Myc protein family, has provided an additional tool to examine the role of the Myc oncoprotein as a sequence-specific DNA binding protein and a potential regulator of gene transcription. Here we report the nucleotide sequence of an avian max gene isolated from a lambda EMBL3 genomic library prepared from size-selected chicken embryo fibroblast DNA. The complete transcription unit encoding chicken Max is contained on a 5.7kbp BglII DNA fragment which expresses an appropriately sized max mRNA of 1.5 kb following transfection of C3H10T1/2 mouse fibroblasts. The coding region of the chicken max gene is organized into five exons and the overall identity between the human and chicken max coding sequences is 85% at the nucleotide level and 96% at the amino acid level. The basic helix - loop - helix/leucine zipper region, the casein kinase II phosphorylation sites and the nuclear localization signal sequence are 100% conserved in all vertebrate Max proteins characterized to date. DNA sequence analysis of the 5' flanking region of the chicken max coding sequence reveals the absence of consensus TATA or CAAT motifs, but the presence of numerous GC-rich sequences that are typical in eukaryotic genes which are expressed constitutively in different tissues and under different growth conditions.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA42835] Funding Source: Medline; NIDDK NIH HHS [DK07532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA042835, R01CA042835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007532] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P381; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KING MW, 1993, CELL GROWTH DIFFER, V4, P85; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MIN SY, 1992, ONCOGENE, V7, P1531; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; VAIDYA TB, 1992, GENE, V116, P223, DOI 10.1016/0378-1119(92)90519-U; VASTRIK I, 1993, ONCOGENE, V8, P503	22	17	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					661	664						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290277				2022-12-28	WOS:A1994MW24800035
J	SCHULZ, RA; HOGUE, DA; THE, SM				SCHULZ, RA; HOGUE, DA; THE, SM			CHARACTERIZATION OF LETHAL ALLELES OF D-ELG, AN ETS PROTOONCOGENE RELATED GENE WITH MULTIPLE FUNCTIONS IN DROSOPHILA DEVELOPMENT	ONCOGENE			English	Article							POSTERIOR DETERMINANT; FAMILY; LOCALIZATION; POLARITY; DOMAIN; MELANOGASTER; SEQUENCE; PRODUCT; EMBRYO; OSKAR	We have used genetic complementation rescue to identify two lethal alleles of D-elg, an ets proto-oncogene related gene of Drosophila. Animals that are hemizygous or trans-heterozygous for the alleles die as pharate adults, demonstrating normal gene function is required to complete Drosophila development. Females trans-heterozygous for the 1(3)902 lethal allele and the previously characterized tne female sterile allele produce embryos with abdominal segmentation defects. This finding implicates a role for the D-elg gene in anterior-posterior patterning. The cloning and sequencing of the lethal alleles identified molecular mutations that may result in ELG protein truncation, altered ELG protein interactions, or defective D-elg mRNA splicing.			SCHULZ, RA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; Ashburner M, 1989, DROSOPHILA LAB HDB, P139; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; GALEWSKY S, 1990, GENE, V96, P227, DOI 10.1016/0378-1119(90)90257-R; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LINDSLEY DL, 1992, GENOME DROSOPHILA MA; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; SCHULZ RA, 1993, IN PRESS P NATL ACAD; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; STJOHNSTON D, 1992, CELL, V68, P201; THE SM, 1992, ONCOGENE, V7, P2471; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; Wieschaus E., 1986, P199	28	7	7	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3369	3374						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247539				2022-12-28	WOS:A1993MG78200021
J	AZIZ, N; WU, J; DUBENDORFF, JW; LIPSICK, JS; STURGILL, TW; BENDER, TP				AZIZ, N; WU, J; DUBENDORFF, JW; LIPSICK, JS; STURGILL, TW; BENDER, TP			C-MYB AND V-MYB ARE DIFFERENTIALLY PHOSPHORYLATED BY P42MAPK IN-VITRO	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; AVIAN-MYELOBLASTOSIS VIRUS; COLONY-STIMULATING FACTOR; SERINE-THREONINE KINASE; LONG TERMINAL REPEAT; MYELIN BASIC-PROTEIN; DNA-BINDING ACTIVITY; MAP KINASE	The product of the c-myb proto-oncogene is a highly conserved transcription factor that has been shown to function as both a transactivator and repressor. The v-myb oncogenes of E26 leukemia virus and avian myeloblastosis virus (AMV) encode proteins truncated at both the amino and carboxy termini, deleting portions of the DNA-binding and negative regulatory domains present in c-Myb. Similar truncations of c-Myb alter its function, suggesting that the viral proteins lack important regulatory sequences. Interestingly, eight potential sites of phosphorylation by proline-directed protein kinases conserved between the avian, murine and human Myb proteins are clustered in or near the negative regulatory domain of c-Myb. The majority of these sites are deleted in both the E26 and AMV viral proteins. In this paper we show that one proline-directed protein kinase, p42mapk, phosphorylates bacterially synthesized avian and murine c-Myb but not AMV v-Myb in vitro. We find that p42mapk phosphorylates c-Myb on serine and threonine, but not on tyrosine. Furthermore, deletion analysis indicates that the sites of phosphorylation map to the C-terminal negative regulatory domain. We speculate that the inability of v-Myb to be phosphorylated by p42mapk may contribute to its oncogenic properties.	SUNY, DEPT MICROBIOL, STONY BROOK, NY 11794 USA; UNIV VIRGINIA, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; University of Virginia; University of Virginia			Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606; Aziz, Natasha/0000-0001-8195-1446	NCI NIH HHS [CA 40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ADDISON C, 1990, ONCOGENE, V5, P423; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BADING H, 1989, ONCOGENE, V4, P33; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOSSELUT R, 1992, VIROLOGY, V186, P764, DOI 10.1016/0042-6822(92)90044-P; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DASGUPTA P, 1992, J VIROL, V66, P270, DOI 10.1128/JVI.66.1.270-276.1992; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NEL AE, 1990, J IMMUNOL, V144, P2683; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKUDA K, 1992, BLOOD, V79, P2880; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAMSAY RG, 1991, ONCOGENE, V6, P1875; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SETH A, 1991, J BIOL CHEM, V266, P23521; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAO H, 1990, J BIOL CHEM, V265, P15471; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	84	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2259	2265						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336948				2022-12-28	WOS:A1993LP17100028
J	TAMURA, K; KANAOKA, Y; JINNO, S; NAGATA, A; OGISO, Y; SHIMIZU, K; HAYAKAWA, T; NOJIMA, H; OKAYAMA, H				TAMURA, K; KANAOKA, Y; JINNO, S; NAGATA, A; OGISO, Y; SHIMIZU, K; HAYAKAWA, T; NOJIMA, H; OKAYAMA, H			CYCLIN-G - A NEW MAMMALIAN CYCLIN WITH HOMOLOGY TO FISSION YEAST CIG1	ONCOGENE			English	Article							CELL-CYCLE; DNA-REPLICATION; IDENTIFICATION; EUKARYOTES; ACTIVATION; PROTEINS; FAMILY; PHASE; SWI4	A new gene encoding a cyclin-like protein has been isolated from a rat fibroblast cDNA library by cross-hybridization with a mixutre of c-src family proto-oncogene kinase domains as a probe. This putative cyclin, called cyclin G, contains a typical cyclin box at the N-terminus but no apparent 'destruction box' or 'PEST' sequence. Interestingly, in its C-terminus region, it has a sequence homologous with a tyrosine phosphorylation site of the epidermal growth factor receptor. Although this cyclin is phylogenetically related to HCS26 of Saccharomyces cerevisiae, it most resembles Cig1, a B-type cyclin, of Schizosaccharomyces pombe, which has been suggested to act at the G1/S phase of the cell cycle. Cyclin G mRNA is induced within 3h after growth stimulation and remains elevated with no apparent cell cycle dependency, indicating its close association with growth stimuli but not with the cell cycle.	OSAKA UNIV, DEPT MOLEC GENET, MICROBIAL DIS RES INST, SUITA, OSAKA 565, JAPAN; RES DEV CORP JAPAN, OKAYAMA CELL SWITCHING PROJECT, KYOTO 606, JAPAN; OSAKA UNIV, DEPT NEUROSURG, OSAKA 553, JAPAN	Osaka University; Japan Science & Technology Agency (JST); Osaka University								BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MINSHULL J, 1989, J CELL SCI, P77; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STUDIER JA, 1988, MOL BIOL EVOL, V5, P729; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	28	146	159	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2113	2118						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336937				2022-12-28	WOS:A1993LP17100011
J	WU, FYH; CHANG, NT; CHEN, WJ; JUAN, CC				WU, FYH; CHANG, NT; CHEN, WJ; JUAN, CC			VITAMIN-K3-INDUCED CELL-CYCLE ARREST AND APOPTOTIC CELL-DEATH ARE ACCOMPANIED BY ALTERED EXPRESSION OF C-FOS AND C-MYC IN NASOPHARYNGEAL CARCINOMA-CELLS	ONCOGENE			English	Article							OXIDATIVE STRESS; GROWTH-FACTOR; DNA DAMAGE; ACTIVATION; LINE; INDUCTION; MENADIONE; ONCOGENE; PROTEIN; INVITRO	Vitamin K3 is known to inhibit the growth of various rodent and human tumor cells. However, the molecular mechanism of its action is still elusive. We have found that vitamin K3 induces cell cycle arrest and apoptotic cell death in nasopharyngeal carcinoma (NPC) cells, as evaluated by flow cytometry and DNA gel electrophoresis. Involvement of c-fos and c-myc proto-oncogenes and expression of their proto-oncoproteins in VK3-induced cell cycle arrest and apoptosis were also investigated. Northern blot analysis of NPC cells treated with 50 mum VK3 showed that c-fos was transiently induced for 60 min after treatment, while c-myc was persistently induced for 1-9 h after drug treatment. Western blot analysis also showed that c-Fos was induced at 4-6 h and at 1-4 h after treatment with 50 mum and 200 mum VK3 respectively, while c-Myc was induced at 1-6 h and at 4-6 h, respectively, after such treatments. These results suggest that the expression of c-fos and c-myc may play an important role in the signaling mechanism of VK3-induced growth arrest and apoptotic cell death.			WU, FYH (corresponding author), ACAD SINICA, INST BIOMED SCI, CANC RES GRP, TAIPEI 11529, TAIWAN.							AGARWAL ML, 1991, CANCER RES, V51, P5993; AKMAN SA, 1988, P AN M AM SOC CLIN, V7, P76; AKMAN SA, 1984, P ASCO, V3, P37; ASKEW DS, 1991, ONCOGENE, V6, P1915; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHANG YS, 1989, CANCER RES, V49, P6752; CHLEBOWSKI RT, 1985, CANCER TREAT REP, V69, P527; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLOTTA F, 1990, BIOCHEM BIOPH RES CO, V168, P1013, DOI 10.1016/0006-291X(90)91130-K; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; GOLD J, 1986, CANCER TREAT REP, V70, P1433; HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438, DOI 10.1128/MCB.9.8.3438; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; JUAN CC, 1993, BIOCHEM BIOPH RES CO, V190, P907, DOI 10.1006/bbrc.1993.1135; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; MALORNI W, 1991, CHEM-BIOL INTERACT, V80, P217, DOI 10.1016/0009-2797(91)90026-4; MARKS DI, 1991, BIOCHEM PHARMACOL, V42, P1859, DOI 10.1016/0006-2952(91)90582-P; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; MITCHELL JS, 1965, ACTA RADIOL THER PHY, V3, P329, DOI 10.3109/02841866509133108; MITCHELL JS, 1974, BRIT J CANCER, V29, P373, DOI 10.1038/bjc.1974.85; MITCHELL JS, 1983, INT J RADIAT ONCOL, V9, P57, DOI 10.1016/0360-3016(83)90209-2; NAGOURNEY R, 1987, P AN M AM SOC CLIN, V6, P359; NGO EO, 1991, BIOCHEM PHARMACOL, V42, P1961, DOI 10.1016/0006-2952(91)90596-W; NOTO V, 1989, CANCER, V63, P901, DOI 10.1002/1097-0142(19890301)63:5<901::AID-CNCR2820630518>3.0.CO;2-G; NUTTER LM, 1991, BIOCHEM PHARMACOL, V41, P1283, DOI 10.1016/0006-2952(91)90099-Q; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SU W-C, 1991, Kaohsiung Journal of Medical Sciences, V7, P454; WICKSTROM EL, 1989, IN VITRO CELL DEV B, V25, P297; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WU FYH, 1991, P AM ASSOC CANC RES, V32, P396; WU FYH, 1993, IN PRESS LIFE SCI; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1987, ARCH TOXICOL, P3; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUH YS, 1989, J BIOL CHEM, V264, P10904; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	45	93	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2237	2244						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336946				2022-12-28	WOS:A1993LP17100025
J	KOHNO, T; TAKAYAMA, H; HAMAGUCHI, M; TAKANO, H; YAMAGUCHI, N; TSUDA, H; HIROHASHI, S; VISSING, H; SHIMIZU, M; OSHIMURA, M; YOKOTA, J				KOHNO, T; TAKAYAMA, H; HAMAGUCHI, M; TAKANO, H; YAMAGUCHI, N; TSUDA, H; HIROHASHI, S; VISSING, H; SHIMIZU, M; OSHIMURA, M; YOKOTA, J			DELETION MAPPING OF CHROMOSOME-3P IN HUMAN UTERINE CERVICAL-CANCER	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; VONHIPPEL-LINDAU DISEASE; HUMAN-BREAST CARCINOMA; LUNG-CANCER; SHORT ARM; SMALL REGION; HETEROZYGOSITY; GENE; RECEPTOR; ALLELES	Deletion mapping of chromosome 3p was performed on 47 cases of human uterine cervical cancer using 24 polymorphic DNA markers including five inter-Alu DNA markers and two NotI-boundary cosmid markers obtained in our laboratory. The most likely order of these 24 polymorphic DNA markers was determined as being cen-[D3S4, H8]-D3S693-D3S659-D3S30-D3S687-[D3S2, UR9, UR47]-J36-J17-GNA12B-D3F15S2-D3S643-D3S32-D3S23-D3S686-H35-UR189-D3S685-D3S11-D3S12-THRB-D3S22-pter, based on the data from radiation hybrid mapping, genetic linkage analysis and in situ hybridization. Loss of heterozygosity (LOH) at one or more loci on chromosome 3p was detected in 21 of 47 cases (45%). Four tumors showed partial or interstitial deletions, and the common region of LOH in these tumors was 3p13-p21.1 between the D3S30 marker and the D3S2 marker. Candidates for tumor-suppressor genes, APEH, D8, GNAI2B, ZNF35, RARB, THRB and RAFI, were all mapped outside of the common region in uterine cervical cancer. However, this region is commonly deleted in carcinoma of the lung, breast and kidney, and encompasses the breakpoint of the (3;8) translocation in hereditary renal cell carcinoma. This result indicates the presence of a novel tumor-suppressor gene in the region of 3p13-p21.1, which is involved in the development of several human cancers.	NATL CANC CTR,RES INST,1-1 TSUKIJI 5-CHOME,CHUO KU,TOKYO 104,JAPAN; HAGEDORN RES INST,DEPT MOLEC ENDOCRINOL,DK-2820 GENTOFTE,DENMARK; TOTTORI UNIV,SCH LIFE SCI,YONAGO,TOTTORI 683,JAPAN	National Cancer Center - Japan; Novo Nordisk; Hagedorn Research Institute; Tottori University				takano, hirokuni/0000-0002-6465-7883				ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; CARRITT B, 1992, CANCER RES, V52, P1536; COTTER FE, 1990, GENOMICS, V7, P257, DOI 10.1016/0888-7543(90)90548-9; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DIDSBURY JR, 1987, FEBS LETT, V211, P160, DOI 10.1016/0014-5793(87)81428-X; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EHREN T, 1990, ONCOGENE, V5, P219; ERLANDSSON R, 1991, ONCOGENE, V6, P1293; FALK CT, 1991, GENOMICS, V9, P120, DOI 10.1016/0888-7543(91)90228-7; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; GEBERT JF, 1991, ONCOGENE, V6, P1859; GINZINGER DG, 1992, AM J HUM GENET, V50, P826; GORADIA TM, 1991, GENOMICS, V10, P748, DOI 10.1016/0888-7543(91)90459-R; GROSVELD FG, 1982, NUCLEIC ACIDS RES, V10, P6715, DOI 10.1093/nar/10.21.6715; GROVER T, 1984, HUM GENET, V67, P136; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HARMER MH, 1978, TNM CLASSIFICATION M; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HIBI K, 1992, ONCOGENE, V7, P445; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LANFRANCONE L, 1992, GENOMICS, V12, P720, DOI 10.1016/0888-7543(92)90301-8; LEDUC F, 1989, AM J HUM GENET, V44, P282; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MAGOVCEVIC I, 1992, GENOMICS, V12, P125, DOI 10.1016/0888-7543(92)90414-N; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; MORI N, 1989, CANCER RES, V49, P5130; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; POULSEN HE, 1975, INT HISTOLOGICAL CLA, V13; RAPP UR, 1988, LUNG CANCER, V4, P162; SATO T, 1991, CANCER RES, V51, P5794; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SHIMIZU M, 1990, ONCOGENE, V5, P185; SITHANANDAM G, 1989, ONCOGENE, V4, P451; TAMARI M, 1992, GENOMICS, V13, P705, DOI 10.1016/0888-7543(92)90145-I; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; 1991, CYTOGENET CELL GENET, V58, P1	51	100	100	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1825	1832						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8099726				2022-12-28	WOS:A1993LG68200014
J	RIETHMACHER, D; LANGHOLZ, O; GODECKE, S; SACHS, M; BIRCHMEIER, C				RIETHMACHER, D; LANGHOLZ, O; GODECKE, S; SACHS, M; BIRCHMEIER, C			BIOCHEMICAL AND FUNCTIONAL-CHARACTERIZATION OF THE MURINE ROS PROTOONCOGENE	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; MOUSE MYELOID CELLS; I CSF-1 RECEPTOR; SEVENLESS PROTEIN; HEMATOPOIETIC-CELLS; EGF RECEPTOR; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; SIGNAL TRANSDUCTION	The ros gene was originally found because it can, when mutated, induce malignant transformation. The proto-oncogene encodes an orphan receptor tyrosine kinase. We report here the isolation and characterization of the mouse c-ros cDNA and, in addition, the biochemical characterization of the receptor. Both, the endogenous c-ros protein from embryonal tissues and the recombinant protein are glycosylated molecules with an apparent molecular weight of 260 000. Pulse-chase analysis in Sf9 cells demonstrates that the c-ros protein is synthesized as a single chain, uncleaved molecule. Since the specific ligand of c-ros is not known, a hybrid receptor (trk/c-ros) which transmits c-ros-specific signals in response to nerve growth factor (NGF) was used to study the biological activities. In NIH3T3 cells, this trk/c-ros hybrid induces growth, a fusiform cell shape, and loss of contact inhibition of growth. However, the active hybrid receptor cannot replace IL-3 as survival factor in 32D myeloid cells. Compared to other receptors, the active c-ros tyrosine kinase domain displays thus overlapping, but not identical signalling specificities.	MAX PLANCK GESELL,MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; MAX DELBRUCK CENTRUM MOLEK MED,D-13122 BERLIN,GERMANY	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Riethmacher, Dieter/A-6242-2010; Riethmacher, Dieter/AAP-2227-2021; Riethmacher, Dieter/AAB-8690-2022	Riethmacher, Dieter/0000-0002-4206-5529; 				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASLER K, 1988, CELL, V54, P299; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BIRCHMEIER C, 1993, BIOESSAYS, V15, P185, DOI 10.1002/bies.950150307; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; CHEN JM, 1991, ONCOGENE, V6, P257; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HARLOW E, 1988, ANTIBODIES LABORATOR; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HSIEH P, 1984, J BIOL CHEM, V259, P2375; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KATO JY, 1990, BLOOD, V75, P1780; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KATZAV S, 1989, ONCOGENE, V4, P1129; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1994, MOL CELL BIOL, V13, P663; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SHARMA S, 1989, ONCOGENE RES, V5, P91; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; SUMMERS M, 1987, TEX AGR EP STN B, V1555; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILKS AF, 1993, ADV CANCER RES, V60, P43; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; ZONG CS, 1993, J VIROL, V67, P6453, DOI 10.1128/JVI.67.11.6453-6462.1993	62	20	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3617	3626						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970722				2022-12-28	WOS:A1994PT39200025
J	WILKIE, TM; SCHMIDT, RA; BAETSCHER, M; MESSING, A				WILKIE, TM; SCHMIDT, RA; BAETSCHER, M; MESSING, A			SMOOTH-MUSCLE AND BONE NEOPLASMS IN TRANSGENIC MICE EXPRESSING SV40 T-ANTIGEN	ONCOGENE			English	Article							SOFT-TISSUE SARCOMAS; LARGE TUMOR-ANTIGEN; HEAT-SHOCK PROTEIN; CHOROID-PLEXUS; P53 GENE; SIMIAN VIRUS-40; HYBRID GENE; GERM-LINE; RETINOBLASTOMA; MUTATION	Transgenic mice carrying the SV40 early region fused to the Drosophila hsp70 promoter developed smooth muscle and bone neoplasms. The smooth muscle tumors appeared in aged mice and were preferentially located on the muzzle or eyelids. Multiple neoplasms were often present and each appeared to be an independent proliferation. In contrast, the bone tumors typically developed in the petrous ridge and had all the features of osteogenic sarcomas, displaying distant metastasis and invasion of the brain. Cells in both types of tumors exhibited nuclear expression of SV40 T antigen. Mice homozygous for the transgene had a shorter latency for appearance of smooth muscle tumors and developed osteosarcomas more frequently than hemizygous mice. This model system implicates the cellular T antigen-binding proteins, such as Rb and p53, in the pathogenesis of bone and soft tissue neoplasms in mice.	UNIV WASHINGTON,HOSP PATHOL RC72,SEATTLE,WA 98195; BIOTRANSPLANT INC,BOSTON,MA 02129; UNIV WISCONSIN,SCH VET MED,MADISON,WI 53706	University of Washington; University of Washington Seattle; University of Wisconsin System; University of Wisconsin Madison	WILKIE, TM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75325, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022475] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11576] Funding Source: Medline; NINDS NIH HHS [NS-22475] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ARTAVANISTSAKONAS S, 1979, CELL, V17, P9, DOI 10.1016/0092-8674(79)90290-3; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; CHEN JD, 1992, ONCOGENE, V7, P1167; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERKINDEREN DJ, 1988, INT J CANCER, V41, P499, DOI 10.1002/ijc.2910410405; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P646; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KHANDJIAN EW, 1983, MOL CELL BIOL, V3, P1; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; KNOWLES BB, 1990, AM J PATHOL, V137, P259; KOTHARY R, 1989, DEVELOPMENT, V105, P707; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI H, 1991, JPN J CANCER RES, V82, P4, DOI 10.1111/j.1349-7006.1991.tb01736.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MESSING A, 1988, ONCOGENE RES, V3, P87; MILLER CW, 1990, CANCER RES, V50, P7950; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OMAR RA, 1984, CANCER RES, V44, P3976; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PORTER PL, 1992, AM J PATHOL, V140, P145; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDGREN EP, 1989, ONCOGENE, V4, P715; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; STRAUSS PG, 1992, INT J CANCER, V50, P252, DOI 10.1002/ijc.2910500215; SYMONDS H, 1991, J VIROL, V65, P5417, DOI 10.1128/JVI.65.10.5417-5424.1991; TOGUCHIDA J, 1992, CANCER RES, V52, P6194	47	20	21	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2889	2895						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084593				2022-12-28	WOS:A1994PG82200014
J	OZAKI, T; SAIJO, M; MURAKAMI, K; ENOMOTO, H; TAYA, Y; SAKIYAMA, S				OZAKI, T; SAIJO, M; MURAKAMI, K; ENOMOTO, H; TAYA, Y; SAKIYAMA, S			COMPLEX-FORMATION BETWEEN LAMIN-A AND THE RETINOBLASTOMA GENE-PRODUCT - IDENTIFICATION OF THE DOMAIN ON LAMIN-A REQUIRED FOR ITS INTERACTION	ONCOGENE			English	Article							LARGE T-ANTIGEN; INTERMEDIATE FILAMENT PROTEINS; SV40 LARGE-T; CELL-CYCLE; SUSCEPTIBILITY GENE; NUCLEAR-ENVELOPE; TUMOR SUPPRESSOR; CARCINOMA-CELLS; RB GENE; BINDING	The retinoblastoma susceptibility gene product (pRB) has been known to function as a negative regulator of cell growth. Recent observations suggest that its biological activity might be modulated by an interaction with nuclear structures. By using in vitro binding assays, we have found that pRB can associate with lamin A, which has been known to be one of the major nuclear matrix proteins. A series of GST-lamin A deletion mutants was constructed to define the amino acid sequence required for binding to pRB. A GST-lamin A (247-355) contained an activity to associate with pRB, while the other constructs, such as GST-lamin A (37-244) or GST-lamin A (356-571), could not bind to pRB. Within the pRB-binding domain of lamin A, there exists the short amino acid sequence which is also present in the pRB-binding region of the transcription factor E2F-1. The similar experiments using a set of GST-RB deletion mutants revealed that a region containing the E1A-binding pocket B and the carboxy-terminal portion of pRB was responsible for binding to lamin A.	CHIBA CANC CTR,RES INST,DIV BIOCHEM,CHUOH KU,CHIBA 260,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUOH KU,TOKYO 104,JAPAN	Chiba Cancer Center; National Cancer Center - Japan								AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GLASS CA, 1993, EMBO J, V12, P4413, DOI 10.1002/j.1460-2075.1993.tb06126.x; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P153; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4297; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; OZAKI T, 1992, FEBS LETT, V312, P165, DOI 10.1016/0014-5793(92)80927-9; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SAIJO M, 1994, FEBS LETT, V340, P181, DOI 10.1016/0014-5793(94)80133-9; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	46	177	180	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2649	2653						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058329				2022-12-28	WOS:A1994PC05400025
J	GARDNER, HAR; BERSE, B; SENGER, DR				GARDNER, HAR; BERSE, B; SENGER, DR			SPECIFIC REDUCTION IN OSTEOPONTIN SYNTHESIS BY ANTISENSE RNA INHIBITS THE TUMORIGENICITY OF TRANSFORMED RAT1 FIBROBLASTS	ONCOGENE			English	Article							NEOPLASTIC TRANSFORMATION; SECRETED PHOSPHOPROTEIN; BONE SIALOPROTEIN; MESSENGER-RNA; DEVELOPMENTAL EXPRESSION; ALPHA-V-BETA-3 INTEGRIN; BINDING-PROPERTIES; TUMOR PROGRESSION; GENE-EXPRESSION; CELL-ADHESION	Osteopontin (OPN) is a secreted phosphoglycoprotein abundant in secretory luminal epithelia (Brown et al., 1992) and in bone (Reinholt et al., 1990). It contains a functional gly-arg-gly-asp-ser (GRGDS) integrin binding domain (Oldberg ct al., 1986), promotes the adhesion of a variety of cell types (Somerman et al., 1989; Brown et al., 1992) and is a ligand for the vitronectin binding integrin alpha v beta 3 (Miyauchi et al., 1991). Elevated expression of OPN correlates with tumorigenic transformation in a great variety of stromal and epithelial cell lines (Senger et al., 1980, 1983, 1989; Craig et al., 1988; Chambers et al., 1992; Chang and Prince, 1993). The protein is also present in excess in the blood of patients with metastatic disease (Senger et al., 1988). To find whether OPN contributes significantly to the tumorigenic phenotype, we expressed antisense mRNA to OPN in high OPN producing malignant B77-Rat1 fibroblasts. This caused a reduction in their OPN secretion and reduced their ability to form both lung tumors in nude mice after intravenous injection, and colonies in soft agar. Antisense transfectants also showed increased spreading on vitronectin. These observations suggest that OPN overproduction is advantageous to the metastatic phenotype, possibly by altering adhesion via, or signal transduction from, vitronectin receptors.	BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center				Berse, Brygida/0000-0002-0735-2792	NCI NIH HHS [CA 34025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA034025, R01CA034025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; BEHREND EI, 1994, CANCER RES, V54, P832; BOUKERCHE H, 1989, BLOOD, V74, P909; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHANG PL, 1993, CANCER RES, V53, P2217; CHEN JK, 1993, MATRIX, V13, P113, DOI 10.1016/S0934-8832(11)80070-3; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; HART IR, 1991, CANCER METAST REV, V10, P115, DOI 10.1007/BF00049409; HWANG S, 1994, J BIOL CHEM, V269, P711; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOHRI K, 1993, J BIOL CHEM, V268, P15180; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; SENGER DR, 1980, NATURE, V286, P619, DOI 10.1038/286619a0; SENGER DR, 1985, CANCER RES, V45, P5818; SENGER DR, 1988, CANCER RES, V48, P5770; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; SOMERMAN MJ, 1989, MATRIX, V9, P49, DOI 10.1016/S0934-8832(89)80018-6; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269	34	97	99	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2321	2326						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036014				2022-12-28	WOS:A1994NX62900025
J	KARAGIANNI, N; TSAWDAROGLOU, N				KARAGIANNI, N; TSAWDAROGLOU, N			THE C-FOS SERUM RESPONSE ELEMENT (SRE) CONFERS NEGATIVE RESPONSE TO GLUCOCORTICOIDS	ONCOGENE			English	Article							HORMONE REGULATORY ELEMENT; MAMMARY-TUMOR VIRUS; DNA-BINDING DOMAIN; NUCLEOSOME STRUCTURE; GENE-EXPRESSION; PROTEIN COMPLEX; TERNARY COMPLEX; PROLACTIN GENE; GROWTH-FACTOR; RECEPTOR	Ligand activated Glucocorticoid Receptor (GR), specifically inhibited the serum induced c-fos promoter activation in NIH3T3 fibroblasts. The negative control was mediated by the c-fos SRE and correlated with the relative abundance of active GR. Serum activated SRE was repressed 3-4-fold by glucocorticoids irrespective of the promoter context (heterologous or authentic). The suppressing ability of GR was absolutely dependent on its DNA binding domain (DBD), since deletion of this region left the serum induction unimpaired. The methylation interference pattern of GR revealed two distinct binding sites within the SRE and identified the GR contact bases, important also for binding and function of SRE targeted transcription factors, such as the Serum Response Factor (SRF) and the p62 Ternary Complex Factor (TCF). We conclude that GR binds to c-fos SRE and inhibits c-fos promoter activation by antagonizing the function of positive transcription factors targeting to overlapping or identical sites. Since the c-fos SRE is activated by multiple mitogenic signalling pathways, inactivation by GR could explain, at least in part, the growth inhibitory response of fibroblasts to glucocorticoid hormones.	NATL HELLEN RES FDN, INST BIOL RES & BIOTECHNOL, GR-11635 ATHENS, GREECE	National Hellenic Research Foundation								ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOULDEN A, 1990, VIROLOGY, V174, P204, DOI 10.1016/0042-6822(90)90069-4; CADEPOND F, 1992, EXP CELL RES, V201, P99, DOI 10.1016/0014-4827(92)90352-9; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; DURANT S, 1986, ENDOCR REV, V7, P254, DOI 10.1210/edrv-7-3-254; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAGOT D, 1991, ENDOCRINOLOGY, V129, P1033, DOI 10.1210/endo-129-2-1033; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HOECK W, 1992, J STEROID BIOCHEM, V41, P283, DOI 10.1016/0960-0760(92)90353-K; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEE H, 1991, FEBS LETT, V280, P134, DOI 10.1016/0014-5793(91)80221-N; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; METZ R, 1991, ONCOGENE, V6, P2165; MILLER AD, 1984, CELL, V36, P51; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; TOURAY M, 1991, ONCOGENE, V6, P1227; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TRESIMAN R, 1990, CANCER BIOL, V1, P47; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	53	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2327	2334						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036015				2022-12-28	WOS:A1994NX62900026
J	TAKESHIMA, H; IZAWA, I; LEE, PSY; SAFDAR, N; LEVIN, VA; SAYA, H				TAKESHIMA, H; IZAWA, I; LEE, PSY; SAFDAR, N; LEVIN, VA; SAYA, H			DETECTION OF CELLULAR PROTEINS THAT INTERACT WITH THE NF2 TUMOR-SUPPRESSOR GENE-PRODUCT	ONCOGENE			English	Article							ASSOCIATION; KINASE; NEUROFIBROMATOSIS-2; IDENTIFICATION; GROWTH; EZRIN; PHOSPHORYLATION; RECEPTOR; RADIXIN; FAMILY	The neurofibromatosis type 2 (Nn) gene was recently cloned, and the protein it encodes (merlin) was revealed to belong to a family of proteins that link cytoskeletal components with proteins in the cell membrane. To elucidate the biological function of merlin, we produced a bacterial fusion protein consisting of glutathione S-transferase and merlin and used it to detect five merlin-binding cellular proteins, designated p165, p145, p125, p85 and p70, by a protein-binding assay. p165 and merlin were phosphorylated on serine/threonine residues, and immunoprecipitation showed that p85 bound the native form of merlin. Although the entire merlin-ezrin-radixin-moesin (MERM) homology domain of merlin was found to be essential for binding to all five proteins, the MERM homology domains of ezrin and moesin did not bind to any of the five proteins. Since most reported NF2 mutations are in the region we determined was necessary for binding, the mutations probably impair binding. Therefore, the formation of the protein complex is probably crucial for tumor suppression.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Saya, Hideyuki/J-4325-2013		NATIONAL CANCER INSTITUTE [P30CA016672, P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, P01-CA55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; CHICCHETTI P, 1992, SCIENCE, V257, P803; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; HARLOW E, 1988, ANTIBODIES LABORATOR; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KRIEG J, 1992, J BIOL CHEM, V267, P19258; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACCOLLIN M, 1993, JAMA-J AM MED ASSOC, V270, P2316, DOI 10.1001/jama.270.19.2316; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; NISHI T, 1991, ONCOGENE, V6, P1555; PRIES PN, 1988, CANCER RES, V48, P4633; PRIES PN, 1988, CANCER RES, V48, P6530; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SATO N, 1992, J CELL SCI, V103, P131; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TOS M, 1984, J LARYNGOL OTOL, V98, P685, DOI 10.1017/S0022215100147292; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; WESTERMARK B, 1973, INT J CANCER, V12, P438, DOI 10.1002/ijc.2910120215	31	62	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2135	2144						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8035998				2022-12-28	WOS:A1994NX62900003
J	BREIT, TM; WOLVERSTETTERO, ILM; VANDONGEN, JJM				BREIT, TM; WOLVERSTETTERO, ILM; VANDONGEN, JJM			LINEAGE-SPECIFIC DEMETHYLATION OF TAL-1 GENE BREAKPOINT REGION DETERMINES THE FREQUENCY OF TAL-1 DELETIONS IN ALPHA-BETA LINEAGE T-CELLS	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; SITE-SPECIFIC DELETIONS; LOOP-HELIX PROTEIN; V(D)J RECOMBINATION; METHYLATION STATUS; CHAIN GENE; SCL GENE; CHROMOSOME-TRANSLOCATION; CHROMATIN STRUCTURE; DNA METHYLATION	tal-1 deletions are caused by a site specific recombination, which exclusively occurs in 12-26% of T-cell acute lymphoblastic leukemias (T-ALL). In a previous study on a large series of T-ALL we demonstrated an apparent preferential occurrence of tal-1 deletions in CD3(-) and CD3(+) alpha beta lineage T-ALL with TcR-delta gene deletions on one or both alleles. In the present study we investigated whether accessibility of the tal-1 deletion breakpoint regions influences the preferential occurrence in specific T-ALL subgroups. Because DNA methylation is assumed to determine accessibility of DNA for recombination, the methylation status of the tal-1 deletion type 1 breakpoint regions (sildb and taldb1) was studied. Although the sildb were completely demethylated in all T-ALL, preferential (de)methylation configurations of the taldb1 were observed in the analysed 119 T-ALL. Most TcR-alpha beta(+) T-ALL contained completely demethylated taldb1 (77%), whereas in most TcR-gamma delta(+) T-ALL partial or complete methylation occurred (42% and 47%, respectively). In T-ALL subgroups defined by different TcR-delta gene configurations also preferential taldb1 (de)methylation patterns were seen, which was most prominent in T-ALL with both TcR-delta genes deleted (84% complete demethylation). The previously observed preferential occurrence of tal-1 deletion type 1 in TcR-alpha beta(+) vs CD3(-) T-ALL and in T-ALL with both vs one TcR-delta genes deleted, disappeared when we retricted to T-ALL with completely demethylated taldb1. Moreover, all T-ALL with a tal-1 deletion type 1 (n = 15) contained completely demethylated taldb1. We therefore conclude that complete demethylation of taldb1 is a prerequisite for tal-1 deletions type I and that the differences in tal-1 deletion frequencies observed in the various T-ALL subgroups are caused by differences in the (de)methylation status of taldb1 in these subgroups.	ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT IMMUNOL,3015 GE ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC			van Dongen, Jacques J.M./F-8537-2015	van Dongen, Jacques J.M./0000-0001-7686-0021; van Dongen, Jacques J.M./0000-0002-3650-7087				ADRIAANSEN HJ, 1991, LEUKEMIA, V5, P744; AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; APLAN PD, 1992, J EXP MED, V176, P1303, DOI 10.1084/jem.176.5.1303; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BORIES JC, 1991, BLOOD, V78, P2053, DOI 10.1182/blood.V78.8.2053.bloodjournal7882053; BREIT TM, 1993, J EXP MED, V177, P965, DOI 10.1084/jem.177.4.965; BREIT TM, 1993, BLOOD, V82, P3063; BREIT TM, 1993, LEUKEMIA, V7, P2004; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; DEVILLARTAY JP, 1988, NATURE, V335, P170, DOI 10.1038/335170a0; ENGLER P, 1991, J IMMUNOL, V146, P2826; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FITZGERALD TJ, 1991, BLOOD, V78, P2686; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HOCKETT RD, 1988, P NATL ACAD SCI USA, V85, P9694, DOI 10.1073/pnas.85.24.9694; HSIEH CL, 1992, J BIOL CHEM, V267, P15613; ISOBE M, 1988, P NATL ACAD SCI USA, V85, P3933, DOI 10.1073/pnas.85.11.3933; JONSSON OG, 1991, J CLIN INVEST, V87, P2029, DOI 10.1172/JCI115232; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LITZ CE, 1992, LEUKEMIA, V6, P35; MACINTYRE EA, 1992, BLOOD, V80, P1511; MARTIN D, 1991, J EXP MED, V173, P639, DOI 10.1084/jem.173.3.639; MINOWADA J, 1988, Cancer Reviews, V10, P1; OETTINGER MA, 1992, TRENDS GENET, V8, P413, DOI 10.1016/0168-9525(92)90323-V; OHYASHIKI JH, 1992, CANCER RES, V52, P6598; OHYASHIKI JH, 1993, LEUKEMIA, V7, P801; SATAYANARANA K, 1988, P NATL ACAD SCI USA, V85, P8166; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SHIEH CL, 1992, EMBO J, V11, P315; TAUCHI T, 1991, CANCER RES, V51, P2917; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TSUKAMOTO N, 1992, EXP HEMATOL, V20, P1061; VANDONGEN JJM, 1990, THYMUS, V16, P207; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1; WAALWIJK C, 1978, NUCLEIC ACIDS RES, V5, P3231, DOI 10.1093/nar/5.9.3231	55	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1847	1853						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208530				2022-12-28	WOS:A1994NR68500006
J	DECSI, A; PEIFFER, RL; QIU, TH; LEE, DC; FRIDAY, JT; BAUTCH, VL				DECSI, A; PEIFFER, RL; QIU, TH; LEE, DC; FRIDAY, JT; BAUTCH, VL			LENS EXPRESSION OF TGF-ALPHA IN TRANSGENIC MICE PRODUCES 2 DISTINCT EYE PATHOLOGIES IN THE ABSENCE OF TUMORS	ONCOGENE			English	Article							GROWTH-FACTOR-ALPHA; MESSENGER-RNAS; DEVELOPMENTAL EXPRESSION; GERM-LINE; GENE; DIFFERENTIATION; OVEREXPRESSION; BETA; EGF; SEQUENCES	Transgenic mice carrying the rat TGF alpha minigene linked to the alpha A crystallin promoter were generated to investigate the effects of expression of this growth factor in the lens of the eye. All transgenic mice exhibited eye abnormalities in the absence of overt tumors, and two distinct and heritable phenotypes were observed. Five lineages produced 'squinting' transgenic mice characterized by microphthalmic eyes with severe lens and retinal dysplasia, and four lineages produced 'bulged' transgenic mice with eyes that exhibited enlarged globes, lens epithelial hyperplasia, anterior segment dysgenesis, and in some cases retinal dysplasia. The eye perturbations of both phenotypes were evident histologically by 1 week of age, and the eyes of squinting mice were abnormal during embryonic development. The squinting phenotype was dominant over the bulged phenotype in intercrosses, suggesting that position effects from the transgene integration site resulted in differences in TGF alpha expression between the two phenotypes. In situ hybridization showed that TGF alpha transgene expression was confined to the lens or lens rudiment of all transgenic eyes despite the involvement of non-lenticular tissues in the pathology. These results show that inappropriate expression of TGF alpha in the eye can disrupt the communication required to coordinate normal eye development.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT OPHTHALMOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043174] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P; BALKAN W, 1992, DEV BIOL, V151, P622, DOI 10.1016/0012-1606(92)90200-Z; BAUTCH VL, 1986, J VIROL, V60, P693, DOI 10.1128/JVI.60.2.693-701.1986; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; CHEPELINSKY AB, 1985, P NATL ACAD SCI USA, V82, P2334, DOI 10.1073/pnas.82.8.2334; COULOMBRE AJ, 1964, J EXP ZOOL, V156, P39, DOI 10.1002/jez.1401560104; DELARCO JE, 1980, J CELL PHYSIOL, V102, P267, DOI 10.1002/jcp.1041020218; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; Green M.C., 1981, GENETIC VARIANTS STR; GRIEP A E, 1990, New Biologist, V2, P727; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HEM E, 1992, OPHTHALMIC PAEDIATRI, V13, P137; HOGEN B, 1986, MANIPULATING MOUSE E; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KHILLAN JS, 1987, GENE DEV, V1, P1327, DOI 10.1101/gad.1.10.1327; LEE DC, 1985, MOL CELL BIOL, V5, P3644, DOI 10.1128/MCB.5.12.3644; LILLIEN L, 1992, DEVELOPMENT, V115, P253; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCAVOY J W, 1990, Progress in Growth Factor Research, V2, P29, DOI 10.1016/0955-2235(90)90008-8; NAKAMURA T, 1989, New Biologist, V1, P193; NISTER M, 1988, CANCER RES, V48, P3910; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PEI YF, 1970, ANAT REC, V168, P105, DOI 10.1002/ar.1091680109; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; REISS M, 1991, CANCER RES, V51, P6254; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SCHULZ MW, 1993, DEVELOPMENT, V118, P117; SHIELDS MB, 1985, SURV OPHTHALMOL, V29, P387, DOI 10.1016/0039-6257(85)90205-X; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; VARNUM DS, 1968, J HERED, V59, P147, DOI 10.1093/oxfordjournals.jhered.a107667; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZWANN J, 1975, DEV BIOL, V44, P306	51	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1965	1975						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208543				2022-12-28	WOS:A1994NR68500021
J	RENAULD, JC; VANDERLUGT, N; VINK, A; VANROON, M; GODFRAIND, C; WARNIER, G; MERZ, H; FELLER, A; BERNS, A; VANSNICK, J				RENAULD, JC; VANDERLUGT, N; VINK, A; VANROON, M; GODFRAIND, C; WARNIER, G; MERZ, H; FELLER, A; BERNS, A; VANSNICK, J			THYMIC LYMPHOMAS IN INTERLEUKIN-9 TRANSGENIC MICE	ONCOGENE			English	Article							CELL GROWTH-FACTOR; ENHANCING ACTIVITY MEA; CD4+ T-CELLS; FACTOR P40; EXPRESSION; CDNA; PROLIFERATION; GLYCOPROTEIN; SEQUENCES; P40/IL-9	Transgenic mice overexpressing the interleukin 9 gene were generated to study the biological activity of this cytokine in vivo. Although no major histological or morphological modifications of the lymphoid system were observed in most animals, similar to 7% of transgenic mice developed thymic lymphomas at the age of 3-9 months. The tumor cells, which were clonal, with unique T cell rearrangements, were double positive for the expression of CD4 and CD8. The need for additional transforming events, suggested by the low incidence of spontaneous tumors, was further indicated by the high susceptibility of the transgenic animals to injections of low doses of N-methyl-N-nitrosourea, a chemical carcinogen with a thymic tropism. Expression of interleukin 9 was required for optimal tumor growth in vivo, as one of the tumors studied, which had lost the transgene, was much more efficiently transplanted into transgenic than in normal mice. Moreover, the in vitro proliferative activity of interleukin 9 on cell lines derived from such transgene-negative tumors suggests that an autocrine loop mediates the proliferation of these cells in vivo. Taken together, these results indicate that dysregulated IL-9 expression could be involved in the development of some T cell malignancies.	UNIV CATHOLIQUE LOUVAIN,DEPT PATHOL,B-1200 BRUSSELS,BELGIUM; UNIV LUBECK,INST PATHOL,W-2400 LUBECK,GERMANY; NETHERLANDS CANC INST,AMSTERDAM,NETHERLANDS	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Lubeck; Netherlands Cancer Institute	RENAULD, JC (corresponding author), UNIV CATHOLIQUE LOUVAIN,LUDWIG INST CANC RES,BRUSSELS BRANCH & EXPTL MED,B-1200 BRUSSELS,BELGIUM.		Feller, Alfred/E-3853-2010; Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BRUCE J, 1981, J IMMUNOL, V127, P2496; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DONAHUE RE, 1990, BLOOD, V75, P2271; DRUEZ C, 1990, J IMMUNOL, V145, P2494; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; GRUSS HJ, 1992, CANCER RES, V52, P1026; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HOUSSIAU FA, 1992, J IMMUNOL, V148, P3147; HOUSSIAU FA, 1993, J IMMUNOL, V150, P2634; HULTNER L, 1990, EXP HEMATOL, V18, P873; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; KELLEHER K, 1991, BLOOD, V77, P1436; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; MERZ H, 1991, BLOOD, V78, P1311; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; RENAULD J-C, 1990, Cytokine, V2, P9, DOI 10.1016/1043-4666(90)90037-T; RENAULD JC, 1990, J IMMUNOL, V144, P4235; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; SCHMITT E, 1989, EUR J IMMUNOL, V19, P2167, DOI 10.1002/eji.1830191130; SIU G, 1984, NATURE, V311, P344, DOI 10.1038/311344a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUDA T, 1990, J IMMUNOL, V144, P1783; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; VANSNICK J, 1989, J EXP MED, V169, P363, DOI 10.1084/jem.169.1.363; VINK A, 1993, EUR J IMMUNOL, V23, P1134, DOI 10.1002/eji.1830230523; WILDE D, 1982, J IMMUNOL, V131, P2178; WILLIAMS DE, 1990, BLOOD, V76, P906; YANG YC, 1989, BLOOD, V74, P1880	36	131	134	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1327	1332						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152793				2022-12-28	WOS:A1994NH40100003
J	BOUWMEESTER, T; VANWIJK, I; WEDLICH, D; PIELER, T				BOUWMEESTER, T; VANWIJK, I; WEDLICH, D; PIELER, T			FUNCTIONAL-ASPECTS OF B-MYB IN EARLY XENOPUS DEVELOPMENT	ONCOGENE			English	Article							C-MYB; DNA-BINDING; A-MYB; EXPRESSION; PROTEIN; DIFFERENTIATION; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; INVITRO	The gene encoding Xenopus B-Myb (XB-Myb), a protein structurally related to the nuclear protooncogene product c-Myb, is expressed in early Xenopus embryogenesis. We report on developmental alterations in the nucleocytoplasmic distribution and phosphorylation of XB-Myb in Xenopus oocytes and embryos, as well as on a negative regulatory role of the carboxyl terminus in sequence specific DNA binding. In growing oocytes and early embryonic stages the protein is primarily located in the nucleus; in the full-grown oocyte, however, it remains sequestered in the cytoplasmic compartment. Upon meiotic maturation of the oocyte, XB-Myb becomes hyperphosphorylated. Oocyte/egg isolates of XB-Myb are inhibited in their specific DNA binding activity; truncation of the carboxyl terminal region relieves this block in nucleic acid recognition. Furthermore, we have used overexpression of XB-Myb in Xenopus embryos by means of mRNA injection as an assay for gene function in vivo. Overexpression of full-length XB-Myb, not of the carboxyl terminal deletion mutant, results in an altered morphology of lateral plate mesoderm.	MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,D-14195 BERLIN,GERMANY; UNIV ULM,BIOCHEM ABT,D-89081 ULM,GERMANY	Max Planck Society; Ulm University								ARSURA M, 1992, BLOOD, V79, P2708; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DANKER K, 1992, DEV DYNAM, V193, P136, DOI 10.1002/aja.1001930205; DENT JA, 1989, DEVELOPMENT, V105, P61; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GARCIA A, 1991, ONCOGENE, V6, P265; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HARLOW E, 1988, ANTIBODIES LABORATOR; HERZBERG F, 1991, MECH DEVELOP, V35, P33, DOI 10.1016/0925-4773(91)90039-9; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KIMELMAN D, 1992, DEVELOPMENT, V114, P261; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCMAHON J, 1988, ONCOGENE, V3, P717; MILLER M, 1991, DEVELOPMENT, V113, P569; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIETFELD W, 1993, J MOL BIOL, V230, P400, DOI 10.1006/jmbi.1993.1158; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	44	10	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1029	1038						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134106				2022-12-28	WOS:A1994NC04800004
J	SANG, BC; CHEN, JY; MINNA, J; BARBOSA, MS				SANG, BC; CHEN, JY; MINNA, J; BARBOSA, MS			DISTINCT REGIONS OF P53 HAVE A DIFFERENTIAL ROLE IN TRANSCRIPTIONAL ACTIVATION AND REPRESSION FUNCTIONS	ONCOGENE			English	Article							WILD-TYPE P53; CELL LUNG-CANCER; DNA-BINDING; T-ANTIGEN; GENE-EXPRESSION; PROTEINS BIND; MUTANT P53; SEQUENCE; MUTATIONS; INVITRO	The wild type p53 tumor suppressor protein transactivates genes carrying p53 responsive elements and represses several TATA containing promoters. We report in vivo gene regulation assays where deletion of the N-terminal 75 residues (Delta N75) results in loss of transactivation of p53CON and repression of an HPV 6 reporter. In contrast, removal of the C-terminal 75 (Delta C75) amino acids resulted in a truncated protein capable of trans-activating p53CON but not able to repress the HPV 6 reporter. In vitro protein association assays revealed that the Delta N75 protein, but not the Delta C75 truncated protein, could oligomerize with the wild type p53 protein. Co-transfection assays with wild type p53 showed that the Delta N75 mutant protein has a dominant negative effect on trans-activation function. However, it does not affect the ability of wild type p53 to repress transcription from the HPV 6 reporter. The Delta C75 protein had no effect on the ability of the wild type p53 to activate p53CON or repress the HPV 6 reporter. These results suggest that distinct regions of p53 have a differential role in transcriptional activation and repression functions.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Chen, Joanne Jeou-Yuan/S-7022-2018		NCI NIH HHS [CA55703, CA58220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055703, P20CA058220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWER M, 1986, CANCER RES, V46, P798; CHEN JY, 1993, ONCOGENE, V8, P2159; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MITSUDOMI T, 1992, ONCOGENE, V7, P171; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1992, ONCOGENE, V7, P1153; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	49	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					853	859						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108128				2022-12-28	WOS:A1994MW55100021
J	FRANKE, TF; TARTOF, KD; TSICHLIS, PN				FRANKE, TF; TARTOF, KD; TSICHLIS, PN			THE SH2-LIKE AKT HOMOLOGY (AH) DOMAIN OF C-AKT IS PRESENT IN MULTIPLE COPIES IN THE GENOME OF VERTEBRATE AND INVERTEBRATE EUKARYOTES - CLONING AND CHARACTERIZATION OF THE DROSOPHILA-MELANOGASTER C-AKT HOMOLOG DAKT1	ONCOGENE			English	Article							PROTEIN-KINASE-C; SEQUENCE-ANALYSIS; GENE; DNA; CHROMOSOME; ONCOGENE	The Akf proto-oncogene encodes a serine-threonine protein kinase whose carboxyterminal catalytic domain is closely related to the catalytic domains of all the known members of the protein kinase C (PKC) family. Akt, however, differs from PKC in its N-terminal region which contains a domain related distantly to the SH2 domain of cytoplasmic tyrosine kinases and other signalling proteins, which we have named Akt homology (AH) domain. Low stringency hybridization of a c-akt AH probe to a panel of genomic DNAs from vertebrate and invertebrate eucaryotes detected multiple DNA bands (perhaps multiple genes) in all tested species. Drosophila DNA contains at least three hybridizing DNA bands. One of them was cloned, and found by sequence analysis, to define an Akt related gene (Dakt1). Comparison between the coding regions of c-akt and Dakt1 revealed 64.6% identity at the nucleotide level and 76.5% similarity at the amino acid level. The highest degree of homology was detected in the AH domain (68.3% similarity at the amino acid level) and the catalytic domain (83.3% similarity). Additional sequence comparisons revealed that the amino acid similarity between the catalytic domains of Dakt1 and the three known members of the Drosophila protein kinase C (PKC) family, Dpkc1, Dpkc2 and Dpkc3, is 68%, 63.6% and 67.1%, respectively. Dakt1 was mapped to Drosophila chromosome 3R 89BC. Its expression is subject to developmental regulation with the highest levels detected within the fourth hour of embryonic development. These results confirm that the AH domain of Akt defines new protein families in both vertebrate and invertebrate eucaryotes. The high degree of homology between the catalytic domains of Dakt1 and the three known members of the Drosophila PKC family suggests an evolutionarily conserved functional relationship between the members of the two families.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-06927, CA-38047] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA038047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BEDIAN V, 1991, DEV GENET, V12, P188, DOI 10.1002/dvg.1020120303; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGELS WR, 1986, FOCUS, V8, P6; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HICKS JL, 1992, J CELL SCI, V101, P247; Jowett T., 1986, DROSOPHILA, P275; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAWRENCE PA, 1992, MAKING FLY, P13; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NELSON CR, 1992, MOL GEN GENET, V235, P11, DOI 10.1007/BF00286176; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; ROSENTHAL A, 1987, EMBO J, V6, P433, DOI 10.1002/j.1460-2075.1987.tb04773.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEGFRIED E, 1990, TRENDS GENET, V6, P357, DOI 10.1016/0168-9525(90)90277-D; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; VASLET CA, 1980, NATURE, V285, P674, DOI 10.1038/285674a0; Wieschaus E., 1986, P199	32	36	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					141	148						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302573				2022-12-28	WOS:A1994MW24700017
J	BHATTACHARYA, G; LEE, L; REDDY, ESP; RAO, VN				BHATTACHARYA, G; LEE, L; REDDY, ESP; RAO, VN			TRANSCRIPTIONAL ACTIVATION DOMAINS OF ELK-1, DELTA-ELK-1 AND SAP-1 PROTEINS	ONCOGENE			English	Note							ETS-RELATED PROTEIN; LONG TERMINAL REPEAT; DNA-BINDING; C-FOS; C-ETS-1 PROTOONCOGENE; FACTOR P62TCF; SEQUENCES; ONCOGENE; GENE; COOPERATE	elk-1, an ets related gene codes for a sequence specific DNA binding transcriptional activator which in association with serum response factor (SRF) forms a ternary complex at the c-fos serum response element (SRE). Recently the C-terminal region of both elk-1 and Delta elk-1 proteins was shown to undergo phosphorylation by MAP kinases and function as an activator of MAP kinases. Here we show that Delta elk-1 and two other elk-1 related proteins SAP-1a and SAP-1b, like elk-1, can function as transcriptional activators. In this report we have localized the transcriptional activation domain of the SAP-I proteins (STA) to a large portion of the carboxy terminal region and have identified two autonomous transcriptional activation domains in the elk-1 protein, one at the amino (ETA-1) and the other at the carboxy terminal region (ETA-2). Delta elk-1 protein contains only the ETA-2 domain indicating differential usage of activation domains as a result of alternative splicing. We can speculate that the ETA-1 domain can function in vivo independent of ETA-2, but the ETA-2 domain can function either in the absence of ETA-1 (as seen in Delta elk-1) or in the presence of accessory proteins like SRF. The role of SRF in the activation of the ternary complex might be to bind to the ETA-1 domain, somehow conceal it's activation domain and in the process unmask the ETA-2 domain (for phosphorylation by MAP kinases) and activate transcription. The ETA-1 domain may be functioning as a negative regulatory transcriptional activation domain for ETA-2 These observations suggest that the elk-1 family of proteins may not only regulate fos and MAP kinases but also other elk-1 target genes that are essential for cellular growth control.	JEFFERSON CANC INST,PHILADELPHIA,PA 19107; PROGRAMME RESOURCES INC,FREDERICK,MD 21702	Jefferson University								BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MAKI RA, 1993, SCIENCE, V259, P1622; MARIAS R, 1993, CELL, V73, P381; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1993, CANCER RES, V53, P3449; RAO VN, 1992, ONCOGENE, V11, P2335; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1991, ONCOGENE, V6, P2285; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; [No title captured]	36	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3459	3464						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247551				2022-12-28	WOS:A1993MG78200033
J	SUZUKI, T; HIRAI, H; FUJISAWA, J; FUJITA, T; YOSHIDA, M				SUZUKI, T; HIRAI, H; FUJISAWA, J; FUJITA, T; YOSHIDA, M			A TRANSACTIVATOR TAX OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1 BINDS TO NF-KAPPA-B P50 AND SERUM RESPONSE FACTOR (SRF) AND ASSOCIATES WITH ENHANCER DNAS OF THE NF-KAPPA-B SITE AND CARG BOX	ONCOGENE			English	Article							TRANSCRIPTIONAL ACTIVATION; HTLV-I; PROTEIN-INTERACTION; GENE-EXPRESSION; P40X; RETROVIRUS; PRECURSOR; PROMOTER; ANTIBODIES; INDUCTION	A transcriptional activator of human T-cell leukemia virus type 1 (HTLV-1) activates at least three distinct enhancers: the viral 21-bp enhancer, the NF-kappaB binding site of the IL-2Ralpha gene and the CArG box of the c-fos gene. To understand the mechanisms of Tax transactivations of the NF-kappaB enhancer and CArG box. the interactions of Tax protein with their binding factors were analysed. Using a DNA affinity precipitation (DNAP) assay, we found here that Tax associates with the DNA sequences of the NF-kappaB site and CArG box. These Tax associations with enhancers were observed only in the presence of a nuclear factor(s) and were equal to the activating capacities of Tax mutants. To identify the nuclear factor(s), we defined conditions under which no Tax binding to the NF-kappaB binding site and CArG box was detected with a nuclear extract of 293T cells. Under these conditions, tranfections with cDNAs of the NF-kappaB p50 and serum response factor (SRF) produced a factor(s) that mediated Tax binding to the NF-kappaB site and the CArG box respectively. Furthermore, purified Tax protein interacted with purified NF-kappaB p50 and purified SRF, indicating their direct bindings. These observations indicate that Tax protein associates with enhancer sequences of the NF-kappaB site and CArG box through NF-kappaB p50 and SRF respectively. Previously we demonstrated that Tax interacts with CREB and CREM proteins that bind to the 21-bp enhancer DNA. These results together suggest that indirect binding of Tax to DNA through each enhancer binding protein is a general mechanism for Tax tran-activation of transcription.	UNIV TOKYO,INST MED SCI,DEPT BIOL ANIM,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; ROCKEFELLER UNIV,NEW YORK,NY 10021	University of Tokyo; Rockefeller University								BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GESSAIN A, 1985, LANCET, V2, P1247; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIYOKAWA T, 1985, VIROLOGY, V147, P462, DOI 10.1016/0042-6822(85)90149-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1987, BIOCHIM BIOPHYS ACTA, V907, P145, DOI 10.1016/0304-419X(87)90003-5; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	35	128	128	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2391	2397						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361755				2022-12-28	WOS:A1993LT36800009
J	SKERKA, C; ZIPFEL, PF; SIEBENLIST, U				SKERKA, C; ZIPFEL, PF; SIEBENLIST, U			2 REGULATORY DOMAINS ARE REQUIRED FOR DOWN-REGULATION OF C-MYC TRANSCRIPTION IN DIFFERENTIATING U937 CELLS	ONCOGENE			English	Article							BURKITT-LYMPHOMA; TRANS-ACTIVATION; DNA-REPLICATION; PROTEIN-BINDING; HL60 CELLS; EXPRESSION; GENE; ONCOGENE; PROMOTER; INITIATION	In many differentiating cells, a reduction of c-myc proto-oncogene expression is a prerequisite for terminal differentiation. The downmodulation of c-myc in differentiating cells is due to at least two different mechanisms: (i) an elongation block to c-myc transcription activated during an early phase of differentiation and (ii) an inhibition of transcription initiation activated during a later phase. In order to determine cis-acting target structures of the c-myc gene required for the late-phase downregulation of transcriptional initiation, we permanently transfected U937 cells with constructs containing the bacterial chloramphenicol acetyl transferase (CAT) gene driven by a 2.8 kb c-myc promoter region or deletions thereof. We determined two distinct domains in the c-myc promoter region both of which are essential for efficient terminal downregulation: a proximal domain and a distal domain which are located between base pairs - 606 to - 101, and between - 2392 to - 1396, respectively, relative to P1. The identification of two distinct regulatory elements suggests the requirement and cooperation of two regulatory factors as an essential event for mediating differentiation-induced downregulation of c-myc in monocytic cells. The implications of these results for deregulation of the translocated c-myc allele in Burkitt's lymphoma are discussed.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	SKERKA, C (corresponding author), BERNHARD NOCHT INST TROP MED,BERNARD NOCHT STR 74,W-2000 HAMBURG 36,GERMANY.							ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; Battey, 1986, BASIC METHODS MOL BI; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; Dimitrovsky E., 1986, NATURE, V322, P748; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GIDLUND M, 1981, NATURE, V292, P848, DOI 10.1038/292848a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KELLY K, 1985, J CLIN IMMUNOL, V5, P65, DOI 10.1007/BF00915003; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; PELLICI PG, 1986, P NATL ACAD SCI USA, V83, P2984; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; SAKELSA K, 1991, ONCOGENE RES, V6, P73; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SLUNGAARD A, 1987, J CLIN INVEST, V79, P1542, DOI 10.1172/JCI112987; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527	37	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2135	2143						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336940				2022-12-28	WOS:A1993LP17100014
J	CHUNG, SW; CAI, YL; NYEIN, R; BRIZZOLARA, E; DERIEL, K; WONG, PMC				CHUNG, SW; CAI, YL; NYEIN, R; BRIZZOLARA, E; DERIEL, K; WONG, PMC			ENDOGENOUS GROWTH-FACTOR PATTERNS MODULATE HEMATOPOIETIC LINEAGE DEVELOPMENT	ONCOGENE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; ABL TYROSINE KINASE; ABELSON VIRUS; C-ABL; AUTOCRINE GROWTH; STEM-CELLS; V-ABL; MYELOPROLIFERATIVE DISEASE	Hemopoietic growth factors play an important role during stem cell differentiation, and multipotent hemopoietic cells expressing abl oncogenes can cause stem cell diseases in mice. To further elucidate the mechanism of disease development, we examined the initial changes of normal and abl-transduced progenitor cells early in culture, including the endogenous production of growth factors. From 2-3 days methycellulose cultures, we isolated colonies of early cells and subjected them to RT-PCR analysis. They were found to produce endogenous IL-1 alpha and IL-4. Treatment of these early cells with the antisense oligonucleotides directed against the mRNA of the growth factors did not prevent colony formation. However, the percentage of pure macrophage colonies in cultures containing the antisense IL-1 alpha was increased from 26-60%. This effect was not observed when the antisense oligomers were added 2 days after initiation of culture. We also transduced the progenitor cells with retrovirus vectors carrying either a neo(r) gene (N2) or a v-abl oncogene (A-MuLV or NSabl). After their culture in methylcellulose, we examined the types of colonies developed, growth factor expression by the early cells and their proliferation rate. While the ratio of erythroid to non-erythroid hemopoietic colonies in uninfected culture and N2-infected culture was 0.8, the ratio in A-MuLV-infected culture was 6.0, and in NSabl-infected culture, 3.1. RT-PCR analysis on colonies of abl-transduced cells from 2-3 day cultures indicated a reduction of IL-4 and IL-1 alpha in these cells, and they entered cell division sooner. Our data suggest that hematopoietic lineage development may be a function of the pattern of endogenous as well as exogenous growth factors, and alteration of this pattern either through antisense treatment or v-abl transduction affects the hemopoietic differentiation program.	TEMPLE UNIV, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, DEPT IMMUNOL & MICROBIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	CHUNG, SW (corresponding author), SUNY HLTH SCI CTR, MORSE INST MOLEC GENET, DEPT MICROBIOL & IMMUNOL, BROOKLYN, NY 11203 USA.				NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041298] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA12227] Funding Source: Medline; NHLBI NIH HHS [HL46547] Funding Source: Medline; NIDDK NIH HHS [DK41298] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CHUNG SW, 1988, BLOOD, V71, P973; CHUNG SW, 1986, BLOOD, V68, P1074; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; CHUNG SW, 1987, RECENT ADV LEUKEMIA, V61, P181; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; Hariharan I K, 1988, Oncogene Res, V3, P387; HERMINE O, 1991, BLOOD, V78, P2253; HUMPHRIES RK, 1988, EXP HEMATOL, V16, P774; JEAN JYW, 1993, CURR BIOL, V3, P35; JOHNSON GR, 1985, EXP HEMATOL, V13, P200; JURGENSEN CH, 1986, J IMMUNOL, V136, P4542; KATAYAMA N, 1993, BLOOD, V81, P610; KELLER G, 1989, GENE DEV, V3, P827, DOI 10.1101/gad.3.6.827; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KISHI K, 1989, J CELL PHYSIOL, V139, P463, DOI 10.1002/jcp.1041390303; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MURAGUCHI A, 1986, J IMMUNOL, V137, P179; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PECH N, 1993, BLOOD, V82, P1502; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; RAMBALDI A, 1987, BLOOD, V69, P1409; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SIRARD C, 1994, BLOOD, V83, P1575; SMITH KA, 1980, J EXP MED, V151, P1551, DOI 10.1084/jem.151.6.1551; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; WANECK GL, 1981, CELL, V26, P79, DOI 10.1016/0092-8674(81)90035-0; WANECK GL, 1986, CELL, V44, P337, DOI 10.1016/0092-8674(86)90768-3; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG PMC, 1987, EXP HEMATOL, V15, P280; WONG PMC, 1988, EXP HEMATOL, V16, P5; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; WONG PMC, 1982, P NATL ACAD SCI-BIOL, V79, P2952, DOI 10.1073/pnas.79.9.2952; WONG PMC, 1987, GENE DEV, V1, P358, DOI 10.1101/gad.1.4.358; ZUBIAGA AM, 1991, J IMMUNOL, V146, P3849	49	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3527	3533						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970713				2022-12-28	WOS:A1994PT39200015
J	KATAHIRA, J; SIOMI, H; ISHIZAKI, T; UMEMOTO, T; TANAKA, Y; SHIDA, H				KATAHIRA, J; SIOMI, H; ISHIZAKI, T; UMEMOTO, T; TANAKA, Y; SHIDA, H			A CELLULAR PROTEIN WHICH IS COPRECIPITATED WITH HTLV-I REX PROTEIN IN THE PRESENCE OF THE TARGET MESSENGER-RNA	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; RNA RESPONSE ELEMENTS; DOMINANT-NEGATIVE MUTANTS; LEUKEMIA-VIRUS; HIV-1 REV; GENE-EXPRESSION; MESSENGER-RNA; TYPE-1 REV; REGULATORY PROTEINS	We examined the cellular protein(s) which can associate with Rex protein of human T cell leukemia virus type I (HTLV-I), using Rex-maltose binding protein (MBP) fusion protein. Immunoprecipitation of RexMBP with anti-MBP antibody revealed that a 24 kD protein (p24) associated with RexMBP only in the presence of Rex-responsive mRNA. The fact that p24 was present in both the nucleus and the cytoplasm is consistent with a role of Rex in the nucleo-cytoplasmic transport of viral mRNAs. P24 did not interact with nonfunctional Rex mutant proteins even if they had RNA binding activity in vitro. These results suggest the possible involvement of p24 in the Rex function through a complex formation with Rex on Rex-responsive mRNA.	KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; KITASATO UNIV,SCH HYG SCI,DEPT IMMUNOL,SAGAMIHARA,KANAGAWA 228,JAPAN; UNIV OSAKA PREFECTURE,COLL AGR,VET PUBL HLTH LAB,SAKAI,OSAKA 591,JAPAN	Kyoto University; University of Pennsylvania; Kitasato University; Osaka Metropolitan University			Siomi, Haruhiko/A-7020-2015	Siomi, Haruhiko/0000-0001-8690-3822				AHMED YF, 1990, GENE DEV, V4, P1014, DOI 10.1101/gad.4.6.1014; ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; BALLAUN C, 1991, J VIROL, V65, P4408, DOI 10.1128/JVI.65.8.4408-4413.1991; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; ETCHISON D, 1987, J VIROL, V61, P2702, DOI 10.1128/JVI.61.9.2702-2710.1987; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; HADZOPOULOUCLAD.M, 1989, J VIROL, V63, P1959; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLLAND MJ, 1990, PCR PROTOCOLS GUIDE, P169; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SAKAI H, 1990, J VIROL, V64, P5833, DOI 10.1128/JVI.64.12.5833-5839.1990; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; TRONO D, 1990, EMBO J, V9, P4155, DOI 10.1002/j.1460-2075.1990.tb07638.x; UNGE T, 1991, P NATL ACAD SCI USA, V88, P7145, DOI 10.1073/pnas.88.16.7145; WEICHSELBRAUN I, 1992, J VIROL, V66, P4540, DOI 10.1128/JVI.66.7.4540-4545.1992; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; WINSLOW BJ, 1993, J VIROL, V67, P2349, DOI 10.1128/JVI.67.4.2349-2354.1993; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	59	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3535	3544						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970714				2022-12-28	WOS:A1994PT39200016
J	SALCINI, AE; MCGLADE, J; PELICCI, G; NICOLETTI, I; PAWSON, T; PELICCI, PG				SALCINI, AE; MCGLADE, J; PELICCI, G; NICOLETTI, I; PAWSON, T; PELICCI, PG			FORMATION OF SHC-GRB2 COMPLEXES IS NECESSARY TO INDUCE NEOPLASTIC TRANSFORMATION BY OVEREXPRESSION OF SHC PROTEINS	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; GRB2 ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; EGF RECEPTOR; RAS; DOMAINS; ACTIVATION; SEVENLESS	The mammalian SHC gene encodes three overlapping proteins which all contain a carboxy-terminal SH2 domain. Shc proteins are phosphorylated on tyrosine by a variety of receptor and cytoplasmic tyrosine kinases. Phosphorylated Shc proteins form a complex with the SH2-SH3 containing Grb2 protein which is implicated in the regulation of Ras, suggesting that Shc is involved in the intracellular transmission of growth signals from activated tyrosine kinases to Ras. Overexpression of Shc proteins in cultured fibroblasts induces a transformed phenotype. We now report that, in vitro, the high affinity binding of Grb2 to Shc proteins requires phosphorylation of Shc at Tyr317, which lies within the high affinity binding motif for the Grb2 SH2 domain, pYVNV, where Asn at the +2 position is crucial for complex formation. In vivo, Tyr317 is the major, but not the only, site for Shc phosphorylation, and is the sole Shc high affinity binding site for Grb2. Mutant Shc proteins with substitution of the Tyr317 by Phe lose the capacity to be highly phosphorylated on tyrosine upon growth factor receptor activation, to bind Grb2 and to induce neoplastic transformation. In contrast, Shc proteins that have an extensive aminoterminal deletion, but retain the Tyr317 site and the SH2 domain conserve the capacity to be phosphorylated, to bind to Grb2 and to induce cell transformation. These data indicate that the formation of the Shc-Grb2 complex is a crucial event in the transformation induced by overexpression of Shc and support the notion that Shc proteins can deliver activation signals to RAS.	UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED 1, I-06100 PERUGIA, ITALY; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	University of Perugia; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013; Salcini, Anna Elisabetta/G-4472-2017; Pelicci, Giuliana/AAA-8921-2022; Pelicci, Pier Giuseppe/AAL-6572-2020	Pelicci, Giuliana/0000-0003-0986-8255; Salcini, Anna Elisabetta/0000-0001-5828-2512				BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWMAN S, 1990, TECHNIQUE, V5, P254; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAMEN JE, 1993, BLOOD, V82, P2296; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	210	215	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2827	2836						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084588				2022-12-28	WOS:A1994PG82200008
J	HUSSAIN, SP; AGUILAR, F; AMSTAD, P; CERUTTI, P				HUSSAIN, SP; AGUILAR, F; AMSTAD, P; CERUTTI, P			OXY-RADICAL INDUCED MUTAGENESIS OF HOTSPOT CODON-248 AND CODON-249 OF THE HUMAN P53 GENE	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; OXIDATIVE DNA DAMAGE; HEPATOCELLULAR-CARCINOMA; MAMMALIAN-CELLS; NITRIC-OXIDE; MUTATIONS; 8-HYDROXYGUANINE; CANCER; SPECIFICITY; PROMOTION	Oxidants are suspected to represent important human carcinogens. They are mutagenic and may participate in the activation of proto-oncogenes and the inactivation of tumor suppressor genes. We have studied the capacity of hydrogen peroxide plus ferric chloride (FeCl3) to induce base pair changes in the hotspot codons 248 and 249 of the p53 tumor suppressor gene in human fibroblasts. In codon 248 (CGG) H2O2/FeCl3 only induced the transversion of G to C in the second position and the transition of G to A in the third position. No evidence was obtained for spontaneous or oxidant-induced deamination of 5-methylcytosine in the CpG dinucleotide of codon 248 since neither C to T transitions in the first position nor G to A transitions in the middle position were observed. H2O2/FeCl3, efficiently induced G to T transversions at both G-residues of codon 249 (AGG) and C to A transversions at the first position of codon 250 (CCC). It is evident that H2O2/FeCI3 possesses essentially the same mutagenic specificity for codons 249 and 250 of p53 as bulky carcinogens such as aflatoxin B1, benzo(a)pyrene or heterocyclic amines. In particular, it is not possible to eliminate oxidants from the list of candidate carcinogens which may be responsible for the high incidence of p53 codon 249 AGT mutations in hepatocellular carcinoma from certain areas of the world.	SWISS INST EXPTL CANC RES,DEPT CARCINOGENESIS,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research				Hussain, S. Perwez/0000-0002-2294-522X				AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; BOS JL, 1989, CANCER RES, V49, P4682; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHENG KC, 1992, J BIOL CHEM, V267, P166; DAYAGROSJEAN L, 1993, CANCER RES, V53, P1625; DECUYPERDEBERGH D, 1987, EMBO J, V6, P3155, DOI 10.1002/j.1460-2075.1987.tb02626.x; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; HAYWARD N, 1993, NATURE, V352, P764; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIE AW, 1986, P NATL ACAD SCI USA, V83, P9616, DOI 10.1073/pnas.83.24.9616; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUSSAIN SP, 1994, ONCOGENE, V9, P13; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KOZUMBO WJ, 1985, CHEM-BIOL INTERACT, V54, P199, DOI 10.1016/S0009-2797(85)80163-0; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LI DZ, 1993, CARCINOGENESIS, V14, P169, DOI 10.1093/carcin/14.2.169; LOEB LA, 1988, P NATL ACAD SCI USA, V85, P3918, DOI 10.1073/pnas.85.11.3918; MCBRIDE T, 1991, BIOCHEMISTRY-US, V30, P208; MORAES EC, 1990, CARCINOGENESIS, V11, P283, DOI 10.1093/carcin/11.2.283; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NISHIDA N, 1993, CANCER RES, V53, P368; REID TM, 1993, P NATL ACAD SCI USA, V90, P3904, DOI 10.1073/pnas.90.9.3904; REID TM, 1992, CANCER RES, V52, P1082; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TKESHELASHVILI LK, 1991, J BIOL CHEM, V266, P6401; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068	35	116	120	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2277	2281						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036011				2022-12-28	WOS:A1994NX62900020
J	ISOBE, M; HINODA, Y; IMAI, K; ADACHI, M				ISOBE, M; HINODA, Y; IMAI, K; ADACHI, M			CHROMOSOMAL LOCALIZATION OF AN SH2 CONTAINING TYROSINE PHOSPHATASE (SH-PTP3) GENE TO CHROMOSOME 12Q24.1	ONCOGENE			English	Note							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SEQUENCE SIMILARITY; MOLECULAR-CLONING; EXPRESSION; ACTIVATION; DOMAINS; TRISOMY-12; CORKSCREW; KINASES; CELLS	A genomic DNA fragment, isolated from a human phage library using a human BPTP3 cDNA probe, was shown to be derived from the human SH-PTP3 (also called SH-PTP2, PTP-1D, PTP-2C, or Syp) locus. We have used fluorescent in situ hybridization (FISH) to map SH-PTP3 in chromosome band 12q24.1, a region vicinity to the second locus for autosomal dominant cerebellar ataxia (SCA2).	SAPPORO MED UNIV,SCH MED,DEPT INTERNAL MED,SECT 1,CHUO KU,SAPPORO 060,JAPAN		ISOBE, M (corresponding author), TOYAMA MED & PHARMACEUT UNIV,ORIENTAL MED RES INST,DEPT PATHOBIOCHEM,2630 SUGITANI,TOYAMA 93001,JAPAN.							ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ADACHI M, 1992, CANCER RES, V52, P737; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BARKER HM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P228, DOI 10.1016/0167-4889(93)90014-G; BASTIEN L, 1993, BIOCHEM BIOPH RES CO, V196, P124, DOI 10.1006/bbrc.1993.2224; EINHORN S, 1990, CANCER GENET CYTOGEN, V48, P183, DOI 10.1016/0165-4608(90)90118-T; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; QUE TH, 1993, BLOOD, V82, P571; SAMANIEGO F, 1990, GENE CHROMOSOME CANC, V1, P289, DOI 10.1002/gcc.2870010406; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	23	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1751	1753						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183573				2022-12-28	WOS:A1994NL81500030
J	ANDRES, AC; REID, HH; ZURCHER, G; BLASCHKE, RJ; ALBRECHT, D; ZIEMIECKI, A				ANDRES, AC; REID, HH; ZURCHER, G; BLASCHKE, RJ; ALBRECHT, D; ZIEMIECKI, A			EXPRESSION OF 2 NOVEL EPH-RELATED RECEPTOR PROTEIN-TYROSINE KINASES IN MAMMARY-GLAND DEVELOPMENT AND CARCINOGENESIS	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; BREAST-CANCER; MEDICAL PROGRESS; FAMILY; GENE; MOUSE; IDENTIFICATION; RNA; ONCOGENE; CLONING	To investigate the involvement of protein tyrosine kinases (PTKs) in the growth control of mammary epithelial cells, we have used PCR based cloning to identify PTKs expressed in a mouse mammary epithelial cell line. This approach led to the isolation of two receptor PTKs of the eph-related subfamily; myk-1, a novel member expressed predominantly in lung, heart and mammary gland and myk-2, a close relative of the human eck gene. Northern blot analysis of RNA from mouse mammary glands at different stages of development revealed that myk-1 and myk-2 expression is induced at puberty and differentially regulated during the estrus cycle. myk-1 and myk-2 expression was downregulated during the pregnancy induced differentiation of the mammary gland. Over-expression of myk-1 and myk-2 was found in the undifferentiated and invasive mammary tumors of transgenic mice expressing the Haras oncogene. In contrast, no elevated expression of either gene could be detected in the well differentiated and non-metastatic mammary tumors of c-myc expressing transgenic mice. These results indicate that myk-1 and myk-2 expression is induced during the proliferation of the mammary gland and down-regulated by its differentiation.	UNIV BERN, CLIN & EXPTL RES LAB, CH-3004 BERN, SWITZERLAND	University of Bern								ANDRES AC, 1991, ONCOGENE, V6, P771; BERNS LMJ, 1992, CANCER RES, V52, P1036; Boehme Beatrix, 1993, Oncogene, V8, P2857; CANTLEY LC, 1991, CELL, V64, P235; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESANTES K, 1992, CANCER RES, V52, P1961; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRATOCHWIL K, 1969, DEV BIOL, V20, P46, DOI 10.1016/0012-1606(69)90004-9; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Lofts F J, 1992, Cancer Treat Res, V61, P161; Maniatis T., 1982, MOL CLONING; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RUSSO J, 1989, DEV ONCOL, V58, P133; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	38	135	152	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1461	1467						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152808				2022-12-28	WOS:A1994NH40100019
J	ETIEMBLE, J; DEGOTT, C; RENARD, CA; FOUREL, G; SHAMOON, B; VITVITSKITREPO, L; HSU, TY; TIOLLAIS, P; BABINET, C; BUENDIA, MA				ETIEMBLE, J; DEGOTT, C; RENARD, CA; FOUREL, G; SHAMOON, B; VITVITSKITREPO, L; HSU, TY; TIOLLAIS, P; BABINET, C; BUENDIA, MA			LIVER-SPECIFIC EXPRESSION AND HIGH ONCOGENIC EFFICIENCY OF A C-MYC TRANSGENE ACTIVATED BY WOODCHUCK HEPATITIS-VIRUS INSERTION	ONCOGENE			English	Article							SURFACE-ANTIGEN GENE; B VIRUS; HEPATOCELLULAR-CARCINOMA; N-MYC; INFECTED WOODCHUCKS; RAT-LIVER; MICE; ENHANCER; TUMORS; DNA	The high oncogenic efficiency of woodchuck hepatitis virus (WHV) has been correlated with the ability of this virus to provoke insertional activation of mye family genes. To assess the impact of viral integration on liver cell transformation, we have generated transgenic mice carrying the mutated c-mye gene and adjacent viral DNA from a woodchuck tumor, in original configuration. Virtually all mice from two different strains developed hepatocellular carcinoma with a mean latency period of 8-12 months. The c-mye transgene was expressed transiently in neonatal livers, and re-expressed at preneoplastic and neoplastic stages in adult livers. Woodchuck c-mye mRNA driven by the normal P1 and P2 promoters and WHV-specific transcripts encoding viral surface antigens were produced in a strictly co-regulated fashion during development and tumorigenesis, indicating a predominant regulatory influence of the viral enhancer. Furthermore, the activity of the viral enhancer in response to various biological stimuli was apparently modulated by glucose uptake and glucogon/insulin balance in differentiated hepatocytes. In this model, a viral integration event selected from a naturally occurring tumor proved to be determinant for induction of hepatocarcinogenesis, although enforced, liver-specific expression of c-mye was limited to a particular developmental stage.	INST PASTEUR, INSERM, U163, UNITE RECOMBINAISON & EXPRESS GENET, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE; HOP BEAUJON, ANATOMOPATHOL LAB, CLICHY, FRANCE; HOP ST LOUIS, UNITE RECOMBINAISON GENET, CNRS, UPR 41, PARIS, FRANCE; INSERM, U271, UNITE RECH HEPATITES, LYON, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)								ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; BABINET C, 1985, SCIENCE, V230, P1160, DOI 10.1126/science.3865370; BEASLEY RP, 1981, LANCET, V2, P1129; BULLA GA, 1988, J VIROL, V62, P1437, DOI 10.1128/JVI.62.4.1437-1441.1988; CARTIER N, 1992, ONCOGENE, V7, P1413; CHANDAR N, 1989, P NATL ACAD SCI USA, V86, P2703, DOI 10.1073/pnas.86.8.2703; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DELOIA JA, 1989, J VIROL, V63, P4069, DOI 10.1128/JVI.63.9.4069-4073.1989; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FARZA H, 1988, J VIROL, V62, P4144, DOI 10.1128/JVI.62.11.4144-4152.1988; FARZA H, 1987, P NATL ACAD SCI USA, V84, P1187, DOI 10.1073/pnas.84.5.1187; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GARCIARUIZ JP, 1978, P NATL ACAD SCI USA, V75, P4189; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KORBA BE, 1987, J VIROL, V61, P1318, DOI 10.1128/JVI.61.5.1318-1324.1987; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; MAKINO R, 1984, BIOCHEM BIOPH RES CO, V119, P1096, DOI 10.1016/0006-291X(84)90887-8; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MCGRANE MM, 1992, TRENDS BIOCHEM SCI, V17, P40, DOI 10.1016/0968-0004(92)90426-A; MORIYAMA T, 1990, SCIENCE, V248, P361, DOI 10.1126/science.1691527; MOROY T, 1985, EMBO J, V4, P1507, DOI 10.1002/j.1460-2075.1985.tb03810.x; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MURAKAMI H, 1993, CANCER RES, V53, P1719; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; RUTHER U, 1993, ONCOGENE, V8, P87; SANDGREN EP, 1989, ONCOGENE, V4, P715; SEEGER C, 1991, J VIROL, V65, P1673, DOI 10.1128/JVI.65.4.1673-1679.1991; SHAMOON BM, 1991, J GEN VIROL, V72, P421, DOI 10.1099/0022-1317-72-2-421; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; SZUMUNESS W, 1978, PROG MED VIROL, V24, P40; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANNICE JL, 1988, J VIROL, V62, P1305, DOI 10.1128/JVI.62.4.1305-1313.1988; VITVITSKI L, 1988, VIRAL HEPATITIS LIVE, P341; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545	53	54	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					727	737						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108115				2022-12-28	WOS:A1994MW55100007
J	BAI, WL; ARLINGHAUS, RB; SINGH, B				BAI, WL; ARLINGHAUS, RB; SINGH, B			ASSOCIATION OF V-MOS WITH SOLUBLE VIMENTIN IN-VITRO AND IN TRANSFORMED-CELLS	ONCOGENE			English	Article							PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; CELLULAR-TRANSFORMATION; INTERMEDIATE FILAMENTS; MEIOTIC MATURATION; OOCYTE MATURATION; PRODUCT; ONCOGENE; PHOSPHORYLATION; P34CDC2	Our previous studies have shown that vimentin can serve as a substrate for the v-Mos protein kinase in vitro. Furthermore, the amount of vimentin molecules in Moloney murine sarcoma virus (Mo-MuSV) transformed cells is decreased relative to uninfected cells and a lower molecular weight form is observed in these v-mos transformed cells (Singh & Arlinghaus, Virology 173: 144-156, 1989). Vimentin filaments are hyperphosphorylated and disassemble when cells enter mitosis. Here, we show that vimentin was coprecipitated with p85gag-mos from mitotic cell extracts by two different anti-Mos antibodies that do not crossreact with vimentin. However, we were unable to detect vimentin/v-Mos complexes in interphase extracts, possibly due to lack of soluble vimentin. p37env-mos was also found to associate with purified bovine lens vimentin in vitro. The significance of these findings with regard to v-mos-induced cellular transformation is discussed.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC PATHOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA45125, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARLINGHAUS RB, 1985, J GEN VIROL, V66, P1845, DOI 10.1099/0022-1317-66-9-1845; BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1991, ONCOGENE, V6, P1715; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BENZEEV A, 1984, BIOCHIM BIOPHYS ACTA, V780, P197, DOI 10.1016/0304-419X(85)90003-4; BIA W, 1992, ONCOGENE, V7, P1757; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; BROWN RL, 1981, P NATL ACAD SCI-BIOL, V78, P5593, DOI 10.1073/pnas.78.9.5593; CARLEY WW, 1981, J CELL BIOL, V90, P797, DOI 10.1083/jcb.90.3.797; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHAN D, 1989, P NATL ACAD SCI USA, V86, P2747, DOI 10.1073/pnas.86.8.2747; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4769, DOI 10.1073/pnas.77.8.4769; GREUENS G, 1983, ALL BIOL INT REP, V7, P35; HERZOG NK, 1988, ONCOGENE, V3, P225; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LIU JX, 1990, ONCOGENE, V5, P171; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1986, P NATL ACAD SCI USA, V83, P3629, DOI 10.1073/pnas.83.11.3629; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1989, VIROLOGY, V173, P144, DOI 10.1016/0042-6822(89)90230-4; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; VIKSTROM KL, 1989, P NATL ACAD SCI USA, V86, P549, DOI 10.1073/pnas.86.2.549; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, ONCOGENE, V355, P649; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	40	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2207	2212						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336943				2022-12-28	WOS:A1993LP17100021
J	INOUE, J; TAKAHARA, T; AKIZAWA, T; HINO, O				INOUE, J; TAKAHARA, T; AKIZAWA, T; HINO, O			BCL-3, A MEMBER OF THE I-KAPPA-B PROTEINS, HAS DISTINCT SPECIFICITY TOWARDS THE REL FAMILY OF PROTEINS	ONCOGENE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; ENHANCER-BINDING-PROTEIN; CELL-CYCLE CONTROL; DNA-BINDING; TRANSCRIPTION FACTOR; PROTOONCOGENE BCL-3; MAMMALIAN-CELLS; P65 SUBUNIT; ACTIVATION; INHIBITION	Expression of the bcl-3 gene is demonstrated to be elevated in some B-cell chronic lymphocytic leukemias with a chromosomal translocation, t(14;19)(q32;q13.1). Bcl-3 protein has seven tandem ankyrin repeats that are also found in IkappaB proteins, inhibitors of Rel/NFkappaB transcription factors. In this paper, we demonstrate that Bcl-3 is a member of IkappaB family of proteins with a novel specificity. Bcl-3 preferentially associates with the p50 of NFkappaB, and the nuclear localization signal of p50 is required for this association. Bcl-3 inhibits the DNA-binding activity of p50 homodimers but not that of p50-p65 heterodimers. Transient transfection experiments revealed that appropriate expression of Bcl-3 results in inhibition of the function of p50 homodimers but not that of p50-p65 heterodimers, whereas pp40 and IkappaBgamma inhibit the function of both p50 homodimers and p50-p65 heterodimers. These studies suggest that Bcl-3 could modulate the transcription in a way different from pp40 and IkappaBgamma.	JAPANESE FDN CANC RES,INST CANC,DEPT EXPTL PATHOL,TOSHIMA KU,TOKYO 170,JAPAN; SETSUNAN UNIV,DEPT ANALYT CHEM,HIRAKATA,OSAKA 573,JAPAN	Japanese Foundation for Cancer Research; Setsunan University	INOUE, J (corresponding author), UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN.							BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JOHANNESS A, 1991, CELL, V65, P1281; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHUTZE S, 1992, CELL, V71, P765; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WULZYN FG, 1992, NATURE, V358, P597; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	40	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2067	2073						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336935				2022-12-28	WOS:A1993LP17100006
J	BRAMBILLA, R; DRAETTA, G				BRAMBILLA, R; DRAETTA, G			MOLECULAR-CLONING OF PISSLRE, A NOVEL PUTATIVE MEMBER OF THE CDK FAMILY OF PROTEIN SERINE/THREONINE KINASES	ONCOGENE			English	Note							CYCLIN-DEPENDENT KINASES; CELL-DIVISION; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; GENE CDC2; P34(CDC2); HOMOLOGY; PHOSPHORYLATION; EXPRESSION; SEQUENCE	Several members of the cdk family of protein kinases are involved in the regulation of the eukaryotic cell cycle. Using a PCR-based strategy we have screened different human tumor cell lines for cdk-related cDNAs. One clone isolated from the bladder carcinoma cell line RT112 encodes a novel protein kinase named PISSLRE, based on its predicted sequence at the conserved PSTAIRE motif. PISSLRE showed 50% amino acid identity with the previously isolated p58(KGTA). PISSLRE contained all the structural elements featured by cyclin dependent kinases, including a proline in the PSTAIRE motif, which might be important for cyclin binding. PISSLRE was found expressed as 2.0 kb messenger RNA in a variety of human cell lines. Its expression was not restricted to tumor cells as it was detectable also in normal fibroblasts. In adult tissues, PISSLRE mRNA showed the highest expression in lung, liver and kidney. The broad expression pattern in adult tissues might suggest that PISSLRE could be involved in processes distinct from cell proliferation.	EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Brambilla, Riccardo/A-6082-2010	Brambilla, Riccardo/0000-0003-3569-5706				BEN DY, 1991, EMBO J, V10, P317; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DE BH, 1993, NATURE, V363, P595; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IRIE K, 1991, CELL, V65, P785, DOI 10.1016/0092-8674(91)90386-D; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; LAPIDOT LY, 1992, P NATL ACAD SCI USA, V89, P579; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEW J, 1992, J BIOL CHEM, V267, P25922; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1993, CURR BIOL, V3, P544, DOI 10.1016/0960-9822(93)90053-Q; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SPURR NK, 1990, DNA SEQUENCE, V1, P48; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299	42	43	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					3037	3041						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084611				2022-12-28	WOS:A1994PG82200034
J	GOLAY, J; LOFFARELLI, L; LUPPI, M; CASTELLANO, M; INTRONA, M				GOLAY, J; LOFFARELLI, L; LUPPI, M; CASTELLANO, M; INTRONA, M			THE HUMAN A-MYB PROTEIN IS A STRONG ACTIVATOR OF TRANSCRIPTION	ONCOGENE			English	Article							DNA-BINDING DOMAIN; GENE V-MYB; HUMAN HEMATOPOIETIC-CELLS; C-MYB; B-MYB; REGULATED EXPRESSION; CELLULAR PROGENITOR; ONCOGENE PRODUCT; LEUKEMIA-VIRUS; LEUCINE-ZIPPER	The A-myb gene belongs to the family of the c-myb proto-oncogene. We report here the cloning from a B lymphocyte cDNA library of the previously missing 3' half of the human A-myb cDNA, thus closing the previously still incomplete open reading frame. Analysis of the homologies between the different myb proteins reveals four domains of high conservation. We show, using a polyclonal rabbit antibody, that the 90 kd human A-myb protein is nuclear and that it activates transcription from the KHK-CAT reporter 6-10 times more strongly than c-myb in NIH3T3 cells. The transactivating function of A-myb depends on the presence of the myb binding site in the reporter, and on both the DNA binding and acidic domains of the A-myb protein. The bacterially expressed protein protects the myb binding sites of the reporter in footprint experiments. Binding of the A-myb protein is shown in gel retardation assays to be specific for the classical c-myb recognition sequence PyAAC(G)/(T)G. In addition, like c-myb, A-myb binds more strongly to the MIM-A synthetic oligonucleotide that carries the TAACGG sequence than to the MBS-I oligonucleotide containing TAAGTG. Finally, DNA binding activity is demonstrated to require the N-terminal portion of the protein containing the three tandem repeats of amino acids conserved in all myb proteins. We have thus shown that the A-myb protein is a strong activator of transcription and that this activity depends on both the DNA-binding and acidic domains.			GOLAY, J (corresponding author), IST RIC FARMACOL MARIO NEGRI, VIA ERITREA 62, I-20157 MILAN, ITALY.		Luppi, Mario/J-3668-2016; Golay, Josee/AAA-4085-2022; Introna, Martino/AAA-5823-2019	Luppi, Mario/0000-0002-0373-1154; Golay, Josee/0000-0002-7932-909X; Introna, Martino/0000-0001-6216-0892				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ARSURA M, 1992, BLOOD, V79, P2708; ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOHMANN D, 1987, NATURE, V325, P268, DOI 10.1038/325268a0; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DASGUPTA P, 1992, J VIROL, V66, P270, DOI 10.1128/JVI.66.1.270-276.1992; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1992, J IMMUNOL, V149, P300; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, IN PRESS J IMMUNOL; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KASTAN MB, 1989, BLOOD, V74, P1517; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAM EWF, 1992, ONCOGENE, V7, P1885; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Maxam A M, 1980, Methods Enzymol, V65, P499; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NOMURA T, 1993, J BIOL CHEM, V268, P21914; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WATSON RJ, 1992, ONCOGENE, V7, P1885; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZOBEL A, 1991, ONCOGENE, V6, P1397	64	55	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2469	2479						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058310				2022-12-28	WOS:A1994PC05400006
J	MARSTON, NJ; CROOK, T; VOUSDEN, KH				MARSTON, NJ; CROOK, T; VOUSDEN, KH			INTERACTION OF P53 WITH MDM2 IS INDEPENDENT OF E6 AND DOES NOT MEDIATE WILD-TYPE TRANSFORMATION SUPPRESSOR FUNCTION	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; CASEIN KINASE-II; MUTANT P53; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION FUNCTION; MONOCLONAL-ANTIBODIES; TUMOR SUPPRESSION; GENE-EXPRESSION; CELL-GROWTH	Using a new series of p53 mutants targeting the conserved regions we have analysed the relationship of various activities of the protein. Mdm-2 and human papillomavirus (HPV) E6, two proteins which interact with and abrogate p53 function, were shown to bind independently. Deletion of the conserved regions of the protein in which most of the naturally occurring mutations are found (boxes II-V) abrogated transcriptional activity and the ability to interact with E6, supporting the importance of this DNA binding domain to these activities. Nevertheless, these mutants retained the ability to interact with mdm2. One mutant, deleted of all the C-terminal sequences, showed loss of mdm2 binding, E6 binding and transcriptional activity. More subtle mutations within the C-terminus of the protein, including alterations of the cdc2 and CKII phosphorylation sites, had no effect on the transcriptional trans-activation, mdm-2 or E6 binding functions, indicating that phosphorylation of these sites is not essential for these activities. Deletion of conserved box I sequences abolished the interaction with mdm-2 without loss of transcriptional activation or transformation suppressor activity, suggesting that mdm-2 is not a downstream effector of p53 function.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								ADDISON C, 1990, ONCOGENE, V5, P423; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, ONCOGENE, V9, P1225; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LEACH FS, 1993, CANCER RES, V53, P2231; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, IN PRESS J VIROL; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P81; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1993, MOL CELL BIOL, V12, P2789; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P275; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILKINSON D, 1988, J EXP MED, V167, P1442, DOI 10.1084/jem.167.4.1442; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	90	71	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2707	2716						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058335				2022-12-28	WOS:A1994PC05400032
J	MUSHINSKI, JF; GOODNIGHT, J; RUDIKOFF, E; MORSE, HC; LANGDON, WY				MUSHINSKI, JF; GOODNIGHT, J; RUDIKOFF, E; MORSE, HC; LANGDON, WY			EXPRESSION OF C-CBL PROTOONCOGENE IS MODULATED DURING DIFFERENTIATION BUT NOT DURING INDUCTION OF PROLIFERATION	ONCOGENE			English	Article							MURINE IMMUNE-SYSTEM; NF-KAPPA-B; V-CBL; POLYCLONAL ACTIVATION; TRANSCRIPTION FACTOR; DNA-BINDING; ZINC FINGER; CELLS; IDENTIFICATION; TRUNCATION	The proto-oncogene c-cbl is expressed as two mRNAs, ca. 10.5 and 3.1 kb, both of which appear to be functional inasmuch as both can be found on polyribosomes in tissues that express both mRNAs. The function of the 120 kDa c-cbl protein is not known, but its primary structure resembles that of a DNA-binding transcription factor with a basic region, a nuclear localization sequence, a zinc finger-like motif and a leucine zipper. To test whether expression of this protein resembles that of regulatory proteins, we studied expression of c-cbl mRNA and protein in differentiating cells and in proliferating cells, conditions in which expression of regulatory proteins commonly is modulated. Differentiation of both erythroleukemia cells and teratocarcinoma cells showed a decrease in c-cbl expression, with kinetics similar to those of transcription factors that are immediate early response genes. Unlike early response genes, however, c-cbl mRNA showed a very long half life in B lymphocytes. Further, in fibroblasts and spleen cells that were induced to proliferate, c-cbl mRNA expression did not change, and expression of c-cbl protein did not change during any stage of the cell cycle. These characteristics indicate that c-cbl does not belong to the immediate early response type of transcription factor. Yet when c-cbl is truncated, as in v-cbl, the protein does enter the nucleus and bind DNA, and it contributes to neoplastic transformation of B lymphocytes and fibroblasts. These findings indicate that the regulation of the c-cbl proto-oncogene is different from that of the proto-oncogenes identified to date and suggest that c-cbl belongs to a new class of proto-oncogenes.	NIAID,IMMUNOPATHOL LAB,BETHESDA,MD 20892; UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Western Australia	MUSHINSKI, JF (corresponding author), NCI,MOLEC GENET SECT,BETHESDA,MD 20892, USA.			Morse, Herbert/0000-0002-9331-3705				BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BRAUN J, 1983, J IMMUNOL, V130, P2113; FINKELMAN FD, 1982, J IMMUNOL, V129, P638; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIEND C, 1978, P NATL ACAD SCI USA, V81, P378; GRUMONT RJ, 1990, CELL GROWTH DIFFER, V1, P345; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LAVU S, 1985, CANCER CELLS, V2, P301; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MATHERLY LH, 1989, ANAL BIOCHEM, V182, P338, DOI 10.1016/0003-2697(89)90605-2; MOUNTZ JD, 1987, J IMMUNOL, V139, P2172; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; REGNIER DC, 1989, J VIROL, V63, P3678, DOI 10.1128/JVI.63.9.3678-3682.1989; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TUNNACLIFFE A, 1990, GENOMICS, V8, P447, DOI 10.1016/0888-7543(90)90030-X; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9	30	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2489	2497						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058312				2022-12-28	WOS:A1994PC05400008
J	ZHANG, W; GUO, XYD; DEISSEROTH, AB				ZHANG, W; GUO, XYD; DEISSEROTH, AB			THE REQUIREMENT OF THE CARBOXYL-TERMINUS OF P53 FOR DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION DEPENDS ON THE SPECIFIC P53 BINDING DNA ELEMENT	ONCOGENE			English	Article							WILD-TYPE P53; MUTANT P53; GENE AMPLIFICATION; MDM-2 ONCOGENE; LEUKEMIA CELLS; PROTEIN; EXPRESSION; SEQUENCE; SUPPRESSOR; GROWTH	The p53 protein specifically binds DNA sequences and activates transcription. In this study, we investigated the requirement of the carboxyl (C)- or amino (N)-terminal domain of p53 for the binding and transactivation of two DNA elements, p53CON and the ribosomal gene cluster (RGC). Three human p53 mutants with deletion in either the C-terminus or N-terminus were used. Mobility-shift assays showed that the oligomerization-defective mutant p53(1-326), from which the final 67 C-terminal amino acids were deleted, retained the wild-type p53's ability to bind the p53CON element in the presence of anti-p53 monoclonal antibody PAb1801. Also, the transient transfection assays showed that the mutant p53(1-326) activated p53CON-mediated transcription. However, this mutant failed to bind the RGC element and was unable to activate RGC-mediated transcription. Thus, the requirement of the C-terminal region of p53 for DNA binding and transcription activation varies with the p53-binding DNA element under study. In contrast, the N-terminus of p53 contains a common transcription activation domain: deletion of the 80 or 159 N-terminal amino acids inactivated both p53CON- and RGC-mediated transactivation. Furthermore, mobility-shift assays did not detect any binding to p53CON and RGC by either of the two N-terminal-deletion mutants. These results suggest that the N-terminus of p53 affects DNA binding.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [P01 CA55164] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN JY, 1993, ONCOGENE, V8, P2159; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FREBOURG T, 1992, CANCER RES, V52, P6976; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TP, 1992, CELL, V27, P875; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PROSSER J, 1990, ONCOGENE, V5, P1573; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STURZBECHER HW, 1992, ONCOGENE, V7, P1515; TARUNINA M, 1993, ONCOGENE, V8, P3165; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHANG W, 1992, ONCOGENE, V7, P1645; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555; ZHANG W, 1994, IN PRESS EMBO J	62	19	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2513	2521						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058314				2022-12-28	WOS:A1994PC05400010
J	BLACK, EJ; CATLING, AD; WOODGETT, JR; KILBEY, A; GILLESPIE, DAF				BLACK, EJ; CATLING, AD; WOODGETT, JR; KILBEY, A; GILLESPIE, DAF			TRANSCRIPTIONAL ACTIVATION BY THE V-JUN ONCOPROTEIN IS INDEPENDENT OF POSITIVE REGULATORY PHOSPHORYLATION	ONCOGENE			English	Note							DNA-BINDING ACTIVITY; C-JUN; PROTEIN-KINASE; MAMMALIAN-CELLS; DELTA DOMAIN; TRANSFORMATION; FIBROBLASTS; INVITRO; SERINE-63; ONCOGENE	Growth factors, phorbol esters, and oncogenes such as uas, svc, and sis are believed to stimulate c-Jun transcriptional activation by inducing increased phosphorylation at two serine residues (S63 and S73) within the N-terminal transactivation domain. Although S63 and S73 are conserved in the mutant v-Jun oncoprotein, they are not phosphorylated by two enzymes which target the corresponding residues in c-Jun in vitro; namely a partially purified c-Jun kinase from TPA-stimulated U937 cells and purified p54 mitogen activated protein (MAP) kinase. In addition, v-Jun activates transcription more strongly than c-Jun when fused to the Gal4 DNA-binding domain, and transcriptional activation by Gal4-v-Jun is unaffected when S63, S73, or both, are replaced with non-phosphorylatable alanine residues, amino acid substitutions which severely impair transcriptional activation by Gal4-c-Jun. The biochemical and transcriptional properties of result from deletion of a 27 amino acid segment, termed delta, which is important for transforming activity. On the basis of these results we propose that unlike c-jun, v-Jun transcriptional activation is independent of positive regulatory phosphorylation and that this may contribute to oncogenesis by v-Jun.	BEATSON INST CANC RES, BEATSON LABS, CANC RES CAMPAIGN, GLASGOW G62 1BD, LANARK, SCOTLAND; ONTARIO CANC INST, DIV CELLULAR & MOLEC BIOL, TORONTO M4X 1K9, ON, CANADA	Beatson Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Gillespie, David/R-4771-2019; Woodgett, Jim/F-1087-2010	Gillespie, David/0000-0002-6338-0544; Woodgett, Jim/0000-0003-3731-5797				Abate C, 1990, Semin Cancer Biol, V1, P19; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CATLING AD, 1993, ONCOGENE, V8, P1875; FRAME MC, 1991, ONCOGENE, V6, P205; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1993, ONCOGENE, V8, P1135; NISHIMURA T, 1988, ONCOGENE, V3, P659; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507	26	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2363	2368						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036019				2022-12-28	WOS:A1994NX62900030
J	SHERRINGTON, PD; FISCH, P; TAYLOR, AMR; RABBITTS, TH				SHERRINGTON, PD; FISCH, P; TAYLOR, AMR; RABBITTS, TH			CLONAL EVOLUTION OF MALIGNANT AND NONMALIGNANT T-CELLS CARRYING T(1414) AND T(X14) IN PATIENTS WITH ATAXIA-TELANGIECTASIA	ONCOGENE			English	Note							ALPHA-CHAIN LOCUS; MOLECULAR ANALYSIS; LYMPHOPROLIFERATIVE DISORDERS; CHROMOSOME-14 INVERSION; LYMPHOCYTIC-LEUKEMIA; GENE REARRANGEMENTS; RECEPTOR; TRANSLOCATION; IMMUNOGLOBULIN; SEQUENCES	People with ataxia telangiectasia (AT) are at a higher than normal risk of T cell leukaemia and often have either non-malignant or malignant T cells with chromosomal abnormalities, typically t(14;14), inversion 14 or more rarely t(X;14). This provides a chance to study the pre-leukaemic phase of the disease. T cells have been studied with either t(14;14)(q11;q32.1) or t(X;14)(q28;q11) from two AT sisters of which the latter developed T cell leukaemia. The telomeric breakpoint of the t(14;14) was cloned and found to occur at 14q32.1 where known tumour-associated breakpoints are located, but the patient remains asymptomatic for leukaemia. Analysis of T cell populations in both patients showed that the cells containing the translocation became oligoclonal with respect to T cell receptor beta rearrangement and complete T cell receptor beta clonality was only established in the patient with t(X;14) by onset of overt disease. Therefore in these chronic diseases, chromosomal translocations can precede T cell receptor rearrangement suggesting a role for these abnormalities as early events of malignant outgrowth.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,CAMBS,ENGLAND; UNIV BIRMINGHAM,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND	MRC Laboratory Molecular Biology; University of Birmingham			Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				BAER R, 1988, EMBO J, V7, P1661, DOI 10.1002/j.1460-2075.1988.tb02993.x; BAER R, 1987, P NATL ACAD SCI USA, V84, P9069, DOI 10.1073/pnas.84.24.9069; BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287; DENNY CT, 1986, NATURE, V320, P549, DOI 10.1038/320549a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCH P, 1993, ONCOGENE, V8, P3271; FOA R, 1986, BLOOD, V67, P247; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GIBSON TJ, 1987, GENE, V53, P283, DOI 10.1016/0378-1119(87)90017-5; HEPPELL A, 1988, HUM GENET, V79, P360; KARN J, 1984, GENE, V32, P217, DOI 10.1016/0378-1119(84)90049-0; KORSMEYER SJ, 1992, BLOOD, V80, P879; MCCAW BK, 1975, P NATL ACAD SCI USA, V83, P2071; MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; OCONNOR NTJ, 1985, LANCET, V1, P1295; OLSON MV, 1979, J MOL BIOL, V132, P387, DOI 10.1016/0022-2836(79)90267-5; OXFORD JM, 1975, J MED GENET, V12, P251, DOI 10.1136/jmg.12.3.251; RABBITTS TH, 1985, EMBO J, V4, P2217, DOI 10.1002/j.1460-2075.1985.tb03917.x; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; STERN MH, 1993, ONCOGENE, V8, P2475; TAYLOR AMR, 1992, LEUKEMIA, V6, P961; TAYLOR AMR, 1986, CANCER, V27, P511; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275; YOSHIKAI Y, 1986, J EXP MED, V164, P90, DOI 10.1084/jem.164.1.90	34	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2377	2381						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036021				2022-12-28	WOS:A1994NX62900032
J	ADAMSON, R; JONES, AS; FIELD, JK				ADAMSON, R; JONES, AS; FIELD, JK			LOSS OF HETEROZYGOSITY STUDIES ON CHROMOSOME-17 IN HEAD-AND-NECK-CANCER USING MICROSATELLITE MARKERS	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; POLYMERASE CHAIN-REACTION; BREAST-CANCER; COLORECTAL-CANCER; ALLELE LOSS; P53 GENE; OVARIAN-CARCINOMA; FREQUENT LOSS; DELETION	In this study we have analysed 38 squamous cell carcinomas (SCC) two basal cell carcinomas (BCC), a malignant salivary gland carcinoma, a neurosarcoma and a Warthins carcinoma, all isolated from patients with head and neck cancers. These tumour types have been examined by PCR for loss of heterozygosity (LOH) on both arms of chromosome 17 using nine polymorphic microsatellite markers. LOH on 17p in SCCHN was found to be 50% (19/38), and often involved TP53 (42%) but more frequently involved the CHRNB1 locus (56%). Twelve tumours showed loss of heterozygosity on 17q (34%) and ten of these also had loss on 17p. Four SCCHN tumours lost an entire copy of chromosome 17. It was of particular note that 77% (10/13) of the SCCHN at the hypopharyngeal site had LOH at CHRNB1. We propose from our data that the 17p12-p11 region contains a novel predisposing gene for hypopharyngeal SCCHN that may function as a tumour suppressor gene.	UNIV LIVERPOOL,SCH DENT,DEPT CLIN DENT SCI,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT OTORHINOLARYNGOL,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool; University of Liverpool			Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BOYD JA, 1990, PHARMACOL THERAPEUT, V46, P469, DOI 10.1016/0163-7258(90)90028-Z; CANN CI, 1985, OTOLARYNG CLIN N AM, V18, P367; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DELATTRE O, 1989, LANCET, V2, P353; ECCLES DM, 1990, ONCOGENE, V5, P1599; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, CELL, V61, P757; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; FIELD JK, 1991, BRIT J CANCER, V64, P573, DOI 10.1038/bjc.1991.352; FIELD JK, 1992, LANCET, V339, P502, DOI 10.1016/0140-6736(92)91122-O; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; FIELD JK, 1994, INT J ONCOL, V4, P543; FIELD JK, 1994, IN PRESS CANCER DETE; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FULTS D, 1989, CANCER RES, V49, P6572; GUZZETTA V, 1992, GENOMICS, V13, P551, DOI 10.1016/0888-7543(92)90124-B; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JONES AS, 1993, CLIN OTOLARYNGOL, V17, P545; KELSELL DP, 1993, GENOMICS, V17, P522, DOI 10.1006/geno.1993.1362; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LARGEY JS, 1993, CANCER, V71, P1933, DOI 10.1002/1097-0142(19930315)71:6<1933::AID-CNCR2820710602>3.0.CO;2-D; LATIF F, 1992, CANCER RES, V52, P1451; LEONE A, 1991, CANCER RES, V51, P2490; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MACKAY J, 1988, LANCET, V2, P1384; MAESTRO R, 1992, ONCOGENE, V7, P1159; MCKUSICK VA, 1993, J MED GENET, V10, P1; MELING GI, 1993, BRIT J CANCER, V67, P88, DOI 10.1038/bjc.1993.14; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; NAKSTAD B, 1992, TIDSSKR NOR LAEGEFOR, V113, P595; OMURA Y, 1993, ACUPUNCTURE ELECTRO, V18, P33, DOI 10.3727/036012993816357601; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; REES M, 1989, BRIT J CANCER, V59, P361, DOI 10.1038/bjc.1989.72; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SAKAI E, 1992, ONCOGENE, V7, P927; SATO T, 1992, CANCER RES, V52, P1643; SATO T, 1990, CANCER RES, V50, P7184; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STELL PM, 1989, EUR J SURG ONCOL, V15, P407; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOGUCHIDA J, 1989, CANCER RES, V49, P6247; TSAO SW, 1991, ANTICANCER RES, V11, P1975; VIANI L, 1991, J LARYNGOL OTOL, V105, P24, DOI 10.1017/S0022215100114732; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAGATA T, 1993, CANCER RES, V53, P846; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; YIN Y, 1993, EUR J CANCER ORAL ON, V29, P257; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	58	61	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2077	2082						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208554				2022-12-28	WOS:A1994NR68500034
J	LEVEDAKOU, EN; HE, M; BAPTIST, EW; CRAVEN, RJ; CANCE, WG; WELCSH, PL; SIMMONS, A; NAYLOR, SL; LEACH, RJ; LEWIS, TB; BOWCOCK, A; LIU, ET				LEVEDAKOU, EN; HE, M; BAPTIST, EW; CRAVEN, RJ; CANCE, WG; WELCSH, PL; SIMMONS, A; NAYLOR, SL; LEACH, RJ; LEWIS, TB; BOWCOCK, A; LIU, ET			2 NOVEL HUMAN SERINE/THREONINE KINASES WITH HOMOLOGIES TO THE CELL-CYCLE REGULATING XENOPUS MO15, AND NIMA KINASES - CLONING AND CHARACTERIZATION OF THEIR EXPRESSION PATTERN	ONCOGENE			English	Article							PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; COLORECTAL-CANCER; CATALYTIC SUBUNIT; FISSION YEAST; LUNG-CANCER; GENE; QUERCETIN; CDC2	Using polymerase chain reaction (PCR)-based methods, we have isolated cDNA clones of two new members of serine/threonine kinases, STK1 and STK2, from a cDNA library constructed from the BT-20 human breast cancer cell line. STK1 is transcribed as a 1.4 kilobase (kb) mRNA encoding for a protein of 346 amino acids. Based on amino acid sequence analysis, STK1 is 86% identical to the Xenopus p40(mol5), a cdc2-related serine/threonine kinase recently found to be the activating kinase for p34(cdc2) and p33(cdk2). Thus, STK1 is most likely the human homologue of MO15. An alternatively spliced STK1 message expressed variably in cell lines and in primary carcinomas generates a predicted 58 amino acid protein that lacks the kinase domain. STK2 is transcribed into a 4.0 kb mRNA encoding for an 841 residue protein which exhibits 50% identity in the kinase domain with the mouse nek1 gene product, the relative of the fungal G(2)-M regulator, nimA. STK1 and STK2 display a variable pattern of expression among a series of primary carcinomas as well as cancer cell lines. Both STK1 and STK2 were expressed at the highest levels in the heart but were also detected in all other organs tested. Tn embryonal tissues, lower levels of expression were noted. Using cell cycle inhibitors, we have shown that both STK1 and STK2 mRNA levels remain relatively invariant through the cell cycle. Chromosomal assignment has localized STK1 on chromosome 2pcen-2p15, a region implicated in hereditary non-polyposis colorectal carcinoma, and STK2 on chromosome 3p21.1, a region frequently showing chromosomal alterations in renal cells carcinomas.	UNIV N CAROLINA, LINEBERGER CANC RES CTR, DEPT MED, CURRICULUM GENET, CHAPEL HILL, NC 27599 USA; UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX USA; UNIV TEXAS, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, SAN ANTONIO, TX 78284 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health San Antonio			Liu, Edison/C-4141-2008	Bowcock, Anne/0000-0001-8691-9090; Leach, Robin/0000-0002-3201-5579	NATIONAL CANCER INSTITUTE [R01CA027632, P50CA058223, K08CA001625] Funding Source: NIH RePORTER; NCI NIH HHS [CA27632, K08 CA01625, 1P50CA58223-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; ANGLARD P, 1992, CANCER RES, V52, P348; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOWCOCK A, 1993, GENOMICS, V15, P376, DOI 10.1006/geno.1993.1071; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CANCE WG, 1993, INT J CANCEER, V54, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GALE M, 1993, MOL BIOCHEM PARASIT, V59, P111, DOI 10.1016/0166-6851(93)90012-M; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOSSMANN H, 1981, N-S ARCH PHARMACOL, V317, P100, DOI 10.1007/BF00506266; GRAZIANI Y, 1983, EUR J BIOCHEM, V135, P583, DOI 10.1111/j.1432-1033.1983.tb07692.x; GRAZIANI Y, 1981, BIOCHIM BIOPHYS ACTA, V714, P415; GSCHWENDT M, 1984, BIOCHEM BIOPH RES CO, V124, P63, DOI 10.1016/0006-291X(84)90916-1; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HUNT T, 1989, NATURE, V342, P483, DOI 10.1038/342483a0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOVACS G, 1991, P NATL ACAD SCI USA, V88, P194, DOI 10.1073/pnas.88.1.194; LANG DR, 1974, BIOCHIM BIOPHYS ACTA, V333, P180, DOI 10.1016/0005-2728(74)90002-4; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LEVEDAKOU EN, 1992, INT J CANCER, V52, P534, DOI 10.1002/ijc.2910520406; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; Melamed M. R., 1990, FLOW CYTOMETRY SORTI; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; MIURA I, 1992, CANCER RES, V52, P1322; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NANUS DM, 1991, ONCOGENE, V6, P2105; NEUBAUER A, 1990, NUCLEIC ACIDS RES, V18, P993, DOI 10.1093/nar/18.4.993; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RAPP UR, 1988, HDB ONCOGENES, P213; REED JC, 1992, CANCER RES, V52, P2802; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SETH A, 1988, ONCOGENE HDB, P195; SHOSHAN V, 1981, J BIOL CHEM, V256, P887; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; SUNARA U, 1991, CELL, V65, P145; Swofford D., 1998, PAUP PHYLOGENETIC AN; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; TODD SK, 1992, THESIS U TEXAS HLTH; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	62	61	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1977	1988						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208544				2022-12-28	WOS:A1994NR68500022
J	SUBLER, MA; MARTIN, DW; DEB, S				SUBLER, MA; MARTIN, DW; DEB, S			OVERLAPPING DOMAINS ON THE P53 PROTEIN REGULATE ITS TRANSCRIPTIONAL ACTIVATION AND REPRESSION FUNCTIONS	ONCOGENE			English	Article							WILD-TYPE P53; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; RESPONSIVE ELEMENT; TRANSFORMED-CELLS; BINDING PROTEIN; GENE-EXPRESSION; T-ANTIGEN; MUTANT; ONCOGENE	Wild-type p53 has been shown to inhibit transcription from several viral and cellular promoters without known p53-binding sites, while transactivating promoters with p53-binding sites. Using a series of N- and C-terminal p53 deletion mutants and wild-type p53, we have defined the domains on p53 responsible for its transcriptional functions. To test transcriptional activation by p53 we have used a promoter-chloramphenicol acetyltransferase (CAT) construct containing synthetic p53-binding sites. To check transcriptional inhibition by p53 we have used a human cytomegalovirus immediate-early promoter construct, CMV-CAT. Using transient transfection-transcription assays in Saos-2 cells, we determined that the p53 transcriptional activation and repression domains overlap at the N-terminus. This suggests the possibility that the same transcriptional machinery is involved in both functions. A C-terminal deletion up to amino acid 327 (del 393-327) eliminated repression of CMV-CAT, while preserving the transactivation function to a large extent. Using gluteraldehyde cross-linking experiments, we observed that the mutant del 393-327, which is transactivation-competent, but repression-defective, could not oligomerize. Thus, oligomerization of p53 is not required for transactivation, but may be essential for repression. Interestingly, transactivation by the oligomerization-defective mutant could be inhibited by cotransfection with a plasmid expressing the transforming mutant p53-175H.	UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHANG W, 1993, ONCOGENE, V8, P2555	73	72	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1351	1359						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152795				2022-12-28	WOS:A1994NH40100006
J	LANOIX, J; LACOSTE, J; PEPIN, N; RICE, N; HISCOTT, J				LANOIX, J; LACOSTE, J; PEPIN, N; RICE, N; HISCOTT, J			OVERPRODUCTION OF NFKB2(LYT-1O) AND C-REL - A MECHANISM FOR HTLV-I TAX-MEDIATED TRANSACTIVATION VIA THE NF-KAPPA-B SIGNALING PATHWAY	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; CANDIDATE PROTOONCOGENE BCL-3; ENHANCER-BINDING PROTEINS; LONG TERMINAL REPEAT; HUMAN T-CELLS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; GENE-EXPRESSION; PROTO-ONCOGENE	Molecular, biochemical and epidemiological evidence implicate HTLV-I as an etiologic agent of adult T cell leukemia (ATL). The Tax protein of HTLV-I, a positive transcriptional activator of HTLV-I gene expression, is a viral oncogene that also increases transcription of cellular genes including GM-CSF, IL-2R alpha and IL-2. One of the cellular targets of the trans-activating effects of Tax is the NF-kappa B/Rel family of transcription factors, pleiotropic regulators of immunoregulatory, cytokine and viral gene expression. In this report, we demonstrate that NFKB2, (lyt-10) and c-Rel are overexpressed in HTLV-I infected and Tax-expressing cells and, together, account for the majority of the constitutive NF-kappa-B binding activity in these cells before and after PMA stimulation. Most importantly, we show a Tax-dependent correlation between expression of NFKB2(p100) and processing to the DNA binding NFKB2(p52) form, induction of c-Rel, and trans-activation of NF-kappa B-mediated gene expression. Furthermore, the NFKB2 precursor is physically associated with c-Rel and with Tax in HTLV-I infected cells. We propose that NFKB2 synthesis and processing allows continuous nuclear expression of an otherwise cytoplasmic protein and, in conjunction with overexpression of c-Rel, NFKB2 alters the NF-kappa B signalling pathway and contributes to leukemic transformation of T cells by HTLV-I.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,ABE STERN CANC RES LAB,MONTREAL H3T 1E2,PQ,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ,CANADA; FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ABL,MOLEC VIROL & CARCINOGENESIS LAB,FREDERICK,MD	Lady Davis Institute; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; COHEN L, 1992, J CELL PHYSIOL, V152, P10, DOI 10.1002/jcp.1041520103; CRENON L, 1993, ONCOGENE, V8, P867; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAERTLE T, 1988, J BIOL CHEM, V263, P5870; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HANNINK M, 1990, ONCOGENE, V5, P1843; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LACOSTE J, 1990, J VIROL, V64, P4726, DOI 10.1128/JVI.64.10.4726-4734.1990; LACOSTE J, 1991, VIROLOGY, V184, P553, DOI 10.1016/0042-6822(91)90425-B; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIWA M, 1984, GANN, V75, P752; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKEUCHI K, 1985, J GEN VIROL, V66, P1825, DOI 10.1099/0022-1317-66-8-1825; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	73	75	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					841	852						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108127				2022-12-28	WOS:A1994MW55100020
J	NG, IOL; CHUNG, LP; TSANG, SWY; LAM, CL; LAI, ECS; FAN, ST; NG, M				NG, IOL; CHUNG, LP; TSANG, SWY; LAM, CL; LAI, ECS; FAN, ST; NG, M			P53 GENE MUTATION SPECTRUM IN HEPATOCELLULAR CARCINOMAS IN HONG-KONG CHINESE	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; CELL-LINES; CANCER; EXPRESSION; OVEREXPRESSION; AFLATOXIN; INVITRO	To examine the significance of mutation of the p53 tumour suppressor gene in the development of human hepatocellular carcinoma in a high-prevalence area for hepatitis B viral infection but a low-exposure area for aflatoxin B1, the spectrum of p53 gene mutations was examined in 21 tumour samples from Hong Kong Chinese patients, all of whom were HBsAg positive. DNA sequencing covering exons 5 to 9 of the p53 gene and Hae III restriction enzyme digestion for preliminary assessment of mutation at codon 249 were performed. Immunohistochemical staining with anti-p53 monoclonal antibodies was done on both tumour and nontumour liver tissues. Six tumours (28.6%) showed a p53 mutation and all were point mutations. Of the six point mutations, two (9.5%) were at codon 249 and both were G to T transversions (AGG-->ATG and AGG-->AGT transversions). The remaining point mutations were transversions scattered at codon 172 (exon 5), 214 (exon 6), 273 (exon 8) and 330 (exon 9). Mutated p53 protein was detected in five of these six cases with demonstrable point mutations by DNA sequencing, in contrast to none detected in all of the 15 cases without demonstrable point mutations. The presence of p53 mutations, including those at codon 249, did not show a significant association with tumour size, sex, age, tumour invasiveness in terms of liver invasion, microsatellites and venous permeation, cirrhosis and encapsulation, but tumours with low cellular differentiation tended to have a higher incidence (71%) of point mutations than those with high cellular differentiation (8%). In conclusion, both the overall p53 mutation rate and that at codon 249 in HCC in Hong Kong Chinese are lower than those reported in tumours from China and sub-Saharan Africa. The low mutation rate at codon 249 is compatible with a low aflatoxin exposure. A special type of p53 mutation has not been found to be associated with hepatitis B viral infection. Mutations of p53 gene tends to occur in tumours with low cellular differentiation, suggesting a late occurrence in the event of tumour progression.	UNIV HONG KONG,QUEEN MARY HOSP,DEPT SURG,HONG KONG,HONG KONG; UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG	University of Hong Kong; University of Hong Kong	NG, IOL (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT PATHOL,HONG KONG,HONG KONG.		Fan, Sheung Tat/C-4138-2009	Ng, Irene Oi-lin/0000-0001-7532-2029				BAKER SJ, 1990, CANCER RES, V50, P7717; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; CAAMANO J, 1991, AM J PATHOL, V139, P839; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHALLEN C, 1992, HEPATOLOGY, V16, P1362, DOI 10.1002/hep.1840160610; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; HARRIS AL, 1991, NATURE, V350, P377, DOI 10.1038/350377a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KASTAN MB, 1991, CANCER RES, V51, P4279; KOHLER MF, 1992, CANCER RES, V52, P1622; LAURENTPUIG P, 1992, HEPATOLOGY, V16, P1171, DOI 10.1016/0270-9139(92)90010-7; LEUNG NWY, 1992, CANCER, V70, P40, DOI 10.1002/1097-0142(19920701)70:1<40::AID-CNCR2820700107>3.0.CO;2-P; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINSELL CA, 1977, T ROY SOC TROP MED H, V71, P471, DOI 10.1016/0035-9203(77)90136-5; LOK ASF, 1990, HEPATOLOGY, V12, P582, DOI 10.1002/hep.1840120322; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NIGRO JM, 1989, NATURE, V342, P505; ODA T, 1992, CANCER RES, V52, P6358; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; SCORSONE KA, 1992, CANCER RES, V52, P1635; SHANK RC, 1972, FOOD COSMET TOXICOL, V10, P51, DOI 10.1016/S0015-6264(72)80046-4; SHANK RC, 1972, FOOD COSMET TOXICOL, V10, P61, DOI 10.1016/S0015-6264(72)80047-6; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; WALKER GJ, 1991, CANCER RES, V51, P4367; 1983, WHO TECH REP SER, V691, P7; 1991, HONG KONG ANN DEP RE; 1992, DATA DEPT HLTH	33	53	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					985	990						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108145				2022-12-28	WOS:A1994MW55100039
J	WIMMEL, A; LUCIBELLO, FC; SEWING, A; ADOLPH, S; MULLER, R				WIMMEL, A; LUCIBELLO, FC; SEWING, A; ADOLPH, S; MULLER, R			INDUCIBLE ACCELERATION OF G(1) PROGRESSION THROUGH TETRACYCLINE-REGULATED EXPRESSION OF HUMAN CYCLIN-E	ONCOGENE			English	Note							CELL-CYCLE; PHASE	Cyclin E is a cell cycle-regulated protein that activates the cdc2-related protein kinases cdk2 shortly before S-phase entry. In order to analyse the biological role of cyclin E, we have generated HeLa cells that allow the conditional expression of ectopic human cyclin E. In these cells, a cyclin E cDNA is under the control of a bacterial tetracycline repressor-VP16 activator hybrid protein. In the absence of tetracycline, the endogenous gene becomes activated and leads to the synthesis of elevated levels of cyclin E. Concomitant with this increase in cyclin E expression we show by a combined time-lapse video recording/5-bromo-deoxyuridine labelling procedure a significant acceleration of G(1) transition by approximately 1.5 hours. This observation is consistent with the idea that cyclin E is a rate-limiting factor with respect to the control of G(1)-->S transition. The experimental system described here should also prove useful to address the function of cyclin E in further detail.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADOLPH S, 1993, J CELL SCI, V105, P113; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; TSAI LH, 1993, ONCOGENE, V8, P1593; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	19	138	150	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					995	997						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108147				2022-12-28	WOS:A1994MW55100041
J	VOLKMANN, M; HOFMANN, WJ; MULLER, M; RATH, U; OTTO, G; ZENTGRAF, H; GALLE, PR				VOLKMANN, M; HOFMANN, WJ; MULLER, M; RATH, U; OTTO, G; ZENTGRAF, H; GALLE, PR			P53 OVEREXPRESSION IS FREQUENT IN EUROPEAN HEPATOCELLULAR-CARCINOMA AND LARGELY INDEPENDENT OF THE CODON-249 HOT-SPOT MUTATION	ONCOGENE			English	Article							HEPATITIS-B VIRUS; CELL-LINE; GENE; EXPRESSION; CONFORMATION; AFLATOXIN; ETIOLOGY	Mutations in the p53 tumour suppressor gene have been recently described in hepatocellular carcinomas (HCC) from high risk areas such as China and South Africa. Our study was designed to assess the importance of p53 aberrations in HCCs from Europe, where the major risk factors in hepatocarcinogenesis, aflatoxin exposure and chronic hepatitis B virus (HBV) infection, do not play a dominant role. We investigated 22 HCCs and, as controls, their corresponding tumour-free liver tissues, seven livers with primary biliary cirrhosis and four morphologically normal livers. p53 overexpression, which is usually associated with point mutations of the p53 gene, was detected in 10 of the 22 HCCs by immunoblotting and immunohistochemistry. p53 expression was restricted to the nucleus in the positive cells, while all cells in the control tissues were negative. There was no obvious etiological preference in the p53 positive tumours. Particularly, underlying chronic HBV infection did not appear to be associated with an increased rate of p53 overexpression in European HCCs. SSCP and sequence analysis of exons 5-8 of the p53 gene revealed point mutations in six out of eight tumours with increased steady state levels of p53. In conclusion, our study demonstrates increased p53 levels due to point mutations in a significant proportion of European HCCs. The codon 249 mutation, which was detected in one of the cases, is not predominant in these tumours.	UNIV HEIDELBERG,DEPT INTERNAL MED,GASTROENTEROL ABT,D-69115 HEIDELBERG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,ANGEW TUMORVIROL,D-69115 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT PATHOL,D-69115 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT SURG,D-69115 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg			Galle, Peter/ABE-2872-2021; Galle, Peter R/T-5292-2018; Martina, Mueller-Schilling/R-4162-2016	Galle, Peter/0000-0001-8294-0992; Galle, Peter R/0000-0001-8294-0992; 				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; CARBONE D, 1991, ONCOGENE, V6, P1691; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; FUSUN Y, 1986, ADV CANCER RES, V47, P297; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN MC, 1993, INT J CANCER, V53, P51, DOI 10.1002/ijc.2910530111; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JOHNSON PJ, 1987, J HEPATOL, V4, P140, DOI 10.1016/S0168-8278(87)80021-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI DZ, 1993, CARCINOGENESIS, V14, P169, DOI 10.1093/carcin/14.2.169; MACNAB GM, 1976, BRIT J CANCER, V34, P509, DOI 10.1038/bjc.1976.205; MURAKAMI Y, 1991, CANCER RES, V51, P552; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHIDA N, 1993, CANCER RES, V53, P368; ODA T, 1992, CANCER RES, V52, P6358; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PUISIEUX A, 1991, CANCER RES, V51, P6185; RAJAGOPALAN MS, 1986, LIFE SCI, V39, P1287, DOI 10.1016/0024-3205(86)90190-6; SCORSONE KA, 1992, CANCER RES, V52, P1635; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X	31	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					195	204						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302580				2022-12-28	WOS:A1994MW24700024
J	CACACE, AM; GUADAGNO, SN; KRAUSS, RS; FABBRO, D; WEINSTEIN, IB				CACACE, AM; GUADAGNO, SN; KRAUSS, RS; FABBRO, D; WEINSTEIN, IB			THE EPSILON ISOFORM OF PROTEIN-KINASE-C IS AN ONCOGENE WHEN OVEREXPRESSED IN RAT FIBROBLASTS	ONCOGENE			English	Article							CELL-LINE; GROWTH-CONTROL; PHORBOL ESTER; PKC-EPSILON; EXPRESSION; FAMILY; TRANSFORMATION; GENE; CONSTRUCTION; PURIFICATION	We have overproduced the Ca2+-independent protein kinase C isoform, nPKCepsilon, in Rat 6 embryo fibroblasts, and examined the effects of this novel isoform on cell growth and transformation. As compared to vector control cell lines expressing only the hygromycin resistance gene, the nPKCepsilon overproducing cell lines exhibited a 7-13-fold increase in Ca2+-independent enzyme activity. Detailed analysis of seven individual nPKCepsilon over-producing clones indicated that those clones that expressed very high activity displayed a number of disorders in growth control, including: formation of dense foci in monolayer culture, decreased doubling time, increased saturation density, decreased serum requirement, growth in soft agar, and tumor formation in nude mice. These findings are in contrast to previous studies from our laboratory indicating that stable expression of high levels of cPKCbeta1 produced only a partially transformed phenotype (Housey et al., 1988). Taken together, these results provide the first direct evidence that distinct isoforms of PKC can exert different effects on growth control and malignant transformation in the same cell type.	COLUMBIA UNIV, DEPT PHARMACOL, 701 W 168 ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10027 USA; COLUMBIA UNIV, CTR CANC, NEW YORK, NY 10027 USA; CIBA GEIGY AG, CH-4002 BASEL, SWITZERLAND; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10027 USA	Columbia University; Columbia University; Columbia University; Novartis; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University								BAXTER G, 1992, J BIOL CHEM, V267, P1910; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BORNER C, 1992, J BIOL CHEM, V267, P12892; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPPOCK DL, 1992, CELL GROWTH DIFFER, V3, P485; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KRAUSS RS, 1989, ONCOGENE, V4, P991; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SOSSIN W, 1992, NEUROSCIENCE, V12, P1160; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEINSTEIN, 1991, COLD SPRING HARBOR S	33	261	262	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2095	2104						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336936				2022-12-28	WOS:A1993LP17100009
J	NAUMANN, M; NIETERS, A; HATADA, EN; SCHEIDEREIT, C				NAUMANN, M; NIETERS, A; HATADA, EN; SCHEIDEREIT, C			NF-KAPPA-B PRECURSOR P100 INHIBITS NUCLEAR TRANSLOCATION AND DNA-BINDING OF NF-KAPPA-B/REL-FACTORS	ONCOGENE			English	Article							CANDIDATE PROTOONCOGENE BCL-3; PROTO-ONCOGENE; P50 PRECURSOR; CYTOPLASMIC RETENTION; TRANSCRIPTION FACTOR; REL ONCOGENE; V-REL; C-REL; SUBUNIT; CLONING	The NF-kappaB precursor p100 (lyt-10, p97, p98) generates after proteolytic processing a 52 kDa subunit, which can bind to kappaB-motifs. A deregulated form of the p100 gene, which is structurally altered by a t(10;14) translocation, has a potential oncogenic role in certain human B cell lymphomas. In this study p100 was analysed for its ability to interact with its own processing product p52, with p50, the product of the NF-kappaB precursor p105, and with other NF-kappaB/rel-proteins. As demonstrated by a combination of Western blot analysis, band shift analysis and indirect immunofluorescence labelling of transfected cells, p100 itself was localized in the cytoplasm and indiscriminately retained each co-expressed NF-kappaB subunit. Thereby it simultaneously inhibited their DNA binding activities. Thus, a major function of p100 is, like p105, to associate with subunits of the rel multigene family in the cytoplasm in an IkappaB-like fashion. The similarity between p100 and p105 is also reflected by equivalent protein interactions of their processing products: like NF-kappaB-p50, also NF-kappaB-p52 heteromerised promiscuously with all rel-factors tested. Moreover, p52 efficiently interacts with the candidate oncogene product Bcl-3 and also binds to the basic-leucine zipper protein NF-IL6.	MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,IHNESTR 73,D-14195 DAHLEM,GERMANY	Max Planck Society			Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, EMBO J, V17, P135; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1989, ONCOGENE, V4, P935; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STORMS RW, 1992, VIROLOGY, V188, P765, DOI 10.1016/0042-6822(92)90531-S; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	42	80	80	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2275	2281						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336950				2022-12-28	WOS:A1993LP17100030
J	MARSHALLHEYMAN, H; ENGEL, G; LJUNGDAHL, S; SHOSHAN, MC; SVENSSON, C; WASYLYK, B; LINDER, S				MARSHALLHEYMAN, H; ENGEL, G; LJUNGDAHL, S; SHOSHAN, MC; SVENSSON, C; WASYLYK, B; LINDER, S			TUMORIGENIC AND METASTATIC PROPERTIES OF 2 RAS-ONCOGENE TRANSFECTED RAT FIBROSARCOMA CELL-LINES DEFECTIVE IN C-JUN	ONCOGENE			English	Article							EMBRYO FIBROBLASTS; TRANSCRIPTIONAL ACTIVATION; MOUSE FIBROBLASTS; MAMMALIAN-CELLS; PHORBOL ESTERS; GENE PROMOTER; GROWTH ARREST; FOS PROTEINS; TRANSFORMATION; AP-1	We here report the spontaneous loss of both homologues of the c-jun gene in two cell lines, isolated after transfection of rat embryo fibroblasts with single ras-oncogenes. These cells lines (designated A14 and B25) grow rapidly in vitro, have transformed morphologies and are invasive through reconstituted basal membranes. Both c-jun defective cell lines were found to be tumorigenic and metastatic in athymic mice. Loss of c-jun was paralleled by a dramatic decrease in interstitial collagenase expression, whereas stromelysin mRNA expression in c-jun(-) A14 and B25 cells was similar to that observed in c-jun(+) transformed cell lines. Transient transfection experiments using reporter plasmids showed that stromelysin promoter activity in A14 cells was severely impaired by a point mutation in the -71 to -65 AP-1 motif, and was inhibited by a Jun dominant negative mutant. Gel mobility shift studies demonstrated the presence of a factor in A14 nuclear extracts capable of binding the stromelysin TRE. This factor bound JunB, JunD and Fos antibodies. Our findings suggest that c-Jun is not required for the tumorigenic and metastatic potential of vas-transformed fibrosarcoma cells, and that AP-1 protein(s) lacking c-Jun are capable of activating the stromelysin gene promoter.	KAROLINSKA HOSP & INST, RADIUM HEMMET, DEPT GEN ONCOL, DIV EXPTL ONCOL, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MICROBIAL GENET, S-17176 STOCKHOLM, SWEDEN; FAC MED STRASBOURG, INST CHIM BIOL,CNRS,U184 BIOL MOLEC,INSERM, GENET MOLEC EUCARYOTES LAB, F-67085 STRASBOURG, FRANCE	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALBINI A, 1987, CANCER RES, V47, P3239; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DELALUNA S, 1992, METHOD ENZYMOL, V216, P376; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; EDMONDS M, 1969, J BIOL CHEM, V244, P1314; ENGEL G, 1993, INT J ONCOL, V3, P457; GINSBERG D, 1991, ONCOGENE, V6, P669; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LINDER S, 1992, ONCOGENE, V7, P439; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL H, 1993, ONCOGENE, V8, P1303; MARSHALL H, 1991, EXP CELL RES, V194, P35, DOI 10.1016/0014-4827(91)90126-F; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	53	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3655	3663						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970724				2022-12-28	WOS:A1994PT39200029
J	SAEZ, R; CHAN, AML; MIKI, T; AARONSON, SA				SAEZ, R; CHAN, AML; MIKI, T; AARONSON, SA			ONCOGENIC ACTIVATION OF HUMAN R-RAS BY POINT MUTATIONS ANALOGOUS TO THOSE OF PROTOTYPE H-RAS ONCOGENES	ONCOGENE			English	Article							GROWTH-FACTOR; NIH3T3 FIBROBLASTS; GENE-PRODUCT; KINASE; RAF-1; TRANSFORMATION; EXPRESSION; CELLS; PROTEINS	R-ras, K-rev-1/rap and TC21, are more closely related to prototype H-vas than any other known members of the vas superfamily. We recently isolated a mutationally activated TC21 oncogene from a human ovarian carcinoma cell line. Based upon these observations, we sought to re-examine the transforming potential of R-ras, which was reported earlier to lack transforming capacity. Mutations were introduced into the R-uas gene at codons 38 or 87, analogous to positions 12 and 61, respectively, responsible for H-ras oncogene activation. While both mutations resulted in acquisition of R-ras transforming capacity for NIH3T3 cells the position 61 was shown to be more active. Transfectants expressing either R-ras mutant formed colonies in soft agar and were tumorigenic in vivo. As has been reported for H-ras, R-ras cooperated with c-raf-1 in inducing transformation of NIH3T3 cells. These results imply interactions in R-ras and c-raf-1 signaling pathways. We observed R-ras transcripts of 4.6 and 1.2 kb ubiquitously expressed in each of a variety of tissues examined. All these findings raise the possibility that R-ras, like prototype vas genes, may be mutationally activated as an oncogene in some human malignancies.	MT SINAI MED CTR,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHAN AML, 1994, IN PRESS P NATL ACAD; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CUADRADO A, 1993, ONCOGENE, V8, P2443; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4648; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	85	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2977	2982						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084601				2022-12-28	WOS:A1994PG82200024
J	HUANG, RP; DARLAND, T; OKAMURA, D; MERCOLA, D; ADAMSON, ED				HUANG, RP; DARLAND, T; OKAMURA, D; MERCOLA, D; ADAMSON, ED			SUPPRESSION OF V-SIS-DEPENDENT TRANSFORMATION BY THE TRANSCRIPTION FACTOR, EGR-1	ONCOGENE			English	Article							WILMS-TUMOR GENE; EMBRYONAL CARCINOMA-CELLS; DNA-BINDING DOMAINS; C-FOS; CULTURED-CELLS; GROWTH-FACTORS; RETINOIC ACID; CHAIN GENE; PROTEIN; EXPRESSION	The transcription factor Egr-1, stimulates the activity of a number of genes and inhibits other genes, by binding to the sequence GCGGGGGCG in 5' enhancer regions, However, the functions of Egr-1 are obscure in spite of its rather ubiquitous expression. Egr-1 may play a role in proliferation in mitogen-stimulated cells but its expression is also correlated with the differentiated state in teratocarcinoma cells. The constitutive expression of Egr-1 appears to have little effect on the growth rate of normal immortalized cell-lines. We show that in NIH3T3 cells that are conditionally transformed by the expression of v-sis, the presence of Egr-1 is inhibitory to the production of transformed colonies (foci) and to growth in soft agar. In addition, the first appearance of tumors in nu/nu mice is delayed in tumorigenicity tests with cells that over-express Egr-1 and tumor growth is suppressed compared to control cells. We used a series of fragments of Egr-1 cloned into expression vectors to show that not only full length, but also truncated Egr-1 fragments inhibit colony formation. Using deletion mutants, we observed that this inhibitory activity is dependent on the presence of the DNA-binding 'zinc-finger' region. Wilm's tumor protein, WT1, (known to be a tumor suppressor gene) that exhibits the same DNA binding activity is also inhibitory. In contrast, colony formation is stimulated by an Egr-1 antisense RNA-expressing plasmid, since colonies grow rapidly and the colony-forming frequency is higher than in the presence of v-sis alone. We conclude that proteins containing the Egr-1 'zinc-finger' domain can bind to the regulatory regions of one or more genes that are required for the transformation of fibroblasts by v-sis thus inhibiting transformation. One function for Egr-1 implied by these results is the restraint of transformed growth in mitogen-stimulated cells.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; SAN DIEGO REG CANC CTR,SAN DIEGO,CA; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego			mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA 49963] Funding Source: Medline; NICHD NIH HHS [HD 28025, HD 21957] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028025, R01HD021957] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA049963] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DARLAND T, 1991, ONCOGENE, V6, P1367; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DEWALD GW, 1985, BLOOD, V66, P189; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GINSBERG D, 1991, ONCOGENE, V6, P669; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEVIIN WJ, 1992, J CELL BIOCHEM, V16, pA240; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MERCOLA D, 1993, FRONTIERS OF OSTEOSARCOMA RESEARCH, P375; MERCOLA D, 1992, ONCOGENE, V7, P1793; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAGONA G, 1991, DNA CELL BIOL, V10, P61, DOI 10.1089/dna.1991.10.61; Sambrook J., 1989, MOL CLONING, V1; Sambrook J, 1989, MOL CLONING, V2; Sambrook J, 1989, MOL CLONING, V3; SHAM MH, 1993, CELL, V72, P83; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; WANG ZY, 1992, J BIOL CHEM, V267, P21999	47	77	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1367	1377						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152797				2022-12-28	WOS:A1994NH40100008
J	VANLAAR, T; STEEGENGA, WT; JOCHEMSEN, AG; TERLETH, C; VANDEREB, AJ				VANLAAR, T; STEEGENGA, WT; JOCHEMSEN, AG; TERLETH, C; VANDEREB, AJ			BLOOMS SYNDROME CELLS GM1492 LACK DETECTABLE P53 PROTEIN BUT EXHIBIT NORMAL G1 CELL-CYCLE ARREST AFTER UV IRRADIATION	ONCOGENE			English	Note							WILD-TYPE P53	The tumor suppressor gene p53 is thought to be a key factor in the onset of G1 cell-cycle arrest following DNA damage. However, here we describe cells derived from a patient with Bloom's syndrome, lacking any detectable p53 protein, that still shows a functional G1 cell-cycle checkpoint after irradiation with UV-C. Comparison with cells from other Bloom's patients showed that the absence of p53 protein is not a specific characteristic of Bloom's syndrome.	LEIDEN UNIV,SYLVIUS LAB,MOLEC CARCINOGENESIS LAB,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC								DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRIEDBERG EC, 1985, DNA REPAIR, P532; FRITSCHE M, 1993, ONCOGENE, V8, P307; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; TISHLER RB, 1993, CANCER RES, V53, P2212; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	21	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					981	983						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108144				2022-12-28	WOS:A1994MW55100038
J	BAIERBITTERLICH, G; RAPPAPORT, J; BAIER, G; LOONEY, D; WONGSTAAL, F				BAIERBITTERLICH, G; RAPPAPORT, J; BAIER, G; LOONEY, D; WONGSTAAL, F			TRANSCELLULAR ACTIVATION OF THE HTLV PROMOTER BY HUMAN HEMATOPOIETIC-CELLS	ONCOGENE			English	Note							LEUKEMIA-LYMPHOMA VIRUS; T-CELL; INTERLEUKIN-2; EXPRESSION; RETROVIRUS; GENE; LYMPHOCYTES; INFECTION; SEQUENCES; DISTINCT	We examined the ability of hematopoietic cells to transactivate the HTLV promoter by a transcellular mechanism. HeLa cells containing a CAT reporter gene driven by the HTLV-2 promoter were cocultivated with hematopoietic cells of the B-(Raji), T-(HuT78, Jurkat) and monocyte/promyelocytic (THP-1, U937 and HL60) lineages. Cocultivation with U937 and HuT78 cells constitutively and significantly transactivated the HTLV-2 promoter, while no effect was observed with the other lines. However, activation of other T-cell lines (CEM, Jurkat, Molt-3 and MT-4) with a combination of phorbolester and phytohemagglutinin also resulted in potent transactivation. Supernatant from HuT78 cells exhibited detectable transactivating activity, suggesting that the activation is mediated by a secreted factor(s). This factor also transactivates the HTLV-1 promoter. We used a panel of HTLV-1 LTR deletion mutants to map the responsive elements to this factor(s). Unlike the response element to the HTLV transactivator protein, Tax, which can be mapped to a small region in the enhancer, maximal transactivation by the cellular factor(s) required the complete U3 sequence. Transcellular activation of the HTLV promoter by activated T-cells may play a role in the development of leukemia in HTLV infected individuals.	UNIV CALIF SAN DIEGO,SAN DIEGO,CA; NIH,BETHESDA,MD; SAN DIEGO VA MED CTR,SAN DIEGO,CA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA	BAIERBITTERLICH, G (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA, USA.		Baier, Gottfried/E-8755-2012	Baier, Gottfried/0000-0002-2085-8325				BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BOEHNLEIN E, 1988, CONTROL HUMAN RETROV, P191; CHEN ISY, 1982, J VIROL, V41, P183, DOI 10.1128/JVI.41.1.183-191.1982; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DAEFLER S, 1991, MOL F ONCOLOGY, P229; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; MANZARI V, 1983, P NATL ACAD SCI-BIOL, V80, P1574, DOI 10.1073/pnas.80.6.1574; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MERL S, 1984, BLOOD, V64, P967; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PAVLAKIS GN, 1988, CONTROL OF HUMAN RETROVIRUS GENE EXPRESSION, P281; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; ROSENBLATT JD, 1988, BLOOD, V71, P363; SAXON A, 1978, ANN INTERN MED, V88, P323, DOI 10.7326/0003-4819-88-3-323; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TEMIN HM, 1974, J VIROL, V13, P291, DOI 10.1128/JVI.13.2.291-297.1974; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	28	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					319	322						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302596				2022-12-28	WOS:A1994MW24700039
J	MURPHY, C; KRETSCHMER, C; BIESINGER, B; BECKERS, J; JUNG, J; DESROSIERS, RC; MULLERHERMELINK, HK; FLECKENSTEIN, BW; RUTHER, U				MURPHY, C; KRETSCHMER, C; BIESINGER, B; BECKERS, J; JUNG, J; DESROSIERS, RC; MULLERHERMELINK, HK; FLECKENSTEIN, BW; RUTHER, U			EPITHELIAL TUMORS INDUCED BY A HERPESVIRUS ONCOGENE IN TRANSGENIC MICE	ONCOGENE			English	Article							SAIMIRI STRAINS; SMALL RNAS; EXPRESSION; REGION; GENE; TRANSFORMATION; IDENTIFICATION; CONSEQUENCES; STP-C488; GENOME	To investigate the role of herpesviral genes in tumourigenesis, transgenic mice were generated expressing STP-C, a transformation associated protein of the lymphoma inducing herpesvirus saimiri. Epithelial tumours developed in the salivary gland, pancreas, thymus and liver of transgenic mice within the first weeks of life. Thus, the target cells for tumour formation in the transgenic mice were surprisingly different from those of the herpesvirus from which the oncogene was derived. Our results identify STP-C as a herpesvirus oncogene sufficient for tumour induction without the cooperation of other viral gene products. Furthermore, the results demonstrate pleiotropic transforming capabilities of the STP-C oncogene and suggest that the specificity of lymphoma induction by the virus is determined by factors other than the oncogene itself.	EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV WURZBURG, INST PATHOL, D-97080 WURZBURG, GERMANY; UNIV ERLANGEN NURNBERG, INST KLIN & MOLEK VIROL, D-91054 ERLANGEN, GERMANY; HARVARD UNIV, SCH MED, NEW ENGLAND REG PRIMATE RES CTR, SOUTHBOROUGH, MA 01772 USA	European Molecular Biology Laboratory (EMBL); University of Wurzburg; University of Erlangen Nuremberg; Harvard University			Beckers, Johannes/K-7237-2012	Beckers, Johannes/0000-0001-7874-3822				ALBRECHT JC, 1992, NUCLEIC ACIDS RES, V20, P1810; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; AZEN EA, 1984, SCIENCE, V226, P967, DOI 10.1126/science.6095444; BIESINGER B, 1990, VIROLOGY, V176, P505, DOI 10.1016/0042-6822(90)90020-R; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BODEMER W, 1986, J VIROL, V60, P114, DOI 10.1128/JVI.60.1.114-123.1986; CASTLE AM, 1992, J BIOL CHEM, V267, P13093; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; FIELDS BN, 1990, FIELDS VIROLOGY, P1373; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P253; GODDARD MJ, 1991, J CLIN PATHOL, V44, P660, DOI 10.1136/jcp.44.8.660; HOGAN B, 1986, MANIPULATING MOUSE E, P230; JUNG JU, 1991, J VIROL, V65, P6953, DOI 10.1128/JVI.65.12.6953-6960.1991; JUNG JU, 1992, J VIROL, V66, P1777, DOI 10.1128/JVI.66.3.1777-1780.1992; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDES C, 1990, EXP PATHOL-JENA, V40, P239, DOI 10.1016/S0232-1513(11)80308-7; MEDVECZKY MM, 1989, J VIROL, V63, P3601, DOI 10.1128/JVI.63.9.3601-3611.1989; MEDVECZKY P, 1984, J VIROL, V52, P938, DOI 10.1128/JVI.52.3.938-944.1984; MELENDEZ LV, 1968, LAB ANIM CARE, V18, P374; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MURTHY S, 1986, EMBO J, V5, P1625, DOI 10.1002/j.1460-2075.1986.tb04405.x; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; RUTHER U, 1989, PROG NUCLEIC ACID RE, V36, P235; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SIMMER B, 1991, J GEN VIROL, V72, P1953, DOI 10.1099/0022-1317-72-8-1953; TRIMBLE JJ, 1988, SCIENCE, V239, P1145, DOI 10.1126/science.2830673; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587	30	51	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					221	226						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302583				2022-12-28	WOS:A1994MW24700027
J	MAXWELL, SA; ROTH, JA				MAXWELL, SA; ROTH, JA			BINDING OF CELLULAR PROTEINS TO A CONFORMATIONAL DOMAIN OF TUMOR-SUPPRESSOR PROTEIN P53	ONCOGENE			English	Note							WILD-TYPE P53; T-ANTIGEN; ACTIVATING MUTATIONS; DNA-REPLICATION; GENE-PRODUCT; LUNG-CANCER; TRANSFORMATION; MUTANT; SEQUENCE; WILD-TYPE-P53	The genes regulated by p53, as well as the factors modulating its function, need to be identified before the mechanism of action of p53 in control of cell growth can be adequately understood, Binding of the SV40 large T-antigen protein to an evolutionally conserved (conformational) domain of p53 inhibits p53's DNA-binding and transcription activation activities. Cellular proteins might also bind to this same region of p53 to regulate its function. A hybrid protein composed of protein A fused to the conformational domain (amino acids 115-295) of p53 was expressed in Escherichia coli and used as an affinity probe for binding proteins in detergent lysates of non-small cell lung carcinoma (NSCLC) cells. The wildtype p53 hybrid protein associated with several major proteins of molecular weights 45 K, 56 K, and 70 K, as web as other minor species ranging in molecular weight from 30 K to 90 K. These proteins bound specifically to the p53 sequence of the hybrid protein. Protein A did not associate with these proteins and the two p53 hybrid proteins containing missense mutations at codons 273 and 175 exhibited a 40-80% weaker association. In addition, T antigen competed with the cellular proteins for binding to the conformational domain. The conditions of cell growth had a profound effect on the expression of the p53 binding proteins. Considerably more p53 binding proteins were expressed in actively growing cells than in culture's maintained under conditions for slow growth. Quantitative differences in expression of p53-binding proteins were observed among different NSCLC cell lines. The expression of p53-binding proteins was not restricted to NSCLC cell lines; detergent extracts of an osteosarcoma cell line yielded similar p53-binding proteins.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CARDIOVASC SURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	MAXWELL, SA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC SURG,1515 HOLCOMBE BLVD,BOX 109,HOUSTON,TX 77030, USA.				NCI NIH HHS [2P30-CA16672-018, NCI CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1993, EUR J CANCER, V29A, P101, DOI 10.1016/0959-8049(93)90584-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1992, CANCER SURV, V12, P59; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEDCALF EA, 1992, ONCOGENE, V7, P71; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER CW, 1990, CANCER RES, V50, P7950; MILNER J, 1990, ONCOGENE, V5, P1683; MITSUDOMI T, 1992, ONCOGENE, V7, P171; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	47	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3421	3426						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247546				2022-12-28	WOS:A1993MG78200028
J	WANG, YS; SZEKELY, L; OKAN, I; KLEIN, G; WIMAN, KG				WANG, YS; SZEKELY, L; OKAN, I; KLEIN, G; WIMAN, KG			WILD-TYPE P53-TRIGGERED APOPTOSIS IS INHIBITED BY BCL-2 IN A V-MYC-INDUCED T-CELL LYMPHOMA LINE	ONCOGENE			English	Note							TUMOR SUPPRESSOR GENE; C-MYC; B-CELLS; CHROMOSOME-TRANSLOCATION; FOLLICULAR LYMPHOMA; MEMBRANE PROTEIN; P53; DEATH; EXPRESSION; BREAKPOINT	Using a temperature sensitive p53 construct (ts p53), we have earlier shown that expression of wild-type (wt) p53 triggers apoptosis in a v-myc-induced T-cell lymphoma line that lacks endogenous p53, and in a Burkitt lymphoma line that carries mutant p53. We have suggested that apoptosis is elicited by the contradictory signals emanating from the constitutively activated myc gene and the growth arresting signal of wt p53 (Ramqvist et al., 1993; Wang et al., 1993). Work in other laboratories has shown that constitutive c-myc expression can induce apoptosis when cell proliferation is inhibited due to the lack of growth stimulating factors. Expression of bcl-2 could inhibit apoptosis. In order to test whether p53-induced apoptosis can be prevented by bcl-2, we have introduced a retrovirally driven bcl-2 construct into our v-myc-induced murine T-cell lymphoma line, previously transfected with ts p53. About 90% of the parental ts p53 transfected cells died of apoptosis within 3 days after induction of wt p53 expression at 32 degrees C. Two clones of ts p53/bcl-2 double transfectants that expressed high levels of bcl-2 from the introduced construct were completely protected from apoptosis, following transfer of the cells to 32 degrees C. One clone that expressed the exogenous bcl-2 only at a low level was partially protected from wt p53-induced apoptosis. Clones of the parental ts p53 carrying cells transfected with the puromycin resistance gene vector, without the bcl-2 gene underwent 90% apoptosis. These results suggest that bcl-2 may prevent apoptosis in cells simultaneously exposed to the proliferation-stimulating effect of activated myc and the growth arresting signal of wt p53.			WANG, YS (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM,SWEDEN.		Wiman, Klas/AAB-8399-2021; Szekely, Laszlo/B-1268-2009	Wiman, Klas/0000-0002-7113-524X; 	NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [CA14054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, CANCER RES, V52, P491; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sambrook J, 1989, MOL CLONING LABORATO; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1992, ONCOGENE, V7, P1241; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WIMAN KG, 1991, ONCOGENE, V6, P1633; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	38	231	243	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3427	3431						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247547				2022-12-28	WOS:A1993MG78200029
J	WEISKIRCHEN, R; BISTER, K				WEISKIRCHEN, R; BISTER, K			SUPPRESSION IN TRANSFORMED AVIAN FIBROBLASTS OF A GENE (CRP) ENCODING A CYSTEINE-RICH PROTEIN CONTAINING LIM DOMAINS	ONCOGENE			English	Article							LOOP HELIX PROTEIN; C-MYC; DNA-BINDING; ACTIVATES TRANSCRIPTION; REGULATORY PROTEINS; STRUCTURAL-ANALYSIS; INTESTINAL PROTEIN; MOLECULAR-CLONING; PLATELET PROTEIN; MESSENGER-RNA	Using cDNA subtraction and differential hybridization techniques, a cDNA library derived from normal quail embryo fibroblasts WaS screened for clones corresponding to genes whose expression was suppressed in v-myc-transformed, as compared with normal, quail embryo fibroblasts. One of the isolated cDNA clones corresponded to a 0.9-kb mRNA that was present in normal quail and chicken embryo fibroblasts, but was virtually absent from all transformed avian cells tested: quail embryo fibroblasts transformed by the v-myc, v-myc/v-mil or v-src oncogenes, cells derived from a methylcholanthrene-induced quail fibrosarcoma or v-myc-transformed chicken macrophages. Nucleotide sequence analysis of the original and supplementary cDNA clones indicated that the corresponding gene encodes a 194 amino acid cysteine-rich protein (M(r) 20 911). A database search revealed that the gene is the avian homolog of a human primary response gene (crp) of unknown function. Both the quail and human CRP proteins contain two copies of a cysteine-rich amino acid sequence motif (LIM) with putative zinc-binding activity that was previously identified in several proteins with presumed regulatory functions essential for cell growth or differentiation.	UNIV COLOGNE,SCH MED,INST BIOCHEM,W-5000 COLOGNE 41,GERMANY	University of Cologne			Weiskirchen, Ralf/O-1734-2018; Bister, Klaus/AFA-9400-2022	Weiskirchen, Ralf/0000-0003-3888-0931; Bister, Klaus/0000-0001-6545-5653				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARKER K, 1990, MOL CELL BIOL, V10, P3813, DOI 10.1128/MCB.10.7.3813; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BISTER K, 1980, P NATL ACAD SCI-BIOL, V77, P7142, DOI 10.1073/pnas.77.12.7142; BISTER K, 1993, IN PRESS GUIDEBOOK O; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOEHM T, 1990, ONCOGENE, V5, P1103; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DAVIES LG, 1986, BASIC METHODS MOL BI; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GONNEVILLE L, 1991, ONCOGENE, V6, P1825; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HEMPE JM, 1991, P NATL ACAD SCI USA, V88, P9671, DOI 10.1073/pnas.88.21.9671; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NAKANO T, 1992, ONCOGENE, V7, P527; NALIK P, 1989, MOL CELL ENDOCRINOL, V62, P235, DOI 10.1016/0303-7207(89)90010-5; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sambrook J, 1989, MOL CLONING LABORATO; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WALTHER N, 1985, J VIROL, V54, P576, DOI 10.1128/JVI.54.2.576-585.1985; WANG XK, 1992, J BIOL CHEM, V267, P9176; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISKIRCHEN R, 1993, GENE, V128, P269, DOI 10.1016/0378-1119(93)90573-L; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	57	68	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2317	2324						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361751				2022-12-28	WOS:A1993LT36800001
J	SOULIER, J; MADANI, A; CACHEUX, V; ROSENZWAJG, M; SIGAUX, F; STERN, MH				SOULIER, J; MADANI, A; CACHEUX, V; ROSENZWAJG, M; SIGAUX, F; STERN, MH			THE MTCP-1 C6.1B GENE ENCODES FOR A CYTOPLASMIC 8-KD PROTEIN OVEREXPRESSED IN T-CELL LEUKEMIA BEARING A T(X,14)-TRANSLOCATION	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ATAXIA-TELANGIECTASIA; CHROMOSOME; ABNORMALITIES	The t(X;14)(q28;q11.2) translocation is associated with mature T-cell proliferations. Recently this translocation has been shown to implicate the MTCP-1/c6.1B gene on chromosome Xq28, leading to aberrant or overexpressed MTCP-1 transcripts. The potential coding role of this gene was made uncertain by the lack of a long open reading frame in its major transcripts. However, a short 204 bases open reading frame is potentially coding for a 68 amino-acid protein. Here, we show that this open reading frame sequence and the deduced product are well conserved in mouse. A 8 kD protein (p8), which corresponds to the predicted molecular weight was revealed in transient transfectants and in cell lines by Western blotting, using a rabbit antiserum. This product was absent in lymphoblastoid cell lines with deletions of the MTCP-1/c6.1B locus. A dramatic overexpression of p8 was found in leukemic cells from a patient with a t(X;14). This small protein was localized in the cytoplasm by immunofluorescence. In conclusion, MTCP-1 encodes for a cytoplasmic 8 kD product. Its potential role in leukemogenesis is supported by its overexpression in leukemia with t(X;14), but its function remains unknown.	HOP ST LOUIS,HEMATOL MOLEC LAB,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Rosenzwajg, Michelle/AAF-6276-2019; Stern, Marc-Henri/A-2728-2011	Rosenzwajg, Michelle/0000-0001-5312-6203; Stern, Marc-Henri/0000-0002-8100-2272				BEATTY DW, 1986, S AFR MED J, V69, P115; CANKI N, 1983, ZDRAV VESTN, V52, P567; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; FISCH P, 1993, ONCOGENE, V8, P3271; GOYNS MH, 1993, LEUKEMIA, V7, P848; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KENWRICK S, 1992, HUM MOL GENET, V1, P179, DOI 10.1093/hmg/1.3.179; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1992, CURRENT PROTOCOLS MO; STERN MH, 1989, BLOOD, V73, P1285; STERN MH, 1993, ONCOGENE, V8, P2475; STERN MH, 1993, CAUSES CONSEQUENCES, P165; TAYLOR AMR, 1981, INT J CANCER, V27, P311, DOI 10.1002/ijc.2910270309; TAYLOR AMR, 1992, LEUKEMIA, V6, P961; THICK J, 1994, LEUKEMIA, V8, P564; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204	18	38	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3565	3570						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970717				2022-12-28	WOS:A1994PT39200019
J	ENOMOTO, H; OZAKI, T; TAKAHASHI, E; NOMURA, N; TABATA, S; TAKAHASHI, H; OHNUMA, N; TANABE, M; IWAI, J; YOSHIDA, H; MATSUNAGA, T; SAKIYAMA, S				ENOMOTO, H; OZAKI, T; TAKAHASHI, E; NOMURA, N; TABATA, S; TAKAHASHI, H; OHNUMA, N; TANABE, M; IWAI, J; YOSHIDA, H; MATSUNAGA, T; SAKIYAMA, S			IDENTIFICATION OF HUMAN DAN GENE, MAPPING TO THE PUTATIVE NEUROBLASTOMA TUMOR-SUPPRESSOR LOCUS	ONCOGENE			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; N-MYC AMPLIFICATION; CELL-LINES; NEURO-BLASTOMA; SHORT ARM; DELETION; EXPRESSION; CHROMOSOME; TUMORIGENICITY; HETEROZYGOSITY	The expression of DAN gene (previously designated as N03 gene) is significantly reduced in a variety of transformed rat fibroblasts, including v-src- (SR-3Y1), SV40- and v-mos-transformed 3Y1 cells, compared with that in parental 3Y1 cells. Recently, DAN gene has been shown to possess a tumor suppressive activity when it is overexpressed in SR-3Y1 cells (Ozaki & Sakiyama, 1994). To assess the involvement of DAN gene,vith human neoplasms, we have isolated human DAN counterpart from a normal lung cDNA library by using rat DAN cDNA as a probe, and determined its chromosomal location. Human DAN gene mapped to chromosome 1p36.11-p36.13, which is well known to show highly significant linkage with the genesis and/or progression of human neuroblastoma. Southern blot analysis on tumor DNA from 26 patients with neuroblastoma has detected three patients showing genomic rearrangement or deletion within or closely linked to the DAN gene locus. Collectively, we propose that human DAN gene is a possible candidate for a tumor suppressor gene of human neuroblastoma.	CHIBA CANC CTR,RES INST,DIV BIOCHEM,CHUOH KU,CHIBA 260,JAPAN; CHIBA UNIV,SCH MED,DEPT PEDIAT,CHUOH KU,CHIBA 260,JAPAN; NATL INST RADIOL SCI,DIV GENET,INAGE KU,CHIBA 263,JAPAN; NIPPON MED COLL,INST GERONTOL,MOLEC BIOL LAB,NAKAHARA KU,KAWASAKI 211,KANAGAWA,JAPAN; NAGOYA UNIV,FAC SCI,DEPT BIOL,CHIGUSA KU,NAGOYA 464,JAPAN; KAZUSA DNA,RES INST,CHUOH KU,CHIBA 260,JAPAN	Chiba Cancer Center; Chiba University; National Institutes for Quantum Science & Technology; Nippon Medical School; Nagoya University; Kazusa DNA Research Institute								BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALABAN G, 1982, CANCER GENET CYTOGEN, V6, P213, DOI 10.1016/0165-4608(82)90058-9; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BIECHE I, 1993, CANCER RES, V53, P1990; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; FRANCKE U, 1978, BIRTH DEFECTS, V12, P131; GILBERT F, 1982, CANCER GENET CYTOGEN, V7, P33, DOI 10.1016/0165-4608(82)90105-4; GILBERT F, 1984, CANCER RES, V44, P5444; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIYAKE K, 1973, AUTONOM NERV SYST JP, V10, P115; MOLEY JF, 1992, CANCER RES, V52, P770; OZAKI T, 1994, CANCER RES, V54, P646; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANBRIDGE EJ, 1992, CANCER SURV, V12, P5; SUGIMOTO T, 1986, CANCER RES, V46, P4765; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKAHASHI E, 1991, CYTOGENET CELL GENET, V57, P109, DOI 10.1159/000133124; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TSUCHIDA Y, 1990, FEBS LETT, V263, P191, DOI 10.1016/0014-5793(90)81370-4; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156	58	79	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2785	2791						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084583				2022-12-28	WOS:A1994PG82200003
J	SUDOL, M				SUDOL, M			YES-ASSOCIATED PROTEIN (YAP65) IS A PROLINE-RICH PHOSPHOPROTEIN THAT BINDS TO THE SH3 DOMAIN OF THE YES PROTOONCOGENE PRODUCT	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; SIGNAL TRANSDUCTION; C-SRC; PHOSPHATIDYLINOSITOL 3'-KINASE; CRYSTAL-STRUCTURE; GENE-PRODUCT; RAS; CELLS; GRB2; EXPRESSION	Yes belongs to the Src family of protein-tyrosine kinases. In order to understand molecular aspects of its signaling, we decided to isolate proteins that bind to the modulatory region of the Yes molecule. By generating anti-idiotypic antibodies against the aminoterminal domain of the Yes protein, we have identified, characterized and cloned a cDNA for a novel protein that binds to the Src homology domain 3 (SH3) of the Yes proto-oncogene product. The protein is of 65 kiloDalton (kDa) molecular mass, it is phosphorylated in vivo on serine and is particularly rich in proline. We named it YAP65 for Yes-Associated Protein of 65 kDa. Within the YAP65 sequence, we identified a motif, PVKQPPPLAP, similar to that found in proteins that bind to the SH3 domain of the Abl kinase. Competition assays with synthetic peptides showed the involvement of the predicted proline-rich sequence in binding between YAP65 and the Yes kinase. The YAP65 protein was also shown to bind to other signaling molecules that contain SH3 domains including Nck, Crk and Src. At lower stoichiometry, YAP65 was also shown to bind to the SH3 domains of Abl and guanosine triphosphatase activating protein (GAP). Further characterization of YAP65 should illuminate Yes signaling pathways and could also identify a novel link between protein-tyrosine and serine kinases.			SUDOL, M (corresponding author), ROCKEFELLER UNIV, MOLEC ONCOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER; NCI NIH HHS [CA45757, CA01605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISEMAN E, 1992, NATURE, V355, P78; FELLER SM, 1994, IN PRESS EMBO J; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAGEN FS, 1974, BIOCHEMISTRY-US, V13, P3394, DOI 10.1021/bi00713a033; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Potts W M, 1988, Oncogene Res, V3, P343; REN R, 1994, IN PRESS GENES DEV; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STROSBERG AD, 1989, METHOD ENZYMOL, V178, P265; SUDOL M, 1989, J NEUROSCI RES, V24, P1, DOI 10.1002/jnr.490240103; SUDOL M, 1993, ONCOGENE, V8, P823; SUDOL M, 1984, BIOCHEM J, V219, P971, DOI 10.1042/bj2190971; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	66	331	362	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2145	2152						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8035999				2022-12-28	WOS:A1994NX62900004
J	ECCLES, MR; GRUBB, G; OGAWA, O; SZETO, J; REEVE, AE				ECCLES, MR; GRUBB, G; OGAWA, O; SZETO, J; REEVE, AE			CLONING OF NOVEL WILMS-TUMOR GENE (WT1) CDNAS - EVIDENCE FOR ANTISENSE TRANSCRIPTION OF WT1	ONCOGENE			English	Note							DENYS-DRASH SYNDROME; UROGENITAL DEVELOPMENT; MUTATIONS; EXPRESSION; REGION; REPRESSION; OPPOSITE; DELETION; SEQUENCE; PROMOTER	WT1 is a tumor suppressor gene that has been implicated in Wilms tumor, and is expressed in cells of mesodermal origin. The Wit-1 gene is located approximately 2 kb from the WT1 gene, and is expressed coordinately with WT1. WT1 and Wit-1 are bi-directionally transcribed from the same promoter region, We have screened a human fetal kidney cDNA library to identify novel WT1 cDNA clones. Here we report the cloning of cDNA clones which span part of intron 1 of WT1, exon 1, upstream sequences between WT1 and Wit-1 and part of the Wit-1 gene. Northern blot and RNAase protection analysis using subcloned fragments of the cDNAs corresponding to regions from within intron 1 of WT1 suggest that a 7-10 Kb RNA is expressed in human fetal kidney, which overlaps with WT1 and is transcribed in the same direction as Wit-1.			ECCLES, MR (corresponding author), UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,POB 56,DUNEDIN,NEW ZEALAND.							ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BAIRD PN, 1992, ONCOGENE, V7, P2141; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1993, IN PRESS ONCOGENE; COPPES MJ, 1992, CANCER RES, V52, P6125; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; COWELL JK, 1991, ONCOGENE, V6, P595; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HOFMANN W, 1993, ONCOGENE, V8, P3123; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; KRIEDBERG JA, 1993, CELL, V74, P1; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; OGAWA O, 1993, HUM MOL GENET, V2, P203, DOI 10.1093/hmg/2.2.203; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SPICER DB, 1992, MOL CELL BIOL, V12, P1324, DOI 10.1128/MCB.12.3.1324; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WANG ZY, 1992, J BIOL CHEM, V267, P21999; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	34	40	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2059	2063						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208551				2022-12-28	WOS:A1994NR68500031
J	PIM, D; STOREY, A; THOMAS, M; MASSIMI, P; BANKS, L				PIM, D; STOREY, A; THOMAS, M; MASSIMI, P; BANKS, L			MUTATIONAL ANALYSIS OF HPV-18 E6 IDENTIFIES DOMAINS REQUIRED FOR P53 DEGRADATION IN-VITRO, ABOLITION OF P53 TRANSACTIVATION IN-VIVO AND IMMORTALIZATION OF PRIMARY BMK CELLS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN KERATINOCYTES; MOUSE CELLS; PROTEIN; ASSOCIATION; EXPRESSION; GENE; E7; TRANSFORMATION; TRANSCRIPTION	The two major transforming proteins of oncogenic human papillomaviruses are encoded by the E6 and E7 oncogenes. Both viral proteins interact specifically with the products of cellular human tumour suppressor genes; E6 with p53 and E7 with Rb. However, the mechanism of action of E6 is still poorly understood in comparison with that of E7. Although extensive in vitro studies have been done with mutant E6 proteins, very little is known about the activities of E6 in vivo. In this study we have analysed the structure-function relationships of HPV-18 E6 in in vitro analyses and we correlate this with in vivo activity. These studies define a number of domains on the E6 molecule which are involved in the ability of E6 to target p53 for degradation in vitro. This analysis demonstrates that domains previously shown to be important in HPV-16 E6 (Crook et al., 1991; Mietz et al., 1992) are also conserved in HPV-18 and also reconciles the differences between these reports. A series of in vivo studies demonstrate that E6 mediated degradation of p53 in vitro is irrelevant both for cell transformation and for the ability of E6 to abolish p53 transcriptional activation. In addition, we show that at least four distinct regions of the E6 protein are involved in the p53 association in vivo.	INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB)				Storey, Alan/0000-0003-2001-9772				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MUNGER K, 1989, J VIROL, V63, P4417; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	28	116	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1869	1876						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208532				2022-12-28	WOS:A1994NR68500009
J	BANERJEE, AC; RECUPERO, AJ; MAL, A; PIOTRKOWSKI, AM; WANG, DM; HARTER, ML				BANERJEE, AC; RECUPERO, AJ; MAL, A; PIOTRKOWSKI, AM; WANG, DM; HARTER, ML			THE ADENOVIRUS E1A 289R AND 243R PROTEINS INHIBIT THE PHOSPHORYLATION OF P300	ONCOGENE			English	Note							REGION 1A PROTEINS; RETINOBLASTOMA PROTEIN; ESCHERICHIA-COLI; ASSOCIATION; KINASE; TRANSCRIPTION; POLYPEPTIDES; COMPLEXES; PRODUCTS; CYCLINS	A protein of 300 kDa (p300) associates with the adenovirus E1A proteins and has been implicated in the control of cell cycle progression. In mammalian cells, p300 is actively phosphorylated in both quiescent and proliferating cells and its level of phosphorylation increases as it travels from late G1 into M phase. E1A requires p300 for the induction of cellular DNA synthesis and the repression of enhancer mediated transcription, suggesting that p300 may be involved in pathways that are important to cell proliferation and gene expression. Since the activities of most cell cycle regulatory proteins depend on their phosphorylation state, the possibility exists that certain activities of p300 might also be controlled by phosphorylation and that E1A might in fact be affecting these events. We show here by in vitro analysis that E1A inhibits the phosphorylation of p300 by decreasing the rate of incorporation of phosphate into p300. We also show that p300 can be used as a substrate for the cyclin-dependent p33(cdk2) and p34(cdc2) kinases, and propose that E1A might be antagonistic to these enzymes in phosphorylating p300. Thus, these results indicate a possible novel function by which E1A can interfere with cellular pathways.	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation								ABRAHAM SE, 1993, ONCOGENE, V8, P1639; BRUNER M, 1988, J BIOL CHEM, V263, P3984; DATTA S, 1991, J VIROL, V65, P5297, DOI 10.1128/JVI.65.10.5297-5304.1991; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1992, CANCER SURV, V12, P161; ENGSTROM L, 1984, METHOD ENZYMOL, V107, P130; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HU Q, 1991, MOL CELL BIOL, V11, P5729; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	22	36	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1733	1737						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183570				2022-12-28	WOS:A1994NL81500027
J	BRISTOW, RG; JANG, A; PEACOCK, J; CHUNG, S; BENCHIMOL, S; HILL, RP				BRISTOW, RG; JANG, A; PEACOCK, J; CHUNG, S; BENCHIMOL, S; HILL, RP			MUTANT P53 INCREASES RADIORESISTANCE IN RAT EMBRYO FIBROBLASTS SIMULTANEOUSLY TRANSFECTED WITH HPV16-E7 AND/OR ACTIVATED H-RAS	ONCOGENE			English	Article							WILD-TYPE P53; SQUAMOUS-CELL CARCINOMAS; IONIZING-RADIATION; INVITRO RADIOSENSITIVITY; SKIN FIBROBLASTS; CYCLE CHECKPOINT; NIH-3T3 CELLS; EXPRESSION; ONCOGENE; CANCER	Recently, it has been suggested that abrogation of the wild type p53 protein function may alter the cellular response to DNA damaging agents, including ionizing radiation. This study was designed to compare the relative radiosensitivity and tumorigenicity of rat embryo fibroblast (REF) cell lines transfected with a mutant form of the p53 gene (plasmid MTp53pro193), alone, or in combination, with the H-ras (plasmid pEJ6.6) and HPV16-E7 (plasmid pJ4 Omega 16.E7) oncogenes. Transfection of the mutant p53pro193 gene alone resulted in selected clones having increased radioresistance in culture which correlated with increased mutant p53 expression in these clones. However, the co-transfection of mutant p53 and H-vas genes or triple transfection of mutant p53, H-uas and E7 genes resulted in clones with high mutant p53 expression, significantly increased radioresistance and uniform tumorigenicity. There was no correlation between intrinsic radioresistance and spontaneous metastasis in the tumorigenic REF transfectant clones. Stepwise acquisition of radioresistance and an aggressive tumor cell phenotype is observed when the mutant p53 gene and HPV E7 co-operate with the ras oncogene in transfection assays, and can be correlated to increases in mutant p53 expression.	PRINCESS MARGARET HOSP, ONTARIO CANC INST, DEPT RES, DIV CELL & MOLEC BIOL, TORONTO M4X 1K9, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	BRISTOW, RG (corresponding author), PRINCESS MARGARET HOSP, ONTARIO CANC INST, DEPT RADIAT ONCOL, DIV EXPTL THERAPEUT, 500 SHERBOURNE ST, TORONTO M4X 1K9, ON, CANADA.			Hill, Richard Peter/0000-0001-5331-8045; Benchimol, Samuel/0000-0003-3433-890X; Bristow, Robert/0000-0002-8553-9544				ALAPETITE C, 1991, INT J RADIAT BIOL, V59, P385, DOI 10.1080/09553009114550351; ALLAM A, 1993, J NATL CANCER I, V85, P1954, DOI 10.1093/jnci/85.23.1954; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BRACHMAN DG, 1993, CANCER RES, V53, P3667; BRISTOW RG, 1990, INT J RADIAT ONCOL, V18, P331, DOI 10.1016/0360-3016(90)90098-5; BROCK WA, 1989, INT J RADIAT BIOL, V56, P751, DOI 10.1080/09553008914552001; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DAVIDOFF AM, 1991, SURGERY, V110, P259; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FUJIWARA T, 1993, CANCER RES, V53, P4129; GIRINSKY T, 1992, INT J RADIAT ONCOL, V25, P3; GRANT ML, 1990, ONCOGENE, V5, P1159; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hill R. P., 1992, BASIC SCI ONCOLOGY, P259; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JUNG M, 1992, CANCER RES, V52, P6390; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASID U, 1993, CANCER RES, V61, P195; KASID UN, 1989, CANCER RES, V49, P3396; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCKENNA WG, 1990, CANCER RES, V50, P97; MENDONCA MS, 1991, INT J RADIAT BIOL, V59, P1195, DOI 10.1080/09553009114551071; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; ONG A, 1993, RADIAT RES, V134, P251, DOI 10.2307/3578467; PARDO FS, 1991, P NATL ACAD SCI USA, V88, P10652, DOI 10.1073/pnas.88.23.10652; PEACOCK J, 1990, ONCOGENE, V2, P1769; PIROLLO KF, 1993, RADIAT RES, V135, P234, DOI 10.2307/3578300; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAMID D, 1991, RADIAT RES, V126, P244, DOI 10.2307/3577825; SASAKI K, 1986, CYTOMETRY, V7, P391, DOI 10.1002/cyto.990070415; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SIDERANSKY D, 1992, NATURE, V355, P846; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEEG PS, 1988, CANCER RES, V48, P6550; STEPHENS LC, 1993, RADIAT RES, V135, P75, DOI 10.2307/3578399; SU LN, 1992, INT J RADIAT BIOL, V62, P461, DOI 10.1080/09553009214552341; SUIT HD, 1992, INT J RADIAT ONCOL, V23, P653, DOI 10.1016/0360-3016(92)90025-D; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; TAYLOR WR, 1992, ONCOGENE, V7, P1383; TISHLER RB, 1993, CANCER RES, V53, P2212; TOMMASINO M, 1993, ONCOGENE, V8, P195; VISAKORPI T, 1992, J NATL CANCER I, V84, P883, DOI 10.1093/jnci/84.11.883; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WEISCHELBAUM RR, 1991, JNCI-J NATL CANCER I, V83, P480; WEST CML, 1993, BRIT J CANCER, V68, P819, DOI 10.1038/bjc.1993.434; YIN XY, 1993, INT J CANCER, V54, P322, DOI 10.1002/ijc.2910540226; YOUNG SD, 1990, JNCI-J NATL CANCER I, V82, P371, DOI 10.1093/jnci/82.5.371; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	59	91	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1527	1536						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183546				2022-12-28	WOS:A1994NL81500002
J	MIYASHITA, T; KRAJEWSKI, S; KRAJEWSKA, M; WANG, HG; LIN, HK; LIEBERMANN, DA; HOFFMAN, B; REED, JC				MIYASHITA, T; KRAJEWSKI, S; KRAJEWSKA, M; WANG, HG; LIN, HK; LIEBERMANN, DA; HOFFMAN, B; REED, JC			TUMOR-SUPPRESSOR P53 IS A REGULATOR OF BCL-2 AND BAX GENE-EXPRESSION IN-VITRO AND IN-VIVO	ONCOGENE			English	Article							HUMAN FOLLICULAR LYMPHOMA; PROGRAMMED CELL-DEATH; WILD-TYPE P53; ANTICANCER AGENTS; INDUCED APOPTOSIS; PROTOONCOGENE; PROTEIN; LINE; ONCOPROTEIN; CARCINOMA	The p53 tumor suppressor gene product can induce apoptotic cell death through an unknown mechanism. Here we demonstrate that a temperature-sensitive p53 induces temperature-dependent decreases in the expression of the apoptosis-suppressing gene bcl-2 in the murine leukemia cell M1, while simultaneously stimulating increases in the expression of bax, a gene which encodes a dominant-inhibitor of the Bcl-2 protein. Mice deficient in p53 exhibit increases in Bcl-2 and decreases in Bax protein levels in several tissues as determined by immunohistochemical and immunoblot methods. The findings suggest a potential mechanism by which p53 regulates apoptosis, as well as responses to radiation and chemotherapeutic drugs in cancer.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV PENN,DEPT PHARMACOL,PHILADELPHIA,PA 19104	Sanford Burnham Prebys Medical Discovery Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania			Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NCI NIH HHS [CA43618, CA-60181, CA51162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060181, R01CA043618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAMPOS L, 1993, BLOOD, V81, P3091; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEJONG D, 1994, CANCER RES, V54, P256; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KITADA S, IN PRESS ANTISENSE R; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1993, BLOOD, V81, P151; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MUNAKATA S, 1993, J HISTOCHEM CYTOCHEM, V41, P1241, DOI 10.1177/41.8.8331288; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; REED JC, 1989, ONCOGENE RES, V4, P271; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG YS, 1993, ONCOGENE, V8, P3427; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605	33	2161	2223	1	126	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1799	1805						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183579				2022-12-28	WOS:A1994NL81500036
J	OETKEN, C; COUTURE, C; BERGMAN, M; BONNEFOYBERARD, N; WILLIAMS, S; ALITALO, K; BURN, P; MUSTELIN, T				OETKEN, C; COUTURE, C; BERGMAN, M; BONNEFOYBERARD, N; WILLIAMS, S; ALITALO, K; BURN, P; MUSTELIN, T			TCR/CD3-TRIGGERING CAUSES INCREASED ACTIVITY OF THE P50(CSK) TYROSINE KINASE AND ENGAGEMENT OF ITS SH2 DOMAIN	ONCOGENE			English	Article							CELL ANTIGEN RECEPTOR; CD45 PHOSPHOTYROSINE PHOSPHATASE; TERMINAL SRC KINASE; PROTEIN-KINASE; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; C-SRC; T-CELLS; AUTOPHOSPHORYLATION SITE; CROSS-LINKING	The majority of known protein tyrosine kinases are integral membrane proteins or bound to cellular membranes via a covalently attached myristic acid. An exception is the newly described p50(csk) tyrosine kinase, which is believed to control the activity of the sue-family of protein tyrosine kinases. This small kinase does not contain a myristylation signal or other known membrane attachment motifs, and indeed appears to be cytosolic. Recently, we found that p50(csk) specifically phosphorylates the negative regulatory Tyr-505 of the T cell-specific sue-family kinase p56(lck), and thereby suppresses its catalytic activity. Here we show that p50(csk) is activated in Jurkat T cells within one minute after stimulation of the cells with anti-CD3 MAbs. In parallel with this activation, p50(csk) formed a stable complex with one major 72 kDa tyrosine phosphorylated protein and minor polypeptides at 90 and 110 kDa. The isolated SH2 domain of p50(csk) specifically bound the 72 kDa protein in lysates from activated, but not resting, T or B cells, By several criteria, the 72 kDa protein was not a tyrosine kinase itself and it did not react with antibodies to a panel of known proteins of this molecular size. Our results suggest that p50(csk) is rapidly engaged via its SH2 domain and participates in the earliest events of T cell activation.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, LA JOLLA, CA 92037 USA; UNIV HELSINKI, DEPT PATHOL, CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES NEW TECHNOL, DEPT BIOL, BASEL, SWITZERLAND	La Jolla Institute for Immunology; University of Helsinki; Roche Holding			Alitalo, Kari K/J-5013-2014; Bonnefoy, Nathalie/J-2536-2012	Alitalo, Kari K/0000-0002-7331-0902; Bonnefoy, Nathalie/0000-0003-4814-6722; Mustelin, Tomas/0000-0001-5912-8840	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-48960] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BENNETT BD, 1994, IN PRESS J BIOL CHEM; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOUGERET C, 1993, ONCOGENE, V8, P1241; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COUTURE C, 1994, IN PRESS P NAT ACAD; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HSI ED, 1989, J BIOL CHEM, V264, P10836; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAGES S, 1994, IN PRESS P NATL ACAD; LIU XQ, 1993, ONCOGENE, V8, P1119; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1989, IMMUNOL TODAY, V10, P189, DOI 10.1016/0167-5699(89)90322-8; MUSTELIN T, 1990, ONCOGENE, V5, P809; MUSTELIN T, 1991, SCAND J IMMUNOL, V34, P259, DOI 10.1111/j.1365-3083.1991.tb01545.x; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OETKEN C, 1992, EUR J HAEMATOL, V49, P208; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PARTANEN J, 1991, ONCOGENE, V6, P2013; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	58	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1625	1631						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183556				2022-12-28	WOS:A1994NL81500013
J	FIJNEMAN, RJA; OPHOFF, RA; HART, AAM; DEMANT, P				FIJNEMAN, RJA; OPHOFF, RA; HART, AAM; DEMANT, P			KRAS-2 ALLELES, MUTATIONS, AND LUNG TURNER SUSCEPTIBILITY IN THE MOUSE - AN EVALUATION	ONCOGENE			English	Article							RECOMBINANT CONGENIC STRAINS; ETHYL-N-NITROSOUREA; TUMOR SUSCEPTIBILITY; MICE; TRAITS; GENES; TOOL	Lung Tumor Susceptibility (LTS) in the mouse has been shown to be influenced by loci within the Major Histocompatibility Complex (MHC) and the Kras-2 regions. In crosses between susceptible and resistant strains, one allele of Kras-2 has been linked with a high LTS, whereas the other allele has been linked with a low LTS. Furthermore, these Kras-2 alleles affect differently the occurrence of Kras-2 mutations in lung tumors. In this study we evaluated the relationship between LTS, Kras-2 alleles and Kras-2 mutations, using Recombinant Congenic Strains with identical MHC haplotypes. The Kras-2 region indeed influences the frequency of Kras-2 mutations in N-ethyl-N-nitrosourea-induced lung tumors. These mutations are associated with larger tumors. However, Kras-2 affects LTS only marginally. Several strains with identical Kras-2 alleles and mutation frequency differ widely in LTS, while some strains with different alleles and mutation frequency do not. We conclude that a considerable part of the genetic variability in LTS is caused by LTS-loci other than Kras-2 and MHC.	NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			Fijneman, Remond/X-4199-2019	Fijneman, Remond/0000-0003-2076-5521				Cochran W.G., 2007, SAMPLING TECHNIQUES; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DIETRICH W, 1992, GENETICS, V131, P423; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; MALKINSON AM, 1991, ENVIRON HEALTH PERSP, V93, P149, DOI 10.2307/3431183; MALKINSON AM, 1992, CANCER RES, V52, pS2670; MOEN CJA, 1992, ONCOGENE, V7, P563; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; NUZUM EO, 1990, MOL CARCINOGEN, V3, P287, DOI 10.1002/mc.2940030509; OOMEN LCJM, 1983, INT J CANCER, V31, P447, DOI 10.1002/ijc.2910310409; OOMEN LCJM, 1991, EXP LUNG RES, V17, P283, DOI 10.3109/01902149109064419; RYAN J, 1987, J NATL CANCER I, V79, P1351; SKOPEK TR, 1992, P NATL ACAD SCI USA, V89, P7866, DOI 10.1073/pnas.89.17.7866; Slebos R J, 1992, Diagn Mol Pathol, V1, P136, DOI 10.1097/00019606-199206000-00007; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; WRIGHT SP, 1992, BIOMETRICS, V48, P1005, DOI 10.2307/2532694; YOU M, 1992, CARCINOGENESIS, V13, P1583, DOI 10.1093/carcin/13.9.1583; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	21	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1417	1421						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152802				2022-12-28	WOS:A1994NH40100013
J	SASSANO, M; GRANUCCI, F; SEVESO, M; MARCONI, G; FOTI, M; RICCIARDICASTAGNOLI, P				SASSANO, M; GRANUCCI, F; SEVESO, M; MARCONI, G; FOTI, M; RICCIARDICASTAGNOLI, P			MOLECULAR-CLONING OF A RECOMBINANT RETROVIRUS CARRYING A MUTATED ENV(AKR)-MYC(MH2) FUSION GENE IMMORTALIZING CELLS OF THE MONOCYTIC-MACROPHAGE LINEAGE	ONCOGENE			English	Note							V-MYC; DNA-BINDING; MYELOMONOCYTIC CELLS; NUCLEOTIDE-SEQUENCE; MURINE RETROVIRUSES; MOUSE MACROPHAGE; LEUKEMIA VIRUSES; TARGET-CELLS; DIFFERENTIATION; ACTIVATION	The VN-11 recombinant retroviruses, originally generated by co-transfection of the avian MH2 and AKRv viral genomes, were molecularly cloned from an infected mouse cell line named N11. The analysis of the proviral genome sequence from one of these recombinants showed a possible env(AKR)-myc(MH2) fusion. Point mutations were also found in this env(AKR)-myc(MH2) gene. The cloned viral genome was co-transfected with the neo gene into the psi 2 packaging cell line. Selected clones were shown to transcribe the viral genome and supernatants from these cultures, containing C-type particles, were used to infect primary cultures from mouse lymphoid tissues and brain. Proliferating macrophages and microglial cell clones were obtained, indicating that various types of cells of the mouse monocytic-macrophage lineage can be immortalized in spite of the absence of selection or special growth conditions.	UNIV MILAN,CTR CYTOPHARMACOL,CNR,I-20129 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Milan			GRANUCCI, Francesca/K-6150-2019	FOTI, MARIA/0000-0002-4481-1900; granucci, francesca/0000-0002-7046-4914				ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BEUG H, 1979, CELL, V18, P559; BICHENALLROBERT.MC, 1989, ONCOGENE, V4, P731; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; CHISHOLM O, 1992, ONCOGENE, V7, P1827; DUESBERG PH, 1979, P NATL ACAD SCI USA, V76, P1633, DOI 10.1073/pnas.76.4.1633; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; KERKHOFF E, 1991, ONCOGENE, V6, P93; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MIN SY, 1992, ONCOGENE, V7, P1531; PIRAMI L, 1991, P NATL ACAD SCI USA, V88, P7543, DOI 10.1073/pnas.88.17.7543; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RICCIARDICASTAGNOLI P, 1992, RES IMMUNOL, V143, P101, DOI 10.1016/0923-2494(92)80086-Z; RIGHI M, 1989, ONCOGENE, V4, P223; RIGHI M, 1991, ONCOGENE, V6, P103; SYMONDS G, 1989, ONCOGENE, V4, P285; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7	27	24	25	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1473	1477						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152810				2022-12-28	WOS:A1994NH40100021
J	JANKOWSKI, SA; MITCHELL, DS; SMITH, SH; TRENT, JM; MELTZER, PS				JANKOWSKI, SA; MITCHELL, DS; SMITH, SH; TRENT, JM; MELTZER, PS			SAS, A GENE AMPLIFIED IN HUMAN SARCOMAS, ENCODES A NEW MEMBER OF THE TRANSMEMBRANE-4-SUPERFAMILY OF PROTEINS	ONCOGENE			English	Article							TUMOR-ASSOCIATED ANTIGEN; CELL-SURFACE PROTEINS; MOLECULAR-CLONING; CD9 ANTIGEN; MRC OX-44; N-MYC; C-MYC; AMPLIFICATION; FAMILY; IDENTIFICATION	Amplification of 12q13-14 occurs in a subset of human sarcomas including malignant fibrous histiocytoma and liposarcoma. This chromosomal region has previously been found to include a number of growth-related genes including the GLI proto-oncogene and the p53-associated protein, MDM2. We now report the characterization of SAS (sarcoma amplified sequence), a novel transcript found in this region. Sequence analysis demonstrates that SAS is a novel member of a transmembrane protein family (transmembrane 4 superfamily or TM4SF) thought to be involved in growth-related cellular processes. This observation adds a TM4SF protein to the cluster of genes at 12q13-14 frequently amplified in human sarcomas.	UNIV MICHIGAN, DEPT PEDIAT,MED SCI RES BLDG 2,RM C560B, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT RADIAT ONCOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [CA-09676, CA-56725, CA-09205] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676, R01CA056725] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; AMIOT M, 1990, J IMMUNOL, V145, P4322; ANDRIA ML, 1991, J IMMUNOL, V147, P1030; ANGELISOVA P, 1990, IMMUNOGENETICS, V32, P281, DOI 10.1007/BF00187099; AZORSA DO, 1991, BLOOD, V78, P280; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; BELLACOSA A, 1991, MOL CELL BIOL, V11, P2864, DOI 10.1128/MCB.11.5.2864; BENOIT P, 1991, HUM GENET, V86, P268, DOI 10.1007/BF00202407; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMETRICK DJ, 1992, J NATL CANCER I, V84, P422, DOI 10.1093/jnci/84.6.422; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EMI N, 1993, IMMUNOGENETICS, V37, P193; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HOTTA H, 1988, CANCER RES, V48, P2955; KHATIB ZA, 1993, CANCER RES, V53, P5535; LEACH FS, 1993, CANCER RES, V53, P2231; LEVY S, 1991, J BIOL CHEM, V266, P14597; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P503; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISHIBORI M, 1993, J CLIN INVEST, V91, P1775, DOI 10.1172/JCI116388; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; ROBERTS WM, 1989, CANCER RES, V49, P5407; Sambrook J, 1989, MOL CLONING LABORATO; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEHAFER JG, 1991, BIOCHEM BIOPH RES CO, V179, P401, DOI 10.1016/0006-291X(91)91384-O; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH SH, 1992, CANCER RES, V52, P3746; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TOMLINSON MG, 1993, EUR J IMMUNOL, V23, P136, DOI 10.1002/eji.1830230122; TRENT JM, 1984, CANCER RES, V44, P233; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; WRIGHT MD, 1990, J IMMUNOL, V144, P3195	44	75	81	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1205	1211						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134123				2022-12-28	WOS:A1994NC04800024
J	BATES, S; BONETTA, L; MACALLAN, D; PARRY, D; HOLDER, A; DICKSON, C; PETERS, G				BATES, S; BONETTA, L; MACALLAN, D; PARRY, D; HOLDER, A; DICKSON, C; PETERS, G			CDK6 (PLSTIRE) AND CDK4 (PSK-J3) ARE A DISTINCT SUBSET OF THE CYCLIN-DEPENDENT KINASES THAT ASSOCIATE WITH CYCLIN D1	ONCOGENE			English	Article							PROTEIN-KINASE; CELL-CYCLE; CANDIDATE ONCOGENE; CHROMOSOME 11Q13; BCL-1 GENE; G1 PHASE; EXPRESSION; FAMILY; IDENTIFICATION; ACTIVATION	Deregulated expression of cyclin D1 is a feature of several neoplastic and proliferative disorders, but its normal role in the cell cycle remains unclear. Here we show that in a squamous carcinoma cell line with ii-fold amplification of the CCND1 gene, cyclin D1 associates specifically with p33(cdk4) (PSK-J3) and p38(cdk6) (PLSTIRE), two closely related members of the cyclin-dependent kinase (CDK) family. In these tumour cells, there is little evidence for an association between cyclin D1 and other CDKs, but in diploid human fibroblasts both CDK2 and CDK5 can be co-precipitated with cyclin D1, as well as CDK4. The data suggest that D-type cyclins participate in multiple interactions with CDKs but that the nature or stoichiometry of these associations may differ in different types of cell.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; DOU QP, 1993, CANCER RES, V53, P1493; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FAUST JB, 1992, CANCER RES, V52, P2460; GOLDFARB M, 1991, ONCOGENE, V6, P65; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HALL FL, 1993, ONCOGENE, V8, P1377; Hancock D C, 1992, Methods Mol Biol, V80, P33, DOI 10.1385/0-89603-204-3:33; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nei M., 1987, MOL EVOLUTIONARY GEN, P287; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKUDA T, 1992, ONCOGENE, V7, P2249; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SEWING A, 1993, J CELL SCI, V104, P545; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	45	284	296	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					71	79						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302605				2022-12-28	WOS:A1994MW24700009
J	BUSCHER, D; DELLOSBARBA, P; HIPSKIND, RA; RAPP, UR; STANLEY, ER; BACCARINI, M				BUSCHER, D; DELLOSBARBA, P; HIPSKIND, RA; RAPP, UR; STANLEY, ER; BACCARINI, M			V-RAF CONFERS CSF-1 INDEPENDENT GROWTH TO A MACROPHAGE CELL-LINE AND LEADS TO IMMEDIATE-EARLY GENE-EXPRESSION WITHOUT MAP-KINASE ACTIVATION	ONCOGENE			English	Article							STIMULATING FACTOR-I; RECOMBINANT MURINE RETROVIRUS; PROTEIN-KINASE; C-FOS; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; BINDING-SITES; BONE-MARROW; RECEPTOR	The BAC-1.2F5 macrophage cell line depends on CSF-1 for proliferation and survival. Phosphorylation and activation of the RAF-1 kinase are among the early events in CSF-1 signal transduction. To characterize the role of RAF-1 in CSF-1-induced proliferation, we overexpressed oncogenically activated RAF-1, cellular RAF-1 and RAF-1 kinase-defective mutant proteins in BAC-1.2F5 cells. We were unable to establish stable cell lines expressing either kinase-negative or full length RAF-1 proteins, implying that expression of these molecules is not tolerated in BAC-1.2F5 cells. Oncogenically activated RAF-1 induces CSF-1-independent growth in the absence of autocrine growth factor production. Autonomous growth is not associated with dedifferentiation, since v-raf-expressing macrophages perform the same immunological functions as control cells. Intriguingly, autonomous growth correlates with the suppression of CSF-1-mediated MAP-Kinase activation and with the low constitutive expression of a number of CSF-1-inducible genes, including fos, jun, ets2, and myc, but also the genes for the inflammatory cytokines TNF alpha and IL-1 beta. Many of these genes have AP-1 binding sites in their promoters, and the v-raf-expressing cells contain constitutive AP-1 binding activity. These data indicate that RAF-1, but not MAP-Kinase, is a key component in CSF-1 mitogenic signal transduction, and are consistent with a working hypothesis in which RAF-1 mediates transcriptional activation of genes via AP-1.	FRAUNHOFER INST TOXICOL & MOLEC BIOL,DEPT IMMUNBIOL,HANNOVER,GERMANY; INST MOLEC BIOL,HANNOVER,GERMANY; UNIV FLORENCE,INST GEN PATHOL,FLORENCE,ITALY; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701; ALBERT EINSTEIN COLL MED,DEPT DEV & MOLEC BIOL,BRONX,NY 10461	Fraunhofer Gesellschaft; University of Florence; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yeshiva University; Albert Einstein College of Medicine			Dello Sbarba, Persio/AAX-9887-2020; Stanley, Evan R/J-9154-2013; Baccarini, Manuela/B-6481-2014	Stanley, Evan R/0000-0002-2910-2065; Baccarini, Manuela/0000-0002-3033-391X	NATIONAL CANCER INSTITUTE [R01CA026504, R37CA026504] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; Baccarini M, 1991, Receptor, V1, P243; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BACCARINI M, 1990, GROWTH FACTORS DIFFE, P188; BEUTLER B, 1988, BIOCHEMISTRY-US, V27, P7575, DOI 10.1021/bi00420a001; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DECKER T, 1986, INFECT IMMUN, V54, P477, DOI 10.1128/IAI.54.2.477-486.1986; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GIFFORD GE, 1987, J NATL CANCER I, V78, P121, DOI 10.1093/jnci/78.1.121; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOWE LR, 1992, CELL, V71, P535; KALTREIDER HB, 1986, AM REV RESPIR DIS, V133, P1097; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, ONCOGENE, V8, P361; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LI W, 1991, J BIOL CHEM, V266, P6808; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANLEY ER, 1985, METHOD ENZYMOL, V116, P565; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WITSELL AL, 1992, P NATL ACAD SCI USA, V89, P4754, DOI 10.1073/pnas.89.10.4754; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	73	52	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3323	3332						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247534				2022-12-28	WOS:A1993MG78200016
J	JIANG, W; KAHN, SM; ZHOU, P; ZHANG, YJ; CACACE, AM; INFANTE, AS; DOI, S; SANTELLA, RM; WEINSTEIN, IB				JIANG, W; KAHN, SM; ZHOU, P; ZHANG, YJ; CACACE, AM; INFANTE, AS; DOI, S; SANTELLA, RM; WEINSTEIN, IB			OVEREXPRESSION OF CYCLIN D1 IN RAT FIBROBLASTS CAUSES ABNORMALITIES IN GROWTH-CONTROL, CELL-CYCLE PROGRESSION AND GENE-EXPRESSION	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CANDIDATE ONCOGENE; CHROMOSOME 11Q13; DNA-REPLICATION; PROTEIN-KINASE; MESSENGER-RNA; BCL-1 GENE; G1 PHASE; CLONING; CANCER	Cyclin D1, a putative G1 cyclin, has been implicated in cell cycle control. The human cyclin D1 gene is located on chromosome 11q13 where DNA rearrangement and amplification have been detected in several types of human cancer. Previous studies demonstrated that the cyclin D1 gene is not only rearranged or amplified but also overexpressed in some of these human tumors and tumor-derived cell lines. To further address the roles of cyclin DI in cell cycle control and tumorigenesis, we have stably overexpressed the human cyclin D1 cDNA in Rat6 embryo fibroblasts by using retrovirus mediated transduction. The cyclin D1 protein was overproduced about Ill-fold and was localized predominately in the nucleus. Cyclin D1 overexpressing cells displayed a decrease in the duration of the G1 phase, decreased cell size, and induced tumors when injected into athymic (nude) mice. In addition, overexpression of cyclin D1 in Rat6 cells perturbed the expression of several cellular growth-related genes including c-myc, c-jun, and cyclin A, but not cyclin D3. Taken together, these results indicate that deregulated expression of the cyclin D1 gene can cause disturbances in cell cycle control and gene expression and also enhance tumorigenesis.	COLUMBIA UNIV, COLL PHYS & SURG, COLUMBIA PRESBYTERIAN CANC CTR, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, INST CANC RES, NEW YORK, NY USA	Columbia University; Columbia University				Jiang, Wei/0000-0002-2309-9571	NCI NIH HHS [CA02111] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CACACE AM, 1993, ONCOGENE, V8, P2095; CHELLAPAN SP, 1991, CELL, V68, P985; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FAUST JB, 1992, CANCER RES, V52, P2460; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HALL FL, 1993, ONCOGENE, V8, P1377; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1992, MOL CARCINOGEN, V5, P140, DOI 10.1002/mc.2940050210; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1992, CANCER RES, V52, P2980; JIANG W, 1993, IN PRESS NATL ACAD S; KATO J, 1993, GENE DEV, V7, P331; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRISSHAN A, 1974, J CELL BIOL, V66, P1974; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEACH FS, 1993, CANCER RES, V53, P1986; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LU XP, 1992, J BIOL CHEM, V267, P2841; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG YJ, 1993, UNPUB	72	450	459	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3447	3457						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247550				2022-12-28	WOS:A1993MG78200032
J	PICHEL, JG; LAKSO, M; WESTPHAL, H				PICHEL, JG; LAKSO, M; WESTPHAL, H			TIMING OF SV40 ONCOGENE ACTIVATION BY SITE-SPECIFIC RECOMBINATION DETERMINES SUBSEQUENT TUMOR PROGRESSION DINING MURINE LENS DEVELOPMENT	ONCOGENE			English	Article							TRANSGENIC MICE; ANTIGEN EXPRESSION; DNA RECOMBINATION; MAMMALIAN-CELLS; MOUSE LENS; GENE; CRYSTALLIN; PROMOTER; DIFFERENTIATION; TUMORIGENESIS	We generated mice that carry copies of a dormant transgene encoding the SV40 tumor antigens. The transgenes are specifically targeted to the lens and contain features that render their expression dependent on the action of Cre, a site-specific bacteriophage DNA recombinase. Timing of oncogene activation was controlled by making Cre available either prior to, or coincident with, the onset of primary fiber differentiation in the embryonic lens vesicle. Early expression of Cre resulted in oncogene activation in undifferentiated lens epithelial cells that rapidly proliferated inside the lens capsule. By contrast, when Cre accumulation was delayed to coincide with the onset of primary lens fiber differentiation, SV40 oncogenes were activated in cells that had begun to elongate and to accumulate lens-specific crystallins. During subsequent proliferation inside the lens capsule, transformed progeny cells maintained the profile of fiber differentiation that their parent cells had acquired at the time of oncogenic conversion. Developing lens tumors were confined within the capsule of the embryonic lens. However, if the capsule was perforated in an embryonic eye in organ culture, cells rapidly grew out while still maintaining features of differentiation. Our findings show that the differentiated state of the primary target cells is an important parameter of subsequent lens oncogenesis, and that an intact lens capsule can restrict invasive neoplastic growth.	NICHHD, MAMMALIAN GENES & DEV LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Pichel, Jose G/AAF-2255-2019	Pichel, Jose G/0000-0001-8580-0952				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; BUTEL JS, 1990, INTERVIROLOGY, V31, P85, DOI 10.1159/000150142; CHEN JD, 1992, ONCOGENE, V7, P1167; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FUKUSHIGE S, 1992, P NATL ACAD SCI USA, V89, P7905, DOI 10.1073/pnas.89.17.7905; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HOGAN B, 1986, MANIPULATING MOUSE E; KHILLAN JS, 1987, GENE DEV, V1, P1327, DOI 10.1101/gad.1.10.1327; KOTHARY R, 1991, MECH DEVELOP, V35, P25, DOI 10.1016/0925-4773(91)90038-8; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; NAKAMURA T, 1989, New Biologist, V1, P193; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; SAUER B, 1987, MOL CELL BIOL, V7, P2087, DOI 10.1128/MCB.7.6.2087; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; TRETON JA, 1991, DIFFERENTIATION, V47, P143, DOI 10.1111/j.1432-0436.1991.tb00232.x; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; WESTPHAL H, 1992, ADV DEV BIOL, V1, P183; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZWAAN J, 1983, DEV BIOL, V96, P173, DOI 10.1016/0012-1606(83)90320-2	28	23	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3333	3342						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247535				2022-12-28	WOS:A1993MG78200017
J	YAGI, T; SHIGETANI, Y; OKADO, N; TOKUNAGA, T; IKAWA, Y; AIZAWA, S				YAGI, T; SHIGETANI, Y; OKADO, N; TOKUNAGA, T; IKAWA, Y; AIZAWA, S			REGIONAL LOCALIZATION OF FYN IN ADULT BRAIN - STUDIES WITH MICE IN WHICH FYN GENE WAS REPLACED BY LACZ	ONCOGENE			English	Article							LONG-TERM POTENTIATION; RAT-BRAIN; TYROSINE PHOSPHORYLATION; NMDA RECEPTOR; STEM-CELLS; PROTEIN; RNA; PROTOONCOGENE; RECOMBINATION; EXPRESSION	Mutant mice in which beta-galactosidase gene (lacZ) was inserted into fyn locus were generated by homologous recombination in embryonic stem cells to examine the Fyn expression in the central nervous system. In adult brain, intensive beta-galactosidase activity was observed in olfactory bulb, cerebellum and hippocampus of the limbic system; the subcellular distribution of the activity was apparent not only in cell body but also in neural processes, and homozygous mutant mice live-born displayed an anatomical abnormality in the neural cell layer of the hippocampal formation. In spinal cord it was specifically expressed in dorsal horn, and in brain stem it was more characteristic in the sensory pathway, suggesting roles of Fyn in the sensory nervous network. In the white matter area, it was intense at postnatal day 10 but not detectable in adult, suggesting Fyn's role in myelinization.	UNIV TSUKUBA, INST BASIC MED SCI, DEPT ANAT, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba	YAGI, T (corresponding author), INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC ONCOL LAB, 3-1-1 KOYADAI, TSUKUBA, IBARAKI 305, JAPAN.							BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; ISHIGURO H, 1991, BRAIN RES, V563, P288, DOI 10.1016/0006-8993(91)91548-F; JACOBSON S, 1963, J COMP NEUROL, V121, P5, DOI 10.1002/cne.901210103; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NOMURA S, 1989, DEVELOPMENT, V105, P575; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAGI T, 1993, IN PRESS ANAL BIOCH; ZHAO YH, 1991, ONCOGENE, V6, P1725	32	81	81	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3343	3351						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247536				2022-12-28	WOS:A1993MG78200018
J	CECCHERINI, I; HOFSTRA, RMW; LUO, Y; STULP, RP; BARONE, V; STELWAGEN, T; BOCCIARDI, R; NIJVEEN, H; BOLINO, A; SERI, M; RONCHETTO, P; PASINI, B; BOZZANO, M; BUYS, CHCM; ROMEO, G				CECCHERINI, I; HOFSTRA, RMW; LUO, Y; STULP, RP; BARONE, V; STELWAGEN, T; BOCCIARDI, R; NIJVEEN, H; BOLINO, A; SERI, M; RONCHETTO, P; PASINI, B; BOZZANO, M; BUYS, CHCM; ROMEO, G			DNA POLYMORPHISMS AND CONDITIONS FOR SSCP ANALYSIS OF THE 20 EXONS OF THE RET PROTOONCOGENE	ONCOGENE			English	Note							SINGLE BASE SUBSTITUTIONS; POINT MUTATIONS; PROTOONCOGENE; MISMATCHES; LINE	Recently identified mutations affecting different domains of the RET proto-oncogene are associated with Multiple Endocrine Neoplasia type 2A (MEN 2A) and type 2B (MEN 2B), familial and sporadic Medullary Thyroid Carcinomas (MTC) and Hirschsprung disease (HSCR). In order to facilitate the screening for RET mutations, and to study possible genotype-phenotype correlations, we established exon-intron junctions and extended the intronic sequences flanking the 20 exons of this gene. This made it possible to design primers and to develop PCR conditions useful for SSCP analysis of the whole RET coding sequence. Nine conformational variants were observed which after sequencing turned out to be 8 silent mutations and a conservative amino acid substitution. Restriction analysis performed on DNA samples from unrelated controls confirmed the polymorphic nature of six of these nucleotide changes and made it possible to estimate the frequency of the corresponding alleles.	IST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; UNIV GRONINGEN,DEPT MED GENET,9713 AW GRONINGEN,NETHERLANDS	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Groningen			Bocciardi, Renata/J-8577-2016; Ceccherini, Isabella/P-8195-2014; Bolino, Alessandra/O-2933-2013; Barone, Virginia/K-8782-2015; Pasini, Barbara/AHI-2004-2022; Nijveen, Harm/L-2272-2014; Ronchetto, Patrizia/AAA-7742-2020; Seri, Marco/A-4339-2014	Bocciardi, Renata/0000-0001-8415-3802; Ceccherini, Isabella/0000-0001-8732-1955; Barone, Virginia/0000-0001-8794-9291; Pasini, Barbara/0000-0002-4373-1212; Nijveen, Harm/0000-0002-9167-4945; Bolino, Alessandra/0000-0002-8980-4878; Hofstra, Robert/0000-0001-7498-3829; Ronchetto, Patrizia/0000-0002-2606-3398; Seri, Marco/0000-0003-2425-2176				BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, J ENDOCRINOL INVEST, V17, P201; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DANENBERG PV, 1992, NUCLEIC ACIDS RES, V20, P573, DOI 10.1093/nar/20.3.573; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; LO YMD, 1992, NUCLEIC ACIDS RES, V20, P1005, DOI 10.1093/nar/20.5.1005; MAHAFFEY SM, 1990, J PEDIATR SURG, V25, P101, DOI 10.1016/S0022-3468(05)80172-1; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VERDY M, 1982, J PEDIATR GASTR NUTR, V1, P603, DOI 10.1097/00005176-198212000-00027; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5	26	159	162	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3025	3029						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084609				2022-12-28	WOS:A1994PG82200032
J	SHALABY, F; SCHUH, AC; BREITMAN, ML				SHALABY, F; SCHUH, AC; BREITMAN, ML			2 DISTINCT TARGET-CELLS FOR V-JUN MEDIATED WOUND TUMORIGENESIS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING ACTIVITY; C-JUN; TRANSGENIC MICE; PROTO-ONCOGENE; FOS JUN; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; ENHANCER ELEMENTS; ACTIVATION	Transgenic mice expressing v-jun under the control of the H-2K promoter develop dermal fibrosarcomas and rhabdomyosarcomas via a multistep process following wounding. To assess the relative roles that wounding and the H-2K promoter play in this process, we compared the phenotype of H-2K-v-jun mice with that of animals expressing v-jun under the control of the metallothionein I (MTI) promoter. MT-v-jun animals also develop wound-induced neoplasms by a multistage process. Both early and late features of tumorigenesis in MT-v-jun mice are different, however, from what is observed in H-2K-v-jun animals. First, the acute hyperplastic response that is characteristic of H-2K-v-jun granulation tissue is not observed in MT-v-jun wounds. Second, the myogenic components that are readily detected in the majority of late stage H-2K neoplasms are never observed in their MT counterparts. Moreover, analysis of wound tumours arising in animals expressing both MT-v-jun and H-2K-v-jun reveals that the two transgenes are not expressed in identical malignant cell populations. These results imply that mesenchymal granulation tissue is heterogeneous in composition and that the different cellular phenotypes of MT-v-jun and H-2K-v-jun malignancies result from oncogenic activation of wound-derived cells which differ in their differentiation potential. Thus, whereas the wounding component of multistage tumorigenesis is attributable to the action of v-jun, the transcriptional regulatory elements which drive its expression determine the nature of the target cells which give rise to wound-induced neoplasms.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Clark R.A.F., 1988, MOL CELLULAR BIOL WO, P3, DOI [10.1007/978-1-4615-1795-5_1, DOI 10.1007/978-1-4615-1795-5_1]; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GROSSI M, 1991, ONCOGENE, V6, P1767; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOGAN B, 1986, MANIPULATING MOUSE E; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOVACS EJ, 1991, IMMUNOL TODAY, V12, P17, DOI 10.1016/0167-5699(91)90107-5; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1993, ONCOGENE, V8, P1135; OEHLER T, 1993, ONCOGENE, V8, P1141; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUH AC, 1992, ONCOGENE, V7, P667; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHUH AC, 1993, CELL GROWTH DIFFER, V4, P177; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SU HY, 1991, ONCOGENE, V6, P1759; VANHAMME L, 1993, CANCER RES, V53, P615; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	45	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2579	2588						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058321				2022-12-28	WOS:A1994PC05400017
J	DIECKMANN, A; KRIPPL, B				DIECKMANN, A; KRIPPL, B			THE E1A TRANSCRIPTIONAL CONTROL REGION IS EFFICIENTLY ACTIVATED IN PROLIFERATING TISSUES OF TRANSGENIC MICE	ONCOGENE			English	Article							EUKARYOTIC TRANSCRIPTION; DNA-REPLICATION; AUTO-REGULATION; GENE; CELLS; INITIATION; EXPRESSION; SEQUENCES; PROTEINS; PRODUCT	To study the in vivo regulation of the adenovirus E1A transcriptional regulatory region in transgenic mice, we have constructed two hybrid genes in which the viral control element regulates the expression of the CAT and the lacZ reporter gene. The fusion constructs were introduced into the mouse germline. The expression of the transgenes were monitored during embryogenesis and during postnatal development as web as in adult organs. We show that the E1A regulatory region is recognized and activated in undifferentiated cells during early embryonic cleavage, in the morula, in the inner cell mass and in the trophectoderm of the blastocyst. Transcription initiation at the E1A promoter leads to higher marker gene expression in proliferative centers in postimplantation embryos at the beginning of the neural tube closure. Analysing marker gene expression during postnatal development, a correlation of transcriptional activity of the E1A regulatory region and cell proliferation could be demonstrated. The expression profile of the transgene in different adult organs parallels with DNA synthesis. Marker gene expression was high in cells of organs known to have a high mitotic rate, such as the intestine, the stomach, the skin and the bone marrow, whereas little activity of the E1A control region was observed in the post-proliferative brain. These results are consistent with the finding that activation of the viral cis-regulating elements dramatically increased in the kidney after mitotic stimulation by folic acid. These observations strongly suggests a cell cycle regulated expression from the E1A enhancer/promoter in the absence of the E1A autoregulatory proteins in the living animal.	RUHR UNIV BOCHUM,FAK MED,INST PHYSIOL CHEM,D-44780 BOCHUM,GERMANY	Ruhr University Bochum								BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; CID A, 1993, J VIROL, V67, P6742, DOI 10.1128/JVI.67.11.6742-6752.1993; CLEAVER JE, 1967, THYMIDINE METABOLISM, P184; COGAN JD, 1992, J VIROL, V66, P3833, DOI 10.1128/JVI.66.6.3833-3845.1992; FUJITA S, 1964, J COMP NEUROL, V122, P311, DOI 10.1002/cne.901220303; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GOSSLER A, 1993, GENE TARGETING PRACT, P181; GROSVELD F, 1992, TRANSGENIC ANIMALS, P79; HATFIELD L, 1993, J VIROL, V67, P3931, DOI 10.1128/JVI.67.7.3931-3939.1993; HEARING P, 1986, CELL, V45, P229, DOI 10.1016/0092-8674(86)90387-9; HEARING P, 1985, MOL CELL BIOL, V5, P3214, DOI 10.1128/MCB.5.11.3214; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HOGAN B, 1986, MANIPULATING MOUSE E; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KRIPPL B, 1988, NUCLEIC ACIDS RES, V18, P8965; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; OSBORNE TF, 1983, J VIROL, V45, P594, DOI 10.1128/JVI.45.2.594-599.1983; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SEIFERT R, 1992, ANAT EMBRYOL, V186, P601; SEISER C, 1989, NUCLEIC ACIDS RES, V17, P185, DOI 10.1093/nar/17.1.185; SNOW MHL, 1978, DEV MAMMALS, P337; TAYLOR DM, 1966, NATURE, V212, P472, DOI 10.1038/212472a0; TIBBETTS C, 1986, J VIROL, V57, P1055, DOI 10.1128/JVI.57.3.1055-1064.1986; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	31	4	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2227	2233						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036008				2022-12-28	WOS:A1994NX62900014
J	CARILLO, S; PARIAT, M; STEFF, AM; ROUX, P; ETIENNEJULAN, M; LORCA, T; PIECHACZYK, M				CARILLO, S; PARIAT, M; STEFF, AM; ROUX, P; ETIENNEJULAN, M; LORCA, T; PIECHACZYK, M			DIFFERENTIAL SENSITIVITY OF FOS AND JUN FAMILY MEMBERS TO CALPAINS	ONCOGENE			English	Article							NEUTRAL PROTEASE CALPAIN; C-FOS; V-FOS; DEPENDENT PROTEASES; MESSENGER-RNAS; PROTEINS; DEGRADATION; PROTEOLYSIS; INVITRO; SYSTEM	Degradation of c-fos protein (c-FOS) in the cytoplasm is very rapid in vivo and constitutes a crucial regulation of the nuclear steady-state level through the control of the amount of full-length molecules available for nuclear transport. Using cytoplasmic extracts from various origins, we report herein that c-FOS degradation can be initiated in a calcium-dependent manner which involves cysteine proteases called milli- and micro-calpain. Interestingly, FOS-B, a member of the fos multigene family, as well as all members of the jun family (JUN-B, c-JUN and JUN-D) are also sensitive to calpains albeit to different extents. FRA-2, which is a c-FOS-related protein, is resistant to micro- but not to milli-calpain whereas FRA-1, another member of the fos family, is resistant to both proteases. Given the fact that a work by others (Hirai et al., 1991b) suggests that calpains can be involved in c-FOS and c-JUN degradation in vivo, our observations raises the possibility of a novel contribution to the regulation of AP-1 transcription complex activity through a differential control of the steady-state level of some of its components that involves calpains.	INST GENET MOLEC MONTPELLIER,UMR 9942,F-34033 MONTPELLIER 01,FRANCE; CTR RECH BIOCHIM MACROMOLEC,CNRS,F-34033 MONTPELLIER 01,FRANCE	Centre National de la Recherche Scientifique (CNRS)			PIECHACZYK, Marc/E-7896-2013; Roux, Pierre/D-8833-2017	PIECHACZYK, Marc/0000-0003-1367-2597; ETIENNE-JULAN, Maryse/0000-0003-1339-6545; Lorca, Thierry/0000-0003-2007-8924; Steff, Ann-Muriel/0000-0002-9817-6164				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; Abate C, 1990, Semin Cancer Biol, V1, P19; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BLANCHARD JM, 1992, MED SCI, V5, P455; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Curran T, 1988, ONCOGENE HDB, P307; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DOHERTY FJ, 1992, INTRACELLULAR DEGRAD; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HIRAI SI, 1990, ONCOGENE, V5, P39; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI M, 1989, J BIOL CHEM, V264, P18866; MATSUI M, 1990, ONCOGENE, V5, P249; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PARNAIK VK, 1990, MOL CELL BIOL, V10, P1287, DOI 10.1128/MCB.10.3.1287; PIECHACZYK M, 1994, IN PRESS CRIT REV ON; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUX P, 1991, ONCOGENE, V6, P2155; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROUX P, 1994, IN PRESS FOS ONCOGEN; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 1989, MOL CLONING; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; TOKES ZA, 1989, J BIOL CHEM, V264, P15059; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VINCENT S, 1990, NUCLEIC ACIDS RES, V18, P3054, DOI 10.1093/nar/18.10.3054; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0	45	75	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1679	1689						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183563				2022-12-28	WOS:A1994NL81500020
J	HODIVALA, KJ; PEI, XF; LIU, QY; JONES, PH; RYTINA, ERC; GILBERT, C; SINGER, A; WATT, FM				HODIVALA, KJ; PEI, XF; LIU, QY; JONES, PH; RYTINA, ERC; GILBERT, C; SINGER, A; WATT, FM			INTEGRIN EXPRESSION AND FUNCTION IN HPV16-IMMORTALIZED HUMAN KERATINOCYTES IN THE PRESENCE OR ABSENCE OF V-HA-RAS - COMPARISON WITH CERVICAL INTRAEPITHELIAL NEOPLASIA	ONCOGENE			English	Note							PAPILLOMAVIRUS TYPE-16 DNA; HUMAN EPIDERMAL-KERATINOCYTES; SQUAMOUS-CELL CARCINOMA; TERMINAL DIFFERENTIATION; MONOCLONAL-ANTIBODIES; FIBRONECTIN; ADHESION; GROWTH; TRANSFORMATION; TRANSFECTION	Keratinocytes express several receptors of the integrin family which regulate both adhesion and differentiation. We have investigated whether HPV immortalisation, which changes the growth and differentiation properties of keratinocytes, is associated with altered integrin expression or function. We compared two HPV 16-immortalised lines of human keratinocytes, up and vp, with the normal keratinocyte strains, u and v, from which they were derived and with upr, obtained by transfection of up with viral Harvey ras. Immunofluorescence, immunoprecipitation and flow cytometry demonstrated that up and vp had lower levels of integrins than u and v, the reduction in up being greater than in vp. Up and vp also had reduced levels of mRNA encoding the beta(1) integrin subunit. Reduced expression of the alpha(5) beta(1) and alpha(2) beta(1) integrins was correlated with reduced adhesion to fibronectin and collagen in up but not in vp and there were no significant differences between the normal and immortalised cells in adhesion to laminin. Reduced integrin expression was correlated with decreased motility, up showing a greater reduction in motility than vp. Introduction of activated ras into up had no effect on integrin levels, cell motility or tumorigenicity in nude mice; the only difference between up and upr was that upr showed increased adhesion to fibronectin. Examination of eight biopsies of cervical intraepithelial neoplasias with evidence of HPV infection revealed reduced, or discontinuous integrin expression in the most severe lesions. We conclude that both in vivo and in cultured keratinocytes the impaired differentiation that is associated with the presence of HPV is correlated with reduced integrin expression.	IMPERIAL CANC RES FUND, KERATINOCYTE LAB, LONDON WC2A 3PX, ENGLAND; IMPERIAL CANC RES FUND, APPL MICROSCOPY LAB, LONDON WC2A 3PX, ENGLAND; WHITTINGTON HOSP, DEPT GYNAECOL, LONDON N19 5NF, ENGLAND	Cancer Research UK; Cancer Research UK; University of London; University College London			Jones, Philip/D-2464-2009; Watt, Fiona/AHB-0226-2022	Jones, Philip/0000-0002-5904-795X; Watt, Fiona/0000-0001-9151-5154; Hodivala-Dilke, Kairbaan/0000-0002-2859-749X				ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALITALO K, 1982, J CELL BIOL, V94, P497, DOI 10.1083/jcb.94.3.497; BRISSETTE JL, 1993, MOL CARCINOGEN, V7, P21, DOI 10.1002/mc.2940070105; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DOWNER CS, 1993, J PATHOL, V171, P183, DOI 10.1002/path.1711710306; DURST M, 1987, ONCOGENE, V1, P251; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HOTCHIN NA, 1993, IN PRESS J CELL SCI; Howley P M, 1987, Important Adv Oncol, P55; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES J, 1993, J PATHOL, V169, P235, DOI 10.1002/path.1711690210; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; KENNEL SJ, 1989, J BIOL CHEM, V264, P15515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; PEI X F, 1991, Carcinogenesis (Oxford), V12, P277, DOI 10.1093/carcin/12.2.277; Pei X F, 1992, Epithelial Cell Biol, V1, P84; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PIRISI L, 1988, CARCINOGENESIS, V9, P1573, DOI 10.1093/carcin/9.9.1573; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RALFKIAER E, 1991, BRIT J DERMATOL, V124, P527, DOI 10.1111/j.1365-2133.1991.tb04944.x; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHIM JS, 1989, ONCOGENE, V4, P1403; RIDDLE PN, 1990, METHOD MOL BIOL, P415; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SONNENBERG A, 1986, J HISTOCHEM CYTOCHEM, V34, P1037, DOI 10.1177/34.8.2426332; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; TERRY G, 1993, ARCH VIROL, V128, P123, DOI 10.1007/BF01309793; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WATT FM, 1993, KERATINOCYTE HDB, P153; WATT FM, 1993, IN PRESS DEV SUPPLEM; WOLF GT, 1990, JNCI-J NATL CANCER I, V82, P1566, DOI 10.1093/jnci/82.19.1566; WOODWORTH CD, 1988, CANCER RES, V48, P4620	52	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					943	948						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108139				2022-12-28	WOS:A1994MW55100032
J	TANIGUCHI, T; MATSUI, T; ITO, M; MURAYAMA, T; TSUKAMOTO, T; KATAKAMI, Y; CHIBA, T; CHIHARA, K				TANIGUCHI, T; MATSUI, T; ITO, M; MURAYAMA, T; TSUKAMOTO, T; KATAKAMI, Y; CHIBA, T; CHIHARA, K			CHOLECYSTOKININ-B/GASTRIN RECEPTOR SIGNALING PATHWAY INVOLVES TYROSINE PHOSPHORYLATIONS OF P125(FAK) AND P42(MAP)	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE CELLS; SWISS 3T3 CELLS; GASTRIN RECEPTOR; MAP KINASES; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; PERTUSSIS TOXIN; PDGF RECEPTOR	The neuro-intestinal peptide hormone cholecystokinin (CCK)/gastrin has been suggested to have a trophic effect on gastro-intestinal tract in vivo as well as in vitro. In the present study, the human CCK-B/gastrin receptor was expressed in mouse NIH3T3 fibroblasts to investigate the molecular basis of signal transduction pathway of the guanine nucleotide regulatory protein (G protein)-coupled receptor. Human CCK-B/gastrin receptor expressed in NIH3T3 cells coupled efficiently to phosphoinositide hydrolysis and mobilization of intracellular Ca2+, and transduced mitogenic signals assessed by [H-3]thymidine incorporation in a dose-dependent manner. Moreover, CCK-8 or gastrin I alone promoted the cell growth in serum-free medium. CCK-8 induced tyrosine phosphorylation of several protein species. Among them, mitogen-activated protein (MAP) kinase was tyrosine phosphorylated and activated in response to CCK-8, as was induced by platelet-derived growth factor (PDGF). In contrast, tyrosine phosphorylation of p125(FAK) (focal adhesion kinase) was induced by CCK-8 but not by PDGF. CCK-8 as well as gastrin I induced the expression of early responsive genes such as c-fos and c-myc. These results suggest that CCK-B/gastrin receptors might transmit mitogenic signals by cross-talking with the tyrosine kinase cascades.	KOBE UNIV,SCH MED,DEPT MED,DIV 3,CHUO KU,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT GERONTOL,CHUO KU,KOBE 650,JAPAN	Kobe University; Kobe University			Matsui, Toshimitsu/E-8065-2010	Matsui, Toshimitsu/0000-0002-2536-7584				AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CREAN GP, 1969, GASTROENTEROLOGY, V57, P147; CROSS AJ, 1988, NEUROPEPTIDES, V11, P73, DOI 10.1016/0143-4179(88)90013-3; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HAKANSON R, 1986, SCAND J GASTROENTERO, V21, P18, DOI 10.3109/00365528609090883; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOOSEIN NM, 1988, CANCER RES, V48, P7179; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ISHIZUKA J, 1992, ANN SURG, V215, P528, DOI 10.1097/00000658-199205000-00016; ITO M, 1993, J BIOL CHEM, V268, P18300; JOHNSON LR, 1982, SCAND J GASTROENTERO, V17, P89; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE YM, 1993, J BIOL CHEM, V268, P8164; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; NAKATA H, 1992, BIOCHEM BIOPH RES CO, V187, P1151, DOI 10.1016/0006-291X(92)91317-J; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; POLACEK MA, 1966, SURGERY, V60, P606; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; RYBERG B, 1990, GASTROENTEROLOGY, V99, P935, DOI 10.1016/0016-5085(90)90610-D; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SETH A, 1991, J BIOL CHEM, V266, P23521; SETHI T, 1991, CANCER RES, V51, P3621; SMITH JP, 1991, REGUL PEPTIDES, V32, P341; SOLL AH, 1984, J CLIN INVEST, V73, P1434, DOI 10.1172/JCI111348; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; TSUKAMOTO T, 1991, J BIOL CHEM, V266, P10143; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZIMONJIC CB, 1993, IN PRESS CYTOGENET C	56	88	92	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					861	867						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108129				2022-12-28	WOS:A1994MW55100022
J	HAJNAL, A; KLEMENZ, R; SCHAFER, R				HAJNAL, A; KLEMENZ, R; SCHAFER, R			SUBTRACTION CLONING OF H-REV107, A GENE SPECIFICALLY EXPRESSED IN H-RAS RESISTANT FIBROBLASTS	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENES; GTPASE-ACTIVATING PROTEIN; WILD-TYPE P53; TRANSFORMED PHENOTYPE; FLAT REVERTANTS; CARCINOMA-CELLS; ADENOVIRUS E1A; T-ANTIGEN; V-MOS; ONCOGENE EXPRESSION	We have isolated by subtractive hybridization a novel gene, called H-rev107, which is specifically expressed in a phenotypic revertant of H-ras transformed 208F rat fibroblasts. Apart from oncogene revertants, strong expression of H-rev107 was found in REF52 and EK-3 cells, two fibroblast lines resistant to transformation by activated H-vas oncogenes. In contrast, transformation-sensitive fibroblasts like 208F or NIH3T3 cells expressed only very little H-rev107 RNA. In H-r as or v-src transformed fibroblasts, H-rev107 RNA was undetectable. Introduction of the adenovirus E1A nuclear oncogene into ras-resistant REF52 cells abolished their transformation resistance and repressed the H-rev107 gene. H-rev107 encodes a protein with a molecular weight of 18 kDa without any structural similarity to known proteins. p18(H-rev107) exists in two forms which can be distinguished by their electrophoretic mobility; one is localized predominantly in cell membranes, the other in the cytoplasm. In confluent contact-inhibited 208F cells, p18(H-rev107) accumulated in cell membranes, while growth arrest induced by serum starvation did not induce H-rev107. In REF52, cell density had no influence on the expression or localization of p18(H-rev107). Repression of the H-rev107 gene may be closely associated with the loss of density-dependent growth inhibition and with the expression of the neoplastic phenotype.	UNIV ZURICH,DEPT PATHOL,DIV CANC RES,CH-8091 ZURICH,SWITZERLAND	University of Zurich				Schafer, Reinhold/0000-0001-7952-2124				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BASSIN RH, 1987, ADV VIRAL ONCOL, V6, P103; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIZDZIEL PE, 1991, MOL CARCINOGEN, V4, P14, DOI 10.1002/mc.2940040105; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DEPPERT W, 1991, ONCOGENE, V6, P1931; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAJNAL A, 1993, CANCER RES, V53, P1; HIGGINS PJ, 1991, BIOCHEM J, V279, P883, DOI 10.1042/bj2790883; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, ONCOGENE, V6, P1211; Iten E, 1989, Recent Results Cancer Res, V113, P78; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JELINEK MA, 1992, ONCOGENE, V7, P1687; KANEKO M, 1989, BRIT J CANCER, V60, P880, DOI 10.1038/bjc.1989.384; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KATZ E, 1989, EUR J CELL BIOL, V49, P221; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIKKAWA U, 1986, ANN REV CELL BIOL, V2, P146; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOLCH W, 1993, ONCOGENE, V8, P361; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LOMBARDI L, 1990, CELL MOTIL CYTOSKEL, V15, P220, DOI 10.1002/cm.970150405; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MERCER WE, 1990, ONCOGENE, V5, P973; MIRANTI C, 1990, SOMAT CELL MOLEC GEN, V16, P67, DOI 10.1007/BF01650481; MORRIS JF, 1991, ONCOGENE, V6, P2339; NEVINS JR, 1992, SCIENCE, V258, P424; NIELSCH U, 1991, ONCOGENE, V6, P1031; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OKAYAMA H, 1982, MOL CELL BIOL, V2, P280; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SAMID D, 1984, BIOCHEM BIOPH RES CO, V119, P21, DOI 10.1016/0006-291X(84)91612-7; SANTOS E, 1984, FED PROC, V43, P2280; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SELIGER B, 1988, J VIROL, V62, P619, DOI 10.1128/JVI.62.2.619-621.1988; SELIGER B, 1987, J VIROL, V61, P2567, DOI 10.1128/JVI.61.8.2567-2572.1987; SERGIESCU D, 1986, P NATL ACAD SCI USA, V83, P5764, DOI 10.1073/pnas.83.16.5764; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; STODDART JH, 1989, EXP CELL RES, V184, P16; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; VANDAM H, 1989, ONCOGENE, V4, P1207; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YAMADA H, 1991, J BIOL CHEM, V266, P4002; YANAGIHARA K, 1990, ONCOGENE, V5, P1179; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	85	99	112	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					479	490						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290259				2022-12-28	WOS:A1994MW24800015
J	SMARDA, J; LIPSICK, JS				SMARDA, J; LIPSICK, JS			C-MYB PREVENTS TPA-INDUCED DIFFERENTIATION AND CELL-DEATH IN V-MYB TRANSFORMED MONOBLASTS	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; NORMAL HUMAN-LYMPHOCYTES; HEMATOPOIETIC-CELLS; GENE-EXPRESSION; LEUKEMIA-VIRUS; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; TRANS-ACTIVATION; E26; INVITRO	Myelomonocytic cells transformed by v-Myb or altered forms of c-Myb do not contain the full-length c-Myb protein found in most immature hematopoietic cells. To determine if c-Myb was a dominant inhibitor of v-Myb, we have induced the synthesis of full-length c-Myb in monoblasts transformed by v-Myb. We found that although some morphological changes occurred, the presence of both c-Myb and v-Myb was compatible with cell growth. However, the response to phorbol ester (TPA) was significantly altered by c-Myb. Monoblasts transformed by v-Myb can be induced to differentiate into macrophages by treatment with TPA. This process is accompanied by a significant amount of cell death. However, when c-Myb was made TPA-inducible in these cells, TPA-induced differentiation into macrophages was blocked and cell death was prevented. These results demonstrate a significant difference in the biological effects of v-Myb and c-Myb in transformed myelomonocytic cells.	STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305	Stanford University					NCI NIH HHS [R01-CA43592, K04 CA01457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001457, R01CA043592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATRON KM, 1992, J IMMUNOL, V148, P934; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HASS R, 1993, CELL GROWTH DIFFER, V4, P159; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LIU JL, 1992, VIROLOGY, V189, P583, DOI 10.1016/0042-6822(92)90581-9; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOSCOVICI C, 1985, RETROVIRUSES HUMAN P, P177; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P325; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MOSCOVICI MG, 1983, P NATL ACAD SCI-BIOL, V80, P1421, DOI 10.1073/pnas.80.5.1421; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PESSANO S, 1979, MICROBIOLOGICA, V2, P379; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SAMBROOK J, 1989, MOL COLONING LABORAT; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SMARDA J, 1993, IN PRESS GENE; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	59	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					237	245						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302585				2022-12-28	WOS:A1994MW24700029
J	MILNER, AE; GRAND, RJA; WATERS, CM; GREGORY, CD				MILNER, AE; GRAND, RJA; WATERS, CM; GREGORY, CD			APOPTOSIS IN BURKITT-LYMPHOMA CELLS IS DRIVEN BY C-MYC	ONCOGENE			English	Article							B-CELLS; GERMINAL-CENTERS; TRANSGENIC MICE; HEMATOPOIETIC-CELLS; PROTEIN EXPRESSION; GENE-EXPRESSION; MESSENGER-RNA; DAUDI CELLS; DEATH; ACTIVATION	Chromosomal translocation and subsequent de-regulation of the c-myc proto-oncogene are considered to be critical events in the multi-stage evolution of Burkitt lymphoma (BL). It is widely accepted that Myc protein functions as a competence factor for proliferation. However, recent studies indicate that it can also act in some cell types as a regulator of apoptosis. BL cell populations display a high frequency of apoptosis in vivo, a property which is also readily demonstrable in vitro in group I BL cell lines. Such lines are known to retain the cell surface marker characteristics of the parental tumour cells and, in the case of Epstein-Barr virus-positive tumours, their restricted viral protein expression. We have shown previously that apoptosis in a group I BL cell line is inhibited by interferon (IFN)-alpha. Here we show that IFN-alpha-mediated suppression of apoptosis in group I BL cells corresponds temporally with inhibition of Myc protein levels. Furthermore, inhibition of Myc expression following treatment with c-myc anti-sense oligonucleotides markedly enhanced survival of group I BL cells. These results indicate that, whilst c-myc may facilitate cycling of tumour cells in which it is de-regulated, it also stimulates their apoptosis.	UNIV BIRMINGHAM, SCH MED, DEPT IMMUNOL, BIRMINGHAM B15 2TT, ENGLAND; UNIV BIRMINGHAM, SCH MED, DEPT CANC STUDIES, BIRMINGHAM B15 2TT, ENGLAND; UNIV MANCHESTER, MOLEC PHARMACOL GRP, MANCHESTER M13 9PT, ENGLAND	University of Birmingham; University of Birmingham; University of Manchester			Gregory, Chris/C-6927-2019	Gregory, Chris/0000-0002-7553-0132	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1986, CURR TOP MICROBIOL, V132, P1; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1992, ONCOGENE, V7, P101; Berard C W, 1985, IARC Sci Publ, P31; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1987, J IMMUNOL, V139, P313; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MANN RB, 1976, NEW ENGL J MED, V295, P685, DOI 10.1056/NEJM197609232951301; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MOGENSEN KE, 1983, EUR J BIOCHEM, V134, P355, DOI 10.1111/j.1432-1033.1983.tb07575.x; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; Penn L J, 1990, Semin Cancer Biol, V1, P69; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE M, 1986, INT J CANCER, V37, P367, DOI 10.1002/ijc.2910370307; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STEIN CA, 1988, CANCER RES, V48, P2659; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATSON PH, 1991, CANCER RES, V51, P3996; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	47	89	89	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3385	3391						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247541				2022-12-28	WOS:A1993MG78200023
J	HALL, PA; MCKEE, PH; MENAGE, HD; DOVER, R; LANE, DP				HALL, PA; MCKEE, PH; MENAGE, HD; DOVER, R; LANE, DP			HIGH-LEVELS OF P53 PROTEIN IN UV-IRRADIATED NORMAL HUMAN SKIN	ONCOGENE			English	Note							DNA POLYMERASE-ALPHA; NUCLEAR ANTIGEN PCNA; CELL-PROLIFERATION; REPAIR SYNTHESIS; GENE; DAMAGE; MUTATIONS; AGENTS; FORM	Exposure of normal adult human skin to doses of UV irradiation that induced mild sunburn resulted in the rapid appearance of p53 protein in the epidermis and superficial dermal fibroblasts. Immunohistological analysis with a panel of antibodies established that while p53 staining was not seen in normal skin it appeared within 2h of UV exposure. The level of p53 immunostaining peaked at 24h and returned to undetectable levels within 360h. The induction of proliferating cell nuclear antigen (PCNA) (which is required for both DNA replication and repair) followed a similar spatial and temporal pattern to p53. The UV irradiation did not induce a mitotic response or the replication-associated antigens DNA polymerase alpha or Ki67. The accumulation of high levels of p53 and PCNA in response to UV doses to which many human populations are routinely exposed provides strong support for a model in which normal p53 acts as part of the DNA damage response in vertebrate cells. Such a model is consistent with the profound tumour-suppressor function of the p53 gene, the high rate of p53 mutation in neoplasia and the exceptionally high tumour susceptibility of p53-deficient mice.	UMDS,DEPT PHOTOBIOL,LONDON SE1 7EH,ENGLAND; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; ICRF,HISTOPATHOL UNIT,LONDON WC1A 7BE,ENGLAND	University of London; King's College London; University of Dundee	HALL, PA (corresponding author), UMDS,DEPT HISTOPATHOL,ST THOMASS CAMPUS,LAMBETH PALACE RD,LONDON SE1 7EH,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; DRESLER SL, 1986, NUCLEIC ACIDS RES, V14, P7093, DOI 10.1093/nar/14.17.7093; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREEMAN SE, 1987, J INVEST DERMATOL, V88, P430, DOI 10.1111/1523-1747.ep12469778; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GARMYN M, 1991, LAB INVEST, V65, P471; GERDES J, 1991, AM J PATHOL, V138, P867; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HALL PA, 1988, J PATHOL, V154, P223, DOI 10.1002/path.1711540305; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HAWK JLM, 1982, SCI PHOTOMECHANISMS, P246; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HONIGSMANN H, 1987, J PHOTOCH PHOTOBIO B, V1, P33, DOI 10.1016/1011-1344(87)80004-0; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P23; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUETHY JD, 1992, CANCER RES, V52, P5; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIDGLEY CA, 1992, J CELL SCI, V101, P183; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RIJZEWIJK JJ, 1989, ACTA DERM-VENEREOL, V69, P512; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIM CS, 1992, J CUTAN PATHOL, V19, P302, DOI 10.1111/j.1600-0560.1992.tb01366.x; SLATER SD, 1992, HISTOPATHOLOGY, V20, P237, DOI 10.1111/j.1365-2559.1992.tb00962.x; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WASEEM NH, 1990, J CELL SCI, V96, P121; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	37	722	728	0	34	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					203	207						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8093810				2022-12-28	WOS:A1993KN00500025
J	FILMUS, J; ROBLES, AI; SHI, W; WONG, MJ; COLOMBO, LL; CONTI, CJ				FILMUS, J; ROBLES, AI; SHI, W; WONG, MJ; COLOMBO, LL; CONTI, CJ			INDUCTION OF CYCLIN D1 OVEREXPRESSION BY ACTIVATED RAS	ONCOGENE			English	Article							INTESTINAL EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; DEPENDENT KINASES; NUCLEAR-PROTEIN; EXPRESSION; FIBROBLASTS; ONCOGENE; G(1); G1; PROGRESSION	Activated ras genes are known to alter control of cell proliferation. This is consistent with the fact that ras proteins are a key component of the biochemical pathway triggered by ligand-bound cell surface receptors that are tyrosine kinases. Although an important part of the ras signaling pathway has been recently uncovered, the molecular target(s) that mediates the effects of ras on cell cycle control remains unknown. Cyclins and cyclin-dependent kinases are key molecules in the control of cell cycle. Cyclin D1, in particular, is a critical target for proliferative signals in G(1) and it has been shown that ectopic overexpression of this cyclin can significantly alter cell cycle regulation. Here we report that activated ras induces significant overexpression of cyclin D1 in epithelial cells derived from normal rat intestine and mouse mammary gland. A definitive causal role for activated ras in this overexpression is demonstrated by using intestinal cells transfected with an inducible ras expression vector. Treatment of the ras-transformed intestinal clones with anti-sense cyclin D1 oligonucleotides reduces their rate of cell proliferation indicating that the increment in cyclin D1 expression induced by activated ras is instrumental in the higher rate of cell proliferation conferred by the ras oncogene to the IEC cells. Based on these results we propose that, at least in certain cell types, cyclin D1 can be one of the mediators of the transforming action of activated ras.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON, CANADA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, DIV RES, HOUSTON, TX USA	University of Toronto; University of Texas System; UTMD Anderson Cancer Center	FILMUS, J (corresponding author), SUNNYBROOK HLTH SCI CTR, DIV CANC RES, S-218, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ON, CANADA.			Robles, Ana/0000-0001-5019-4374				ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; ARNOLD A, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63; ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FILMUS J, 1992, ONCOGENE, V7, P521; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QUARONI A, 1981, J NATL CANCER I, V67, P1353; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHAO JM, 1993, EXP CELL RES, V204, P82, DOI 10.1006/excr.1993.1011	42	280	282	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3627	3633						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970723				2022-12-28	WOS:A1994PT39200026
J	BRADBURY, JM; NIEMEYER, CC; DALE, TC; EDWARDS, PAW				BRADBURY, JM; NIEMEYER, CC; DALE, TC; EDWARDS, PAW			ALTERATIONS OF THE GROWTH-CHARACTERISTICS OF THE FIBROBLAST CELL-LINE C3H 10T1/2 BY MEMBERS OF THE WNT GENE FAMILY	ONCOGENE			English	Article							MAMMARY ONCOGENE INT-1; NUCLEOTIDE-SEQUENCE; EXPRESSION INVITRO; PROTEIN; TRANSFORMATION; PROTOONCOGENE; GLAND; CONSTRUCTION; HYPERPLASIA; RETROVIRUS	Retroviral vectors were used to introduce members of the Wnt gene family into the embryonic fibroblast cell line C3H 10T1/2. In contrast to previous reports where no effect of Wnt genes on fibroblasts was seen, we found that the expression of Wnt-1, Wnt-6 and Wnt-7b altered the appearance of the cells when maintained at confluence. The cells were smaller and grew to a higher density than cells containing a control. retrovirus or cells expressing Wnt-4 or Wnt-5b. Detailed analysis of growth characteristics of polyclonally infected cultures demonstrated that the Wnt-1, Wnt-6 and Wnt-7b expressing cells grew to a higher density in 5% fetal calf serum than control or Wnt-5b expressing cells. Wnt-4 expressing cells grew to a marginally higher density than control cells. In 0.5% serum, growth of the Wnt-1, Wnt-6 and Wnt-7b containing cells appeared to be inhibited. No growth in soft agar was observed for either control cells or Wnt expressing cells. We conclude that at least some mesenchymal cells can respond to Wnt gene products. Our results are also the first report of biological effects of Wnt-6 and Wnt-7b.	INST CANC RES,HADDOW LABS,SUTTON SM2 5NG,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK	BRADBURY, JM (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		Edwards, Paul A/M-8291-2014; Dale, Trevor C/D-3749-2009	Edwards, Paul A/0000-0002-4789-3374; Dale, Trevor C/0000-0002-4880-9963				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADBURY JM, 1988, INT J CANCER, V42, P923, DOI 10.1002/ijc.2910420623; BRADBURY JM, 1991, INT J CANCER, V48, P908, DOI 10.1002/ijc.2910480619; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK FAM, 1986, NUCLEIC ACIDS RES, V14, P693, DOI 10.1093/nar/14.2.693; Sambrook J, 1989, MOL CLONING LABORATO; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; WEBERHALL SJ, IN PRESS DIFFERENTIA	36	46	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2597	2603						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058323				2022-12-28	WOS:A1994PC05400019
J	CHEN, SY; HUFF, SY; LAI, CC; DER, CJ; POWERS, S				CHEN, SY; HUFF, SY; LAI, CC; DER, CJ; POWERS, S			RAS-15A PROTEIN SHARES HIGHLY SIMILAR DOMINANT-NEGATIVE BIOLOGICAL PROPERTIES WITH RAS-17N AND FORMS A STABLE, GUANINE-NUCLEOTIDE RESISTANT COMPLEX WITH CDC25 EXCHANGE FACTOR	ONCOGENE			English	Article							HA-RAS MUTATION; SACCHAROMYCES-CEREVISIAE; ACTIVATION; MUTANTS; BINDING; P21RAS; SIGNAL; KINASES; INHIBITION; CYTOSOL	We show that expression of Ras-15A, previously shown to be a dominant-negative mutant in yeast, is a potent inhibitor of endogenous Ras protein function in mammalian cells. Expression of Ras-15A did not inhibit the growth of cells containing an oncogenic ras gene nor did it interfere with the ability of transiently expressed oncogenic ras or raf genes to activate transcription from a Ras-responsive ets1/AP-1 promoter. In contrast, expression of Ras-15A completely blocked growth of normal cells and activation of the ets1/AP-1 promoter by transiently overexpressed SOS1 and normal Ras proteins. These results suggest that Ras-15A, like Ras-17N, blocks endogenous Ras function by interfering with upstream activation of Ras proteins rather than downstream effects. To test whether Ras-15A and Ras-17N interfere with Ras function by blocking GDP-GTP exchange proteins, we examined their physical interaction with the CDC25 exchange protein. All three proteins formed stable complexes with CDC25 in the absence of guanine-nucleotides, but only Ras-15A was not released from CDC25 by physiological concentrations of GDP or GTP. These results establish that Ras-15A blocks the activation of normal Ras proteins by sequestering GDP-GTP exchange factors into nonproductive complexes. In contrast, it would appear that the similar biological properties of Ras-17N are mediated by a reversible, competitive sequestration of exchange factors.	ONYX PHARMACEUT,RICHMOND,CA 94806; RUTGERS STATE UNIV,GRAD PROGRAM BIOCHEM & MOLEC BIOL,PISCATAWAY,NJ 08854; UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599	Rutgers State University New Brunswick; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Powers, Scott/0000-0003-2769-1932; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041258] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978] Funding Source: Medline; NIGMS NIH HHS [GM41258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; DER CJ, 1988, ONCOGENE, V3, P105; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JOHN J, 1993, J BIOL CHEM, V268, P923; JUNG V, 1994, IN PRESS MOL CELL BI; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; POWERS S, 1991, CELL, V65, P1255; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	28	74	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2691	2698						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058333				2022-12-28	WOS:A1994PC05400030
J	DOBROWOLSKI, SF; STACEY, DW; HARTER, ML; STINE, JT; HIEBERT, SW				DOBROWOLSKI, SF; STACEY, DW; HARTER, ML; STINE, JT; HIEBERT, SW			AN E2F DOMINANT-NEGATIVE MUTANT BLOCKS E1A INDUCED CELL-CYCLE PROGRESSION	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; DNA-BINDING PROPERTIES; MURINE THYMIDINE KINASE; HUMAN MYC PROMOTER; ESCHERICHIA-COLI; GROWTH SUPPRESSION; FUNCTIONAL DOMAINS; TRANS-ACTIVATION; S-PHASE	E2F is a cellular transcription factor that is regulated during the cell cycle through interactions with the product of the retinoblastoma susceptibility gene (RB1) and the pRb-like p107 and p130 proteins. Analysis of mutations within both adenovirus E1A and pRb, which affected their ability to regulate cellular proliferation and alter E2F activity, suggested that E2F may play a role in cell cycle progression. Microinjection of a GST-E2F-1 fusion protein into quiescent Balb/c 3T3 cells induced DNA synthesis whereas co-injection of GST-E2F-1 and GST-E2F(95-191) protein, encoding only the DNA binding domain of E2F-1, blocked the induction of S-phase. While E1A likely targets multiple cellular pathways, co-injection of the GST-E2F(95-191) dominant inhibitory protein with 12S E1A protein blocked E1A-mediated induction of DNA synthesis, suggesting that the E2F-dependent pathway is dominant. Analysis of the interval required for microinjected quiescent cells to enter S-phase indicated that E2F-1 acted faster than either E1A or serum.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA; CLEVELAND CLIN FDN, RES INST, DEPT MOLEC BIOL, CLEVELAND, OH 44195 USA	St Jude Children's Research Hospital; Cleveland Clinic Foundation					NATIONAL CANCER INSTITUTE [R01CA053496, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA 21765, CA53496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRUNER M, 1988, J BIOL CHEM, V263, P3984; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KO JL, 1986, EMBO J, V5, P1645, DOI 10.1002/j.1460-2075.1986.tb04407.x; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEVINS JR, 1990, UCLA SYM BI, V124, P417; NEVINS JR, 1992, SCIENCE, V258, P424; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PEARSON BE, 1991, MOL CELL BIOL, V11, P2181; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROUSSEL MF, 1994, ONCOGENE, V9, P405; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STACEY DW, 1993, IN PRESS EMBO J; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	64	56	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2605	2612						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058324				2022-12-28	WOS:A1994PC05400020
J	LAI, C; GORE, M; LEMKE, G				LAI, C; GORE, M; LEMKE, G			STRUCTURE, EXPRESSION, AND ACTIVITY OF TYRO-3, A NEURAL ADHESION-RELATED RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; NERVOUS-SYSTEM; HIPPOCAMPAL-NEURONS; SIGNAL-TRANSDUCTION; SH3 DOMAINS; PROTEIN; BINDING; BRAIN; ENCODES	We have isolated mouse cDNA clones encoding Tyro 3, a receptor protein-tyrosine kinase (PTK) of the mammalin central nervous system (CNS). Expression of the Tyro 3 gene is strongly up-regulated in neurons of the mouse neocortex, cerebellum, and hippocampus after the day of birth, during periods of active synaptogenesis, and high expression is maintained in the adult CNS. The sequence of Tyro 3 cDNAs predicts a glycoprotein receptor with similarity to neural cell recognition and adhesion molecules - the extracellular (ligand binding) region of this receptor is composed of two immunoglobulin-related domains followed by two fibronectin type III repeats. Immunoblot and immunoprecipitation analyses with anti-Tyro 3 antibodies indicate that the 125 kD Tyro 3 protein is abundantly expressed in CNS synaptosomes, and immunohistochemical analysis of cultured hippocampal cells demonstrates that Tyro 3 is a product of neurons. Rat-2 fibroblasts stably transfected with a Tyro 3 expression construct acquire the ability to grow in soft agar, suggesting that Tyro 3 is potentially oncogenic.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	Salk Institute; Scripps Research Institute; University of California System; University of California San Diego								AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BASLER K, 1988, CELL, V54, P299; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAI W, 1994, ONCOGENE, V9, P975; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FAUST M, 1992, ONCOGENE, V7, P1287; FUJIMOTO J, 1994, ONCOGENE, V9, P693; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HUNTER T, 1990, N HORIZ TH, P119; HUNTER T, 1993, FRONTIERS BIOL PROTE; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; JIA R, 1992, VIROLOGY, V66, P5975; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; MARK MR, 1994, J BIOL CHEM, V269, P10720; MOODY SA, 1989, J COMP NEUROL, V279, P567, DOI 10.1002/cne.902790406; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; O'Leary D D, 1992, Curr Opin Neurobiol, V2, P70, DOI 10.1016/0959-4388(92)90165-H; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; POLVI A, 1993, GENE, V134, P289, DOI 10.1016/0378-1119(93)90109-G; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; RESCIGNO J, 1991, ONCOGENE, V6, P1909; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEINMASTER G, 1990, EMBO J, V9, P915, DOI 10.1002/j.1460-2075.1990.tb08189.x; WEINMASTER GA, 1988, J VIROL, V62, P2016, DOI 10.1128/JVI.62.6.2016-2025.1988; WILKIE T M, 1991, Methods (Orlando), V2, P32, DOI 10.1016/S1046-2023(05)80123-9; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	148	166	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2567	2578						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058320				2022-12-28	WOS:A1994PC05400016
J	QUINLAN, MP				QUINLAN, MP			ENHANCED PROLIFERATION, GROWTH-FACTOR INDUCTION AND IMMORTALIZATION BY ADENOVIRUS E1A 12S IN THE ABSENCE OF E1B	ONCOGENE			English	Article							PRIMARY EPITHELIAL-CELLS; TUMOR-ANTIGEN; MORPHOLOGICAL TRANSFORMATION; 19-KILODALTON PROTEIN; MOLECULAR MECHANISMS; GENE-EXPRESSION; E1A-12S PROTEIN; DNA-SYNTHESIS; P53; TYPE-5	Immortalization and transformation of primary epithelial cells requires expression of the adenovirus E1A and E1B genes, respectively. The E1A gene is involved in growth stimulatory processes. Little is known about the mechanism utilized by E1B, however, roles in growth stimulatory processes have also been implied. To determine whether there are any functional interactions between E1A 12S and the E1B 55K and 19K polypeptides, primary epithelial cells were infected with 12S viruses with different E1B regions. In the absence of both E1B proteins, there was an increase in 12S expression. This resulted in increased levels of DNA synthesis, entry into S-phase of the cell cycle and increased levels of proliferation, in the presence or absence of serum. There was also a higher induction of growth factor activity. In the presence of the 55K and absence of the 19K protein, there was a decrease in 12S expression. However, the highest induction of proliferative responses was observed. This suggests that expression of the 19K polypeptide inhibits 12S function directly. The lack of 19K expression also enabled the epithelial cells to have a much higher plating efficiency, achieve a greater cell density and reach the immortalized state faster. Although some modest differences in p53 expression were observed when compared to mock, they could not be correlated with any phenotype.			QUINLAN, MP (corresponding author), UNIV TENNESSEE, DEPT MICROBIOL & IMMUNOL, 858 MADISON AVE, MEMPHIS, TN 38163 USA.				NCI NIH HHS [CA50540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CAIRNS J, 1978, CANCER SOC; DEPPERT W, 1990, ONCOGENE, V5, P1701; Flint S. J, 1981, DNA TUMOR VIRUSES; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GIORDANO A, 1991, ONCOGENE, V6, P481; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KUPPUSWAMY M, 1988, ONCOGENE, V2, P613; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1993, ONCOGENE, V8, P3289; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1993, ONCOGENE, V8, P257; QUINLAN MP, 1986, CANCER CELL, V4, P27; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SENEAR AW, 1986, MOL CELL BIOL, V6, P1253, DOI 10.1128/MCB.6.4.1253; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SHENK T, 1991, ADV CANCER RES, V57, P47; SHIMOJO H, 1968, VIROLOGY, V36, P422, DOI 10.1016/0042-6822(68)90167-0; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAUB M, 1984, METHODS SERUM FREE C; TELLING GC, 1993, J VIROL, V67, P1600, DOI 10.1128/JVI.67.3.1600-1611.1993; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; Weinberg R. A., 1989, ONCOGENES MOL ORIGIN; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WHITE E, 1986, MOL CELL BIOL, V6, P3763, DOI 10.1128/MCB.6.11.3763; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	53	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2639	2647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058328				2022-12-28	WOS:A1994PC05400024
J	SEKIDO, Y; BADER, S; LATIF, F; GNARRA, JR; GAZDAR, AF; LINEHAN, WM; ZBAR, B; LERMAN, MI; MINNA, LD				SEKIDO, Y; BADER, S; LATIF, F; GNARRA, JR; GAZDAR, AF; LINEHAN, WM; ZBAR, B; LERMAN, MI; MINNA, LD			MOLECULAR ANALYSIS OF THE VON HIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE IN HUMAN LUNG-CANCER CELL-LINES	ONCOGENE			English	Article							CLONAL CHROMOSOME-ABNORMALITIES; HUMAN BREAST CARCINOMAS; FREE DEFINED MEDIUM; SHORT ARM; HOMOZYGOUS DELETION; CLINICAL SPECIMENS; SMALL REGION; P53 GENE; HETEROZYGOSITY; 3P	The deletion of the short arm of chromosome 3 is frequently observed in lung cancer. To determine whether the von Hippel-Lindau (VHL) disease tumor suppressor gene located at 3p25 is responsible for oncogenesis in lung cancer, we searched the known open reading frame using the single-strand conformation polymorphism (SSCP) technique for mutations in the VHL gene in 72 cancer cell lines including small cell (SCLC) and nonsmall cell (NSCLC) lung cancers, carcinoids, and mesotheliomas. SSCP analysis showed that four cell lines have altered SSCP patterns within the coding region and one in an intron of the VHL gene. SCLC line NCI-H1672 had a somatic mutation, G to A at nucleotide (nt) 530, leading to amino acid substitution (glycine to aspartic acid) compared to normal DNA from the same patient. Mesothelioma line NCI-H28 had T to A mutation at nt 479 leading to leucine to histidine amino acid change. We found one frequent polymorphism A (0.72) or G (0.28) at nt 19 resulting in either serine or glycine at this position, changes also found in normal peripheral blood cell DNA, often in a heterozygous state. In addition, we found single rare polymorphisms which did not alter the coding region including: C to G at mt 396, G to T at nt 843, and C to T change in an intron. These results suggest that the VHL gene is only rarely mutated in thoracic malignancies.	UNIV TEXAS,SOUTHWESTERN MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,FREDERICK,MD 21702; NCI,SURG BRANCH,UROL ONCOL SECT,BETHESDA,MD 20892	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Sekido, Yoshitaka/P-9756-2015	Gnarra, James/0000-0002-6369-3110; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [P20CA058220] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA58220-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGERHEIM U, 1989, CANCER RES, V49, P1390; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; BROWER M, 1986, CANCER RES, V46, P798; CARNEY DN, 1985, CANCER RES, V45, P2913; CHIBA I, 1990, ONCOGENE, V5, P1603; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DALY MC, 1993, ONCOGENE, V8, P1721; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; GAZDAR AF, 1986, CANCER RES, V46, P6011; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1992, ONCOGENE, V7, P445; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LAMIELL JM, 1989, MEDICINE, V68, P1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEDUC F, 1989, AM J HUM GENET, V44, P282; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P151, DOI 10.1002/gcc.2870060304; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Sambrook J, 1989, MOL CLONING LABORATO; SATO T, 1991, CANCER RES, V51, P5794; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SITHANANDAM G, 1989, ONCOGENE, V4, P451; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOTA J, 1989, CANCER RES, V49, P3598; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	47	90	94	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1599	1604						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183553				2022-12-28	WOS:A1994NL81500010
J	HOLLAND, EA; BEATON, SC; EDWARDS, BG; KEFFORD, RF; MANN, GJ				HOLLAND, EA; BEATON, SC; EDWARDS, BG; KEFFORD, RF; MANN, GJ			LOSS OF HETEROZYGOSITY AND HOMOZYGOUS DELETIONS ON 9P21-22 IN MELANOMA	ONCOGENE			English	Article							CYTOGENETIC ANALYSIS; LINKAGE MAP; SHORT ARM; CHROMOSOME-9; REGION; LOCUS; GENES	Recent studies have implicated chromosome 9p21-22 as a location for a gene involved in cutaneous melanoma (CM). Deletion mapping in 35 matched tumour-constitutional DNA pairs from metastatic melanomas (including one melanoma cell line) and one dysplastic naevus has been performed using six short tandem repeat polymorphic (STRP) markers (D9S157-D9S162-LFNA-D9S171-D9S126-D9S104) which span approximately 19 cM across the 9p21-22 region. Both heterozygous and homozygous deletions were observed across the region in melanomas from both sporadic and familial cases. Overall 57% (20/35) of the samples displayed some form of loss. A deletion map identifies two areas of common loss either side of the interferon gene cluster. Familial CM has previously been shown to link to the more proximal of these regions. The deleted region distal to IFNA has not been previously described in melanoma. The results imply the involvement of more than one tumour suppressor gene on 9p in CM.			HOLLAND, EA (corresponding author), UNIV SYDNEY,WESTMEAD CTR,DEPT MED ONCOL,WESTMEAD,NSW 2145,AUSTRALIA.		Mann, Graham J/G-4758-2014	Mann, Graham J/0000-0003-1301-405X; Kefford, Richard/0000-0001-9251-9229				ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; COLEMAN A, 1993, AM J HUM GENET S, V53, pA287; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DRACOPOLI NC, 1985, P NATL ACAD SCI USA, V82, P1470, DOI 10.1073/pnas.82.5.1470; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FOUNTAIN JW, 1992, GENOMICS, V14, P105, DOI 10.1016/S0888-7543(05)80290-3; FOUNTAIN JW, 1993, AM J HUM GENET S, V53, pA170; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; Greene MH, 1979, HUMAN MALIGNANT MELA, P139; HALUSKA FG, 1993, AM J HUM GENET S, V53, pA306; JAMES CD, 1993, CANCER RES, V53, P3674; JONASSON J, 1977, J CELL SCI, V24, P217; KARLBOM AE, 1993, HUM GENET, V92, P169; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KWIATKOWSKI DJ, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658-a; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LINDBLOM A, 1993, HUM GENET, V91, P6; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; PETTY EM, 1993, AM J HUM GENET, V53, P96; RUSTGI AK, 1992, ANNU REV MED, V43, P61, DOI 10.1146/annurev.me.43.020192.000425; Sambrook J, 1989, MOL CLONING LABORATO; SCHWECHHEIMER K, 1993, CLIN INVESTIGATOR, V71, P488; TAGUCHI T, 1993, CANCER RES, V53, P4349; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILKIE PJ, 1992, GENOMICS, V12, P607, DOI 10.1016/0888-7543(92)90456-3; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	37	84	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1361	1365						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152796				2022-12-28	WOS:A1994NH40100007
J	CARE, A; MATTIA, G; MONTESORO, E; PAROLINI, I; RUSSO, G; COLOMBO, MP; PESCHLE, C				CARE, A; MATTIA, G; MONTESORO, E; PAROLINI, I; RUSSO, G; COLOMBO, MP; PESCHLE, C			C-FES EXPRESSION IN ONTOGENIC DEVELOPMENT AND HEMATOPOIETIC DIFFERENTIATION	ONCOGENE			English	Article							SERUM-FREE CULTURE; TYROSINE PHOSPHORYLATION; PROTO-ONCOGENE; BETA-SUBUNIT; GM-CSF; GROWTH; CDNA; PROGENITORS; RECEPTORS; EMBRYOS	The c-fes protein (NCP92) is a tyrosine-specific protein kinase, capable of both autophosphorylation and phosphorylation of other substrates. We have analysed c-fes RNA expression in human/murine ontogenetic development and in homogenous populations of embryonic and adult human hematopoietic cells. c-fes expression has been observed in rapidly proliferating embryonic-fetal tissues originating from different germinal layers, but not in adult non-hematopoietic tissues. In particular, a spatially and temporally regulated transcription was observed in the central nervous system and in developing cartilage. Expression in hematopoietic cells was evaluated in progenitors purified from embryonic-fetal liver and adult peripheral blood differentiating gradually and specifically along the erythroid or granulomonocytic lineage. In both embryonic and adult hematopoietic cells c-fes was abundantly expressed in undifferentiated progenitors of both lineages, as well as in differentiated granulomonocytic precursors, but not in erythroblasts. This expression pattern correlates with that of GM-CSF and in part IL-3 receptors (Testa et al., 1993 and our unpublished results). Altogether, these results suggest a possible role for c-fes in signal transduction, in both embryonic non-hematopoietic tissues and embryonic/ adult hematopoietic cells, following interaction of growth factors with their tyrosine-kinase negative receptors (i.e., GM-CSF and IL-3 receptors in adult hematopoietic cells and other hypothetical growth factor(s) receptors during embryonic development).	IST SUPER SANITA, DEPT HEMATOL ONCOL, I-00161 ROME, ITALY; OSPED AVELLINO, DIV OBSTET & GYNECOL, I-83100 AVELLINO, ITALY; IST NAZL STUDIO & CURA TUMORI, DIV EXPTL ONCOL D, I-20133 MILAN, ITALY; THOMAS JEFFERSON UNIV, THOMAS JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA	Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University			Colombo, Mario P./V-7166-2017; CARE', Alessandra/H-5090-2016; Mattia, Gianfranco/K-5194-2016; parolini, Isabella/J-9955-2016; felli, nadia/G-2088-2012	Colombo, Mario P./0000-0003-0042-7955; CARE', Alessandra/0000-0003-4106-3342; Mattia, Gianfranco/0000-0001-7047-6360; parolini, Isabella/0000-0001-9863-1051; felli, nadia/0000-0001-6763-3361				ALCALAY M, 1990, ONCOGENE, V5, P267; BISHOP JM, 1982, MRNA TUMOR VIRUSES M, P267; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; ELIASON JF, 1986, J CELL PHYSIOL, V128, P231, DOI 10.1002/jcp.1041280214; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HOGAN B, 1986, MOL CLONING LABORATO; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LANFRANCONE L, 1989, INT J CANCER, P35; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; MIGLIACCIO G, 1986, J CLIN INVEST, V78, P51, DOI 10.1172/JCI112572; Moore, 1982, DEV HUMAN; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; PLACZEK M, 1990, DEVELOPMENT, V110, P19; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Sambrook J, 1989, MOL CLONING LABORATO; SORENSEN PHB, 1989, BLOOD, V73, P406; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; TESTA U, 1993, BLOOD, V81, P1442; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VALTIERI M, 1989, BLOOD, V74, P460; YEE SP, 1989, P NATL ACAD SCI USA, V86, P5873, DOI 10.1073/pnas.86.15.5873	29	47	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					739	747						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108116				2022-12-28	WOS:A1994MW55100008
J	DAI, W; PAN, HQ; HASSANAIN, H; GUPTA, SL; MURPHY, MJ				DAI, W; PAN, HQ; HASSANAIN, H; GUPTA, SL; MURPHY, MJ			MOLECULAR-CLONING OF A NOVEL RECEPTOR TYROSINE KINASE, TIF, HIGHLY EXPRESSED IN HUMAN OVARY AND TESTIS	ONCOGENE			English	Note							HUMAN INTERFERON-GAMMA; LEUKEMIA-CELLS; GENE	Using a combination of polymerase chain reaction and conventional cDNA library screening approaches, we have cloned and characterized a putative receptor tyrosine kinase termed tif. The extracellular domain of tif has an immunoglobulin-like loop and a fibronectin type III structure. The intracellular domain contains a tyrosine kinase domain. Compared with ryk, a ubiquitously expressed receptor tyrosine kinase, tif expression is tissue-specific with human ovary and testis containing the highest amount of tif mRNA. Many other tested human tissues such as heart, liver, pancreas and thymus do not contain detectable levels of tif mRNA. The molecular cloning and characterization of tif cDNA will facilitate the identification of a potential ligand(s) for the putative receptor and the study of its biological role.	HIPPLE CANC RES CTR,BIOL RESPONSE MODIFIERS LAB,DAYTON,OH 45439; HIPPLE CANC RES CTR,BLOOD CELL GROWTH FACTOR LAB,DAYTON,OH 45439		DAI, W (corresponding author), HIPPLE CANC RES CTR,MOLEC BIOL LAB,4100 S KETTERING BLVD,DAYTON,OH 45439, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032483] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI32483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DAI W, 1990, BIOCHEM BIOPH RES CO, V168, P1, DOI 10.1016/0006-291X(90)91666-G; DAI W, 1993, BLOOD, V5, P1214; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; Sambrook J, 1989, MOL CLONING LABORATO; SIMONEAUX DK, 1992, J CELL BIOCHEM, V16, P101; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; TSIFTSOGLOU AS, 1991, EXP HEMATOL, V19, P928; TUY FPD, 1983, NATURE, V305, P435; ULLRICH A, 1990, CELL, V61, P201; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	20	62	63	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					975	979						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108143				2022-12-28	WOS:A1994MW55100037
J	LUKAS, J; PAGANO, M; STASKOVA, Z; DRAETTA, G; BARTEK, J				LUKAS, J; PAGANO, M; STASKOVA, Z; DRAETTA, G; BARTEK, J			CYCLIN D1 PROTEIN OSCILLATES AND IS ESSENTIAL FOR CELL-CYCLE PROGRESSION IN HUMAN TUMOR-CELL LINES	ONCOGENE			English	Article							CHROMOSOME 11Q13; SQUAMOUS-CELL; MESSENGER-RNA; S-PHASE; EXPRESSION; CLONING; KINASE; GENES; AMPLIFICATION; MITOSIS	Among the key cell cycle regulators, cyclin D1 has been implicated most strongly in oncogenesis. This G1 cyclin is a putative proto-oncogene whose clonal rearrangement and/or amplification and mRNA overexpression occurs in several types of human neoplasias. We have now raised a series of monoclonal antibodies to human cyclin D1 and analysed its regulation at the protein level in 40 human tumour cell lines. We found that 12 cell lines displayed low or undetectable cyclin D1 protein level, while the remaining lines accumulated the protein to a level comparable to, or moderately higher than, that of four normal diploid non-immortalized cell types. The cell cycle-dependent oscillation and subcellular localization of cyclin D1 were similar in both tumour and normal cells. The protein localized to the nucleus of G1 cells, and it was reduced to immunocytochemically undetectable level in DNA-replicating cells. At the functional level, microinjection and electroporation of anti-D1 antibodies revealed that in most tumour cell lines studied, including those with amplification at the cyclin D1 locus, this cyclin is essential for cell cycle progression in G1. Some tumours, however, seem to have evolved mechanism(s) that enable them to bypass the requirement for functional cyclin D1.	DANISH CANC SOC, DIV CANC BIOL, DK-2100 COPENHAGEN 0, DENMARK; EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, W-6900 HEIDELBERG, GERMANY; MITOTIX, CAMBRIDGE, MA 02139 USA	Danish Cancer Society; European Molecular Biology Laboratory (EMBL)			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; pagano, michele/0000-0003-3210-2442				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTEK J, 1993, STEM CELLS, V11, P51, DOI 10.1002/stem.5530110611; BERENSON JR, 1990, ONCOGENE, V5, P1343; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUMBERT C, 1992, J CELL SCI, V103, P97; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PALMERO I, 1993, ONCOGENE, V8, P1049; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PROCTOR AJ, 1991, ONCOGENE, V6, P789; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TOMMASINO M, 1993, ONCOGENE, V8, P195; TSAI LH, 1993, ONCOGENE, V8, P1593; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	63	300	306	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					707	718						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108113				2022-12-28	WOS:A1994MW55100005
J	MACLEAN, K; ROGAN, EM; WHITAKER, NJ; CHANG, ACM; ROWE, PB; DALLAPOZZA, L; SYMONDS, G; REDDEL, RR				MACLEAN, K; ROGAN, EM; WHITAKER, NJ; CHANG, ACM; ROWE, PB; DALLAPOZZA, L; SYMONDS, G; REDDEL, RR			IN-VITRO TRANSFORMATION OF LI-FRAUMENI SYNDROME FIBROBLASTS BY SV40 LARGE T-ANTIGEN MUTANTS	ONCOGENE			English	Article							HUMAN-DIPLOID FIBROBLASTS; CANCER-PRONE FAMILY; LARGE TUMOR-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; SIMIAN VIRUS-40; CELL-TRANSFORMATION; P53 GENE; IMMORTALIZATION; SPAN; EXPRESSION	Transfection of SV40 early region DNA into normal human diploid fibroblasts (NHDFs) increases their proliferative potential to a limited extent. We have investigated the roles of the SV40 large T antigen (LTAg) regions responsible for binding to the protein products of the retinoblastoma (Rb) and p53 genes in this temporary escape from senescence. Plasmids encoding LTAg mutants were transfected into NHDFs and into Li-Fraumeni syndrome (LFS) fibroblasts which are heterozygous wild-type (wt)/null-mutant for p53. A LTAg mutated in the p53-binding region (T402DE) had greatly reduced efficiency of focus formation, and a p110(Rb)-binding mutant was unable to induce any foci. T402DE-induced NHDF foci senesced at the same time as untransfected cells, but the equivalent LFS foci all had increased proliferative potentials, with the greatest increase being seen in clones that lost the wt p53 allele. One LFS clone expressed the T402DE mutant during focus formation, but later lost both the T402DE DNA and the wt p53 allele. We conclude that SV40-induced focus formation in NHDFs requires the LTAg p110(Rb)-binding region, and is enhanced by loss of normal p53 function. In contrast, increased proliferative potential is primarily due to loss of p53 function.	CHILDRENS MED RES INST,WESTMEAD,NSW 2145,AUSTRALIA; ROYAL ALEXANDRA HOSP CHILDREN,ONCOL UNIT,CAMPERDOWN,NSW 2050,AUSTRALIA	Children's Medical Research Institute - Australia			Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				BISCHOFF FZ, 1990, CANCER RES, V50, P7979; CHANG S E, 1986, Biochimica et Biophysica Acta, V823, P161, DOI 10.1016/0304-419X(86)90001-6; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERONDE A, 1989, VIROLOGY, V171, P160; DESILVA R, 1993, CELL MOL BIOL RES, V39, P101; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HAYFLICK L, 1965, EXP CELL RES, V37, P611; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; PEREIRASMITH OM, 1981, SOMAT CELL GENET, V7, P411, DOI 10.1007/BF01542986; SACK GH, 1981, IN VITRO CELL DEV B, V17, P1; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SOUDON J, 1991, LEUKEMIA, V5, P917; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRAUSS M, 1992, ONCOGENE, V7, P769; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WHITAKER NJ, 1992, J VIROL, V66, P1202, DOI 10.1128/JVI.66.2.1202-1206.1992; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	41	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					719	725						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108114				2022-12-28	WOS:A1994MW55100006
J	JACOBS, SM; GORSE, KM; WESTIN, EH				JACOBS, SM; GORSE, KM; WESTIN, EH			IDENTIFICATION OF A 2ND PROMOTER IN THE HUMAN C-MYB PROTOONCOGENE	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; CYCLE-RELATED GENES; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; MAMMALIAN-CELLS; V-MYB; DNA; ACTIVATION; SEQUENCES; BINDING	We have previously described an alternatively spliced cDNA clone of the human c-myb proto-oncogene which has been shown to enhance the differentiation of Friend murine erythroleukemia cells. This clone, pMbm-2, contains unique 5' sequences which replace exon 1. The human c-myb intron 1 was sequenced to determine the exact position of this unique sequence and to further characterize the role of intron 1 in the regulation of the human c-myb gene. Here we report that intron 1 of c-myb is highly conserved between human and mouse throughout the intron, while only those sequences directly adjacent to exons 1 and 2 are conserved between human and chicken. The unique sequence of pMbm-2 was located directly adjacent to exon 2, suggesting that it arose as a product of alternative transcription initiation within intron 1. RNAase protection analysis was used to map a cluster of transcription start sites at the 5' end of exon 2. Levels of messages utilizing these start sites are proportional to those arising from the primary promoter. Functional characterization of this region revealed that this region can function as a promoter. Deletion studies have revealed the presence of negative and positive regulatory elements within this region which are utilized with different efficiencies in different cell lines. These studies suggest that cis or trans factors acting in this region may serve a dual function in both attenuation and transcription initiation.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MICROBIOL IMMUNOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, DIV HEMATOL ONCOL, RICHMOND, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University								ANDERSSON LC, 1979, INT J CANCER, V23, P143, DOI 10.1002/ijc.2910230202; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BOISE LH, 1992, CELL GROWTH DIFFER, V3, P53; BOISE LH, 1992, ONCOGENE, V7, P1817; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DVORAK M, 1989, NUCLEIC ACIDS RES, V17, P5651; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HRUBY DE, 1990, BIOTECHNIQUES, V8, P170; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KORNELUK RG, 1985, GENE, V40, P317, DOI 10.1016/0378-1119(85)90055-1; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LI WH, 1985, MOL BIOL EVOL, V2, P150; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Maniatis T, 1989, MOL CLONING; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OHYASHIKI K, 1988, CANCER GENET CYTOGEN, V33, P83, DOI 10.1016/0165-4608(88)90053-2; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; ROSSON D, 1990, VIROLOGY, V175, P562, DOI 10.1016/0042-6822(90)90441-S; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; TORELLI U, 1986, LEUKEMIA RES, V10, P1249, DOI 10.1016/0145-2126(86)90244-4; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	56	30	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					227	235						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302584				2022-12-28	WOS:A1994MW24700028
J	DSOUZA, B; BERDICHEVSKY, F; KYPRIANOU, N; TAYLORPAPADIMITRIOU, J				DSOUZA, B; BERDICHEVSKY, F; KYPRIANOU, N; TAYLORPAPADIMITRIOU, J			COLLAGEN-INDUCED MORPHOGENESIS AND EXPRESSION OF THE ALPHA-2-INTEGRIN SUBUNIT IS INHIBITED IN C-ERBB2-TRANSFECTED HUMAN MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article							MONOCLONAL-ANTIBODIES; C-ERBB-2 PROTEIN; BREAST; TUMORS; GLAND; GENE; ADENOCARCINOMA; AMPLIFICATION; KERATIN-19; DISTINCT	The c-erbB2 (or Her2) oncogene is amplified and/or overexpressed in a significant proportion of breast cancers. To assess the role of the c-erbB2 oncogene in mammary tumorigenesis, we have transfected the corresponding human c-erbB2 cDNA into an immortalized human mammary epithelial cell line, MTSV1-7, that was derived from luminal epithelial cells cultured from milk. Three transfectants expressing different levels of the c-erbB2 gene product have been isolated which form colonies in agar and produce tumours in nude mice with high efficiency. We have observed that MTSV1-7 cells form three-dimensional structures in collagen gels and that alpha2beta1-integrin plays a crucial role in the process of morphogenesis. We now find that the c-erbB2 transfectants exhibit an impaired ability to undergo morphogenesis in collagen gets as compared with the parental cell line or the control neomycin transfectant, and that the degree of impairment is related to the level of c-erbB2 expression. Moreover, overexpression of the c-erbB2 product was found to be correlated with a specific decrease in the expression of alpha2beta1-integrin subunit and in the alpha2-mRNA. The breast cancer cell line SKBr3, which carries multiple copies of the c-erbB2 gene and overexpresses the 185-kDa product, was also found to express very low levels of the alpha2-integrin protein and mRNA. Our results confirm the involvement of the alpha2beta1-integrin in collagen-induced morphogenesis of mammary epithelial cells and suggest that the c-erbB2 gene product may inhibit this morphogenesis by inhibiting the expression of the alpha2-integrin subunit.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; UNIV MARYLAND HOSP,DEPT SURG,DIV UROL,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Cancer Research UK; University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BARTEK J, 1986, EUR J CANCER CLIN ON, V22, P1441, DOI 10.1016/0277-5379(86)90077-5; BARTEK J, 1985, J CELL SCI, V75, P17; BARTEK J, 1985, INT J CANCER, V36, P299, DOI 10.1002/ijc.1985.36.3.299; BERDICHEVSKY F, 1991, EXP CELL RES, V194, P267, DOI 10.1016/0014-4827(91)90364-Z; BERDICHEVSKY F, 1992, J CELL SCI, V102, P437; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KYPRIANOU N, 1991, ONCOGENE, V7, P77; LONARDO F, 1990, New Biologist, V2, P992; Maniatis T., 1982, MOL CLONING; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHEARER M, 1992, INT J CANCER, V51, P602, DOI 10.1002/ijc.2910510417; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Taylor-Papadimitriou J., 1987, The mammary gland. Development, regulation, and function., P181; TAYLORPAPADIMIT.J, 1992, BREAST CANCER CELLUL, V3, P355; TAYLORPAPADIMIT.J, 1987, GROWTH DIFFERENTIATI, P1; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; VANLEEUWEN F, 1990, ONCOGENE, V5, P497; ZUTTER MM, 1990, AM J PATHOL, V137, P863	33	77	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1797	1806						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8099725				2022-12-28	WOS:A1993LG68200011
J	HENNIGAN, RF; HAWKER, KL; OZANNE, BW				HENNIGAN, RF; HAWKER, KL; OZANNE, BW			FOS-TRANSFORMATION ACTIVATES GENES ASSOCIATED WITH INVASION	ONCOGENE			English	Article							C-FOS; BINDING-PROTEIN; CELL-LINE; CATHEPSIN-L; DIFFERENTIAL EXPRESSION; SIGNAL-TRANSDUCTION; METASTATIC CELLS; EARLY RESPONSE; GROWTH-FACTORS; FIBROBLASTS	Fos oncoproteins transform cells by functioning as transcription factors. Over-expression of c-fos results in minimal morphological transformation while the two viral isolates, FBJ and FBR v-fos, result in full morphological transformation. Fos-transformed cells are serum dependent for proliferation but not for morphological transformation. To identify Fos target genes which might be involved in morphological transformation me screened a cDNA library constructed from RNA isolated from serum starved FBR-transformed cells with cDNA probes prepared from both FBR-transformed cells and untransformed parental fibroblasts, 208F. We identified 10 genes which are differentially expressed between FBR and 208F cells. One is a novel gene. Nine are upregulated in c-fos- and FBJ-transformed cells and also in mutant c-Ha-Ras-transformed 208Fs. All nine of the upregulated genes have been associated previously with invasion or metastasis. We demonstrate that the FBR-transformed cells are invasive in an in vitro assay and that their ability to invade is enhanced by platelet derived growth factor. We conclude that the fos oncogenes target genes involved in morphological transformation, and invasion.	BEATSON INST CANC RES, CRC, BEATSON LABS, GLASGOW G61 1BD, LANARK, SCOTLAND; UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA	Beatson Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								Angel P, 1992, Matrix Suppl, V1, P156; ANGEL P, 1987, J CELL BIOCHEM, V42, P193; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BECKNER ME, 1993, J NATL CANCER I, V1990, P1836; BURCK KB, 1988, ONCOGENES INTRO CONC; CHAUHAN SS, 1991, CANCER RES, V51, P1478; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1989, ONCOGENE HDB; DAVIES BR, 1993, ONCOGENE, V8, P999; DELARCOJ, 1978, P NATL ACAD SCI USA, V70, P369; DENHARDT DT, 1987, ONCOGENE, V2, P55; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; EPNER DE, 1993, CANCER RES, V53, P1995; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FINKEL MP, 1975, FRONT RAD THER ONCOL, V10, P205; FRIGERI LG, 1992, J IMMUNOL, V148, P861; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HIRAI SI, 1990, ONCOGENE, V5, P39; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JIA SH, 1988, J BIOL CHEM, V263, P6009; KANE SE, 1988, MOL CELL BIOL, V8, P3316, DOI 10.1128/MCB.8.8.3316; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; Kerr L D, 1992, Matrix Suppl, V1, P176; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOLCH W, 1993, ONCOGENE, V8, P361; KONDOH N, 1992, CANCER RES, V52, P791; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LITZJACKSON S, 1992, BLOOD, V79, P2404; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOTAN R, 1983, CANCER RES, V43, P2088; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MECHAM RP, 1991, ANNU REV CELL BIOL, V7, P71, DOI 10.1146/annurev.cb.07.110191.000443; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; MERCOLA D, 1987, BIOCHEM BIOPH RES CO, V147, P288, DOI 10.1016/S0006-291X(87)80119-5; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MILLER AD, 1984, CELL, V36, P51; MINAFRA S, 1992, J CELL SCI, V102, P323; OCHIENG J, 1992, BIOCHEM BIOPH RES CO, V186, P1674, DOI 10.1016/S0006-291X(05)81601-8; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PARK AJ, 1991, J BIOL CHEM, V266, P1584; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PRICE CHG, 1972, BRIT J CANCER, V26, P15, DOI 10.1038/bjc.1972.5; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1984, EMBO J, V3, P2979, DOI 10.1002/j.1460-2075.1984.tb02244.x; RAZ A, 1986, CANCER RES, V46, P3667; RAZ A, 1981, CANCER RES, V41, P3642; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sambrook J, 1989, MOL CLONING LABORATO; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3212; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TANIGUCHI S, 1989, CANCER RES, V49, P6738; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TROEN BR, 1991, CELL GROWTH DIFFER, V2, P23; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERMA IM, 1992, PROG CLIN BIOL RES, V376, P41; WICK M, 1992, ONCOGENE, V7, P859; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	71	129	131	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3591	3600						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970719				2022-12-28	WOS:A1994PT39200022
J	HUANG, F; HSU, S; YAN, ZF; WINAWER, S; FRIEDMAN, E				HUANG, F; HSU, S; YAN, ZF; WINAWER, S; FRIEDMAN, E			THE CAPACITY FOR GROWTH-STIMULATION BY TGF-BETA-1 SEEN ONLY IN ADVANCED COLON CANCERS CANNOT BE ASCRIBED TO MUTATIONS IN APC, DCC, P53 OR RAS	ONCOGENE			English	Note							HEXAMETHYLENE BISACETAMIDE; COLORECTAL TUMORIGENESIS; CARCINOMA CELLS; GENE-MUTATIONS; DIFFERENTIATION; IDENTIFICATION; FACTOR-BETA-1; EXPRESSION; ONCOGENES; CHROMOSOME-5Q21	Human colon cancer development is associated with the accumulation of mutations and deletions in the suppressor genes DCC, APC and p53 and mutations in the dominant oncogene K-ras, with loss of wild type alleles. In earlier studies we had observed that about half of the resected human colon cancers placed into primary culture were growth stimulated by TGF beta 1. This group included the more advanced cancers which were either poorly differentiated primary-site cancers or metastases. In contract, the more differentiated colon cancers were inhibited or unaffected by TGF beta 1, indicating that a switch fn response to TGF beta 1 occurs during colon cancer progression. Different sublines of the HT29 colon carcinoma cell line model the resected cancers, responding to TGF beta 1 by proliferation, inhibition or no growth modulation. The current study shows that while the poorly differentiated, TGF beta 1-stimulated sublines are most tumorigenic, all the sublines have the same spectrum of mutations: truncating mutations in both APC (adenomatous polyposis coli) alleles, no activated vas genes, mutated and thus overexpressed p53, and very low expression of DCC compared to normal colon cells. Genes other than the four already implicated in colon carcinoma evolution are responsible for the mitogenic response to TGF beta 1 found in the more advanced cancers.	MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [IT32CAO9628] Funding Source: Medline; PHS HHS [R0145783, R0150645] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009628] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHROY P, 1990, CANCER RES, V50, P261; SCHROY PC, 1988, CANCER RES, V48, P5487; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YAN ZF, 1993, CELL GROWTH DIFFER, V4, P785; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YAN ZF, 1992, ONCOGENE, V7, P801	26	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3701	3706						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970729				2022-12-28	WOS:A1994PT39200035
J	MORGAN, IM; HAVARSTEIN, LS; WONG, WY; LUU, P; VOGT, PK				MORGAN, IM; HAVARSTEIN, LS; WONG, WY; LUU, P; VOGT, PK			EFFICIENT INDUCTION OF FIBROSARCOMAS BY V-JUN REQUIRES MUTATIONS IN THE DNA-BINDING REGION AND THE TRANSACTIVATION DOMAIN	ONCOGENE			English	Article							C-JUN; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-PROTEIN; LEUCINE ZIPPER; FOS; TRANSFORMATION; ONCOGENE; AP-1; DELTA	v-jun is the transforming gene of ASV 17, a retrovirus isolated from a spontaneous chicken fibrosarcoma. There are three mutations in the viral Jun protein (v-Jun) as compared to its cellular progenitor c-Jun: a deletion in the transactivation domain (called delta) and two amino acid substitutions in and near the DNA binding region. The effect of each of these mutations on fibrosarcoma development is described. All three mutations contribute towards tumor formation, and their cumulative effect makes v-Jun more tumorigenic compared to Jun proteins that carry only one or two of the mutations. Viruses rescued from tumors induced by c-Jun carrying the two amino acid substitutions in the DNA binding region have increased transforming and tumorigenic potential. These increases are probably due to further mutations that result in the expression of a rearranged Jun protein. Taken together the results show that the evolution of the c-Jun oncoprotein to an efficient carcinogen requires mutations in the transactivation and DNA binding regions.	NLVF, MICROBIAL GENE THERAPY LAB, AS, NORWAY; UNIV SO CALIF, LOS ANGELES CTY MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90033 USA; TULARIK INC, San Francisco, CA 94080 USA	University of Southern California	MORGAN, IM (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500; Havarstein, Leiv Sigve/0000-0001-8250-4322	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ANGEL P, 1989, New Biologist, V1, P35; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; FRAME MC, 1991, ONCOGENE, V6, P205; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WONG WY, 1992, ONCOGENE, V7, P2077; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	24	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2793	2797						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084584				2022-12-28	WOS:A1994PG82200004
J	HIGINBOTHAM, KG; RICE, JM; BUZARD, GS; PERANTONI, AO				HIGINBOTHAM, KG; RICE, JM; BUZARD, GS; PERANTONI, AO			ACTIVATION OF THE K-RAS GENE BY INSERTION MUTATIONS IN CHEMICALLY-INDUCED RAT RENAL MESENCHYMAL TUMORS	ONCOGENE			English	Article							HA-RAS; POINT MUTATIONS; ONCOGENE; CARCINOGENESIS; PROGRESSION; CARCINOMAS; INITIATION; AMPLIFICATION; MECHANISMS; METHYLUREA	Previously we reported the detection of transforming K-ras sequences in methyl(methoxymethyl)nitrosamine (DMN-OMe)-induced rat renal mesenchymal tumors by NIH3T3 transfection assays. Subsequent analysis by selective oligonucleotide hybridization revealed a variety of activating point mutations in codon 12 of K-ras in most of these tumors and in their NIH3T3 transformants, but in some, point mutations could not be detected by this technique. In the current study, insertion mutations were detected in two DMN-OMe-induced tumors from this group with previously undefined transforming K-ras alterations. These primary tumors and their NIH3T3 transformants contained K-ras sequences with either a 9 bp or a 12 bp repeat in exon one, both of which included codon 12. No other mutations in the entire coding region of the K-ras gene were observed. Site-directed mutagenesis studies by others have determined that deletions and insertions near codon 12 can activate the ras gene, but this is the first demonstration of insertional activation of K-ras in a chemically induced rat tumor.	NCI,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702; PRI DYNCORP,BCDP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [N01-CO-7412] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; AUSUBEL FM, 1989, CURRENT PROTOCOLS S9, V1; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CHIPPERFIELD RG, 1985, MOL CELL BIOL, V5, P1809, DOI 10.1128/MCB.5.8.1809; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; ENOMOTO T, 1990, CANCER RES, V50, P6139; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HIGINBOTHAM KG, 1992, MOL CARCINOGEN, V5, P136, DOI 10.1002/mc.2940050209; HIGINBOTHAM KG, 1992, CANCER RES, V52, P4747; JEGO N, 1993, ONCOGENE, V8, P209; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; MCMAHON G, 1987, P NATL ACAD SCI USA, V84, P4974, DOI 10.1073/pnas.84.14.4974; PERANTONI AO, UNPUB; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SLOAN SR, 1990, MOL CELL BIOL, V10, P405, DOI 10.1128/MCB.10.1.405; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; SUKUMAR S, 1986, MOL CELL BIOL, V6, P2716, DOI 10.1128/MCB.6.7.2716; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WIEST JS, 1994, IN PRESS ONCOGENE, V9; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	30	18	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2455	2459						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058308				2022-12-28	WOS:A1994PC05400004
J	KITAGAWA, M; HIGASHI, H; TAKAHASHI, IS; OKABE, T; OGINO, H; TAYA, Y; NISHIMURA, S; OKUYAMA, A				KITAGAWA, M; HIGASHI, H; TAKAHASHI, IS; OKABE, T; OGINO, H; TAYA, Y; NISHIMURA, S; OKUYAMA, A			A CYCLIN-DEPENDENT KINASE INHIBITOR, BUTYROLACTONE-I, INHIBITS PHOSPHORYLATION OF RB PROTEIN AND CELL-CYCLE PROGRESSION	ONCOGENE			English	Article							MATURATION-PROMOTING FACTOR; RETINOBLASTOMA-SUSCEPTIBILITY GENE; FISSION YEAST; CDC2 KINASE; MAMMALIAN FIBROBLASTS; TRANSCRIPTION FACTOR; DNA-REPLICATION; PRODUCT; PHASE; CDK2	Butyrolactone I is a selective inhibitor of the cyclin-dependent kinase (cdk) family. It inhibits both cdk2 and cdc2 kinase, but scarcely affects C-kinase, A-kinase, casein kinases, MAP kinase or EGF receptor-tyrosine kinase (Kitagawa et al., 1993, Oncogene, 8, 2425-2432). We studied the effects of butyrolactone I on the cell cycle as well as on phosphorylation of retinoblastoma protein (pRB). Butyrolactone I inhibited phosphorylation of pRB catalyzed by cyclin A-cdk2 produced by baculovirus in vitro. Furthermore, it inhibited phosphorylation of pRB and cell cycle progression from G1 to S phase in WI38 cell cultures. WI38 cells arrested at the G0 phase by serum starvation progressed in the cell cycle after serum stimulation. pRB was phosphorylated after 10 h serum stimulation. Incorporation of [H-3]thymidine into the cells began to increase after 16 h serum stimulation. These processes were inhibited by butyrolactone I. Flow cytometric analysis showed that exposure to butyrolactone I inhibited progression of the cell cycle from G1 to S phase. These data suggested that initiation of DNA synthesis was inhibited by butyrolactone I and that the cell cycle was arrested in the G1 phase. Butyrolactone I also inhibited H1 histone phosphorylation in human WI38 cells and their G2/M progression, tsFT210 cells, a temperature-sensitive cdc2 mutant cell line, were synchronized at G2/M at a nonpermissive temperature, butyrolactone I inhibited the cell cycle progression of these cells at G2/M at the permissive temperature. Thus butyrolactone I, a cyclin-dependent kinase family inhibitor, which prevented the phosphorylations of the cell cycle-regulating proteins pRB and H1 histone, inhibited the cell cycle at G1/S and G2/M, respectively. These results suggest that the phosphorylations of pRB and H1 histone may play crucial roles in G1/S and G2/M progression, respectively, although it is possible that phosphorylations of other proteins by cdks are involved in G1/S and G2/M progression.	MERCK RES LABS,BANYU TSUKUBA RES INST,TSUKUBA,IBARAKI 30033,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	Merck & Company; National Cancer Center - Japan			Higashi, Hideaki/F-6872-2012					AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; AKIYAMA T, 1990, ONCOGENE, V5, P179; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATUURA Y, 1987, J GEN VIROL, V68, P1233; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1038; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1990, New Biologist, V2, P389; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SOMEYA A, 1994, BIOCHEM BIOPH RES CO, V198, P535; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105	56	116	119	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2549	2557						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058318				2022-12-28	WOS:A1994PC05400014
J	OKAZAWA, H; KAMEI, M; IMAFUKU, I; KANAZAWA, I				OKAZAWA, H; KAMEI, M; IMAFUKU, I; KANAZAWA, I			GENE-REGULATION OF TRKB AND TRKC IN THE CHICK RETINA BY LIGHT/DARKNESS EXPOSURE	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; PROTEIN-TYROSINE KINASE; NEUROTROPHIC FACTOR; NEURONAL DEATH; TRANSCRIPTION FACTOR; RAT HIPPOCAMPUS; FACTOR PROMOTES; FACTOR PREVENTS; GANGLION-CELLS	The trk gene family members; the neurotrophic receptors for neurotrophins, are implicated in the survival and the differentiation of neurons. The roles of these protooncogenes have been argued in the pathological conditions and in the specific developmental stage when the programmed cell death occurs to neurons. Here we studied a physiological role of the trk family members in the retina through observations of their gene regulation by light/darkness exposure. Northern blot analysis and immunohistochemistry demonstrate that trkB and trkC are up-regulated by light exposure and down-regulated by darkness in the rod/cone layer, the outer nuclear layer, and the ganglion cell layer. This physiological regulation suggests that these trk family members play a protective role from the damaging effect of light exposure in the retinal neurons.			OKAZAWA, H (corresponding author), UNIV TOKYO, FAC MED, DEPT NEUROL, BUNKYO KU, 7-3-1 HONGO, TOKYO 113, JAPAN.							BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES AM, 1985, DEV BIOL, V111, P62, DOI 10.1016/0012-1606(85)90435-X; DECHANT G, 1993, DEVELOPMENT, V119, P545; DUGICHDJORDJEVIC MM, 1992, NEUROSCIENCE, V47, P303, DOI 10.1016/0306-4522(92)90246-X; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HEFTI F, 1986, J NEUROSCI, V6, P2155; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JELSMA TN, 1993, J NEUROBIOL, V24, P1207, DOI 10.1002/neu.480240907; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KORSCHING S, 1993, J NEUROSCI, V13, P2739; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; OKAZAWA H, 1993, FEBS LETT, V329, P171, DOI 10.1016/0014-5793(93)80216-H; OKAZAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P683, DOI 10.1006/bbrc.1993.1876; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RICHTER A, 1975, J PHYSIOL-LONDON, V248, P317, DOI 10.1113/jphysiol.1975.sp010976; RODRIGUEZTEBAR A, 1989, DEV BIOL, V136, P296, DOI 10.1016/0012-1606(89)90256-X; RODRIGUEZTEBAR A, 1993, EUR J BIOCHEM, V211, P789, DOI 10.1111/j.1432-1033.1993.tb17610.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SCHWARTZ EA, 1974, J PHYSIOL-LONDON, V236, P211, DOI 10.1113/jphysiol.1974.sp010431; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SHINTANI A, 1992, BIOCHEM BIOPH RES CO, V182, P325, DOI 10.1016/S0006-291X(05)80148-2; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VAIENZUELLA DM, 1993, NEURON, V10, P963; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YOSHIDA K, 1993, NEURON, V10, P1049, DOI 10.1016/0896-6273(93)90053-T; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	54	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1813	1818						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208527				2022-12-28	WOS:A1994NR68500002
J	AOKI, K; NAKAHARA, K; IKEGAWA, C; SETO, M; TAKAHASHI, T; MINOWADA, J; STROMINGER, JL; MAZIARZ, RT; KASAI, M				AOKI, K; NAKAHARA, K; IKEGAWA, C; SETO, M; TAKAHASHI, T; MINOWADA, J; STROMINGER, JL; MAZIARZ, RT; KASAI, M			NUCLEAR PROTEINS BINDING TO A NOVEL TARGET SEQUENCE WITHIN THE RECOMBINATION HOTSPOT REGIONS OF BCL-2 AND THE IMMUNOGLOBULIN-D(H) GENE FAMILY	ONCOGENE			English	Article							T-CELL LEUKEMIA; CHROMOSOMAL BREAKPOINT; FOLLICULAR LYMPHOMA; DNA-REPLICATION; TRANSLOCATION; T(14-18); MECHANISM; CONSENSUS; NEOPLASMS; CLONING	The chromosomal breakpoints of follicular lymphomas carrying the t(14;18)(q32;q21) are known to be clustered within a 150-bp region in the major breakpoint region (mbr) of the Bc1-2 oncogene. We have demonstrated that nuclear proteins specifically bind to a novel target sequence within this 150-bp region and a region of Dxp genes, members of the immunoglobulin (Ig) diversity (D(H)) gene family. One protein, designated BCLF-1, appears to be specifically expressed in lymphoid lineage cells. Two other proteins, BCLF-2 and -3, bind only to the complementary single strand of the target sequence. The manner in which these proteins interact with the target sequence is similar to the interaction of the ReHF-1 and -2 proteins to the signal-like sequence at the chromosomal breakpoint junctions in patients with the t(8;14)(q24;q11) and t(1;14)(p32;q11) translocations. It was further suggested that the BCLF-1 is quite similar to or identical to the ReHF-1. It is therefore hypothesized that these conserved target sequences found in recombination hotspot regions may define novel sequence motifs recognized by two classes of DNA binding proteins. One class of DNA binding proteins is specifically expressed in lymphoid cells while the other class binds to the complementary single strand DNA. These binding activities may play a crucial role in chromosomal translocation in lymphoid neoplasms.	NATL INST HLTH,DEPT IMMUN,1-23-1 TOYAMA,SHINJUKU KU,TOKYO 162,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 1,BUNKYO KU,TOKYO 113,JAPAN; KYORIN UNIV,SCH MED,DEPT CLIN PATHOL,MITAKA,TOKYO 181,JAPAN; AICHI CANC CTR,CHEMOTHERAPY LAB,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LAB,CHIYODA KU,NAGOYA,AICHI 464,JAPAN; HAYASHIBARA BIOCHEM LABS INC,FUJISAKI CELL CTR,OKAYAMA 702,JAPAN; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; OREGON HLTH SCI UNIV,DIV HEMATOL ONCOL,PORTLAND,OR 97201; VAMC,PORTLAND,OR 97207	University of Tokyo; Kyorin University; Aichi Cancer Center; Aichi Cancer Center; Hayashibara Biochemical Laboratories, Inc.; Harvard University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System								BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER F, 1990, BLOOD, V76, P131; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; JAEGER U, 1993, BLOOD, V81, P1883; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; KASAI M, 1993, UNPUB; KOBAYASHI I, 1984, COLD SPRING HARB SYM, V49, P497, DOI 10.1101/SQB.1984.049.01.056; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; MAZIARZ RT, 1992, BLOOD, V79, P1523; MINOWADA J, 1988, Cancer Reviews, V10, P1; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; SETO M, 1991, JPN J CANCER RES, V82, P65, DOI 10.1111/j.1349-7006.1991.tb01747.x; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; TAYLOR AF, 1988, REC BCD ENZYME ESCHE, P231; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; UMEK RM, 1989, BIOCHIM BIOPHYS ACTA, V1007, P1, DOI 10.1016/0167-4781(89)90123-1; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	28	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1109	1115						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134113				2022-12-28	WOS:A1994NC04800013
J	CHEN, JH; WRIGHT, CD				CHEN, JH; WRIGHT, CD			PEA3, OCT-1 AND OCT-2 POSITIVELY REGULATE THE HUMAN ETS1 PROMOTER	ONCOGENE			English	Article							LONG TERMINAL REPEAT; GLUTATHIONE-S-TRANSFERASE; C-ETS; TRANSCRIPTIONAL ACTIVATION; EXPRESSION SYSTEM; ESCHERICHIA-COLI; DNA-BINDING; GENE; ONCOGENE; C-ETS-1	The promoter of the human ETS1 gene contains binding site motifs for transcription factors Sp1, Ap1, Ap2, ETS, PEA3 and Oct. It has been shown previously that Ap1, Ap2, and ETS are positive regulators for the transcription of the ETS1 gene and that the ETS1 gene is autoregulated. In addition, two regions on the ETS1 promoter that contain negative regulatory sequences have also been identified. In this study, GST/PEA3 and GST/ets1 fusion proteins were used in gel mobility assays to analyse the interaction between these transcription factors with the binding motifs of PEA3 and ETS in the ETS1 promoter. Promoter constructs in which the binding site motifs are mutated were used to examine the effect of mutation on the activities of transcription factors PEA3, ets1 and Oct. Reporter plasmids containing different deletion mutants of the ETS1 promoter were used to examine the effect of different transcription factors (PEA3, Oct 1 and Oct 2) upon the expression of the ETS1 gene. The results of these studies indicate that PEA3 is a strong positive regulator of the ETS1 promoter and that other transcription factors increase the activity of the ETS1 promoter in an additive rather than synergistic fashion.			CHEN, JH (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX 77030, USA.							BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CHEN JH, 1993, ONCOGENE, V8, P133; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1990, ONCOGENE RES, V5, P277; FISHER RJ, 1991, ONCOGENE, V6, P2249; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKA T, 1991, ONCOGENE, V6, P2077; PROGNONEC B, 1988, EMBO J, V7, P979; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1992, GENE DEV, V6, P9665; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOOD WM, 1989, J BIOL CHEM, V264, P14840; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	30	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3375	3383						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247540				2022-12-28	WOS:A1993MG78200022
J	JUVEN, T; BARAK, Y; ZAUBERMAN, A; GEORGE, DL; OREN, M				JUVEN, T; BARAK, Y; ZAUBERMAN, A; GEORGE, DL; OREN, M			WILD-TYPE P53 CAN MEDIATE SEQUENCE-SPECIFIC TRANSACTIVATION OF AN INTERNAL PROMOTER WITHIN THE MDM2 GENE	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENE; BINDING-SITE; PROTEIN; EXPRESSION; CELLS; MUTANT; TRANSFORMATION; SARCOMAS; PRODUCT; FORMS	The p53 tumor suppressor gene product can complex with polypeptides encoded by the mdm2 putative protooncogene. In addition, mdm2 mRNA levels have been shown to increase following the activation of wild type (wt) p53. To determine the basis for the effect of wt p53 on mdm2 mRNA, we studied the interaction of the mdma gene with p53. We report that wt p53 can bind sequence-specifically to a DNA region residing downstream to exon 1 of the mdm2 gene. This is correlated with a pronounced p53-dependent transcriptional activation. Efficient p53-dependent transactivation can be obtained with an mdm2 genomic DNA fragment lacking the putative mdm2 promoter. These findings suggest that p53 can induce transcription from an internal promoter located within the mdm2 gene. These findings raise the possibility that, in addition to increasing the overall levels of mdm2 mRNA, wt p53 may also modulate the repertoire of mdm2 transcripts present within the cell.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; UNIV PENN,DEPT GENET,PHILADELPHIA,PA 19104	Weizmann Institute of Science; University of Pennsylvania			Juven-Gershon, Tamar/AAC-7799-2022	Juven-Gershon, Tamar/0000-0003-2607-5476	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1993, MOL CELL BIOL, V3, P301; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1990, ONCOGENE, V5, P1285; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, Critical Reviews in Oncogenesis, V3, P233; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Rotter Varda, 1993, Trends in Cell Biology, V3, P46, DOI 10.1016/0962-8924(93)90151-P; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; TRUANT R, 1993, J BIOL CHEM, V268, P2284; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	39	374	381	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3411	3416						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247544				2022-12-28	WOS:A1993MG78200026
J	LEE, ST; STRUNK, KM; SPRITZ, RA				LEE, ST; STRUNK, KM; SPRITZ, RA			A SURVEY OF PROTEIN-TYROSINE KINASE MESSENGER-RNAS EXPRESSED IN NORMAL HUMAN MELANOCYTES	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; POLYMERASE CHAIN-REACTION; C-KIT; HUMAN PIEBALDISM; CATALYTIC DOMAIN; INSULIN-RECEPTOR; LEUKEMIA-CELLS; GENE; FAMILY; PROTOONCOGENE	We have used the reverse transcription-polymerase chain reaction to survey the repertoire of protein tyrosine kinases expressed in cultured normal human melanocytes, a differentiated cell type derived from the neural crest. We identified 25 different tyrosine kinase cDNAs among a total of 608 protein tyrosinase kinase-related cDNAs analyzed. Six encode receptor tyrosine kinases for known ligands, several of which have been implicated in controlling melanocyte proliferation in vitro. Two others encode apparent receptor tyrosine kinases for unknown ligands. Four encode known non-receptor tyrosine kinases and five encode previously identified anonymous protein tyrosine kinases. Of the eight other melanocyte-associated protein tyrosine kinases, most or all appear to be novel. These 25 protein tyrosine kinase genes exhibit distinct patterns of expression in cultured human melanocytes, human erythroleukemia cells, and a variety of normal human tissues. We mapped 16 of the corresponding protein tyrosine kinase genes to specific human chromosomes, identifying a total of 19 human genetic loci, some of which may constitute candidate genes for genetic disorders of mammalian development.	UNIV WISCONSIN, DEPT MED GENET, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Lee, Seung-Taek/0000-0001-7300-9784	ACF HHS [AF-39892] Funding Source: Medline	ACF HHS		BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DEAN M, 1987, Genomics, V1, P167, DOI 10.1016/0888-7543(87)90009-7; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FLEISCHMAN RA, 1992, J CLIN INVEST, V89, P1713, DOI 10.1172/JCI115772; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FRANCKE U, 1986, COLD SPRING HARB SYM, V51, P855, DOI 10.1101/SQB.1986.051.01.099; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GIEBEL LB, 1992, ONCOGENE, V7, P2207; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HALABAN R, 1992, ONCOGENE, V7, P2195; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ISACCHI A, 1990, NUCLEIC ACIDS RES, V18, P1906, DOI 10.1093/nar/18.7.1906; JHANWAR SC, 1984, CYTOGENET CELL GENET, V38, P73, DOI 10.1159/000132033; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LYON MF, 1990, GENETIC VARIANTS STR; MANO H, 1993, ONCOGENE, V8, P417; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MORRIS C, 1990, CYTOGENET CELL GENET, V53, P196, DOI 10.1159/000132929; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PITTELKOW MR, 1989, J CELL PHYSIOL, V140, P565, DOI 10.1002/jcp.1041400323; POLVI A, 1993, IN PRESS GENE; PRITCHARD MA, 1992, MAMM GENOME, V3, P36, DOI 10.1007/BF00355839; RUTA M, 1988, ONCOGENE, V3, P9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHISHIDO E, 1991, FEBS LETT, V289, P235, DOI 10.1016/0014-5793(91)81078-M; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; SPRITZ RA, 1992, AM J HUM GENET, V51, P1058; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; TRASK B, 1993, GENOMICS, V15, P133, DOI 10.1006/geno.1993.1021; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; ULLRICH A, 1990, CELL, V61, P2003; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YUE CC, 1991, MOL IMMUNOL, V28, P399	53	98	117	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3403	3410						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247543				2022-12-28	WOS:A1993MG78200025
J	BASU, T; WARNE, PH; DOWNWARD, J				BASU, T; WARNE, PH; DOWNWARD, J			ROLE OF SHC IN THE ACTIVATION OF RAS IN RESPONSE TO EPIDERMAL GROWTH-FACTOR AND NERVE GROWTH-FACTOR	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; GRB2 ADAPTER PROTEIN; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCTION; SEVENLESS GENE; PC12 CELLS; PHOSPHORYLATION; DOMAINS; P21RAS	Treatment of the rat pheochromocytoma cell line PC12 with nerve growth factor (NGF) or epidermal growth factor (EGF) is known to result in activation of Ras. In response to EGF treatment, complexes form between Sos, Grb2 and tyrosine phosphorylated She and/or EGF receptor. In response to NGF treatment, complexes form between Sos, Grb2 and tyrosine phosphorylated Shc. While She is also found bound to the activated NGF receptor, Trk, no complexes were detectable that contained both Trk and Grb2 or Sos. In streptolysin O permeabilised cells, a tyrosine phosphopeptide, EGFR-Y1068P, which binds to the SH2 domain of Grb2, totally blocks growth factor induced formation of complexes between Grb2 and She or EGF receptor, and also blocks activation of nucleotide exchange on Ras. At low concentrations, another tyrosine phosphopeptide, TRK-Y490P, which binds to the SH2 domain of She, blocks growth factor induced formation of complexes between Shc and the EGF receptor or Trk, but fails to block activation of nucleotide exchange on Ras. Higher concentrations of TRK-Y490P inhibit tyrosine phosphorylation of She and the formation of She complexes with Grb2: this results in strong inhibition of Ras activation by NGF and partial inhibition of Ras activation by EGF. These data demonstrate that the formation of a trimeric complex between tyrosine phosphorylated Shc, Grb2 and Sos is the key event in the activation of Ras in response to NGF. The binding of Sos to tyrosine phosphorylated receptor, via Grb2 may also contribute to Ras activation by EGF but not NGF, while stable complex formation between She and receptors is not necessary for Ras activation by either growth factor.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK				Downward, Julian/0000-0002-2331-4729				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU BX, 1993, ONCOGENE, V8, P3081; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MUROYA K, 1992, ONCOGENE, V7, P277; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OUWENS DM, 1993, J CELL BIOCH S A, V17, P237; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	80	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3483	3491						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970708				2022-12-28	WOS:A1994PT39200010
J	PRASAD, DDK; OUCHIDA, M; LEE, L; RAO, VN; REDDY, ESP				PRASAD, DDK; OUCHIDA, M; LEE, L; RAO, VN; REDDY, ESP			TLS FUS FUSION DOMAIN OF TLS FUS-ERG CHIMERIC PROTEIN RESULTING FROM THE T(1621) CHROMOSOMAL TRANSLOCATION IN HUMAN MYELOID-LEUKEMIA FUNCTIONS AS A TRANSCRIPTIONAL ACTIVATION DOMAIN	ONCOGENE			English	Article							ETS-RELATED GENE; SERUM RESPONSE FACTOR; RNA-BINDING PROTEIN; DNA-BINDING; FLI-1 GENE; FAMILY; ELK-1; C-ETS-1; MEMBER; ERYTHROLEUKEMIA	EWS and TLS/FUS genes, which code for RNA binding proteins are involved in a wide variety of human solid tumors. The TLS/FUS gene is involved both in human myxoid liposarcomas which carry a characteristic chromosomal translocation, t(12;16)(q13;p11) and in human myeloid leukemias with recurrent chromosomal translocation, t(16;21)(p11:q22). The TLS/FUS gene is fused to a transcriptional repressor, CHOP (in human myxoid liposarcomas) or transcriptional activator, erg (in human myeloid leukemias). To understand better the functional role of TLS/FUS-erg in human myeloid leukemias, we have cloned the TLS/FUS and TLS/FUS-erg cDNAs and studied the functional properties of their gene products. TLS/FUS protein binds to RNA in vitro and shows preferential binding to poly G. Both the amino- and the carboxy- terminal regions of TLS/FUS containing the conserved RNA binding motifs are needed for poly G specific RNA binding activity. The TLS/FUS fusion domain (TFD) appears to regulate the DNA binding activity of TLS/FUS-erg chimeric protein which shows weaker transcriptional activation properties compared to normal erg proteins. Mutational analysis of the TLS/FUS-erg chimeric protein reveals TFD to function as a transcriptional activation domain thus replacing the amino terminal transcriptional activation domain of the erg protein. Therefore alterations in both DNA binding and transcriptional activation properties of aberrant erg proteins may be responsible for the genesis of t(16;21) chromosomal translocation-bearing human myeloid leukemias.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,FREDERICK,MD 21702	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [CA 58642, CA 57157, CA 51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058642, R01CA057157, P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; HAYNES SR, 1992, NEW BIOL, V4, P421; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LADANYI M, 1994, CANCER RES, V54, P2837; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD DDK, 1992, CANCER RES, V52, P5833; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1990, CANCER RES, V50, P5013; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; [No title captured]	51	138	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3717	3729						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970732				2022-12-28	WOS:A1994PT39200038
J	MATSUYAMA, H; PAN, Y; SKOOG, L; TRIBUKAIT, B; NAITO, K; EKMAN, P; LICHTER, P; BERGERHEIM, USR				MATSUYAMA, H; PAN, Y; SKOOG, L; TRIBUKAIT, B; NAITO, K; EKMAN, P; LICHTER, P; BERGERHEIM, USR			DELETION MAPPING OF CHROMOSOME 8P IN PROSTATE-CANCER BY FLUORESCENCE IN-SITU HYBRIDIZATION	ONCOGENE			English	Note							INSITU HYBRIDIZATION; COLORECTAL-CANCER; ALLELIC LOSS; ADENOCARCINOMA; ABERRATIONS; CARCINOMA; CELLS; LOCI; RETINOBLASTOMA; ONCOGENES	Double-target fluorescence in situ hybridization (FISH) was applied to 42 cases of prostate cancer and seven cases of histologically proven benign prostate hyperplasia for the detection of structural aberrations of chromosome 8. Cosmid probes for two chromosome 8p loci (LPL/8p22 and D8S7/8p23) were used in 34 specimens of malignant tumors obtained by the touch biopsy technique. Deletion was defined as when the number of cosmid signals was lower than the number of centromere signals in more than 35% of all nuclei observed. In total; thirty of the 42 (71%) specimens demonstrated any type of 8p deletion. Out of the 34 cases in which deletion mapping could be evaluated, distal deletion (D8S7) was detected in 17 (50%), of which 10 also showed deletion of LPL. Deletion of LPL was detected in 18 cases (53%), of which 8 (24%) retained the D8S7 (interstitial deletion). When the deletion pattern was graded as (1) no deletion (2) partial deletion (either D8S7 or LPL deleted) and (3) both deletions, the degree of deletion was well correlated with the tumor grade (P = 0.0009) and with stage (P = 0.0072, Fisher's Exact test). These data support the hypothesis that tumor suppressor gene(s) may be located in the chromosomal region 8p22, hence 8p deletions may play a crucial role in the pathogenesis of prostate cancer.	KAROLINSKA HOSP,DEPT UROL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT MED RADIOBIOL,STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT PATHOL,S-10401 STOCKHOLM,SWEDEN; DEUTSCH KREBSFORSCHUNGSZENTRUM,HEIDELBERG,GERMANY; YAMAGUCHI UNIV,SCH MED,DEPT UROL,UBE,YAMAGUCHI 755,JAPAN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Yamaguchi University			Matsuyama, Hideyasu/AAC-7487-2020	Matsuyama, Hideyasu/0000-0001-5607-7769				ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1993, CANCER-AM CANCER SOC, V71, P1179, DOI 10.1002/1097-0142(19930201)71:3+<1179::AID-CNCR2820711442>3.0.CO;2-B; BOVA GS, 1993, CANCER RES, V53, P3869; BROTHMAN AR, 1990, CANCER RES, V50, P3795; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CREMER T, 1986, HUM GENET, V74, P346, DOI 10.1007/BF00280484; CREMER T, 1988, HUM GENET, V80, P235, DOI 10.1007/BF01790091; EMI M, 1992, CANCER RES, V52, P5368; ESPOSTI P L, 1971, Scandinavian Journal of Urology and Nephrology, V5, P199, DOI 10.3109/00365597109133601; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GIBAS Z, 1985, CANCER GENET CYTOGEN, V16, P301, DOI 10.1016/0165-4608(85)90237-7; HOPMAN AHN, 1988, HISTOCHEMISTRY, V89, P307, DOI 10.1007/BF00500631; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KNUDSON AG, 1985, CANCER RES, V45, P1437; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; MATSUMURA K, 1992, CANCER RES, V52, P3474; MATSUYAMA H, 1994, IN PRESS CANCER GENE; MCNEAL JE, 1986, LANCET, V1, P60; Mostofi FK, 1973, INT CLASSIFICATION T; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STILGENBAUER S, 1993, BLOOD, V81, P2118; TRIBUKAIT B, 1989, RAPID FLOW CYTOMETRY; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114	28	81	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3071	3076						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084616				2022-12-28	WOS:A1994PG82200040
J	NILSSON, P; MEHLE, C; REMES, K; ROOS, G				NILSSON, P; MEHLE, C; REMES, K; ROOS, G			TELOMERASE ACTIVITY IN-VIVO IN HUMAN-MALIGNANT HEMATOPOIETIC-CELLS	ONCOGENE			English	Note							TRANSFERASE-ACTIVITY; HUMAN FIBROBLASTS; IDENTIFICATION; REDUCTION; RNA	In somatic cells, each DNA replication round gives a shortening of the telomere ends as a consequence of incomplete lagging strand synthesis. Telomeres are essential for chromosomal integrity and extensive telomere length reduction is associated with increased instability of the genome. In germ line cells and in established cell lines, telomerase activity maintains the length of the telomeres by de novo synthesis of telomeric repeats, in humans (T(2)AG(3))(n). Recently, it was for the first time shown the existence of telomerase activity in human ovarian carcinomas. In the present study we show that telomerase activation can also occur in human hematopoietic tumor cells in vivo. Cell extracts from 19 cases with leukemia, lymphoma and myeloma were tested for telomerase activity using an in vitro assay with (T(2)AG(3))(3) or permutations of this sequence as primers. Eight cases demonstrated an RNAse A sensitive ability to add new nucleotides to the human telomere sequence. Nine acute leukemias were tested telomerase negative. Our data demonstrate that telomerase activation in vivo seems to be a common event in B cell neoplasias with a mature immunophenotype like non-Hodgkin's lymphoma and myeloma, in contrast to acute leukemias of B, T or myeloid cell origin. Telomere length evaluation indicated no marked differences between samples with or without telomerase activity which could argue for a telomere length independent mechanism for telomerase activation in at least some cases.	UMEA UNIV, DEPT PATHOL, S-90187 UMEA, SWEDEN	Umea University								ADAMSON DJA, 1992, CANCER GENET CYTOGEN, V61, P204, DOI 10.1016/0165-4608(92)90088-P; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Greider CW, 1991, CURR OPIN CELL BIOL, V3, P444, DOI 10.1016/0955-0674(91)90072-7; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MCCAFFREY R, 1975, NEW ENGL J MED, V292, P775, DOI 10.1056/NEJM197504102921504; MEHLE C, 1994, CANCER RES, V54, P236; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8	20	98	104	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3043	3048						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084612				2022-12-28	WOS:A1994PG82200035
J	SAITOH, S; CUNNINGHAM, J; DEVRIES, EMG; MCGOVERN, RM; SCHROEDER, JJ; HARTMANN, A; BLASZYK, H; WOLD, LE; SCHAID, D; SOMMER, SS; KOVACH, JS				SAITOH, S; CUNNINGHAM, J; DEVRIES, EMG; MCGOVERN, RM; SCHROEDER, JJ; HARTMANN, A; BLASZYK, H; WOLD, LE; SCHAID, D; SOMMER, SS; KOVACH, JS			P53 GENE-MUTATIONS IN BREAST CANCERS IN MIDWESTERN US WOMEN - NULL AS WELL AS MISSENSE-TYPE MUTATIONS ARE ASSOCIATED WITH POOR-PROGNOSIS	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; HEPATOCELLULAR CARCINOMAS; MOLECULAR EPIDEMIOLOGY; SKIN; OCCUR; AMPLIFICATION; PATTERN	We determined the pattern of mutations in exons 2-11 and adjacent intronic regions in breast cancers from Midwestern US white women. Twenty-one mutations were detected in 53 tumors (39.6%). Comparisons of the pattern of mutations within exons 5-9 showed that the frequency of missense mutations (44%) was lower in breast cancers of US Midwestern women than in most tumor types including breast cancers in other populations. Compared to breast cancers reported in a Scottish population, US women had a high frequency of microdeletion mutations (P = 0.006) and a low frequency of G:C-->T:A transversions (P = 0.046). These findings suggest that environmental or endogenous factors contribute to p53 mutagenesis in mammary tissue to different extents among different populations. With a median follow-up of 19 months, the presence of a mutation was associated with shorter time to disease recurrence (P = 0.05) and shorter survival (P = 0.003). Putative dominant negative missense-type mutations (missense and in-frame microdeletions; P = 0.001) and null mutations (hemizygous nonsense and frameshift mutations; P = 0.007) were equally ominous. Thus, tumors with missense p53 mutations resulting in overexpression of a dysfunctional but otherwise intact protein have a clinical outcome similar to tumors with null mutations resulting in a truncated or garbled protein.	MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA56881, CA15086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; BLASZYK H, 1994, IN PRESS HUMAN MUT; BORING CC, 1994, CA-CANCER J CLIN, V43, P7; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHIBA I, 1990, ONCOGENE, V5, P1603; COLEMAN MP, 1993, IARC SCI PUBLICATION, V121; COLES C, 1992, CANCER RES, V52, P5291; COURSAGET P, 1993, BRIT J CANCER, V67, P1395, DOI 10.1038/bjc.1993.258; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; ELLEDGE RM, 1993, BREAST CANCER RES TR, V27, P95, DOI 10.1007/BF00683196; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES PA, 1991, CANCER RES, V51, P3617; KANJILAL S, 1993, CANCER RES, V53, P2961; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRESS S, 1992, CANCER RES, V52, P6400; MAZARS R, 1992, CANCER RES, V52, P3918; MOLES JP, 1993, ONCOGENE, V8, P583; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; Osborne CK, 1991, BREAST DIS, P301; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; Sommer Steve S., 1994, P214; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; THORLACIUS S, 1993, CANCER RES, V53, P1637; TSUDA H, 1993, JPN J CANCER RES, V84, P394, DOI 10.1111/j.1349-7006.1993.tb00149.x; 1991, STAT XACT VER 2 0	33	70	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2869	2875						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084591				2022-12-28	WOS:A1994PG82200012
J	HAHN, SL; WASYLYK, B				HAHN, SL; WASYLYK, B			THE ONCOPROTEIN V-ETS IS LESS SELECTIVE IN DNA-BINDING THAN C-ETS-1 DUE TO THE C-TERMINAL SEQUENCE CHANGE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR GATA-1; CHICKEN ERYTHROID-CELLS; GENE FAMILY; REDOX REGULATION; LEUKEMIA-VIRUS; ONCOGENIC CONVERSION; PROMOTER SEQUENCES; PUTATIVE ONCOGENE; MYB ONCOPROTEIN; PROTEIN	The oncogene v-ets and the proto-oncogene c-ets-1 code for members of the Ets family of transcription factors that bind to DNA motifs comprising GGA(A/T) through the conserved Ets domain. c-Ets-1 and v-Ets are very similar, differing in sequence only at three positions. In this report we demonstrate that v-Ets has a less stringent target sequence requirement than c-Ets-1. v-Ets binds strongly to a broad spectrum of DNA sequence motifs, and consequently, weaker binding sites have a much greater affinity for v-Ets than c-Ets-1. c-Ets-1 carries two inhibitory domains: the D domain present N-terminal to the DNA binding domain and the C-terminal domain which is mutated in v-Ets. Our results show that the D domain has a stronger inhibitory effect than the C-terminal sequence. The on- and off-rates of c-Ets-1 vary greatly depending on the DNA binding sequences, in contrast to those of v-Ets. The c-Ets-1 on- and off-rates are higher with a strong site than with a weak site. Our data suggest that DNA sequences help c-Ets-1 change from a closed to an open, DNA-binding-competent structure, facilitating its binding to DNA, whereas v-Ets functions without such a process presumably because its different C-terminal sequence generates a constitutively open conformation. The loss of a stringent target sequence selectivity by v-Ets suggests that it might transform cells by altering expression of tightly regulated genes with non-consensus Ets binding sites.	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,LGME,F-67085 STRASBOURG,FRANCE; FAC MED STRASBOURG,INST CHIM BIOL,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; AZIZ N, 1993, ONCOGENE, V8, P2259; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; FISHER RJ, 1991, ONCOGENE, V6, P2249; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; Forrest D, 1992, CURR OPIN GENET DEV, V2, P19, DOI 10.1016/S0959-437X(05)80316-8; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIGGS DR, 1993, CURR BIOL, V3, P548, DOI 10.1016/0960-9822(93)90054-R; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAUTENBERGER JA, 1993, J VIROL, V67, P610, DOI 10.1128/JVI.67.1.610-612.1993; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEPRINCE D, 1993, VIROLOGY, V194, P855, DOI 10.1006/viro.1993.1330; LEPRINCE D, 1992, ONCOGENE, V7, P9; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1992, ONCOGENE, V7, P597; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORGAN IM, 1993, ONCOGENE, V8, P1135; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOSIALOS G, 1993, ONCOGENE, V8, P721; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OKUNO H, 1993, ONCOGENE, V8, P695; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; POGNONEC P, 1990, ONCOGENE, V5, P603; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAKAR S, 1993, ONCOGENE, V8, P2245; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; STIEGLER P, 1993, MECH DEVELOP, V41, P163, DOI 10.1016/0925-4773(93)90046-Z; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	74	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2499	2512						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058313				2022-12-28	WOS:A1994PC05400009
J	BATSCHE, E; LIPP, M; CREMISI, C				BATSCHE, E; LIPP, M; CREMISI, C			TRANSCRIPTIONAL REPRESSION AND ACTIVATION IN THE SAME CELL-TYPE OF THE HUMAN C-MYC PROMOTER BY THE RETINOBLASTOMA GENE PROTEIN - ANTAGONISATION OF BOTH EFFECTS BY SV40 T-ANTIGEN	ONCOGENE			English	Article							ADENOVIRUS E1A PROTEINS; TRANS-ACTIVATION; SUSCEPTIBILITY GENE; RB PROTEIN; PRODUCT; E2F; BINDING; EXPRESSION; GROWTH; CYCLE	The c-myc promoter was investigated as a possible cellular target for SV40 large T (LT) antigen. In fibroblast and epithelial cell lines, the human c-myc promoter was transactivated by LT. This transactivation was dependent of the interaction of LT with the retinoblastoma (RB) protein. The use of deletions and point mutations of the c-myc promoter demonstrated that in both cell, types, the E2F binding sites are necessary for such transactivation. Unexpectedly however, over-expression of RB caused an overall transcriptional activation of the c-myc promoter. We resolved this apparent paradox by demonstrating that this activation is a combination of two antagonistic effects: transcriptional repression mediated by the E2F factor, and transcriptional activation independent of this factor. RB was also found to prevent LT-mediated transactivation, and LT inhibited RB-mediated activation independently of the E2F factor. LT therefore antagonizes both the transcriptional repression and activation mediated by RB.	INST PASTEUR,UNITE TECHNOL CELLULAIRE,F-75724 PARIS 15,FRANCE; MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Lipp, Martin/G-2235-2010	Batsche, Eric/0000-0002-5145-5270				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BORRELLI E, 1986, P NATL ACAD SCI USA, V83, P2846, DOI 10.1073/pnas.83.9.2846; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LIPP M, 1989, ONCOGENE, V4, P535; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEVINS JR, 1992, SCIENCE, V258, P424; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAFFER JD, 1990, P NATL ACAD SCI USA, V77, P5706; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG HWH, 1991, MOL CELL BIOL, V11, P288; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YU DH, 1992, J BIOL CHEM, V267, P10203; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	39	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2235	2243						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036009				2022-12-28	WOS:A1994NX62900015
J	CLARKE, AR; GLEDHILL, S; HOOPER, ML; BIRD, CC; WYLLIE, AH				CLARKE, AR; GLEDHILL, S; HOOPER, ML; BIRD, CC; WYLLIE, AH			P53 DEPENDENCE OR EARLY APOPTOTIC AND PROLIFERATIVE RESPONSES WITHIN THE MOUSE INTESTINAL EPITHELIUM FOLLOWING GAMMA-IRRADIATION	ONCOGENE			English	Article							CELL-CYCLE CHECKPOINT; WILD-TYPE P53; P53-DEFICIENT MICE; IONIZING-RADIATION; COLORECTAL-CANCER; DNA-SYNTHESIS; MUTATIONS; TUMORS; GENE; IDENTIFICATION	p53 is now well characterised as a tumour suppressor gene, with loss of normal p53 function being recorded as the commonest genetic event associated with human malignancy. In particular, its involvement with tumorigenesis within the intestine is well established. Normal p53 function has been shown to be crucial for the induction of apoptosis in tumour cell lines, murine thymocytes and murine haematopoietic cells following DNA damage. To elucidate further the role of p53 in the cellular response to DNA damage we have investigated the response to gamma-irradiation of crypt cells in vivo from the small and large intestine of mice bearing a constitutive p53 deletion. Four hours after gamma-irradiation, a time point at which wild type crypt cells show abundant apoptosis, crypt cells from p53-deficient mice differed in that they were completely resistant to the induction of apoptosis. The p53 dose dependence of this phenomenon was clearly shown by the intermediate level of apoptosis observed in p53 heterozygotes. Analysis of the mitotic index and the bromodeoxyuridine labelling index showed that two other responses of wild type crypts to gamma-irradiation, namely the G2 block and the reduction in bromodeoxyuridine incorporation, were both largely intact in p53 deficient animals. These observations demonstrate that p53 function is essential for a major component of the normal response to gamma-irradiation induced DNA damage in intestinal mucosal cells, and suggest that p53 deficiency permits a population of cells bearing DNA damage to escape the normal process of deletion.			CLARKE, AR (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				ARMITAGE P, 1987, STATISTICAL METHODS, P372; BRUGAL G, 1992, CYTOMETRY, V13, P109, DOI 10.1002/cyto.990130202; CHAWLINSKI S, 1988, CELL TISSUE KINET, V21, P317; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LALLEV A, 1993, EUR J BIOCHEM, V216, P177, DOI 10.1111/j.1432-1033.1993.tb18130.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERRITT AJ, 1994, IN PRESS CANCER RES; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; PURDIE CA, 1994, ONCOGENE, V9, P603; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SU LK, 1992, SCIENCE, V256, P688; TSUKADA T, 1993, ONCOGENE, V8, P3313; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570	41	272	272	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1767	1773						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183575				2022-12-28	WOS:A1994NL81500032
J	FUNABIKI, T; KREIDER, BL; IHLE, JN				FUNABIKI, T; KREIDER, BL; IHLE, JN			THE CARBOXYL DOMAIN OF ZINC FINGERS OF THE EVI-1 MYELOID TRANSFORMING GENE BINDS A CONSENSUS SEQUENCE OF GAAGATGAG	ONCOGENE			English	Article							DNA-BINDING; RETROVIRAL INSERTIONS; RNA GENE; EXPRESSION; PROTEIN; TRANSCRIPTION; SPECIFICITY; TRANSLOCATIONS; RECOGNITION; ACTIVATION	Inappropriate expression of the Evi-1 zinc finger gene is associated with myeloid leukemia and myelodysplastic syndromes in mice and humans and has been hypothesized to contribute to pathology by blocking myeloid differentiation. Evi-1 contains two domains of zinc fingers, an amino-terminal domain of seven fingers and a carboxyl domain of three fingers. The first domain binds a consensus sequence of GA(C/T)AAGATAAGATAA in binding and amplication reactions or GATA repeat containing regions of genomic DNA. The experiments described here, establish a consensus sequence for the carboxyl domain of zinc fingers consisting of GAAGATGAG. Unlike the first domain, the consensus sequence established for the carboxyl domain is identical to that which would be predicted by the current rules relating to C2H2 zinc fingers and DNA recognition. Substitution of sequences in finger 8 with those in finger 9, demonstrate that the individual fingers bind the predicted region of the consensus sequence. In an attempt to engineer binding of constructs containing the carboxyl domain, a variety of mutations were made in the middle finger that would be predicted to change the consensus sequence in specific ways. Remarkably, most of the mutations were deleterious and destroyed specific DNA binding. Although Evi-1 contains potential transcriptional activation domains, it was not able to activate gene transcription from CAT constructs containing the consensus sequence.	UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765, CA51020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7344; FUNABIKI T, 1993, UNPUB; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; HUPPI K, 1990, P NATL ACAD SCI USA, V87, P6964, DOI 10.1073/pnas.87.18.6964; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LEVY ER, 1994, BLOOD, V83, P1348; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MATSUGI T, 1993, UNPUB; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; OTSUKA S, 1993, UNPUB; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THUKRAL SK, 1991, P NATL ACAD SCI USA, V88, P9188, DOI 10.1073/pnas.88.20.9188; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784	28	87	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1575	1581						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183551				2022-12-28	WOS:A1994NL81500007
J	ING, YL; LEUNG, IWL; HENG, HHQ; TSUI, LC; LASSAM, NJ				ING, YL; LEUNG, IWL; HENG, HHQ; TSUI, LC; LASSAM, NJ			MLK-3 - IDENTIFICATION OF A WIDELY-EXPRESSED PROTEIN-KINASE BEARING AN SH3 DOMAIN AND A LEUCINE ZIPPER-BASIC REGION DOMAIN	ONCOGENE			English	Note							RECEPTOR TYROSINE KINASES; ENDOCRINE NEOPLASIA TYPE-1; LIGAND-BINDING SITE; CRYSTAL-STRUCTURE; MESSENGER-RNAS; DNA-BINDING; FAMILY; CHROMOSOME-11; SPECIFICITY; FEATURES	We have identified a novel protein kinase, designated MLK-3, from human thymus using RT-PCR and cDNA library screening. The deduced open reading frame, derived from sequencing a 3.5 kb MLK-3 cDNA, encodes a protein of 847 amino acids with several interesting structural features. These include an SH3 domain in the absence of an SH2 domain, a region containing two leucine zippers with an adjacent carboxy-terminal basic region, and a proline rich region. This kinase shows homology with the mixed-lineage family of protein kinases (MLK) and shares the unusual leucine zipper-basic motif found in previously identified MLK kinases. By northern analysis, MLK-3 mRNA was detected in a wide variety of normal and transformed human cell lines and tissue specimens. The gene encoding MLK-3 has been mapped using fluorescence in situ hybridization to human chromosome 11 q13.1-13.3, a region frequently altered in human malignancies.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT MED,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Tsui, Lap-chee/A-1081-2010					BALE SJ, 1989, GENOMICS, V4, P320, DOI 10.1016/0888-7543(89)90336-4; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Borson N D, 1992, PCR Methods Appl, V2, P144; CLARK SG, 1992, NATURE, V356, P87; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENG HHQ, 1993, IN PRESS METHODS MOL; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LEE ST, 1993, ONCOGENE, V8, P3403; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; MUSACCHIO A, 1992, FEBS LETT, V359, P851; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANHEECKEREN W, 1992, NUCLEIC ACIDS RES, V14, P3721; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	34	87	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1745	1750						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183572				2022-12-28	WOS:A1994NL81500029
J	WALKER, GJ; PALMER, JM; WALTERS, MK; NANCARROW, DJ; PARSONS, PG; HAYWARD, NK				WALKER, GJ; PALMER, JM; WALTERS, MK; NANCARROW, DJ; PARSONS, PG; HAYWARD, NK			REFINED LOCALIZATION OF THE MELANOMA (MLM) GENE ON CHROMOSOME 9P BY ANALYSIS OF ALLELIC DELETIONS	ONCOGENE			English	Article							LINKAGE MAP; POLYMORPHISMS; DNA	Various lines of evidence including linkage analysis, frequent homozygous and heterozygous deletions in melanoma DNAs, and the finding of a patient with multiple primary melanomas who harbours a 5p/9p translocation involving loss of several 9p markers, have indicated that the 9p22-p13 region harbours a gene important for the development of melanoma (MLM). We have used eight short tandem repeat polymorphism (STRP) markers mapping to this region to look for allelic losses in DNA from melanoma biopsies and cell lines. Heterozygous losses were found in 8/14 (57%) fresh melanoma biopsy DNAs with the smallest region of overlap (SRO) being between IFNA and D9S169. In addition, when DNA from 30 melanoma cell lines was studied, four cell lines (13%) were found to be homozygously deleted for various 9p markers. Two of these cell lines define the borders of overlapping homozygous deletions within a 4cM region of 9p21 between IFNA and D9S171. Moreover, a further 14 melanoma cell lines were hemizygous for the IFNA/ D9S171/D9S126 region. These data support the hypothesis that the MLM gene acts as a tumour suppressor, and provide a refinement of its localization on 9P.	QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,JOINT EXPTL ONCOL PROGRAM,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute			hayward, nick/AAV-8802-2020; hayward, nicholas k/C-1367-2015; Parsons, Peter G/H-8163-2015	hayward, nicholas k/0000-0003-4760-1033; Parsons, Peter G/0000-0002-0473-3346				CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; COWAN JN, 1988, J NATL CANCER I, V80, P201; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FOUNTAIN JW, 1993, HUM MOL GENET, V2, P823, DOI 10.1093/hmg/2.6.823-a; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; KWIATKOWSKI DJ, 1993, HUM MOL GENET, V8, P658; LIMON J, 1988, CANCER GENET CYTOGEN, V30, P201, DOI 10.1016/0165-4608(88)90186-0; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MCDANIEL DO, 1993, BIOTECHNIQUES, V15, P140; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; PEDERSEN MI, 1986, CANCER GENET CYTOGEN, V20, P11, DOI 10.1016/0165-4608(86)90103-2; PETTY EM, 1993, AM J HUM GENET, V53, P96; WEBER JL, 1991, GENOMICS, V11, P695, DOI 10.1016/0888-7543(91)90077-R; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILKIE PJ, 1992, GENOMICS, V12, P607, DOI 10.1016/0888-7543(92)90456-3	19	43	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					819	824						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108124				2022-12-28	WOS:A1994MW55100017
J	LI, L; WYSK, M; GONZALEZ, FA; DAVIS, RJ				LI, L; WYSK, M; GONZALEZ, FA; DAVIS, RJ			GENOMIC LOCI OF HUMAN MITOGEN-ACTIVATED PROTEIN-KINASES	ONCOGENE			English	Note							INSULIN; RAF	Mitogen-activated protein (MAP) kinases [also known as Erks] have been established to function as important mediators of signal transduction by growth factor receptors. Several components of the MAP kinase signal transduction pathway have been demonstrated to be oncogenically activated in malignant tumors. These include growth factor receptors, the GTP-binding protein Ras, and the protein kinase Raf. The genes that encode MAP kinases therefore represent potential targets of carcinogenic insults. Here, we report the genomic loci of three MAP kinase genes are widely distributed within the human genome: p41(mapk) (Erk2) at 22q11.2; p44(mapk) (Euk1) at 16p11.2; and p63(mapk) (Erk3-related) at 18q12-21.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA58396] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILE H, 1992, NATURE, V358, P414; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HEIM S, 1987, CANCER CYTOGENETICS; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SETH A, 1992, J BIOL CHEM, V267, P24796; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VERMA RS, 1989, HUMAN CHROMOSOMES; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; 1993, GENOME DATA BASE	33	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					647	649						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290275				2022-12-28	WOS:A1994MW24800033
J	MAVROTHALASSITIS, G; FISHER, RJ; SMYTH, F; WATSON, DK; PAPAS, TS				MAVROTHALASSITIS, G; FISHER, RJ; SMYTH, F; WATSON, DK; PAPAS, TS			STRUCTURAL INFERENCES OF THE ETS1 DNA-BINDING DOMAIN DETERMINED BY MUTATIONAL ANALYSIS	ONCOGENE			English	Article							GENE FAMILY; C-FOS; TRANSCRIPTION FACTORS; ONCOGENIC ACTIVITY; PROTEIN; C-ETS-1; CELLS; MOTIF; PROTOONCOGENE; SEQUENCE	The ets family of transcription factors is characterized by a conserved region that harbors the DNA-binding activity. We performed extensive deletion and mutational analyses, as well as DNA-peptide interaction studies necessary to identify the determinants of the DNA-binding activity of the ETS1 oncoprotein. We found that amino acids beyond the 85 amino acid conserved region are required in order to afford maximum DNA-binding activity in a heterologous system. Mutation throughout the binding domain can have a detrimental effect on binding activity, indicating that proper folding of the entire domain is necessary for DNA binding. A peptide, as small as 37 residues (K37N), derived from the basic region of the ETS1 binding domain, is sufficient to exhibit sequence-specific DNA recognition. Total randomization of Lysine 379, Lysine 381 and Arginine 391 within this region fails to provide functional substitutions, indicating that these specific amino acids within the basic region are required for binding. Transactivation activity of the ETS1 proteins bearing mutations was consistent with their DNA-binding activity, indicating that the primary (if not only) function of this domain is to provide sequence-specific DNA recognition activity. Our mutational analysis, as well as modeling predictions, lead us to propose a helix-turn-helix structure for the basic region of the ETS1 binding domain that is able to interact directly with DNA. We also propose that the hydrophobic alpha-helical region, surrounding tryptophan 338, is fundamental for proper protein folding and;functioning of the ets binding domain.	PROGRAM RESOURCES INC,DYNCORP,FREDERICK,MD 21701		MAVROTHALASSITIS, G (corresponding author), NCI,MOLEC ONCOL LAB,POB B,FREDERICK,MD 21702, USA.		Fisher, Robert/B-1431-2009					BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1989, J IMMUNOL, V142, P672; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FISHER RJ, 1991, ONCOGENE, V6, P2249; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Leung DW, 1989, TECHNIQUE, V1, P11; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNERT N, 1992, AM J PATHOL, V140, P119; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	35	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					425	435						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290254				2022-12-28	WOS:A1994MW24800009
J	HOEVER, M; CLEMENT, JH; WEDLICH, D; MONTENARH, M; KNOCHEL, W				HOEVER, M; CLEMENT, JH; WEDLICH, D; MONTENARH, M; KNOCHEL, W			OVEREXPRESSION OF WILD-TYPE P53 INTERFERES WITH NORMAL DEVELOPMENT IN XENOPUS-LAEVIS EMBRYOS	ONCOGENE			English	Article							TISSUE-SPECIFIC EXPRESSION; CELL-CYCLE CONTROL; PROTO-ONCOGENE; INSITU HYBRIDIZATION; MOUSE EMBRYOGENESIS; MESSENGER-RNAS; ANTIGEN; LOCALIZATION; EF-1-ALPHA; TRANSITION	We have cloned and sequenced a Xenopus p53 homologue which differs by one amino acid deletion from a previously published Xenopus sequence (Soussi et al., 1987). Transcription analysis revealed that this gene is activated during early oogenesis and that zygotic transcription initiates after midblastula transition. Transcripts are also present in all tested tissues of adult animals. Whole mount in situ hybridization with Xenopus oocytes and embryos revealed, that transcripts are ubiquitously distributed although some accumulation is observed in certain tissues. Microinjection of p53 mRNA into early cleavage stages effectively resulted in overexpression of p53 protein and interfered with normal development. Lethal defects until and during gastrulation and aberrant phenotypes of surviving embryos were probably caused by cleavage arrest or cleavage delay of injected cells with subsequent distortions of cell movements, induction processes and tissue differentiations.	UNIV ULM, BIOCHEM ABT, D-89069 ULM, GERMANY; UNIV SAARLAND, D-66421 HOMBURG, GERMANY	Ulm University; Saarland University			Montenarh, Mathias/AAB-6689-2020	Clement, Joachim H./0000-0002-6601-2456				BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; KASTAN MB, 1991, CANCER RES, V51, P4279; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOHUN TJ, 1989, DEVELOPMENT, V107, P835; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; POTING A, 1990, DIFFERENTIATION, V44, P103; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, CANCER RES, V51, P5232; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; VIZE PD, 1990, DEVELOPMENT, V110, P885; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	41	52	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					109	120						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302570				2022-12-28	WOS:A1994MW24700014
J	SENECA, S; PUNYAMMALEE, B; SUREAU, A; PERBAL, B; DVORAK, M; CRABEEL, M				SENECA, S; PUNYAMMALEE, B; SUREAU, A; PERBAL, B; DVORAK, M; CRABEEL, M			THE CARBOXY-TERMINAL DOMAIN OF C-MYB ACTIVATES REPORTER GENE-EXPRESSION IN YEAST	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; V-MYB; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; FUNCTIONAL DOMAINS; ONCOGENE PRODUCT; SPLICING FACTOR; CELLS; PROTOONCOGENE	We have shown previously that c-myb expressed in the yeast S. cerevisiae mediated efficient transcriptional activation of reporter genes designed with specific Myb Recognition Elements (MRE's), confirming that this proto-oncogene is able to function as a regulator of transcription in that heterologous context. Here we show that in yeast, as in higher eucaryotic cells, the central domain of c-Myb displays transactivating capacity. In yeast, however, the carboxy-terminal region, defined as a negative regulatory domain in higher cells, activates transcription as well and appears to be a more potent transactivating domain than the central domain itself. Within this region two domains, namely C1 and C2, have been defined that contribute about equally to the activity of the carboxy-terminal region. C1 spans the sequences missing in AMV v-myb while C2, which contains the leucine-zipper motif is specifically absent in the E26 v-myb in addition to C1. The c-Myb DNA-binding domain itself has no effect on the level of transcription in yeast. We also show that AMV v-Myb stimulates gene expression in yeast with about half the efficiency of full length c-Myb. The fact that the carboxy-terminal region either stimulates or inhibits transactivation properties of c-Myb, depending on the cellular context, stresses the participation of putative c-Myb partner proteins in Myb regulated processes and reopens the question of whether the oncogenic activation of c-myb is indeed due to the increased transactivation capacity of its onco derivatives.	INST CURIE, ONCOL VIRALE & MOLEC LAB, F-91405 ORSAY, FRANCE; CZECHOSLOVAK ACAD SCI, INST MOLEC GENET, CS-16637 PRAGUE 6, CZECHOSLOVAKIA; UNIV PARIS 07, UFR BIOCHIM, F-75221 PARIS 05, FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; UDICE-French Research Universities; Universite Paris Cite	SENECA, S (corresponding author), VRIJE UNIV BRUSSELS, RES INST CERIA COOVI, 1 E GRYSONLANE, B-1070 BRUSSELS, BELGIUM.		Dvorak, Michal/G-5861-2014; Dvořák, Michal/I-9939-2014; Sureau, Alain/M-1998-2017	Sureau, Alain/0000-0003-1523-0207; Seneca, Sara/0000-0002-0853-9890				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARTUNEK P, 1992, VIROLOGY, V190, P882, DOI 10.1016/0042-6822(92)90930-N; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Broach J. R., 1983, EXPT MANIPULATION GE, P83; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JONES RH, 1988, CELL, V53, P659, DOI 10.1016/0092-8674(88)90581-8; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAURENT BC, 1992, IN PRESS GENES DEV; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PERBAL B, 1986, BIOCHIMIE, V68, P969, DOI 10.1016/S0300-9084(86)80040-2; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; RAMSAY RG, 1991, ONCOGENE, V6, P1875; ROSSON D, 1990, VIROLOGY, V175, P562, DOI 10.1016/0042-6822(90)90441-S; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SENECA S, 1991, ONCOGENE, V6, P357; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; VELLARD M, 1991, ONCOGENE, V6, P505; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	43	10	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2335	2342						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361752				2022-12-28	WOS:A1993LT36800003
J	FOOS, G; GRIMM, S; KLEMPNAUER, KH				FOOS, G; GRIMM, S; KLEMPNAUER, KH			THE CHICKEN A-MYB PROTEIN IS A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Article							DNA-BINDING DOMAIN; ONCOGENE C-MYB; V-MYB; B-MYB; MIM-1 GENE; TRANS-ACTIVATION; CDNA CLONES; EXPRESSION; DIFFERENTIATION; SEQUENCE	c-myb encodes a trans-activator that is essential for the proliferation of most hematopoietic precursor cells but lacks a major role in non-hematopoietic cells. The recent identification of two myb-related genes (A-myb and B-myb) in several vertebrate species has raised the possibility that these genes perform c-myb like functions in non-hematopoietic cells. Here, we report the isolation and preliminary characterization of the chicken A-myb gene. Like other members of the myb family, the A-myb protein contains an N-terminally located repeat domain that is highly homologous to the DNA-binding domain of the c-myb protein. Unlike c-myb, A-myb is expressed in fibroblasts, suggesting that it functions in non-hematopoietic cells. We demonstrate that A-myb transactivates myb-responsive reporter genes. Furthermore, when stably expressed in a chicken macrophage cell line, A-myb causes activation of several myb-inducible endogenous genes. These findings show that A-myb encodes a transactivating member of the myb family whose functional properties resemble those of the c-myb and v-myb proteins. Thus, our results support the idea that A-myb is a functional equivalent of c-myb.	MAX PLANCK INST IMMUNBIOL,HANS SPERMANN LAB,D-79108 FREIBURG,GERMANY	Max Planck Society								BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAM EWF, 1992, ONCOGENE, V7, P1885; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; QUEVA C, 1992, DEVELOPMENT, V114, P125; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3173; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	52	40	41	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2481	2488						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058311				2022-12-28	WOS:A1994PC05400007
J	MULERIS, M; ALMEIDA, A; DUTRILLAUX, AM; PRUCHON, E; VEGA, F; DELATTRE, JY; POISSON, M; MALFOY, B; DUTRILLAUX, B				MULERIS, M; ALMEIDA, A; DUTRILLAUX, AM; PRUCHON, E; VEGA, F; DELATTRE, JY; POISSON, M; MALFOY, B; DUTRILLAUX, B			ONCOGENE AMPLIFICATION IN HUMAN GLIOMAS - A MOLECULAR CYTOGENETIC ANALYSIS	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; MALIGNANT HUMAN GLIOMAS; COMPARATIVE GENOMIC HYBRIDIZATION; CENTRAL-NERVOUS-SYSTEM; GENE AMPLIFICATION; CHROMOSOMAL-ABNORMALITIES; HUMAN GLIOBLASTOMA; DNA-AMPLIFICATION; SOLID TUMORS; CELL-LINES	Nine cases of malignant gliomas were selected for the presence of double minutes (dmin) or homogeneously staining regions (hsr) detected by conventional cytogenetics. Analyses were performed on fresh (2 cases) or xenografted (5 cases) tumors or both (2 cases). A modified comparative genomic hybridization technique (mCGH) was applied exhibiting a single amplified locus in 8 tumors and 4 amplified loci in one tumor. Recurrent sites of amplification were detected in 7p11-p12 (5 cases) and 1q32.1 (2 cases). Signals were also observed in 4q11-q12, 5p15.1, 7q31, 8q24.1 and 9p2 in one tumor each. Southern blotting demonstrated that the genes for EGFR (epidermal growth factor receptor), PDGFRA (platelet derived growth factor receptor alpha), MET and MYC oncogenes were involved in 7p11-p12, 4q11-q12, 7q31 and 8q24.1 amplifications, respectively. These amplifications were found by ill situ hybridization on tumor spreads, in dmin or episomes for EGFR, dmin for PDGFRA and MET, and hsr and dmin for MYC genes. Other mCGH signals, for which no target genes could be proposed, were confirmed by chromosome paintings on tumor metaphases. In one of the tumors, the coamplification of DNA from 5p15.1 and 9p2 bands in the same dmin was demonstrated.	CEA,DSV DPTE LCG,F-92265 FONTENAY ROSES,FRANCE; HOP LA PITIE SALPETRIERE,PARIS,FRANCE	CEA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	MULERIS, M (corresponding author), INST CURIE,CNRS,BIOL SECT,URA 620,26 RUE ULM,F-75231 PARIS 05,FRANCE.							ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; Bigner SH, 1990, BRAIN PATHOL, V1, P12, DOI 10.1111/j.1750-3639.1990.tb00633.x; BIGNER SH, 1990, CANCER RES, V50, P8017; BIGNER SH, 1988, CANCER RES, V48, P405; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; BIGNER SH, 1989, CANCER GENET CYTOGEN, V40, P111, DOI 10.1016/0165-4608(89)90152-0; BIGNER SH, 1988, ISI ATLAS-BIOCHEM, V1, P333; BIGNER SH, 1987, CANCER GENET CYTOGEN, V29, P165, DOI 10.1016/0165-4608(87)90045-8; BIGNER SH, 1984, HEREDITAS, V101, P103, DOI 10.1111/j.1601-5223.1984.tb00455.x; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COLLINS VP, 1993, SEMIN CANCER BIOL, V4, P27; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CUTICCHIA AJ, 1993, GENOME PRIORITY REPO, V1; DIRENZO MF, 1993, ONCOGENE, V8, P219; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; FATH I, 1993, NUCLEIC ACIDS RES, V21, P4398, DOI 10.1093/nar/21.18.4398; FLEMING TP, 1992, CANCER RES, V52, P4550; FULLER GN, 1992, MUTAT RES, V276, P299, DOI 10.1016/0165-1110(92)90016-3; HUMPHREY PA, 1988, CANCER RES, V48, P2231; JENKINS EP, 1991, GENOMICS, V11, P1102, DOI 10.1016/0888-7543(91)90038-G; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; JOOS S, 1993, HUM GENET, V90, P584, DOI 10.1007/BF00202475; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI OP, 1993, SEMIN CANCER BIOL, V4, P41; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KUMABE T, 1992, ONCOGENE, V7, P627; LEFRANCOIS D, 1989, INT J CANCER, V44, P871, DOI 10.1002/ijc.2910440521; MULERIS AM, IN PRESS GENES CHROM; MULERIS M, 1994, CYTOGENET CELL GENET, V65, P82, DOI 10.1159/000133605; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; PRUCHON E, IN PRESS CANCER GENE; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SPEICHER MR, 1993, HUM MOL GENET, V2, P1907; THIEL G, 1992, CANCER GENET CYTOGEN, V58, P109, DOI 10.1016/0165-4608(92)90095-P; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; WAHL GM, 1989, CANCER RES, V49, P1333; WELTER C, 1990, CANCER LETT, V52, P57, DOI 10.1016/0304-3835(90)90077-B; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WULCH KJ, 1979, INT HISTOLOGICAL CLA, V21; WULLICH B, 1993, EUR J CANCER, V29A, P1991, DOI 10.1016/0959-8049(93)90460-W; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0	43	81	81	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2717	2722						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058336				2022-12-28	WOS:A1994PC05400033
J	SARGIACOMO, M; SCHERER, PE; TANG, ZL; CASANOVA, JE; LISANTI, MP				SARGIACOMO, M; SCHERER, PE; TANG, ZL; CASANOVA, JE; LISANTI, MP			IN-VITRO PHOSPHORYLATION OF CAVEOLIN-RICH MEMBRANE DOMAINS - IDENTIFICATION OF AN ASSOCIATED SERINE KINASE-ACTIVITY AS A CASEIN KINASE II-LIKE ENZYME	ONCOGENE			English	Article							TRANS-GOLGI-NETWORK; ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; GROWTH-FACTOR; CELL-SURFACE; 3T3-L1 CELLS; INSULIN; PROTEIN; BINDING; DIFFERENTIATION	Caveolae are flask-shaped micro-invaginations associated with the plasma membrane of a wide variety of cell types. Caveolin, an integral membrane component of caveolae, was first identified as the major phosphoprotein whose phosphorylation was elevated in v-Src transformed cells. As both v-Src transformation and elevated caveolin phosphorylation were dependent on membrane attachment of v-Src, it has been suggested that caveolin is a critical target in v-Src transformation. Although an increase in tyrosine phosphorylation of caveolin was evident, the increase in caveolin phosphorylation was predominantly on serine residues. In accordance with these in vivo observations, isolated caveolin-rich membrane domains undergo phosphorylation in vitro predominantly on serine and contain an unidentified serine kinase activity. Here, we have identified this serine kinase activity as a casein kinase II-like enzyme, since the phosphorylation of caveolin-rich membrane domains is stimulated and inhibited by known effecters of casein kinase II (poly-L-lysine, endogenous polyamines, and a casein kinase II inhibitor peptide), but is unaffected by modulators of other known kinases. In support of these observations, caveolin contains a consensus sequence for casein kinase II phosphorylation in its cytoplasmic N-terminal domain (Ser-88). A peptide containing this sequence inhibits the in vitro phosphorylation of caveolin-rich membrane domains, while many other peptides derived from the N-terminal domain of caveolin do not affect phosphorylation. Caveolin-rich membrane domains were also a substrate for exogenously added purified casein kinase II, but not casein kinase I. Finally, immunoblotting of these domains with an antibody directed against the alpha and alpha' subunits of casein kinase II reveals two bands with apparent molecular weights consistent with the known molecular weights of the alpha and alpha' subunits of casein kinase II. As casein kinase II appears to play a role in mitogenic signalling events and casein kinase II activators (endogenous polyamines) are required for v-Src transformation, our results may have implications for understanding the mechanism of v-Src oncogenesis.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MASSACHUSETTS GEN HOSP E,DEPT PEDIAT GASTROENTEROL,DIV MUCOSAL IMMUNOL,BOSTON,MA 02129	Massachusetts Institute of Technology (MIT); Whitehead Institute			Lisanti, Michael P/C-6866-2013; Scherer, Philipp E/K-7819-2012; Lisanti, Michael/B-6131-2018	Scherer, Philipp E/0000-0003-0680-3392; Lisanti, Michael/0000-0003-2034-1382; Sargiacomo, Massimo/0000-0003-4040-706X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047618, R37DK047618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47618] Funding Source: Medline; NIGMS NIH HHS [GM-50443, GM-49516] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FAN JY, 1983, J CELL SCI, V61, P219; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MCDONALD OB, 1991, J BIOL CHEM, V266, P21773; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SEVERS NJ, 1988, J CELL SCI, V90, P341; SMART EJ, 1993, J CELL BIOL, V124, P307; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TELLEZ R, 1992, FEBS LETT, V308, P113, DOI 10.1016/0014-5793(92)81255-K; TRAVIS J, 1993, SCIENCE, V262, P1208, DOI 10.1126/science.8235646; VILLAMORUZZI E, 1991, BIOCHEM BIOPH RES CO, V177, P1019, DOI 10.1016/0006-291X(91)90640-S	36	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2589	2595						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058322				2022-12-28	WOS:A1994PC05400018
J	WIEST, JS; BURNETT, VL; ANDERSON, MW; REYNOLDS, SH				WIEST, JS; BURNETT, VL; ANDERSON, MW; REYNOLDS, SH			A NOVEL MECHANISM OF IN-VIVO RAS GENE ACTIVATION INVOLVING TANDEM DUPLICATION OF CODING SEQUENCES	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; P21 TRANSFORMING PROTEIN; POINT MUTATION; GTP HYDROLYSIS; HAMSTER-CELLS; APRT LOCUS; K-RAS; ONCOGENE; MOUSE; DNA	A series of weakly transforming c-K-ras genes have been detected in spontaneously occurring and chemically induced mouse adenomas. DNA sequence analysis of these weakly transforming ras oncogenes showed that activation occurred by a novel mechanism involving duplication of nine or ten codon segments flanking codon 61 in exon 2. The codon repetitions in exon 2 are directly preceded by a number of potentially recombinogenic DNA sequences which may have been involved in the genesis of the codon repetitions through mechanisms involving recombination or DNA slippage. Duplication of DNA sequences such as those observed in the mouse c-K-ras gene may represent a new mechanism for both tumor suppressor gene inactivation and proto-oncogene activation.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	WIEST, JS (corresponding author), NIEHS,MOLEC TOXICOL LAB,RES TRIANGLE PK,NC 27709, USA.							BARACID M, 1987, AM REV BIOCH, V56, P779; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHIPPERFIELD RG, 1985, MOL CELL BIOL, V5, P1809, DOI 10.1128/MCB.5.8.1809; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; ELLIS RW, 1982, MOL CELL BIOL, V2, P1339, DOI 10.1128/MCB.2.11.1339; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HIGINBOTHAM KG, 1992, MOL CARCINOGEN, V5, P136, DOI 10.1002/mc.2940050209; HIGINBOTHAM KG, 1994, UNPUB; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JEFFREYS AJ, 1987, NUCLEIC ACIDS RES, V15, P2823, DOI 10.1093/nar/15.7.2823; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; NALBANTOGLU J, 1988, J MOL BIOL, V200, P449, DOI 10.1016/0022-2836(88)90535-9; NALBANTOGLU J, 1987, MOL CELL BIOL, V7, P1445, DOI 10.1128/MCB.7.4.1445; ORITA S, 1991, VIRUS GENES, V5, P75, DOI 10.1007/BF00571733; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATEL G, 1992, ONCOGENE, V7, P283; PICOLLI SP, 1984, NATURE, V310, P327; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; SHIH TY, 1979, VIROLOGY, V93, P64; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SLOAN SR, 1990, MOL CELL BIOL, V10, P405, DOI 10.1128/MCB.10.1.405; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	39	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2449	2454						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058307				2022-12-28	WOS:A1994PC05400003
J	KEEN, AJ; KNOWLES, MA				KEEN, AJ; KNOWLES, MA			DEFINITION OF 2 REGIONS OF DELETION ON CHROMOSOME-9 IN CARCINOMA OF THE BLADDER	ONCOGENE			English	Article							TRANSITIONAL-CELL-CARCINOMA; ALLELIC LOSSES; CANCER; GENE; MELANOMA; LOCALIZATION; INTERFERON; AMPLIFICATION; PROGRESSION; ASSIGNMENT	Loss of heterozygosity (LOH) at loci on chromosome 9 can be detected in more than 50% of bladder tumours, suggesting the presence on this chromosome of one or more suppressor genes for bladder carcinogenesis, Localisation of the target gene(s) by deletion mapping has previously proved difficult due to the uneven distribution of polymorphic loci and the finding of LOH at all these loci in the majority of tumours. We have used a panel of 22 highly informative microsatellite markers, evenly distributed along chromosome 9 to analyse LOH in 95 cases of primary transitional cell carcinoma of the bladder. Forty nine tumours (53%) showed LOH at one or more loci. Of these, 30 had LOH at all informative loci, indicating probable monosomy 9. Nineteen tumours (22%) had subchromosomal deletions, 5 of 9p only, 9 of 9q only and 5 of both 9p and 9q with a clear region of retention of heterozygosity between. The patterns of LOH in these tumours indicated a common region of deletion on 9p between D9S126 (9p21) and IFNA (9p21). A single tumour showed a second site of deletion on 9p telomeric to IFNA indicating the possible existence of 2 target genes on 9p. All deletions of 9q were large, with a common region of deletion between D9S15 (9q13-q21.1) and D9S60 (9q33-q34.1), These results indicate a much higher frequency of subchromosomal deletion than has previously been detected and provide evidence for the simultaneous involvement of distinct suppressor loci on 9p and 9q in bladder carcinoma.	MARIE CURIE RES INST,MOLEC GENET LAB,OXTED RH8 0TL,SURREY,ENGLAND					Knowles, Margaret/0000-0002-9363-8657				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BERNUES M, 1993, CANCER GENET CYTOGEN, V69, P76, DOI 10.1016/0165-4608(93)90120-B; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1993, CANCER RES, V53, P1230; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; FOSS KB, 1992, CYTOGENET CELL GENET, V60, P22, DOI 10.1159/000133286; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GIBAS Z, 1984, CANCER RES, V44, P1257; GULCHER JR, 1990, GENOMICS, V6, P616, DOI 10.1016/0888-7543(90)90495-G; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HUEBNER K, 1992, GENOMICS, V14, P220, DOI 10.1016/S0888-7543(05)80209-5; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAMES CD, 1991, CANCER RES, V51, P1684; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAO CH, 1993, GENE CHROMOSOME CANC, V8, P155, DOI 10.1002/gcc.2870080304; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KWIATKOWSKI DJ, 1988, AM J HUM GENET, V42, P565; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, CANCER RES, V52, P2523; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RUPPERT JM, 1993, CANCER RES, V53, P5093; SANDBERG AA, 1986, CANCER GENET CYTOGEN, V19, P335, DOI 10.1016/0165-4608(86)90063-4; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SUNG LA, 1992, J BIOL CHEM, V267, P2616; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSAI YC, 1990, CANCER RES, V50, P44; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; 1973, HISTOLOGICAL CLASSIF, V10; 1978, INT UNION CANCER	42	117	117	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2083	2088						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208555				2022-12-28	WOS:A1994NR68500035
J	LEGROS, Y; LAFON, C; SOUSSI, T				LEGROS, Y; LAFON, C; SOUSSI, T			LINEAR ANTIGENIC SITES DEFINED BY THE B-CELL RESPONSE TO HUMAN P53 ARE LOCALIZED PREDOMINANTLY IN THE AMINO AND CARBOXY-TERMINI OF THE PROTEIN	ONCOGENE			English	Note							TUMOR SUPPRESSOR GENE; LARGE T-ANTIGEN; MONOCLONAL-ANTIBODIES; BREAST-CANCER; ESCHERICHIA-COLI; IMMUNE-RESPONSE; LUNG-CANCER; MUTATIONS; EXPRESSION; CONFORMATION	Using a set of overlapping peptides of the human p53 protein, we analysed the epitopes recognized by 18 monoclonal antibodies specific far human p53. We showed that most of these epitopes correspond to linear antigenic determinants which lie predominantly in the amino- or carboxy-terminus of the p53 protein. Using either truncated p53 or the set of human p53 peptides, we directly analysed the sera of animals immunized with human p53, These sera contained antibodies which also recognized the regions corresponding to the extremity of the p53 protein. These p53 regions were similar to those recognized by p53-specific antibodies present in sera of patients with cancer. Preferential recognition of these regions by antibodies specific for non conformational epitopes suggested that these regions are localized at the surface of the p53 protein as unfolded structures.	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; ESTBA,F-75020 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				soussi, thierry/0000-0001-8184-3293				BAKER SJ, 1990, CANCER RES, V50, P7717; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; DEFROMENTEL CC, 1987, INT J CANCER, V39, P185, DOI 10.1002/ijc.2910390211; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GILLET D, 1992, PROTEIN ENG, V5, P273, DOI 10.1093/protein/5.3.273; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAINAUT P, 1993, CANCER RES, V53, P1739; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JONVEAUX P, 1991, ONCOGENE, V6, P2243; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; LEGROS Y, 1993, B CANCER, V80, P102; LUBIN R, 1993, CANCER RES, V53, P5872; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MAZARS R, 1991, ONCOGENE, V6, P1685; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLER CW, 1990, CANCER RES, V50, P7950; PROSSER J, 1990, ONCOGENE, V5, P1573; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WINTER SF, 1992, CANCER RES, V52, P4168; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	39	67	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2071	2076						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208553				2022-12-28	WOS:A1994NR68500033
J	RODRIGUES, GA; PARK, M				RODRIGUES, GA; PARK, M			AUTOPHOSPHORYLATION MODULATES THE KINASE-ACTIVITY AND ONCOGENIC POTENTIAL OF THE MET RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; ATP-BINDING-SITE; FUJINAMI SARCOMA-VIRUS; INSULIN-RECEPTOR; BETA-SUBUNIT; PROTEIN-KINASE; EGF-RECEPTOR; PHOSPHORYLATION SITE; SIGNAL TRANSDUCTION	The met oncogene is activated by a genomic rearrangement that generates a hybrid protein containing tpr sequences at its amino terminus fused directly to the met (hepatocyte growth factor/scatter factor) receptor tyrosine kinase domain. The resultant p65(Tpr-Met) hybrid protein possesses tyrosine kinase activity and is constitutively phosphorylated on tyrosine in vivo. A substitution of the conserved lysine in the catalytic domain abolished kinase activity and the transforming potential of Tpr-Met demonstrating the requirement for kinase activity for transformation. To study the role of autophosphorylation at particular tyrosine residues on the transforming activity of Tpr-Met, the major autophosphorylation sites were identified by two dimensional phosphopeptide mapping. Two tyrosine residues in the catalytic domain, tyrosine 365 and tyrosine 366, were found to be the major autophosphorylation sites both in vitro and in vivo. Mutation of these sites singly or together modulates the biochemical and biological properties of Tpr-Met. Compared with the wild-type Tpr-Met, mutants have a reduced in vitro kinase activity when measured by levels of autophosphorylation and by their ability to phosphorylate an exogenous substrate and have little or no transforming activity. These results indicate that autophosphorylation at critical tyrosine residues is required for activation of the kinase activity of Tpr-Met and for cell transformation by this oncogene.	MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT ONCOL, MOLEC ONCOL GRP, MONTREAL H3A 1A1, PQ, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT MED, MONTREAL H3A 1A1, PQ, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MONTREAL H3A 1A1, PQ, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital								ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kriegler M., 1990, GENE TRANSFER EXPRES; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MECKLINGHANSEN K, 1987, EMBO J, V6, P659, DOI 10.1002/j.1460-2075.1987.tb04805.x; MITRA G, 1991, ONCOGENE, V6, P2237; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RODRIGUES GA, 1993, HEPATOCYTE GROWTH FA, P167; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI N, 1985, J BIOL CHEM, V260, P9793; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YU KT, 1984, J BIOL CHEM, V259, P5277; YU KT, 1986, J BIOL CHEM, V261, P1341; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHO H, 1994, CELL GROWTH DIFFER, V5, P1	64	96	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2019	2027						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208547				2022-12-28	WOS:A1994NR68500026
J	LEBRUN, DP; CLEARY, ML				LEBRUN, DP; CLEARY, ML			FUSION WITH E2A ALTERS THE TRANSCRIPTIONAL PROPERTIES OF THE HOMEODOMAIN PROTEIN PBX1 IN T(119) LEUKEMIAS	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GLUTATHIONE-S-TRANSFERASE; HUMAN PROTOONCOGENE PBX1; LOOP-HELIX PROTEINS; DNA-BINDING; MAMMALIAN-CELLS; PRE-B; CHROMOSOMAL TRANSLOCATIONS; ENHANCER BINDING; GENE	The t(1;19) chromosomal translocation is observed in pre-B cell acute lymphoblastic leukemias and results in expression of chimeric E2A-PBX1 proteins that contain transcriptional activation domains from E2A and the homeodomain of PBX1. Since homeodomains mediate DNA-binding, a potential model for the action of E2A-PBX1 is that it disrupts the transcriptional regulation of genes normally controlled by PBX1 or its closely-related family members PBX2 or PBX3. Using a binding site selection assay, we identified a consensus nucleotide sequence ATCAATCA specifically bound by the PBX1 homeodomain and those of its closely-related family members PBX2 and PBX3. An endogenous protein with the properties of PBX3b specifically bound to this sequence in nuclear extracts of precursor B cells. Transfection of reporter genes containing PBX binding sites linked to a minimal promoter demonstrated transactivation by E2A-PBX1 fusion protein dependent upon presence of the homeodomain. In contrast, wild-type PBX proteins were incapable of activating transcription. The striking differences in transcriptional properties of fusion and wild-type PBX proteins,provides strong functional evidence for the importance of aberrant transcriptional regulation in the genesis of t(l;19)-bearing leukemias.			LEBRUN, DP (corresponding author), STANFORD UNIV,MED CTR,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305, USA.				NCI NIH HHS [CA42971] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BURGLIN TR, 1992, NAT GENET, V1, P319, DOI 10.1038/ng0892-319; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CRIST WM, 1990, BLOOD, V76, P117; DOLAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1088, P155, DOI 10.1016/0167-4781(91)90051-M; FAINSOD A, 1991, NUCLEIC ACIDS RES, V19, P4005, DOI 10.1093/nar/19.14.4005; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; WEISS MJ, 1988, J BIOL CHEM, V263, P12002; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3	31	82	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1641	1647						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183558				2022-12-28	WOS:A1994NL81500015
J	SELVAKUMARAN, M; LIN, HK; MIYASHITA, T; WANG, HG; KRAJEWSKI, S; REED, JC; HOFFMAN, B; LIEBERMANN, D				SELVAKUMARAN, M; LIN, HK; MIYASHITA, T; WANG, HG; KRAJEWSKI, S; REED, JC; HOFFMAN, B; LIEBERMANN, D			IMMEDIATE-EARLY UP-REGULATION OF BAX EXPRESSION BY P53 BUT NOT TGF-BETA-1 - A PARADIGM FOR DISTINCT APOPTOTIC PATHWAYS	ONCOGENE			English	Article							LEUKEMIA INHIBITORY FACTOR; WILD-TYPE P53; CELL-CYCLE CHECKPOINT; GROWTH-ARREST; TERMINAL DIFFERENTIATION; C-MYC; BCL-2 GENE; EARLY RESPONSE; MYELOID CELLS; DEATH	Recently, both Bcl-2, which promotes cell survival, and Bax, which promotes cell death, have been implicated as major players in the control of apoptotic pathways, and it has been suggested that the ratio of Bcl-2 and Bax protein controls the relative susceptibility of cells to death stimuli. We have used M1 myeloid leukemia cells and genetically engineered M1 variants as a model system to study apoptosis induced by two distinct apoptotic stimuli. This includes apoptosis induced by activation of wild type p53 function of a temperature sensitive p53 transgene expressed in M1 cells, which do not express endogenous p53, and apoptosis induced by TGF beta 1. It is shown that the kinetics of apoptosis induced by p53 is more rapid than apoptosis induced by TGF beta 1. It is also shown that ectopic expression of Bcl-2, at levels which blocked TGF beta 1-induced apoptosis of M1 cells, delayed, but did not block, p53-induced apoptosis. Both p53 and TGF beta 1 down-regulated endogenous Bcl-2 expression, but only p53 up-regulated Bax expression, where bax has been identified as a p53 immediate early response gene. Thus, the p53-mediated up-regulation of Bax may provide at least a partial explanation for the more rapid rate of apoptosis induced by p53 compared to by TGF beta 1, as well as for the ineffectiveness of ectopic Bcl-2 to abrogate p53-mediated apoptosis. These findings provide first insights to the molecular mechanisms which mediate p53-induced apoptosis, identifying bax and bcl-2 as p53 regulated genes, and serve as a paradigm of how the intracellular balance of Bcl-2 to Bax is differentially altered by distinct death stimuli.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; LA JOLLA CANC RES FDN, CANC RES CTR, ONCOGENE & TUMOR SUPPRESSOR GENE PROGRAM, LA JOLLA, CA 92037 USA; UNIV PENN, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Sanford Burnham Prebys Medical Discovery Institute; University of Pennsylvania			Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NATIONAL CANCER INSTITUTE [R01CA043618, R01CA060181, R01CA051162] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA43618, CA-60181, 1RO1CA51162] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUVEN T, 1993, ONCOGENE, V8, P3411; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KITADA S, 1992, BLOOD, V80, P879; KORSMEYER SJ, 1992, CELL, V71, P587; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; LOTEM J, 1990, BLOOD, V76, P1315; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; QUESENBERRY PJ, 1990, HEMATOLOGY, P129; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REISS M, 1993, CANCER RES, V53, P899; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG YS, 1993, ONCOGENE, V8, P3427; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	58	537	552	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1791	1798						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183578				2022-12-28	WOS:A1994NL81500035
J	NEGISHI, Y; NISHITA, Y; SAEGUSA, Y; KAKIZAKI, I; GALLI, I; KIHARA, F; TAMAI, K; MIYAJIMA, N; IGUCHIARIGA, SMM; ARIGA, H				NEGISHI, Y; NISHITA, Y; SAEGUSA, Y; KAKIZAKI, I; GALLI, I; KIHARA, F; TAMAI, K; MIYAJIMA, N; IGUCHIARIGA, SMM; ARIGA, H			IDENTIFICATION AND CDNA CLONING OF SINGLE-STRANDED-DNA BINDING-PROTEINS THAT INTERACT WITH THE REGION UPSTREAM OF THE HUMAN C-MYC GENE	ONCOGENE			English	Article							TRANSCRIPTIONAL ENHANCER; SACCHAROMYCES-CEREVISIAE; GEL-ELECTROPHORESIS; REPLICATION ORIGIN; MESSENGER-RNA; SEQUENCES; PROMOTER; ELEMENT; NUCLEAR; INITIATION	We have previously reported that a c-myc protein complex binds to the region upstream of the c-myc gene, where exist an origin of cellular DNA replication (ori) and a transcriptional enhancer. Both functions require a 21 bp long sequence, while the c-myc protein complex recognizes a 7 bp consensus therein. It was recently reported that single-stranded DNA binding proteins bound specifically to sequences that play roles in DNA replication or transcription. We examined for proteins binding to the single-stranded DNAs of the 21 bp element (myc(H-P)21). In a band shift assay with HL60 cells nuclear extract, probes of either the plus strand or the minus strand gave rise to specific signals. Mutation introduced within a short consensus (A/(T)CT(A)/T(A)/(T)T) present in both strands completely abolished binding in either case. Southwestern blotting analysis showed that proteins of molecular weight 105, 80, 50, 45, 40, 39.5 and 14 kDa bound sequence-specifically to either strand and 22 kDa to minus strand to the cognate A/(T)CT(A)/(T)A/(T)T consensus. These single-stranded DNA binding proteins were named MSSP, c-myc gene single strand binding proteins. We attempted to isolate the cDNAs encoding these proteins by screening a human cDNA library with the plus single-stranded oligonucleotide as a probe. Among several positive clones, we have characterized one, termed MSSP-1. MSSP-1 produced in E. coli as a fusion protein with GST specifically interacted with single-stranded TCTTAT (plus myc(H-P)21) and ACT-ATT (in minus myc(H-P)21), the consensus of which can be referred to as A/(T)CT(A)/T(A)/(T)T. Sequence analysis of MSSP-1 cDNA revealed that two domains thereof are homologous to the RNA binding motifs common to several ribonucleoproteins. Interestingly, the MSSP-1/GST fusion protein specifically recognized myc(H-P)21 not only in single-stranded but also in double-stranded forms. Binding properties of MSSP-1 imply its functions in DNA replication. Furthermore, when the AT stretch in the SV40 ori core was substituted by TCTTAT, MSSP-1 promoted viral DNA replication depending on the consensus sequences.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,KITA 12 NISHI 6,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; MBL CO LTD,INA LABS,INA 396,JAPAN; INST PHYS & CHEM RES,TSUKUBA,IBARAKI 305,JAPAN; HOKKAIDO UNIV,COLL MED TECHNOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; RIKEN; Hokkaido University			Kakizaki, Ikuko/AAO-5489-2020; Ariga, Hiroyoshi/B-5895-2013; Tamai, Katsuyuki/F-4743-2013	Kakizaki, Ikuko/0000-0002-6702-5830; Ariga, Hiroyoshi/0000-0001-7384-2143; Tamai, Katsuyuki/0000-0003-4094-3911				ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; FINOCCHIARO LME, 1991, NUCLEIC ACIDS RES, V19, P4279, DOI 10.1093/nar/19.15.4279; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6501; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GALLI I, 1992, NUCLEIC ACIDS RES, V20, P3333, DOI 10.1093/nar/20.13.3333; GALLI I, 1993, FEBS LETT, V318, P335, DOI 10.1016/0014-5793(93)80541-2; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4471; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOFFMANN J, 1991, CELL, V64, P951; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KITAURA H, 1991, FEBS LETT, V289, P1; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KUMANO M, 1992, FEBS LETT, V309, P146, DOI 10.1016/0014-5793(92)81083-X; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; NEGISHI Y, 1992, ONCOGENE, V7, P543; PAN WT, 1990, J BIOL CHEM, V265, P7022; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SIERAKOWSKA H, 1986, NUCLEIC ACIDS RES, V14, P5241, DOI 10.1093/nar/14.13.5241; SINGH H, 1988, CELL, V52, P514; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SWANSON MS, 1988, EMBO J, V11, P3519; TOMILIN NV, 1990, FEBS LETT, V263, P69, DOI 10.1016/0014-5793(90)80707-P; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949	49	58	60	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1133	1143						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134115				2022-12-28	WOS:A1994NC04800016
J	BASSETSEGUIN, N; DEMOLY, P; MOLES, JP; TESNIERES, A; GAUTHIERROUVIERE, C; RICHARD, S; BLANCHARD, JM; GUILHOU, JJ				BASSETSEGUIN, N; DEMOLY, P; MOLES, JP; TESNIERES, A; GAUTHIERROUVIERE, C; RICHARD, S; BLANCHARD, JM; GUILHOU, JJ			COMPARATIVE-ANALYSIS OF CELLULAR AND TISSULAR EXPRESSION OF C-FOS IN HUMAN KERATINOCYTES - EVIDENCE OF ITS ROLE IN CELL-DIFFERENTIATION	ONCOGENE			English	Article							PROTOONCOGENE EXPRESSION; GENE-TRANSCRIPTION; PROTO-ONCOGENE; ONC GENES; ACTIVATION; CALCIUM; GROWTH; MOUSE; SKIN; FIBROBLASTS	Recent studies on normal and pathological skin have suggested a role of the c-fos proto-oncogene in keratinocyte differentiation. To further elucidate this question we have used keratinocyte and skin culture models to study in vitro regulation of c-fos expression and attempted to correlate it with the keratinocyte maturation process. Our results show that c-fos expression is prolonged in keratinocyte monolayers both at the mRNA and protein level. Extracellular calcium which stimulate keratinocyte differentiation is able to induce c-fos expression in the presence of growth factors. However this c-fas expression cannot be maintained by these factors as seen in normal human skin in vivo. Conversely, spontaneous expression of c-fos can be seen in reconstituted skin when the neo-epidermis has completed its differentiation. All these data strongly support a role of c-fos as a switch between the early and late phases of keratinocyte differentiation allowing them to be definitively committed to their elimination process. Additionally, a differential regulation of c-fos seems to exist between keratinocyte culture and reconstituted epidermis, suggesting that tissular and serum factors are involved in the prolonged c-fos expression observed in human epidermis.	SERV PNEUMOL,CNRS,UMR 9942,MONTPELLIER,FRANCE; CNRS,UMR 9942,INSERM,U249,MONTPELLIER,FRANCE; INST GENET MOLEC,CNRS,UMR 9942,MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS)	BASSETSEGUIN, N (corresponding author), DERMATOL MOLEC LAB,CNRS,UMR 9942,MONTPELLIER,FRANCE.		Molès, Jean-Pierre/M-2286-2017; Richard, Sylvain/C-9695-2016; Demoly, Pascal/Y-9938-2019	Molès, Jean-Pierre/0000-0002-6863-6350; Demoly, Pascal/0000-0001-7827-7964; Richard, Sylvain/0000-0001-9460-6705; GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882				BASSET N, 1987, DERMATOLOGICA, V175, P296, DOI 10.1159/000248838; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BASSETSEGUIN N, 1991, J INVEST DERMATOL, V97, P672, DOI 10.1111/1523-1747.ep12483807; BASSETSEGUIN N, 1990, DIFFERENTIATION, V44, P232, DOI 10.1111/j.1432-0436.1990.tb00622.x; BELL E, 1983, J INVEST DERMATOL, V81, pS2, DOI 10.1111/1523-1747.ep12539993; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; COULOMB B, 1986, BRIT J DERMATOL, V114, P91, DOI 10.1111/j.1365-2133.1986.tb02783.x; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; FISHER C, 1991, DEVELOPMENT, V111, P253; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; MULLER R, 1983, EMBO J, V2, P679, DOI 10.1002/j.1460-2075.1983.tb01484.x; MULLER R, 1986, EMBO J, V3, P311; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PANTERNE B, 1992, ONCOGENE, V7, P2341; PRUNIERAS M, 1979, J INVEST DERMATOL, V73, P135, DOI 10.1111/1523-1747.ep12556751; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SPIEGELMAN BM, 1988, J CELL BIOL, V107, P829, DOI 10.1083/jcb.107.3.829; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TINOIS E, 1987, ARCH DERMATOL RES, V279, P241, DOI 10.1007/BF00417322; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x	31	32	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					765	771						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108118				2022-12-28	WOS:A1994MW55100011
J	CHANG, CC; ZHANG, JD; LOMBARDI, L; NERI, A; DALLAFAVERA, R				CHANG, CC; ZHANG, JD; LOMBARDI, L; NERI, A; DALLAFAVERA, R			MECHANISM OF EXPRESSION AND ROLE IN TRANSCRIPTIONAL CONTROL OF THE PROTOONCOGENE NFKB-2/LYT-10	ONCOGENE			English	Article							NF-KAPPA-B; CELL-CYCLE CONTROL; DNA-BINDING; P65 SUBUNIT; GENE-PRODUCT; REL; HOMOLOGY; CLONING; P50; ACTIVATION	The NFKB-2 gene (previously LYT-10, NF-kappa Bp100 or NF-kappa Bp97) codes for a NF-kappa B/rel related protein which is highly homologous to NFKB-1 (previously NF-kappa Bp105) within its rel, poly-glycine and ankyrin domains. The NFKB-2 gene is a candidate proto-oncogene since it is involved in lymphoma-associated chromosomal aberrations. In order to gain insight into the physiological function and role in tumorigenesis of NFKB-2, we have analysed its mechanism of expression and role in transcriptional regulation. We report that, contrary to previous studies, a single 3.2 kb mRNA species and its 100 kD (p100) primary translation product is detectable in all cell types tested. A second NFKB-2 protein, p52, corresponding to the amino-terminal half (rel domain) of NFKB-2 p100, is detectable in the same cell types and derives from the post-translational processing of p100. While p100 is constitutively localized in the cytoplasm, NF-kappa B induction by TPA treatment of Hela cells is associated with cytoplasmic/nuclear translocation of NFKB-2 p52 and its appearance within DNA-binding NF-kappa B complexes. NFKB-2 p52 differs from NFKB-1p50 in its differential affinity for kappa B sequences: by itself it binds H2/HLA-kappa B sites more efficiently than HIV/ IgK-kappa B sites, while it can bind both sites efficiently,when complexed with Rel-A(p65). Transient co-transfection of expression and reporter plasmids in cells devoid of endogenous NF-kappa B activity showed that p52 has no intrinsic transcriptional activation capabilities: it can stimulate Rel-A(p65)-driven transcription by formation of p65/p52 heterodimers, whereas, overexpressed, it down-regulates p65-dependent transcription by formation of inactive p52/p52 homodimers. These results indicate that the NFKB-2 gene codes for an inducible NF-kappa B transcription factor with the capability of differentially regulating NF-kappa B transcription depending on its abundance in,the nucleus.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; UNIV MILAN,OSPED MAGGIORE,IRCCS,IST SCI MED,SERV EMATOL,MILAN,ITALY	Columbia University; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan			Neri, Antonino/I-9690-2014	Neri, Antonino/0000-0001-9047-5912	NCI NIH HHS [CA 44029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUERLE PA, 1988, SCIENCE, V242, P540; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V344, P36; BROWNELL E, 1989, ONCOGENE, V4, P935; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GRILLI M, 1992, INT REV CYTOL, V48, P1; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MERCURIO F, 1993, GENE DEV, V7, P75; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAKSELA K, UNPUB; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	41	51	52	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					923	933						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108136				2022-12-28	WOS:A1994MW55100029
J	DANIEL, J; BUSH, J; CARDELLI, J; SPIEGELMAN, GB; WEEKS, G				DANIEL, J; BUSH, J; CARDELLI, J; SPIEGELMAN, GB; WEEKS, G			ISOLATION OF 2 NOVEL RAS GENES IN DICTYOSTELIUM-DISCOIDEUM - EVIDENCE FOR A COMPLEX, DEVELOPMENTALLY-REGULATED RAS GENE SUBFAMILY	ONCOGENE			English	Article							GTP-BINDING PROTEIN; VULVAR INDUCTION; PLASMA-MEMBRANE; AMINO-ACIDS; CELL-LINE; P21 RAS; ONCOGENE; GAP; ACTIVATION; DOMAIN	In Dictyostelium discoideum, three ras genes (rasD, rasG and rasB) and one uas-related gene (rap1) have been previously isolated and characterized, and the deduced amino acid sequence of their predicted protein products share at least 50% sequence identity with the human H-Ras protein. We have now cloned and characterized two additional members of the ras gene subfamily in Dictyostelium, rasC and rasS. These genes are developmentally regulated and unlike the previously isolated Dictyostelium ras genes, maximum levels of their transcripts were detected during aggregation, suggesting that the encoded proteins have distinct functions during aggregation. The rasC cDNA encodes a 189 amino acid protein that is 65% identical to the Dictyostelium RasD and RasG proteins and 56% identical to the human H-Ras protein. The predicted 194 amino acid gene product encoded by rasS is 60% identical to the Dictyostelium RasD and RasG proteins and 54% identical to the human H-Ras protein. Whereas RasD, RasG, RasB and Rap1 are totally conserved in their putative effector domains relative to H-Ras, RasC and RasS have single amino acid substitutions in their effector domains, consistent with the idea that they have unique functions. In RasC, aspartic acid-38 has been replaced by asparagine (D38N), and in RasS, isoleucine-36 has been replaced by leucine (I36L). In addition, both proteins have several differences in the effector-proximal domain, a domain which is believed to play a role in Ras target activation. In RasC, there is a single conservative amino acid change in the canonical sequence of the binding site for the Ras-specific monoclonal antibody Y13-259, and consequently, RasC is less immunoreactive with the antibody than either of the Dictyostelium RasD or RasG proteins. In contrast, RasS, which has three substitutions in the Y13-259 binding site, does not react with the Y13-259 antibody.	UNIV BRITISH COLUMBIA,DEPT MICROBIOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1Z3,BC,CANADA; LOUISIANA STATE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,SHREVEPORT,LA 71130	University of British Columbia; University of British Columbia; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BONNER JT, 1947, J EXP ZOOL, V106, P1, DOI 10.1002/jez.1401060102; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DANIEL J, 1993, ONCOGENE, V8, P1041; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; KRISTENSEN T, 1987, NUCLEIC ACIDS RES, V15, P5507, DOI 10.1093/nar/15.14.5507; LACAL JC, 1986, MOL CELL BIOL, V6, P1002, DOI 10.1128/MCB.6.4.1002; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; Maniatis T., 1982, MOL CLONING; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; PAWSON T, 1985, MOL CELL BIOL, V5, P33, DOI 10.1128/MCB.5.1.33; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBBINS SM, 1990, NUCLEIC ACIDS RES, V18, P5265, DOI 10.1093/nar/18.17.5265; ROBBINS SM, 1989, P NATL ACAD SCI USA, V86, P938, DOI 10.1073/pnas.86.3.938; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4724; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THIERY R, 1992, BIOCHEM CELL BIOL, V70, P1193, DOI 10.1139/o92-165; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	54	38	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					501	508						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290260				2022-12-28	WOS:A1994MW24800017
J	MOSCOW, JA; HE, R; GNARRA, JR; KNUTSEN, T; WENG, YK; ZHAO, WP; WHANGPENG, J; LINEHAN, WM; COWAN, KH				MOSCOW, JA; HE, R; GNARRA, JR; KNUTSEN, T; WENG, YK; ZHAO, WP; WHANGPENG, J; LINEHAN, WM; COWAN, KH			EXAMINATION OF HUMAN TUMORS FOR RHOA MUTATIONS	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; GLUTATHIONE-PEROXIDASE GENE; LUNG-CANCER; SHORT ARM; ADP-RIBOSYLTRANSFERASE; DNA-SEQUENCE; REGION 3P21; CHROMOSOME-3; HETEROZYGOSITY; LOCALIZATION	rhoA encodes a ras-related GTP-binding protein that is thought to play a role in cytoskeletal organization. Recent evidence has suggested both that rhoA could act either as a dominant oncogene, since transfection of both normal and activated who genes confer a transformed phenotype on fibroblast cells in culture, or as a recessive tumor suppressor gene, by virtue, in part, of its chromosomal location at 3p21, a site deleted in many human malignancies. In either case, a role for rhoA in the oncogenesis of human tumors would be supported by the finding of rhoA mutations in tumors. We therefore examined human tumors and cell lines for mutations in the protein coding regions of rhoA by RNAase protection analysis. We first examined the expression of rhoA in renal cell carcinoma cell lines in which 3p21 was heterozygously deleted or retained. We found no evidence for rhoA mutations in these specimens. We also examined RNA from lung, breast, colon or ovarian tumors and also found no evidence of activating rhoA mutations. Furthermore, there was no relation between the level of rhoA mRNA expression and the presence or absence of 3p21 deletions in the renal cell carcinoma specimens. Thus, although rhoA has transforming potential in vitro, there is no evidence that it is activated by mutation in human malignancies, or that it could act as a tumor suppressor gene in tumors in which 3p21 is deleted.	NCI,PEDIAT BRANCH,BETHESDA,MD 20892; NCI,SURG BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MOSCOW, JA (corresponding author), NCI,MED BRANCH,BETHESDA,MD 20892, USA.			Gnarra, James/0000-0002-6369-3110				ANGLARD P, 1992, CANCER RES, V52, P348; ANGLARD P, 1991, CANCER RES, V51, P1071; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CANNIZZARO LA, 1990, GENOMICS, V6, P197, DOI 10.1016/0888-7543(90)90557-B; CARRITT B, 1986, AM J HUM GENET, V38, P428; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DOROSHOW JH, 1990, PHARMACOL THERAPEUT, V47, P359, DOI 10.1016/0163-7258(90)90062-7; DUTRILLAUX B, 1981, HUM GENET, V57, P93; Flohe L., 1989, GLUTATHIONE CHEM BIO, P644; FUJIMOTO E, 1988, NUCLEIC ACIDS RES, V16, P10943, DOI 10.1093/nar/16.22.10943; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; KARGER S, 1991, GUIDELINES CANCER CY; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEDUC F, 1989, AM J HUM GENET, V44, P282; MCBRIDE O W, 1988, Biofactors, V1, P285; MIURA Y, 1993, J BIOL CHEM, V268, P510; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; MOSCOW JA, 1989, CANCER RES, V49, P1422; MOSCOW JA, IN PRESS; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; OGOROCHI T, 1989, BIOCHEM BIOPH RES CO, V163, P1175, DOI 10.1016/0006-291X(89)92344-9; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; PERONA R, 1993, ONCOGENE, V8, P1285; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU M, 1990, ONCOGENE, V5, P185; SZUCS S, 1986, CANCER GENET CYTOGEN, V26, P369; TJIO JH, 1962, STAIN TECHNOL, V37, P17, DOI 10.3109/10520296209114563; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOSHIDA MA, 1986, CANCER RES, V46, P2139; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	47	47	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					189	194						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302578				2022-12-28	WOS:A1994MW24700023
J	TAKAHASHI, K; SUZUKI, K				TAKAHASHI, K; SUZUKI, K			DNA SYNTHESIS-ASSOCIATED NUCLEAR EXCLUSION OF P53 IN NORMAL HUMAN BREAST EPITHELIAL-CELLS IN CULTURE	ONCOGENE			English	Article							TRANSFORMATION-RELATED PROTEIN; MONOCLONAL-ANTIBODIES; 3T3 CELLS; WILD-TYPE; GROWTH; PHOSPHORYLATION; LYMPHOCYTES; ANTIGEN; CYCLE; MOUSE	Immunohistochemical staining using three monoclonal antibodies to p53 revealed that most normal human breast epithelial cells (HBEC) in the exponential growth phase, have p53 located in the nucleus but that some cells have the protein in the cytoplasm. Cytoplasmic staining of p53 with the monoclonal antibody PAb240 was inhibited by the specific oligopeptide, NTFRHSVVVP, that corresponds to the amino acids between 210 and 219 in p53 and which includes the epitope domain for PAb240. It was not inhibited by the control oligopeptide SPFVTVHNVR. Growth arrest of HBEC achieved by EGF depletion resulted in predominant nuclear location of p53 and stimulation of arrested cells with EGF induced transient nuclear exclusion of the protein when the induced DNA synthesis level was maximal. These observations suggest that p53 in normal HBEC becomes inactivated by nuclear exclusion during cellular DNA synthesis.			TAKAHASHI, K (corresponding author), KANAGAWA CANC CTR,RES INST,DEPT BIOCHEM,ASAHI KU,54-2 NAKAO CHO,YOKOHAMA,KANAGAWA 241,JAPAN.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KERN SE, 1991, ONCOGENE, V6, P131; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOSNER J, 1992, ONCOGENE, V7, P661; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; STEINMEYER K, 1988, ONCOGENE, V3, P501; SUZUKI K, 1992, BIOCHEM BIOPH RES CO, V183, P1175, DOI 10.1016/S0006-291X(05)80314-6; TAKAHASHI K, 1989, INT J CANCER, V43, P870, DOI 10.1002/ijc.2910430522; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ZHANG W, 1992, ONCOGENE, V7, P1645	31	41	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					183	188						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302577				2022-12-28	WOS:A1994MW24700022
J	WILSON, BA; KHALIL, M; TAMANOI, F; CANNON, JF				WILSON, BA; KHALIL, M; TAMANOI, F; CANNON, JF			NEW ACTIVATED RAS2 MUTATIONS IDENTIFIED IN SACCHAROMYCES-CEREVISIAE	ONCOGENE			English	Note							GUANINE-NUCLEOTIDE; ADENYLATE-CYCLASE; GTPASE ACTIVITY; PROTEINS; YEAST; GENE; PATHWAY; IRA2; P21; GAP	Activating mutations in RAS proto-oncogenes encode proteins with greater GTP binding. Such mutant proteins are responsible for many human cancers. Six new amino acids were discovered that can yield an activated Saccharomyces cerevisiae RAS2 protein when they are altered. These new RAS2 alleles were found among a collection of 35 random mutations that exhibit a dominant reduction of glycogen accumulation. The RAS2-P41S and RAS2-E99K alleles encode proteins that have lost responsiveness to GTPase activating proteins. They affect amino acids in loop 2 and helix 3 respectively and illustrate that GTPase activating proteins recognize a larger portion of the RAS structure than previously realized. RAS2 mutations E130K, S153F, A154T, and A157S alter amino acids proximal to the guanine binding site and probably influence nucleotide binding either directly or indirectly.	UNIV MISSOURI, SCH MED, DEPT MOLEC MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA	University of Missouri System; University of Missouri Columbia; University of California System; University of California Los Angeles				Cannon, John/0000-0001-6698-176X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030054] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30054] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CANNON JF, 1986, GENETICS, V113, P247; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARUTA H, 1991, J BIOL CHEM, V266, P11661; Matsumoto K, 1985, Yeast, V1, P15, DOI 10.1002/yea.320010103; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TAMANOI F, 1988, BIOCHIM BIOPHYS ACTA, V948, P1, DOI 10.1016/0304-419X(88)90002-9; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1992, MOL CELL BIOL, V12, P631, DOI 10.1128/MCB.12.2.631; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; THON VJ, 1993, J BIOL CHEM, V268, P7509; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934	34	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3441	3445						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247549				2022-12-28	WOS:A1993MG78200031
J	YEUNG, RS; BELL, DW; TESTA, JR; MAYOL, X; BALDI, A; GRANA, X; KLINGALEVAN, K; KNUDSON, AG; GIORDANO, A				YEUNG, RS; BELL, DW; TESTA, JR; MAYOL, X; BALDI, A; GRANA, X; KLINGALEVAN, K; KNUDSON, AG; GIORDANO, A			THE RETINOBLASTOMA-RELATED GENE, RB2, MAPS TO HUMAN-CHROMOSOME-16Q12 AND RAT CHROMOSOME-19	ONCOGENE			English	Article							BREAST-CANCER; ALLELOTYPE; PROTEIN; PRODUCT	A retinoblastoma-related human gene, referred to as R B 2, has been cloned based on sequence homology of the E1A-binding domain of the retinoblastoma gene. Structural homology with the retinoblastoma gene suggests a possible function of R B 2 as a tumor suppressor gene. In this study, we have mapped this gene to human chromosome 16q12.2 and rat chromosome 19, using fluorescence in situ hybridization and somatic hybrid cell analysis, respectively. Based on known syntenic relationships among human, rat and mouse, the data suggest that the mouse homolog resides on chromosome 8. Deletions of chromosome 16q have been found in several human neoplasias (including breast, ovarian, hepatic, and prostatic cancers) which is in support of an involvement of R B 2 in human cancer as a tumor suppressor gene.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; UNIV GOTHENBURG,DEPT GENET,S-41390 GOTHENBURG,SWEDEN	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Gothenburg	YEUNG, RS (corresponding author), FOX CHASE CANC CTR,DIV MED SCI,7701 BURHOLME AVE,PHILADELPHIA,PA 19111, USA.		Giordano, Antonio/F-1927-2010; Mayol, Xavier/C-1391-2012; Baldi, Alfonso/ABG-2397-2021	Giordano, Antonio/0000-0002-5959-016X; Grana, Xavier/0000-0001-7134-0473; Baldi, Alfonso/0000-0002-8693-3842; Mayol, Xavier/0000-0001-7288-195X	NCI NIH HHS [CA-06927, CA-45745] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045745, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FUJIMORI M, 1991, CANCER RES, V51, P89; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; LINDBLOM A, 1993, CANCER RES, V53, P3707; MAYOL X, 1993, ONCOGENE, V8, P261; NEVINS JR, 1992, SCIENCE, V258, P424; REEDERS ST, 1991, CYTOGENET CELL GENET, V58, P643, DOI 10.1159/000133176; SATO T, 1991, CANCER RES, V51, P5118; SATO T, 1990, CANCER RES, V50, P7184; SERIKAWA T, 1992, GENETICS, V131, P701; TAGUCHI T, 1993, CANCER RES, V53, P4349; YEUNG RS, 1993, CYTOGENET CELL GENET, V62, P149, DOI 10.1159/000133459; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	18	76	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3465	3468						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247552				2022-12-28	WOS:A1993MG78200034
J	METIVIER, C; PIU, F; PFARR, CM; YANIV, M; LOISEAU, L; CASTELLAZZI, M				METIVIER, C; PIU, F; PFARR, CM; YANIV, M; LOISEAU, L; CASTELLAZZI, M			IN-VITRO TRANSFORMING CAPACITIES OF MOUSE C-JUN-JUND CHIMERIC GENES	ONCOGENE			English	Note							TRANSCRIPTIONAL ACTIVATION; EMBRYO FIBROBLASTS; ONCOGENE JUN; V-JUN; FOS; AP-1; PHOSPHORYLATION; DOMAIN; CELLS; DNA	Among the murine Jun family of transcription factors, c-Jun and JunD are closely-related proteins with similar dimerization, DNA binding and transactivating properties. However, when expressed from a self-replicating retroviral RCAS vector, c-jun, but not junD, transforms chick embryo fibroblasts. We attempted to map the regions of c-jun which are important for transformation by constructing hybrids between c-jun and junD. Using common restriction sites, we prepared six different chimeric molecules. All of these c-jun:junD hybrids code for transactivators of AP1-containing promoters. An N-terminal segment of 79 amino acids of c-Jun converts JunD into a strong transforming protein, while other segments of c-Jun contribute to a lesser extent. Contrary to what has been reported with rat embryo fibroblasts, a c-Jun derivative with serines substituted by alanines in positions 63 and 73 still transforms CEFs efficiently.	ECOLE NORMALE SUPER, CNRS,UMR49,BIOL MOLEC & CELLULAIRE LAB, 46 ALLEE ITALIE, F-69364 LYON 07, FRANCE; INST PASTEUR, DEPT BIOTECHNOL,CNRS,URA 1644, UNITE VIRUS ONCOGENES, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Pfarr, Curt/HHD-1410-2022					ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BERGER I, 1991, ONCOGENE, V6, P561; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1991, ONCOGENE, V6, P1623; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1990, New Biologist, V2, P126; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, ONCOGENE, V3, P659; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANG-YEN H-F, 1990, New Biologist, V2, P351	38	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2311	2315						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336952				2022-12-28	WOS:A1993LP17100036
J	AGOFF, SN; WU, B				AGOFF, SN; WU, B			CBF MEDIATES ADENOVIRUS ELA TRANSACTIVATION BY INTERACTION AT THE C-TERMINAL PROMOTER TARGETING DOMAIN OF CONSERVED REGION-3	ONCOGENE			English	Note							E2F TRANSCRIPTION FACTOR; HUMAN HSP70 PROMOTER; E1A GENE-PRODUCTS; PROTEIN; TRANSACTIVATION; TRANSFORMATION; COMPLEXES; MUTANTS; FAMILY; BINDS	Genetic and biochemical evidence suggest that conserved region 3 (CR3) of the adenovirus Ela polypeptide can provide two distinct and separable functions: an N-terminal transcriptional activation region and a C-terminal promoter targeting region. It is thought that the promoter targeting region of Ela CR3 interacts with promoter-specific transcription factors, thereby bringing the activation region of Ela CR3 in proximity of the promoter. Here we report that CBP, a CCAAT-box-binding factor that regulates hsp70 gene expression and mediates Ela trans-activation in vivo, interacts with the promoter targeting region of Ela CR3 in vitro. Point mutations in Ela CR3 that are defective in stimulating transcription from the hsp70 promoter are also defective in stimulating transcription directed by a synthetic activator, GAL-CBF, composed of the DNA-binding domain of yeast GAL4 fused to CBF. These mutations fall into two classes with respect to their abilities to interact with CBF in vitro. Mutations in the transcriptional activation region of Ela CR3 do not affect binding to CBF, but mutation of the promoter targeting region of Ela CR3 prevents association with CBF in vitro.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	Northwestern University								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CHATTERJEE P, 1988, EMBO J, V5, P835; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GLENN GM, 1987, MOL CELL BIOL, V7, P1004, DOI 10.1128/MCB.7.3.1004; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILLIE JW, 1987, CELL, V61, P1217; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WINBERG G, 1984, EMBO J, V3, P1907, DOI 10.1002/j.1460-2075.1984.tb02066.x; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	28	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3707	3711						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970730				2022-12-28	WOS:A1994PT39200036
J	GAO, XA; WU, N; GRIGNON, D; ZACHAREK, A; LIU, H; SALKOWSKI, A; LI, GY; SAKR, W; SARKAR, F; PORTER, AT; CHEN, YQ; HONN, KV				GAO, XA; WU, N; GRIGNON, D; ZACHAREK, A; LIU, H; SALKOWSKI, A; LI, GY; SAKR, W; SARKAR, F; PORTER, AT; CHEN, YQ; HONN, KV			HIGH-FREQUENCY OF MUTATOR PHENOTYPE IN HUMAN PROSTATIC ADENOCARCINOMA	ONCOGENE			English	Article							NONPOLYPOSIS COLON-CANCER; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; GENETIC INSTABILITY; CARCINOMA; P53; MUTATIONS; CELLS; SUPPRESSION; ASSOCIATION	Mutator phenotype of nucleotide repeats has been implicated to be involved in human cancer and other diseases. This type of instability may be the direct result of DNA replication and/or repair errors. To examine mutator phenotype during the development of human prostate cancer, we undertook this study to screen 57 patients with prostatic adenocarcinoma for possible mutator phenotype at 18 microsatellite marker loci on 12 chromosomes (3p, 5q, 6p, 7p, 8p, 10q, 11p, 13q, 16q, 17p, 18q and Xq) Overall, in 37 of 57 patients, we have found positive mutator phenotype in at least one of the loci analysed. A significantly greater number of cases mere found to be positive for this phenotype among the poorly differentiated than the moderately- and well-differentiated prostatic adenocarcinomas. Our data suggest that mutator phenotype may play an important role in the development and progression of human prostate cancer.	WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,DETROIT,MI 48202	Wayne State University; Wayne State University			Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANWAR K, 1992, CANCER RES, V52, P5991; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHIARODO A, 1991, CANCER RES, V51, P2498; EFFERT PJ, 1993, J UROLOGY, V150, P257, DOI 10.1016/S0022-5347(17)35458-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GAO X, 1993, CANCER RES, V53, P2723; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISAACS WB, 1991, CANCER RES, V51, P4716; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1993, CANCER RES, V53, P5849; MANDEL JL, 1993, NAT GENET, V4, P8, DOI 10.1038/ng0593-8; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, CANCER RES, V53, P5853; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; STEVENBOVA G, 1993, CANCER RES, V53, P3869; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	34	78	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2999	3003						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084604				2022-12-28	WOS:A1994PG82200027
J	YAMAIZUMI, M; SUGANO, T				YAMAIZUMI, M; SUGANO, T			UV-INDUCED NUCLEAR ACCUMULATION OF P53 IS EVOKED THROUGH DNA-DAMAGE OF ACTIVELY TRANSCRIBED GENES INDEPENDENT OF THE CELL-CYCLE	ONCOGENE			English	Article							TUMOR-ANTIGEN; COCKAYNE SYNDROME; SV40-TRANSFORMED CELLS; ATAXIA-TELANGIECTASIA; ULTRAVIOLET-RADIATION; TRANSFORMED-CELLS; ALPHA-AMANITIN; T-ANTIGEN; PROTEIN; REPAIR	Induction of p53 in u.v.-irradiated primary human fibroblasts was monitored by immunostaining and Western blotting. Minimum u.v. doses required for induction of nuclear accumulation of p53 (minimum response dose: MRD) were estimated in various cells with different DNA repair capacities. The MRD in repair deficient xeroderma pigmentosum (XP) group A cells is eightfold lower than in normal cells, indicating that nuclear accumulation of p53 is related to DNA repair capacity. Cells from patients with another u.v. sensitive disorder, Cockayne syndrome (CS), which have normal repair capacity for the overall genome but have a specific defect in preferential repair of lesions in active genes, have the same low MRD as of XP-A cells. Furthermore, the MRD in XP-C cells, which have normal preferential repair but have defects in overall genome repair, is as high as that of normal cells. DNA damage induced by X-ray is repaired at similar rates in normal, XP and CS cells. In contrast to u.v.-irradiation, the minimum dose of X-rays that induces nuclear accumulation of p53 is the same in these cells. Inhibition of transcription with alpha-amanitin evokes nuclear accumulation of p53 both in normal cells and in XP cells. These results strongly suggest that u.v.-induced nuclear accumulation of p53 is evoked through DNA damage of actively transcribed genes. Nuclear accumulation of p53 is observed in any phase of the cell cycle at both low and high u.v. doses.			YAMAIZUMI, M (corresponding author), KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,KUMAMOTO 862,JAPAN.							AHMED FE, 1978, BIOCHIM BIOPHYS ACTA, V521, P805, DOI 10.1016/0005-2787(78)90319-2; ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEAVER J, 1989, METABOLIC BASIS INHE, P2948; COULIER F, 1985, EMBO J, V4, P3413, DOI 10.1002/j.1460-2075.1985.tb04098.x; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDBERG EC, 1985, DNA REPAIR, P503; Harlow E, 1988, ANTIBODIES LABORATOR, P359; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACOB ST, 1970, NATURE, V225, P60, DOI 10.1038/225060b0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE DP, 1992, NATURE, V358, P17; LEHMANN AR, 1977, CANCER RES, V37, P904; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1983, EMBO J, V2, P1633, DOI 10.1002/j.1460-2075.1983.tb01637.x; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WADE MH, 1979, MUTAT RES, V59, P49, DOI 10.1016/0027-5107(79)90194-5; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	40	234	235	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2775	2784						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084582				2022-12-28	WOS:A1994PG82200002
J	GOTOH, Y; MATSUDA, S; TAKENAKA, K; HATTORI, S; IWAMATSU, A; ISHIKAWA, M; KOSAKO, H; NISHIDA, E				GOTOH, Y; MATSUDA, S; TAKENAKA, K; HATTORI, S; IWAMATSU, A; ISHIKAWA, M; KOSAKO, H; NISHIDA, E			CHARACTERIZATION OF RECOMBINANT XENOPUS MAP KINASE KINASES MUTATED AT POTENTIAL PHOSPHORYLATION SITES	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; THREONINE TYROSINE KINASE; SIGNAL-TRANSDUCTION; SUBSTRATE RECOGNITION; NUCLEOTIDE-SEQUENCE; A431 CELLS; IDENTIFICATION; YEAST; GENE; CASCADE	Xenopus mitogen-activated protein kinase kinase (MAPKK) previously inactivated with protein phosphatase 2A can be reactivated by serine phosphorylation catalyzed by a partially purified MAPKK kinase (MAPKK-K), and is phosphorylated by MAPK on a threonine residue. The sequence analysis of a threonine-phosphorylated tryptic peptide of Xenopus MAPKK from mature oocytes suggested that Thr388 is phosphorylated in vivo. A mutant MAPKK that has Thr388 changed to Ala (T388A-MAPKK) was not phosphorylated by purified MAPK, indicating that Thr388 is phosphorylated by MAPK. We then produced and analysed MAPKKs mutated at potential serine phosphorylation sites (S218A-MAPKK and S222A-MAPKK). The wild-type MAPKK (WT-MAPKK), T388A-MAPKK and a kinase-deficient (K97S)-MAPKK were phosphorylated efficiently by MAPKK-Ks purified from Xenopus eggs, and WT-MAPKK and T388A-MAPKK became activated. In contrast, neither S218A-MAPKK nor S222A-MAPKK was phosphorylated and activated efficiently by the Xenopus MAPKK-Ks. Similarly, WT-MAPKK, but not S218A-MAPKK or S222A-MAPKK, was activated efficiently by an active Raf-1 immunoprecipitate. However, when the recombinant STE11, a putative MAPKK-K in S. cerevisiae, was used as a source of MAPKK-K, S218A-MAPKK as well as WT-MAPKK, but not S222A-MAPKK, was phosphorylated and activated. Furthermore, replacement of Ser222 with an acidic residue (S222E) elevated substantially the basal kinase activity of MAPKK, while replacement of Ser218 (S218E) did not. These results may suggest an essential role for Ser222 phosphorylation in activating Xenopus MAPKK.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA 187,TOKYO,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA,JAPAN	Kyoto University; National Center for Neurology & Psychiatry - Japan; Kirin Brewery Company Limited								Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; AHN NG, 1991, J BIOL CHEM, V266, P4220; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVIN DE, 1993, CURR OPIN CELL BIOL, V5, P245; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEIMAN AM, 1994, IN PRESS P NATL ACAD; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OTSU M, 1993, FEBS LETT, V320, P246, DOI 10.1016/0014-5793(93)80596-M; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	56	67	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1891	1898						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208535				2022-12-28	WOS:A1994NR68500012
J	JANKNECHT, R; ZINCK, R; ERNST, WH; NORDHEIM, A				JANKNECHT, R; ZINCK, R; ERNST, WH; NORDHEIM, A			FUNCTIONAL DISSECTION OF THE TRANSCRIPTION FACTOR ELK-1	ONCOGENE			English	Note							ETS-RELATED PROTEIN; DNA-BINDING MOTIF; PUTATIVE ONCOGENE; FACTOR P62TCF; DOMAIN; EXPRESSION; KINASE; SRF; TRANSLOCATION; PROTOONCOGENE	The ternary complex factor Elk-1 belongs to the Ets oncoprotein family. We demonstrate that this transcription factor is localized predominantly in the nucleus, for which at least two regions of Elk-I are required. One of these regions is part of the N-terminal ETS-domain, while the other encompasses amino acids 137-157. In conjunction with the ETS-domain, which mediates autonomous binding of Elk-1 to some DNA target sequences, the conserved B-region is both necessary and sufficient for ternary complex formation with the c-fos serum response element and the serum response factor. However, the B-region must be linked to the ETS-domain by a spacer. Furthermore, the B-region impedes autonomous DNA-binding, possibly by masking the ETS-domain. A point mutation within the ETS-domain, homologous to the ts1.1 point mutation of v-Ets in the E26 virus, affects DNA-binding of Elk-1 in a temperature-dependent manner, which by analogy might be causative for the altered phenotype of ts1.1 E26. Finally we show that amino acids 83-428 contribute to Elk-1 mediated transactivation. In particular, the region 376-404 is indispensable for transactivation, while flanking amino acids on both sides are only required for enhancement of transcriptional efficacy.	HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School				Janknecht, Ralf/0000-0003-1741-1562				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1993, EUR J BIOCHEM, V216, P469, DOI 10.1111/j.1432-1033.1993.tb18165.x; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	29	87	87	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1273	1278						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134131				2022-12-28	WOS:A1994NC04800034
J	EDELHOFF, S; AYER, DE; ZERVOS, AS; STEINGRIMSSON, E; JENKINS, NA; COPELAND, NG; EISENMAN, RN; BRENT, R; DISTECHE, CM				EDELHOFF, S; AYER, DE; ZERVOS, AS; STEINGRIMSSON, E; JENKINS, NA; COPELAND, NG; EISENMAN, RN; BRENT, R; DISTECHE, CM			MAPPING OF 2 GENES ENCODING MEMBERS OF A DISTINCT SUBFAMILY OF MAX INTERACTING PROTEINS - MAD TO HUMAN-CHROMOSOME-2 AND MOUSE CHROMOSOME-6, AND MXI1 TO HUMAN-CHROMOSOME-10 AND MOUSE CHROMOSOME-19	ONCOGENE			English	Note							INSITU HYBRIDIZATION; DNA-SEQUENCES; LEUKEMIA; MYC; BINDING	Both the MAD and the MXI1 genes encode basic-helix-loop-helix-leucine zipper (bHLH-Zip) transcription factors which bind Max in vitro, forming a sequence-specific DNA-binding complex similar to the Myc-Max heterodimer. Mad and Myc compete for binding to Max. In addition, Mad has been shown to act as a transcriptional repressor while Myc appears to function as an activator. Mxi1 also appears to lack a transcriptional activation domain. Therefore, Mxi1 and Mad might antagonize Myc function and are candidate tumor suppressor genes. We report here the mapping of the MAD and MXI1 genes in human and mouse by fluorescence in situ hybridization (FISH) and by recombination mapping. The MAD gene was mapped to human chromosome 2 at band p13 by FISH and to mouse chromosome 6 by meiotic mapping. The MXI1 gene was mapped to human chromosome 10 at band q25 and on mouse chromosome 19 at region D by FISH. There was a second site of hybridization on mouse chromosome 2 at region C, which may represent a pseudogene or a related sequence. The mapping results confirm regions of conservation between human chromosome 2p13 and mouse chromosome 6 and between chromosome 10q25 and mouse chromosome 19D. Human chromosomes 2p13 and 10q25 have been involved in specific tumors where the role of Mad and Mxi1 can now he investigated.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Steingrimsson, Eirikur/0000-0001-5826-7486; Ayer, Donald/0000-0002-5595-3269	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, IN PRESS GENES DEV; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; GILLADOGA AD, 1992, ONCOGENE, V7, P1249; Green EL, 1981, GENETICS PROBABILITY, P77; INABA T, 1991, LEUKEMIA, V5, P719; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KRETZNER L, 1992, NATURE, V359, P423; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7841; MERTENS F, 1989, CANCER GENET CYTOGEN, V39, P227, DOI 10.1016/0165-4608(89)90189-1; MOORE KJ, 1992, GENOMICS, V12, P388, DOI 10.1016/0888-7543(92)90389-A; MOYZIS RK, 1987, CHROMOSOMA, V95, P375, DOI 10.1007/BF00333988; NADEAU JH, 1992, MAMM GENOME, V3, P480, DOI 10.1007/BF00778825; NEUMANN HPH, 1988, CANCER GENET CYTOGEN, V31, P41, DOI 10.1016/0165-4608(88)90009-X; OCHI H, 1988, JPN J CANCER RES, V79, P1024, DOI 10.1111/j.1349-7006.1988.tb00069.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RICHARDSON AL, 1992, ONCOGENE, V7, P961; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; 1990, CYTOGENET CELL GENET, V55, P1	26	111	111	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					665	668						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290278				2022-12-28	WOS:A1994MW24800036
J	GU, ZM; PIM, D; LABRECQUE, S; BANKS, L; MATLASHEWSKI, G				GU, ZM; PIM, D; LABRECQUE, S; BANKS, L; MATLASHEWSKI, G			DNA-DAMAGE INDUCED P53 MEDIATED TRANSCRIPTION IS INHIBITED BY HUMAN PAPILLOMAVIRUS TYPE-18 E6	ONCOGENE			English	Article							PRIMARY HUMAN KERATINOCYTES; WILD-TYPE P53; TRANSFORMING ACTIVITY; CERVICAL-CANCER; E5 GENE; CELLS; PROTEIN; TRANSACTIVATION; SEQUENCES; IDENTIFICATION	Cervical cancer is similar to other human cancers in that it develops through a multistep process. However, infection with oncogenic human papillomaviruses (HPVs) is believed to be essential for the initiation of this disease. Although HPV may play a central role in the early stages of neoplasia, the accumulation of mutations in an assortment of genes precedes the development of malignant cervical carcinoma. The mechanisms by which abnormalities accumulate are various, but it is possible that viral proteins are involved. In particular, the viral E6 oncoprotein has been shown to interact with the cellular tumour suppressor protein p53, which is involved in DNA damage repair pathways. Hence, E6 may contribute to the genomic instability through this interaction with p53. We have tested this hypothesis by monitoring the effects of E6 upon DNA damage induced p53 transcriptional activity. This study shows that HPV-18 E6 inhibits p53 transcriptional activity following genotoxic stress with UV radiation. No effect was observed when a mutant E6 unable to direct the degradation of p53 was included in this assay. These results suggest that continued E6 expression may contribute to the accumulation of DNA damage associated with the progression of cervical cancer.	MCGILL UNIV, INST PARASITOL, ST ANNE DE BELLEVUE H9X 3V9, PQ, CANADA; MCGILL UNIV, CTR CANC, MONTREAL, PQ, CANADA; INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY	McGill University; McGill University; International Center for Genetic Engineering & Biotechnology (ICGEB)								AUERSPERG N, 1964, J NATL CANCER I, V32, P135; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CHEN SL, 1990, J VIROL, V64, P3226, DOI 10.1128/JVI.64.7.3226-3233.1990; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRANCO EL, 1993, INFECT MED, V10, P57; HALL PA, 1993, ONCOGENE, V8, P203; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MUNGER K, 1989, J VIROL, V63, P4417; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1992, ONCOGENE, V7, P27; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; TOMMASINO M, 1993, ONCOGENE, V8, P195; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	42	49	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					629	633						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290274				2022-12-28	WOS:A1994MW24800031
J	PRASAD, DDK; RAO, VN; LEE, L; REDDY, ESP				PRASAD, DDK; RAO, VN; LEE, L; REDDY, ESP			DIFFERENTIALLY SPLICED ERG-3 PRODUCT FUNCTIONS AS A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Note							ETS-RELATED PROTEIN; PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; DNA-BINDING DOMAIN; C-ETS-1 PROTOONCOGENE; C-FOS; GENE FAMILY; FLI-1 GENE; V-ETS	ets oncogene superfamily consists of a family of transcriptional factors that functions as activators and/or repressors. Previously, we have identified a member of this ets superfamily namely erg, ets related gene. erg gene was shown to code for at least two proteins erg-1 and erg-2 because of alternative splicing and alternative usage of initiation codon. In this report we show that erg gene codes for an additional erg variant protein, erg-3 as a result of differential splicing which results in the insertion of 24 amino acids in the coding region of erg-2 protein. RNAase protection analysis revealed that erg-3 transcripts are expressed in a variety of cells. Erg-3 was also found to activate the transcription of the reporter TK-CAT gene linked to er g target sequences suggesting that erg3 codes for a sequence specific transcriptional activator.	JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; NCI,FCRDC,PROGRAM RESOURCES INC,FREDERICK,MD 21702	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [CA 51083, CA 57157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R01CA057157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P85; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; OHNO T, 1993, IN PRESS CANCER RES; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRASAD DDK, 1992, CANCER RES, V52, P5833; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1990, CANCER RES, V50, P5013; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1990, ONCOGENE, V5, P1761; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; [No title captured]	53	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					669	673						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290279				2022-12-28	WOS:A1994MW24800037
J	CARLESSO, N; GRIFFIN, JD; DRUKER, BJ				CARLESSO, N; GRIFFIN, JD; DRUKER, BJ			USE OF A TEMPERATURE-SENSITIVE MUTANT TO DEFINE THE BIOLOGICAL EFFECTS OF THE P210(BCR-ABL) TYROSINE KINASE ON PROLIFERATION OF A FACTOR-DEPENDENT MURINE MYELOID CELL-LINE	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; MIDDLE-T-ANTIGEN; V-ABL ONCOGENE; BCR-ABL; INTERLEUKIN-3 DEPENDENCE; PHILADELPHIA-CHROMOSOME; INVITRO TRANSFORMATION; HEMATOPOIETIC-CELLS; PROTEIN-KINASE	The Philadelphia chromosome, detected in virtually all cases of chronic myelogenous leukemia, is formed by a reciprocal translocation between chromosomes 9 and 22 that fuses BCR encoded sequences upstream of exon 2 of c-ABL. This oncogene produces a fusion protein, p210(BCR-ABL), in which the ABL tyrosine kinase activity is elevated. This elevated kinase activity is essential for transformation, but the mechanisms involved are unknown. To investigate p210(BCR-ABL) function we constructed a model system in which the tyrosine kinase activity of p210(BCR-ABL) was inducible. Two amino acid substitutions, Arg to His at amino acid 457 and Tyr to His at amino acid 469 of c-abl, modeled on mutations known to render v-src temperature-sensitive for tyrosine kinase activity, were introduced into p210(BCR-ABL). This mutant was characterized in an IL-3 growth factor dependent murine myeloid cell line, 32Dc13. Cell lines expressing the temperature-sensitive mutant remained factor dependent at the non-permissive temperature, but at the permissive temperature displayed a marked reduction in cell death in the absence of growth factor and an exaggerated proliferative response to low levels of IL-3. Both the kinase activity of the mutant and the levels of tyrosine phosphorylated proteins are increased in the temperature-sensitive mutant at the permissive temperature. Further, tyrosine phosphorylation of potential substrates of the p210(BCR-ABL) tyrosine kinase, p120 rasGAP and its associated proteins of p190 and p62, only occurs at the permissive temperature in cells expressing the temperature-sensitive mutant.	DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV TURIN, DEPT EXPTL MED & ONCOL, HEMATOL SECT, TURIN, ITALY; DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Turin; Harvard University; Dana-Farber Cancer Institute				Druker, Brian/0000-0001-8331-8206	NATIONAL CANCER INSTITUTE [R01CA036167, R37CA036167, K08CA001422] Funding Source: NIH RePORTER; NCI NIH HHS [CA36167, CA01422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNETT MJ, 1989, BONE MARROW TRANSPL, V4, P345; BEDI A, 1992, BLOOD S, V80, pA154; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BROXMEYER HE, 1987, J CLIN INVEST, V79, P721, DOI 10.1172/JCI112877; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DONAHUE RE, 1988, SCIENCE, V241, P1820, DOI 10.1126/science.3051378; DRUKER B, 1992, BLOOD, V79, P2215; DRUKER BJ, 1991, NUCLEIC ACIDS RES, V19, P6855, DOI 10.1093/nar/19.24.6855; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ENGELMAN A, 1987, P NATL ACAD SCI USA, V84, P8021, DOI 10.1073/pnas.84.22.8021; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; ENGELMAN A, 1990, MOL CELL BIOL, V10, P4365, DOI 10.1128/MCB.10.8.4365; EVANS CA, 1993, CANCER RES, V53, P1735; FINCHAM VJ, 1986, J VIROL, V58, P694, DOI 10.1128/JVI.58.2.694-699.1986; Gishizky M L, 1992, Curr Top Microbiol Immunol, V182, P65; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HONMA Y, 1992, LEUKEMIA, V6, P229; HURLEY TR, 1992, J VIROL, V66, P7406, DOI 10.1128/JVI.66.12.7406-7413.1992; KANAKURA Y, 1990, BLOOD, V76, P706; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LANEUVILLE P, 1992, BLOOD, V80, P1788; LANEUVILLE P, 1991, ONCOGENE, V6, P275; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATULONIS U, 1993, IN PRESS EXP HEMATOL; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; METCALF D, 1986, BLOOD, V68, P46; MOORE MAS, 1977, CLIN HAEMATOL, V6, P97; NOWELL PC, 1960, SCIENCE, V132, P1497; RISSER R, 1978, J EXP MED, V148, P714, DOI 10.1084/jem.148.3.714; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798	49	85	88	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					149	156						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302574				2022-12-28	WOS:A1994MW24700018
J	SEHGAL, PB; MARGULIES, L				SEHGAL, PB; MARGULIES, L			CELL-TYPE-DEPENDENT AND PROMOTER-DEPENDENT TS PHENOTYPE OF P53 VAL(135)	ONCOGENE			English	Note							WILD-TYPE P53; INTERLEUKIN-6 PROMOTER; RESPONSIVE ELEMENT; GENE-PRODUCT; ENHANCER; INHIBITION; REPRESSION; EXPRESSION; PROTEIN; MUTANT	The p53 mutant Val(135) is widely considered to have a wild-type (wt) phenotype at 32.5 degrees C, but not at 37 degrees C. The ability of wt murine p53 and its Val(135) mutant to modulate transcription from the muscle-specific creatine kinase promoter (- 3.3 kb pMCK), from a reporter construct containing two copies of the p53-binding DNA element from within MCK (p50-2), and from the interleukin-6 (IL-6) promoter (pTC225) was evaluated in transient transfection experiments in CV1 and HeLa cells. In CV1 cells, wt p53 was confirmed to activate the pMCK and p50-2 reporters, but to repress the IL-6 promoter. However, although in these cells p53 Val(135) had the expected wt-like phenotype with respect to activation of the p50-2 reporter at 32.5 degrees C (32.5 degrees C) 37 degrees C), this mutant had little effect on expression from pMCK at either temperature, and activated rather than repressed the IL-6 promoter at 32.5 degrees C. In HeLa cells, although wt p53 activated p50-2 but repressed the MCK and IL-6 promoters, p53 Val(135) activated all three reporters. Unexpectedly, in these cells the upregulation of p50-2 and pIC225 was basically temperature-independent, and that of pMCK was inversely ts (37 degrees C>32.5 degrees C). The novel ts properties of p53 Val(135) show that this mutant is not always wt-like at 32.5 degrees C but exhibits strong cell-type and promoter-dependent differences in its ts phenotype for transcriptional modulation.	NEW YORK MED COLL, DEPT MED, VALHALLA, NY 10595 USA	New York Medical College	SEHGAL, PB (corresponding author), NEW YORK MED COLL, DEPT MICROBIOL & IMMUNOL, VALHALLA, NY 10595 USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	20	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3417	3419						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247545				2022-12-28	WOS:A1993MG78200027
J	CHEN, JY; FUNK, WD; WRIGHT, WE; SHAY, JW; MINNA, JD				CHEN, JY; FUNK, WD; WRIGHT, WE; SHAY, JW; MINNA, JD			HETEROGENEITY OF TRANSCRIPTIONAL ACTIVITY OF MUTANT P53 PROTEINS AND P53 DNA TARGET SEQUENCES	ONCOGENE			English	Article							WILD-TYPE P53; CELL LUNG-CANCER; TUMOR SUPPRESSOR GENE; BINDING PROTEIN; T-ANTIGEN; MUTATIONS; EXPRESSION; CYCLE; INVITRO; GROWTH	Transcriptional activity of p53 was monitored by co-transfection of pCMV expression vectors containing wild-type and mutant p53 cDNAs into the p53-null H1299 lung cancer cells along with luciferase reporter plasmids containing different p53 target sequences in the 5' regulatory region: fragment A of the ribosomal gene cluster (RGC); p53 consensus sequence (p53CON); or a tandemly linked RGC+p53CON sequence. Our results show: (1) wild-type p53 stimulates the transcription of reporter genes with p53CON and RGC in their 5' region while most p53 mutants occurring in human cancers have lost this activity; (2) the R273H mutant retains transcriptional activity for the p53CON sequence but not RGC; (3) some mutants are temperature-sensitive for the transcriptional activity with the p53CON but not the RGC sequence; (4) p53 mutants vary in their ability to inhibit wild-type p53 transactivation but there is no difference between p53CON and RGC sequences; (5) lung cancer cells with endogenous mutant p53 proteins (M246I in H23 cells and R248L in H322 cells) retain transcriptional activity for the p53CON but not the RGC sequence. We conclude that p53 DNA target sequences vary in their response to mutant p53 proteins, and that p53 mutants vary in several transactivation related functions.	UNIV TEXAS,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	CHEN, JY (corresponding author), UNIV TEXAS,SIMMONS CANC CTR,DALLAS,TX 75235, USA.		Chen, Joanne Jeou-Yuan/S-7022-2018; Shay, Jerry W/F-7878-2011					AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BODNER SM, 1992, ONCOGENE, V7, P743; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BROWER M, 1986, CANCER RES, V46, P798; CARON DFC, 1992, GENE CHROMOSOME CANC, V4, P1; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DAMICO D, 1992, ONCOGENE, V7, P339; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1992, ONCOGENE, V7, P71; MERCER WE, 1990, ONCOGENE, V5, P973; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1992, ONCOGENE, V7, P661; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OROURKE RW, 1990, ONCOGENE, V5, P1829; QUINLAN DC, 1992, CANCER RES, V52, P4828; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952	70	165	168	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2159	2166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336941				2022-12-28	WOS:A1993LP17100016
J	CHEN, HC; WANG, LM; BANERJEE, S				CHEN, HC; WANG, LM; BANERJEE, S			ISOLATION AND CHARACTERIZATION OF THE PROMOTER REGION OF HUMAN NM23-H1, A METASTASIS SUPPRESSOR GENE	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; HUMAN BREAST-CARCINOMA; MESSENGER-RNA; GOOD PROGNOSIS; EXPRESSION; CANCER; OVEREXPRESSION; AMPLIFICATION; ASSOCIATION; PRODUCT	Allelic deletions in the nm23, a metastasis suppressor gene, are known to occur in neuroblastomas, breast and colorectal carcinomas. Down-regulation of nm23 expression has been reported in various rodent and human tumor cells with high metastasis phenotype. Colorectal tumors showed overexpression of nm23. To elucidate the regulatory mechanisms of nm23, we isolated, cloned and sequenced the presumptive regulatory DNA fragment spanning the 5' region of the human nm23-H1 gene. The region's nucleotide sequence shows the presence of motifs typical for transcriptional elements such as TFIID, AP-1 and CTF/NF1. A common transcription initiation site is located at - 136 upstream from the first ATG codon in placenta tissue, in breast, colorectal, prostate tumor cell lines and in primary colorectal tumor. Multiple transcription start sites were identified in tumor cell lines and colorectal tumor. When the promoter element was linked to a reporter gene, chloramphenicol acetyltransferase (CAT) and transfected in human 2fTGH cells, strong CAT activity was detected, which also showed that the presence of AP-1 and CTF/NF1 elements are essential for promoter activity. A detailed study of the structure and function of the promoter element of the nm23-H1 gene will help in understanding the regulatory mechanisms of nm23 expression and its role in tumor progression, especially in metastasis.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation								Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; BACKER JM, 1993, ONCOGENE, V8, P497; BEVILACQUA G, 1989, CANCER RES, V49, P5185; CLARK GM, 1991, CANCER RES, V51, P944; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FLORENES VA, 1992, CANCER RES, V52, P6088; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOLDEN A, 1993, ONCOGENES TUMOR SUPP, P345; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HONOKI K, 1993, CANCER RES, V53, P5038; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LASKO M, 1992, CELL GROWTH DIFFER, V3, P876; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; LEONE A, 1991, CANCER RES, V51, P2490; Maniatis T, 1989, DECONTAMINATION DILU; MCALPINE PJ, 1991, CYTOGENET CELL GENET, V58, P5, DOI 10.1159/000133160; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MYEROFF LL, 1993, J NATL CANCER I, V85, P147, DOI 10.1093/jnci/85.2.147; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; RADINSKY R, 1992, CANCER RES, V52, P5808; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKINNER A, 1993, ONCOGENE, V8, P3393; STAHL JA, 1991, CANCER RES, V51, P445; VARESCO L, 1992, GENE CHROMOSOME CANC, V4, P84, DOI 10.1002/gcc.2870040113; WANG LM, 1993, CANCER RES, V53, P717	36	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2905	2912						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084595				2022-12-28	WOS:A1994PG82200016
J	GALANG, CK; DER, CJ; HAUSER, CA				GALANG, CK; DER, CJ; HAUSER, CA			ONCOGENIC RAS CAN INDUCE TRANSCRIPTIONAL ACTIVATION THROUGH A VARIETY OF PROMOTER ELEMENTS, INCLUDING TANDEM C-ETS-2 BINDING-SITES	ONCOGENE			English	Article							NF-KAPPA-B; C-JUN ACTIVITY; GENE-EXPRESSION; PROTEIN-KINASE; SIGNAL TRANSDUCTION; REQUIRES RAF-1; DOMAIN; CELLS; PHOSPHORYLATION; TRANSACTIVATION	Oncogenic Ras activates the transcription of a variety of viral and cellular genes through promoter elements consisting of two closely linked binding sites for transcription factors from several distinct families. To better understand what constitutes a promoter oncogene response element (ORE), various transcription factor binding site configurations were inserted into a reporter gene, and transactivation by oncogenic Ras was measured by cotransfection assays in NIH3T3 cells. We show that a single copy of two closely linked binding sites for either AP-1, Ets, NF-kappa B, or single closely linked Ets and AP-1 binding sites, are sufficient to confer at least 10-fold transactivation by similar amounts of oncogenic Ras. Single binding sites for these factors, or several other pairings of binding sites, are not sufficient to confer Ras responsiveness. The effect of altered ORE binding site spacing and orientation was systematically analysed, and limited flexibility was observed. The novel observation that two adjacent c-Ets-2 binding sites are sufficient to act as an ORE, indicates that Ets family proteins are a target of the Ras pathway distinct from AP-1. This ORE also mediates equivalent transactivation by c-Ets-2, and mutant OREs show a parallel decrease in Ras and c-Ets-2 responsiveness. Together, these data help to define transcriptional targets of the Ras signal transduction pathway.	LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	Sanford Burnham Prebys Medical Discovery Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Der, Channing/0000-0002-7751-2747	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD028525] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978] Funding Source: Medline; NICHD NIH HHS [HD28525] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOS JL, 1989, CANCER RES, V49, P4682; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COFFER P, 1994, ONCOGENE, V9, P911; DER CJ, 1988, ONCOGENE, V3, P105; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; HERBOMEL P, 1990, New Biologist, V2, P1063; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAVROTHALASSITIS GJ, 1991, CELL GROWTH DIFFER, V2, P215; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PETTERSSON M, 1990, J MOL BIOL, V214, P373, DOI 10.1016/0022-2836(90)90187-Q; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SETH A, 1993, ONCOGENE, V8, P1783; SIF S, 1993, ONCOGENE, V8, P2501; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	53	129	130	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2913	2921						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084596				2022-12-28	WOS:A1994PG82200017
J	DEVLIN, J; KEEN, AJ; KNOWLES, MA				DEVLIN, J; KEEN, AJ; KNOWLES, MA			HOMOZYGOUS DELETION MAPPING AT 9P21 IN BLADDER-CARCINOMA DEFINES A CRITICAL REGION WITHIN 2CM OF IFNA	ONCOGENE			English	Note							ALLELIC LOSSES; SHORT ARM; CHROMOSOME-9; CANCER; MELANOMA	We have screened 165 cases of primary transitional cell carcinoma of the bladder for loss of heterozygosity of markers on chromosome 9. High density deletion mapping was then carried out on a panel of 16 tumours with partial deletions of 9p using 15 microsatellite markers. Seven tumours had hemizygous deletions which included small interstitial losses and large terminal deletions. Homozygous deletions of one or more markers were identified in the remaining 9 tumours. By comparing the limits of hemi- and homozygous deletions in these tumours we have defined a single common region of 2cM flanked by IFNA and D9S171.	MARIE CURIE RES INST,GENET MOLEC LAB,OXTED,SURREY RH8 0TL,ENGLAND					Knowles, Margaret/0000-0002-9363-8657				CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1993, CANCER RES, V53, P1230; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; CHENG JQ, 1993, CANCER RES, V53, P4761; COLEMAN A, 1994, CANCER RES, V54, P344; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; HOLLAND EA, 1994, ONCOGENE, V9, P1361; JAMES CD, 1993, CANCER RES, V53, P3674; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P1; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; MERLO A, 1994, CANCER RES, V54, P2322; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; POVEY S, 1994, IN PRESS ANN HUM GEN; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RUPPERT JM, 1993, CANCER RES, V53, P5093; STADLER WM, 1994, CANCER RES, V54, P2060; TSAI YC, 1990, CANCER RES, V50, P44; VANDERRIET P, 1994, CANCER RES, V54, P1156	27	66	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2757	2760						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058343				2022-12-28	WOS:A1994PC05400041
J	RAMOSMORALES, F; DRUKER, BJ; FISCHER, S				RAMOSMORALES, F; DRUKER, BJ; FISCHER, S			VAV BINDS TO SEVERAL SH2/SH3 CONTAINING PROTEINS IN ACTIVATED LYMPHOCYTES	ONCOGENE			English	Article							T-CELL ACTIVATION; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL-3 KINASE; HEMATOPOIETIC-CELLS; PDGF RECEPTOR; BETA-SUBUNIT; EGF RECEPTOR; SH2 DOMAINS; SITE	In T lymphocytes, several proteins are rapidly phosphorylated on tyrosine after stimulation. In this study we examine the ability of tyrosine phosphorylated proteins from Jurkat T cells stimulated by CD2 or T cell receptor-CD3 to interact with the src homology 2 or src homology 3 domains from eight different proteins involved in signal transduction in lymphocytes: Vav, Shc, Nck, phosphatidylinositol-3-kinase, phospholipase C-gamma 1, Ras-GTPase activating protein, c-Crk and Grb2. Our data show that different SH2 domains have distinct pattern of binding to phosphotyrosine containing proteins. We show that Vav, a protein expressed only in hematopoietic cells that may have guanine nucleotide releasing factor activity, is able to interact with certain SH2-containing proteins depending on its tyrosine phosphorylation and with Grb2 in a manner independent of phosphorylation on tyrosine. Coimmunoprecipitation experiments support the idea of a trimolecular complex Shc-Grb2-Vav in vivo. These data suggest a central role played by Vav and provide insight in the complexity and specificity of protein-protein interactions in the signaling events in lymphocytes.	OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA	Oregon Health & Science University	RAMOSMORALES, F (corresponding author), HOP COCHIN, INSERM, U363, INST COCHIN GENET MOLEC, 27 RUE FAUBOURG ST JACQUES, F-75014 PARIS, FRANCE.		Ramos-Morales, Francisco/C-5734-2008	Ramos-Morales, Francisco/0000-0002-1151-4547; Druker, Brian/0000-0001-8331-8206				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HSI ED, 1989, J BIOL CHEM, V264, P10836; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P688; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PUIL L, 1992, Current Biology, V2, P275, DOI 10.1016/0960-9822(92)90396-R; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SONGYANG Z, 1993, CELL, V72, P1; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	38	76	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1917	1923						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208538				2022-12-28	WOS:A1994NR68500015
J	BRAIN, R; JENKINS, JR				BRAIN, R; JENKINS, JR			HUMAN P53 DIRECTS DNA STRAND REASSOCIATION AND IS PHOTOLABELED BY 8-AZIDO ATP	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; LARGE T-ANTIGEN; NUCLEOTIDE-SEQUENCE; HELICASE ACTIVITY; PROTEIN; TRANSFORMATION; GENE; REPLICATION; ONCOGENE; INVITRO	p53 is the most frequent known target for mutation in human cancer. Evidence suggests that p53 protein may be involved variously in transcription and cell cycle control, in DNA replication and in G1 checkpoint control following the cellular response to radiation induced DNA damage. p53 blocks DNA replication of the small DNA tumour virus, simian virus 40, by inhibiting unwinding of the viral origin of replication by the DNA helicase activity of the virally encoded large T antigen protein. Here we report the novel observation that human p53 protein can bind ATP and exhibits an intrinsic ATP stimulated DNA strand reassociation activity. Both activities map to the carboxyl terminal 128 amino acids of p53. Thus, in addition to any role in transcription, our results indicate that p53 is potentially capable of inhibiting mammalian replicative DNA synthesis by blocking the DNA strand separation step during replication origin recruitment. However, the ability of p53 to modulate the topological relationship between complementary nucleotide strands is also compatible with a direct role for p53 in other aspects of DNA synthesis, recombination or repair,	MARIE CURIE RES INST,CELL PROLIFERAT LAB,OXTED RH8 0TL,SURREY,ENGLAND									ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; COX MM, 1981, NUCLEIC ACIDS RES, V9, P389, DOI 10.1093/nar/9.2.389; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; KANDA T, 1994, IN PRESS MOL CELL BI; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; ROVINSKI B, 1988, ONCOGENE, V2, P445; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	37	73	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1775	1780						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183576				2022-12-28	WOS:A1994NL81500033
J	GORUPPI, S; GUSTINCICH, S; BRANCOLINI, C; LEE, WMF; SCHNEIDER, C				GORUPPI, S; GUSTINCICH, S; BRANCOLINI, C; LEE, WMF; SCHNEIDER, C			DISSECTION OF C-MYC DOMAINS INVOLVED IN S-PHASE INDUCTION OF NIH3T3 FIBROBLASTS	ONCOGENE			English	Article							DNA-BINDING; CELL-CYCLE; NUCLEAR-LOCALIZATION; PROTEIN EXPRESSION; MURINE FIBROBLASTS; SURVIVAL FACTORS; MESSENGER-RNA; TRANSFORMATION; GENE; MAX	The product of the c-myc proto-oncogene is an important regulator of cell proliferation and apoptosis in murine fibroblasts. Addition of the tumor promoter, phorbol myristate acetate (PMA), prevents apoptotic cell death induced by low serum concentrations in NIH3T3 cells that constitutively express and are transformed by v-myc. The protective effect of PMA allowed us to analyse the ability of normal c-Myc and Myc deletion mutants to induce serum starved, untransformed NIH3T3 cells to enter S phase. By microinjecting these quiescent cells with wild type and mutant human c-myc plasmids, we showed that full length c-myc is able to induce S phase entry in presence of PMA, but that c-Myc mutants that delete amino acids Delta 7/91, Delta 41/53, Delta 56/103, Delta 106/143, Delta 265/317 and Delta 414/433 are totally inactive. c-Myc did not shorten the period before entry into S phase, since Myc overexpressing cells entered S phase with the same kinetics as control cells when both were stimulated with 20% fetal calf serum (FCS). However, c-Myc overexpression did increase the percentage of cells entering S phase when these cells were stimulated with 2% fetal calf serum. Interestingly, this ability to enhance stimulation by a suboptimal concentration of FCS was retained to a significant degree by Myc mutants that delete amino acids Delta 41/53, Delta 56/103 or Delta 265/317. Finally, Myc mutants that delete Delta 106/143 or Delta 414/433 exerted a dominant negative effect on S phase entry both in quiescent cells stimulated with 2% FCS and in unsynchronized, cycling cells.	LNCIB, I-34012 TRIESTE, ITALY; UNIV PENN, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA; UNIV UDINE, DIPARTIMENTO SCI & TECNOL BIOMED, SEZ BIOL, I-33100 UDINE, ITALY	University of Pennsylvania; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine				Gustincich, Stefano/0000-0002-2749-2514; BRANCOLINI, Claudio/0000-0002-6597-5373				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; BIGNAMI M, 1988, ONCOGENE, V2, P509; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KARN J, 1989, ONCOGENE, V4, P773; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; OHMORI Y, 1993, ONCOGENE, V8, P379; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Sambrook J, 1989, MOL CLONING LABORATO; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; TAMM I, 1990, J CELL PHYSIOL, V143, P494, DOI 10.1002/jcp.1041430314; TAMM I, 1991, J CELL PHYSIOL, V148, P85, DOI 10.1002/jcp.1041480111; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WATERS CM, 1991, ONCOGENE, V6, P797; WATERS CM, 1992, CELL, V69, P119	42	20	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1537	1544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183547				2022-12-28	WOS:A1994NL81500003
J	ISSHIKI, K; SENG, BA; ELDER, DE; GUERRY, D; LINNENBACH, AJ				ISSHIKI, K; SENG, BA; ELDER, DE; GUERRY, D; LINNENBACH, AJ			CHROMOSOME-9 DELETION IN SPORADIC AND FAMILIAL MELANOMAS IN-VIVO	ONCOGENE			English	Article							HUMAN-MALIGNANT MELANOMA; HOMOZYGOUS DELETIONS; COLORECTAL-CANCER; TUMOR PROGRESSION; DYSPLASTIC NEVUS; CELL-LINES; SHORT ARM; LOCUS; GENE; LINKAGE	Twenty microsatellite loci on chromosome 9 were analysed for allelic losses in DNAs from 30 uncultured melanomas from 25 patients, relative to DNA from autologous peripheral blood lymphocytes. All patients were constitutionally heterozygous at several loci, and loss of heterozygosity (LOH) affecting 9p was observed in melanoma DNAs from 18 individuals (72%). Observations of losses of identical alleles in different metastatic lesions from the same patients, and of LOH in a vertical growth phase primary melanoma, were consistent with previous reports of chromosome 9 deletion early in melanoma development. LOH data suggested the loss of entire copies of chromosome 9 in 11 cases, and the terminal deletion of all or a portion of 9p in six cases. A somatic interstitial deletion of 9p between D9S162 and D9S169 was seen in a familial melanoma. This 21 cM deleted region corresponded with the previously reported positions of homozygous deletions in melanoma cell lines, and of the familial melanoma susceptibility locus (MLM). As 16 of the 18 cases of 9p LOH in the present study were observed in individuals with no family history of melanoma, it is likely that the MLM locus plays a role in the development of most sporadic melanomas.	WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NATIONAL CANCER INSTITUTE [P01CA025874, R01CA025298, P30CA010815] Funding Source: NIH RePORTER; NCI NIH HHS [CA25874, CA10815, CA25298] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; Cowan J M, 1991, Cancer Treat Res, V54, P3; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRACOPOLI NC, 1985, P NATL ACAD SCI USA, V82, P1470, DOI 10.1073/pnas.82.5.1470; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; Greene MH, 1979, HUMAN MALIGNANT MELA, P139; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISSHIKI K, 1993, GENE CHROMOSOME CANC, V8, P178, DOI 10.1002/gcc.2870080307; JAMES CD, 1993, CANCER RES, V53, P3674; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; LINNENBACH AJ, 1994, NATURE, V367, P419, DOI 10.1038/367419b0; LITT M, 1989, AM J HUM GENET, V44, P397; MILLIKIN D, 1991, CANCER RES, V51, P5449; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; Parmiter A., 1988, MALIGNANT MELANOMA B, P47; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PETTY EM, 1993, AM J HUM GENET, V53, P96; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	32	54	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1649	1653						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183559				2022-12-28	WOS:A1994NL81500016
J	SHIPLEY, JM; CLARK, J; CREW, AJ; BIRDSALL, S; ROCQUES, PJ; GILL, S; CHELLY, J; MONACO, AP; ABE, S; GUSTERSON, BA; COOPER, CS				SHIPLEY, JM; CLARK, J; CREW, AJ; BIRDSALL, S; ROCQUES, PJ; GILL, S; CHELLY, J; MONACO, AP; ABE, S; GUSTERSON, BA; COOPER, CS			THE T(X18)(P11.2Q11.2) TRANSLOCATION FOUND IN HUMAN SYNOVIAL SARCOMAS INVOLVES 2 DISTINCT LOCI ON THE X-CHROMOSOME	ONCOGENE			English	Article							BREAKPOINT; LIBRARIES	A high proportion of synovial sarcomas contain the reciprocal translocation t(X;18)(p11.2;q11.2). We have previously localized the breakpoint on the X chromosome between the X chromosome marker DXS255 and an ornithine aminotransferase (OAT) pseudogene region designated OATL2. Subsequently by fluorescence in situ hybridization (FISH) we provided evidence that YACs corresponding to the OATL2 locus spanned the breakpoint. In order to confirm the position of this breakpoint cosmids corresponding to the OATL2 region were isolated. Most of these cosmids mapped to four cosmid contigs designated C1-C4. Analysis of two contigs, C1-and C4, using FISH established that in four of six synovial sarcomas examined the breakpoint occurs between these two contigs: C1 lies distal to the breakpoint while C4 is proximal. In contrast we provide evidence that the breakpoint in the remaining two tumours mapped to a second pseudogene region called OATL1 that is telomeric to the OATL2 locus. This heterogeneity of the breakpoint position on the X chromosome explains why in previous mapping studies there have been discrepancies between the results obtained by different laboratories.	INST CANC RES, MOLEC CARCINOGENESIS SECT, SUTTON SM2 5NG, SURREY, ENGLAND; JOHN RADCLIFFE HOSP, IMPERIAL CANC RES FUND, HUMAN GENET LAB, OXFORD OX3 9DU, ENGLAND; HOKKAIDO UNIV, FAC SCI, CHROMOSOME RES UNIT, SAPPORO, HOKKAIDO, JAPAN	University of London; Institute of Cancer Research - UK; University of Oxford; Hokkaido University	SHIPLEY, JM (corresponding author), INST CANC RES, CELL BIOL & EXPTL PATHOL SECT, 15 COTSWOLD RD, SUTTON SM2 5NG, SURREY, ENGLAND.		gusterson, barry a/D-3752-2009; Monaco, Anthony P/A-4495-2010; Chelly, Jamel/J-7528-2015	Monaco, Anthony P/0000-0001-7480-3197; Chelly, Jamel/0000-0002-0939-8719; Shipley, Janet/0000-0001-6748-8678				BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; COOPER CS, 1993, ADV CANCER RES, V60, P75; COOPER CS, 1991, CARCINOGENESIS, V12, P155, DOI 10.1093/carcin/12.2.155; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; Coulson Alan, 1988, P19; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELEEUW B, 1993, ONCOGENE, V8, P1457; DELEEUW B, 1993, GENE CHROMOSOME CANC, V6, P182, DOI 10.1002/gcc.2870060309; Enzinger RM., 2011, SOFT TISSUE TUMORS, P1178; GERAGHTY MT, 1993, GENOMICS, V16, P440, DOI 10.1006/geno.1993.1208; GILGENKRANTZ S, 1990, ONCOGENE, V5, P1063; GREIG GM, 1993, HUM MOL GENET, V2, P1611; KNIGHT JC, 1992, HUM MOL GENET, V1, P633, DOI 10.1093/hmg/1.8.633; KNIGHT JC, 1992, INT J ONCOL, V1, P747; LAFRENIERE RG, 1991, GENOMICS, V10, P276, DOI 10.1016/0888-7543(91)90512-D; LIMON J, 1991, GENE CHROMOSOME CANC, V3, P338, DOI 10.1002/gcc.2870030504; LITTLE PFR, 1987, DNA CLONING PRACTICA, V3, P19; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; NOJIMA T, 1990, ACTA PATHOL JAPON, V40, P486; REEVES BR, 1989, ONCOGENE, V4, P373; RUBIN CM, 1988, P NATL ACAD SCI USA, V85, P2795, DOI 10.1073/pnas.85.8.2795; SHENG WW, 1987, CANCER GENET CYTOGEN, V29, P179, DOI 10.1016/0165-4608(87)90048-3; SHIPLEY JM, 1993, CYTOGENET CELL GENET, V64, P233, DOI 10.1159/000133585; SMITH S, 1987, CANCER GENET CYTOGEN, V26, P179, DOI 10.1016/0165-4608(87)90147-6; SONOBE H, 1992, LAB INVEST, V67, P498; TACHIBANA K, 1993, GENE, V124, P231, DOI 10.1016/0378-1119(93)90398-M; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160	29	53	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1447	1453						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152806				2022-12-28	WOS:A1994NH40100017
J	MEERABUX, JM; COTTER, FE; KEARNEY, L; NIZETIC, D; DHUT, S; GIBBONS, B; LISTER, TA; YOUNG, BD				MEERABUX, JM; COTTER, FE; KEARNEY, L; NIZETIC, D; DHUT, S; GIBBONS, B; LISTER, TA; YOUNG, BD			MOLECULAR-CLONING OF A NOVEL 11Q23 BREAKPOINT ASSOCIATED WITH NON-HODGKINS-LYMPHOMA	ONCOGENE			English	Article							B-CELL LYMPHOMA; ACUTE LEUKEMIAS; CHROMOSOME-TRANSLOCATION; DROSOPHILA-TRITHORAX; INSITU HYBRIDIZATION; GENE; ABNORMALITIES; T(4-11); IDENTIFICATION; DISTINCT	Chromosomal analysis of a non-Hodgkin's lymphoma revealed a t(11;14)(q23;q32) translocation amongst other abnormalities. To investigate the molecular basis of this translocation, a cosmid library was constructed from the tumour DNA and the rearranged IGH locus was isolated in a single cosmid. Fluorescence in situ hybridization confirmed that the cloned region contained sequences from chromosome 11q23 fused to chromosome 14q32. Sequence analysis identified the breakpoint as a fusion between a region from the switch segment of the C gamma 4 gene of the IGH locus and an unknown sequence on chromosome 11. The chromosome 11 sequence maps proximal to the CD3 gene cluster and is therefore distinct from both the HTRX1 gene (rearranged in acute leukaemias) and the RCK gene (rearranged in a cell line derived from a histiocytic B-cell lymphoma). This newly identified region contains a cluster of rare cutting restriction enzyme sites located within 200 bases of the breakpoint, suggestive of a CpG island. Although this t(11;14)(q23;q32) translocation and that in the RC-K8 cell line affect different regions on chromosome 11, the breakpoints on chromosome 14 were found to have occurred at equivalent positions of S gamma 2 and S gamma 4 segments.	ST BARTHOLOMEWS HOSP,DEPT MED ONCOL,IMPERIAL CANC RES FUND,LONDON EC1A 7BE,ENGLAND; INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND; IMPERIAL CANC RES FUND,GENOME ANAL LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; University of London; Queen Mary University London; University of London; University College London; Cancer Research UK; The Genome Analysis Centre (TGAC)			Nizetic, Dean/F-9509-2015	Nizetic, Dean/0000-0001-5486-5761				AKAO Y, 1991, CANCER RES, V51, P1574; AKAO Y, 1992, CANCER RES, V52, P6083; AKAO Y, 1990, CANCER RES, V50, P4856; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; CABANILLAS F, 1988, BLOOD, V71, P1615; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COTTER FE, 1990, GENOMICS, V7, P257, DOI 10.1016/0888-7543(90)90548-9; DAS S, 1992, GENE CHROMOSOME CANC, V5, P244, DOI 10.1002/gcc.2870050312; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIBSON TJ, 1987, GENE, V53, P275, DOI 10.1016/0378-1119(87)90016-3; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; KEARNEY L, 1992, BLOOD, V80, P1659; KIEVITS T, 1990, CYTOGENET CELL GENET, V53, P134, DOI 10.1159/000132913; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LEVINE EG, 1985, BLOOD, V66, P1414; MCKEITHAN TW, 1990, GENE CHROMOSOME CANC, V1, P247, DOI 10.1002/gcc.2870010310; MILLS FC, 1990, NUCLEIC ACIDS RES, V18, P7305, DOI 10.1093/nar/18.24.7305; MOLLER P, 1986, VIRCHOWS ARCH A, V409, P79, DOI 10.1007/BF00705408; NISHIDA Y, 1982, P NATL ACAD SCI-BIOL, V79, P3833, DOI 10.1073/pnas.79.12.3833; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; PARRY P, 1993, P NATL ACAD SCI USA, V90, P4738, DOI 10.1073/pnas.90.10.4738; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; RADICE P, 1992, GENE CHROMOSOME CANC, V5, P50, DOI 10.1002/gcc.2870050108; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARPA A, 1987, VIRCHOWS ARCH A, V412, P17, DOI 10.1007/BF00750725; SCARPA A, 1991, BLOOD, V78, P780; TAKAHASHI N, 1980, NUCLEIC ACIDS RES, V8, P5983, DOI 10.1093/nar/8.24.5983; TAKAHASHI N, 1982, CELL, V29, P671, DOI 10.1016/0092-8674(82)90183-0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	34	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					893	898						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108133				2022-12-28	WOS:A1994MW55100026
J	BAZENET, CE; KAZLAUSKAS, A				BAZENET, CE; KAZLAUSKAS, A			THE PDGF RECEPTOR-ALPHA SUBUNIT ACTIVATES P21(RAS) AND TRIGGERS DNA-SYNTHESIS WITHOUT INTERACTING WITH RASGAP	ONCOGENE			English	Article							PHOSPHOLIPASE-C-GAMMA; GROWTH-FACTOR RECEPTORS; GAP-ASSOCIATED PROTEINS; FACTOR-I RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL KINASE; BINDING; CELLS; SRC	There are two closely related, but distinct platelet-derived growth factor receptor (PDGFR) subunits: alpha and beta. Recent studies have indicated that relay of a biological signal from the activated PDGFR P subunit is determined to a large degree by the intracellular signal transduction enzymes with which the beta subunit associates. Like the beta subunit, the PDGFR alpha subunit encodes a tyrosine kinase that is activated and tyrosine phosphorylated upon binding of PDGF. To investigate the mechanism by which the PDGFR alpha subunit mediates signal transduction, we examined the proteins that associate with the activated PDGFR alpha subunit. The human alpha subunit was expressed in PhB cells, fibroblasts derived from Ph/Ph mouse embryos, which express the beta subunit but do not express the PDGFR alpha subunit. In response to binding of PDGF, the alpha subunit stably associated with phospholipase C gamma 1 (PLC-gamma 1), phosphatidylinositol 3 kinase (PI3K), the phosphotyrosine phosphatase Syp, and a 120 kd protein. These same proteins were detected binding to the activated PDGFR beta subunit. Unlike the PDGFR beta subunit, the PDGF-activated alpha subunit did not stably associate with the GTPase activating protein of ras (rasGAP), nor did it mediate tyrosine phosphorylation of rasGAP. Despite its apparent inability to interact with rasGAP, the alpha subunit was fully able to trigger PDGF-dependent p21(ras) activation and DNA synthesis. We conclude that the PDGFR alpha subunit does not mediate tyrosine phosphorylation or associate with rasGAP, and that these events are not required for PDGF-AA-mediated activation of p21(ras) or DNA synthesis.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA	National Jewish Health					NATIONAL CANCER INSTITUTE [R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER; NCI NIH HHS [CA55063] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALK SD, 1971, P NATL ACAD SCI USA, V68, P271, DOI 10.1073/pnas.68.2.271; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PALMIERI SL, 1992, MECH DEVELOP, V39, P181, DOI 10.1016/0925-4773(92)90045-L; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCATTERMAN GC, 1992, DEVELOPMENT, V115, P123; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YEH HJ, 1993, P NATL ACAD SCI USA, V90, P1952, DOI 10.1073/pnas.90.5.1952; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	77	43	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					517	525						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290262				2022-12-28	WOS:A1994MW24800019
J	ROUSSEL, MF; DAVIS, JN; CLEVELAND, JL; GHYSDAEL, J; HIEBERT, SW				ROUSSEL, MF; DAVIS, JN; CLEVELAND, JL; GHYSDAEL, J; HIEBERT, SW			DUAL CONTROL OF MYC EXPRESSION THROUGH A SINGLE DNA-BINDING SITE TARGETED BY ETS FAMILY PROTEINS AND E2F-1	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; STIMULATING FACTOR-I; HUMAN C-MYC; RETINOBLASTOMA PROTEIN; TRANS-ACTIVATION; CELL-CYCLE; PUTATIVE ONCOGENE; LEUKEMIA-VIRUS; NUCLEAR FACTOR; GENE-PRODUCT	NIH3T3 cells expressing a mutant colony-stimulating factor-1 receptor (CSF-1R) containing a phenylalanine for tyrosine substitution in the tyrosine kinase domain at codon 809 exhibit defective myc regulation and do not enter S phase when stimulated by CSF-1. Enforced expression of either ets-1 or ets-2 in these cells restores their mitogenic response, albeit less efficiently than myc itself, suggesting that ets proteins may regulate c-myc expression. Ets-1 transactivates reporter genes driven by the human and mouse c-myc promoters through the binding site for the transcription factor E2F, the latter being required for E1A- and serum-induced c-mye expression. Analysis of E2F-1 sequences identified a minimal DNA binding domain that is related to those of ets proteins. Although E2F and ets proteins interact with similar consensus DNA binding sites, in vitro binding assays revealed that E2F can bind DNA as a homodimer, whereas ets proteins bind these sites as monomers. E2F and ets proteins do not form heterodimers in vitro and do not transactivate c-mye synergistically. Thus, E2F-1 and ets family members may independently regulate c-mye transcription through the same binding site at different times following growth factor stimulation.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; INST CURIE, CNRS, URA 1443, F-91405 ORSAY, FRANCE	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	ROUSSEL, MF (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA.		GHYSDAEL, Jacques/F-3377-2013; Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139	NCI NIH HHS [CA-47064, CA-56819] Funding Source: Medline; NIDDK NIH HHS [DK 44158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047064, R01CA056819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Ghysdael J, 1991, CURR OPIN CELL BIOL, V3, P484, DOI 10.1016/0955-0674(91)90077-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCKEON C, 1988, CANCER RES, V48, P4307; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; POGNONEC P, 1990, ONCOGENE, V5, P603; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1993, CURR OPIN HEMATOL, V1, P11; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	59	126	126	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					405	415						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290253				2022-12-28	WOS:A1994MW24800007
J	HOGG, D; GUIDOS, C; BAILEY, D; AMENDOLA, A; GROVES, T; DAVIDSON, J; SCHMANDT, R; MILLS, G				HOGG, D; GUIDOS, C; BAILEY, D; AMENDOLA, A; GROVES, T; DAVIDSON, J; SCHMANDT, R; MILLS, G			CELL-CYCLE DEPENDENT REGULATION OF THE PROTEIN-KINASE TTK	ONCOGENE			English	Article							TYROSINE PHOSPHATASE; ACTIVATES P34CDC2; CDC25 PROTEIN; S-PHASE; PHOSPHORYLATION; DEPHOSPHORYLATION; IDENTIFICATION; TRANSITIONS; COMPLEX; G1	TTK is a novel protein kinase detectable in all proliferating human cells and tissues. Expression of the TTK gene is markedly reduced or absent in resting cells and in tissues with a low proliferative index. In view of the apparent association between TTK gene expression and cell proliferation, we examined the regulation of this protein kinase during transit of the cell cycle. We found very low levels of TTK mRNA and protein in starved cells. When cells are induced to enter the cell cycle, levels of TTK mRNA, protein and kinase activity increase at the G1/S phase of the cell cycle and peak in G2/M. TTK mRNA levels, as well as kinase activity, drop sharply in early G1, whereas protein levels are largely maintained. TTK may play a role in cell cycle control.	TORONTO HOSP, DEPT PATHOL, TORONTO M5T 2S8, ON, CANADA; HOSP SICK CHILDREN, DIV IMMUNOL & CANC, TORONTO M5G 1X8, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; BASERGA R, 1990, CANCER RES, V50, P6769; Bauer K D, 1990, Methods Cell Biol, V33, P235; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; JOLOMON M, 1993, EMBO J, V12, P3133; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LINDBERG RA, 1993, ONCOGENE, V8, P351; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLS GB, 1992, J BIOL CHEM, V267, P16000; MORIA AO, 1989, CELL, V58, P193; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	44	45	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					89	96						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302607				2022-12-28	WOS:A1994MW24700011
J	WELCH, DR; CHEN, PC; MIELE, ME; MCGARY, CT; BOWER, JM; STANBRIDGE, EJ; WEISSMAN, BE				WELCH, DR; CHEN, PC; MIELE, ME; MCGARY, CT; BOWER, JM; STANBRIDGE, EJ; WEISSMAN, BE			MICROCELL-MEDIATED TRANSFER OF CHROMOSOME-6 INTO METASTATIC HUMAN C8161 MELANOMA-CELLS SUPPRESSES METASTASIS BUT DOES NOT INHIBIT TUMORIGENICITY	ONCOGENE			English	Article							HUMAN-MALIGNANT MELANOMA; NM23 GENE; NEGATIVE REGULATION; NUDE-MICE; EXPRESSION; PROGRESSION; CANCER; PHENOTYPE; INVASION; GROWTH	Structural alterations of chromosome 6, including del(6q), are often associated with metastatic melanoma; therefore, we hypothesized that a metastasis-suppressor gene could be coded on human chromosome 6. Highly metastatic C8161 human malignant melanoma cells exhibit chromosomal changes typical of late-stage melanomas. Using microcell-mediated chromosome transfer, a copy of a normal human chromosome 6 was introduced into C8161. Three randomly selected hybrid clones (neo6/C8161.1, neo6/C8161.2 and neo6/C8161.3) were assayed for metastasis in athymic nude mice. All controls - parental C8161 cells, randomly-selected single cell clones, neo-transfected cell clones, neo11/CS161.2 and neo11/C8161.3 - were tumorigenic (270/272 mice) and metastatic (208/272 mice). neo6/C8161 hybrid cells were still tumorigenic (91/93 mice) but were not metastatic (0/195 mice). The presence of the added chromosomes was verified in cultured and tumor cells by amplification of polymorphic (CA), markers using PCR-RFLP. The neo6/C8161 hybrids display growth and morphological patterns of more differentiated cells than C8161. In Northern blot analysis an inverse relationship between metastatic ability and metastasis-suppressor gene, nm23-H1, expression is observed - with clone neo6/C8161.1 expressing the highest level of nm23 transcripts, neo6/C8161.2 and neo6/C8161.3 expressing intermediate levels, and barely detectable levels are seen in C8161. Collectively, these results suggest that a malignant melanoma metastasis-regulatory gene may be located on human chromosome 6. These results further demonstrate that tumorigenicity and metastatic ability are distinct phenotypes.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27514; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27514; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Irvine	WELCH, DR (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PATHOL,DIV EXPTL PATHOL,HERSHEY,PA 17033, USA.				NCI NIH HHS [R01-CA19401, R01-CA44470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044470, R01CA019401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1991, CANCER RES, V51, P4815; ALHADEFF B, 1977, CYTOGENET CELL GENET, V19, P234; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOBROW M, 1974, NATURE, V251, P77, DOI 10.1038/251077a0; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CHAMBERS AF, 1990, INVAS METAST, V10, P225; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CHURCH SL, 1992, GENOMICS, V14, P823, DOI 10.1016/S0888-7543(05)80202-2; CLARK WH, 1991, CANCER METAST REV, V10, P83, DOI 10.1007/BF00049406; CONWAY K, 1992, CANCER RES, V52, P6487; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRACOPOLI NC, 1988, SEMIN ONCOL, V15, P541; DRACOPOLI NC, 1992, AM J HUM GENET, V54, pA51; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FLORENES VA, 1992, CANCER RES, V52, P6088; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FOUNTAIN JW, 1992, AM J HUM GENET, V54, pA51; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUAN XY, 1992, GENOMICS, V14, P680, DOI 10.1016/S0888-7543(05)80168-5; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HIGASHIYAMA M, 1992, BRIT J CANCER, V66, P533, DOI 10.1038/bjc.1992.308; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; KJELDSEN L, 1992, BIOCHEM J, V287, P603, DOI 10.1042/bj2870603; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0292-54; LIOTTA LA, 1991, CANCER RES, V51, pS5054; MILLIKIN D, 1991, CANCER RES, V51, P5449; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P4743, DOI 10.1093/nar/16.10.4743; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; NEGRINI M, 1992, CANCER RES, V52, P1297; NICHOLAS CD, 1991, P NATL ACAD SCI USA, V82, P1470; NICOLSON GL, 1993, EXP CELL RES, V204, P171, DOI 10.1006/excr.1993.1022; NICOLSON GL, 1993, HOSP PRAC, P43; PARMITER AH, 1988, MALIGNANT MELANOMA B, P43; RADINSKY R, 1992, CANCER RES, V52, P5808; Radinsky R, 1991, Semin Cancer Biol, V2, P169; RODECK U, 1991, CANCER METAST REV, V10, P89, DOI 10.1007/BF00049407; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; Sambrook J, 1989, MOL CLONING LABORATO; SANFORD JA, 1987, SOMAT CELL MOLEC GEN, V13, P279, DOI 10.1007/BF01535210; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SCHLATTER B, 1992, P NATL ACAD SCI USA, V89, P9986, DOI 10.1073/pnas.89.21.9986; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; Trent J M, 1989, Carcinog Compr Surv, V11, P165; TRENT JM, 1991, CANCER METAST REV, V10, P103, DOI 10.1007/BF00049408; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TUCK AB, 1990, CLIN EXP METASTAS, V8, P417, DOI 10.1007/BF00058153; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4636, DOI 10.1093/nar/18.15.4636-a; WEISSMAN BE, 1983, JNCI-J NATL CANCER I, V70, P667; WELCH DR, 1983, INVAS METAST, V3, P65; WELCH DR, 1989, INT J CANCER, V43, P449, DOI 10.1002/ijc.2910430318; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105	63	153	160	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					255	262						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302587				2022-12-28	WOS:A1994MW24700031
J	LOFTS, FJ; HURST, HC; STERNBERG, MJE; GULLICK, WJ				LOFTS, FJ; HURST, HC; STERNBERG, MJE; GULLICK, WJ			SPECIFIC SHORT TRANSMEMBRANE SEQUENCES CAN INHIBIT TRANSFORMATION BY THE MUTANT NEU GROWTH-FACTOR RECEPTOR IN-VITRO AND IN-VIVO	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; ONCOGENIC ACTIVATION; SIGNAL TRANSDUCTION; TRUNCATED RECEPTOR; POINT MUTATION; EGF RECEPTOR; PROTEIN; DOMAIN; DIMERIZATION; EXPRESSION	The neu oncogene is activated by a point mutation within its transmembrane domain that results in the substitution of glutamic acid for valine at position 664, and is associated with constitutive activation of the tyrosine kinase. It has been proposed that the mutation allows for stabilization of homodimers of the receptor that are necessary for transduction of the mitogenic signal. To investigate the role of the alpha-helical transmembrane sequence in the function of neu, we constructed an expression vector to produce a variety of short transmembrane neu proteins, lacking ligand binding or intracellular kinase domains. Such sequences should interact with full-length receptors and prevent receptor dimerization and thus act as specific inhibitors of function. These small proteins all included a pentapeptide from position 661-665, which has been proposed to be necessary for packing. We show that the short transmembrane molecules are expressed at the cell surface and can retard the growth of neu-transformed cells in monolayers, as colonies in soft agar and as tumours in animals. As predicted by molecular modelling, the magnitude of inhibition depended on the nature of the packing surface, suggesting that the neu transmembrane domain is directly involved in neu protein dimerization.	HAMMERSMITH HOSP,ICRF,ONCOL GRP,MOLEC ONCOL LAB,DU CANE RD,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,ICRF,ONCOL GRP,GENE TRANSCRIPT LAB,LONDON W12 0HS,ENGLAND; ICRF,BIOMOLEC MODELLING LAB,LONDON WC2A 3PX,ENGLAND	Imperial College London; Imperial College London				Sternberg, Michael/0000-0002-1884-5445				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BARGMANN CI, 1986, CELL, V45, P469; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2921; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1992, J BIOL CHEM, V267, P20489; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Gullick W J, 1988, Methods Mol Biol, V3, P341, DOI 10.1385/0-89603-126-8:341; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	43	70	74	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2813	2820						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8104327				2022-12-28	WOS:A1993LX34300023
J	HARVEY, M; SANDS, AT; WEISS, RS; HEGI, ME; WISEMAN, RW; PANTAZIS, P; GIOVANELLA, BC; TAINSKY, MA; BRADLEY, A; DONEHOWER, LA				HARVEY, M; SANDS, AT; WEISS, RS; HEGI, ME; WISEMAN, RW; PANTAZIS, P; GIOVANELLA, BC; TAINSKY, MA; BRADLEY, A; DONEHOWER, LA			IN-VITRO GROWTH-CHARACTERISTICS OF EMBRYO FIBROBLASTS ISOLATED FROM P53-DEFICIENT MICE	ONCOGENE			English	Article							WILD-TYPE P53; TUMOR-ANTIGEN; GENE-PRODUCT; T-ANTIGEN; DNA; CELLS; PROTEIN; IMMORTALIZATION; TRANSFORMATION; EXPRESSION	Fibroblast cultures were derived from mouse embryos containing either one (p53+/-) or two (p53-/-) inactivated p53 alleles and compared to normal embryo fibroblasts for a number of growth parameters. Early passage p53-deficient embryo fibroblasts (p53-/-) divided faster than normal embryo fibroblasts, achieved higher confluent densities, and had a higher fraction of division-competent cells under conditions of low cell density. Flow cytometry studies of early passage embryo fibroblasts showed that the percent of p53-deficient cells in G0/G1 was lower than in normal cells, consistent with the argument that p53 mediates a GI block. When p53-deficient and normal cells were passaged for long periods of time, the homozygote (p53-/-) fibroblasts grew at a high rate for over 50 passages and never entered a non-growing senescent phase characteristic of the heterozygote (p53+/-) and normal (p53+/+) cells. The p53-deficient fibroblasts were genetically unstable during passaging, with the p53-/- cells showing a high degree of aneuploidy and the p53+/- cells displaying a moderate level of chromosomal abnormalities by passage 25. Surprisingly, the heterozygote cells lost their single wild type allele very early during culturing and in spite of this loss most heterozygote lines entered into senescence. We conclude that the loss of p53 by itself is insufficient to confer immortality on a cell, but does confer a growth advantage. Taken together, the findings confirm that the absence of p53 promotes genomic instability, which in turn may result in genetic alterations which directly produce immortality.	BAYLOR COLL MED,DEPT MOLEC VIROL,HOUSTON,TX 77030; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; STEHLIN FDN CANC RES,HOUSTON,TX 77002; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; UNIV TEXAS,M D ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center			Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495; Tainsky, Michael/0000-0002-0261-831X; Bradley, Allan/0000-0002-2349-8839	NATIONAL CANCER INSTITUTE [R01CA054897] Funding Source: NIH RePORTER; NCI NIH HHS [CA54897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFFIE A, IN PRESS; DIETRICH W, 1992, GENETICS, V131, P423; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; Newbold R F, 1985, Carcinog Compr Surv, V9, P17; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RITTLING SR, 1992, ONCOGENE, V7, P935; ROVINSKI B, 1988, ONCOGENE, V2, P445; Sambrook J, 1989, MOL CLONING LABORATO; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; ULLRICH E, 1992, GENE DEV, V6, P876; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WARE LM, 1972, VIROLOGY, V50, P339, DOI 10.1016/0042-6822(72)90385-6	46	479	486	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2457	2467						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8103211				2022-12-28	WOS:A1993LT36800017
J	FOX, PL; SA, G; DOBROWOLSKI, SF; STACEY, DW				FOX, PL; SA, G; DOBROWOLSKI, SF; STACEY, DW			THE REGULATION OF ENDOTHELIAL-CELL MOTILITY BY P21 RAS	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; METASTATIC PHENOTYPE; NIH/3T3 CELLS; ONCOGENE; PROTEIN; MICROINJECTION; PROLIFERATION; TRANSFORMATION; NIH-3T3-CELLS	Directed endothelial cell (EC) movement is required for the development and repair of blood vessels and plays a critical role in angiogenic processes obligatory for large tumor formation. We now report that vas proteins have a critical role in regulation of movement of normal mammalian cells. Bovine aortic EC microinjected with oncogenic Ha-ras enter further into an artificial wound than uninjected cells. Treatment with oncogenic Ha-ras also converts the cell paths from nearly linear in control cells to apparent 'random-walk' trajectories in treated cells, suggesting that oncogenic vas alters the normal control processes regulating cell motility. Botulinum toxin C blocks uas-stimulated motility indicating that a member of the p21 rho family is a downstream participant in the motile pathway. In related experiments we have observed that microinjection of the neutralizing, Pas-specific, Y13-259 monoclonal antibody completely blocks both basal and basic fibroblast growth factor-stimulated movement of aortic EC. Y13-259 blocks the initiation of EC movement, as well as the continued progress of cells already in motion, suggesting that uas activity is continuously required throughout the motile process. Together these data indicate that ras is an integral component of the signaling pathway regulating cell movement.	CLEVELAND CLIN,RES INST,DEPT BIOL MOLEC,CLEVELAND,OH 44195	Cleveland Clinic Foundation	FOX, PL (corresponding author), CLEVELAND CLIN,RES INST,DEPT CELL BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NCI NIH HHS [CA53496] Funding Source: Medline; NHLBI NIH HHS [HL41178, HL40352] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053496] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040352, R01HL041178] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651; CHAMBERS AF, 1988, ANTICANCER RES, V8, P861; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KLEINSOYER C, 1992, BIOL CELL, V75, P155, DOI 10.1016/0248-4900(92)90136-O; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUNG HF, 1986, EXP CELL RES, V162, P363, DOI 10.1016/0014-4827(86)90341-1; LINDNER V, 1990, J CLIN INVEST, V85, P2004, DOI 10.1172/JCI114665; MERWIN JR, 1991, AM J PATHOL, V138, P37; MOHLER JL, 1993, CANCER METAST REV, V12, P53, DOI 10.1007/BF00689790; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MURUGESAN G, 1994, CIRC RES, V74, P1149, DOI 10.1161/01.RES.74.6.1149; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; MYRDAL SE, 1985, EXP CELL RES, V159, P441, DOI 10.1016/S0014-4827(85)80017-3; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NICHOLSON GL, 1992, ONCOGENE, V7, P1127; OCHIENG J, 1991, INVAS METAST, V11, P38; PARTIN AW, 1988, CANCER RES, V48, P6050; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; REIF F, 1965, FUNDAMENTALS STATIST; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSEN EM, 1990, CANCER INVEST, V8, P647, DOI 10.3109/07357909009018936; SA G, 1994, J BIOL CHEM, V269, P3219; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STRACKE ML, 1987, BIOCHEM BIOPH RES CO, V146, P339, DOI 10.1016/0006-291X(87)90730-3; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VARANI J, 1986, INVAS METAST, V6, P335	42	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3519	3526						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970712				2022-12-28	WOS:A1994PT39200014
J	BALUDA, MA; REDDY, EP				BALUDA, MA; REDDY, EP			ANATOMY OF AN INTEGRATED AVIAN-MYELOBLASTOSIS PROVIRUS - STRUCTURE AND FUNCTION	ONCOGENE			English	Review							ROUS-SARCOMA VIRUS; AMINO-ACID-SEQUENCE; V-MYB ONCOGENE; DNA-BINDING DOMAIN; RNA TUMOR-VIRUS; MOLONEY MURINE LEUKEMIA; LONG TERMINAL REPEAT; C-MYB; NUCLEOTIDE-SEQUENCE; REVERSE-TRANSCRIPTASE		TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,SCH MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P30CA012227, P01CA052009, R01CA010197] Funding Source: NIH RePORTER; NCI NIH HHS [CA 12227, CA 10197, CA 52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER F, 1987, J VIROL, V61, P534, DOI 10.1128/JVI.61.2.534-542.1987; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BALUDA MA, 1983, FOLIA BIOL-PRAGUE, V29, P18; BALUDA MA, 1974, COLD SPRING HARB SYM, V39, P869, DOI 10.1101/SQB.1974.039.01.101; BALUDA MA, 1964, NATL CANCER I MONOGR, V17, P449; BEAUDREAU GS, 1960, J NATL CANCER I, V24, P395; BENNETT RP, 1991, J VIROL, V65, P272, DOI 10.1128/JVI.65.1.272-280.1991; BERGMANN DG, 1981, J VIROL, V40, P450, DOI 10.1128/JVI.40.2.450-455.1981; BERGMANN DG, 1980, J VIROL, V34, P366, DOI 10.1128/JVI.34.2.366-372.1980; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; BHOWN AS, 1980, J BIOL CHEM, V255, P6962; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOLOGNESI DP, 1973, VIROLOGY, V56, P549, DOI 10.1016/0042-6822(73)90057-3; BOLOGNESI DP, 1970, VIROLOGY, V42, P1097, DOI 10.1016/0042-6822(70)90357-0; BOWLES NE, 1993, J VIROL, V67, P623, DOI 10.1128/JVI.67.2.623-631.1993; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BURMESTER BR, 1959, JNCI-J NATL CANCER I, V23, P277; BURSTEIN H, 1991, J VIROL, V65, P6165, DOI 10.1128/JVI.65.11.6165-6172.1991; BURSTEIN H, 1992, J VIROL, V66, P1781, DOI 10.1128/JVI.66.3.1781-1785.1992; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; CARLBERG K, 1988, J VIROL, V62, P1617, DOI 10.1128/JVI.62.5.1617-1624.1988; CHEN JH, 1981, VIROLOGY, V110, P128, DOI 10.1016/0042-6822(81)90014-3; CHEN JH, 1974, J VIROL, V13, P340, DOI 10.1128/JVI.13.2.340-346.1974; COFFIN J, 1985, RNA TUMOR VIRUSES, V2, P17; COPELAND TD, 1980, J VIROL, V36, P115, DOI 10.1128/JVI.36.1.115-119.1980; CORDELL B, 1976, J VIROL, V19, P548, DOI 10.1128/JVI.19.2.548-558.1976; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; CRAVEN RC, 1991, J VIROL, V65, P6205, DOI 10.1128/JVI.65.11.6205-6217.1991; CROCHET J, 1986, VIROLOGY, P252; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DETHE G, 1964, JNCI-J NATL CANCER I, V32, P201; DOUGHERTY RM, 1965, VIROLOGY, V27, P351, DOI 10.1016/0042-6822(65)90115-7; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; DUESBERG PH, 1980, P NATL ACAD SCI-BIOL, V77, P5120, DOI 10.1073/pnas.77.9.5120; DUPRAZ P, 1993, J VIROL, V67, P3826, DOI 10.1128/JVI.67.7.3826-3834.1993; DUPRAZ P, 1990, J VIROL, V64, P4978, DOI 10.1128/JVI.64.10.4978-4987.1990; EISENMAN RN, 1980, J VIROL, V36, P62, DOI 10.1128/JVI.36.1.62-78.1980; ENGELKE V, 1994, J VIROL, V68, P2752; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; FURUICHI Y, 1975, NATURE, V257, P618, DOI 10.1038/257618a0; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; GONDA TJ, 1981, CELL, V23, P279, DOI 10.1016/0092-8674(81)90292-0; GRANDGENETT D, 1985, J BIOL CHEM, V260, P8243; HACKETT PB, 1982, J VIROL, V41, P527, DOI 10.1128/JVI.41.2.527-534.1982; HALL W. J., 1941, AMER JOUR VET RES, V2, P272; HANAFUSA H, 1963, P NATL ACAD SCI USA, V49, P572, DOI 10.1073/pnas.49.4.572; HANAFUSA H, 1963, P NATL ACAD SCI USA, V49, P576; HIPPENMEYER PJ, 1984, VIROLOGY, V137, P358, DOI 10.1016/0042-6822(84)90228-9; HIZI A, 1977, J BIOL CHEM, V252, P2290; HORTON R, 1991, J VIROL, V65, P1141, DOI 10.1128/JVI.65.3.1141-1148.1991; HOUTS GE, 1978, J VIROL, V25, P546, DOI 10.1128/JVI.25.2.546-552.1978; HUNTER E, 1983, J VIROL, V45, P885, DOI 10.1128/JVI.45.2.885-888.1983; HUNTER E, 1983, J VIROL, V46, P920, DOI 10.1128/JVI.46.3.920-936.1983; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; JENTOFT JE, 1988, P NATL ACAD SCI USA, V85, P7094, DOI 10.1073/pnas.85.19.7094; JOHNSON SP, 1983, J VIROL, V45, P876, DOI 10.1128/JVI.45.2.876-881.1983; JOLIOT V, 1993, VIROLOGY, V195, P812, DOI 10.1006/viro.1993.1436; KAN NC, 1985, VIROLOGY, V145, P323, DOI 10.1016/0042-6822(85)90166-7; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATZ RA, 1988, J VIROL, V62, P528, DOI 10.1128/JVI.62.2.528-533.1988; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KEITH J, 1975, P NATL ACAD SCI USA, V72, P3347, DOI 10.1073/pnas.72.9.3347; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KNIGHT JB, 1994, J VIROL, V68, P4493, DOI 10.1128/JVI.68.7.4493-4502.1994; KUNG HJ, 1975, J VIROL, V16, P397, DOI 10.1128/JVI.16.2.397-411.1975; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIN TH, 1991, J BIOL CHEM, V266, P1635; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LIPSICK JS, 1987, J VIROL, V61, P933, DOI 10.1128/JVI.61.3.933-936.1987; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LIPSICK JS, 1984, CANCER CELLS, V2, P143; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAK J, 1994, J VIROL, V68, P2065, DOI 10.1128/JVI.68.4.2065-2072.1994; Maxam A M, 1980, Methods Enzymol, V65, P499; MERIC C, 1986, J VIROL, V60, P450; MERIC C, 1988, J VIROL, V62, P3328; MERREGAERT J, 1987, VIROLOGY, V158, P88, DOI 10.1016/0042-6822(87)90241-8; MISONO KS, 1980, FED P EXP BIOL ABS, V60, P1611; MIZUTANI S, 1971, NATURE-NEW BIOL, V230, P232, DOI 10.1038/newbio230232a0; MOELLING K, 1980, J VIROL, V33, P680, DOI 10.1128/JVI.33.2.680-688.1980; MOMMAERTS EB, 1952, P SOC EXP BIOL MED, V79, P450, DOI 10.3181/00379727-79-19409; MONTELARO RC, 1978, VIROLOGY, V84, P19, DOI 10.1016/0042-6822(78)90215-5; MOSCOVIC.C, 1968, VIROLOGY, V35, P487, DOI 10.1016/0042-6822(68)90278-X; MOSCOVICI C, 1970, VIROLOGY, V42, P61, DOI 10.1016/0042-6822(70)90238-2; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PANET A, 1975, J VIROL, V16, P146, DOI 10.1128/JVI.16.1.146-152.1975; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PEARL LH, 1987, NATURE, V328, P482, DOI 10.1038/328482b0; PEPINSKY RB, 1979, J MOL BIOL, V131, P819, DOI 10.1016/0022-2836(79)90203-1; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; PERBAL B, 1985, J VIROL, V56, P240, DOI 10.1128/JVI.56.1.240-244.1985; PETERS GG, 1980, J VIROL, V36, P692, DOI 10.1128/JVI.36.3.692-700.1980; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; PRESS RD, 1992, J VIROL, V66, P5373, DOI 10.1128/JVI.66.9.5373-5383.1992; REDDY EP, 1981, SCIENCE, V214, P445, DOI 10.1126/science.6170110; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; RUSHLOW KE, 1982, J VIROL, V42, P840, DOI 10.1128/JVI.42.3.840-846.1982; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SAUER RT, 1981, BIOCHEMISTRY-US, V20, P3784, DOI 10.1021/bi00516a018; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SILVA RF, 1982, J VIROL, V44, P422, DOI 10.1128/JVI.44.1.422-425.1982; SORET J, 1988, FEBS LETT, V232, P227, DOI 10.1016/0014-5793(88)80422-8; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; SOUZA LM, 1980, J VIROL, V36, P325, DOI 10.1128/JVI.36.2.325-336.1980; SOUZA LM, 1980, J VIROL, V36, P317, DOI 10.1128/JVI.36.2.317-324.1980; SRIVATSAN ES, 1980, J VIROL, V34, P288, DOI 10.1128/JVI.34.1.288-292.1980; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; STEWART L, 1991, J VIROL, V65, P6218, DOI 10.1128/JVI.65.11.6218-6231.1991; STEWART L, 1993, J VIROL, V67, P7582, DOI 10.1128/JVI.67.12.7582-7596.1993; STOBERGRASSER U, 1988, J VIROL, V62, P1093; STOCKING C, 1985, P NATL ACAD SCI USA, V82, P5746, DOI 10.1073/pnas.82.17.5746; SWANSTROM R, 1982, J VIROL, V41, P535, DOI 10.1128/JVI.41.2.535-541.1982; SWANSTROM R, 1981, P NATL ACAD SCI-BIOL, V78, P124, DOI 10.1073/pnas.78.1.124; TAYLOR JM, 1975, VIROLOGY, V65, P248, DOI 10.1016/0042-6822(75)90025-2; TAYLOR JM, 1975, J VIROL, V16, P553, DOI 10.1128/JVI.16.3.553-558.1975; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VOGT VM, 1985, J VIROL, V56, P31, DOI 10.1128/JVI.56.1.31-39.1985; VONDERHELM K, 1977, P NATL ACAD SCI USA, V74, P911; WANG LH, 1976, P NATL ACAD SCI USA, V73, P447, DOI 10.1073/pnas.73.2.447; Waters L C, 1977, Prog Nucleic Acid Res Mol Biol, V20, P131; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILLS JW, 1983, J CELL BIOCHEM, V23, P81, DOI 10.1002/jcb.240230109; WILLS JW, 1991, J VIROL, V65, P3804, DOI 10.1128/JVI.65.7.3804-3812.1991; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; YAMAMOTO T, 1980, CELL, V22, P787, DOI 10.1016/0092-8674(80)90555-3; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	160	22	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2761	2774						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084581				2022-12-28	WOS:A1994PG82200001
J	SANDMOLLER, A; HALTER, R; GOMEZLAHOZ, E; GRONE, HJ; SUSKE, G; PAUL, D; BEATO, M				SANDMOLLER, A; HALTER, R; GOMEZLAHOZ, E; GRONE, HJ; SUSKE, G; PAUL, D; BEATO, M			THE UTEROGLOBIN PROMOTER TARGETS EXPRESSION OF THE SV40 T-ANTIGEN TO A VARIETY OF SECRETORY EPITHELIAL-CELLS IN TRANSGENIC MICE	ONCOGENE			English	Article							TISSUE-SPECIFIC EXPRESSION; RABBIT UTEROGLOBIN; GENE REGION; HORMONAL-REGULATION; RIBONUCLEIC-ACID; RAT; PROTEIN; LUNG; TRANSCRIPTION; ENDOMETRIUM	Adenocarcinomas derived from the lining epithelia of various organs are the most common malignant tumors in human pathology and about 50% are hormone dependent. The tissue-specific and hormally regulated expression of the rabbit uteroglobin gene is secretory epithelial cells could provide a means of establishing in vivo models for a variety of human tumors originating from such tissues. We have generated trangenic mice inheriting a hybrid gene containing 4.7 kb of the rabbit uteroglobin 5'-flanking sequences fused to the SV40 T antigen encoding region. All transgenic founders examined exhibited bronchio-alveolar adenocarcinomas, probably due to expression of the transgene in Clara cells. Most founders also developed tumors of the submandibular salivary gland, and adenocarcinomas of the stomach. Adenocarcinomas and dysplasias in epithelial cells of the male and female genital tract were found in single founders. Immunohistochemical analysis showed that T antigen expression interfered with stable maintenance of the differentiated phenotype as documented by expression of the endogenous uteroglobin gene. One founder gave rise to a mouse Line, UT7.1. Transgenic descendants of UT7.1 developed lung adenocarcinomas and, depending on the genetic background, exhibited tumors of the stomach, the salivery gland and the pancreas. Sporadically male descendants developed prostatic adenocarcinoma whereas females developed dysplasias and adenocarcinomas of the uterus and the oviduct. Thus, the UT7.1 mouse line could be a useful model for several epithelial neoplasias.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; FRAUNHOFER INST TOXIKOL & MOLEK BIOL,D-30625 HANNOVER 41,GERMANY; UNIV MARBURG,MED ZENTRUM PATHOL,D-35033 MARBURG,GERMANY	Philipps University Marburg; Fraunhofer Gesellschaft; Philipps University Marburg			Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222; Suske, Guntram/0000-0002-4807-0513				BEATO M, 1978, J REPROD FERTIL, V53, P305; BEATO M, 1983, REGULATION GENE EXPR, P151; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BEIER HM, 1975, CELL TISSUE RES, V165, P1; CATO ACB, 1984, EMBO J, V3, P2771, DOI 10.1002/j.1460-2075.1984.tb02208.x; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEHARO MSL, 1985, BIOCHEM J, V225, P255; DEHARO MSL, 1988, BIOCHEM J, V250, P647, DOI 10.1042/bj2500647; DEMAYO FJ, 1991, AM J PHYSIOL, V261, pL70, DOI 10.1152/ajplung.1991.261.2.L70; DEMAYO FJ, 1991, MOL ENDOCRINOL, V5, P311, DOI 10.1210/mend-5-3-311; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HEINS B, 1981, MOL CELL ENDOCRINOL, V17, P71; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HELFTENBEIN G, 1991, EUR J CELL BIOL, V56, P49; HELFTENBEIN G, 1993, ONCOGENE, V8, P2075; HOGAN B, 1986, MANIPULATING MOUSE E; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; JEFFERY PK, 1983, AM REV RESPIR DIS, V128, P14; KAY E, 1972, BIOCHIM BIOPHYS ACTA, V271, P436, DOI 10.1016/0005-2795(72)90219-X; KIRCHNER C, 1976, CELL TISSUE RES, V170, P415, DOI 10.1007/BF00219420; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; KULKA U, 1993, MUTAGENESIS, V8, P193, DOI 10.1093/mutage/8.3.193; KURMAN RJ, 1987, ENDOMETRIAL CARCINOM; Maniatis T., 1982, MOL CLONING; MARGRAF LR, 1993, AM J RESP CELL MOL, V9, P231, DOI 10.1165/ajrcmb/9.3.231; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V19, P2849, DOI 10.1093/nar/19.11.2849; MULLER H, 1980, EUR J BIOCHEM, V112, P235, DOI 10.1111/j.1432-1033.1980.tb07199.x; NOSKE IG, 1976, BIOL REPROD, V15, P704, DOI 10.1095/biolreprod15.5.704; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PAUL D, 1988, EXP CELL RES, V175, P334; RAY MK, 1993, BIOCHEM BIOPH RES CO, V197, P163, DOI 10.1006/bbrc.1993.2455; RENKAWITZ R, 1984, CELL, V37, P503, DOI 10.1016/0092-8674(84)90380-5; SANDMOLLER A, 1991, MECH DEVELOP, V34, P57, DOI 10.1016/0925-4773(91)90091-J; SAVOURET JF, 1980, J BIOL CHEM, V255, P4131; SINGH G, 1984, J HISTOCHEM CYTOCHEM, V32, P49, DOI 10.1177/32.1.6418790; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; Suske Guntram, 1992, Gene Expression, V2, P339; WAREMBOURG M, 1986, ENDOCRINOLOGY, V119, P1632, DOI 10.1210/endo-119-4-1632; WEINBERG RA, 1991, ORIGINS OF HUMAN CANCER, P1; WIEHLE RD, 1990, ONCOGENE, V5, P787	41	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2805	2815						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084586				2022-12-28	WOS:A1994PG82200006
J	WONG, WT; CARLOMAGNO, F; DRUCK, T; BARLETTA, C; CROCE, CM; HUEBNER, K; KRAUS, MH; DIFIORE, PP				WONG, WT; CARLOMAGNO, F; DRUCK, T; BARLETTA, C; CROCE, CM; HUEBNER, K; KRAUS, MH; DIFIORE, PP			EVOLUTIONARY CONSERVATION OF THE EPS8 GENE AND ITS MAPPING TO HUMAN-CHROMOSOME 12Q23-Q24	ONCOGENE			English	Note							RECEPTOR TYROSINE KINASES; SIGNALING PROTEINS; SH3 DOMAINS; IDENTIFICATION; PURIFICATION; SUBSTRATE; BINDS; CELLS	We have previously isolated the coding sequence for a novel substrate for tyrosine kinases, eps8, from NIH3T3 fibroblasts. Eps8 was phosphorylated in vivo by several receptor tyrosine kinases (RTKs) and, upon overexpression, was able to enhance EGFR-mediated mitogenic signaling in NIH3T3 cells. To gain understanding of eps8 function as well as its role in normal and neoplastic proliferation, we cloned the human eps8 coding sequence and studied expression of the human RNA and protein, evolutionary conservation, and chromosomal location. In addition to a previously identified SH3 domain, the predicted amino acid sequence of human eps8 revealed a non-random distribution of prolines, clustered in a way to suggest SH3-binding sites and a putative PH domain. Eps8 was expressed in all epithelial and fibroblastic lines examined and in some, but not all, hematopoietic cells. An essential function of eps8 in cell growth regulation was underscored by its conservation during evolution, where eps8-related sequences were detected as early as in Saccaromyces cerevisiae. Finally, the human EPS8 locus was mapped to chromosome 12q23-q24.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; ATENEO FEDERICIANO, FAC MED & CHIRURG, DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL, NAPLES, ITALY; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA; REGINA ELENA INST CANC RES, MOLEC PATHOL & IMMUNOL LAB, ROME, ITALY; FAC MED & CHIRURG BARI, IST MICROBIOL, BARI, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita degli Studi di Bari Aldo Moro			Young, Richard A/F-6495-2012; Di Fiore, Pier Paolo/K-2130-2012	Young, Richard A/0000-0001-8855-8647; Di Fiore, Pier Paolo/0000-0002-2252-0950	NCI NIH HHS [CA51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CRAIG IW, 1993, 1992 CHROM COORD M, P402; CUTICCHIA AJ, 1993, GENOME PRIORITY REPO, V1; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1991, METHOD ENZYMOL, V196, P65; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUEBNER K, 1991, AM J HUM GENET, V48, P726; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3228; Katz Wendy S., 1992, Current Opinion in Cell Biology, V4, P939, DOI 10.1016/0955-0674(92)90122-S; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MITELMAN F, 1993, 1992 CHROM COORD M, P700; MURANO I, 1989, HUM GENET, V83, P45, DOI 10.1007/BF00274145; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OZISIK YY, 1993, CANCER GENET CYTOGEN, V69, P35, DOI 10.1016/0165-4608(93)90109-Y; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHOUTEN HC, 1989, BLOOD, V73, P2149; SHILO BZ, 1992, FASEB J, V6, P2915, DOI 10.1096/fasebj.6.11.1322852; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STREHL S, 1993, CANCER GENET CYTOGEN, V71, P94, DOI 10.1016/0165-4608(93)90207-3; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	35	29	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					3057	3061						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084614				2022-12-28	WOS:A1994PG82200037
J	GRIMM, S; BAEUERLE, PA				GRIMM, S; BAEUERLE, PA			FAILURE OF THE SPLICING VARIANT P65-DELTA OF THE NF-KAPPA-B SUBUNIT P65 TO TRANSFORM FIBROBLASTS	ONCOGENE			English	Note							REL ONCOGENE ENCODES; PROTEIN KINASE-C; DNA-BINDING; TRANSCRIPTION FACTOR; TUMORIGENIC CONVERSION; THYMIDINE KINASE; GENE-EXPRESSION; ACTIVATION; CELLS; TRANSLOCATION	A naturally occurring splice variant of the p65 subunit of the inducible transcription factor NK-kappa B, called p65 Delta, has recently been reported to transform rat-1 fibroblasts in transfection experiments. Criteria for transformation included focus formation, growth in soft agar and tumor formation in athymic mice. In the present study we provide evidence that p65 Delta cannot transform either rat-1 or rat-2 cells although p65 Delta was efficiently expressed and showed all transcriptional activities reported previously. Eleven rat-1 fibroblast cells lines selected for stably overexpressing p65 Delta also showed neither focus formation nor anchorage-independent growth in soft agar. No transformation of primary rat fibroblasts was evident when p65 Delta was cotransfected with either ras or myc oncogenes, whereas a combination of the two oncogenes caused focus formation. We submit that the transforming potential of p65 Delta is highly conditional and presumably restricted to a particular subclone of rat-1 cells.	UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY	University of Freiburg								BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWNELL E, 1988, ONCOGENE, V2, P527; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MATHEW S, 1993, ONCOGENE, V8, P191; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YACOPOULOS GD, 1985, P NATL ACAD SCI USA, V83, P5455; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZERLIN M, 1987, ONCOGENE, V1, P19	36	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2391	2398						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036023				2022-12-28	WOS:A1994NX62900034
J	SOLER, C; ALVAREZ, CV; BEGUINOT, L; CARPENTER, G				SOLER, C; ALVAREZ, CV; BEGUINOT, L; CARPENTER, G			POTENT SHC TYROSINE PHOSPHORYLATION BY EPIDERMAL GROWTH-FACTOR AT LOW RECEPTOR DENSITY OR IN THE ABSENCE OF RECEPTOR AUTOPHOSPHORYLATION SITES	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTPASE-ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; MAP KINASE; ADAPTER PROTEIN; RAS; GRB2; SOS; INTERNALIZATION	The importance of epidermal growth factor (EGF) receptor expression level and autophosphorylation sites in src homology and collagen protein (SHC) tyrosine phosphorylation has been studied. In contrast to EGF-induced tyrosine phosphorylation of the GTPase-activating protein for ras (rasGAP) and phospholipase C-gamma 1 (PLC-gamma 1), SHC tyrosine phosphorylation occurs at a very low receptor density in parental NIH3T3 mouse fibroblasts expressing less than 1 x 10(4) EGF receptors per cell. In transfected NlH3T3 cells expressing human EGF receptors (similar to 4 x 10(5) receptors per cell), maximal levels of SHC and PLC-gamma 1 tyrosine phosphorylation occur when approximately 4 x 10(4) receptors or more are occupied by ligand. At lower levels of receptor occupancy only SHC posphorylation was significant. Also, EGF treatment of mouse keratinocytes, which represent a physiological target of EGF, express a low number of EGF receptors (similar to 2 x 10(4) receptors per cell), and stringently require EGF to grow, results in intense SHC tyrosine phosphorylation, compared to rasGAP or PLC-gamma 1. SHC is also efficiently tyrosine phosphorylated by an EGF receptor deletion mutant (Dc214) that is devoid of autophosphorylation sites, but which remains mitogenically responsive to EGF. The EGF receptor mutant Dc214 is able to activate the ras guanine nucleotide exchanger and phosphorylate mitogen-activated protein kinase (MAPK), presumable as a result of complex formation between tyrosine phosphorylated SHC and GRB2. These results indicate that potent EGF-induced SHC tyrosine phosphorylation can be triggered in cells having relatively few receptors. Also, our data show that EGF receptors are able to phosphorylate SHC, activate the exchange of guanine nucleotide on ras and phosphorylate MAPK by a mechanism that does not require receptor autophosphorylation sites and, therefore, the src homology 2 (SH2):phosphotyrosine-dependent interaction of SHC or GRB2 with the EGF receptor.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; CNR, DIBIT, MOLEC ONCOL LAB, I-20133 MILAN, ITALY; CNR, INST NEUROSCI & BIOIMMOGINI, I-20133 MILAN, ITALY	Vanderbilt University; Vanderbilt University; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)			Soler, Concepció/L-1185-2014; Alvarez, Clara V/AAN-4173-2020	Soler, Concepció/0000-0001-6502-5012; Alvarez, Clara V/0000-0003-1500-4058	NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER; NCI NIH HHS [CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1993, FORUM TRENDS EXPT CL, V3, P35; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COHEN S, 1962, J BIOL CHEM, V237, P1555; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HACK N, 1993, J BIOL CHEM, V268, P26441; HELIN K, 1991, ONCOGENE, V6, P825; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MASUI H, 1991, CANCER RES, V51, P6170; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHNEIDER CA, 1986, P NATL ACAD SCI USA, V83, P333, DOI 10.1073/pnas.83.2.333; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SOLER C, 1994, J BIOL CHEM, V269, P12320; SOLER C, 1993, J BIOL CHEM, V268, P22010; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZENDEGUI J G, 1988, Journal of Cellular Physiology, V136, P257, DOI 10.1002/jcp.1041360207	42	62	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2207	2215						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036006				2022-12-28	WOS:A1994NX62900012
J	THAKUR, S; LIN, HC; TSENG, WT; KUMAR, S; BRAVO, R; FOSS, F; GELINAS, C; RABSON, AB				THAKUR, S; LIN, HC; TSENG, WT; KUMAR, S; BRAVO, R; FOSS, F; GELINAS, C; RABSON, AB			REARRANGEMENT AND ALTERED EXPRESSION OF THE NFKB-2 GENE IN HUMAN CUTANEOUS T-LYMPHOMA CELLS	ONCOGENE			English	Article							NF-KAPPA-B; ENHANCER-BINDING PROTEINS; DNA-BINDING; C-REL; CHROMOSOMAL TRANSLOCATION; TRANSCRIPTION FACTORS; ANTISENSE INHIBITION; LEUKEMIA-VIRUS; P50 PRECURSOR; HOMEOBOX GENE	The NF-kappa B/Rel and I kappa B proteins are important regulators of lymphocyte activation and gene expression. We have identified a rearrangement of the NFKB-2 gene in the HUT 78 human cutaneous T-cell leukemia (CTCL) line. cDNA and genomic DNA sequence predicted the presence of a truncated 80 kD NFKB-2 precursor protein (p80HT), instead of the normal p100 protein. No wild-type allele was identified. Elevated levels of two aberrantly sized RNAs were detected, and high levels of p80HT and processed p52 protein were present in HUT 78 cell nuclei. The p52 protein bound to a palindromic KB DNA motif, however p80HT did not. Rearrangement of the NFKB-2 gene was also detected in DNA from two patients with CTCL. Rearrangement and overexpression of the NFKB-2 gene may contribute to the genesis of a subset of T-cell malignancies.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; BOSTON UNIV,SCH MED,DEPT MED,MED ONCOL SECT,BOSTON,MA 02118	Rutgers State University New Brunswick; Rutgers State University Medical Center; Bristol-Myers Squibb; Boston University					NCI NIH HHS [CA55487] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055487] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; CHEN TR, 1992, J NATL CANCER I, V84, P1922, DOI 10.1093/jnci/84.24.1922; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DALESSANDRO E, 1990, CANCER GENET CYTOGEN, V45, P231, DOI 10.1016/0165-4608(90)90087-Q; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DUBE ID, 1991, BLOOD, V78, P2996; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FINGER LR, 1988, P NATL ACAD SCI USA, V85, P9158, DOI 10.1073/pnas.85.23.9158; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GAZDAR AF, 1980, BLOOD, V55, P409; GIMBLE JM, 1988, J VIROL, V62, P4104, DOI 10.1128/JVI.62.11.4104-4112.1988; GRILLI M, 1993, INT REV CYTOL, V148, P1; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LANOIX J, 1994, ONCOGENE, V9, P841; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAN L, 1991, CLIN EXP IMMUNOL, V86, P240; POPOVIC M, 1984, LANCET, V2, P1472; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; POTTER DA, 1993, J BIOL CHEM, V268, P18882; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THEILEN GH, 1966, J NATL CANCER I, V37, P731; TSUDO M, 1987, P NATL ACAD SCI USA, V84, P4215, DOI 10.1073/pnas.84.12.4215	65	83	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2335	2344						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036016				2022-12-28	WOS:A1994NX62900027
J	RADINSKY, R; FIDLER, IJ; PRICE, JE; ESUMI, N; TSAN, R; PETTY, MC; BUCANA, CD; BARELI, M				RADINSKY, R; FIDLER, IJ; PRICE, JE; ESUMI, N; TSAN, R; PETTY, MC; BUCANA, CD; BARELI, M			TERMINAL DIFFERENTIATION AND APOPTOSIS IN EXPERIMENTAL LUNG METASTASES OF HUMAN OSTEOGENIC-SARCOMA CELLS BY WILD-TYPE P53	ONCOGENE			English	Article							CHRONIC MYELOCYTIC-LEUKEMIA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; TUMOR PROGRESSION; MUTANT; MUTATIONS; PROTEIN; GROWTH; GENE; INDUCTION	Human SAOS-2 osteogenic sarcoma cells are not metastatic in nude mice and do not express p53. We have selected a variant line (SAOS-LM2) that is tumorigenic and metastatic in nude mice. These cells were transfected with the p53 wild-type (p53(wt)) or mutated (p53(mut) 143A) gene, whose expression was verified by reverse transcriptase PCR, cDNA sequencing, and protein immunoprecipitation. Cells were injected i.v. into nude mice, and 4 months later, the mice were necropsied. All cell lines produced a similar number of visible lung metastases, albeit of different sizes, Microscopic examination revealed that most lung metastases in mice injected with p53(wt) cells (but not p53(mut) 143A or control cells) consisted of osteoid matrix and apoptotic;cells. Expression of either p53(wt) or p53(mut) 143A verified the origin of the metastases. These data suggest that transfection of SAOS-LM2 cells with p53(wt) is associated with in vivo induction of terminal differentiation and apoptosis that inhibit progressive growth of metastases.			RADINSKY, R (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HMB 173,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NCI NIH HHS [R35-CA 42107, CA 41525, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042107, P30CA016672, R01CA041525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARELI M, 1993, ANTICANCER RES, V13, P1619; BARELI M, 1989, BLOOD, V73, P281; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Coolidge BJ, 1979, ANIMAL HISTOLOGY PRO; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIAS L, 1991, LEUKEMIA, V5, P879; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIDLER IJ, 1990, CANCER RES, V50, P6130; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; FOTI A, 1991, BLOOD, V77, P2441; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, ONCOGENE, V6, P131; KEY L, 1984, NEW ENGL J MED, V310, P409, DOI 10.1056/NEJM198402163100701; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUCA M, 1993, INT J ONCOL, V3, P19; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOTYKA B, 1991, EUR J IMMUNOL, V21, P1951, DOI 10.1002/eji.1830210825; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RADINSKY R, 1991, INT J CANCER, V48, P148; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Rodan GA, 1983, BONE MINERAL RES ANN, V2, P244; RODAN SB, 1987, CANCER RES, V47, P4961; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPIESS YH, 1986, ENDOCRINOLOGY, V118, P1340, DOI 10.1210/endo-118-4-1340; Thompson SW, 1966, SELECTED HISTOCHEMIC; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1993, ONCOGENE, V8, P2555	48	92	93	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1877	1883						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208533				2022-12-28	WOS:A1994NR68500010
J	BOURS, V; AZARENKO, V; DEJARDIN, E; SIEBENLIST, U				BOURS, V; AZARENKO, V; DEJARDIN, E; SIEBENLIST, U			HUMAN RELB (I-REL) FUNCTIONS AS A KAPPA-B SITE-DEPENDENT TRANSACTIVATING MEMBER OF THE FAMILY OF REL-RELATED PROTEINS	ONCOGENE			English	Article							DNA-BINDING SUBUNIT; V-REL; TRANSCRIPTION ACTIVATOR; ONCOPROTEIN BCL-3; PROTO-ONCOGENE; CLONING; P50; GENE; EXPRESSION; HOMOLOGY	RelB belongs to the family of Rel-related proteins, dimers of which determine NF-kappa B activity. The murine RelB protein has been reported to be a dimerizing partner in kappa B-binding complexes which are capable of transactivation. On the other hand, the I-Rel protein, the presumed human homolog of RelB, was proposed to be an inhibitor whose presence in dimeric complexes interfered with their kappa B binding and therefore interfered also with transactivation. We demonstrate that human RelB (I-Rel) forms with p50 and p52 (p50B) kappa B-binding heterodimeric complexes which potently transactivate kappa B-dependent constructs in transfection studies. It is concluded that human RelB (I-Rel) and murine RelB can both function as transactivators and that no significant species-specific differences exist.	UNIV LIEGE,METASTASIS RES LAB,B-4000 LIEGE,BELGIUM	University of Liege	BOURS, V (corresponding author), NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892, USA.		Dejardin, Emmanuel/AAE-9076-2021					BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Bours V, 1992, Curr Top Microbiol Immunol, V182, P411; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1989, ONCOGENE, V4, P935; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1993, INT REV CYTOL, V148, P1; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464	30	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1699	1702						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183565				2022-12-28	WOS:A1994NL81500022
J	ONYIA, JE; HALLADAY, DL; MESSINA, JL				ONYIA, JE; HALLADAY, DL; MESSINA, JL			IDENTIFICATION OF BETA-ACTIN SEQUENCES NECESSARY FOR INDUCTION BY PHORBOL ESTERS AND CALCIUM IONOPHORES	ONCOGENE			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; ACETYLTRANSFERASE GENE-EXPRESSION; SIGNAL-TRANSDUCTION PATHWAYS; 3' UNTRANSLATED REGIONS; FACTOR-ALPHA GENE; CHLORAMPHENICOL ACETYLTRANSFERASE; TRANSCRIPTIONAL REGULATION; MESSENGER-RNAS	Transcription of the cytoskeletal beta-actin gene is rapidly induced by phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore, A23187, in cultured H4IIE hepatoma (H4) cells. PMA directly activates protein kinase C (PKC) and activation of PKC is necessary for the cellular actions of PMA, including induction of beta-actin gene transcription. In the present study, we determined the DNA sequence requirements for induction of the beta-actin gene by PMA and A23187. Constructs containing progressive deletions of normal and mutated human beta-actin 5' sequences fused to the reporter gene, bacterial chloramphenicol acetyltransferase, were analysed in transient transfections of H4 cells. We delineated the PMA response DNA element of the human beta-actin gene to the proximal CCArGG box (-62 to -53) in the 5' flanking region. In contrast, A23187 did not induce expression of transfected gene constructs containing this CCArGG box. Additionally, we demonstrated that CCArGG boxes from two other PMA-induced genes in H4 cells, c-fos and gamma-actin, could confer PMA inducibility to a heterologous promoter. This CCArGG box specifically interacts with one or more proteins present in nuclear extracts of H4 cells. These results indicate that in cultured cells, PMA-dependent induction of the beta-actin gene is mediated through the proximal CCArGG box. This suggests that the CCArGG box is a target for PKC action and may be involved in the control of other PKC regulated genes.	SUNY HLTH SCI CTR,DEPT PHYSIOL,SYRACUSE,NY; SUNY HLTH SCI CTR,CELL & MOLEC BIOL PROGRAM,SYRACUSE,NY	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NIDDK NIH HHS [DK40456] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040456] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUMBERG PM, 1981, CRC CR REV TOXICOL, V8, P199, DOI 10.3109/10408448109109658; BUSCHER M, 1988, ONCOGENE, V3, P301; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLARKE M, 1977, ANNU REV BIOCHEM, V46, P797, DOI 10.1146/annurev.bi.46.070177.004053; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; EASTMAN A, 1987, BIOTECHNIQUES, V5, P730; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HYDER SM, 1991, GENE, V105, P281, DOI 10.1016/0378-1119(91)90164-7; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIU ZJ, 1991, GENE, V108, P211, DOI 10.1016/0378-1119(91)90436-F; LIU ZJ, 1990, MOL CELL BIOL, V10, P3432, DOI 10.1128/MCB.10.7.3432; LOHSE P, 1988, NUCLEIC ACIDS RES, V16, P2787, DOI 10.1093/nar/16.7.2787; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; Messina J. L., 1990, HDB EXPT PHARM, V92, P399; MESSINA JL, 1992, EXP CELL RES, V200, P532, DOI 10.1016/0014-4827(92)90206-N; MESSINA JL, 1989, ENDOCRINOLOGY, V124, P754, DOI 10.1210/endo-124-2-754; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; MESSINA JL, 1992, MOL ENDOCRINOL, V6, P112, DOI 10.1210/me.6.1.112; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NG SY, 1989, NUCLEIC ACIDS RES, V17, P601, DOI 10.1093/nar/17.2.601; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORITA S, 1989, GENE, V75, P13; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P7539; RENAN MJ, 1986, BIOSCIENCE REP, V6, P819, DOI 10.1007/BF01117105; RENAN MJ, 1985, BIOSCIENCE REP, V5, P739, DOI 10.1007/BF01119872; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; RIDDLE VGH, 1979, P NATL ACAD SCI USA, V76, P1298, DOI 10.1073/pnas.76.3.1298; RIVERA V M, 1990, New Biologist, V2, P751; ROBIN P, 1991, BIOCHEM BIOPH RES CO, V181, P353, DOI 10.1016/S0006-291X(05)81426-3; ROESLER WJ, 1990, TRENDS ENDOCRIN MET, V1, P347, DOI 10.1016/1043-2760(90)90082-E; RUEDELHUBER T, 1984, NATURE, V312, P700; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; SUGIYAMA H, 1988, GENE, V65, P135; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; WEINSTOCK RS, 1988, ENDOCRINOLOGY, V123, P366, DOI 10.1210/endo-123-1-366; WEINSTOCK RS, 1993, AM J PHYSIOL, V264, pE519, DOI 10.1152/ajpendo.1993.264.4.E519; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YAFFE D, 1985, NUCLEIC ACIDS RES, V13, P3723, DOI 10.1093/nar/13.10.3723	75	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1713	1722						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183567				2022-12-28	WOS:A1994NL81500024
J	BERBERICH, S; COLE, M				BERBERICH, S; COLE, M			THE MDM-2 ONCOGENE IS TRANSLOCATED AND OVEREXPRESSED IN A MURINE PLASMACYTOMA CELL-LINE EXPRESSING WILD-TYPE P53	ONCOGENE			English	Note							C-MYC; BURKITT-LYMPHOMA; GENE; PROTEIN; MUTATION; REQUIRES; TUMORS; RAS	The cellular p53 protein has been demonstrated to possess growth-inhibitory activity. Recent work suggests that the murine double minute gene (mdm-2) encodes a protein that may function as a cellular regulator or mediator of p53 function. We were interested in determining if the mdm-2 gene was overexpressed in mouse tumor cells, in particular mouse plasmacytomas that harbor wild type-p53 protein. A novel chromosomal translocation of the mdm-2 gene was detected in the SP2 cell line, that is derived from plasmacytoma MOPC21. The translocation results in a head-to-head arrangement of the mdm-2 gene (chromosome 10) with the immunoglobulin CK gene (chromosome 6), analogous to the translocations that activate the c-mye gene in murine plasmacytomas. Based on Northern blot analysis, the translocation induces a 10-fold elevation of mdm-2 RNA. Primer extension assays demonstrate that the 5' end of the mdm-2 RNA from the translocated gene is colinear with the 5' mdm-2 mRNA from an unrearranged gene, suggesting that the mRNA and encoded protein are unaltered. This chromosomal translocation represents the first example in which mdm-2 overexpression is activated by a genetic alteration other than gene amplification.	WRIGHT STATE UNIV,KETTERING MED CTR,CLIN MOLEC GENET LAB,DAYTON,OH 45435; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Wright State University Dayton; Princeton University	BERBERICH, S (corresponding author), WRIGHT STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,DAYTON,OH, USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; COWAN NJ, 1974, J MOL BIOL, V90, P691, DOI 10.1016/0022-2836(74)90533-6; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; LADANYI M, 1993, CANCER RES, V53, P16; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERLMUTTER RM, 1984, NATURE, V307, P473, DOI 10.1038/307473a0; WIMAN KG, 1991, ONCOGENE, V6, P1633; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	22	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1469	1472						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152809				2022-12-28	WOS:A1994NH40100020
J	KEEN, N; ELSTON, R; CRAWFORD, L				KEEN, N; ELSTON, R; CRAWFORD, L			INTERACTION OF THE E6 PROTEIN OF HUMAN PAPILLOMAVIRUS WITH CELLULAR PROTEINS	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; LARGE TUMOR-ANTIGEN; CERVICAL-CARCINOMA; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; TYPE-16; P53; E7; KERATINOCYTES; TRANSCRIPTION	The E6 proteins of the oncogenic Human Papillomavirus (HPV) types 16 and 18 are known to bind two cellular proteins, the tumour suppressor protein p53 and a 100 kDa protein named E6-AP. In this paper we describe the expression and purification of biologically active E6 fusion proteins and their specific association with additional cellular proteins. HPV16E6 specifically associated with at least seven cellular proteins which have been designated pp212, pp182, p100, p81, p75, p53 and p33 respectively, on the basis of molecular mass and phosphorylation. We have also shown that the complex of cellular proteins associated with HPV16, 18, 6 and 11 E6 proteins contains a protein kinase. This protein kinase phosphorylated exogenous histone H1 and the E6 associated protein pp182.	UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,CAMBRIDGE CB2 1QP,CAMBS,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND,TUMOUR VIRUS GRP,CAMBRIDGE CB2 1QP,ENGLAND	University of Cambridge; University of Cambridge	KEEN, N (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,CAMBS,ENGLAND.							BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GUIS D, 1988, J VIROL, V62, P665; Harlow E., 1988, ANTIBODIES LABORATOR, P341; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LIANG XH, 1993, ONCOGENE, V8, P2645; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Maniatis T., 1982, MOL CLONING; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MUNGER K, 1989, J VIROL, V63, P4417; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; TOMMASINO M, 1993, ONCOGENE, V8, P195; Vousden K H, 1990, Semin Cancer Biol, V1, P415; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; 1991, PHARM ANALECTS, V19, P1	39	56	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1493	1499						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152813				2022-12-28	WOS:A1994NH40100024
J	HENKEMEYER, M; MARENGERE, LEM; MCGLADE, J; OLIVIER, JP; CONLON, RA; HOLMYARD, DP; LETWIN, K; PAWSON, T				HENKEMEYER, M; MARENGERE, LEM; MCGLADE, J; OLIVIER, JP; CONLON, RA; HOLMYARD, DP; LETWIN, K; PAWSON, T			IMMUNOLOCALIZATION OF THE NUK RECEPTOR TYROSINE KINASE SUGGESTS ROLES IN SEGMENTAL PATTERNING OF THE BRAIN AND AXONOGENESIS	ONCOGENE			English	Article							CELL-ADHESION MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; MOUSE DEVELOPMENT; NERVOUS-SYSTEM; INT-1 PROTOONCOGENE; ECTOPIC EXPRESSION; NEURITE OUTGROWTH; XENOPUS EMBRYOS; PROTEIN-KINASES; OPTIC CHIASM	Neural kinase (Nuk) encodes a murine receptor-like tyrosine kinase belonging to the Eph/Elk/Eck family. Protein localization studies indicate that during early embryogenesis Nuk is confined to the developing nervous system, where it marks segments along the axis of the neural tube in the hindbrain (rhombomeres r2, r3 and r5) and specific morphological bulges of the midbrain and forebrain. Subcellular localization of Nuk indicates that this receptor is concentrated at sites of cell-cell contact, often involving migrating neuronal cells or their extensions. Most notably, high levels of Nuk protein are found within initial axon outgrowths and associated nerve fibers. The axonal localization of Nuk is transient and is not detected after migrations have ceased, suggesting a role for this tyrosine kinase during the early pathfinding and/or fasciculation stages of axonogenesis. The subcellular localization of Nuk, as well as the presence of fibronectin type III and immunoglobulin-like adhesive domains on the extracellular region, suggest this receptor tyrosine kinase may function to regulate specific cell-cell interactions during early development of the murine nervous system.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto	HENKEMEYER, M (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Pawson, Tony J/E-4578-2013	Henkemeyer, Mark/0000-0002-7525-1061				BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOHME B, 1993, ONCOGENE, V8, P2857; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; Carpenter M.B., 1985, CORE TEXT NEUROANATO, V3rd; CHAN J, 1991, ONCOGENE, V6, P1057; CHITNIS AB, 1990, J NEUROSCI, V10, P1892; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; Edelman GM, 1985, CELL CONTACT ADHESIO; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; Guild SR, 1927, AM J ANAT, V39, P57, DOI 10.1002/aja.1000390103; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HENDRIKS DM, 1973, S AFR MED J, V47, P2294; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; Kaufman M. H, 1990, POSTIMPLANTATION MAM, P81; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; KLEIN R, 1990, DEVELOPMENT, V109, P845; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LANDMESSER L, 1992, NEURON, V8, P291, DOI 10.1016/0896-6273(92)90296-P; LETWIN K, 1988, ONCOGENE, V3, P621; LEVITT P, 1981, J NEUROSCI, V1, P27, DOI 10.1523/JNEUROSCI.01-01-00027.1981; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LIESI P, 1985, EMBO J, V4, P1163, DOI 10.1002/j.1460-2075.1985.tb03755.x; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LOGAN C, 1992, DEV GENET, V13, P345, DOI 10.1002/dvg.1020130505; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NAKANISHI S, 1983, DEV BIOL, V95, P305, DOI 10.1016/0012-1606(83)90031-3; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; RUGH R, 1968, MOUSE ITS REPRODUCTI; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SHER AE, 1971, ACTA OTO-LARYNGOL, P1; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SRETAVAN DW, 1990, J NEUROSCI, V10, P1995; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THEILER K, 1989, HOUSE MOUSE; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; TOSNEY KW, 1985, J NEUROSCI, V5, P2336; TOSNEY KW, 1984, J NEUROSCI, V4, P2518; VANDEWATER TR, 1991, ANN NY ACAD SCI, V630, P116; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILSON SW, 1990, DEVELOPMENT, V108, P121; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4	89	190	195	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1001	1014						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134103				2022-12-28	WOS:A1994NC04800001
J	ALBERT, T; URLBAUER, B; KOHLHUBER, F; EICK, D; HAMMERSEN, B				ALBERT, T; URLBAUER, B; KOHLHUBER, F; EICK, D; HAMMERSEN, B			ONGOING MUTATIONS IN THE N-TERMINAL DOMAIN OF C-MYC AFFECT TRANSACTIVATION IN BURKITTS-LYMPHOMA CELL-LINES	ONCOGENE			English	Article							NUCLEOTIDE-SEQUENCE; PROTEIN-KINASE; SWITCH REGION; EXPRESSION; GENE; PHOSPHORYLATION; TRANSFORMATION; FIBROBLASTS; APOPTOSIS; ONCOGENE	A panel of 18 Burkitt's lymphoma (BL) and nine other cell Lines was examined for mutations in the N-terminal transactivation domain of c-Myc. Mutations leading to exchange of amino acids were detected in 13 BL but in none of the control cell lines. Mutations in c-Mye clustered between amino acid positions 57 and 62. Thr-58 and Ser-62 are known phosphorylation sites of c-Myc in vivo. BL cell lines derived from the same tumour revealed different mutations. Mutant cDNAs of the BL cell line Raji differed at 14 positions indicating ongoing mutation of the translocated c-myc during long-term propagation in cell culture. The effect of mutations on transactivation by c-Mye was tested by expression of GAL4/c-Myc fusion proteins in the BL cell line Raji. Mutants with an amino acid exchange at positions 58 or 60 transactivated a reporter gene two- to fivefold weaker than wildtype c-Myc, Thr-58 and Ser-62 were replaced by aspartic acid to mimic constitutively phosphorylated forms of c-Myc. These mutants transactivated two- to three-fold weaker than wildtype c-Mye indicating that a negative charge at positions 58 and/or 62 per se does not enhance transactivation. We propose that mutations in the N-terminal domain of c-Mye correlate with reduced transactivation and provide a growth advantage for BL cells.	GSF MUNICH,UMWELT & GESUNDHEIT FORSCHUNGSZENTRUM,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health				Albert, Thomas Karl/0000-0002-2488-0706				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; APEL TW, 1992, ONCOGENE, V7, P1267; ASKEW DS, 1991, ONCOGENE, V6, P1915; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EICK D, 1990, ONCOGENE, V5, P1397; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FALK MH, 1993, INT J CANCER, V55, P1; FRYKBERG L, 1987, ONCOGENE, V1, P415; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HENRIKSSONM, 1993, ONCOGENE, V8, P3199; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; LILLIE JW, 1989, NATURE, V341, P179; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SETH A, 1992, J BIOL CHEM, V267, P24796; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SYMONDS G, 1989, ONCOGENE, V4, P285; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; YANO T, 1993, ONCOGENE, V8, P2741; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	36	62	63	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					759	763						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108117				2022-12-28	WOS:A1994MW55100010
J	KERPPOLA, TK; CURRAN, T				KERPPOLA, TK; CURRAN, T			MAF AND NRL CAN BIND TO AP-1 SITES AND FORM HETERODIMERS WITH FOS AND JUN	ONCOGENE			English	Article							DNA-BINDING; LEUCINE ZIPPER; TRANSCRIPTION FACTORS; YEAST GCN4; GENE; INVITRO; PROTEINS; TRANSFORMATION; ONCOGENE; ENCODES	The c-maf proto-oncogene and the neural retina specific gene nrl encode members of a new bZIP protein subfamily. We have examined the dimerization and DNA binding properties of this new protein family using polypeptides encompassing the leucine zipper and basic regions. Purified polypeptides bound specifically to the AP-1 and CRE sites as well as to variants of the AP-1 site. Maf and Nrl were also able to form heterodimers with Fos and Jun in vitro. All pairwise combinations of Maf, Nrl, Fos and Jun could be co-immunoprecipitated by antisera directed against either subunit. Heterodimers among these proteins bound to the AP-1 site, although with different affinities. Mutations in the leucine zipper dimerization interface or in the basic DNA contact region inhibited heterodimer formation and binding to the AP-1 site. These results indicate that Maf and Nrl together with Fos and Jun family proteins form a bZIP protein superfamily whose members can form an array of heterodimers that have overlapping DNA binding specificities.			KERPPOLA, TK (corresponding author), ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110, USA.		Kerppola, Tom/AAG-4457-2022; Curran, Tom/D-7515-2011; Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Kerppola, Tom/AFK-6155-2022; Curran, Tom/C-1164-2008	Kerppola, Tom/0000-0002-0611-9446; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Curran, Tom/0000-0003-1444-7551				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1987, ONCOGENE, V2, P79; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OKUNO H, 1991, ONCOGENE, V6, P1491; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	37	169	172	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					675	684						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108109				2022-12-28	WOS:A1994MW55100001
J	DEGROOT, RP; DELMAS, V; SASSONECORSI, P				DEGROOT, RP; DELMAS, V; SASSONECORSI, P			DNA BENDING BY TRANSCRIPTION FACTORS CREM AND CREB	ONCOGENE			English	Article							CYCLIC-AMP; BINDING-PROTEINS; GENE-TRANSCRIPTION; SOMATOSTATIN GENE; C-FOS; ELEMENT; ACTIVATION; SITE; PROMOTER; IDENTIFICATION	DNA bending is postulated to be a major determinant of gene expression and has been shown to be specifically induced by some regulatory proteins with DNA-binding properties. Here we show that nuclear factors which naturally bind to CREs (cAMP-responsive elements) are able to induce bending in the sequences flanking this recognition site. In our assays we used a permutated binding site/gel retardation assay and bacterially generated nuclear factors. We have been studying the cAMP-responsive-element modulator (CREM) gene, which encodes both repressors (CREM alpha, beta and gamma) and an activator (CREM tau) of cAMP-responsive transcription by alternative splicing. Tn addition, two alternative DNA-binding domains can be encoded in different CREM isoforms. No differences in induction of DNA bending by the CREM proteins with the two DNA binding domains were detected. The activator CREB induced DNA bending in a fashion similar to CREM. Importantly, we show that phosphorylation of CREM or CREB alters their mobilities in a regular gel shift assay as well as enhances the angle of DNA bending induced by these proteins.	INST CHIM BIOL,FAC MED,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Delmas, veronique/0000-0001-7368-3664				ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MELLSTROM B, 1993, NEURON, V10, P655, DOI 10.1016/0896-6273(93)90167-P; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	47	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					463	468						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290258				2022-12-28	WOS:A1994MW24800013
J	SANTORO, M; DATHAN, NA; BERLINGIERI, MT; BONGARZONE, I; PAULIN, C; GRIECO, M; PIEROTTI, MA; VECCHIO, G; FUSCO, A				SANTORO, M; DATHAN, NA; BERLINGIERI, MT; BONGARZONE, I; PAULIN, C; GRIECO, M; PIEROTTI, MA; VECCHIO, G; FUSCO, A			MOLECULAR CHARACTERIZATION OF RET/PTC3 - A NOVEL REARRANGED VERSION OF THE RET PROTOONCOGENE IN A HUMAN THYROID PAPILLARY CARCINOMA	ONCOGENE			English	Article							RET PROTO-ONCOGENE; TRANSFORMING GENE; TYROSINE KINASE; MESSENGER-RNAS; II ONCOGENE; ACTIVATION; PROTOONCOGENE; PRODUCT; PTC; IDENTIFICATION	The RET proto-oncogene encodes a transmembrane receptor of the tyrosine kinase family and has frequently been found activated in human thyroid carcinomas of the papillary subtype. In most cases the activation consisted of the fusion of its tyrosine-kinase domain with the 5'-terminal region of a gene designated H4 or D10S170. We have named the resulting H4/RET chimeric oncogene RET/PTC. Another activated form of the RET oncogene has subsequently been found in a thyroid carcinoma and is now referred to as RET/PTC2. Here we report the identification and cloning of a novel rearranged version of the RET oncogene in a human thyroid papillary carcinoma. In this case the tyrosine-kinase domain of RET was fused to a sequence 790 bp long belonging to a new gene that we have named RFG (RET I;used Gene). This novel chimeric oncogene has been designated RET/PTC3. In order to have more insights into the function of RI;G we have completely cloned and sequenced its cDNA. RFG predicted amino-acid sequence does not have any significant homology to any already known genes and is ubiquitously expressed in human and mouse tissues. Finally we provide evidence indicating that the rearrangement leading to the generation of RET/PTC3 occurred in vivo in the original tumor DNA.	UNIV NAPOLI,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,I-20133 MILAN,ITALY; CTR HOSP LYON SUD,HISTOL & CYTOL LAB,F-69310 PIERRE BENITE,FRANCE; FAC MED LYON SUD,CNRS,URA 1454,F-69600 OULLINS,FRANCE; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CANTANZARO,ITALY	University of Naples Federico II; Fondazione IRCCS Istituto Nazionale Tumori Milan; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Universita Mediterranea di Reggio Calabria	SANTORO, M (corresponding author), CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,VIA S PANSINI 5,I-80131 NAPLES,ITALY.		Bongarzone, Italia/B-9544-2017	Bongarzone, Italia/0000-0003-2530-9170; Grieco, Michele/0000-0002-4212-7814; Pierotti, Marco Alessandro/0000-0002-7431-8332; Fusco, Alfredo/0000-0003-3332-5197				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FUSCO A, 1987, NATURE, V328, P7072; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; JHIANG SM, 1992, ONCOGENE, V7, P1331; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANZI C, 1992, ONCOGENE, V7, P2189; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OU JH, 1984, P NATL ACAD SCI USA, V82, P83; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1993, BRIT J CANCER, V68, pH60; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; [No title captured]	32	289	299	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					509	516						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290261				2022-12-28	WOS:A1994MW24800018
J	XU, NZ; MCCORMICK, F; GUTKIND, JS				XU, NZ; MCCORMICK, F; GUTKIND, JS			THE NONCATALYTIC DOMAIN OF RAS-GAP INHIBITS TRANSFORMATION-INDUCED BY G-PROTEIN COUPLED RECEPTORS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; OVEREXPRESSION; CELLS; DNA	We have studied the relationship between vas-GAP and G protein coupled receptors in a proliferative setting comprised of NIH3T3 expressing transfected muscarinic receptors (mAChRs). GAP expression plasmids were engineered to encode wild-type GAP, its carboxyl-terminal catalytic domain, a mutant lacking a portion of the catalytic domain, and an amino-terminal domain which contained the hydrophobic region as well as SH2-SH3 domains. Cotransfection of each GAP expression plasmid into NIH3T3 cells did not affect the transforming ability of the v-mos oncogene, but plasmids encoding wild-type GAP or the mutant consisting of an intact catalytic domain inhibited transformation induced by normal c-ras. Wild-type GAP also prevented transformation by mi mAChRs, whereas the mutant consisting of only its catalytic domain lacked any demonstrable effect. In contrast, the N-terminal non-catalytic domain of GAP effectively prevented m1-induced focus-formation. Cell lines coexpressing m1 receptors and each of the GAP constructs revealed that GAP proteins do not affect mi receptor density, receptor ligand binding characteristics or coupling to the PI-PLC signal transduction pathway. Thus, our findings suggest a role for the N-terminal non-catalytic domain of GAP in regulating biological functions mediated by G protein-coupled receptors.	NIDR,CELLULAR DEV & ONCOL LAB,MOLEC SIGNALING UNIT,BETHESDA,MD 20892; ONYX PHARMACEUT,RICHMOND,CA 94806	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUIDEON P, 1992, MOL CELL BIOL, V12, P2050; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	23	16	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					597	601						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290270				2022-12-28	WOS:A1994MW24800027
J	WILSON, RE; TAYLOR, SL; ATHERTON, GT; JOHNSTON, D; WATERS, CM; NORTON, JD				WILSON, RE; TAYLOR, SL; ATHERTON, GT; JOHNSTON, D; WATERS, CM; NORTON, JD			EARLY RESPONSE GENE SIGNALING CASCADES ACTIVATED BY IONIZING-RADIATION IN PRIMARY HUMAN B-CELLS	ONCOGENE			English	Article							PROTEIN-KINASE-C; LYMPHOCYTIC-LEUKEMIA CELLS; INDUCED PLASMACYTOID DIFFERENTIATION; IONIZING-RADIATION; MYC PROTEIN; TRANSCRIPTION FACTORS; BINDING-ACTIVITY; CULTURED-CELLS; GROWTH-FACTORS; EXPRESSION	We have used a panel of 13 protein kinase C-responsive immediate early gene probes to dissect the cellular signalling pathways activated by ionising gamma radiation in primary human B cells. Of these 13 genes, a delayed transient induction was observed for only 8: c-fos, c-jun, jun-B, jun-D, c-myc, ergI/krox 24 and two 'anonymous' genes, 3L3 and 19A. Expression of c-myc and c-fos mRNAs was paralleled by the appearance of their encoded proteins suggesting that these oncoproteins may couple radiation signalling to cellular responses. Of three protein kinase C-coupled transcription factors examined by gel retardation assay, (AP1, NF kappa B, EgrI/Krox24) only NF kappa B and, to a lesser extent, AP1 was stimulated in response to irradiation. These observations are not obviously compatible with a simple model invoking protein kinase C in radiation signalling in primary B cells and suggest that the pleiotropic effects of ionising radiation on this cell type are mediated through a distinct cellular signalling cascade.	CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC,DEPT CARCINOGENESIS,MANCHESTER M20 9BX,ENGLAND; CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,DEPT GENE REGULAT,MANCHESTER M20 9BX,ENGLAND; UNIV MANCHESTER,DEPT PHYSIOL SCI,MOLEC PHARMACOL & TOXICOL GRP,MANCHESTER M13 9PT,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester			Atherton, Graham/GZK-4237-2022	Atherton, Graham/0000-0002-7425-3153	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; Anderson R E, 1976, Adv Immunol, V24, P215, DOI 10.1016/S0065-2776(08)60331-4; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRACH MA, 1993, BIOL CHEM, V268, P8466; CELANO P, 1989, BIOFEEDBACK, V7; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHILES TC, 1991, J IMMUNOL, V146, P1730; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DEED RW, 1993, ONCOGENE, V8, P599; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FACHINI A, 1976, RADIAT RES, V68, P339; FOLCH H, 1982, IMMUNOL LETT, V5, P337, DOI 10.1016/0165-2478(82)90124-9; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P17; HALLAHAN DE, 1992, RADIAT RES, V129, P345, DOI 10.2307/3578035; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; LARSSON LG, 1987, P NATL ACAD SCI USA, V84, P223, DOI 10.1073/pnas.84.1.223; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEEK DW, 1992, BIOCHEM J, V287, P1; MOORE JP, 1988, BIOCHIM BIOPHYS ACTA, V965, P60, DOI 10.1016/0304-4165(88)90151-1; MURPHY JJ, 1990, FEBS LETT, V267, P242, DOI 10.1016/0014-5793(90)80935-C; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; MURPHY JJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P110, DOI 10.1016/0167-4889(91)90184-Y; MURPHY JJ, 1993, IN PRESS LEUKAEMIA R; OBRIAN CA, 1988, BIOCHEM BIOPH RES CO, V155, P1374, DOI 10.1016/S0006-291X(88)81293-2; OJEDA F, 1990, INT J RADIAT BIOL, V59, P53; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARKCHAE H, 1993, CANCER RES, V53, P447; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHERMAN ML, 1991, J CLIN INVEST, V87, P1794, DOI 10.1172/JCI115199; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SONOBE MH, 1991, ONCOGENE, V6, P1531; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; WATERS CM, 1990, ONCOGENE, V5, P669; WATERS CM, 1991, ONCOGENE, V6, P797; WITTE L, 1989, CANCER RES, V49, P5066; WOLOSCHAK GE, 1990, CANCER RES, V50, P3963; WOLOSCHAK GE, 1990, CANCER RES, V50, P339; WOLTERS H, 1987, INT J RADIAT BIOL, V51, P619, DOI 10.1080/09553008414552151; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	62	56	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3229	3237						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247526				2022-12-28	WOS:A1993MG78200005
J	BUSAM, KJ; GEISER, AG; ROBERTS, AB; SPORN, MB				BUSAM, KJ; GEISER, AG; ROBERTS, AB; SPORN, MB			SYNERGISTIC INCREASE OF PHORBOL ESTER-INDUCED C-FOS MESSENGER-RNA EXPRESSION BY RETINOIC ACID THROUGH STABILIZATION OF THE C-FOS MESSAGE	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; GENE-EXPRESSION; GROWTH-FACTORS; POSTTRANSCRIPTIONAL REGULATION; COLLAGENASE PRODUCTION; HOMEOBOX GENES; TRANSCRIPTION; INHIBITION; AP-1	Retinoic acid (RA) has been shown to be able to antagonize or synergize with phorbol 12-myristate 13-acetate (PMA). In contrast to its antagonistic effects on PMA-dependent gene expression, no molecular target or mechanism of synergism has been characterized yet. We now report, that RA synergistically enhances the induction of c-fos, but not c-jun mRNA by PMA in cells whose growth was stimulated by RA alone. The responding cells were hybrids of tumor cell lines whose growth and PMA-dependent c-fos mRNA expression remained unaffected by RA. The increase in PMA-dependent c-fos expression required pretreatment of cells with RA for at least 2 - 4 h and was achieved at doses as low as 10(-10) M. Nuclear run-on experiments and transient transfection assays using a chimeric reporter gene construct with sequences from the c-fos promoter indicated that RA did not affect PMA-dependent c-fos transcription. Instead, RA stabilized the c-fos message after induction by PMA as assessed by measuring the half-life of c-fos mRNA in actinomycin D-treated cells. This post-transcriptional regulation provides a mechanism whereby RA can synergistically enhance gene expression by PMA.			BUSAM, KJ (corresponding author), NCI, CHEMOPREVENT LAB, BETHESDA, MD 20892 USA.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BRINCKERHOFF CE, 1980, NEW ENGL J MED, V303, P432, DOI 10.1056/NEJM198008213030805; BRINCKERHOFF CE, 1983, SCIENCE, V221, P756, DOI 10.1126/science.6308759; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DICKER P, 1979, BIOCHEM BIOPH RES CO, V91, P1203, DOI 10.1016/0006-291X(79)91195-1; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEISER AG, 1989, CANCER RES, V49, P1572; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JETTEN AM, 1983, CANCER RES, V43, P68; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; MILLER WH, 1990, ONCOGENE, V5, P511; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; RADZIOCH D, 1991, MOL CELL BIOL, V11, P2718, DOI 10.1128/MCB.11.5.2718; REPRESA J, 1990, DEVELOPMENT, V110, P1081; ROBERTS AB, 1984, RETINOIDS, V2, P209; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHRODER EW, 1980, CANCER RES, V40, P3089; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1989, Molecular Reproduction and Development, V1, P107, DOI 10.1002/mrd.1080010205; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; YANGYEN HF, 1991, NEW BIOL, V3, P1206	38	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2267	2273						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336949				2022-12-28	WOS:A1993LP17100029
J	TANAKA, K; YANOSHITA, R; KONISHI, M; OSHIMURA, M; MAEDA, Y; MORI, T; MIYAKI, M				TANAKA, K; YANOSHITA, R; KONISHI, M; OSHIMURA, M; MAEDA, Y; MORI, T; MIYAKI, M			SUPPRESSION OF TUMORIGENICITY IN HUMAN COLON-CARCINOMA CELLS BY INTRODUCTION OF NORMAL CHROMOSOME 1P36 REGION	ONCOGENE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; ENDOCRINE NEOPLASIA; COLORECTAL TUMORS; HIGH-FREQUENCY; WILMS-TUMOR; SHORT ARM; TUMORIGENICITY; DNA; SEQUENCE; GENE	Development of colon carcinomas appears to be associated with inactivation of multiple tumour suppressor genes. Cytogenetic and DNA analyses of colon carcinomas have detected a high frequency of chromosome 1p deletion, which suggests the presence of a tumour suppressor gene. We therefore introduced normal human chromosome 1 into colon carcinoma COKFu cells, through microcell hybridization. Six clones of hybrid cells containing normal chromosome 1 were obtained, four of which had a small fragment of the introduced chromosome 1, including 1p36-34. The morphology of hybrid cells with chromosome 1 markedly altered to a flat shape. The cloning efficiency of all six hybrid cells in soft agar was significantly reduced, and the tumourigenicity in athymic nude mice was completely suppressed. Hybrid cells containing only the region of 1p36-34, as well as those containing intact chromosome 1, showed suppressed transformed phenotype. Furthermore, several tumourigenic revertant cells were obtained from the hybrid cells. These revertant cells had a morphology similar to that of COKFu cells, and were found to have lost the 1p36 region from the introduced chromosome 1. These results indicate that a normal chromosome 1p36 carries a tumour suppressor gene for colon carcinogenesis.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,3-18-22 HONKOMAGOME,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT CHEMOTHERAPY & SURG,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tottori University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital								BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BENEDICT WF, 1984, CANCER RES, V44, P3471; COUTURIERTURPIN MH, 1992, HUM GENET, V88, P431, DOI 10.1007/BF00215678; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DRACOPOLI N C, 1988, Genomics, V3, P124, DOI 10.1016/0888-7543(88)90142-5; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KLEIN G, 1971, J CELL SCI, V8, P659; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MIYAKI M, 1990, CANCER RES, V50, P7166; MOLEY JF, 1992, CANCER RES, V52, P770; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P9367, DOI 10.1093/nar/16.19.9367; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P9368, DOI 10.1093/nar/16.19.9368; NAKAMURA Y, 1987, NUCLEIC ACIDS RES, V15, P9622, DOI 10.1093/nar/15.22.9622; NEGRINI M, 1992, CANCER RES, V52, P1297; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; PARASKEVA C, 1988, INT J CANCER, V41, P908; PARASKEVA C, 1989, CANCER RES, V49, P1282; REICHMANN A, 1984, CANCER GENET CYTOGEN, V12, P295, DOI 10.1016/0165-4608(84)90062-1; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHIMIZU M, 1990, ONCOGENE, V5, P185; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VANNI R, 1990, GENE CHROMOSOME CANC, V2, P255, DOI 10.1002/gcc.2870020316; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISS MJ, 1987, NUCLEIC ACIDS RES, V15, P860, DOI 10.1093/nar/15.2.860; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WILLIAMS AC, 1990, CANCER RES, V50, P4724; YANOSHITA R, 1992, CANCER RES, V52, P3965	45	91	101	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2253	2258						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8101648				2022-12-28	WOS:A1993LP17100027
J	ZENKLUSEN, JC; OSHIMURA, M; BARRETT, JC; CONTI, CJ				ZENKLUSEN, JC; OSHIMURA, M; BARRETT, JC; CONTI, CJ			INHIBITION OF TUMORIGENICITY OF A MURINE SQUAMOUS-CELL CARCINOMA (SCC) CELL-LINE BY A PUTATIVE TUMOR-SUPPRESSOR GENE ON HUMAN-CHROMOSOME-7	ONCOGENE			English	Article							IDENTIFICATION; EXPRESSION; DELETION; CANCER; NEUROFIBROMATOSIS; HETEROZYGOSITY; CLONING; DISEASE; HYBRIDS; GROWTH	Alterations in oncogenes and tumor suppressor genes (TSG) are considered to be critical steps in oncogenesis. However information on putative TSG involved in the developement of squamous cell carcinomas (SCC) is very limited. In this study we confirmed the existence of a tumor suppressor gene (TSG) on human chromosome 7 (hchr 7) that suppresses the tumorigenicity of squamous cell carcinomas (SCCs). We injected seven clones of CH72 cells (a murine SCC-derived cell line) bearing a hchr 7 (CH72/hchr 7) introduced by microcell fusion, two clones bearing human chromosome 12 (CH72/hchr 12) and parental CH72 cells into athymic Balb/c nude mice. The sizes of the tumors were determined twice a week until tumors reached 12 mm diameter. In situ hybridization for centromeric repetitive sequences of the transferred chromosomes were performed on the cell lines injected and the tumors arising after the injection. Southern blots and polymerase chain reaction (PCR) amplifications of near terminal sequences and (CA) microsatellite repeats were done to test the integrity of the introduced chromosomes. Five out of seven CH72/ hchr 7 clones had a twofold and threefold longer latency periods than CH72 cells. The remaining CH72/hchr 7 clones (MF 6 and 13 no. 4) had latency periods similar to that of parental CH72; MF 6 had a deletion in the introduced chromosome 7 involving q31.3-q31.3, whereas the other hybrid (MF 13 no. 4) seemed to have an intact hchr 7. Tumor-derived cells from CH72/hchr 7 hybrids with a delayed latency had lost centromeric and telomeric sequences of Chr 7. In constrast, tumors derived from the MF 6 and MF 13 no. 4 as well as the CH72/hchr 12 clones retained the introduced human chromosome as shown by chromosome 7 or 12 centromeric and telomeric sequences. These results indicate that the tumorigenicity of CH72 murine SCC cells was suppressed by hchr 7 and that the CH72/hchr 7 regain the tumorigenic phenotype after loss of the introduced chromosome, suggesting the presence of a TSG on hchr 7.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV RES,SMITHVILLE,TX 78957; TOTTORI UNIV,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI,JAPAN; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	University of Texas System; UTMD Anderson Cancer Center; Tottori University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)					NCI NIH HHS [CA53123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1986, CANCER GENET CYTOGEN, V20, P223, DOI 10.1016/0165-4608(86)90077-4; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V1, pCH2; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CONTI CJ, 1988, CANCER RES, V48, P435; CONWAY K, 1992, CANCER RES, V52, P6487; DORNISKELLER H, 1987, CELL, V51, P319; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HANSEN MF, 1987, CANCER RES, V47, P5518; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEFRANC MP, 1986, P NATL ACAD SCI USA, V83, P9596, DOI 10.1073/pnas.83.24.9596; MYERS JC, 1981, P NATL ACAD SCI-BIOL, V78, P3516, DOI 10.1073/pnas.78.6.3516; NEUMAN WL, 1992, BLOOD, V79, P1501; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; OSLO P, 1992, CANCER GENET CYTOGEN, V59, P73; PORTEOUS DJ, 1989, GENOMICS, V5, P680, DOI 10.1016/0888-7543(89)90108-0; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHANNON KM, 1992, BLOOD, V79, P1311; TANAKA K, 1990, SCIENCE, V247, P568; THEUNE S, 1991, GENOMICS, V9, P511, DOI 10.1016/0888-7543(91)90418-E; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; ZAR JH, 1992, BIOSTATISTICAL ANAL, pCH16	37	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2817	2825						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084587				2022-12-28	WOS:A1994PG82200007
J	GRUDA, MC; KOVARY, K; METZ, R; BRAVO, R				GRUDA, MC; KOVARY, K; METZ, R; BRAVO, R			REGULATION OF FRA-1 AND FRA-2 PHOSPHORYLATION DIFFERS DURING THE CELL-CYCLE OF FIBROBLASTS AND PHOSPHORYLATION IN-VITRO BY MAP KINASE AFFECTS DNA-BINDING ACTIVITY	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; IMMEDIATE-EARLY GENE; FOS-JUN INTERACTION; SWISS 3T3 CELLS; C-JUN; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; G0-TO-G1 TRANSITION; NEGATIVE REGULATOR	The Fos family of transcription factors, c-Fos, FosB, Fra-1 and Fra-2, are rapidly induced in quiescent fibroblasts following serum or growth factor stimulation. The Fos proteins show distinct patterns of expression during cell growth with only Fra-1 and Fra-2 maintained at significant levels in growing cells, suggesting that the different family members direct unique functions for cell growth. Post-translational modification of Fos proteins has been observed following serum stimulation, which may allow an additional level of regulation. Our studies show that the synthesis and post-translational modification of Fra-1 and Fra-2 in Swiss 3T3 cells is serum-dependent during G(1) following the transition from G(0) and during asynchronous growth but is serum-independent during S phase and mitosis. Post-translational modification of Fra-1 and Fra-2 causes a significant shift in their gel mobility which is eliminated by alkaline phosphatase treatment. Several kinases can phosphorylate Fra-1 and Fra-2 in vitro, including cAMP-dependent kinase (PKA), protein kinase C (PKC), cyclin-dependent kinase 1-cdc2 (cdc2), and mitogen activated protein (MAP) kinase. From these, MAP kinase is the only one that causes a shift in gel mobility similar to that observed in vivo. One dimensional phosphopeptide maps of Fra-1 and Fra-2 phosphorylated by MAP kinase in vitro are similar to those of in vivo labeled Fra-1 and Fra-2, suggesting that MAP kinase may also phosphorylate Fra-1 and Fra-2 in vivo. We have also determined that phosphorylation of Fra-1 and Fra-2 by MAP kinase increases their DNA binding activity.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb			Kovary, Karla/E-3979-2013					ABATE C, 1991, ONCOGENE, V6, P2179; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAVO R, 1990, GROWTH FACTORS DIFFE; BRAVO R, 1980, J CELL BIOL, V84, P796; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEGROOT RP, 1992, ONCOGENE, V7, P841; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GILLE H, 1992, NATURE, V358, P433; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAU LF, 1991, HORMONAL CONTROL REG; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MATSUI M, 1990, ONCOGENE, V5, P249; MEEK DW, 1992, BIOCHEM J, V287, P1; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELECH SL, 1987, J BIOL CHEM, V262, P11598; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RYSECK RP, 1991, ONCOGENE, V6, P533; RYSECK RP, 1990, ONCOGENE, V5, P1091; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Summers MD, 1987, TEXAS AGR EXPT STATI; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUZUKI T, 1992, NUCLEIC ACIDS RES, V19, P5537; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	67	134	135	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2537	2547						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058317				2022-12-28	WOS:A1994PC05400013
J	RAKOTOMAHANINA, CK; HILGER, C; FINK, T; ZENTGRAF, H; SCHRODER, CH				RAKOTOMAHANINA, CK; HILGER, C; FINK, T; ZENTGRAF, H; SCHRODER, CH			BIOLOGICAL-ACTIVITIES OF A PUTATIVE TRUNCATED HEPATITIS-B VIRUS-X GENE-PRODUCT FUSED TO A POLYLYSIN STRETCH	ONCOGENE			English	Article							SURFACE-ANTIGEN GENE; HEPATOCELLULAR-CARCINOMA; DNA-SEQUENCES; MAMMALIAN-CELLS; PLASMID DNA; MOUSE CELLS; VIRAL-DNA; PROTEIN; TRANSFORMATION; TRANSFECTION	Truncated transcripts terminating within the HBx frame have been recognized previously in tumor and liver tissue of HCC patients. In this study biological activities of a predicted truncated HBx fused to a polysin stretch (HBtx-polylysin) and of full length HBx were compared in NIH3T3 cells transfected with respective cDNA plasmids. Transactivation of a co-transfecting reporter gene and influence on neo' DNA mediated transformation to G418 resistance were determined. In comparison to full length HBx the data indicate for HBtx-polylysin a lower transactivating capacity and as judged by the yield of colonies on a solid surface, a lower capacity to stimulate neo(r) DNA mediated transformation. In soft agar the outgrowth into G418 resistant colonies was dependent on co-transfecting HBx cDNA. In providing this condition HBtx-polylysin had a much higher relative activity than full length HBx. Large cointegrants consisting of the plasmids carrying truncated HBx cDNA and neo(r) DNA respectively were identified by chromosomal in situ hybridization. Based on Southern blot analyses extended concatemeres of the HBx cDNA plasmid constituted a main part of the cointegrants. Expression of truncated HBx cDNA was followed on the RNA and the protein level. The presence of this cDNA could be correlated to a compact spindle like cell appearance, its loss after prolonged passaging in the absence of G418 to a concomitant reversion to the phenotype of the NIH3T3 cell. Interspersed selection for G418 resistance stabilized the morphologically transformed phenotype. These results provide a basis to manipulate expression of truncated HBx and to recognize thereby processes leading to transformation.	DEUTSCH KREBSFORSCHUNGSZENTRUM,DEPT VIRUS WECHSELWIRKUNGEN,D-69009 HEIDELBERG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,DEPT ORG KOMPLEXER GENOME,D-69009 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)				Hilger, Christiane/0000-0001-9455-5442				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECHOT C, 1981, LANCET, V2, P765; CATTANEO R, 1983, NATURE, V305, P336, DOI 10.1038/305336a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GRUMMT F, 1989, CELL, V56, P143, DOI 10.1016/0092-8674(89)90886-6; HARNES BD, 1984, TRANSCRIPTION TRANSL; HILGER C, 1991, J VIROL, V65, P4284, DOI 10.1128/JVI.65.8.4284-4291.1991; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOLST A, 1988, CELL, V52, P355; IMAZEKI F, 1987, HEPATOLOGY, V7, P753, DOI 10.1002/hep.1840070423; KESSLER C, 1990, BIOL CHEM H-S, V371, P917, DOI 10.1515/bchm3.1990.371.2.917; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KLEIN R, 1991, VIRUS GENES, V5, P157, DOI 10.1007/BF00571930; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUPPER H, 1984, EXPRESSION FOOT MOUT, P222; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LICHTER P, 1992, HUMAN CYTOGENETICS P, V1, P157; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; POURCEL C, 1982, J VIROL, V42, P100, DOI 10.1128/JVI.42.1.100-105.1982; PULM W, 1985, MOL CELL BIOL, V5, P295; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; RAIMONDO G, 1988, VIROLOGY, V166, P103, DOI 10.1016/0042-6822(88)90151-1; SCHEK N, 1991, ONCOGENE, V6, P1735; SHAFRITZ DA, 1981, HEPATOLOGY, V1, P1, DOI 10.1002/hep.1840010102; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; ZASTROW G, 1989, NUCLEIC ACIDS RES, V17, P1867, DOI 10.1093/nar/17.5.1867	40	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2613	2621						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058325				2022-12-28	WOS:A1994PC05400021
J	DEHBI, M; BEAULIEU, S; COHEN, EA; BEDARD, PA				DEHBI, M; BEAULIEU, S; COHEN, EA; BEDARD, PA			ACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS-1 GENE-EXPRESSION BY THE SRC ONCOPROTEIN	ONCOGENE			English	Note							NF-KAPPA-B; LONG TERMINAL REPEAT; T-CELLS; TRANSFORMED-CELLS; TRANSCRIPTION; PROMOTER; INDUCTION; ENHANCER; REPLICATION; PP60V-SRC	Several genes are induced constitutively in cells transformed by the v-src oncoprotein. This induction is generally dependent on the activation of transcription factors binding to src-responsive elements of the promoter. In previous studies, we showed that the induction of the CEF-4/9E3 cytokine gene by pp60(v-src) is dependent on the PRDII/kappa B domain of the promoter (Dehbi et al., 1992). In this investigation, we describe the activation of the HIV-1 LTR by pp60(v-src) and show that a region of 30 bp containing the two IVF-kappa B binding sites is critical for activation of the promoter. The induction was dependent on transformation since non-transforming forms of pp60(v-src) had little or no effect on the promoter. The expression of proviral DNA and the release of p24 antigen were also increased by v-src indicating that viral replication was stimulated in src-transformed cells. The effect of v-src on HIV-1 gene expression occurred in the presence or in the absence of the tat viral trans-activator, in fibroblasts and in Jurkat T lymphocytes. These results indicate that several promoters controlled by PRDII/kappa B may be activated constitutively in v-src transformed cells and suggest that oncogenic tyrosine kinases may play a role in the induction of viruses with a PRDII/kappa B-controlled promoter.	YORK UNIV, DEPT BIOL, N YORK M3J 1P3, ON, CANADA; UNIV MONTREAL, DEPT BIOCHIM, MONTREAL H3C 3J7, PQ, CANADA; UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, PQ, CANADA	York University - Canada; Universite de Montreal; Universite de Montreal								ARENZANASEISDEDOS F, 1989, ONCOGENE, V4, P1359; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; DEHBI M, 1992, BIOCHEM CELL BIOL, V70, P980, DOI 10.1139/o92-142; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DUTTA A, 1990, P NATL ACAD SCI USA, V87, P608, DOI 10.1073/pnas.87.2.608; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EMERMAN M, 1987, EMBO J, V6, P3755, DOI 10.1002/j.1460-2075.1987.tb02710.x; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; KIM YS, 1993, J VIROL, V67, P239, DOI 10.1128/JVI.67.1.239-248.1993; KOWALIK TF, 1993, P NATL ACAD SCI USA, V90, P1107, DOI 10.1073/pnas.90.3.1107; LACOSTE J, 1991, VIROLOGY, V184, P553, DOI 10.1016/0042-6822(91)90425-B; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LIN G, 1990, DEV BIOL, V139, P186, DOI 10.1016/0012-1606(90)90287-S; LU YC, 1989, J VIROL, V63, P4115, DOI 10.1128/JVI.63.9.4115-4119.1989; MARONEY AC, 1992, ONCOGENE, V7, P1207; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PAYA CV, 1992, P NATL ACAD SCI USA, V89, P7826, DOI 10.1073/pnas.89.16.7826; RAZIUDDIN, 1991, P NATL ACAD SCI USA, V88, P9426, DOI 10.1073/pnas.88.21.9426; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P3857, DOI 10.1073/pnas.86.10.3857; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; WELHAM MJ, 1990, ONCOGENE, V5, P161; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	28	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2399	2403						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036024				2022-12-28	WOS:A1994NX62900035
J	FERNANDEZ, A; MARIN, MC; MCDONNELL, T; ANANTHASWAMY, HN				FERNANDEZ, A; MARIN, MC; MCDONNELL, T; ANANTHASWAMY, HN			DIFFERENTIAL SENSITIVITY OF NORMAL AND HA-RAS-TRANSFORMED C3H MOUSE EMBRYO FIBROBLASTS TO TUMOR-NECROSIS-FACTOR - INDUCTION OF BCL-2, C-MYC, AND MANGANESE SUPEROXIDE-DISMUTASE IN RESISTANT CELLS	ONCOGENE			English	Article							WILD-TYPE P53; FACTOR-MEDIATED CYTOTOXICITY; FACTOR-ALPHA; INTERFERON-GAMMA; MALIGNANT TRANSFORMATION; CHROMOSOMAL BREAKPOINT; ONCOGENE EXPRESSION; FOLLICULAR LYMPHOMA; DNA FRAGMENTATION; FACTOR RECEPTORS	In this study, we investigated the role of activated Ha-ras oncogene on the growth-regulatory properties of tumor necrosis factor (TNF) in C3H mouse embryo fibroblasts. TNF-resistant 10T1/2 cells transfected with an activated Ha-ras oncogene not only produced tumors in nude mice but also exhibited extreme sensitivity to cytolysis by TNF. TNF-induced cell death was mediated through apoptosis. The differential sensitivity of normal and Ha-ras transformed cells to TNF was not due to differences in the number of TNF receptors on their cell surface. However, TNF-resistant cells, but not sensitive cells, overexpressed bcl-2, c-myc, and manganese superoxide dismutase (MnSOD) mRNA following exposure to TNF. In addition, TNF treatment resulted in a marginal induction of p53 mRNA in both TNF-sensitive and resistant cells. These results suggest that TNF-induced cytotoxicity involves apoptosis and that TNF-induced over-expression of bcl-2, c-myc, and MnSOD genes is associated with TNF resistance in C3H mouse embryo fibroblasts.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marín Vieira, María del Carmen/B-8108-2015; Marin, Maria C/G-1040-2010	Marín Vieira, María del Carmen/0000-0002-7149-287X; Marin, Maria C/0000-0002-7149-287X	NATIONAL CANCER INSTITUTE [R01CA046523] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09255-02, R01-CA-46523] Funding Source: Medline; NCRR NIH HHS [RR5S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; ASHER A, 1987, J IMMUNOL, V138, P963; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BALKWILL FR, 1986, CANCER RES, V46, P3990; BARRETT K, 1991, EUR J IMMUNOL, V21, P1649, DOI 10.1002/eji.1830210710; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOSS JM, 1991, IMMUNOLOGY, V73, P309; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERNANDEZ A, 1992, LYMPHOKINE CYTOK RES, V11, P79; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GONEN B, 1992, CANCER IMMUNOL IMMUN, V35, P388, DOI 10.1007/BF01789017; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELSON L, 1975, NATURE, V258, P731, DOI 10.1038/258731a0; HENNET T, 1993, CANCER RES, V53, P1456; HIMENO T, 1992, INT J CANCER, V50, P458, DOI 10.1002/ijc.2910500322; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HSIO WL, 1984, SCIENCE, V226, P552; HUANG MN, 1990, BIOTECHNIQUES, V9, P711; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; ITOH N, 1993, J IMMUNOL, V151, P621; KETTELHUT IC, 1987, P NATL ACAD SCI USA, V84, P4273, DOI 10.1073/pnas.84.12.4273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEHMANN V, 1986, EUR J BIOCHEM, V158, P1, DOI 10.1111/j.1432-1033.1986.tb09712.x; LICHTENSTEIN A, 1990, CANCER RES, V50, P7364; Maniatis T., 1982, MOL CLONING; MATHEWS N, 1987, IMMUNOLOGY, V62, P153; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MONOHARAN TH, 1985, CARCINOGENESIS, V6, P1295; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROBAYE B, 1991, AM J PATHOL, V138, P447; RUBIN BY, 1988, CANCER RES, V48, P6006; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SATOMI N, 1988, J BIOL RESP MODIF, V7, P54; SELIGER B, 1988, J IMMUNOL, V141, P2138; SELIGER B, 1988, J CELL BIOCHEM, V38, P205, DOI 10.1002/jcb.240380308; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1989, ANTICANCER RES, V9, P1149; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; SUEN TC, 1990, LYMPHOKINE RES, V9, P15; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIMMERMAN RJ, 1989, J IMMUNOL, V142, P1405	75	52	61	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2009	2017						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208546				2022-12-28	WOS:A1994NR68500025
J	PARK, DJ; NAKAMURA, H; CHUMAKOV, AM; SAID, JW; MILLER, CW; CHEN, DL; KOEFFLER, HP				PARK, DJ; NAKAMURA, H; CHUMAKOV, AM; SAID, JW; MILLER, CW; CHEN, DL; KOEFFLER, HP			TRANSACTIVATIONAL AND DNA-BINDING ABILITIES OF ENDOGENOUS P53 IN P53 MUTANT-CELL LINES	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENE; WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; MUTATIONS; EXPRESSION; ANTIGEN; CARCINOMAS	Cells with divergent mutant alleles of the p53 gene have different biological and biochemical properties in vitro. Increasing evidence indicates that p53 is a transcriptional activator, and recently, high affinity DNA binding sites for p53 have been identified. The purpose of this study was to determine in vivo, the effect that various mutant p53 proteins have on their ability to mediate transactivation and to bind specifically to DNA. Either a p53 responsive or control reporter gene was transfected into 18 human carcinoma cell lines, having various p53 mutations, either with or without a wild-type p53 expression vector, The CAT activity and DNA gel retardation were studied to measure transactivation and DNA binding by these endogenous p53s. As expected, the endogenously produced wild-type p53 binds to DNA binding sequences and can transactivate a reporter construct containing a p53 high affinity DNA binding site. Four of five cell lines with homozygous p53 mutations at codon 273 (273(His)), contained p53 which had the ability to bind to p53 DNA binding sequences and transactivate. In contrast, all the homozygous, non-codon 273 mutant p53s (156(Pro), 175(His), 223(Leu), 248(Gln), 248(Trp), 280(Lys)) present in the other cell lines had no transactivating ability. These findings suggest that the biology of cancers with mutations at codon 273 may be different than those with p53 mutations at other sites. The p53 from WRO, a thyroid carcinoma cell line with p53 mutation at codon 223 (223(Leu)), was able to bind p53 DNA recognition sequences, but was unable to transactivate. Interestingly, in a vulvar carcinoma cell line (A431) with a p53 mutation at codon 273 (273(His)), the p53 was unable to transactivate and gave an aberrant band on gel retardation. Both CEM and SK-UT-1, which have compound heterozygous mutations at codons 175/248 (175(His)/248(His)), produced p53 which can complex with DNA, as well as transactivate. In contrast, the p53 in cell lines with either homozygous 175(His) or 248(His) p53 mutations, were unable either to transactivate or bind to the p53 response element. A cell line (NPA) heterozygous for 266(Glu) p53 mutation, was able to efficiently transactivate a reporter containing a p53 DNA binding site, therefore showing no evidence of a dominant negative effect of the endogenous p53 mutant allele. In summary, this in vivo study further supports the idea that different p53 mutant alleles have various properties which may affect their function.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	PARK, DJ (corresponding author), UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DIV HEMATOL ONCOL,8700 BEVERLY BLVD,B-210,LOS ANGELES,CA 90048, USA.		Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166	NCI NIH HHS [CA42710] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042710, P01CA042710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1993, EUR J CANCER, V29A, P101, DOI 10.1016/0959-8049(93)90584-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHEN JY, 1993, ONCOGENE, V8, P2159; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELDEIRY WS, 1992, NAT GENET, V1, P44; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEVINE AJ, 1992, CANCER SURV, V12, P59; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILLER C W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P386; MILLER CW, 1993, ONCOGENE, V8, P1815; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SAID JW, 1992, AM J PATHOL, V141, P1343; SAKASHITA A, 1992, BLOOD, V79, P477; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P636; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SLINGERLAND JM, 1991, BLOOD, V77, P1500; STEINMEYER K, 1988, ONCOGENE, V3, P501; STRATTON MR, 1990, ONCOGENE, V5, P1297; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YAGINUMA Y, 1992, CANCER RES, V52, P4196; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555	70	150	152	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1899	1906						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208536				2022-12-28	WOS:A1994NR68500013
J	TASHIRO, S; KOTOMURA, N; TANAKA, K; SUZUKI, K; KYO, T; DOHY, H; NIWA, O; KAMADA, N				TASHIRO, S; KOTOMURA, N; TANAKA, K; SUZUKI, K; KYO, T; DOHY, H; NIWA, O; KAMADA, N			IDENTIFICATION OF ILLEGITIMATE RECOMBINATION HOT-SPOT OF THE RETINOIC ACID RECEPTOR-ALPHA GENE INVOLVED IN 15,17-CHROMOSOMAL TRANSLOCATION OF ACUTE PROMYELOCYTIC LEUKEMIA	ONCOGENE			English	Article							MOLECULAR ANALYSIS; MAMMALIAN-CELLS; T(15-17) TRANSLOCATION; DNA FRAGMENTS; RAR-ALPHA; PML; SEQUENCES; ONCOGENE; REARRANGEMENTS; AMPLIFICATION	Acute promyelocytic leukemia (APL) has been characterized by 15;17 chromosomal translocation, which involves the retinoic acid receptor alpha (RARA) gene on chromosome 17 and the PML gene on chromosome 15. The breakpoints have been mapped to three cluster regions in the PML gene, and to RARA gene intron 2. We have examined the distribution of breakpoints within RARA gene intron 2. An extremely restricted region (ERR) of 50 bp within RARA gene intron 2 was identified as the duster region of breakpoints by polymerase chain reaction and sequence analysis of DNA from APL patients. To study experimentally the mechanism involved in the translocation, ERR was tested in NIH3T3 cells by in vitro transfection-recombination assay, in which target sequences were placed either downstream of the SV40 promoter or upstream of the neo gene. Cells were conferred resistance to G418 only when the promoter was fused to the neo gene by recombination of two target sequences during transfection. The molecular junctions were analysed in five clones, and all of them were shown to be confined within a 20 bp region in a 148 bp DNA fragment containing ERR. This suggests that ERR might be the illegitimate recombination hot spot in mammalian cells.	HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT HEMATOL,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT PATHOL,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT BIOPHYS & BIOCHEM,HIROSHIMA 734,JAPAN; HIROSHIMA RED CROSS HOSP,DEPT INTERNAL MED 4,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT PEDIAT,HIROSHIMA 734,JAPAN	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University								BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHAKRABARTI S, 1986, MOL CELL BIOL, V6, P2520, DOI 10.1128/MCB.6.7.2520; CHAMPOUX JJ, 1988, GENETIC RECOMBINATIO, P655; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; DARBY MK, 1986, EMBO J, V5, P2257, DOI 10.1002/j.1460-2075.1986.tb04493.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DONG S, 1993, GENE CHROMOSOME CANC, V6, P133, DOI 10.1002/gcc.2870060302; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; JAEGER U, 1993, BLOOD, V81, P1833; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMADA N, 1981, BLOOD, V58, P1213; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MORRIS T, 1993, P NATL ACAD SCI USA, V90, P1392, DOI 10.1073/pnas.90.4.1392; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; ROWLEY JD, 1977, LANCET, V1, P549; RUBNITZ J, 1986, MOL CELL BIOL, V6, P1608, DOI 10.1128/MCB.6.5.1608; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; TASHIRO S, 1992, ONCOGENE, V7, P573; TASHIRO S, 1992, CANCER-AM CANCER SOC, V70, P2809, DOI 10.1002/1097-0142(19921215)70:12<2809::AID-CNCR2820701214>3.0.CO;2-#; TASHIRO S, 1993, JPN J CANCER RES, V84, P110, DOI 10.1111/j.1349-7006.1993.tb02841.x; TSUKIYAMA T, 1989, MOL CELL BIOL, V9, P4670, DOI 10.1128/MCB.9.11.4670; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; Yunis J J, 1986, Important Adv Oncol, P93	33	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1939	1945						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208541				2022-12-28	WOS:A1994NR68500018
J	VELASCO, JA; CASTRO, R; AVILA, MA; LABORDA, J; DIPAOLO, JA; CANSADO, J; NOTARIO, V				VELASCO, JA; CASTRO, R; AVILA, MA; LABORDA, J; DIPAOLO, JA; CANSADO, J; NOTARIO, V			CPH, A NOVEL ONCOGENE WHICH COOPERATES WITH H-RAS IN THE TRANSFORMATION OF NIH3T3 FIBROBLASTS	ONCOGENE			English	Note							BLADDER-CARCINOMA ONCOGENE; POINT MUTATION; PROTO-ONCOGENE; NEU ONCOGENE; ACTIVATION; CELLS; GENE; SEQUENCES; CANCER; ACQUISITION	We have performed the molecular cloning of the non-ras transforming sequences previously detected in neoplastic Syrian hamster embryo fibroblasts initiated in vitro with 3-methylcholanthrene (MCA) (Notario et at, 1990). These sequences were isolated using cosmid-rescue techniques from a third-cycle NIH3T3 transformant obtained by sequential transfections of genomic DNA from MCA-initiated hamster fetal cells. Rescued (C-5) clones encompassed about 42.5 kbp of Syrian hamster genomic DNA containing hamster-specific repetitive elements (HRS). An internal 19 kbp BamHI fragment (B-1) was the only C-5 fragment which recognized specific transcripts in poly(A)(+) RNA from hamster embryo cells, The same mRNA species were present in both normal and MCA-initiated neoplastic cells: a major transcript of about 2.5 kb, and other less abundant ones, ranging from approximately 2.0 kb to 5.0 kb. These mRNA species were detected consistently by each of several B-1 DNA subfragments located at positions spanning almost the entire B-1 length. The nucleotide sequence of some transcript-positive (S5P2 and S-6) genomic B-1 fragments was determined. No significant homology exists between the nucleotide sequences of these B-1 subfragments and established DNA databases. Therefore, the C-5 cosmid clone contains novel genomic sequences. Transfection of C-5 DNA into mouse NIH3T3 cells resulted in the appearance of transformed foci (about five foci per mu g of DNA) within 25 days post-transfection, thus demonstrating the transforming activity of the C-5 clone, which was consequently renamed as the cph oncogene. Co-transfection of the cph oncogene with the human H-ras oncogene (T24), demonstrated a synergistic action between the two oncogenes in the transformation of murine fibroblasts.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,DIV EXPTL CARCINOGENESIS,WASHINGTON,DC 20007; NCI,BIOL LAB,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			/AFP-0764-2022; /AAB-6461-2022; Cansado, Jose/ABC-6872-2020; Cansado, Jose/K-5212-2014; Avila, Matias A/Y-6342-2019; Laborda, Jorge/L-5726-2014	Cansado, Jose/0000-0002-2342-8152; Avila, Matias A/0000-0001-6570-3557; Laborda, Jorge/0000-0002-9210-838X	NATIONAL CANCER INSTITUTE [R29CA049858] Funding Source: NIH RePORTER; NCI NIH HHS [CA49858] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BERWALD Y, 1965, J NATL CANCER I, V35, P641; BOREK C, 1987, P NATL ACAD SCI USA, V84, P794, DOI 10.1073/pnas.84.3.794; BOS JL, 1989, CANCER RES, V49, P4682; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASTRO R, 1990, CELL MOL NEUROBIOL, V10, P281, DOI 10.1007/BF00734581; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICHUTEK K, 1986, P NATL ACAD SCI USA, V83, P2340, DOI 10.1073/pnas.83.8.2340; CUADRADO A, 1993, ONCOGENE, V8, P2443; DIPAOLO JA, 1969, J NATL CANCER I, V42, P867; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GILMER TM, 1988, MOL CARCINOGEN, V1, P180, DOI 10.1002/mc.2940010306; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NOTARIO V, 1990, ONCOGENE, V5, P1425; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	34	29	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2065	2069						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208552				2022-12-28	WOS:A1994NR68500032
J	SAKANO, S; IWAMA, A; INAZAWA, J; ARIYAMA, T; OHNO, M; SUDA, T				SAKANO, S; IWAMA, A; INAZAWA, J; ARIYAMA, T; OHNO, M; SUDA, T			MOLECULAR-CLONING OF A NOVEL NONRECEPTOR TYROSINE KINASE, HYL (HEMATOPOIETIC CONSENSUS TYROSINE-LACKING KINASE)	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; PROTEIN-KINASE; CONSERVED FEATURES; CATALYTIC DOMAIN; MESSENGER-RNAS; FAMILY; GENE; SEQUENCE	We identified a novel non-receptor tyrosine kinase from a human megakaryoblastic cell line, UT-7, by means of a PCR-based cloning method. The HYL gene contained a SH2 and SH3 domain and a tyrosine kinase catalytic domain. The deduced amino acid sequence of the protein encoded by this gene was most homologous to CSK (c-src kinase). This gene and CSK shared some unique structural properties such as the absence of a myristylation signal and phosphorylation sites of tyrosine residues corresponding to tyrosines 416 and 527 of chicken p60c-src. Unlike CSK, the SH3 domain of HYL was unique since the ALYDY motif was absent. Northern blot analysis revealed a 2.2 kb transcript in various myeloid cell lines but not in adult tissues except for the brain and the lung, whereas CSK mRNA was ubiquitously expressed. The expression of HYL was upregulated when these myeloid cells were differentiated by induction with phorbol myristate acetate. We named this gene, hematopoietic consensus tyrosine-lacking kinase, HYL. The HYL gene was assigned to chromosome 19 at band p13. It is suggested that HYL plays a significant role in the signal transduction of hematopoietic cells.	KUMAMOTO UNIV, SCH MED,INST MOLEC EMBRYOL & GENET, DEPT DIFFERENTIAT,2-2-1 HONJO, KUMAMOTO 860, JAPAN; ASAHI CHEM IND CO LTD, FUNDAMENTAL RES LAB LIFE SCI, FUJI, SHIZUOKA 416, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT HYG HEMATOL & ONCOL UNIT, KYOTO 602, JAPAN	Kumamoto University; Kyoto Prefectural University of Medicine			Suda, Toshio/H-6761-2013	Suda, Toshio/0000-0001-7540-1771				ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KOMATSU N, 1991, CANCER RES, V51, P341; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Maniatis T., 1982, MOL CLONING; MATUDA M, 1992, MOL CELL BIOL, V12, P3482; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PARTANEN J, 1991, ONCOGENE, V6, P2013; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TABILIO A, 1983, CANCER RES, V43, P4569; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	44	60	67	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1155	1161						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134117				2022-12-28	WOS:A1994NC04800018
J	EZOE, K; LEE, ST; STRUNK, KM; SPRITZ, RA				EZOE, K; LEE, ST; STRUNK, KM; SPRITZ, RA			PTK1, A NOVEL PROTEIN-KINASE REQUIRED FOR PROLIFERATION OF HUMAN MELANOCYTES	ONCOGENE			English	Note							CELL-LINE; SEQUENCE; DOMAINS	We have identified and characterized PTK1, a novel human non-receptor protein kinase. Partial PTK1 cDNA was initially isolated by RT-PCR from mRNA of normal human melanocytes. Northern blot hybridization detected a 3.8-kb PTK1 mRNA in ah tissues and cell types studied. Nucleotide sequence analysis of a full-length PTK1 cDNA showed it to encode an 847-amino acid polypeptide with an amino-terminal SH3 domain, a kinase catalytic domain, a leucine zipper-like domain, and a carboxyl proline-rich domain. The PTK1 kinase domain contains motifs generally considered diagnostic of serine/threonine kinases but also contains amino acids highly conserved among the tyrosine kinases. This suggests that PTK1 is a serine/threonine kinase, but one very closely related to the tyrosine kinase superfamily. When normal human melanocytes were exposed to antisense PTK1 oligonucleotide, cell growth was inhibited, whereas a corresponding sense oligonucleotide had no inhibitory effect. These data indicate that PTK1 plays an important role in the proliferation of normal human melanocytes.	UNIV WISCONSIN,DEPT MED GENET,MADISON,WI 53706; UNIV WISCONSIN,DEPT PEDIAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Lee, Seung-Taek/0000-0001-7300-9784	NIAMS NIH HHS [AR39892] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039892] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BOLEN JB, 1993, ONCOGENE, V8, P2025; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; FENG XH, 1993, BIOCHIM BIOPHYS ACTA, V1172, P200, DOI 10.1016/0167-4781(93)90295-O; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE ST, 1993, ONCOGENE, V8, P3403; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TVEIT KM, 1980, BRIT J CANCER, V41, P724, DOI 10.1038/bjc.1980.134	14	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					935	938						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108137				2022-12-28	WOS:A1994MW55100030
J	MOASSER, MM; DEBLASIO, A; DMITROVSKY, E				MOASSER, MM; DEBLASIO, A; DMITROVSKY, E			RESPONSE AND RESISTANCE TO RETINOIC ACID ARE MEDIATED THROUGH THE RETINOIC ACID NUCLEAR RECEPTOR-GAMMA IN HUMAN TERATOCARCINOMAS	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; RIBONUCLEIC-ACID; X-RECEPTOR; BETA-GENE; DIFFERENTIATION; ALPHA; EXPRESSION; CLONING; LINE; EFFICIENCY	All-trans-retinoic acid (RA) treatment of the multipotent human teratocarcinoma (TC) cell line NTERA-2 clone D1 (abbreviated NT2/D1) induces a neuronal phenotype. Compared to untreated NT2/D1 cells, RA treated cells have reduced proliferative potential. To identify which retinoic acid receptor (RAR) is directly linked to RA response in these cells, nine RA resistant subclones were derived and characterized. Unlike parental NT2/D1 cells, all these subclones and a de novo RA resistant human TC cell line, N2102Ep clone 2AG (abbreviated N2102ep), exhibited reduced RAR gamma expression. The RAR gamma gene was studied within NT2/D1 cells and a representative RA resistant NT2/D1 subclone called NT2/D1-R1 by Southern analysis and by the transcriptional properties of cloned RAR gamma cDNAs. No structural or functional differences between these RAR gamma species were found suggesting that RA resistance is due to reduced levels of RAR gamma expressed in NT2/D1-R1 cells. To explore this possibility an RAR gamma cDNA was stably transfected into NT2/D1-R1 cells. Expression of this cDNA partially restored the response to RA in NT2/D1-R1 cells. The role of RAR gamma in parental NT2/D1 cells was studied in transient transfection assays using an FGF4 promoter-enhancer reporter construct that is transcriptionally active in undifferentiated but not in differentiated TC cells. The dose dependent co-transfection of an expressed RAR gamma cDNA with this reporter more efficiently repressed its transcriptional activity in the presence of RA than transfection of the reporter without expressed RAR gamma. Co-transfection also decreased reporter activity in the absence of exogenously added ligand, Together, these findings reveal that RAR gamma expression is tightly coupled to RA response and resistance in human TC cells. These data implicate an important role for RAR gamma in the RA-mediated differentiation of these TCs.	MEM SLOAN KETTERING CANC CTR,RECEPTOR BIOL LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MOLEC MED LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA01712, 1R01-CA54494-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001712, R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1980, INT J CANCER, V26, P269, DOI 10.1002/ijc.2910260304; ANDREWS PW, 1984, LAB INVEST, V50, P147; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KLIEWER SA, 1992, NATURE, V355, P441; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KURIE JM, 1993, DIFFERENTIATION, V54, P123; KURIE JM, 1993, DIFFERENTIATION, V54, P115; KURIE JM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P203, DOI 10.1016/0167-4889(93)90142-C; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Maniatis T, 1989, DECONTAMINATION DILU; MCCUE PA, 1983, DEV BIOL, V96, P416, DOI 10.1016/0012-1606(83)90179-3; MILLER WH, IN PRESS DIFFERENTIA; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WONG SY, 1984, J BIOL CHEM, V259, P5899; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	34	68	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					833	840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108126				2022-12-28	WOS:A1994MW55100019
J	PAPKOFF, J				PAPKOFF, J			IDENTIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF SECRETED WNT-1 PROTEIN FROM P19 EMBRYONAL CARCINOMA-CELLS INDUCED TO DIFFERENTIATE ALONG THE NEUROECTODERMAL LINEAGE	ONCOGENE			English	Note							MOUSE MAMMARY ONCOGENE; INT-1 PROTOONCOGENE; XENOPUS EMBRYOS; EXPRESSION; DROSOPHILA; PRODUCTS; WINGLESS; REGION; AXIS; RNA	Previous studies have described Wnt-1 protein synthesized by cell lines transfected with Wnt-1 cDNA. This report presents the first identification and biochemical characterization of native Wnt-1 protein, from P19 embryonal carcinoma cells undergoing neuroectodermal differentiation. The data demonstrate that P19 cells efficiently process and secrete glycosylated Wnt-1 protein species of 40kD and 42kD. Similar to recombinant Wnt-1 proteins, native Wnt-1 proteins are associated with the cell surface upon secretion and can be released by suramin treatment of the cells. Non-reducing gel analysis showed that Wnt-1 proteins are secreted as monomers.			PAPKOFF, J (corresponding author), SUGEN INC, 515 GALVESTON DR, REDWOOD CITY, CA 94063 USA.							ARIAS AM, 1988, DEVELOPMENT, V103, P157; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHUURING E, 1989, MOL CELL BIOL, V9, P1357, DOI 10.1128/MCB.9.3.1357; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STARNAUD R, 1989, ONCOGENE, V4, P1077; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	23	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					313	317						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302595				2022-12-28	WOS:A1994MW24700038
J	KARN, T; HOLTRICH, U; BRAUNINGER, A; BOHME, B; WOLF, G; RUBSAMENWAIGMANN, H; STREBHARDT, K				KARN, T; HOLTRICH, U; BRAUNINGER, A; BOHME, B; WOLF, G; RUBSAMENWAIGMANN, H; STREBHARDT, K			STRUCTURE, EXPRESSION AND CHROMOSOMAL MAPPING OF TKT FROM MAN AND MOUSE - A NEW SUBCLASS OF RECEPTOR TYROSINE KINASES WITH A FACTOR VIII-LIKE DOMAIN	ONCOGENE			English	Note							FIBROBLAST GROWTH-FACTOR; HUMAN INSULIN-RECEPTOR; CDNA CLONING; PUTATIVE RECEPTOR; FAMILY; GENE; SEQUENCE; PROTEINS; ENCODES; DEFINE	Using a polymerase chain reaction-mediated approach we have characterized cDNAs from human and mouse origin representing a novel type of receptor protein tyrosine kinase (RTK). The deduced amino acid sequence (855 amino acids) of the Longest open reading frame has a unique extracellular region encompassing a factor VIII-like domain, not previously described for RTKs. The most closely related RTKs are members of the neurotrophin receptors (TRK), which showed 47-49% homology with the kinase domain of the new RTK. Therefore, the new gene has been called TKT (Tyrosine-Kinase related to TRK). TKT orthologs from man and mouse were 98% similar. In both species a major transcript of 10 kb was found to be expressed at high levels in heart and lung. Low levels of this mRNA-species were detected in human brain, placenta, liver, skeletal muscle, kidney and in mouse brain and testis. Analysing human/mouse somatic cell hybrids we demonstrated that TKT segregates with human chromosome 1.	CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY				Strebhardt, Klaus/E-8765-2011; karn, t/C-7452-2013; Karn, Thomas/AAE-7723-2019	karn, t/0000-0002-3264-6573; Karn, Thomas/0000-0002-3264-6573; Strebhardt, Klaus/0000-0003-2173-9763				BOHME B, 1993, IN PRESS ONCOGENE; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DUMONT DJ, 1993, ONCOGENE, V8, P1293; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORRIS CM, 1991, ONCOGENE, V6, P1093; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SHIER P, 1989, J BIOL CHEM, V264, P14605; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	36	67	76	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3433	3440						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247548				2022-12-28	WOS:A1993MG78200030
J	BUCKLEY, MF; SWEENEY, KJE; HAMILTON, JA; SINI, RL; MANNING, DL; NICHOLSON, RI; DEFAZIO, A; WATTS, CKW; MUSGROVE, EA; SUTHERLAND, RL				BUCKLEY, MF; SWEENEY, KJE; HAMILTON, JA; SINI, RL; MANNING, DL; NICHOLSON, RI; DEFAZIO, A; WATTS, CKW; MUSGROVE, EA; SUTHERLAND, RL			EXPRESSION AND AMPLIFICATION OF CYCLIN GENES IN HUMAN BREAST-CANCER	ONCOGENE			English	Article							CELL-CYCLE; ESTROGEN-RECEPTOR; CANDIDATE ONCOGENE; PUTATIVE ONCOGENE; CHROMOSOME 11Q13; PROMOTING FACTOR; POOR PROGNOSIS; PROTEIN-KINASE; MESSENGER-RNAS; BCL-1 GENE	Cyclins, the regulatory subunits of cyclin-dependent kinases, play an important role in the control of cellular proliferation. Since dysregulated expression of these genes may contribute to the malignant phenotype the expression and amplification of cyclin A, B1, C, D1, D2, D3 and E genes were studied in 20 breast cancer cell lines. Increased expression of one or more of the cyclin A, B1, D1 or E genes was found in seven cell lines (35%); of these five (25%) showed increased expression of cyclin D1. Overexpression occurred in both the presence and absence of gene amplification. Conversely, amplification did not invariably lead to overexpression. Cyclin D2 expression was lower in breast cancer cell tines than in cultured normal breast epithelial cells. Cyclin D1 expression was further investigated in breast tumour biopsies: 56 of 124 specimens (45%) expressed higher levels of cyclin D1 mRNA than normal breast tissue. These data implicate dysregulated expression of several cyclin genes, particularly cyclin D1, as a potential factor in the pathogenesis of breast cancer.	ST VINCENTS HOSP, GARVAN INST MED RES, DIV CANC BIOL, DARLINGHURST, NSW 2010, AUSTRALIA; UNIV WALES COLL MED, TENOVUS CANC RES CTR, BREAST CANC LAB, CARDIFF CF4 4XX, S GLAM, WALES	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Cardiff University			deFazio, Anna/D-3939-2013; Sutherland, Robert L/A-8378-2008; DeFazio, Anna/O-2385-2019	deFazio, Anna/0000-0003-0057-4744; DeFazio, Anna/0000-0003-0057-4744; buckley, michael/0000-0002-8298-8758				ADNANE J, 1989, ONCOGENE, V4, P1389; ALI IU, 1989, ONCOGENE, V4, P89; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; CHAN YL, 1984, J BIOL CHEM, V259, P224; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FAUST JB, 1992, CANCER RES, V52, P2460; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GRAHAM ML, 1989, CANCER RES, V49, P3943; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIS S, 1990, J CLIN PATHOL, V43, P385, DOI 10.1136/jcp.43.5.385; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LISCIA DS, 1989, ONCOGENE, V4, P1219; LOVEKIN C, 1991, BRIT J CANCER, V63, P439, DOI 10.1038/bjc.1991.101; MANNING DL, 1990, CANCER RES, V50, P4098; MANNING DL, 1993, IN PRESS EUR J CANCE; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MATTEI MG, 1988, HUM GENET, V78, P96, DOI 10.1007/BF00291245; MEYERS SL, 1990, CANCER RES, V50, P5911; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MUSGROVE EA, UNPUB; NICHOLSON RI, 1991, EUR J CANCER, V27, P908, DOI 10.1016/0277-5379(91)90145-4; NICHOLSON RI, 1993, IN PRESS EUR J CANCE; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ORMANDY CJ, 1992, BIOCHEM BIOPH RES CO, V182, P740, DOI 10.1016/0006-291X(92)91794-Q; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REDDEL RR, 1988, CANCER RES, V48, P4340; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; ROSENBERG CL, 1991, ONCOGENE, V6, P449; SAMBROOK J, 1908, MOL CLONING LABORATO; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; SUTHERLAND MC, 1991, REGULATORY MECHANISM, P3; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; THEILLET C, 1990, ONCOGENE, V5, P147; TSUDA H, 1989, CANCER RES, V49, P3104; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WALKER KJ, 1988, CANCER RES, V48, P6517; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	58	689	704	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2127	2133						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336939				2022-12-28	WOS:A1993LP17100013
J	TORNALETTI, S; ROZEK, D; PFEIFER, GP				TORNALETTI, S; ROZEK, D; PFEIFER, GP			THE DISTRIBUTION OF UV PHOTOPRODUCTS ALONG THE HUMAN P53 GENE AND ITS RELATION TO MUTATIONS IN SKIN-CANCER	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMAS; LIGATION-MEDIATED PCR; TUMOR SUPPRESSOR GENE; XERODERMA PIGMENTOSUM; ESCHERICHIA-COLI; N-RAS; METHYLATION ANALYSIS; PYRIMIDINE DIMERS; 6-4 PHOTOPRODUCTS; MAMMALIAN-CELLS	Mutations in the p53 gene have been found in a large proportion of human skin cancers. These mutations show the same characteristics as mutations induced by UV light in experimental systems. To establish correlations between formation of DNA adducts by a known carcinogen nd incidence of mutations within a specific human gene, we have investigated the formation of UV-induced photoproducts along exons 5-9 of the p53 gene after UV irradiation of human cells. The two major types of DNA photoproducts, cyclobutane pyrimidine dimers and pyrimidine (64) pyrimidone photoproducts [(6-4) photoproducts], were mapped at the DNA sequence level by strand cleavage at the sites of photoproducts. This was followed by ligation-mediated polymerase chain reaction (LMPCR) to amplify gene-specific fragments. In human skin cancers, mutations were most frequently found at codons 151/152, 245, 248, 278 and 286 of the p53 gene. The frequency of UV photoproducts is particularly high at codon 286, which is within a run of 12 adjacent pyrimidines. High levels of both photoproducts were also seen at codons 151 and 278. However, UV-induced DNA adducts are barely detectable at codons 245 and 248, which are mutation hotspots also for internal malignancies. At these positions, the frequency of photoproducts is much lower than at surrounding dipyrimidine sequences. These findings have some implications on molecular mechanisms of mutagenesis in the human genome.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NIEHS NIH HHS [1RO1ES06070-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBINO AP, 1989, ONCOGENE, V4, P1363; ANATHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119; ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BOURRE F, 1987, NUCLEIC ACIDS RES, V15, P8861, DOI 10.1093/nar/15.21.8861; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; CHUMAKOV PM, 1991, GENBANK LOCUS HUMP53; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; GLICKMAN BW, 1986, P NATL ACAD SCI USA, V83, P6945, DOI 10.1073/pnas.83.18.6945; GORDON LK, 1980, J BIOL CHEM, V255, P2047; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JONES PA, 1991, CANCER RES, V51, P3617; KEIJZER W, 1989, CANCER RES, V49, P1229; KRESS S, 1992, CANCER RES, V52, P6400; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MOLES JP, 1993, ONCOGENE, V8, P583; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; Pfeifer G P, 1992, PCR Methods Appl, V2, P107; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFEIFER GP, 1993, METHODS MOL BIOL SEL, P153; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RADY P, 1992, CANCER RES, V52, P3804; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SHUKLA VK, 1989, ONCOGENE RES, V5, P121; SUAREZ HG, 1989, CANCER RES, V49, P1223; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; TORMANEN VT, 1992, ONCOGENE, V7, P1729; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	54	133	134	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2051	2057						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336934				2022-12-28	WOS:A1993LP17100004
J	BOULUKOS, KE; ZIFF, EB				BOULUKOS, KE; ZIFF, EB			ADENOVIRUS 5 E1A PROTEINS DISRUPT THE NEURONAL PHENOTYPE AND GROWTH-FACTOR RESPONSIVENESS OF PC12 CELLS BY A CONSERVED REGION 1-DEPENDENT MECHANISM	ONCOGENE			English	Article							INTERMEDIATE FILAMENT PROTEIN; RETINOBLASTOMA GENE-PRODUCT; HUMAN CYCLIN-A; TRK PROTOONCOGENE; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; FACTOR RECEPTORS; TERMINAL REGION; KINASE-ACTIVITY; NGF RECEPTOR	Expression in PC12 cells of adenovirus 5 E1a proteins dramatically changes cell morphology and disrupts neuronal differentiation. We demonstrate that the nerve growth factor (NGF) receptors, p140trk and p75NGFR, as well as the epidermal growth factor receptor are undetectable in E1a-expressing PC12 cells. This correlates with a repression of mRNAs for the chromaffin- and neuronal-specific proteins, tyrosine hydroxylase and peripherin, while more ubiquitously expressed genes remain unaffected. One possible mechanism of E1a action could thus be the repression of a coordinately regulated group of chromaffin- and/or neuronal-specific genes. Furthermore, we show that E1a conserved region 1, which binds p105Rb and p300, is necessary for this E1a-dependent effect. This indicates that cellular proteins interacting with E1a conserved region 1 may be implicated in growth arrest, expression of neuron-specific functions and orderly differentiation of PC12 cells in response to NGF.	NYU HOSP, HOWARD HUGHES MED INST, DEPT BIOCHEM, 1ST AVE, NEW YORK, NY 10016 USA; NYU HOSP, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	Howard Hughes Medical Institute; New York University; New York University				Ziff, Edward/0000-0001-7389-8649				BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GAYNOR RB, 1984, P NATL ACAD SCI-BIOL, V81, P1193, DOI 10.1073/pnas.81.4.1193; GIORDANO A, 1991, ONCOGENE, V6, P481; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOSANG M, 1985, J BIOL CHEM, V260, P655; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEVI-MONTALCINI RITA, 1966, HARVEY LECT, V60, P217; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARUYAMA K, 1987, ONCOGENE, V1, P361; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; PARYSEK LM, 1987, J NEUROSCI, V7, P781; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P215, DOI 10.1159/000112348; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SMITH DH, 1985, MOL CELL BIOL, V5, P2684, DOI 10.1128/MCB.5.10.2684; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; SVENSSON C, 1984, EMBO J, V3, P789, DOI 10.1002/j.1460-2075.1984.tb01886.x; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	53	50	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					237	248						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8093977				2022-12-28	WOS:A1993KN00600002
J	HOSONO, S; CHOU, MJ; LEE, CS; SHIH, C				HOSONO, S; CHOU, MJ; LEE, CS; SHIH, C			INFREQUENT MUTATION OF P53 GENE IN HEPATITIS-B VIRUS POSITIVE PRIMARY HEPATOCELLULAR CARCINOMAS	ONCOGENE			English	Note							C VIRUS; BREAST-CANCER; LIVER-CANCER; LUNG-CANCER; ALLELE LOSS; CELL-LINES; CHROMOSOME-17; FREQUENT; TAIWAN; HETEROZYGOSITY	Somatic mutation of the p53 oncogene/anti-oncogene allele has been shown to be involved in many different human solid tumors. Recently, there have been reports that p53 mutations are found to occur at high frequency (50%) in aflatoxin-related human primary hepatocellular carcinomas (HCC) (Hsu et al., 1991 Nature, vol 350, p. 427; Bressac et al., 1991 Nature, vol 350, p. 429). Most strikingly, a hotspot G to T mutation at amino acid position 249 was identified. These reports appear to contradict our earlier publications that although p53 mutation is found frequently in human HCC cell lines, it is rarely found in primary tumors. In this paper, we have further examined 20 different primary HCC samples (17 were hepatitis B surface antigen positive) and their adjacent nontumorous tissues, using restriction fragment length polymorphism (RFLP) analyses. Clear loss of heterozygosity (LOH) was found in only 3 out of 20 samples. All three samples were also found to carry a point mutation within the remaining p53 allele. None of these mutations was found to be at the proposed aflatoxin hotspot of amino acid 249. All three point mutations are of somatic origin. Ten samples, randomly chosen from the remaining 17 LOH negative HCC tumors, were analyzed further by DNA sequencing and Western blot analyses. No point mutations of p53 were found. Taken together with our previous report (Hosono et al., 1991, Oncogene vol 6, p. 237-243), we conclude that p53 mutation occurs infrequently, only approximately 18%, in HBV-positive primary hepatomas from Taiwan. Furthermore, p53 mutation appears to be acquired later in tumor development at least in some HCC samples.	UNIV TEXAS,MED BRANCH,SCH MED,DEPT PATHOL,GALVESTON,TX 77550; NATL TAIWAN UNIV,COLL MED,TAIPEI,TAIWAN	University of Texas System; University of Texas Medical Branch Galveston; National Taiwan University			Shih, Chiaho/S-7017-2018		NATIONAL CANCER INSTITUTE [R01CA048198] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA48198, KO4 CA01399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEASLEY RP, 1981, LANCET, V2, P1129; BLUMBERG BS, 1981, NEW ENGL J MED, V304, P782, DOI 10.1056/NEJM198103263041312; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHEN DS, 1990, J INFECT DIS, V162, P817, DOI 10.1093/infdis/162.4.817; CHIBA I, 1990, ONCOGENE, V5, P1603; DAVIDOFF AM, 1991, J SURG ONCOL, V48, P260, DOI 10.1002/jso.2930480409; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; FUJIMOTO Y, 1992, CANCER RES, V52, P1044; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HAYWARD NK, 1991, NATURE, V352, P764, DOI 10.1038/352764a0; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; LAI MY, 1991, PARIS PASTEUR I M HE, P142; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SCORSONE KA, 1992, CANCER RES, V52, P1635; SHIH CH, 1987, J VIROL, V61, P3491, DOI 10.1128/JVI.61.11.3491-3498.1987; SLAGLE BL, 1991, CANCER RES, V51, P49; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOGUCHIDA J, 1989, CANCER RES, V49, P6247; WALKER GJ, 1991, CANCER RES, V51, P4367; WANG WL, 1991, CANCER RES, V51, P4971; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YU MW, 1991, CANCER RES, V51, P5621; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	41	80	81	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					491	496						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8093978				2022-12-28	WOS:A1993KN00600029
J	KHARBANDA, S; YUAN, ZM; TANEJA, N; WEICHSELBAUM, R; KUFE, D				KHARBANDA, S; YUAN, ZM; TANEJA, N; WEICHSELBAUM, R; KUFE, D			P56/P53(LYN) TYROSINE KINASE ACTIVATION IN MAMMALIAN-CELLS TREATED WITH MITOMYCIN-C	ONCOGENE			English	Article							DNA-BINDING PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; NITROGEN-MUSTARD; LYMPHOCYTES-B; CROSS-LINKING; MEMBRANE IMMUNOGLOBULIN; PHOSPHORYLATION; MECHANISM; P34CDC2; DAMAGE	The present studies have examined the effects of mitomycin C (MMC), a genotoxic alkylating agent, on the activation of Src-like protein tyrosine kinases in HL-60 myeloid leukemia cells. The results demonstrate no detectable induction of p59/(fyn) or pp60(c-src) activity. The response of HL-60 cells to MMC however was associated with rapid activation of p56/p53(lyn). Similar findings were obtained with other alkylating agents such as nitrogen mustard and cis-platinum. Activation of p56/p53(lyn) was associated with increased autophosphorylation on tyrosine and sensitivity to the tyrosine kinase inhibitors herbimycin A and genistein. Studies with a glutathione S-transferase-Lyn fusion protein were performed to explore the potential significance of p56/p53(lyn) activation. Analysis of the adsorbates demonstrates interaction of Lyn with the cell cycle regulatory protein, p34(cdc2). Coimmunoprecipitation studies further confirmed the association of p56/p53(lyn) and p34(cdc2) in MMC-treated cells. We also demonstrate that p34(cdc2) undergoes increased phosphorylation on tyrosine following MMC exposure and that p56/p53(lyn) phosphorylates the Tyr-15 site of p34(cdc2)in vitro. These findings indicate that the cellular response to MMC includes activation of p56/p53(lyn) and that this event may contribute to signals transduced by the DNA damage-dependent mitotic checkpoint.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA019589] Funding Source: NIH RePORTER; NCI NIH HHS [CA19589] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P592; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BHUYAN BK, 1992, CANCER RES, V52, P5687; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRANO AV, 1979, MUTAT RES, V63, P175, DOI 10.1016/0027-5107(79)90114-3; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUSRE L, 1989, CHEM-BIOL INTERACT, V71, P63, DOI 10.1016/0009-2797(89)90090-2; EWIG RAG, 1977, CANCER RES, V37, P2114; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GOLD MR, 1992, J IMMUNOL, V148, P2012; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTLEY JA, 1992, NUCLEIC ACIDS RES, V20, P3175, DOI 10.1093/nar/20.12.3175; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HURLEY LH, 1984, SCIENCE, V226, P843, DOI 10.1126/science.6494915; KATAGIRI K, 1991, J IMMUNOL, V146, P701; KHARBANDA S, 1994, CANCER RES, V54, P1412; KONOPA J, 1988, BIOCHEM PHARMACOL, V37, P2303, DOI 10.1016/0006-2952(88)90355-3; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LOCK RB, 1990, CANCER RES, V50, P3761; NAKAMURA S, 1988, EUR J BIOCHEM, V174, P471, DOI 10.1111/j.1432-1033.1988.tb14122.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PINES J, 1990, New Biologist, V2, P389; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; TOMASZ M, 1988, BIOCHEMISTRY-US, V27, P3182, DOI 10.1021/bi00409a009; UEHARA Y, 1989, CANCER RES, V49, P780; WONG TW, 1984, J BIOL CHEM, V259, P8505; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	50	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					3005	3011						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084605				2022-12-28	WOS:A1994PG82200028
J	HEIGHWAY, J; WHITE, GRM; HARTLEY, AL; BIRCH, JM; SANTIBANEZKOREF, MF				HEIGHWAY, J; WHITE, GRM; HARTLEY, AL; BIRCH, JM; SANTIBANEZKOREF, MF			RARE VARIANT (GLU TO LYS) IN THE LEUCINE-ZIPPER REGION OF CHOP (GADD153)	ONCOGENE			English	Note							GENE; TRANSCRIPTION; LIPOSARCOMA; PROTEIN; FUSION	CHOP (GADD153) has been shown to be a dominant negative inhibitor of specific transcription factors. Direct sequencing of the gene, amplified from the DNA of a Li-Fraumeni family index case (liposarcoma, breast cancer) revealed a constitutional variant within the coding region. This alteration, though not responsible for the Li-Fraumeni phenotype, resulted in a glutamic acid to lysine switch within the leucine zipper domain, at a residue conserved between CHOP and its potential target molecules and between the human and hamster sequences. The variant created a Tag I restriction fragment length polymorphism (RFLP) facilitating screening. Analysis of 159 breast tumour DNA samples detected two encoding variant alleles (tumour and constitutional DNA).	CHRISTIE CRC RES CTR,CRC,PAEDIAT & FAMILIAL RES GRP,MANCHESTER,LANCS,ENGLAND		HEIGHWAY, J (corresponding author), CHRISTIE CRC RES CTR,PATERSON INST CANC RES,CRC,DEPT CANC GENET,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.							AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; BIRCH JM, 1994, CANCER RES, V54, P1298; BRUGIERES L, 1993, CANCER RES, V53, P452; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439	9	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2737	2738						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058339				2022-12-28	WOS:A1994PC05400037
J	PICKSLEY, SM; VOJTESEK, B; SPARKS, A; LANE, DP				PICKSLEY, SM; VOJTESEK, B; SPARKS, A; LANE, DP			IMMUNOCHEMICAL ANALYSIS OF THE INTERACTION OF P53 WITH MDM2 - FINE MAPPING OF THE MDM2 BINDING-SITE ON P53 USING SYNTHETIC PEPTIDES	ONCOGENE			English	Article							TUMOR-SUPPRESSOR P53; VIRUS-40 T-ANTIGEN; MONOCLONAL-ANTIBODIES; PROTEIN COMPLEXES; GENE-EXPRESSION; DNA-BINDING; 3T3 CELLS; TRANSCRIPTION; ONCOPROTEIN; MUTANT	The function of p53 is modulated by binding to a number of cellular and viral proteins, such as MDM2 and SV40 large T antigen. An initial immunochemical characterization of the p53-MDM2 complex in a rat fibroblast cell line (Clone 6) suggested that the anti-p53 monoclonal antibody Bp53-19 failed to immunoprecipitate the complex, and only recognized a fraction of the available p53 protein. Following the recent identification of the Bp53-19 epitope at the N-terminal end of p53, in the vicinity of where MDM2 protein was known to bind, we investigated the possibility that Bp53-19 might identify a region of p53 that interacts with MDM2 protein. MDM2 was found to bind with great specificity to short synthetic peptides derived from the N-terminus of p53. Several p53 synthetic peptides libraries, and an alanine substitution series at the optimal binding site, were used to establish the MDM2 binding site, in fine detail, to the sequence TFSGLW (aa 18-23) in mouse and TFSDLW in man (aa 18-23). The key residues required for MDM2 binding are almost identical to those required for the monoclonal antibody Bp53-19 to bind and this region of p53 is recognised by many other anti-p53 antibodies.	UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CRC,CELL TRANSFORMAT GRP,DUNDEE DD1 4HN,SCOTLAND; MASARY MEM CANC INST,ZLUTY KOPEC,CR-65653 BRNO,CZECH REPUBLIC	University of Dundee; Masaryk Memorial Cancer Institute			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHLICHTHOLTZ B, 1993, CANCER RES, V52, P6380; SOUSSI T, 1990, ONCOGENE, V5, P945; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	38	241	273	1	15	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2523	2529						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058315				2022-12-28	WOS:A1994PC05400011
J	ASAI, A; MIYAGI, Y; SUGIYAMA, A; NAGASHIMA, Y; KANEMITSU, H; OBINATA, M; MISHIMA, K; KUCHINO, Y				ASAI, A; MIYAGI, Y; SUGIYAMA, A; NAGASHIMA, Y; KANEMITSU, H; OBINATA, M; MISHIMA, K; KUCHINO, Y			THE S-MYC PROTEIN HAVING THE ABILITY TO INDUCE APOPTOSIS IS SELECTIVELY EXPRESSED IN RAT EMBRYO CHONDROCYTES	ONCOGENE			English	Article							C-MYC; CELL-DEATH; MAMMALIAN-CELLS; DIFFERENTIATION; BCL-2; PHOSPHORYLATION; IDENTIFICATION; PROTOONCOGENE; MECHANISMS; DOMAIN	Gene transfection experiments demonstrated that overexpression of the s-myc gene under the control of a human metallothionein promoter induced apoptosis in cells such as rat and human glioma cells. In contrast to c-Myc-mediated apoptosis requiring withdrawal of serum growth factors, s-myc expression induced apoptosis in glioma cells in the presence of 10% fetal calf serum. Whereas, s-Myc-mediated apoptosis was suppressed in proportion to the increase of bcl-2 expression as seen in c-Myc mediated apoptosis. The s-myc gene was expressed in rat embryo cells being committed to differentiate to hypertrophic chondrocytes which undergo programmed cell death. CAT assay demonstrated that in the NH,terminal region, the s-Myc protein contains a domain structure required for expression of transactivation activity that is approximately six times higher than that of c-Myc. Therefore, these findings strongly suggest that s-Myc may play an important role in transcription regulation of a set of genes whose expression induces programmed cell death in vitro and in vivo.	NATL CANC CTR, RES INST, DIV BIOPHYS, CHUO KU, TOKYO 104, JAPAN; YOKOHAMA CITY UNIV, SCH MED, DEPT PATHOL 2, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN; TEIKYO UNIV, SCH MED, DEPT NEUROSURG, ITABASHI KU, TOKYO 173, JAPAN; TOHOKU UNIV, INST DEV AGING & CANC, DEPT CELL BIOL, AOBA KU, SENDAI, MIYAGI 980, JAPAN	National Cancer Center - Japan; Yokohama City University; Teikyo University; Tohoku University								AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ASAI A, IN PRESS J NEUROONCO; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARQUHARSON C, 1992, J CELL PHYSIOL, V152, P135, DOI 10.1002/jcp.1041520118; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KUCHINO Y, 1990, GENETIC BASIS CARCIN, P239; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MEEK DW, 1992, BIOCHEM J, V287, P1; NAGANE M, 1992, JPN J CLIN ONCOL, V22, P143; NEMOTO Y, 1990, GENE, V91, P261, DOI 10.1016/0378-1119(90)90097-B; PENN LJZ, 1990, CANCER BIOL, V1, P69; SETH A, 1991, J BIOL CHEM, V266, P23521; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMEYNE RJ, 1993, SCIENCE, V363, P166; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	30	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2345	2352						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036017				2022-12-28	WOS:A1994NX62900028
J	GRANA, X; CLAUDIO, PP; DELUCA, A; SANG, NL; GIORDANO, A				GRANA, X; CLAUDIO, PP; DELUCA, A; SANG, NL; GIORDANO, A			PISSLRE, A HUMAN NOVEL CDC2-RELATED PROTEIN-KINASE	ONCOGENE			English	Article							GLUTATHIONE-S-TRANSFERASE; TRANSLATIONAL INITIATION; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SEQUENCE HOMOLOGY; CDC28 MUTATION; GENE ENCODES; CYCLIN-A; FAMILY	The cell division cycle have been shown to be regulated by a closely-related family of protein kinases named CDKs (by cyclin-dependent kinases). Using a PCR-based cloning technique, we have isolated cDNAs encoding a human CDC2-related protein kinase. The full-length cDNA accommodates an open reading frame that does not contain any ATG initiation codon upstream of the sequence encoding the catalytic domain of this putative kinase. Three putative non-ATG initiation codons have been detected. Starting at the most 5' non-ATG initiation site, the encoded product is 316 amino acids long with a predicted molecular weight of 35.8 kDa. Analysis of the deduced amino acid sequence showed it to contain the XI subdomains present in all known protein kinases and a PSTAIRE-like motive, PISSLRE, which temporarily names this kinase. PISSLRE is most related to p58/GTA (55% identity in the catalytic domain), the galactosyl transferase associated protein, which has been shown to inhibit entry into S-phase when over-expressed in CHO cells. PISSLRE shares 38-45% identity with all CDKs and contains the regulatory Tyr and Thr residues present in most of the members of the CDK family of protein kinases, which suggests similar modes of regulation. PISSLRE is expressed in all human tissues tested, including those which contain high proportion of terminally differentiated cells. However, the levels of the PISSLRE transcripts are dissimilar among different tissues.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	GRANA, X (corresponding author), TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT PATHOL, 3307 N BROAD ST, PHILADELPHIA, PA 19140 USA.		Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021	Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622; Grana, Xavier/0000-0001-7134-0473	NCI NIH HHS [R01 CA 6099-01A1] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Ausubel FM, 1988, MOL REPROD DEV; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEW J, 1992, J BIOL CHEM, V267, P25922; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; OKUDA T, 1992, ONCOGENE, V7, P2249; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	43	56	60	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2097	2103						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208557				2022-12-28	WOS:A1994NR68500037
J	GUPTA, K; CHEVRETTE, M; GRAY, DA				GUPTA, K; CHEVRETTE, M; GRAY, DA			THE UNP PROTOONCOGENE ENCODES A NUCLEAR-PROTEIN	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; LARGE T-ANTIGEN; TRE ONCOGENE; NUCLEOTIDE-SEQUENCES; CELLULAR PROTEINS; BINDING; ADENOVIRUS-E1A; CLONING; RECOMBINATION; EXPRESSION	The mouse Unp gene is related to TRE17, a human oncogene, but is not its mouse homolog. Unp is a ubiquitously expressed gene producing two related mRNAs. The protein product of Unp is localized in the nucleus. Expression of Unp from a highly active promoter results in tumorigenic transformation of NIH3T3 cells injected into athymic mice. Unp therefore encodes a novel nuclear oncoprotein.	UNIV OTTAWA,DEPT BIOCHEM,OTTAWA K1H 8M5,ON,CANADA; UNIV OTTAWA,DEPT MED,OTTAWA K1H 8M5,ON,CANADA	University of Ottawa; University of Ottawa			/U-3554-2018	/0000-0002-8634-4984				CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARNELL J, 1986, MOL CELL BIOL, P319; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GALLIONE CJ, 1981, J VIROL, V39, P529, DOI 10.1128/JVI.39.2.529-535.1981; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUPTA K, 1993, ONCOGENE, V8, P2307; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUEBNER K, 1988, ONCOGENE, V3, P449; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NEVINS JR, 1992, SCIENCE, V258, P424; ONNO M, 1992, ONCOGENE, V7, P2519; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Sambrook J, 1989, MOL CLONING LABORATO; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993	24	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1729	1731						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183569				2022-12-28	WOS:A1994NL81500026
J	CHAN, AML; MCGOVERN, ES; CATALANO, G; FLEMING, TP; MIKI, T				CHAN, AML; MCGOVERN, ES; CATALANO, G; FLEMING, TP; MIKI, T			EXPRESSION CDNA CLONING OF A NOVEL ONCOGENE WITH SEQUENCE SIMILARITY TO REGULATORS OF SMALL GTP-BINDING PROTEINS	ONCOGENE			English	Article							SIGNAL TRANSDUCTION; VAV PROTOONCOGENE; SACCHAROMYCES-CEREVISIAE; TRANSFORMING ACTIVITY; GENE-PRODUCT; CELL-CYCLE; PROTO-DBL; CANCER; CDC24; RECEPTOR	We generated a cDNA expression library from a human mammary epithelial cell line for detection of novel oncogenes by focus formation assay in NIH3T3 cells. A morphologically unique focus was identified and the transforming plasmid was isolated. The transforming gene, designated TIM, encoded a predicted protein species of 60 kDa containing a Dbl-Homology (DH) motif. This motif is also present in other growth regulatory molecules including Bcr, Cdc24, Vav, Ras-grf, and Ect2 which have been implicated as regulators of small GTP-binding proteins. NIH3T3 cells transfected with TIM expression plasmid showed altered growth properties in vitro and were tumorigenic when injected into nude mice. The 6.5 kilobasepair (kb) transcript of the TIM gene was mainly expressed in kidney, liver, pancreas, lung, and placenta. By analysing a panel of human-hamster somatic celt hybrids, we localized the TIM gene to human chromosome 7.			CHAN, AML (corresponding author), NCI, CELLULAR & MOLEC BIOL LAB, BLDG 37, 1E24, BETHESDA, MD 20892 USA.		Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				ADAMS JM, 1992, ONCOGENE, V7, P611; BOS JL, 1989, CANCER RES, V49, P4682; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AML, 1993, ONCOGENE, V8, P1329; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; DOWNWARD J, 1992, NATURE, V358, P282, DOI 10.1038/358282a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Maniatis T., 1982, MOL CLONING; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	33	53	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1057	1063						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134109				2022-12-28	WOS:A1994NC04800008
J	CHAN, TA; CHU, CA; RAUEN, KA; KROIHER, M; TATAREWICZ, SM; STEELE, RE				CHAN, TA; CHU, CA; RAUEN, KA; KROIHER, M; TATAREWICZ, SM; STEELE, RE			IDENTIFICATION OF A GENE ENCODING A NOVEL PROTEIN-TYROSINE KINASE CONTAINING SH2 DOMAINS AND ANKYRIN-LIKE REPEATS	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; BUDDING STRAIN L4; DROSOPHILA-MELANOGASTER; DEVELOPMENTAL MECHANISMS; SEQUENCE-ANALYSIS; NERVOUS-SYSTEM; LEUKEMIA-CELLS; DNA-SEQUENCE; SRC GENE; HYDRA	Using the polymerase chain reaction with primers corresponding to conserved regions in the kinase domain of protein-tyrosine kinases, we amplified segments of several protein-tyrosine kinase genes from Hydra vulgaris, a member of the ancient metazoan phylum Cnidaria. Characterization of cDNA clones for one of these genes, HTK16, revealed that it encodes a non-receptor protein-tyrosine kinase with two SH2 domains but no SH3 domain. In this regard the predicted HTK16 protein resembles two mammalian non-receptor protein-tyrosine kinases, the products of the ZAP-70 and syk genes. However, the HTK16 protein contains five ankyrin-like repeats, a structural motif which has not previously been found in protein-tyrosine kinases. The HTK16 protein also contains a potential tyrosine phosphorylation site in its carboxyl-terminal tail which resembles the phosphorylation site in members of the src family. RNA hybridization analysis indicates that the HTK16 gene is expressed in epithelial cells, cells which also express the Hydra homologue of the src protein. Our finding of the HTK16 gene in Hydra indicates that diversification of genes encoding non-receptor protein-tyrosine kinases was a very early event in metazoan evolution.	UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, CTR DEV BIOL, IRVINE, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine			Chan, Timothy A/ABD-5850-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009755] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR09755-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; Bode H.R., 1983, P291; BODE HR, 1978, PROG BIOPHYS MOL BIO, V33, P189; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DAVID CN, 1973, ROUX ARCH DEV BIOL, V171, P259, DOI 10.1007/BF00577724; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; GRIMMELIKHUIJZEN CJP, 1982, HISTOCHEMISTRY, V73, P499, DOI 10.1007/BF00493364; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HOLSTEIN TW, 1990, NATURE, V346, P21, DOI 10.1038/346021b0; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KATZEN AL, 1991, MOL CELL BIOL, V11, P226, DOI 10.1128/MCB.11.1.226; KHANDJIAN EW, 1987, BIO-TECHNOL, V5, P165, DOI 10.1038/nbt0287-165; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LENHOFF H M, 1970, Laboratory Animals (London), V4, P139, DOI 10.1258/002367770781036463; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MACAULEY A, 1990, New Biologist, V2, P828; MANO H, 1990, ONCOGENE, V5, P1781; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OTTILIE S, 1992, ONCOGENE, V7, P1625; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; RUBIN DI, 1982, DEV BIOL, V89, P332, DOI 10.1016/0012-1606(82)90322-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHISHIDO E, 1991, FEBS LETT, V289, P235, DOI 10.1016/0014-5793(91)81078-M; SHORT JM, 1992, METHOD ENZYMOL, V216, P495; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; TAKANO J, 1984, J EMBRYOL EXP MORPH, V80, P155; TAKANO J, 1983, J EMBRYOL EXP MORPH, V78, P141; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	60	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1253	1259						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134129				2022-12-28	WOS:A1994NC04800031
J	HORIO, Y; SUZUKI, H; UEDA, R; KOSHIKAWA, T; SUGIURA, T; ARIYOSHI, Y; SHIMOKATA, K; TAKAHASHI, T; TAKAHASHI, T				HORIO, Y; SUZUKI, H; UEDA, R; KOSHIKAWA, T; SUGIURA, T; ARIYOSHI, Y; SHIMOKATA, K; TAKAHASHI, T; TAKAHASHI, T			PREDOMINANTLY TUMOR-LIMITED EXPRESSION OF A MUTANT ALLELE IN A JAPANESE FAMILY CARRYING A GERMLINE P53 MUTATION	ONCOGENE			English	Note							LI-FRAUMENI SYNDROME; CANCER-PRONE FAMILY; CELL LUNG-CANCER; MESSENGER-RNA; BREAST-CANCER; WILD-TYPE; GENE; SARCOMA; ABNORMALITIES; LESIONS	Germline mutations of p53 have been implicated as a cause of cancer susceptibility in the Li-Fraumeni syndrome. Since inactivation of p53 has been suggested to play an important causative role in lung cancer, the present study of the prevalence of germline mutations in 148 patients with this neoplasm was performed. None of 138 randomly chosen patients were found to carry such mutations, while a single patient had a nonsense mutation at codon 213 among 10 patients selected for early onset and/or occurrence of multiple primary cancers. In contrast to the previous report of biallelic expression of p53 in a case with a germline missense mutation, preferential expression of the wild-type allele was observed in the heterozygous state in both normal lung and peripheral blood lymphocytes of our case, whereas expression of mutant mRNA was readily detectable in her lung cancer in the absence of the remaining wild-type allele. Interestingly, the family history of the proband showed a mild aggregation of adulthood cancers and a high prevalence of stomach cancer, a rare component in American families affected by the syndrome. These observations suggest the presence of heterogeneity with regard to molecular and clinical features of germline p53 mutations.	AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,CLIN LABS,CHIKUSA KU,NAGOYA 464,JAPAN; AICHI CANC CTR HOSP,DEPT INTERNAL MED,CHIKUSA KU,NAGOYA 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University			Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Horio, Yoshitsugu/0000-0003-4661-6399				CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FELIX CA, 1993, ONCOGENE, V8, P1203; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KUROISHI T, 1992, JPN J CLIN ONCOL, V22, P365; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LYNCH HT, 1978, CANCER, V41, P2055, DOI 10.1002/1097-0142(197805)41:5<2055::AID-CNCR2820410554>3.0.CO;2-X; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MATSUDA R, 1993, AM J PATHOL, V142, P339; MINNA JD, 1991, MOL MECHANISMS THEIR, P63; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; UCHINO S, 1993, INT J CANCER, V54, P759, DOI 10.1002/ijc.2910540509; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; 1992, CANCER INCIDENCE 5 C, V6, P876	30	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1231	1235						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134126				2022-12-28	WOS:A1994NC04800027
J	BOND, JA; WYLLIE, FS; ROWSON, J; RADULESCU, A; WYNFORDTHOMAS, D				BOND, JA; WYLLIE, FS; ROWSON, J; RADULESCU, A; WYNFORDTHOMAS, D			IN-VITRO RECONSTRUCTION OF TUMOR INITIATION IN A HUMAN EPITHELIUM	ONCOGENE			English	Article							RET ONCOGENE ACTIVATION; COLORECTAL TUMORIGENESIS; THYROID-TUMORS; RAS ONCOGENE; MUTATIONS OCCUR; HIGH-FREQUENCY; CELL-LINE; PAPILLARY; CARCINOMAS; MARKERS	Knowledge of tumour initiation in human epithelia is limited by sample availability and difficulty in experimental manipulation of human cells. The thyroid is a useful model since, in addition to multiple tumour stages, it presents two distinct 'pathways' of tumorigenesis: 'follicular' tumours, in which vas oncogene mutations occur at high frequency and 'papillary' tumours, associated with ret (or trk) activation. We have used these observations to reconstruct early thyroid tumorigenesis, using amphotropic retroviral vectors. When introduced into normal thyroid epithelial cells, mutant vas induces self-limiting growth of well-demarcated, differentiated colonies - a phenotype consistent with follicular adenoma. Activated ret on the other hand induces smaller, poorly demarcated colonies with a morphology consistent with early papillary tumours. Mutant p53 - which occurs only in the latest stages of thyroid cancer - was without effect. Our results provide the first direct experimental evidence in a human epithelium for alternative initiating oncogenes and their determination of the subsequent 'direction' of tumour development.	UNIV WALES COLL CARDIFF,COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL RES GRP,CARDIFF,S GLAM CF4 4XN,WALES	Cardiff University								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BONGARZONE I, 1989, ONCOGENE, V4, P1457; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; Hedinger CE., 1988, HISTOLOGICAL TYPING; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ITO T, 1992, CANCER RES, V52, P1369; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LANE EB, 1982, J CELL BIOL, V92, P665, DOI 10.1083/jcb.92.3.665; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SCHRODER S, 1985, AM J SURG PATHOL, V9, P619, DOI 10.1097/00000478-198509000-00001; SHEPARD TH, 1968, GEN COMP ENDOCR, V10, P174, DOI 10.1016/0016-6480(68)90024-5; SUAREZ HG, 1990, ONCOGENE, V5, P565; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; WILLIAMS DW, 1989, THYROID TUMOURS MOL, P57; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WRIGHT PA, 1989, BRIT J CANCER, V60, P576, DOI 10.1038/bjc.1989.316; WRIGHT PA, 1993, J PATH S, V169, P230; WYNFORDTHOMAS D, 1991, J PATHOL, V165, P187, DOI 10.1002/path.1711650302	32	81	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					281	290						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302590				2022-12-28	WOS:A1994MW24700034
J	VERDERAME, MF; VARMUS, HE				VERDERAME, MF; VARMUS, HE			HIGHLY CONSERVED AMINO-ACIDS IN THE SH2 AND CATALYTIC DOMAINS OF V-SRC ARE ALTERED IN NATURALLY-OCCURRING, TRANSFORMATION-DEFECTIVE ALLELES	ONCOGENE			English	Article							TERMINAL REGULATORY DOMAIN; TYROSINE PROTEIN-KINASES; C-ABL; ONCOGENIC ACTIVATION; CELL-TRANSFORMATION; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; POINT MUTATIONS; SARCOMA-VIRUS; PP60C-SRC	We have identified 11 novel point mutations that abolish the transforming capacity of the oncogene v-src. These transformation-defective alleles were originally identified in morphologically flat subclones of rat cells transformed by wild type v-src. Nine of the mutations affect amino acid residues that are highly conserved in the catalytic domain of pp60(v-src) and completely abolish kinase activity. The other 2 mutations alter conserved residues in the SH2 domain (Phe-172 replaced with Val in one case [F172V] and Leu-186 replaced with Phe in the other [L186F]), drastically reducing, but not eliminating, kinase activity. The enzymatic and transforming functions of one of the SH2 mutants, L186F are host dependent; the mutant protein is active in chicken cells, but inactive in rat cells, as previously observed for some other SH2 mutants. These results are interpreted in relation to the recently described three-dimensional structures of SH2 domains and of the catalytic domain of a protein kinase. In addition, they support a role for the SH2 domain in the regulation of kinase activity.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	VERDERAME, MF (corresponding author), PENN STATE UNIV, COLL MED, DEPT MICROBIOL & IMMUNOL, HERSHEY, PA 17033 USA.			Verderame, Michael F./0000-0001-7046-0879	NATIONAL CANCER INSTITUTE [R01CA052791, R35CA039832] Funding Source: NIH RePORTER; NCI NIH HHS [CA52791, CA39832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; LIEBL EC, 1993, VIROLOGY, V195, P265, DOI 10.1006/viro.1993.1371; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OPPERMANN H, 1981, VIROLOGY, V108, P47, DOI 10.1016/0042-6822(81)90526-2; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1990, ONCOGENE, V5, P1437; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7	40	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					175	182						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302576				2022-12-28	WOS:A1994MW24700021
J	TALMAGE, DA; LISTERUD, M				TALMAGE, DA; LISTERUD, M			RETINOIC ACID SUPPRESSES POLYOMA-VIRUS TRANSFORMATION BY INHIBITING TRANSCRIPTION OF THE C-FOS PROTOONCOGENE	ONCOGENE			English	Article							SERUM RESPONSE ELEMENT; MIDDLE T-ANTIGEN; TUMOR-INDUCTION; CELL-LINE; EXPRESSION; GENE; PHOSPHORYLATION; GROWTH; JUN; REPLICATION	In a previous paper, we predicted that retinoic acid suppressed polyoma virus transformation of rat F111 fibroblasts by affecting the expression of one or more genes that are involved in signalling pathways normally activated by the viral mT oncogene (Talmage and Lackey, Oncogene 7, 1837-1845, 1992). We had identified the cellular c-fos proto-oncogene as a possible candidate target for both polyoma virus mT and retinoic acid regulated expression. In this report we present the results of experiments that demonstrate that retinoic acid does indeed inhibit transcriptional transactivation of the c-fos promoter by polyoma virus, as well as by calf serum and purified serum growth factors. Further experiments demonstrate that inhibition of c-fos expression with antisense fos RNA also prevents polyoma virus induced transformation. Restoration of c-fos expression, even in the presence of retinoic acid, restored transformation, indicating that retinoic acid inhibition of c-fos expression is sufficient to explain the retinoid suppression of transformation. These results identify the c-fos protooncogene as a key nuclear target for mT-dependent transformation and show that the anticarcinogenic properties of retinoic acid can be brought about by inhibiting c-fos expression.			TALMAGE, DA (corresponding author), COLUMBIA UNIV,INST HUMAN NUTR,NEW YORK,NY 10032, USA.			Talmage, David/0000-0003-4627-3007	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026854] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26854] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENJAMIN TL, 1982, BIOCHIM BIOPHYS ACTA, V695, P69, DOI 10.1016/0304-419X(82)90018-X; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DUBENSKY TW, 1991, J VIROL, V65, P342, DOI 10.1128/JVI.65.1.342-349.1991; FREUND R, 1991, J VIROL, V65, P335, DOI 10.1128/JVI.65.1.335-341.1991; FREUND R, 1992, VIROLOGY, V191, P716, DOI 10.1016/0042-6822(92)90247-M; GARCEA RL, 1989, VIROLOGY, V168, P312, DOI 10.1016/0042-6822(89)90271-7; GIESE NA, 1985, J NATL CANCER I, V74, P1135; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; JAFFEY P, 1992, CANCER RES, V52, P2384; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KOLCH W, 1993, ONCOGENE, V8, P361; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LOTAN R, 1977, J NATL CANCER I, V59, P1717, DOI 10.1093/jnci/59.6.1717; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MERCOLA D, 1987, BIOCHEM BIOPH RES CO, V147, P288, DOI 10.1016/S0006-291X(87)80119-5; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SCHNEIDTMAN KH, 1991, MOL CELL BIOL, V11, P1996; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TALMAGE DA, 1992, VIROLOGY, V187, P734, DOI 10.1016/0042-6822(92)90476-6; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P51; TALMAGE DA, 1992, ONCOGENE, V7, P1837; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; Treisman R, 1990, Semin Cancer Biol, V1, P47; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2721; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WICK M, 1992, ONCOGENE, V7, P859; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	46	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3557	3563						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970716				2022-12-28	WOS:A1994PT39200018
J	ZHAN, QM; FAN, SJ; BAE, I; GUILLOUF, C; LIEBERMANN, DA; OCONNOR, PM; FORNACE, AJ				ZHAN, QM; FAN, SJ; BAE, I; GUILLOUF, C; LIEBERMANN, DA; OCONNOR, PM; FORNACE, AJ			INDUCTION OF BAX BY GENOTOXIC STRESS IN HUMAN-CELLS CORRELATES WITH NORMAL P53 STATUS AND APOPTOSIS	ONCOGENE			English	Article							WILD-TYPE P53; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; NITROGEN-MUSTARD; BINDING-SITE; CYCLE ARREST; PROTEIN; BCL-2; DEATH; GENE	DNA-damaging agents such as ionizing radiation (IR) activate the tumor suppressor p53 and in some cases can cause apoptosis. M1 cells, which do not express the endogenous tumor suppressor gene p53, undergo apoptosis following activation of a temperature sensitive p53 transgene, where it has been shown that bax, an important mediator of apoptosis, is a p53 target gene (Selvakumaran et al, Oncogene 9, 1791-8, 1994). Since p53 can function as a transcription factor after activation by IR, the genetic response to this stress was examined in a panel of human cells with defined p53 status. Like the p53-regulated gene gadd45, bax was rapidly induced, as measured by increased mRNA levels,in the p53 wt (wild type) human myeloid line ML-1, and it was not induced in cells lacking functional p53. However, unlike other p53-regulated genes, bax was only induced in p53 wt cells in which IR also triggered apoptosis. In the case of bc12, which opposes bax function, mRNA levels were reduced in ML-1 cells after IR. Thus, bax appears to be an unique p53-regulated gene in that its induction by IR not only requires functional p53 but also requires that the cells be apoptosis ''proficient.''	NCI, DIV CANC TREATMENT, MOLEC PHARMACOL LAB, DEV THERAPEUT PROGRAM, BETHESDA, MD 20892 USA; TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NCI NIH HHS [1RO1CA43618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1994, IN PRESS CANCER RES; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DOLE M, 1994, CANCER RES, V54, P3253; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN S, 1994, IN PRESS CANCER RES; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORNACE AJ, 1980, BIOCHIM BIOPHYS ACTA, V607, P432, DOI 10.1016/0005-2787(80)90153-7; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FORNACE AJ, 1980, MUTAT RES, V70, P323, DOI 10.1016/0027-5107(80)90022-6; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARPER JW, 1993, CELL, V75, P805; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1989, CANCER RES, V49, P1687; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KHANNA KK, 1993, ONCOGENE, V8, P3307; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIYASHITA T, 1994, NOCOGENE, V9, P1799; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OCONNOR PM, 1993, CANCER RES, V53, P4776; OCONNOR PM, 1991, CANCER RES, V51, P6550; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; STAMATO TD, 1982, SOMAT CELL GENET, V8, P643, DOI 10.1007/BF01542857; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALTON MI, 1993, CANCER RES, V53, P1853; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	45	413	423	1	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3743	3751						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970735				2022-12-28	WOS:A1994PT39200041
J	MIZUNO, K; OKANO, I; OHASHI, K; NUNOUE, K; KUMA, K; MIYATA, T; NAKAMURA, T				MIZUNO, K; OKANO, I; OHASHI, K; NUNOUE, K; KUMA, K; MIYATA, T; NAKAMURA, T			IDENTIFICATION OF A HUMAN CDNA-ENCODING A NOVEL PROTEIN-KINASE WITH 2 REPEATS OF THE LIM DOUBLE ZINC-FINGER MOTIF	ONCOGENE			English	Article							CYSTEINE-RICH PROTEIN; TYROSINE KINASE; CONSERVED FEATURES; CATALYTIC DOMAIN; ACTIVIN RECEPTOR; SERINE KINASE; INSULIN GENE; FAMILY; SEQUENCE; MEMBER	By low-stringency screening of a human hepatoma HepG2 cell cDNA library, using the genomic fragment of chick c-sea receptor tyrosine kinase as a probe, we isolated overlapping cDNAs encoding a novel protein kinase, which we termed LIM-kinase (LIMK). The predicted open reading frame encodes a 647-amino-acid polypeptide containing a putative protein kinase structure in the C-terminal half. In addition, LIMK has two repeats of cysteine-rich LIM/double zinc finger motif at the most N-terminus. To our knowledge, this is the first protein kinase seen to contain the LIM motif(s) in the molecule. Although the protein kinase domain of LIMK has highly conserved sequence elements of protein kinases, phylogenetic analysis revealed that LIMK cannot be classified into any subfamily of known protein kinases. Northern blot analysis revealed that the single species of LIMK mRNA of 3.3 kb was expressed in various human epithelial and hematopoietic cell lines. In rat tissues, LIMK mRNA was expressed in the brain, at the highest level. LIM is suggested to be involved in protein-protein interactions by binding to another LIM motif. As the LIM domain is frequently present in the homeodomain-containing transcriptional regulators and oncogenic nuclear proteins, LIMK may be involved in developmental or oncogenic processes through interactions with these LIM-containing proteins.	KYOTO UNIV, FAC SCI, DEPT BIOPHYS, KYOTO 60601, JAPAN; OSAKA UNIV, SCH MED, BIOMED RES CTR, OSAKA 565, JAPAN	Kyoto University; Osaka University	MIZUNO, K (corresponding author), KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 812, JAPAN.		Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X				BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1328; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHASHI K, 1994, ONCOGENE, V9, P699; OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG XK, 1992, J BIOL CHEM, V267, P9176; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	42	181	190	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1605	1612						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183554				2022-12-28	WOS:A1994NL81500011
J	PASTOR, R; BERNAL, J; RODRIGUEZPENA, A				PASTOR, R; BERNAL, J; RODRIGUEZPENA, A			UNLIGANDED C-ERBA THYROID-HORMONE RECEPTOR INDUCES TRKB EXPRESSION IN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; THYROID-HORMONE; NEUROTROPHIC FACTOR; 3,5,3'-TRIIODOTHYRONINE RECEPTOR; MORPHOLOGICAL-DIFFERENTIATION; BRAIN-DEVELOPMENT; RETINOIC ACID; GENE ENCODES; PC12 CELLS	Neurotrophins are responsible for the differentiation and survival of neurons in the developing and in the adult nervous system. They bind to specific membrane receptors with tyrosine kinase activity whose prototype is the product of the trkA proto-oncogene. TrkB, a member of this family, is the receptor for the neurotrophins brain derived growth factor (BDNF) and neurotrophins-3, 4/5. In this study, we show that stable expression of the c-erbA proto-oncogene, which encodes the alpha1-isoform of the nuclear receptor for thyroid hormone (Tralpha1) induces the expression of trkB mRNA with a concomitant decrease to undetectable levels of trkA and trkC mRNAs in the mouse neuroblastoma N2a cell line. trkB induction by c-erbA is ligand independent, since addition of T3 had no effect. The induced trkB transcript encodes a functional gp145trkB protein, which is phosphorylated on tyrosine in response to BDNF. Furthermore, induction of trkB mRNA is also caused by transient expression of either TR alpha1 or beta1 isoforms. Our results are compatible with the idea that there are certain pathways which are under control of unliganded thyroid hormone receptor, and that one of these pathways results in regulation of trk expression.	UNIV AUTONOMA MADRID,FAC MED,CONSEJO SUPER INVEST CIENTIFICAS,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Bernal, Juan/J-6086-2014	Bernal, Juan/0000-0002-5867-4951; Rodriguez-Pena, Angeles/0000-0002-2515-4626				ALTIN JG, 1992, NEUROTROPHIC FACTORS, P129; BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; Barbacid Mariano, 1993, P123; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERNAL J, 1984, ENDOCRINOLOGY, V114, P677, DOI 10.1210/endo-114-2-677; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clos J, 1990, GROWTH FACTORS, V3, P205, DOI 10.3109/08977199009043905; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DIAZNIDO J, 1988, J CELL BIOL, V106, P2057, DOI 10.1083/jcb.106.6.2057; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORREST D, 1991, EMBO J, V10, P269, DOI 10.1002/j.1460-2075.1991.tb07947.x; GLOWACKA D, 1990, J NEUROSCI RES, V25, P453, DOI 10.1002/jnr.490250403; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; KAPLAN DR, 1993, NEURON, V11, P1; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MELLSTROM B, 1991, MOL ENDOCRINOL, V5, P1339, DOI 10.1210/mend-5-9-1339; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MUNOZ A, 1990, MOL ENDOCRINOL, V4, P312, DOI 10.1210/mend-4-2-312; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; PATTERSON PH, 1993, NEURON S, V10, P123; PEREZCASTILLO A, 1985, ENDOCRINOLOGY, V117, P2457, DOI 10.1210/endo-117-6-2457; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHEA TB, 1985, DEV BRAIN RES, V21, P307, DOI 10.1016/0165-3806(85)90220-2; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	45	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1081	1089						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134111				2022-12-28	WOS:A1994NC04800010
J	HASHIMOTO, Y; MATUOKA, K; TAKENAWA, T; MUROYA, K; HATTORI, S; NAKAMURA, S				HASHIMOTO, Y; MATUOKA, K; TAKENAWA, T; MUROYA, K; HATTORI, S; NAKAMURA, S			DIFFERENT INTERACTIONS OF GRB2/ASH MOLECULE WITH THE NGF AND EGF RECEPTORS IN RAT PHEOCHROMOCYTOMA PC12 CELLS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; SH3 DOMAINS; SIGNAL TRANSDUCTION; TRK PROTOONCOGENE; PROTEIN-KINASE; SRC; ACTIVATION; ACCUMULATION; ASSOCIATION	We have previously shown that nerve growth factor (NGF) induces a rapid and relatively continuous activation of pas in rat pheochromocytoma PC12 cells while epidermal growth factor (EGF) activates Ras transiently, and that tyrosine kinase activity of the NGF receptor is essential for the activation of pas (Muroya et al., Oncogene, 7, 277-281, 1992). In order to explore the signaling mechanism from tyrosine kinase to Ras activation in more detail, interactions between two adaptor molecules, She and Grb2/Ash, which contain Src homology regions, and their interactions with the NGF and EGF receptors were examined. Both NGF and EGF induced rapid tyrosine phosphorylation of She and its association with both the receptors and with Grb2/Ash. When cells were stimulated with EGF at 4 degrees C, the activation of pas proceeded slowly and MAP kinase activation was quite low. Under such restricted conditions, tyrosine-phosphorylated She formed a complex with Grb2/Ash, suggesting that the complex formation may be one of the immediate early responses. In contrast to She, Grb2/Ash bound to EGF receptor but did not form a stable complex with the NGF receptor. These results suggest that there may be an alternative pathway for the activation of Ras in PC12 cells.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO,TOKYO 173,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,MINATO KU,TOKYO,TOKYO 108,JAPAN	National Center for Neurology & Psychiatry - Japan; Tokyo Metropolitan Institute of Gerontology; University of Tokyo								BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1994, IN PRESS P NATL ACAD; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P277; MUROYA K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P353, DOI 10.1016/0167-4889(92)90243-5; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409	39	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					869	875						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108130				2022-12-28	WOS:A1994MW55100023
J	LAI, C; LEMKE, G				LAI, C; LEMKE, G			STRUCTURE AND EXPRESSION OF THE TYRO-10 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; TRK PROTOONCOGENE PRODUCT; NEUROTROPHIC FACTOR; PROTEIN-KINASE; VISUAL CENTERS; FACTOR FAMILY; FACTOR-VIII; DOMAINS; SEQUENCE; MOLECULE	We have isolated cDNA clones encoding Tyro 10, a novel receptor protein-tyrosine kinase (PTK) whose catalytic domain exhibits significant similarity to the Trk family of neurotrophin receptors (Lai and Lemke, 1991). We find that the Tyro 10 gene is widely expressed, both within and outside the nervous system, and in both developing and mature neural tissue. The primary structure of Tyro 10, deduced from cDNA sequence, defines a new sub-family of receptor PTKs. Although the Tyro 10 kinase domain is more closely related to the equivalent domains of Trk, TrkB and TrkC than to the catalytic domains of other receptor PTKs, it is less closely related to these Trk domains than they are to each other. More significantly, the Tyro 10 extracellular (ligand binding) domain is not structurally related to the extracellular domains of the Trk receptors, but instead bears homology to cell surface mediators of protein-protein interactions, including blood coagulation Factors V and VIII, and the neuronal recognition protein A5. These appear to be structural features of a distinct receptor PTK sub-family, in that they are also found in the recently-described discoidin domain receptor (DDR).	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Salk Institute; Scripps Research Institute								BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERKEMEIER LR, 1992, SOMAT CELL MOLEC GEN, V18, P233, DOI 10.1007/BF01233860; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FUJISAWA H, 1989, DEV BIOL, V135, P231, DOI 10.1016/0012-1606(89)90175-9; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1990, N HORIZ TH, P119; HUNTER T, 1993, IN PRESS FRONTIERS B; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RODRIGUEZTEBAR A, 1991, PHILOS T ROY SOC B, V331, P255, DOI 10.1098/rstb.1991.0013; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	60	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					877	883						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108131				2022-12-28	WOS:A1994MW55100024
J	WU, C; AKIYAMA, Y; IMAI, K; MIYAKE, S; NAGASAKI, H; OTO, M; OKABE, S; IWAMA, T; MITAMURA, K; MASUMITSU, H; NOMIZU, T; BABA, S; MARUYAMA, K; YUASA, Y				WU, C; AKIYAMA, Y; IMAI, K; MIYAKE, S; NAGASAKI, H; OTO, M; OKABE, S; IWAMA, T; MITAMURA, K; MASUMITSU, H; NOMIZU, T; BABA, S; MARUYAMA, K; YUASA, Y			DNA ALTERATIONS IN CELLS FROM HEREDITARY NONPOLYPOSIS COLORECTAL-CANCER PATIENTS	ONCOGENE			English	Note							GENE; IDENTIFICATION; MUTATIONS; CHROMOSOME-5Q21; LOCUS; SUSCEPTIBILITY; CARCINOMA; PRODUCTS; FAP	To determine if the MCC, DCC or p53 gene is associated with susceptibility to hereditary non-polyposis colorectal cancer (HNPCC), these genes in normal cells from 12 HNPCC patients were analysed by polymerase chain reaction-single strand conformation polymorphism analysis. No changes which may alter the amino acid sequences of these genes were detected, suggesting that these genes are not associated with the susceptibility to HNPCC. Only one of nine HNPCC cancers showed mutations in the MCC and p53 genes on the same analysis. Loss of heterozygosity in chromosomes 5q, 17p, 18q and 22 was detected in four of the nine cancers, all of them being positive as to metastasis to lymph nodes. Abnormalities of the (CA)n repeat were found in six cancers, including all four without metastasis. These data indicate that tumor suppressor genes in chromosomes 5q, 17p, 18q and 22 are associated with the late stage of colorectal tumorigenesis in HNPCC, whereas the (CA)n repeat abnormalities are an early event of tumorigenesis and more essential to HNPCC.	TOKYO MED & DENT UNIV, SCH MED, DEPT HYG & ONCOL, TOKYO, TOKYO 113, JAPAN; TOKYO MED & DENT UNIV, SCH MED, DEPT SURG, TOKYO, TOKYO 113, JAPAN; SHOWA UNIV, SCH MED, DEPT INTERNAL MED, TOKYO, TOKYO 142, JAPAN; TOKYO METROPOLITAN PUBL HLTH PROMOT FDN, TAMA CANC DETECT CTR, TOKYO, TOKYO 183, JAPAN; HOSHI GEN HOSP, DEPT SURG, FUKUSHIMA, FUKUSHIMA 963, JAPAN; HAMAMATSU UNIV SCH MED, DEPT SURG, HAMAMATSU, SHIZUOKA 43131, JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Showa University; Hamamatsu University School of Medicine								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JINNAI D, 1983, JPN J SURG, V13, P557; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LYNCH HT, 1985, CANCER, V56, P939, DOI 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5705, DOI 10.1093/nar/16.12.5705; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1991, CANCER RES, V51, P4135; PELTOMAKI P, 1992, CANCER RES, V52, P4530; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA, P3	22	43	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					991	994						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108146				2022-12-28	WOS:A1994MW55100040
J	LAVENU, A; POURNIN, S; BABINET, C; MORELLO, D				LAVENU, A; POURNIN, S; BABINET, C; MORELLO, D			THE CIS-ACTING ELEMENTS KNOWN TO REGULATE C-MYC EXPRESSION EX-VIVO ARE NOT SUFFICIENT FOR CORRECT TRANSCRIPTION IN-VIVO	ONCOGENE			English	Article							LOCUS ACTIVATION REGION; RNA POLYMERASE-II; TRANSGENIC MICE; BURKITT-LYMPHOMA; CHROMATIN STRUCTURE; MESSENGER-RNA; CHROMOSOME-TRANSLOCATION; EFFICIENT TRANSCRIPTION; MODULATE EXPRESSION; NEOPLASTIC-CELLS	Much of our knowledge about the regulation of the c-myc proto-oncogene expression has come from studies of c-myc gene expression in several well defined ex vivo systems, including differentiation systems and tumor cells. However, very few investigations have been performed to determine the factors and cis-acting sequences that regulate c-myc expression in vivo. In order to obtain information on the sequences required to regulate c-myc gene transcription from the two major P1 and P2 initiation sites in the mouse, we have generated several constructs containing human or murine c-myc genomic sequences with various 5' flanking sequences and derived corresponding transgenic mice. A sensitive S1 nuclease protection assay was performed to analyse and to compare transgene expression with that of the endogeneous c-myc mRNA, either in adult organs, or during development. None of the transgenic mice expressed the construct appropriately, although several strains exhibited unexpected expression most probably due to position effects. Our results indicate that the cis-acting elements described to regulate c-myc expression ex vivo are not sufficient to drive the correct expression of c-myc gene in vivo and strongly suggest that additional regulatory elements located upstream from -3500 (with respect to mouse P1 promoter) and downstream 1500 bp from polyadenylation sites are required.	INST PASTEUR, DEPT IMMUNOL, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ASSELIN C, 1989, ONCOGENE, V4, P549; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DUBIK D, 1992, ONCOGENE, V7, P1587; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FINVER SN, 1988, P NATL ACAD SCI USA, V85, P3052, DOI 10.1073/pnas.85.9.3052; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAMMER RE, 1987, MOL CELL BIOL, V7, P2956, DOI 10.1128/MCB.7.8.2956; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KUMAR S, 1991, J MOL BIOL, V222, P45, DOI 10.1016/0022-2836(91)90736-P; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MANGO SE, 1989, MOL CELL BIOL, V9, P3482, DOI 10.1128/MCB.9.8.3482; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1989, ONCOGENE RES, V4, P111; MORELLO D, 1993, ONCOGENE, V8, P1921; NISHIKURA K, 1985, MOL CELL BIOL, V5, P1434, DOI 10.1128/MCB.5.6.1434; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; ROBERTS S, 1992, GENE DEV, V6, P1562, DOI 10.1101/gad.6.8.1562; ROLAND J, 1993, CELL GROWTH DIFFER, V4, P891; SACCA R, 1990, ONCOGENE, V5, P1499; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEI Y, 1990, GENE, V93, P301, DOI 10.1016/0378-1119(90)90240-R; WEISINGER G, 1988, ONCOGENE, V3, P635; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; ZOBEL A, 1991, ONCOGENE, V6, P1397	65	30	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					527	536						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290263				2022-12-28	WOS:A1994MW24800020
J	GRAEF, E; CASELMANN, WH; WELLS, J; KOSHY, R				GRAEF, E; CASELMANN, WH; WELLS, J; KOSHY, R			INSERTIONAL ACTIVATION OF MEVALONATE KINASE BY HEPATITIS-B VIRUS-DNA IN A HUMAN HEPATOMA-CELL LINE	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; INBORN ERROR; ACIDURIA; GENE; BIOSYNTHESIS; CHOLESTEROL; INTEGRATION; P21RAS	Insertional mutagenesis of growth related genes by hepatitis B virus (HBV) DNA is presumed to play a role in hepatocarcinogenesis. Here, we report on insertional activation of the mevalonate kinase (MK) gene in the human hepatoma cell line PLC/PRF/5, Integration of HBV DNA dissociated the promoter and upstream regulatory elements of the gene from its coding sequences. This led to the over-expression of hybrid transcripts arising from an HBV promoter and the consequent over-production of functionally active mevalonate kinase. MK phosphorylates mevalonate, a major intermediate in the branched cholesterol/isoprenoid biosynthetic pathway. Isoprenylation is crucial to the functions of cellular proteins related to growth control, including the proto-oncogene ras. As the enzymes of these biosynthetic pathways are regulated at multiple points by negative feedback, both transcriptionally and at the protein level, the results discussed here support the idea that aberrant growth could result from deregulated overexpression of MK and, perhaps, other enzymes in the cholesterol pathway. These results invoke novel mechanisms by which cell transformation might occur.	ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED 2,W-8000 MUNICH,GERMANY; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,CAMBS,ENGLAND	Imperial College London; Max Planck Society; University of Munich; University of Cambridge								BARBU V, 1990, ONCOGENE, V5, P1077; BERGER R, 1985, CLIN CHIM ACTA, V152, P219, DOI 10.1016/0009-8981(85)90195-0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CATTANEO R, 1984, EMBO J, V3, P2191, DOI 10.1002/j.1460-2075.1984.tb02113.x; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOCH S, 1984, NUCLEIC ACIDS RES, V12, P6871, DOI 10.1093/nar/12.17.6871; KOSHY R, 1992, REV MED VIROL, V2, P131, DOI 10.1002/rmv.1980020303; OU J, 1985, P NATL ACAD SCI USA, V82, P83, DOI 10.1073/pnas.82.1.83; POPJAK G, 1969, METHOD ENZYMOL, V15, P393; QUESNEYHUNEEUS V, 1983, J BIOL CHEM, V258, P378; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; ZHANG XK, 1992, BIOCHEM BIOPH RES CO, V188, P344, DOI 10.1016/0006-291X(92)92391-A	24	60	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					81	87						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302606				2022-12-28	WOS:A1994MW24700010
J	JOLLY, KW; MALKIN, D; DOUGLASS, EC; BROWN, TF; SINCLAIR, AE; LOOK, AT				JOLLY, KW; MALKIN, D; DOUGLASS, EC; BROWN, TF; SINCLAIR, AE; LOOK, AT			SPLICE-SITE MUTATION OF THE P53 GENE IN A FAMILY WITH HEREDITARY BREAST-OVARIAN CANCER	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; SINGLE BASE SUBSTITUTIONS; LI-FRAUMENI SYNDROME; GEL-ELECTROPHORESIS; GERMLINE MUTATIONS; PRONE FAMILY; DNA; NEOPLASMS; P53-GENE; JUNCTION	Germline mutations within evolutionary conserved exons of the p53 gene predispose to tumor development in several familial cancer syndromes. We now report identification of a novel p53 mutation affecting the splice acceptor site of exon 6 in the germline DNA of a family with hereditary breast-ovarian cancer. This splice-site mutation, which results in omission of exon 6 and creates a frame-shift and premature stop codon in transcripts from the mutant allele, was found in seven family members-four of whom have developed breast, ovarian or choroid plexus tumors before age 35. Our finding suggests the need to examine the entire p53 gene for frame-shift, and nonsense (as well as missense) mutations in families with early-onset hereditary breast and breast-ovarian cancers not linked to the BRCA1 gene on chromosome 17q. We propose that the term 'p53 familial cancer syndrome' be applied to dusters of tumors in families with documented germline p53 mutations, regardless of the histopathologic findings or pattern of tumor development.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; HOSP SICK CHILDREN, DEPT PEDIAT, DIV ONCOL, TORONTO M5G 1X8, ON, CANADA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)					NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-23099, CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORRESEN AL, 1992, CANCER RES, V52, P3234; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; Bunn HF, 1986, HEMOGLOBIN MOL GENET; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GARBER JE, 1990, CANCER-AM CANCER SOC, V66, P2658, DOI 10.1002/1097-0142(19901215)66:12<2658::AID-CNCR2820661232>3.0.CO;2-C; GITSCHIER J, 1991, THROMB HAEMOSTASIS, V66, P37; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; JENKINS JR, 1988, ONCOGENE HDB, P403; KING MC, 1992, NAT GENET, V2, P89, DOI 10.1038/ng1092-89; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LAW JC, 1991, CANCER RES, V51, P6385; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1988, CANCER RES, V48, P5381; LIVINGSTON D, 1992, CANCER RES, V52, P3246; LYNCH HT, 1978, CANCER-AM CANCER SOC, V41, P1543, DOI 10.1002/1097-0142(197804)41:4<1543::AID-CNCR2820410444>3.0.CO;2-Y; LYNCH HT, 1984, CANCER GENET CYTOGEN, V13, P43, DOI 10.1016/0165-4608(84)90087-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MONTENARH M, 1992, ONCOGENE, V7, P1673; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NAROD SA, 1991, LANCET, V338, P82; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PUISIEUX A, 1991, CANCER RES, V51, P6185; REES DJG, 1985, NATURE, V316, P643, DOI 10.1038/316643a0; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	40	82	82	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					97	102						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302608				2022-12-28	WOS:A1994MW24700012
J	FISCH, P; FORSTER, A; SHERRINGTON, PD; DYER, MJS; RABBITTS, TH				FISCH, P; FORSTER, A; SHERRINGTON, PD; DYER, MJS; RABBITTS, TH			THE CHROMOSOMAL TRANSLOCATION T(X14)(Q28Q11) IN T-CELL PRO-LYMPHOCYTIC LEUKEMIA BREAKS WITHIN ONE GENE AND ACTIVATES ANOTHER	ONCOGENE			English	Article							ATAXIA TELANGIECTASIA; MOLECULAR ANALYSIS; LEUKEMIA; SEQUENCE; PATIENT; MECHANISM; INVERSION; CLONING; LOCUS; DNA	Chromosomal translocation t(X;14)(q28;q11) has been observed in patients with pro-lymphocytic T-cell leukaemia (T-PLL). In two cases of T-PLL, one of which was associated with Ataxia telangiectasia (AT), the chromosomal break occurred in two different introns of a gene c6.1A, located at the Xq28 locus. Fusion transcripts, consisting of 5' sequences of c6.1A and the TCR alpha constant (C) region, were expressed at high levels in the leukaemic cells from both patients, but in only one case did this fusion generate an in-frame c6.1A-C alpha mRNA. However, the breaks within c6.1A seem to affect another gene, cd.1B, which is transcribed from the same CpG rich island as c6.1A but in the opposite transcriptional orientiation. The c6.1B gene is not damaged by the translocation but is transcribed in both T-PLL cases. Furthermore, c6.1B may lack protein coding capacity and thus this translocation might result in a novel mechanism in tumorigenesis. In any event, this is the first cloned gene which is implicated in pathogenesis of chronic/pro-lymphocytic leukaemia of the T-cell lineage.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, CAMBS, ENGLAND; ROYAL CANC HOSP, INST CANC RES, SUTTON SM2 5NG, SURREY, ENGLAND	MRC Laboratory Molecular Biology; University of London; Institute of Cancer Research - UK			Dyer, Martin/F-2691-2014; Rabbitts, Terence/D-6262-2016	Dyer, Martin/0000-0002-5033-2236; Rabbitts, Terence/0000-0002-4982-2609				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAER R, 1987, CELL, V50, P97, DOI 10.1016/0092-8674(87)90666-0; BAER R, 1988, EMBO J, V7, P1611; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; DEAR TN, 1991, BIOCHEMISTRY-US, V30, P10376, DOI 10.1021/bi00107a003; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDMAN MA, 1992, NAT GENET, V2, P169, DOI 10.1038/ng1192-169; KAISERMCCAW B, 1975, P NATL ACAD SCI USA, V72, P2071; KENWRICK S, 1992, HUM MOL GENET, V1, P179, DOI 10.1093/hmg/1.3.179; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; LEVITT R, 1978, BLOOD, V52, P1003; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217; TAYLOR AMR, 1986, INT J CANCER, V37, P511, DOI 10.1002/ijc.2910370407; TAYLOR AMR, IN PRESS LEUKAEMIA; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x	26	58	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3271	3276						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247530				2022-12-28	WOS:A1993MG78200010
J	CHEN, SC; REDENIUS, D; YOUNG, JC; SCHWARTZ, RC				CHEN, SC; REDENIUS, D; YOUNG, JC; SCHWARTZ, RC			SYNERGY OF IL-7 AND V-HA-RAS IN THE IN-VITRO NEOPLASTIC PROGRESSION OF MURINE PRE-B CELLS	ONCOGENE			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; INOSITOL PHOSPHOLIPID TURNOVER; LEUKEMIA-VIRUS; LYMPHOID-CELLS; INTERLEUKIN-7; CONSTRUCTION; EXPRESSION; ONCOGENES; GROWTH; DIFFERENTIATION	A recombinant retrovirus expressing IL-7 was super-infected into a murine pre-B cell line previously infected with a retrovirus expressing v-Ha-ras. Populations of cells polyclonal for integration of the IL-7 virus and independent of IL-7 for growth were generated. These cells were highly tumorigenic. Similarly, co-infection of murine bone marrow with retroviruses expressing IL-7 and v-Ha-ras generated a pre-B lymphoid outgrowth that was tumorigenic. While IL-7 and v-Ha-ras expression are not individually sufficient to induce tumorigenicity, their co-expression yields highly tumorigenic pre-B lymphoid cell lines. IL-7 expression may be equivalent to v-myc expression for synergy with v-H-ras in the neoplastic transformation of murine pre-B cells.	MICHIGAN STATE UNIV,DEPT MIKROBIOL,E LANSING,MI 48824; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024	Michigan State University; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R29CA045360] Funding Source: NIH RePORTER; NCI NIH HHS [CA45360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHANG JM, 1989, BLOOD, V73, P1487; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEEKER TC, 1990, BLOOD, V76, P285; MORRISSEY PJ, 1989, J EXP MED, V169, P707, DOI 10.1084/jem.169.3.707; MUIRHEAD M, 1990, INT J CELL CLONING, V8, P392, DOI 10.1002/stem.5530080643; MUIRHEAD M, 1992, LYMPHOKINE CYTOK RES, V11, P167; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; OVERELL RW, 1991, MOL CELL BIOL, V11, P1590, DOI 10.1128/MCB.11.3.1590; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAVE N, 1979, NUCLEIC ACIDS RES, V6, P3559, DOI 10.1093/nar/6.11.3559; ROIFMAN CM, 1992, J IMMUNOL, V148, P1136; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHWARTZ RC, 1986, CURR TOP MICROBIOL, V132, P75; SCHWARTZ RC, 1981, J IMMUNOL, V126, P2104; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SCHWARTZ RC, 1988, MUTAT RES, V195, P245, DOI 10.1016/0165-1110(88)90003-6; SEIDMAN JG, 1978, NATURE, V276, P790, DOI 10.1038/276790a0; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WHITLOCK CA, 1983, CELL, V32, P903, DOI 10.1016/0092-8674(83)90075-2; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WONG PMC, 1989, MOL CELL BIOL, V9, P797; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	31	4	4	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2119	2125						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336938				2022-12-28	WOS:A1993LP17100012
J	SARKAR, S; GILMORE, TD				SARKAR, S; GILMORE, TD			TRANSFORMATION BY THE VREL ONCOPROTEIN REQUIRES SEQUENCES CARBOXY-TERMINAL TO THE REL HOMOLOGY DOMAIN	ONCOGENE			English	Article							NF-KAPPA-B; CHICKEN-EMBRYO FIBROBLASTS; VIRUS-STRAIN-T; V-REL; C-REL; RETICULOENDOTHELIOSIS VIRUS; SPLEEN-CELLS; TRANSCRIPTIONAL ACTIVATOR; ONCOGENIC TRANSFORMATION; CELLULAR PROTEINS	The vRel oncoprotein of the avian Rev-T retrovirus is a member of the Rel/NF-kappaB family of transcription factors. The highly conserved amino-terminal Rel Homology (RH) domain in these proteins is required for DNA binding, protein-protein interactions and nuclear localization, and many mutations within this domain abolish transformation by vRel. We demonstrate here that overexpression of the vRel RH domain alone is insufficient to induce transformation of chicken spleen cells, indicating that sequences from the nonconserved carboxy terminus are necessary for the vRel transforming function. Thererfore, we constructed and assayed several vRel mutants with deletions of carboxy-terminal sequences. These mutant vRel proteins did not transform spleen cells with equal efficiency, even though they were functionally similar by several other criteria. Our results demonstrate that there are two regions (aa 389 to 432 and aa 437 to 503) within the carboxy-terminal half of vRel that are important for transformation: mutant vRel proteins containing the RH domain and one or both of these carboxy-terminal regions can transform at roughly wild-type levels. Analysis of Gal4 fusion proteins containing carboxy-terminal sequences from the vRel mutants indicated that there is a correlation between the ability of these mutant proteins to transform avian spleen cells and their ability to activate transcription. These observations suggest that vRel induces malignant transformation by directly altering gene expression.	BOSTON UNIV,DEPT BIOL,5 CUMMINGTON ST,BOSTON,MA 02215	Boston University					NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GARSON K, 1990, ONCOGENE, V5, P1431; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	44	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2245	2252						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336947				2022-12-28	WOS:A1993LP17100026
J	SEGATTO, O; PELICCI, G; GIULI, S; DIGIESI, G; DIFIORE, PP; MCGLADE, J; PAWSON, T; PELICCI, PG				SEGATTO, O; PELICCI, G; GIULI, S; DIGIESI, G; DIFIORE, PP; MCGLADE, J; PAWSON, T; PELICCI, PG			SHC PRODUCTS ARE SUBSTRATES OF ERBB-2 KINASE	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; AUTOPHOSPHORYLATION SITES; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; EGF RECEPTOR; NEU ONCOGENE; HUMAN-BREAST; PROTEIN; PHOSPHORYLATION	The shc gene encodes three widely expressed proteins of 46, 52 and 66 kDa. Overexpression of p46shc and p52shc in NIH3T3 fibroblasts induces a tumorigenic phenotype. Shc products are phosphorylated on tyrosine by the activated epidermal growth factor receptor (EGFR) and become physically associated with EGFR via their SH2 domain. Thus Shc oncoproteins may play a role in mitogenic signal transduction. Here we report that Shc products are substrates also of the erbB-2 kinase and form complexes with the erbB-2 product in intact cells. In vitro, the bacterially expressed Shc SH2 domain is sufficient to reconstitute the high affinity Shc/erbB-2 interaction. The erbB-2 region required for Shc binding was narrowed down to the most COOH-terminal 179 residues of gp185erbB-2; within this region, phosphorylation of one or more of the erbB-2 autophosphorylation sites is required for Shc/gp185erbB-2 complex formation as well as optimal phosphorylation of Shc products by the erbB-2 kinase. Thus, Shc proteins may play a role in signal transduction by gp185erbB-2.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED 1, I-06100 PERUGIA, ITALY	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Perugia	SEGATTO, O (corresponding author), IST REGINA ELENA, CTR RIC SPERIMENTALE, IMMUNOL LAB, VIA MESSI ORO 156, I-00158 ROME, ITALY.		Pawson, Tony J/E-4578-2013; Pelicci, Giuliana/AAA-8921-2022; Di Fiore, Pier Paolo/K-2130-2012; Pelicci, Pier Giuseppe/AAL-6572-2020	Pelicci, Giuliana/0000-0003-0986-8255; Di Fiore, Pier Paolo/0000-0002-2252-0950; Segatto, Oreste/0000-0003-2561-1142				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JANCHILL JL, 1969, J VIROL, V4, P549; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOCH CA, 1991, SCIENCE, V252, P669; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHAVASHAIO H, 1989, EMBO J, V8, P159; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1992, ONCOGENE, V7, P1339; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	45	130	133	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2105	2112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8101647				2022-12-28	WOS:A1993LP17100010
J	JANES, PW; DALY, RJ; DEFAZIO, A; SUTHERLAND, RL				JANES, PW; DALY, RJ; DEFAZIO, A; SUTHERLAND, RL			ACTIVATION OF THE RAS SIGNALING PATHWAY IN HUMAN BREAST-CANCER CELLS OVEREXPRESSING ERBB-2	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-C-GAMMA; NIH 3T3 CELLS; EGF RECEPTOR; PROTO-ONCOGENE; SH2 DOMAIN; ADAPTER PROTEIN; OVARIAN-CANCER; TUMOR-CELLS	The c-erbB-2 proto-oncogene encodes a receptor tyrosine kinase (RTK) closely related to the epidermal growth factor receptor (EGFR). Overexpression of erbB-2 occurs in approximately 20% of human breast tumours, where increased expression correlates with poor patient prognosis. The EGFR is coupled to the Pas signalling pathway by interaction with the adaptor protein Grb2, and Sos, a Pas GDP-GTP exchange factor. In this study, activation of the erbB-2 receptor and its association with Grb2 and Sos was investigated in breast cancer cell lines which overexpress erbB-2. The receptor was found to be tyrosine phosphorylated in all cell lines in which it is overexpressed. Western blotting of Grb2 and Sos immuneprecipitates from such cells revealed co-precipitation of erbB-2, demonstrating association of the Grb2/Sos complex with erbB-2 in vivo. Furthermore, a fusion protein containing only the SH2 domain of Grb2 bound to erbB-2 immobilized on nitrocellulose, indicating that association with Grb2 is direct and mediated by the SH2 domain of Grb2. The degree of association between the erbB-2 receptor and Grb2 in vivo was related to erbB-2 overexpression, and MAP kinase, which functions downstream from Ras, displayed markedly increased activity in cell Lines overexpressing erbB-2. These results demonstrate that erbB-2 is coupled to Pas signalling via the Grb2/Sos complex, and that overexpression of this receptor in breast cancer cells leads to amplification of the Ras signalling pathway.	ST VINCENTS HOSP, GARVAN INST MED RES, DIV CANC BIOL, DARLINGHURST, NSW 2010, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Sutherland, Robert L/A-8378-2008; DeFazio, Anna/O-2385-2019; Daly, Roger J/C-8179-2009; deFazio, Anna/D-3939-2013	DeFazio, Anna/0000-0003-0057-4744; deFazio, Anna/0000-0003-0057-4744; Daly, Roger/0000-0002-5739-8027				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BERCHUCK A, 1990, CANCER RES, V50, P4087; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DALY RJ, 1994, IN PRESS ONCOGENE; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULLICK WJ, 1990, INT J CANCER, P55; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JALLAL B, 1992, J BIOL CHEM, V267, P4357; KAMEDA T, 1990, CANCER RES, V50, P8002; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEGATTO O, 1993, ONCOGENE, V8, P2105; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WARE JL, 1991, HUM PATHOL, V22, P254, DOI 10.1016/0046-8177(91)90159-M; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	196	207	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3601	3608						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970720				2022-12-28	WOS:A1994PT39200023
J	JANS, DA; JANS, P				JANS, DA; JANS, P			NEGATIVE CHARGE AT THE CASEIN KINASE-II SITE FLANKING THE NUCLEAR-LOCALIZATION SIGNAL OF THE SV40 LARGE T-ANTIGEN IS MECHANISTICALLY IMPORTANT FOR ENHANCED NUCLEAR IMPORT	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; RENAL EPITHELIAL-CELLS; DNA-BINDING ACTIVITY; NF-KAPPA-B; PHOSPHORYLATION SITES; CATALYTIC SUBUNIT; GENE-PRODUCT; VASOPRESSIN V2-RECEPTOR; BETA-GALACTOSIDASE	Nuclear import of SV40 large T-antigen (T-ag) is completely dependent on the T-ag nuclear localization sequence (amino acids 126-132), but the rate of nuclear import is greatly increased by the additional presence of the N-terminal flanking sequence (amino acids 111-125), which includes a site for casein kinase II (CKII) (Ser(111/112)). The role of this site was investigated by site-directed mutagenesis and analysis of the effects on phosphorylation and on nuclear import at the single cell level using microinjection and quantitative fluorescent techniques. Removal of the CKII site either by substitution of S-111/112 by nonphosphorylatable amino acid residues, or mutation of the Asp-Asp-Glu(113/115) CKII recognition sequence to Asn-Asn-Gln, resulted in nuclear import rates less than 4% wild type, demonstrating that the CKII site was responsible for the enhancement of nuclear import conferred by T-ag amino acids 111-125. The substitution of Asp for Ser(112), the serine preferentially phosphorylated by purified CKII, enhanced nuclear import to about 45% maximal wild type rates. It is concluded that negative charge at the CKII site, normally provided by phosphorylation, is mechanistically important for nuclear transport enhancement. There was no evidence or a direct role for phosphatases or dephosphorylation in the transport process.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOLEC BIOL, CANBERRA, ACT 2601, AUSTRALIA	Australian National University; John Curtin School of Medical Research	JANS, DA (corresponding author), MAX PLANCK INST BIOPHYS, W-6000 FRANKFURT, GERMANY.							ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ADAM S, 1989, NATURE, V227, P276; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BOTTERELL SH, 1987, EUR J BIOCHEM, V164, P39, DOI 10.1111/j.1432-1033.1987.tb10989.x; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GRZIWA A, 1992, J STRUCT BIOL, V109, P168, DOI 10.1016/1047-8477(92)90048-F; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; JANS DA, 1989, EMBO J, V8, P2481, DOI 10.1002/j.1460-2075.1989.tb08384.x; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; JANS DA, 1991, J CELL BIOL, V114, P53, DOI 10.1083/jcb.114.1.53; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JANS DA, 1992, BIOCHIM BIOPHYS ACTA, V1113, P271, DOI 10.1016/0304-4157(92)90001-Q; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KALDERON D, 1984, NATURE, V311, P499; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEE H Y, 1991, Korean Journal of Genetics, V13, P1; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MOLL T, 1991, CELL, V66, P1; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PEARSON D, 1991, EXP CELL RES, V192, P315, DOI 10.1016/0014-4827(91)90193-X; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RIHS HP, 1989, THESIS U GIESSEN GIE; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUSHLOW CA, 1989, CELL, V59, P1167; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDTMANN KH, 1986, VIROLOGY, V150, P85, DOI 10.1016/0042-6822(86)90268-0; SCHEIDTMANN KH, 1991, J VIROL, V65, P2098, DOI 10.1128/JVI.65.4.2098-2101.1991; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; TANAKA K, 1992, NEW BIOL, V4, P173; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; YONEDA Y, 1988, SCIENCE, V242, P275, DOI 10.1126/science.3051382	65	89	90	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2961	2968						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084599				2022-12-28	WOS:A1994PG82200022
J	SAVOYSKY, E; MIZUNO, T; SOWA, Y; WATANABE, H; SAWADA, J; NOMURA, H; OHSUGI, Y; HANDA, H; SAKAI, T				SAVOYSKY, E; MIZUNO, T; SOWA, Y; WATANABE, H; SAWADA, J; NOMURA, H; OHSUGI, Y; HANDA, H; SAKAI, T			THE RETINOBLASTOMA BINDING-FACTOR-1 (RBF-1) SITE IN RB GENE PROMOTER BINDS PREFERENTIALLY E4TF1, A MEMBER OF THE ETS TRANSCRIPTION FACTORS FAMILY	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; DNA-BINDING; AFFINITY PURIFICATION; C-FOS; PROTEIN; EXPRESSION; SEQUENCE; DIFFERENTIATION; ACTIVATION; ONCOGENE	The tumor suppressor retinoblastoma gene product, pRB, is a well known regulator of G1/S cell cycle progression. Moreover, mutational inactivations within the retinoblastoma gene (RB) are found in many human malignant tumors, and thus, believed to be an essential step in tumor formation. The human RB gene is considered as a housekeeping gene with no characteristic TATA or CAAT elements in its promoter region, but the sequence between 206 and 185 bases upstream of the initiation codon, essential for RB promoter activity, contains putative Sp1 and ATF recognition sites. We have previously reported that point mutations in this region, causing low penetrance retinoblastomas, completely reduced RB promoter activity, and that a nuclear factor, named RBF-1 (retinoblastoma binding factor 1), could specifically bind to this sequence, overlapping Sp1 recognition sequence. We show here, that RBF-1 can recognize a specific DNA sequence, 5'-GGCGGAAGT-3', overlapping the Sp1 and ATF sites and corresponding to the consensus DNA binding site for members of Ets transcription factors family. When RBF-1 site was used for sequence specific DNA affinity purification from erythroleukemia cells, reconstitution assays, immunoblotting analysis and peptide mapping show that the two major co-purified proteins are identical to human E4TF1-60 and -53 proteins. This reveals that E4TF1 can bind to the RBF-1 site of RB gene promoter, which, thus, constitutes a new target for this member of Ets transcription factors family.	KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; CHUGAI PHARMACEUT CO LTD,FUJI GOTEMBA RES LABS,GOTEMBA,SHIZUOKA 412,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	Kyoto Prefectural University of Medicine; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Tokyo Institute of Technology								BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; FISHER RJ, 1991, ONCOGENE, V6, P2249; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GABRIELSEN OS, 1989, NUCLEIC ACIDS RES, V17, P6253, DOI 10.1093/nar/17.15.6253; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MURAKAMI K, 1993, ONCOGENE, V8, P1559; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SLACK RS, 1993, ONCOGENE, V8, P1585; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATANABE H, 1988, MOL CELL BIOL, V8, P190; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343	41	45	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1839	1846						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208529				2022-12-28	WOS:A1994NR68500005
J	WILLIAMS, AC; BROWNE, SJ; MANNING, AM; DAFFADA, P; COLLARD, TJ; PARASKEVA, C				WILLIAMS, AC; BROWNE, SJ; MANNING, AM; DAFFADA, P; COLLARD, TJ; PARASKEVA, C			TRANSFECTION AND EXPRESSION OF MUTANT P53 PROTEIN DOES NOT ALTER THE IN-VIVO OR IN-VITRO GROWTH-CHARACTERISTICS OF THE AA/C1 HUMAN ADENOMA DERIVED CELL-LINE, INCLUDING SENSITIVITY TO TRANSFORMING GROWTH-FACTOR-BETA-1	ONCOGENE			English	Note							WILD-TYPE P53; POLYPOSIS COLI PATIENTS; GENE-MUTATIONS; CANCER CELLS; COLORECTAL-CANCER; SUPPRESSES GROWTH; RAS; CARCINOMAS; PROMOTER; INVITRO	Mutation of the p53 gene is thought to be a late event in human colorectal carcinogenesis, involved in the malignant conversion of the adenoma to the carcinoma. One of the questions that we hoped to address was whether, in vivo, a single mutational event in one p53 gene is sufficient to confer a significant growth advantage on a colonic epithelial cell. Such a growth advantage could result either from an increase in growth rate and/or loss of response to inhibitory growth signals naturally present in the colonic crypt. We therefore introduced the pC53-SCX3 143 (Val-Ala) p53 mutation into a non tumorigenic adenoma derived cell line, AA/C1, which contained a truncating APC mutation, activating K-ras mutation but was wild-type for the p53 protein. High levels of mutant p53 protein were detected in the pC53-SCX3 transfected AA/C1 cell lines but was found not to affect either the in vitro (colony forming efficiency, anchorage independence) or in vivo (tumorigenicity in nude mice) growth, when compared to vector control or the parental AA/C1 cell line. In addition, to test whether the cells become less sensitive to inhibitory growth factors, the response of the cell lines to the naturally occurring growth inhibitor TGF beta was also investigated. Even though TGF beta had previously been implicated in the control of growth of intestinal epithelium, expression of the mutant p53 protein did not affect the sensitivity of the parental AA/C1 cell line to TGF beta. Under the experimental conditions tested expression of the 143 (Val-Ala) p53 protein was unable to affect the in vitro or in vivo growth characteristics of the adenoma derived AA/C1 cell line. When compared to other studies, these results suggest that the genetic background of the individual recipient cell may greatly influence the effect of expression of a particular p53 mutation.			WILLIAMS, AC (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,CRC,COLORECTAL TUMOUR BIOL RES GRP,UNIV WALK,BRISTOL BS8 1TD,ENGLAND.			Williams, Ann/0000-0002-6009-7137				AVERY A, 1993, BRIT J CANCER, V68, P137, DOI 10.1038/bjc.1993.301; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BODNER SM, 1992, ONCOGENE, V7, P743; CAJOT JF, 1992, CANCER RES, V52, P6956; CARDER P, 1993, ONCOGENE, V8, P1397; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; ISAACS WB, 1991, CANCER RES, V51, P4716; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LEIBOVITZ A, 1976, CANCER RES, V36, P3562; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MANNING AM, 1991, ONCOGENE, V6, P1471; MATOZAKI T, 1992, CANCER RES, V52, P4335; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARASKEVA C, 1988, INT J CANCER, V41, P908; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; REISS M, 1993, CANCER RES, V53, P899; RIDGWAY PJ, 1993, ONCOGENE, V8, P1069; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TAKAHASHI K, 1992, JPN J CANCER RES, V83, P358, DOI 10.1111/j.1349-7006.1992.tb00115.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WHITEHEAD RH, 1991, INT J CANCER, V48, P693, DOI 10.1002/ijc.2910480511; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; WILLIAMS AC, 1992, INT J CANCER, V52, P785, DOI 10.1002/ijc.2910520519; WILLSON JKV, 1987, CANCER RES, V47, P2704; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WUYLLIE FS, 1993, MOL CARCINOGEN, V7, P83; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	52	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1479	1485						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152811				2022-12-28	WOS:A1994NH40100022
J	JORDAN, KL; HAAS, AR; LOGAN, TJ; HALL, DJ				JORDAN, KL; HAAS, AR; LOGAN, TJ; HALL, DJ			DETAILED ANALYSIS OF THE BASIC DOMAIN OF THE E2F1 TRANSCRIPTION FACTOR INDICATES THAT IT IS UNIQUE AMONG BHLH PROTEINS	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; LEUCINE ZIPPER; MINOR GROOVE; CYCLIN-A; C-MYC; HELIX; DIMERIZATION; COMPLEX; BOX; SPECIFICITY	The E2F1 transcription factor binds to sites within the promoters of a number of cell cycle regulated genes through a basic-helix-loop-helix motif (bHLH). It is shown here that the basic region of E2F1 is distinct from that of all other bHLH proteins. The center of the basic region contains a helix breaking proline-glycine pair, (P122, G123), implying a turn within this region. This is in contrast to the known bHLH containing proteins where the basic region is alpha-helical. Substitution of P122 and G123 with alanines results in a significant reduction in DNA binding levels, with the predicted formation of an alpha-helix. Also in contrast to other bHLH proteins, mutations generated in conserved basic residues of E2F1 do not effect DNA binding. In addition, a single leucine (191) between helix no. 2 and the leucine zipper is required for DNA binding while the leucine zipper itself is not necessary. Finally, E2F1 interacts with ail of the G-residues in the sequence GGCGG-GAAA while the A-residues are not required for DNA binding. The uniqueness of the E2F1 DNA binding domain is likely to play a role in its binding a DNA site that is distinct from that of all other bHLH proteins (CACGTG).	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,233 S 10TH ST,PHILADELPHIA,PA 19107	Jefferson University			Jordan-Sciutto, Kelly L/A-1046-2007		NCI NIH HHS [CA51170] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051170] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HALL DJ, 1990, ONCOGENE, V5, P47; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES N, 1992, CELL, V70, P351; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEVINS JR, 1992, SCIENCE, V258, P424; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722	34	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1177	1185						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134120				2022-12-28	WOS:A1994NC04800021
J	LERHUN, Y; DUTHU, A; EHRHART, JC; MICHIELS, F; MAY, E; MAY, P				LERHUN, Y; DUTHU, A; EHRHART, JC; MICHIELS, F; MAY, E; MAY, P			DIRECTIONAL SELECTION ASSOCIATED WITH CLONAL EXPANSION OF P53 MUTANT-CELLS DURING NEOPLASTIC DEVELOPMENT OF CARCINOGEN-TREATED RAT EMBRYO LUNG EPITHELIAL-CELLS	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; HEAT-SHOCK PROTEINS; SV40-TRANSFORMED CELLS; SUPPRESSOR GENE; CYCLE CONTROL; TRANSFORMATION; MUTATIONS; ONCOGENE; SEQUENCE	In this study, rat embryo lung organ cultures were exposed to benzo[a]pyrene (B[a]P). After carcinogen-treatment the cells were dissociated and an epithelial cell line (BP) was developed from the primary cell culture derived from the carcinogen-treated explants. Investigations were performed on the sequential changes occurring in the course of neoplastic progression of BP cells and in the tumor cells that arose in vivo from implanted BP cells. During the neoplastic progression a mutation was shown to occur in p53 gene at codon 130 (AAG > AGG; Lys > Arg) in a single cell which expanded and gave rise to a predominant subpopulation. This mutational event was already detected at passage 14 but was probably not a direct consequence of a specific alteration caused by the carcinogen in the target cell. This mutation was retained through the subsequent progressional steps first as a heterozygous mutation, then converted to a homozygous state. From passage 18 on, it was possible in BP cell. cultures to detect foci of larger morphologically distinct cells emerging on a background of cells maintaining the original morphology. These foci were shown to derive from a single cell carrying the p53 mutation in a homozygous state. During the neoplastic progression the mutant p53 allele frequency steadily increased and this mutant allele eventually came to predominate completely in the late stages of the neoplastic progression, including in the transplantation-induced tumors. The pattern of a directional selection for mutant p53 gene towards fixation is probably applicable to a wide range of human malignancies and may reflect the particular importance of this gene for tumorigenesis.	IRSC,ONCOL MOLEC LAB,CNRS,F-94801 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS)								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTKOVA J, 1993, EUR J CANCER, V29A, P881, DOI 10.1016/S0959-8049(05)80431-9; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; EHRHART JC, 1988, ONCOGENE, V3, P595; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUJIMOTO K, 1992, CANCER RES, V52, P1393; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JONES PA, 1991, CANCER RES, V51, P3617; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LILLEBERG SL, 1992, MOL CARCINOGEN, V6, P159, DOI 10.1002/mc.2940060211; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAKINO H, 1992, P NATL ACAD SCI USA, V89, P4850, DOI 10.1073/pnas.89.11.4850; MANIATIS T, 1982, MOL CLONING LABORATO, P368; MERCER WE, 1990, ONCOGENE, V5, P973; MICHIELS F, 1981, CARCINOGENESIS, V2, P885, DOI 10.1093/carcin/2.9.885; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROTHFELS KH, 1958, STAIN TECHNOL, V33, P73, DOI 10.3109/10520295809111827; RUGGERI B, 1993, P NATL ACAD SCI USA, V90, P1013, DOI 10.1073/pnas.90.3.1013; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1993, CARCINOGENESIS, V14, P503, DOI 10.1093/carcin/14.3.503; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STURZBECHER HW, 1990, ONCOGENE, V5, P795; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	63	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					263	271						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302588				2022-12-28	WOS:A1994MW24700032
J	ROSS, IL; DUNN, TL; YUE, X; ROY, S; BARNETT, CJK; HUME, DA				ROSS, IL; DUNN, TL; YUE, X; ROY, S; BARNETT, CJK; HUME, DA			COMPARISON OF THE EXPRESSION AND FUNCTION OF THE TRANSCRIPTION FACTOR PU.1 (SPI-1 PROTOONCOGENE) BETWEEN MURINE MACROPHAGES AND B-LYMPHOCYTES	ONCOGENE			English	Article							HEAVY-CHAIN GENE; CELL-LINE; NUCLEAR FACTOR; ENHANCER; ACTIVATION; IDENTIFICATION; INVOLVEMENT; TUMOR	The expression of mRNA encoding the DNA-binding protein PU.1(Spi-1) is restricted to B lymphocytes and macrophages. The role of PU.1 in tissue-specific transcriptional regulation in the two cell types was examined by co-transfection of a PU.1 expression plasmid with vectors containing B cell (IgH enhancer) or macrophage-specific (c-fms) transcription control elements. Cotransfection of the PU.1 expression plasmid in MOPC31C B cells trans-repressed the IgH enhancer but trans-activated the c-fms promoter. The latter was insufficient to overcome a block to transcription elongation that determines macrophage-specific c-fms gene expression. In the macrophage line RAW264, PU.1 had no effect on the c-fms promoter, but trans-repressed the activity of a c-fms reporter plasmid containing the transcription attenuator. The effects of PU.1 in both cell types were distinct from those of c-ets-2, a related factor, which trans-activated the c-fms promoter in both B cells and macrophages but also repressed the IgH enhancer. PU.1 was shown to be one of several nuclear proteins that bound a critical cis-acting element of the IgH enhancer, mu B, but analysis of nuclear extracts of a wide range of B cell and macrophage lines demonstrated a strong correlation between macrophage phenotype and nuclear PU.1 expression. The data suggest that differences in nuclear PU.1 expression and function between macrophages and B cells may play a role in lineage divergence.	UNIV QUEENSLAND,CTR MOLEC BIOL & BIOTECHNOL,ST LUCIA,QLD 4072,AUSTRALIA	University of Queensland			Ross, Ian/A-8622-2011; Hume, David A/C-7695-2013	Ross, Ian/0000-0002-2389-4292; Hume, David/0000-0002-2615-1478				ARAKI K, 1988, CELL, V53, P723, DOI 10.1016/0092-8674(88)90090-6; BAUER SR, 1986, J IMMUNOL, V136, P4695; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BOYD AW, 1982, NATURE, V297, P691, DOI 10.1038/297691a0; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DAVIDSON WF, 1988, J EXP MED, V168, P1293; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FISHER CL, 1991, J IMMUNOL, V146, P1743; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; HUME DA, 1989, IMMUNOL CELL BIOL, V67, P243, DOI 10.1038/icb.1989.37; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAUL HL, 1993, J BIOL CHEM, V268, P5014; PETERSSON M, 1987, GENE DEV, V1, P962; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; Sambrook J., 1989, MOL CLONING; SCHEUTZE S, 1992, MOL CELL BIOL, V12, P2967; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; YUE X, 1993, BRIT J HAEMATOL, V84, P392	31	63	63	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					121	132						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302571				2022-12-28	WOS:A1994MW24700015
J	TONISSEN, KF; KRIEG, PA				TONISSEN, KF; KRIEG, PA			ANALYSIS OF A VARIANT MAX SEQUENCE EXPRESSED IN XENOPUS-LAEVIS	ONCOGENE			English	Article							C-MYC; DNA-BINDING; RAS COTRANSFORMATION; TRANSCRIPTION; PROTEIN; REQUIRES; ONCOGENE; CELLS; FORMS	Max is a small helix-loop-helix protein which forms heterodimers with members of the Myc protein family. Myc/Max heterodimers exhibit sequence-specific DNA binding with much greater affinity than Myc homodimers. The Xenopus laevis homologue of Max, XMax, is shorter than the equivalent mammalian protein. This difference results from the deletion of a 24 amino acid sequence located near the C-terminus of the protein. Xenopus max transcripts undergo alternative splicing. In addition to the 27 base alternatively spliced sequence (exon A) previously detected in mice and humans, some Xmax transcripts also contain an 81 base sequence (exon B) at a second site within the coding sequence. Although exon B insertion alters part of the leucine zipper protein/protein interaction domain, the resulting XMax protein retains the ability to form stable heterodimers with both c-Myc acid N-Myc. Xmax mRNA is present at approximately constant levels during early development. This contrasts with the rapidly changing levels of c-myc and N-myc mRNA in the embryo and has implications for regulation of gene expression during differentiation. All four alternatively spliced forms of Xmax mRNA are present during development and in all adult tissue examined.	UNIV TEXAS,CTR DEV BIOL,DEPT ZOOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin			Tonissen, Kathryn F/E-9424-2010	Tonissen, Kathryn F/0000-0002-1018-2798	NICHD NIH HHS [HD25179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025179] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Battey, 1986, BASIC METHODS MOL BI; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DEAN M, 1986, J BIOL CHEM, V261, P9161; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; GERHART JG, 1980, MECHANISMS REGULATIN, P133; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HOURDRY J, 1988, DEVELOPMENT, V104, P631; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MELTON DA, 1979, CELL, V18, P1165, DOI 10.1016/0092-8674(79)90229-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VASTRIK I, 1993, ONCOGENE, V8, P503; VIZE PD, 1990, DEVELOPMENT, V110, P885	30	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					33	38						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302600				2022-12-28	WOS:A1994MW24700005
J	HILDT, E; URBAN, S; LAUER, U; HOFSCHNEIDER, PH; KEKULE, AS				HILDT, E; URBAN, S; LAUER, U; HOFSCHNEIDER, PH; KEKULE, AS			ER-LOCALIZATION AND FUNCTIONAL EXPRESSION OF THE HBV TRANSACTIVATOR MHBS(T)	ONCOGENE			English	Article							HEPATITIS-B-VIRUS; HUMAN HEPATOCELLULAR-CARCINOMA; TRANSCRIPTIONAL TRANSACTIVATOR; NUCLEOTIDE-SEQUENCE; SURFACE-ANTIGEN; DNA; REGION; INTEGRATION	In two recently reported cases, integrated hepatitis B virus (HBV) DNAs cloned from hepatocellular carcinoma were found to express a transcriptional transactivator from 3'-terminally truncated HBV surface (preS/S) genes. In this study, we characterized the transactivator at the protein level. Expression of a 3'-truncated preS2/S gene in Spodoptera frugiperda (Sf9) insect cells resulted in a C-terminally truncated middle surface protein of 76 amino acids (MHBs(t76)), which was found to be associated with membranes of the endoplasmic reticulum and retained from Golgi processing and secretion, Accordingly, the microsome fraction of MHBs(t76)-expressing Sf9 cells displayed transactivator activity after electric field-mediated transfer into Chang liver cells. In contrast to full-length MHBs, MHBs(t76) is unglycosylated, and glycosylation is not required for transactivation as shown by mutation of the glycosylation site at asparagine-4. Since highly purified MHBs(t76) derived from an E. coli expression system also showed transactivator activity, it is concluded that unglycosylated MHBs(t76) protein is the authentic transactivating factor. As the transactivator protein derives from inactive MHbs by rearrangements of integrated HBV DNA, it may be important for HBV-associated liver carcinogenesis.			HILDT, E (corresponding author), MAX PLANCK INST BIOCHEM, DEPT VIRUS RES, D-82152 MARTINSRIED, GERMANY.		Hildt, Eberhard/A-1040-2015					BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; EBLE BE, 1990, J VIROL, V64, P1414, DOI 10.1128/JVI.64.3.1414-1419.1990; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GANEM D, 1991, CURR TOP MICROBIOL, V168, P61; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARTELSCHENK S, 1991, BIOCHIM BIOPHYS ACTA, V1115, P108, DOI 10.1016/0304-4165(91)90019-D; Heermann KH, 1991, MOL BIOL HEPATITIS B, P109; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; MATSUBARA K, 1991, MOL BIOL HEPATITIS B, P245; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; MIMMS LT, 1990, VIROLOGY, V176, P604, DOI 10.1016/0042-6822(90)90031-L; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NATOLI G, 1992, VIROLOGY, V187, P663, DOI 10.1016/0042-6822(92)90469-6; NEURATH AR, 1987, MOL IMMUNOL, V24, P975, DOI 10.1016/0161-5890(87)90009-5; OZOLS J, 1990, METHOD ENZYMOL, V182, P225; SAMBROOK J, 1989, MOL CLONING LABORATO, P1402; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLUTER V, 1992, UNPUB J CLIN INVEST; SCULLY LJ, 1988, VIRAL HEPATITIS LIVE, P365; SHERKER AH, 1991, ANNU REV MICROBIOL, V45, P475; Summers MD, 1987, MANUAL METHODS BACUL; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WILL H, 1985, P NATL ACAD SCI USA, V82, P891, DOI 10.1073/pnas.82.3.891	31	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3359	3367						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247538				2022-12-28	WOS:A1993MG78200020
J	SKINNER, A; HURST, HC				SKINNER, A; HURST, HC			TRANSCRIPTIONAL REGULATION OF THE C-ERBB-3 GENE IN HUMAN BREAST-CARCINOMA CELL-LINES	ONCOGENE			English	Article							OVEREXPRESSION; AMPLIFICATION; MECHANISMS; EXPRESSION; PROMOTER; ONCOGENE; MEMBER; FAMILY; CANCER; ERBB3	The c-erbB-3 gene is a member of the EGF receptor family of membrane tyrosine kinases. Previous work has shown that the expression of this gene is frequently unregulated in human breast carcinoma-derived cell lines and in tumour biopsy material. As there is no evidence of gene amplification, we decided to examine the control of c-erbB-3 transcription in overexpressing cells. In this paper we describe the cloning of the c-erbB-3 promoter and its functional analysis within mammary-derived cell lines. We show that the promoter is more active in overexpressing cells and this is largely due to the action of the OB2-1 transcription factor which we have recently identified as mediating overexpression of the c-erbB-2 promoter in similar cell lines.	HAMMERSMITH HOSP,RPMS,ICRF,ONCOL GRP,GENE TRANSCRIPT LAB,LONDON W12 0HS,ENGLAND	Imperial College London								Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HURST HC, 1991, METHOD MOL BIOL, V8, P141; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; Maniatis T, 1989, DECONTAMINATION DILU; Merlino G T, 1990, Semin Cancer Biol, V1, P277; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597	19	37	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3393	3401						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247542				2022-12-28	WOS:A1993MG78200024
J	HEVEZI, P; ALIN, K; GOFF, SP				HEVEZI, P; ALIN, K; GOFF, SP			TRANSFORMING ACTIVITY AND TISSUE TROPISM OF HYBRID RETROVIRAL GENOMES CONTAINING PORTIONS OF THE V-ABL AND V-SRC ONCOGENES	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; ROUS-SARCOMA VIRUS; AMINO-TERMINAL DOMAIN; CELL TRANSFORMATION; HOMOLOGY REGION-2; TYROSINE KINASE; LYMPHOID-CELLS; INVITRO TRANSFORMATION; SIGNAL TRANSDUCTION; SH3 DOMAINS	The v-abl and v-src oncogenes encode activated cytoplasmic tyrosine kinases with considerable sequence similarity. The v-abl oncogene of the Abelson murine leukemia virus exhibits a narrow tissue tropism for transformation, almost exclusively forming pre-B-cell tumors, while the v-src oncogene can induce a variety of sarcomas and other tumors. To localize the determinants of the narrow tropism of the v-abl gene, we generated a series of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes in a Moloney murine leukemia virus backbone. Each virus was tested for transforming activity in NIH3T3 cells; for transforming activity on bone marrow cultures; and for pathogenicity in newborn mice. Many of the hybrid oncogenes carried by these viruses exhibited transforming activity, and demonstrate that the SH2 domain of each oncogene can be utilized by the kinase domain of the other oncogene for that activity. The results further suggest that a portion of the C-terminal region of v-abl is necessary for the pre-B-cell specificity of the oncogene.	COLUMBIA UNIV,DEPT MICROBIOL,NEW YORK,NY 10032	Columbia University								ABELSON HT, 1970, CANCER RES, V30, P2213; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; BALTIMORE D, 1979, IMMUNOL REV, V48, P3, DOI 10.1111/j.1600-065X.1979.tb00296.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHESTERMAN FC, 1966, CANCER RES, V26, P1759; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; FEUERMAN MH, 1985, J VIROL, V54, P804, DOI 10.1128/JVI.54.3.804-816.1985; FEUERMAN MH, 1988, MOL CARCINOGEN, V1, P57, DOI 10.1002/mc.2940010112; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; HEVEZI P, 1991, J VIROL, V65, P5333, DOI 10.1128/JVI.65.10.5333-5341.1991; HEVEZI P, 1992, ONCOGENE, V7, P2323; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARDON G, 1983, CELL, V32, P871, DOI 10.1016/0092-8674(83)90072-7; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; PARMAR K, 1991, J VIROL, V65, P6478, DOI 10.1128/JVI.65.12.6478-6485.1991; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P80; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; PIERCE JH, 1984, P NATL ACAD SCI-BIOL, V81, P2374, DOI 10.1073/pnas.81.8.2374; Potts W M, 1988, Oncogene Res, V3, P343; PRATT DM, 1977, CELL, V12, P683, DOI 10.1016/0092-8674(77)90268-9; PRIVALSKY ML, 1987, J VIROL, V61, P1938, DOI 10.1128/JVI.61.6.1938-1948.1987; PRYWES R, 1985, J VIROL, V54, P123, DOI 10.1128/JVI.54.1.123-132.1985; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REESJONES RW, 1988, J VIROL, V62, P978, DOI 10.1128/JVI.62.3.978-986.1988; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROSENBERG N, 1980, VIRAL ONCOLOGY, P187; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WANG LH, 1988, VIRUS RES, V9, P159; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WILKERSON VW, 1985, J VIROL, V55, P314, DOI 10.1128/JVI.55.2.314-321.1985; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807	57	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2413	2423						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361756				2022-12-28	WOS:A1993LT36800012
J	TENHOEVE, J; MORRIS, C; HEISTERKAMP, N; GROFFEN, J				TENHOEVE, J; MORRIS, C; HEISTERKAMP, N; GROFFEN, J			ISOLATION AND CHROMOSOMAL LOCALIZATION OF CRKL, A HUMAN CRK-LIKE GENE	ONCOGENE			English	Article							INTERPHASE CELL-NUCLEI; SH3 DOMAINS; GENOMIC DISTANCE; DNA-SEQUENCES; NCK PROTEIN; PHOSPHORYLATION; RECEPTORS; LEUKEMIA; BCR	We have identified and partially characterized a gene located on chromosome 22, band q11, centromeric of the chronic myelogenous leukemia breakpoint region. A number of overlapping cDNAs were isolated from this locus and the largest of 1.8 kb was sequenced. Its deduced amino acid sequence shows homology to the SH2 domains of protein tyrosine kinases such as FER. and is strikingly similar to the cellular part of the v-crk oncogene product. We identified one SH2 and two SH3 domains within the 303 amino acid open reading frame of this crk-like gene, CRKL. The CRKL gene product is predicted to have a molecular mass of 36 kDa. In addition, we demonstrate that this gene does not represent the human homolog of v-crk but rather a novel gene potentially capable of mediating the transduction of intracellular signals.	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAG SECT,4650 SUNSET BLVD,LOS ANGELES,CA 90027; CHRISTCHURCH HOSP,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND	Children's Hospital Los Angeles; Christchurch Hospital New Zealand			Morris, Christine/G-1690-2011; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R01CA047456] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA 47456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER SR, 1988, IMMUNOGENETICS, V28, P328, DOI 10.1007/BF00364231; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; HEISTERKAMP N, 1983, Journal of Molecular and Applied Genetics, V2, P57; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P8045, DOI 10.1093/nar/16.16.8045; HEITER PA, 1981, NATURE, V294, P536; KAPLAN JC, 1987, J MED GENET, V24, P65, DOI 10.1136/jmg.24.2.65; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORRIS C, 1993, HUM GENET, V91, P31, DOI 10.1007/BF00230218; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; TRASK BJ, 1991, AM J HUM GENET, V48, P1; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; Williams Lewis T., 1992, Current Biology, V2, P601, DOI 10.1016/0960-9822(92)90169-B	28	204	208	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2469	2474						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361759				2022-12-28	WOS:A1993LT36800018
J	VANAMSTERDAM, JR; WANG, Y; SULLIVAN, RC; ZARBL, H				VANAMSTERDAM, JR; WANG, Y; SULLIVAN, RC; ZARBL, H			ELEVATED EXPRESSION OF THE JUNB PROTOONCOGENE IS ESSENTIAL FOR V-FOS INDUCED TRANSFORMATION OF RAT-1 CELLS	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; C-JUN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; NEGATIVE REGULATOR; MOLECULAR-CLONING; MOUSE FIBROBLASTS; LEUCINE ZIPPER; GENE; AP-1	We previously described the isolation of non-tumorigenic revertants from mutagenized populations of v-fos-transformed Rat-1 cells (Zarbl et al., 1987). In the present study we examined the possibility that the revertant phenotype resulted from mutations that altered the expression or activities of the c-jun or junB protooncogenes. The results demonstrated that levels of the c-jun mRNA and protein were unchanged in the revertants when compared to the transformed parental cells, and ectopic overexpression of c-jun failed to retransform the revertants. Although one mutant allele was detected in revertant EMS-1-19, overexpression of this mutant allele failed to inhibit v-fos induced cell transformation. Together these results indicated that the revertant phenotype did not result from altered expression or mutations in the c-jun gene. In contrast to the results obtained with c-jun, the levels of junB mRNA and protein were found to be reduced two- or threefold in revertant EMS-1-19. Ectopic overexpression of junB induced transformation of revertant EMS-1-19, but failed to transform Rat-1 cells. Moreover, about 10% of v-fos transformed cells transfected with vectors that express antisense junB mRNA acquired a non-transformed phenotype. Together these results indicate that expression of junB above a threshold level is essential for v-fos-induced transformation of Rat-1 fibroblasts.	MIT, WHITAKER COLL HLTH SCI & TECHNOL, DIV TOXICOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA047571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007020] Funding Source: NIH RePORTER; NCI NIH HHS [CA47571] Funding Source: Medline; NIEHS NIH HHS [2-T32-ES07020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLAN MO, 1991, J CELL BIOCHEM, V46, P199, DOI 10.1002/jcb.240460303; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KHO CJ, 1992, P NATL ACAD SCI USA, V89, P2200, DOI 10.1073/pnas.89.6.2200; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OKUNO H, 1991, ONCOGENE, V6, P1491; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	43	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2969	2976						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084600				2022-12-28	WOS:A1994PG82200023
J	LIU, XH; GE, RW; WESTMORELAND, S; COONEY, AJ; TSAI, SY; TSAI, MJ; RICCIARDI, RP				LIU, XH; GE, RW; WESTMORELAND, S; COONEY, AJ; TSAI, SY; TSAI, MJ; RICCIARDI, RP			NEGATIVE REGULATION BY THE R2 ELEMENT OF THE MHC CLASS-I ENHANCER IN ADENOVIRUS-12 TRANSFORMED-CELLS CORRELATES WITH HIGH-LEVELS OF COUP-TF BINDING	ONCOGENE			English	Article							PROMOTER-TRANSCRIPTION FACTOR; RETINOID-X-RECEPTOR; HORMONE RECEPTOR; ORPHAN RECEPTORS; THYROID-HORMONE; RAT-CELLS; RESPONSE ELEMENT; GENE-EXPRESSION; ACID RECEPTORS; DNA-BINDING	The transcriptional down-regulation of the major histocompatibility complex (MHC) class I antigens in adenovirus type 12 (Ad12) transformed cells gives them the potential to escape immunosurveillance and to form tumors. The enhancer of the class I promoter is the target of transcriptional repression which is mediated by the E1A gene of Ad12. The R2 region within the class I enhancer acts as a negative element in Ad12-transformed cells and exhibits a stronger binding activity than is observed in nontumorigenic Ad5-transformed cells, which are not reduced in class I expression. The R2 element contains a nuclear hormone receptor half-site consensus sequence, AGGTCA, which is required for both the binding activity and the ability of R2 to act as a negative element in Ad12-transformed cells. In this study, we show that an orphan hormone receptor protein, COUP-TF, contributes to the differential R2 binding activity observed between Ad12- and Ad5-transformed cells. Additionally, COUP-TF was shown to bind as a dimer to the R2 element and to use the consensus AGGTCA as one half-site and its 3' flanking sequence as a probable second degenerate half-site. Since COUP-TF can act as a transcriptional repressor, we suggest that the higher COUP-TF binding activity to the R2 element in Ad12-transformed cells contributes to down-regulation of class I transcription and, consequently, tumorigenesis.	UNIV PENN, SCH DENT MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	University of Pennsylvania; Baylor College of Medicine			Ge, Ruowen/D-8352-2012	Ge, Ruowen/0000-0002-0750-7336	NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045641, R01DK045641] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29797] Funding Source: Medline; NIDDK NIH HHS [DK-45641] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKRILL AM, 1988, ONCOGENE, V3, P483; ACKRILL AM, 1989, VIROLOGY, V172, P643, DOI 10.1016/0042-6822(89)90207-9; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; HWUNG YP, 1988, J BIOL CHEM, V263, P13470; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; KRALLI A, 1991, THESIS U PENNSYLVANI; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; QIU Y, 1994, IN PRESS P NATL ACAD; Sambrook J, 1989, MOL CLONING LABORATO; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YEWDELL JW, 1988, VIROLOGY, V162, P236, DOI 10.1016/0042-6822(88)90413-8	37	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2183	2190						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036004				2022-12-28	WOS:A1994NX62900009
J	NEHLS, M; PFEIFER, D; BOEHM, T				NEHLS, M; PFEIFER, D; BOEHM, T			EXON AMPLIFICATION FROM COMPLETE LIBRARIES OF GENOMIC DNA USING A NOVEL PHAGE VECTOR WITH AUTOMATIC PLASMID EXCISION FACILITY - APPLICATION TO THE MOUSE NEUROFIBROMATOSIS-1 LOCUS	ONCOGENE			English	Article							CDNAS; GENES; YEAST; EXPRESSION; FRAGMENTS; SELECTION; DELETION; PCR	The identification of transcription units in the vicinity of chromosomal lesions found in tumours is an essential step in the identification of new oncogenes. Here, we describe a lambda phage vector system for genomic exon-trapping (lambda GET), which dramatically simplifies the task of exon amplification from genomic DNA. The vector accommodates about 6.5 to 19 kb of DNA and allows inserts to be automatically subcloned as multi-copy plasmids containing splice donor and acceptor sites positioned flanking the inserted genomic DNA, RNA transcripts derived from such plasmids are processed in vivo and exons contained within the inserted genomic fragments become flanked by known sequences in the resulting mRNAs. RNA-based PCR can then be used for subsequent cloning and sequence analysis of trapped exons. We have exploited the large cloning capacity of lambda GET to construct highly redundant complete genomic libraries from Sau3AI partially digested vertebrate DNAs. Using this system, we have analysed a region of about 1 MB around the mouse neurofibromatosis-1 locus and have identified novel transcription units flanking the Nf-1 gene.	UNIV FREIBURG,DEPT MED 1,MOLEC MED GRP,D-79106 FREIBURG,GERMANY	University of Freiburg								ANDREADIS A, 1993, NUCLEIC ACIDS RES, V21, P2217, DOI 10.1093/nar/21.9.2217; AUCH D, 1990, NUCLEIC ACIDS RES, V18, P6743, DOI 10.1093/nar/18.22.6743; BIRD A, 1986, NATURE, V321, P309; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P3927, DOI 10.1073/pnas.88.9.3927; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FORSTER A, 1993, ONCOGENE, V8, P3157; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; KARN J, 1984, GENE, V32, P219; KAYES LM, 1992, J MED GENET, V29, P686, DOI 10.1136/jmg.29.10.686; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NEHLS M, 1993, TRENDS GENET, V9, P336, DOI 10.1016/0168-9525(93)90024-C; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; RUBY SW, 1991, TRENDS GENET, V7, P79; Sambrook J., 1989, MOL CLONING	22	42	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2169	2175						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036002				2022-12-28	WOS:A1994NX62900007
J	BATES, S; PARRY, D; BONETTA, L; VOUSDEN, K; DICKSON, C; PETERS, G				BATES, S; PARRY, D; BONETTA, L; VOUSDEN, K; DICKSON, C; PETERS, G			ABSENCE OF CYCLIN-D CDK COMPLEXES IN CELLS LACKING FUNCTIONAL RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; HUMAN BREAST-CANCER; GENE-PRODUCT; DEPENDENT KINASES; RB GENE; P53; LINES; ASSOCIATION; PHOSPHORYLATION; EXPRESSION	Cyclins D1, D2 and D3 are thought to function in the G1 phase of the cell division cycle by regulating the activity of cyclin-dependent protein kinases. All three D-type cyclins can be shown to associate with two specific kinases, cdk4 and cdk6, providing at least six possible combinations. To establish whether different cell types require different subsets of these complexes and whether they are altered in tumours where D-cyclin expression is perturbed, we surveyed a series of tumour cell lines and compared them where possible to non-tumorigenic counterparts. Although complexes involving cdk4 or cdk6 were readily observed in many of the cell lines, no complexes were detectable in human cells harbouring, DNA tumour virus oncoproteins or in which the retinblastoma gene product (pRb) is mutated or missing. These data suggest that as well as being a potential substrate for D-cyclin-kinases, functional pRb contributes to the formation or stability of the complexes, at least in human cells.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND	Cancer Research UK; Imperial College London; Ludwig Institute for Cancer Research								AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BARTEK J, 1990, ONCOGENE, V5, P893; BATES S, 1994, ONCOGENE, V9, P71; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1994, IN PRESS CANCER SURV, V18; FAUST JB, 1992, CANCER RES, V52, P2460; GOLDFARB M, 1991, ONCOGENE, V6, P65; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL FL, 1993, ONCOGENE, V8, P1377; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KATO J, 1993, GENE DEV, V7, P331; KHATIB ZA, 1993, CANCER RES, V53, P5535; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUKAS J, 1994, ONCOGENE, V9, P707; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OOKAWA K, 1993, ONCOGENE, V8, P2175; PALMERO I, 1993, ONCOGENE, V8, P1049; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHUURING E, 1992, ONCOGENE, V7, P355; SOULE HD, 1990, CANCER RES, V50, P6075; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1993, ONCOGENE, V8, P1593; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	55	195	203	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1633	1640						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183557				2022-12-28	WOS:A1994NL81500014
J	OGAWA, S; TOYOSHIMA, H; KOZUTSUMI, H; HAGIWARA, K; SAKAI, R; TANAKA, T; HIRANO, N; MANO, H; YAZAKI, Y; HIRAI, H				OGAWA, S; TOYOSHIMA, H; KOZUTSUMI, H; HAGIWARA, K; SAKAI, R; TANAKA, T; HIRANO, N; MANO, H; YAZAKI, Y; HIRAI, H			THE C-TERMINAL SH3 DOMAIN OF THE MOUSE C-CRK PROTEIN NEGATIVELY REGULATES TYROSINE-PHOSPHORYLATION OF CRK ASSOCIATED P130 IN RAT 3Y1 CELLS	ONCOGENE			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; GUANINE-NUCLEOTIDE EXCHANGE; V-CRK; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; ONCOGENE PRODUCT; ADAPTER PROTEIN; SARCOMA-VIRUS; RECEPTOR; KINASE	We have isolated the mouse c-crk cDNA from a mouse liver cDNA library. It encodes 304 amino acids and consists mainly of SH2/SH3 regions. In Northern blot analysis, the mouse c-crk mRNA is expressed ubiquitously in every tissue and organ, suggesting that the c-Crk protein may be a common signal transducing molecule among tissues. In contrast to the v-Crk protein, which has a single SH3 domain, the c-Crk protein contains two, the more N-terminal SH3(1) domain and the C-terminal SH3(2) domain. To elucidate functions of these SH3 domains, we have constructed two c-crk mutants, B-cuk and D-crk which lack the SH3(2) and the SH3(1) domain, respectively. These mutants were expressed in rat 3Y1 cells, and examined for their transforming ability in terms of morphological phenotypes and for tyrosine phosphorylation profiles of cells expressing the mutant proteins. Morphological alteration and increased tyrosine phosphorylation of 130-140 kDa proteins, the major component of which is the Crk-associated p130, were observed in cells expressing B-Crk as well as those expressing v-Crk, but little in cells expressing c-Crk even at a similar level of expression. Although a highly tyrosine-phosphorylated form of the p130 was coimmunoprecipitated with c-Crk as well as B-Crk, the relative level of tyrosine phosphorylation of the p130, which is normalized to the amount of Crk protein immunoprecipitated, was 10 to 20 times higher in B-Crk-expressing cells than in c-Crk- or D-Crk-expressing cells. The present results indicate that the SH3(2) domain of mouse c-Crk protein negatively regulates tyrosine phosphorylation of the p130, and that lack of the SH3(2) domain in B-Crk and v-Crk may contribute, at least partly, to their morphological alteration or transforming ability through increasing tyrosine phosphorylation of the p130.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; JICHI MED SCH,DEPT MOLEC BIOL,MINAMI KAWACHI,TOCHIGI,JAPAN	University of Tokyo; Jichi Medical University				Sakai, Ryuichi/0000-0001-6833-1103				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GISH GD, 1992, CELL, V71, P359; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; POTTS MW, 1987, J VIROL, V60, P494; Potts W M, 1988, Oncogene Res, V3, P343; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P113; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1988, SCIENCE, V242, P1692; TSUCHIE H, 1989, ONCOGENE, V4, P1281; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79	42	50	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1669	1678						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183562				2022-12-28	WOS:A1994NL81500019
J	YAMAMOTO, H; LAMPHIER, MS; FUJITA, T; TANIGUCHI, T; HARADA, H				YAMAMOTO, H; LAMPHIER, MS; FUJITA, T; TANIGUCHI, T; HARADA, H			THE ONCOGENIC TRANSCRIPTION FACTOR IRF-2 POSSESSES A TRANSCRIPTIONAL REPRESSION AND A LATENT ACTIVATION DOMAIN	ONCOGENE			English	Article							INTERFERON-BETA GENE; NF-KAPPA-B; IFN-INDUCIBLE GENES; REGULATORY ELEMENTS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; VIRUS INDUCTION; ALPHA PROMOTER; LEXA GENE; EXPRESSION	IRF-1 and IRF-2 are two structurally related transcription factors originally identified as regulators of the type I interferon (IFN) system. IRF-1 functions as an activator whereas IRF-2 binds to the same cis-elements and can repress IRF-1 action. More recently these two factors have been shown to act in a mutually antagonistic manner to regulate cell growth; overexpression of the repressor IRF-2 leads to cell transformation, whereas concomitant overexpression of IRF-1 leads to reversion. Previous studies have identified DNA-binding domains in IRF-1 and IRF-2 and an activation domain in IRF-1. In the present study we show that IRF-2 also possesses a transcriptional repression domain in its carboxyl terminal region. We further observe that a LexA-IRF2 fusion can inhibit the function of an activator positioned nearby in the promoter. Thus, repression by IRF-2 may involve both competition with IRF-1 for binding to the promoter as well as the 'silencing' of nearby activators. Furthermore, we demonstrate the presence of a latent activation domain in the central region of IRF-2 and speculate that IRF-2 may contribute to gene activation under certain conditions.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Osaka University			Harada, Hisashi/H-2815-2019	Harada, Hisashi/0000-0001-5993-1289				AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; COHEN L, 1991, CELL GROWTH DIFFER, V2, P323; Demaeyer E., 1988, INTERFERONS OTHER RE; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; HAGGARTY A, 1991, CELL GROWTH DIFFER, V2, P503; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HORII T, 1981, CELL, V23, P689, DOI 10.1016/0092-8674(81)90432-3; ITOH S, 1989, NUCLEIC ACIDS RES, V17, P8372, DOI 10.1093/nar/17.20.8372; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; JAYNES J, 1988, EMBO J, V10, P1427; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARKHAM BE, 1981, NUCLEIC ACIDS RES, V9, P4149, DOI 10.1093/nar/9.16.4149; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SALTMAN DL, 1993, GENOMICS, V16, P726, DOI 10.1006/geno.1993.1254; SEN GC, 1992, J BIOL CHEM, V267, P5017; TAMM I, 1987, INTERFERON, V9, P14; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VILCEK J, 1990, PEPTIDE GROWTH FACTO, V2, P3; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156	48	65	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1423	1428						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152803				2022-12-28	WOS:A1994NH40100014
J	LIAUDET, E; GARCIA, M; ROCHEFORT, H				LIAUDET, E; GARCIA, M; ROCHEFORT, H			CATHEPSIN-D MATURATION AND ITS STIMULATORY EFFECT ON METASTASIS ARE PREVENTED BY ADDITION OF KDEL RETENTION SIGNAL	ONCOGENE			English	Article						CATHEPSIN-D OVEREXPRESSION; METASTASIS; PROTEOLYSIS; KDEL SIGNAL	BREAST-CANCER-CELLS; LUMINAL ER PROTEINS; FACTOR-II RECEPTOR; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; LYSOSOMAL PROENZYMES; AUTOCRINE GROWTH; GOLGI-COMPLEX; MCF7 CELLS; SECRETION	Cathepsin D is overexpressed in most primary breast cancers where its concentration is correlated with increased metastatic potential. To investigate the possible role and mechanism of this lysosomal protease in metastasis, we transfected low-metastatic rat tumor cells with wild-type human cathepsin D, or mutated forms obtained by insertion of a KDEL peptide signal responsible for ER retention, or a control KDAS peptide. The overexpressed pro-cathepsin D in wild-type and KDAS clones was normally sorted and maturated in lysosomes. In KDEL clones, pro-cathepsin D was mostly retained in the ER or partially secreted by high-producer clones but was not maturated. While overexpressed cathepsin D increased experimental metastasis in athymic mice, the pro-cathepsin/D-KDEL was totally ineffective. Moreover, the effect of cathepsin D on metastasis did not seem to be due to saturation of the mannose-6-phosphate receptor since the secretion of two other rat lysosomal enzymes was unaffected by cathepsin D overexpression. We conclude that pro-cathepsin D overexpression facilitates tumor metastasis only when maturated into an active enzyme.	INSERM,U148,UNITE HORMONES & CANC,60 RUE NAVACELLES,F-34090 MONTPELLIER,FRANCE; UNIV MONTPELLIER 1,F-34090 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier			Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690				BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BRIOZZO P, 1988, CANCER RES, V48, P3688; BROUILLET JP, 1991, CLIN BIOCHEM, V24, P491, DOI 10.1016/S0009-9120(05)80008-6; BROUILLET JP, 1993, EUR J CANCER, V29A, P1248, DOI 10.1016/0959-8049(93)90066-O; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; CAPONY F, 1990, BIOCHEM BIOPH RES CO, V171, P972, DOI 10.1016/0006-291X(90)90779-M; CAPONY F, 1989, CANCER RES, V49, P3904; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FREISS G, 1988, CANCER RES, V48, P3709; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; GOTTESMAN MM, 1990, SEMINARS CANCER BIOL; GRASSEL S, 1992, BIOCHEM BIOPH RES CO, V182, P276, DOI 10.1016/S0006-291X(05)80141-X; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; KIESS W, 1987, J BIOL CHEM, V262, P12745; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maniatis T., 1982, MOL CLONING; MAREEL MM, 1991, MECHANISMS INVASION; MATHIEU M, 1991, MOL ENDOCRINOL, V5, P815, DOI 10.1210/mend-5-6-815; MONTCOURRIER P, 1993, CR ACAD SCI III-VIE, V316, P421; MONTCOURRIER P, 1990, CANCER RES, V50, P6045; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; SPYRATOS F, 1989, LANCET, V2, P1115; TANDON AK, 1990, NEW ENGL J MED, V322, P297, DOI 10.1056/NEJM199002013220504; THORPE SM, 1989, CANCER RES, V49, P6008; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WESTLEY B, 1980, CELL, V20, P352; YAMASHITA T, 1980, INT J CANCER, V26, P435, DOI 10.1002/ijc.2910260408	42	71	71	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1145	1154						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134116				2022-12-28	WOS:A1994NC04800017
J	LU, YM; USSERY, GD; MUNCASTER, MM; GALLIE, BL; BLANCK, G				LU, YM; USSERY, GD; MUNCASTER, MM; GALLIE, BL; BLANCK, G			EVIDENCE FOR RETINOBLASTOMA PROTEIN (RB) DEPENDENT AND INDEPENDENT IFN-GAMMA RESPONSES - RB COORDINATELY RESCUES IFN-GAMMA INDUCTION OF MHC CLASS-II GENE-TRANSCRIPTION IN NONINDUCIBLE BREAST-CARCINOMA CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; MALIGNANT PHENOTYPE; DERMAL FIBROBLASTS; SURFACE EXPRESSION; MESSENGER-RNAS; TUMOR-CELLS; CHAIN GENE; HLA-DR; C-FOS; ANTIGENS	The class II major histocompatibility (MHC) genes encode cell surface heterodimers that present processed antigen to CD4 positive T-cells. The class II genes are expressed constitutively on B-cells and can be induced by IFN-gamma on a variety of other cell types. Because the class II genes are aberrantly expressed on many mesenchymal tumors, which are frequently defective for the retinoblastoMa tumor suppressor protein (RB), we investigated the role of RB in the regulation of HLA-DR and -DP. The RB defective breast carcinomas cell line, MDA-468-S4 (S4), as well as S4 subclones reconstituted with RB coding sequences under the control of a zinc inducible promoter, were treated with IFN-gamma and examined for DR and DP expression. Surface DR is not inducible in S4 cells, but inducibility is rescued by RB. DP is only slightly inducible in S4, but inducible to a much higher level in the RB positive subclones of S4. IFN-gamma induction of DR and DP mRNAs are correspondingly dependent on RB. IFN-gamma receptors are present on S4 cells, and the guanylate binding protein and ICAM-1 genes respond to IFN-gamma, ruling out the possibility that all IFN-gamma signal transduction pathways are defective in S4 cells. These data indicate RB regulates the coordinate response of class II genes to IFN-gamma. Possible roles for RB in this process are discussed, as well as the role of the class II-noninducible phenotype in tumor rejection.	UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV TORONTO,DEPT MOLEC GENET,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA; HOSP SICK CHILDREN,DIV IMMUNOL & CANC RES,TORONTO M5G 1X8,ONTARIO,CANADA	State University System of Florida; University of South Florida; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Blanck, George/A-5365-2012	Gallie, Brenda/0000-0002-9697-9211				ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; ANDERSSON M, 1987, J IMMUNOL, V138, P3960; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BASTA PV, 1987, J IMMUNOL, V138, P1275; BERNARD DJ, 1992, BRIT J CANCER, V66, P88, DOI 10.1038/bjc.1992.222; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; BLANCK G, 1992, J FLORIDA MED ASS, V79, P97; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; CALMAN AF, 1987, J IMMUNOL, V139, P2489; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEMENTS VK, 1992, J IMMUNOL, V149, P2391; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; DETRICK B, 1988, CANCER RES, V48, P1633; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GLADSTONE P, 1978, NATURE, V271, P459, DOI 10.1038/271459a0; HAMMEL PA, 1992, MOL CELL BIOL, V12, P3431; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUME CR, 1989, HUM IMMUNOL, V26, P288, DOI 10.1016/0198-8859(89)90007-4; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LIOU HC, 1990, SCIENCE, V24, P1581; MAUER DH, 1987, TISSUE ANTIGENS, V31, P174; MOLLER P, 1989, AM J PATHOL, V135, P73; MUNCASTER MM, 1992, CANCER RES, V52, P654; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; ONO SJ, 1991, J EXP MED, V173, P629, DOI 10.1084/jem.173.3.629; OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCOTLANDI K, 1992, ANTICANCER RES, V12, P767; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SRIKUMAR P, 1991, CELL, V65, P1053; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANG Z, 1988, EMBO J, V7, P1965, DOI 10.1002/j.1460-2075.1988.tb03034.x; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	48	59	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1015	1019						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134104				2022-12-28	WOS:A1994NC04800002
J	HAINZL, T; BOEHM, T				HAINZL, T; BOEHM, T			A VERSATILE EXPRESSION VECTOR FOR THE IN-VITRO STUDY OF PROTEIN-PROTEIN INTERACTIONS - CHARACTERIZATION OF E47 MUTANT PROTEINS	ONCOGENE			English	Article							GLUTATHIONE-S-TRANSFERASE; HELIX ZIPPER PROTEIN; DNA-BINDING; ESCHERICHIA-COLI; ENHANCER-BINDING; TRANSLOCATION; CLONING; MYC; PURIFICATION; DIMERIZATION	Several mutants of the E47 protein, a member of the family of basic/helix-loop-helix (b-HLH) transcriptional regulators, were examined for their ability to homo- and heterodimerize with the protein product of the T-cell oncogene tal-1/SCL. For this purpose, a novel bacterial expression system was developed in which proteins are expressed as fusions appended to glutathione-S-transferase via a thrombin cleavage site and either one or four protein kinase recognition sites embedded in a glycine-rich domain. Since the interaction domain can be purified away from the glutathione-S-transferase moiety and the radioactive label is located in a flexible N-terminal tag, protein folding should occur normally. Our studies with E47 proteins prepared in this system indicate that the ratio between E47 homodimers and E47/tal-1 heterodimers can dramatically shift upon subtle mutations in the loop region and the second helix of the E47 protein. This unexpected result suggests a novel mechanism to alter the equilibrium between different transactivating protein complexes of the b-HLH class.	UNIV FREIBURG, DEPT MED 1, MOLEC MED GRP, D-79106 FREIBURG, GERMANY	University of Freiburg								BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GREEN AR, 1992, ONCOGENE, V7, P653; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEHLS M, 1993, TRENDS GENET, V9, P336, DOI 10.1016/0168-9525(93)90024-C; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RABBITTS TH, 1994, IN PRESS NATURE; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; SACCHETTA P, 1993, EUR J BIOCHEM, V215, P741, DOI 10.1111/j.1432-1033.1993.tb18087.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUJN XH, 1991, MOL CELL BIOL, V11, P5603; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722	30	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					885	891						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108132				2022-12-28	WOS:A1994MW55100025
J	STONGE, L; BASTIN, M				STONGE, L; BASTIN, M			TRANSCRIPTION ACTIVATION MEDIATED BY CHROMOSOMAL INVERSION IN RAT-CELLS	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION; INTRACHROMOSOMAL RECOMBINATION; GENE-AMPLIFICATION; DNA METHYLATION; MAMMALIAN-CELLS; STEM-CELLS; POLYOMAVIRUS; VIRUS; TRANSFORMATION; FIBROBLASTS	To investigate the relationship between the local configuration of a gene and its level of expression, we constructed a rat cell line, Hy5, carrying a mutant polyomavirus middle T oncogene (pmt) whose overexpression converted the cells to the transformed state. The structure of the transgene was such that pmt was able to undergo chromosomal inversion at a relatively high rate by a cross-over in flanking pBR322 sequences. Hy5 cells became spontaneously transformed at a rate of 10(-5) per cell generation and all of the transformants analysed had sustained pmt inversion. CpG sequences were partially methylated in the Hy5 insert but appeared demethylated in transformants. In two subclones derived from untransformed Hy5 cells, the pmt insert was densely methylated, transcriptionally inactive and unable to undergo homologous recombination. Our results suggest that DNA repair associated with recombinational events leads to a heritable hypomethylation of the locus which is responsible for its activation.	UNIV SHERBROOKE,DEPT BIOCHEM,SHERBROOKE J1H 5N4,PQ,CANADA	University of Sherbrooke								ALT FW, 1978, J BIOL CHEM, V253, P1357; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ASSELIN C, 1986, J VIROL, V57, P165, DOI 10.1128/JVI.57.1.165-172.1986; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird A.J., 1980, CATALYSIS ORGANIC SY, P61; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BOUCHARD L, 1987, J VIROL, V61, P2448, DOI 10.1128/JVI.61.8.2448-2453.1987; BOUCHARD L, 1987, ONCOGENE, V2, P379; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Croce C M, 1986, Horiz Biochem Biophys, V8, P545; CROCE CM, 1985, BLOOD, V65, P1; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; GELINAS C, 1985, VIROLOGY, V146, P233, DOI 10.1016/0042-6822(85)90007-8; GREEN AR, 1986, EMBO J, V5, P707, DOI 10.1002/j.1460-2075.1986.tb04271.x; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; JAT P, 1982, NUCLEIC ACIDS RES, V10, P871, DOI 10.1093/nar/10.3.871; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; KASTAN MB, 1982, CELL, V30, P509, DOI 10.1016/0092-8674(82)90248-3; KEIL RL, 1984, CELL, V39, P377, DOI 10.1016/0092-8674(84)90016-3; LAROSE A, 1990, VIROLOGY, V176, P98, DOI 10.1016/0042-6822(90)90234-I; Luria SE, 1943, GENETICS, V28, P491; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHEYPREVOT B, 1984, J VIROL, V50, P325, DOI 10.1128/JVI.50.2.325-334.1984; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NICKOLOFF JA, 1990, MOL CELL BIOL, V10, P4837, DOI 10.1128/MCB.10.9.4837; NICKOLOFF JA, 1992, MOL CELL BIOL, V12, P5311, DOI 10.1128/MCB.12.12.5311; NOTTENBURG C, 1987, J VIROL, V61, P1828, DOI 10.1128/JVI.61.6.1828-1833.1987; PALL ML, 1981, P NATL ACAD SCI-BIOL, V78, P2465, DOI 10.1073/pnas.78.4.2465; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RENZO A, 1989, ONCOGENE, V4, P1469; ROGINSKI RS, 1983, CELL, V35, P149, DOI 10.1016/0092-8674(83)90217-9; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SHAD D, 1986, SCIENCE, V233, P478; SHENKAR R, 1991, MOL CELL BIOL, V11, P1813, DOI 10.1128/MCB.11.4.1813; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONGE L, 1990, J VIROL, V64, P2958, DOI 10.1128/JVI.64.6.2958-2966.1990; STONGE L, 1993, J VIROL, V67, P1788, DOI 10.1128/JVI.67.4.1788-1795.1993; STONGE L, 1991, NUCLEIC ACIDS RES, V19, P6619, DOI 10.1093/nar/19.23.6619; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; VARSHAVSKY A, 1981, CELL, V25, P561, DOI 10.1016/0092-8674(81)90074-X; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	47	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					781	789						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108120				2022-12-28	WOS:A1994MW55100013
J	BOYER, MJ; GUTMANN, DH; COLLINS, FS; BARSAGI, D				BOYER, MJ; GUTMANN, DH; COLLINS, FS; BARSAGI, D			CROSS-LINKING OF THE SURFACE-IMMUNOGLOBULIN RECEPTOR IN B-LYMPHOCYTES INDUCES A REDISTRIBUTION OF NEUROFIBROMIN BUT NOT P120-GAP	ONCOGENE			English	Article							TYPE-1 GENE-PRODUCT; RAS PROTEINS; CELLS; GAP; P21; IDENTIFICATION; MUTATIONS; SEQUENCE; ENCODES; MUTANTS	The activation of Ras proteins is a key step in the signal transduction pathways triggered by ligand-bound cell surface receptors. The GTPase activating proteins (GAPs) p120-GAP and neurofibromin, the neurofibromatosis-type 1 (NF1) gene product, are thought to play an essential role in the regulation of Ras activity by increasing the GTPase activity of wild type, but not activated Ras in vitro. Both GAPs are widely expressed in mammalian tissues thus raising the question of whether or not they have different regulatory functions. In this study, we have analysed the distribution of p120-GAP and neurofibromin in splenic B lymphocytes by immunofluorescent staining. Crosslinking of surface immunoglobulin (sig), the B-lymphocyte antigen receptor, induced the redistribution of neurofibromin. In contrast, no apparent change in the cellular localization of p120-GAP occurred followed the cross-linking of sig. The redistribution of neurofibromin coincided both spatially and temporally with the relocalization of crosslinked slg and was inhibited by the cytoskeletal disrupting agents colchicine and cytochalasin D. These findings indicated that neurofibromin and p120-GAP can be differentially regulated in vivo and suggest that neurofibromin is a component of the signaling pathway initiated by crosslinking of B lymphocyte sig. Furthermore, our observations that cocapping neurofibromin with sig is independent of the p21(ras) redistribution suggests that the role of neurofibromin in B cells is not solely related to its ability to act as a Ras regulator.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	Cold Spring Harbor Laboratory; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan				Bar-Sagi, Dafna/0000-0003-2597-8948; Gutmann, David/0000-0002-3127-5045	NATIONAL CANCER INSTITUTE [R37CA055360, R01CA055360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001590] Funding Source: NIH RePORTER; NCI NIH HHS [CA55360] Funding Source: Medline; NINDS NIH HHS [NS-01590, NS02340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADCOCK MR, 1993, NATURE, V363, P83; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BORISY GG, 1967, J CELL BIOL, V34, P525, DOI 10.1083/jcb.34.2.525; BOURGUIGNON LYW, 1978, J CELL PHYSIOL, V95, P239, DOI 10.1002/jcp.1040950302; BRAUN J, 1980, IMMUNOL REV, V52, P3, DOI 10.1111/j.1600-065X.1980.tb00328.x; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DATSON MM, 1992, NEURON, V8, P415; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EDELMAN GM, 1973, P NATL ACAD SCI USA, V70, P1442, DOI 10.1073/pnas.70.5.1442; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GABBIANI G, 1977, NATURE, V269, P697, DOI 10.1038/269697a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOLD MR, 1993, J IMMUNOL, V150, P377; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1993, J NEUROSCI RES, V36, P206; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; QIU MS, 1991, J CELL BIOL, V115, P795, DOI 10.1083/jcb.115.3.795; SEVERSON CD, 1987, IMMUNOL LETT, V15, P291, DOI 10.1016/0165-2478(87)90130-1; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; Weihing R R, 1979, Methods Achiev Exp Pathol, V8, P42; WESSELLS NK, 1971, SCIENCE, V171, P135, DOI 10.1126/science.171.3967.135; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAHARA I, 1978, CELL, V15, P251, DOI 10.1016/0092-8674(78)90100-9	41	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					349	357						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290249				2022-12-28	WOS:A1994MW24800002
J	CHATTON, B; BOCCO, JL; GOETZ, J; GAIRE, M; LUTZ, Y; KEDINGER, C				CHATTON, B; BOCCO, JL; GOETZ, J; GAIRE, M; LUTZ, Y; KEDINGER, C			JUN AND FOS HETERODIMERIZE WITH ATFA, A MEMBER OF THE ATF/CREB FAMILY AND MODULATE ITS TRANSCRIPTIONAL ACTIVITY	ONCOGENE			English	Article							ELEMENT-BINDING-PROTEIN; AMP RESPONSE ELEMENT; LEUCINE ZIPPER STRUCTURE; NUCLEAR FACTOR CREB; DNA-BINDING; CYCLIC-AMP; CDNA CLONES; HELA-CELLS; CROSS-TALK; ENHANCER	Three related clones encoding proteins (ATFa1, 2 and 3) with specific ATF/CRE DNA-binding activities have been isolated from HeLa cell cDNA libraries. All three isoforms have weak effects on the basal activity of the adenovirus E2a promoter. We present evidence suggesting that a C-terminal element of the ATFa molecules negatively interferes with the intrinsic activation function of these proteins. We also show that coexpression of ATFa with c-Jun, Jun-B or Jun-D stimulates ATFa-dependent reporter activity, while coexpression of c-Fos has no effect. Deletion analyses indicate that the metal-binding region of ATFa is dispensible for this effect, but that the domain comprising the leucine-zipper region of ATFa is required. Reciprocal co-immunoprecipitation experiments and electrophoretic band-shift assays with in vitro synthesized proteins reveal direct interactions between ATFa and Jun or Fos. The ATFa/c-Jun heterodimers, but not the ATFa/c-Fos complexes, bind efficiently to ATF, CRE or AP1 sites. The detection of ATFa-Jun complexes in crude extracts from HeLa cells transfected with ATFa and c-Jun expression vectors suggests that such ATFa/c-Jun heterodimers also form in vivo. Altogether these results indicate that the ATFa proteins may contribute to the modulation of the activity of the Jun/Fos complexes by altering their DNA-binding and transcriptional properties.	INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67000 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119; Bocco, Jose Luis/0000-0002-9682-1270				ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ABDELHAFIZ HAM, 1992, MOL ENDO, V6, P2080; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; FLINT KJ, 1991, ONCOGENE, V6, P2019; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAPRINSKI BA, 1992, P NATL ACAD SCI USA, V85, P7192; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1992, J CELL SCI, V103, P9; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; MERMOD N, 1989, CELL, V57, P859; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NOMURA N, 1993, J BIOL CHEM, V268, P4259; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZU YL, 1991, J BIOL CHEM, V35, P24134	62	78	80	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					375	385						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290251				2022-12-28	WOS:A1994MW24800004
J	HAINAUT, P; HALL, A; MILNER, J				HAINAUT, P; HALL, A; MILNER, J			ANALYSIS OF P53 QUATERNARY STRUCTURE IN RELATION TO SEQUENCE-SPECIFIC DNA-BINDING	ONCOGENE			English	Article							TUMOR SUPPRESSOR PROTEIN; WILD-TYPE; MUTANT P53; CELL-CYCLE; GENE-EXPRESSION; CONFORMATION; FORMS; TRANSFORMATION; TRANSCRIPTION; PROLIFERATION	Quaternary interactions of p53 influence its tertiary structure which, in turn, is critical for sequence-specific DNA binding and tumour suppressor function. Given its regulatory potential we have sought to define the quaternary structure of p53 involved in sequence-specific DNA binding. Double stranded DNA [5'-GGACATGCCCG GGCATGTCC-3'; Funk et al. (1992) Mol. Cell. Biol., 12, 2866-2871] was used to test p53 binding capacity in vitro. The p53 protein was translated in vitro and size fractionated prior to the DNA binding reaction. Two independent DNA binding assays were employed. The first detected electromobility shift of P-32-labelled DNA and was carried out in the presence of PAb421, which stabilises and supershifts p53-DNA complexes. The second detected S-35-labelled p53 bound to biotinylated target DNA in the absence of PAb421. Sequence-specific DNA binding was found to be a property of full length, oligomeric p53. Greatest binding activity involved tetramers and/or higher molecular weight forms of p53, minimal binding was observed for dimers. This size profile was unaffected by PAb421 and it therefore seems unlikely that PAb421 dissociates high molecular weight forms of p53 into dimers. We conclude that high molecular weight forms of p53 are the most effective structures for sequence-specific DNA binding in vitro; these structures may represent tetramers and/or heterogeneous complexes of p53 with other proteins.	UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK			Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P1266; GANNON JV, 1990, EMBO J, V9, P1591; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALAZONETIS TD, 1993, EMBO J, V12, P1221; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1992, ONCOGENE, V7, P71; MEDCALF EA, 1993, IN PRESS ONCOGENE; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIVAS CI, 1992, BLOOD, V79, P1982; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TRUANT R, 1993, J BIOL CHEM, V268, P2284; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHANG W, 1992, ONCOGENE, V7, P1039	48	41	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					299	303						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302593				2022-12-28	WOS:A1994MW24700036
J	BASELGA, J; MAERZ, WJ; MOY, D; MILLER, WH; CASTRO, L; REUTER, VE; YAO, TJ; MASUI, H; DMITROVSKY, E				BASELGA, J; MAERZ, WJ; MOY, D; MILLER, WH; CASTRO, L; REUTER, VE; YAO, TJ; MASUI, H; DMITROVSKY, E			OVER-EXPRESSION OF TRANSFORMING GROWTH-FACTOR-ALPHA ANTAGONIZES THE ANTI-TUMORIGENIC BUT NOT THE DIFFERENTIATION ACTIONS OF RETINOIC ACID IN A HUMAN TERATOCARCINOMA CELL	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; RIBONUCLEIC-ACID; LINE TERA-2; RECEPTOR; INVITRO; CANCER; ANTIBODIES; INDUCTION; CLONING	All-trans retinoic acid (RA) treatment of the multipotent human teratocarcinoma (TC) cell line NTERA-2 clone D1 (abbreviated NT2/D1) induces a neuronal phenotype and other cell lineages. NT2/D1 cells basally express transforming growth factor alpha (TGF-alpha) mRNA and secreted protein. After RA-treatment TGF-alpha expression is markedly reduced. This decline in TGF-alpha expression accompanies the induction of the neuronal phenotype and a marked reduction of tumorigenicity in athymic mice. This suggested a causal link between reduced TGF-alpha expression and the induced differentiation or loss of tumorigenicity of these RA-treated TC cells. To evaluate this possibility, an RA-refractory NT2/D1 subclone was analysed. This subclone, designated NT2/D1-R1, failed to induce differentiation or to decrease TGF-alpha expression despite RA treatment. To further explore the relationship between TGF-alpha expression and RA actions in this human TC cell, a TGF-alpha cDNA was stably transfected and expressed in NT2/D1 cells. RA-treatment of independently obtained TGF-alpha over-expressing clones and a representative control transfectant only expressing the neomycin resistance gene produced a neuronal phenotype similar to parental NT2/D1 cells as assessed by morphologic, immunophenotypic, and gene expression markers of differentiation. RA-treatment of these clones also induced a G1 arrest similar to parental cells. However, only the TGF-alpha over-expressing clones that secreted high levels of TGF-alpha protein into the conditioned media before and after RA treatment still developed tumors in athymic mice despite prior exposure of these cells to RA. This finding demonstrates that TGF-alpha can inhibit the anti-tumorigenic effects of RA in human TCs. Thus, over-expression of a single growth factor that normally declines with RA treatment antagonizes the antitumorigenic but not the differentiation actions of RA in this human tumor cell.	CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,MOLEC MED LAB,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,RECEPT BIOL LAB,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT BIOSTAT,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [1R01-CA54494-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1986, DIFFERENTIATION, V31, P119, DOI 10.1111/j.1432-0436.1986.tb00392.x; ANDREWS PW, 1984, LAB INVEST, V50, P147; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BRAND N, 1988, NATURE, V332, P851; BROOKES S, 1989, ONCOGENE, V4, P429; CARLIN CR, 1985, EXP CELL RES, V159, P17, DOI 10.1016/S0014-4827(85)80033-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DAVIS LG, 1986, BASIC METHODS MOL BI, P286; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DIPPOLD WG, 1980, P NATL ACAD SCI-BIOL, V77, P6114, DOI 10.1073/pnas.77.10.6114; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ENGSTROM W, 1985, J CELL SCI, V73, P361; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; FOGH J, 1978, NUDE MOUSE EXPT CLIN, P215; GILL GN, 1984, J BIOL CHEM, V259, P7755; GROUCH GD, 1991, CANCER RES, V51, P4882; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; KURIE JM, IN PRESS DIFFERENTIA; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MIETTINEN OS, 1985, THEORETICAL EPIDEMIO, P135; MILLER WH, 1990, ONCOGENE, V5, P511; MILLER WH, 1993, IN PRESS DIFFERENTIA; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SCHOFIELD PN, 1987, J CELL SCI, V88, P57; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WEIMA SM, 1989, DIFFERENTIATION, V41, P245, DOI 10.1111/j.1432-0436.1989.tb00753.x; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129	34	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3257	3263						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247529				2022-12-28	WOS:A1993MG78200008
J	QUINLAN, MP				QUINLAN, MP			E1A 12S IN THE ABSENCE OF E1B OR OTHER COOPERATING ONCOGENES ENABLES CELLS TO OVERCOME APOPTOSIS	ONCOGENE			English	Article							RAT VENTRAL PROSTATE; PRIMARY EPITHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; GROWTH FACTOR-BETA; ADENOVIRUS TYPE-5; C-MYC; E1A-12S PROTEIN; TERMINAL REGION; GENE-PRODUCTS; DNA FRAGMENTS	Neonatal rat kidneys are still undergoing growth and differentiation. Within 24 h after placing these cells in culture, programmed cell death has been activated. This is evidence by intranucleosomal DNA digestion. Cellular DNA synthesis and proliferation cease between 48 and 72 h after plating and the epithelial cells begin to die. The adenovirus E1A 12S gene, in the presence or absence of the E1B gene products, restarts the proliferation program of these cells, retaining their differentiated states. 12S can accomplish this in the presence and absence of serum. Expression of the E1A 13S gene results in cellular DNA degradation due to necrosis, but not apoptosis, brought on by the expression of the 13S-dependent viral genes. Those cells that retain the 12S sequences escape apoptosis and proceed to become immortal. In addition, 12S enables Madin Darby canine kidney (MDCK) epithelial cells to overcome TGF-beta 1 induced inhibition of proliferation and apoptosis. Thus, E1A 12S may be an anti-apoptotic gene.			QUINLAN, MP (corresponding author), UNIV TENNESSEE, DEPT MICROBIOL & IMMUNOL, 858 MADISON AVE, MEMPHIS, TN 38163 USA.				NCI NIH HHS [CA50540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI GR, 1990, J VIROL, V64, P3427, DOI 10.1128/JVI.64.7.3427-3436.1990; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BERK AJ, 1986, CANCER SURV, V5, P367; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRENNER BM, 1990, J AM SOC NEPHROL, V1, P127; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; COLOMBEL M, 1992, CANCER RES, V52, P4313; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GAYNOR RB, 1983, CELL, V33, P683, DOI 10.1016/0092-8674(83)90011-9; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; KERR JFR, 1965, J PATHOL BACTERIOL, V90, P419, DOI 10.1002/path.1700900210; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; LASTER SM, 1988, J IMMUNOL, V141, P2629; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; QUINLAN MP, 1989, ONCOGENE, V4, P1051; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1993, ONCOGENE, V8, P257; QUINLAN MP, 1986, CANCER CELL, V4, P327; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROTELLO R J, 1990, Journal of Cell Biology, V111, p477A; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SEARLE J, 1982, PATHOL ANNU, V17, P229; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHENK T, 1991, ADV CANCER RES, V57, P47; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAUB M, 1984, METHODS SERUM FREE C, P3; TELLING GC, 1993, J VIROL, V67, P1600, DOI 10.1128/JVI.67.3.1600-1611.1993; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V155, P324, DOI 10.1016/S0006-291X(88)81088-X; Tomei LD, 1991, APOPTOSIS MOL BASIS, P279; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	59	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3289	3296						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247531				2022-12-28	WOS:A1993MG78200012
J	ZACKSENHAUS, E; GILL, RM; PHILLIPS, RA; GALLIE, BL				ZACKSENHAUS, E; GILL, RM; PHILLIPS, RA; GALLIE, BL			MOLECULAR-CLONING AND CHARACTERIZATION OF THE MOUSE RB1 PROMOTER	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; CELL-CYCLE; SUSCEPTIBILITY GENE; REGULATORY ELEMENT; C-MYC; EXPRESSION; PROTEIN; PHOSPHORYLATION; DIFFERENTIATION	We report the isolation and characterization of the mouse RB1 promoter and surrounding DNA sequences, and the identification of elements required for basal transcriptional activity. The mouse RB1 promoter, like the human homologue, has a high G + C content, constitutes a CpG island and is devoid of typical TATA and CAAT boxes. The first 235 base-pairs upstream of the translation initiation codon in the mouse promoter exhibit 80% sequence homology with the human sequence. This homology includes a region which contains putative binding sites for the transcription factors Sp1, ATF and E2F/DRTF1. Four major transcription initiation sites were identified downstream of this conserved region. Mutational analysis revealed that the Sp1 and ATF binding sites, but not the putative E2F/DRTF1 binding site, are critical for promoter activity. Complete disruption of the putative Sp1 and ATF sites abrogated transcription, whereas the introduction of point mutations, previously identified in the Sp1 and ATF sites in two low penetrance retinoblastoma families, reduced promoter activity in a cell type specific manner. Less reduction in activity occured in retinoic acid induced differentiated P19 cells and NIH3T3 mouse fibroblasts than in undifferentiated embryonal carcinoma P19 cells. Activity of the RB1 promoter was found to be stimulated in retinoic-acid induced differentiated P19 cells compared to undifferentiated P19; this stimulation required intact Sp1 and ATF sites but not the putative E2F/DRTF1 binding site. Our results indicate that basal level of RB1 expression is governed by Sp1 and ATF.			ZACKSENHAUS, E (corresponding author), HOSP SICK CHILDREN,DIV IMMUNOL & CANC RES,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.		Zacksenhaus, Eldad/AAD-3584-2020	Gallie, Brenda/0000-0002-9697-9211				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNN JM, 1989, MOL CELL BIOL, V9, P4594; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORD GM, 1990, GENOMICS, V6, P284, DOI 10.1016/0888-7543(90)90568-F; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; PUGH BF, 1992, J BIOL CHEM, V267, P679; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SLACK RS, 1993, IN PRES ONCOGENE; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STARNAUD R, 1988, ONCOGENE, V3, P553; TANG A, 1989, ONCOGENE, V4, P401; TASSIOS P T, 1990, New Biologist, V2, P1123; ZACHSENHAUS E, 1993, ADV CANCER RES, V61, P115; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	39	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2343	2351						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361753				2022-12-28	WOS:A1993LT36800004
J	STICKLAND, JE; TOMLINSON, IPM; RAMSHAW, AL; BROMLEY, L; POTTER, CG; MCGEE, JO				STICKLAND, JE; TOMLINSON, IPM; RAMSHAW, AL; BROMLEY, L; POTTER, CG; MCGEE, JO			QUANTIFICATION OF ONCOGENE DOSAGE IN TUMORS BY SIMULTANEOUS DUAL-LABEL HYBRIDIZATION	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; HUMAN-BREAST CANCER; PROTO-ONCOGENE; MESSENGER-RNA; AMPLIFICATION; QUANTITATION; INT-2; DNA	Gene amplification and allele loss occur in a variety of human tumours and some have prognostic value. Therefore, techniques which facilitate detection and quantification of gene dosage could have wide applicability in cancer research. Using the INT-2 gene as a model system, a quantitative procedure has been developed for measuring gene copy number using dual-label hybridization to DNA dot blots. A probe specific for the INT-2 gene was labelled with [alpha-P-32]dCTP and a probe to beta-actin, the control locus, was labelled with [alpha-S-35]dATP. Flat-bed scintillation counting was used to detect and separate the emissions resulting from each bound probe, and gene dosage was calculated from the ratio of INT-2 to the beta-actin probe compared with the ratio derived from constitutional DNA. Calculated ratios of greater than 1.22 and less than 0.78 indicated gene amplification and allelic loss respectively, at the 99% confidence limit derived from the population of 35 constitutional DNAs. The results were validated by RFLP analysis. It is expected that this technique will permit precise gene dosage quantification in many areas.	UNIV OXFORD,NUFFIELD DEPT PATHOL & BACTERIOL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford								ADNANE J, 1989, ONCOGENE, V4, P1389; BLOCH W, 1991, BIOCHEMISTRY-US, V30, P2735, DOI 10.1021/bi00225a001; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CALLAHAN R, 1989, BREAST CANCER RES TR, V13, P191, DOI 10.1007/BF02106570; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; DONOVANPELUSO M, 1991, AM J PATHOL, V138, P835; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; LASKEY RA, 1990, RADIOISOTOPES BIOL; MACHOTKA SV, 1989, CLIN CHIM ACTA, V184, P207, DOI 10.1016/0009-8981(89)90053-3; NEUBAUER A, 1992, ONCOGENE, V7, P1019; Sambrook J, 1989, MOL CLONING LABORATO; TSUDA H, 1989, CANCER RES, V49, P3104; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	15	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					223	227						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8093811				2022-12-28	WOS:A1993KN00500029
J	LEE, JM; ABRAHAMSON, JLA; KANDEL, R; DONEHOWER, LA; BERNSTEIN, A				LEE, JM; ABRAHAMSON, JLA; KANDEL, R; DONEHOWER, LA; BERNSTEIN, A			SUSCEPTIBILITY TO RADIATION CARCINOGENESIS AND ACCUMULATION OF CHROMOSOMAL BREAKAGE IN P53 DEFICIENT MICE	ONCOGENE			English	Article							WILD-TYPE P53; CELL-CYCLE ARREST; IONIZING-RADIATION; TRANSCRIPTIONAL ACTIVATION; GENE AMPLIFICATION; DNA DAMAGE; APOPTOSIS; CANCER; INDUCTION; PROTEIN	The p53 tumour suppressor gene is an important participant in the cellular response to ionizing radiation and other DNA damaging agents. Cells which lack p53 are unable to arrest cell cycle or enter into apoptotic cell death following irradiation. Moreover, these p53 deficient cells exhibit an increased resistance to DNA damaging agents, including radiation. The significance of this radiation-resistance and its relationship to the role that p53 plays in tumour suppression and the cellular radiation response has not yet been determined. In this report we have analyzed p53 deficient mice, expressing either a mutant p53 transgene or having a targeted p53 null allele, in order to investigate the role that p53 plays in governing susceptibility to radiation-carcinogenesis and in controlling the in vivo accumulation of chromosomal abnormalities. We show that wild-type p53 plays a critical role in controlling susceptibility to gamma-radiation-induced tumorigenesis, and sarcomas and lymphomas rapidly appear in irradiated p53 transgenic mice. Moreover, this susceptibility to radiation-carcinogenesis is associated with a two-fold increase in the in vivo accumulation of radiation-induced double stranded chromosomal breaks relative to that observed in wild-type animals. Taken together, these observations suggest that p53 acts to suppress tumour formation in vivo by preventing the accumulation of cells that have sustained radiation-induced DNA damage.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ON,CANADA; MT SINAI HOSP,DEPT PATHOL,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Baylor College of Medicine			Kandel, Rita/E-2149-2017; Kandel, Rita/AAU-9908-2021	Kandel, Rita/0000-0003-4047-3913; Kandel, Rita/0000-0003-4047-3913	NATIONAL CANCER INSTITUTE [R01CA054897] Funding Source: NIH RePORTER; NCI NIH HHS [CA54897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDBERG EC, 1979, ADV RADIAT BIOL, V8, P85; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P5413; Haran-Ghera N, 1979, Adv Cancer Res, V30, P45, DOI 10.1016/S0065-230X(08)60894-5; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2456; HEDDLE JA, 1973, MUTAT RES, V18, P187, DOI 10.1016/0027-5107(73)90035-3; HUTCHINSON F, 1993, SEMIN CANCER BIOL, V4, P85; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERSEY JH, 1973, INT J CANCER, V12, P333, DOI 10.1002/ijc.2910120204; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE JM, 1994, MUTAT RES, V307, P573, DOI 10.1016/0027-5107(94)90267-4; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKUMOTO M, 1990, CANCER RES, V50, P3848; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHMID W, 1975, MUTAT RES, V31, P9, DOI 10.1016/0165-1161(75)90058-8; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOMETSKO AM, 1992, MUTAT RES, V292, P145; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	45	115	117	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3731	3736						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970733				2022-12-28	WOS:A1994PT39200039
J	PAJUSOLA, K; APRELIKOVA, O; PELICCI, G; WEICH, H; CLAESSONWELSH, L; ALITALO, K				PAJUSOLA, K; APRELIKOVA, O; PELICCI, G; WEICH, H; CLAESSONWELSH, L; ALITALO, K			SIGNALING PROPERTIES OF FLT4, A PROTEOLYTICALLY PROCESSED RECEPTOR TYROSINE KINASE RELATED TO 2 VEGF RECEPTORS	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; HEPARIN-LIKE MOLECULES; PROTO-ONCOGENE; CELL-SURFACE; FACTOR GENE; SH2 DOMAIN; BINDING; EXPRESSION; ANGIOGENESIS	The FLT4, FLT1 and KDR/FLK1 genes encode, structurally similar endothelial cell receptor tyrosine kinases. Recently it has been shown that the FLT1 and KDR/FLK-1 proteins function as high-affinity receptors for vascular endothelial growth factor (VEGF). Here we show that FLT4 does not act as a receptor for VEGF, as VEGF did not show specific binding to the FLT4 tyrosine kinase or induce its autophosphorylation. Also, FLT4 did not interact with KDR in response to VEGF. However, when fused with the ligand binding domain of the colony stimulating factor-1 receptor (CSF-1R), the FLT4 tyrosine kinase was specifically activated by CSF-1. The activated FLT4 tyrosine kinase domain was found to interact with the Src homology 2 domains of the SHC and GRB2 adaptor proteins in vitro and with SHC in cells. CSF-1 stimulation of the CSF-1R/FLT4 receptor chimera induced thymidine incorporation in serum-starved NIH3T3 fibroblasts, but not in porcine aortic or murine lung capillary endothelial cells, although tyrosyl phosphorylation of the receptor and SHC occurred in these cells as well. These results suggest that the endothelial cell FLT4 receptor tyrosine kinase transmits signals for an as yet unidentified growth factor.	UNIV HELSINKI, DEPT PATHOL, MOLEC CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED, I-06100 PERUGIA, ITALY; GESELL BIOTECHNOL FORSCH MBH, DEPT GENE EXPRESS, W-3300 BRAUNSCHWEIG, GERMANY; LUDWIG INST CANC RES, UPPSALA BRANCH, S-75124 UPPSALA, SWEDEN	University of Helsinki; University of Perugia; Gesellschaft fur Biotechnologische Forschung mbH; Ludwig Institute for Cancer Research			Alitalo, Kari K/J-5013-2014; Pelicci, Giuliana/AAA-8921-2022	Alitalo, Kari K/0000-0002-7331-0902; Pelicci, Giuliana/0000-0003-0986-8255				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; APRELIKOVA O, 1992, CANCER RES, V52, P746; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BROWN LF, 1993, AM J PATHOL, V143, P1255; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FIEBICH BL, 1993, EUR J BIOCHEM, V211, P19, DOI 10.1111/j.1432-1033.1993.tb19865.x; GALLAND F, 1993, ONCOGENE, V8, P1233; GIORDANO S, 1989, ONCOGENE, V4, P1383; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; LAULAJAINEN T, 1993, LAB INVEST, V69, P183; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MARK MR, 1992, J BIOL CHEM, V267, P26166; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROBINSON DH, 1991, BLOOD, V77, P294; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WALTENBERGER J, 1994, IN PRESS J BIOL CHEM; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	121	136	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3545	3555						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970715				2022-12-28	WOS:A1994PT39200017
J	PATEL, U; GRUNDFESTBRONIATOWSKI, S; GUPTA, M; BANERJEE, S				PATEL, U; GRUNDFESTBRONIATOWSKI, S; GUPTA, M; BANERJEE, S			MICROSATELLITE INSTABILITIES AT 5 CHROMOSOMES IN PRIMARY BREAST-TUMORS	ONCOGENE			English	Note							DNA-POLYMERASE-BETA; DENYS-DRASH SYNDROME; COLORECTAL-CANCER; WILMS-TUMOR; LENGTH-POLYMORPHISMS; REPEAT POLYMORPHISM; SUPPRESSOR GENES; POINT MUTATIONS; LINKAGE MAP; WT1 GENE	The microsatellite instabilities at nine loci of chromosomes 2p, 8p, 10p and lip and the nm23-H1 locus on 17q21.3 were studied in primary breast tumors. Alterations in the short interspersed tandem repeats in tumor DNA in the form of either larger allele, smaller allele or LOH were observed. Significantly, a high occurrence of alterations in microsatellite polymorphisms at the ANK1, D8S135 and LPL loci of chromosome 8p (46-54%), the D2S119 locus of chromosome 2p (56%), the D10S197 locus at chromosome 10p (88%), and the nm23-H1 locus of chromosome 17q21.3 (46%) were observed in breast tumors. These results provide the first evidence for genomic instabilities at 2p, 8p and 10p in primary ductal and lobular breast carcinomas. No correlation has been found between the stage of the tumor and microsatellite instability, suggesting that microsatellite instability is an early genetic event in breast carcinogenesis.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT GEN SURG,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT CLIN PATHOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation								AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; BACKER JM, 1993, ONCOGENE, V8, P497; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1992, CANCER RES, V52, P5368; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FERRELL RE, 1983, AM J HUM GENET, V35, P78; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUTREAL PA, 1992, CANCER RES, V52, P2624; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; HAN HJ, 1993, CANCER RES, V53, P5087; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KING MC, 1992, NAT GENET, V2, P125; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1991, CANCER RES, V51, P2490; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MCBRIDE OW, 1987, P NATL ACAD SCI USA, V84, P503, DOI 10.1073/pnas.84.2.503; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Patel U., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P184; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; RHYU MG, 1994, ONCOGENE, V9, P29; SADAKANE Y, 1994, BIOCHEM BIOPH RES CO, V200, P219, DOI 10.1006/bbrc.1994.1437; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SWEASY JB, 1993, P NATL ACAD SCI USA, V90, P4626, DOI 10.1073/pnas.90.10.4626; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VARLEY JM, 1989, ONCOGENE, V4, P725; WADEY RB, 1990, ONCOGENE, V5, P901; WANG LM, 1992, CANCER RES, V52, P4824; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YEE CJ, 1994, CANCER RES, V54, P1641; ZULIANI G, 1990, NUCLEIC ACIDS RES, V18, P4958, DOI 10.1093/nar/18.16.4958-a; 1993, LOCUS MAPS COMPLEX G; 1993, CELL, V72, P971	53	75	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3695	3700						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970728				2022-12-28	WOS:A1994PT39200034
J	WASYLYK, C; MAIRA, SM; SOBIESZCZUK, P; WASYLYK, B				WASYLYK, C; MAIRA, SM; SOBIESZCZUK, P; WASYLYK, B			REVERSION OF RAS TRANSFORMED-CELLS BY ETS TRANSDOMINANT MUTANTS	ONCOGENE			English	Article							MATRIX-DEGRADING METALLOPROTEINASES; TRANSCRIPTION FACTORS; PROTEIN-KINASE; SIGNAL TRANSDUCTION; ACTIVATION DOMAIN; GENE FAMILY; PHOSPHORYLATION; PHOTORECEPTOR; DROSOPHILA; CASCADE	Considerable progress has been made in elucidating the components of the Ras signalling pathway, from both biochemical and genetic investigations. However little is known about the nuclear targets of the pathway, and in particular those that mediate the long-term changes in gene expression resulting from Ras transformation. Ets family members may be involved in these processes since Ras stimulates transcription through ets-DNA binding sites. We show that a mutated Ets protein, Delta PU.1, inhibits Ras activation of transcription. Stable expression of Delta PU.1 in Ras transformed NIH3T3 fibroblasts reverts the transformed phenotype by many characteristics, including morphology, anchorage independent growth, saturation density, growth in low serum, tumour formation in nude mice and to some extent sensitivity to apoptotic cell death. Similar trans-dominant mutants of c-Ets-1 and c-Ets-2, the most divergent members of the Ets-family to PU.1, also revert Ras transformed cells, as indicated by morphology, anchorage-independent growth, saturation density and doubling time in low serum. Reversion may result from a shared property of the mutants, such as binding to ets motifs in promoters. These results provide evidence for an important role for Ets proteins in Ras transformation.	FAC MED STRASBOURG, INST CHIM BIOL, CNRS, LGME, INSERM, U184, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ADLER V, 1992, J BIOL CHEM, V267, P17001; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; HANCOCK JF, 1993, CURR BIOL, V3, P770, DOI 10.1016/0960-9822(93)90027-L; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK B, 1993, EUR J BIOCHEM, V21, P523; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WHARTON W, 1989, CELL GROWTH DIVISION, P139	37	85	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3665	3673						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970725				2022-12-28	WOS:A1994PT39200030
J	COTTER, FE; JOHNSON, P; HALL, P; POCOCK, C; ALMAHDI, N; COWELL, JK; MORGAN, G				COTTER, FE; JOHNSON, P; HALL, P; POCOCK, C; ALMAHDI, N; COWELL, JK; MORGAN, G			ANTISENSE OLIGONUCLEOTIDES SUPPRESS B-CELL LYMPHOMA GROWTH IN A SCID-HU MOUSE MODEL	ONCOGENE			English	Article							NON-HODGKINS LYMPHOMA; T(14-18) CHROMOSOMAL TRANSLOCATION; BCL-2 GENE; FOLLICULAR LYMPHOMA; MEMBRANE PROTEIN; LEUKEMIA; DISEASE; MICE; PROGRESSION; APOPTOSIS	The t(14;18) translocation is found in the majority follicular lymphomas and some high grade B-cell lymphomas. This is results in deregulation of the BCL-2 gene and appears to play a role in oncogenesis. Various numbers of cells from a cell line derived spontaneously from a patient with B-cell lymphoma bearing the t(14;18) translocation and negative for the Epstein-Barr virus (EBV) were injected by IP, IV, and SC routes into SCID mice. The mice developed lymphoma bearing the t(14;18) translocation with as few as 5 x 10(6) cells within 28 days. This was determined by histological examination. The higher the cell inoculation the more rapidly the lymphoma developed. Engraftment of the tumour cells was determined by PCR for the t(14;18) breakpoint region on peripheral blood samples and could be detected prior to development of overt lymphoma. Having established a lymphoma model the cells were treated with antisense oligonucleotides to the first open reading frame of the BCL-2 gene prior to inoculation of the SCID mice. Control treatments with sense and nonsense oligonucleotides was also performed. At 28 days the sense, nonsense and untreated cell SCID mice had developed lymphoma, however, the antisense treated group failed to develop lymphoma. The findings demonstrate the modelling of B-cell lymphoma bearing the t(14;18) translocation and the ability to modify the lymphoma process with the use of antisense oligonucleotides to the BCL-2 gene. Reduction of the BCL2 protein suppresses the oncogenic potential of these lymphoma cells confirming that it plays an essential role in the development of malignancy.	IMPERIAL CANC RES FUND,ONCOL GRP,LONDON WC1N 1EH,ENGLAND; INST CHILD HLTH,MOLEC IMMUNOL UNIT,LONDON WC1N 1EH,ENGLAND; ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT ONCOL,LONDON EC1 1BB,ENGLAND; ST THOMAS HOSP,DEPT HISTOPATHOL,LONDON SE1 7EH,ENGLAND	Cancer Research UK; University of London; University College London; Cancer Research UK; University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust	COTTER, FE (corresponding author), LRF,DEPT HAEMATOL & ONCOL,LONDON WC1N 1EH,ENGLAND.		Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Cowell, John/0000-0002-2079-5950				AMADORI A, 1992, LEUKEMIA, V6, pS23; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CULLEN MH, 1979, CANCER, V44, P645, DOI 10.1002/1097-0142(197908)44:2<645::AID-CNCR2820440234>3.0.CO;2-Y; ERSBOLL J, 1989, EUR J HAEMATOL, V42, P155; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GARVIN AJ, 1983, CANCER-AM CANCER SOC, V52, P393, DOI 10.1002/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M; HAGENBEEK A, 1992, LEUKEMIA, V6, P12; HALL PA, 1980, HISTOPATHOLOGY, V13, P149; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUA C, 1988, ONCOGENE RES, V2, P263; KAMELREID S, 1991, BLOOD, V78, P2973; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; KNOWLES DM, 1989, BLOOD, V73, P1635; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1993, BLOOD, V81, P151; NGAN BY, 1989, BLOOD, V73, P1735; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; PEZELLA F, 1990, NOUV REV FR HEMATOL, V32, P397; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; RISDALL R, 1979, CANCER, V44, P529, DOI 10.1002/1097-0142(197908)44:2<529::AID-CNCR2820440222>3.0.CO;2-Y; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STETLERSTEVENSON M, 1990, J NATL CANCER I, V82, P855, DOI 10.1093/jnci/82.10.855; THOMAS JA, 1993, BLOOD, V81, P3350; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YANO T, 1992, BLOOD, V80, P758	32	190	204	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3049	3055						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084613				2022-12-28	WOS:A1994PG82200036
J	KOZUTSUMI, H; TOYOSHIMA, H; HAGIWARA, K; YAZAKI, Y; HIRAI, H				KOZUTSUMI, H; TOYOSHIMA, H; HAGIWARA, K; YAZAKI, Y; HIRAI, H			HUMAN LTK RECEPTOR TYROSINE KINASE BINDS TO PLC-GAMMA-1, PI3-K, GAP AND RAF-1 IN-VIVO	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; EGF RECEPTOR; PDGF RECEPTOR; PROTEIN; RAS; ASSOCIATION; GRB2	Leukocyte tyrosine kinase (ltk) is a receptor-type tyrosine kinase which is suggested to be expressed in hematopoietic cells and neuronal cells in human. Recently we have cloned a full sized human ltk cDNA which has a 423 amino acid extracellular domain which may bind to unknown ligand(s), and a 415 amino acid cytoplasmic domain which contains a tyrosine kinase domain. To identify the cellular signal transducer proteins binding to the ltk protein, we have analysed the recombinant ltk protein transiently expressed in COS cells. By an in vitro immune complex kinase assay, a major 140 kDa phosphoprotein and other cellular phosphoproteins were co-immunoprecipitated with the 100 kDa ltk protein using anti-ltk monoclonal antibodies. Western blot analysis revealed that the wild-type ltk protein was tyrosine-phosphorylated in vivo and associated with SH2 containing proteins, PLC-gamma 1, p85 subunit of PI3-K and GAP, in vivo. Furthermore, the wild-type ltk protein also binds to a serine/threonine kinase, Raf-1, in vivo. In contrast, none of these signal transducer proteins were associated with a kinase-negative ltk mutant (K544M-ltk) in which methionine at the putative ATP binding site was replaced with lysine. These results suggest that the associations of the ltk protein with those signaling molecules depend on the tyrosine kinase activity of the ltk protein. This is the first detection of cytoplasmic signal transducers that bind to the ltk protein in vivo.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	University of Tokyo								BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOZUTSUMI H, 1993, BIOCHEM BIOPH RES CO, V190, P674, DOI 10.1006/bbrc.1993.1101; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARU Y, 1990, ONCOGENE RES, V5, P199; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1773; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	39	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2991	2998						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084603				2022-12-28	WOS:A1994PG82200026
J	GOLDSTONE, SD; LAVIN, MF				GOLDSTONE, SD; LAVIN, MF			PROLONGED EXPRESSION OF C-JUN AND ASSOCIATED ACTIVITY OF THE TRANSCRIPTION FACTOR AP-1, DURING APOPTOSIS IN A HUMAN LEUKEMIC-CELL LINE	ONCOGENE			English	Article							PROTO-ONCOGENE; IONIZING-RADIATION; CYCLE PROGRESSION; DNA FRAGMENTATION; GENE-EXPRESSION; LEUCINE ZIPPER; V-JUN; FOS; DEATH; GROWTH	The product of the c-jun gene is a component of the transcription factor AP-1, which plays a critical regulatory role in the cellular response to certain proliferative stimuli. In this report, we demonstrate the prolonged expression of c-jun mRNA during apoptosis induced in a human leukaemic T-cell line, CEM C7, by treatment with either dexamethasone or gamma-radiation. However, overexpression of the c-jun mRNA was not accompanied by either increased expression of jun protein, or increased AP-1 DNA binding activity. Indeed, a decrease in AP-1 DIVA binding activity was seen in response to both inducing stimuli. This decrease in AP-1.binding activity may be mediated by an increase in the activity of an AP-1 inhibitory factor, as the steady state levels of jun protein remained constant during the onset of apoptosis, and cytosolic AP-1 inhibitory activity was found to increase, concomitant with the decrease in AP-1 DNA binding activity. Our data demonstrate the complexity of the mechanisms involved in the regulation of c-jun expression during the onset of apoptosis, and suggest a novel mode for the regulation of AP-1 activity during the cessation of proliferation.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BANCROFT CTR,BRISBANE,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	GOLDSTONE, SD (corresponding author), UNIV SYDNEY,DEPT PATHOL,DO6,SYDNEY,NSW 2006,AUSTRALIA.		Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUWERX J, 1992, ONCOGENE, V7, P2271; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAXTER GD, 1992, J IMMUNOL, V148, P1949; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CARTER R, 1991, ONCOGENE, V6, P229; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASSON JC, 1983, J CELL BIOL, V96, P409, DOI 10.1083/jcb.96.2.409; GOLDSTONE SD, 1991, BIOCHEM BIOPH RES CO, V178, P746, DOI 10.1016/0006-291X(91)90171-3; GUNJI H, 1991, CANCER RES, V51, P741; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438, DOI 10.1128/MCB.9.8.3438; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOSHIKAWA Y, 1988, ENDOCRINOL JAPON, V35, P429; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8454; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; YUH YS, 1989, J BIOL CHEM, V264, P10904; YUH YS, 1987, SOMAT CELL MOLEC GEN, V13, P33, DOI 10.1007/BF02422297; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	45	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2305	2311						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036012				2022-12-28	WOS:A1994NX62900023
J	MITCHELL, PJ; BARKER, KT; MARTINDALE, JE; KAMALATI, T; LOWE, PN; PAGE, MJ; GUSTERSON, BA; CROMPTON, MR				MITCHELL, PJ; BARKER, KT; MARTINDALE, JE; KAMALATI, T; LOWE, PN; PAGE, MJ; GUSTERSON, BA; CROMPTON, MR			CLONING AND CHARACTERIZATION OF CDNAS ENCODING A NOVEL NONRECEPTOR TYROSINE KINASE, BRK, EXPRESSED IN HUMAN BREAST-TUMORS	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; SH3 DOMAINS; PROTEIN OVEREXPRESSION; SIGNAL TRANSDUCTION; PROGNOSTIC VALUE; RNA ISOLATION; CANCER; ONCOGENE; GENE; AMPLIFICATION	Using a polymerase chain reaction based differential screening approach, we have isolated and characterised a cDNA from a human metastatic breast tumour representing a novel protein tyrosine kinase (brk). Sequencing of brk cDNAs isolated from T-47D and MCF-7 human breast tumour cell lines indicate that they encode a protein with the features of a novel nonreceptor tyrosine kinase, including amino terminal SH3 and SH2 domains. When synthesised in recombinant baculovirus and bacterial expression systems, brk protein products are capable of autophosphorylation on tyrosine residues. Initial expression studies have detected low levels of brk transcripts in some human breast tumours and breast tumour cell lines, but not in normal breast tissue.	INST CANC RES,CELL BIOL & EXPTL PATHOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND	University of London; Institute of Cancer Research - UK; GlaxoSmithKline; Wellcome Research Laboratories			gusterson, barry a/D-3752-2009; Mitchell, Philip J/F-6393-2013					ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P4107, DOI 10.1093/nar/20.15.4107; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRIMAUX M, 1989, BREAST CANCER RES TR, V14, P77, DOI 10.1007/BF01805978; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HENNIPMAN A, 1989, CANCER RES, V49, P516; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE ST, 1993, ONCOGENE, V8, P3403; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NICOLSON S, 1991, BRIT J CANCER, V63, P146; OKADA M, 1991, J BIOL CHEM, V266, P24249; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATERSON MC, 1991, CANCER RES, V51, P556; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAINSBURY JRC, 1987, LANCET, V1, P1398; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TOI M, 1989, INT J CANCER, V43, P220, DOI 10.1002/ijc.2910430208; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; 1989, BREAST SCREENING PUB	49	149	158	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2383	2390						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036022				2022-12-28	WOS:A1994NX62900033
J	SOLDI, R; GRAZIANI, A; BENELLI, R; GHIGO, D; BOSIA, A; ALBINI, A; BUSSOLINO, F				SOLDI, R; GRAZIANI, A; BENELLI, R; GHIGO, D; BOSIA, A; ALBINI, A; BUSSOLINO, F			ONCOSTATIN-M ACTIVATES PHOSPHATIDYLINOSITOL-3-KINASE IN KAPOSIS-SARCOMA CELLS	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; RECEPTOR TYROSINE KINASES; HEPATOCYTE GROWTH-FACTOR; IL-6 SIGNAL TRANSDUCER; POLYOMAVIRUS MIDDLE-T; SH2 DOMAINS; ERYTHROPOIETIN RECEPTOR; PDGF RECEPTOR; BINDING-SITE; PI 3-KINASE	Oncostatin M (OM) is a polypeptide cytokine that induces autocrine and paracrine effects on AIDS-Kaposi's sarcoma (KS) cells (Nair et al., Science, 255, 1430-1432, 1992; Miles et al., Science, 255, 1432-1434, 1992). The signalling pathways underlying this activation are largely unknown. We have found that OM binding to KS cell Lines in vitro identifies a higher affinity binding site (Kd 10-20 pM) with a lower affinity (Kd 1.5 nM), high capacity binding site. The binding of OM to its receptor at the KS cell surface stimulates a rapid tyrosine phosphorylation of multiple proteins, including the p85 regulatory subunit of phosphatidylinositol-3-kinase (PI3K). In addition OM can stimulate the in vivo activation of PI3K and increases the PI3K activity in anti-phosphotyrosine and anti-src kinase family antibody directed immunoprecipitates. Genistein, an inhibitor of tyrosine kinases, inhibits the synthesis of phosphatidylinistol 3,4-biphosphate and the growth of KS cells. Finally, OM enhances tyrosine kinase activity in immune complex kinase assay performed with antibody anti-src kinase family. These data suggest that in KS cells OM can stimulate formation of tyrosine kinase co-ordinate signalling complexes, containing at least src kinase family and PI3K, which can drive the accumulation of the putative second-messengers D3-phosphorylated phosphoinositides.	DIPARTIMENTO GENET BIOL & CHIM MED, I-10100 TURIN, ITALY; DIPARTIMENTO SCI BIOMED & ONCOL, I-10100 TURIN, ITALY; IST NAZL RIC CANC, I-16100 GENOA, ITALY	University of Genoa; IRCCS AOU San Martino IST			graziani, andrea/B-2554-2009; Bussolino, Federico/AES-3951-2022; Graziani, Andrea/AAB-6301-2022; Bussolino, Federico/K-2500-2016	graziani, andrea/0000-0002-6302-2317; Graziani, Andrea/0000-0002-6302-2317; Bussolino, Federico/0000-0002-5348-1341; Ghigo, Dario/0000-0001-6050-1577; Benelli, Roberto/0000-0002-9769-0954; Albini, Adriana/0000-0002-9624-5103				ALBINI A, 1992, INT J ONCOL, V1, P723; AMARAL MC, 1993, J CLIN INVEST, V92, P848, DOI 10.1172/JCI116659; AMREIN KE, 1993, P NATL ACAD SCI USA, V90, P10285, DOI 10.1073/pnas.90.21.10285; ARMES J, 1989, ADV CANCER RES, V53, P73; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGER KR, 1992, J BIOL CHEM, V267, P5408; AUGER RK, 1990, METHODS INOSITIDES R, P155; BROWN TJ, 1993, BLOOD, V82, P33, DOI 10.1182/blood.V82.1.33.bloodjournal82133; BROWN TJ, 1991, J IMMUNOL, V147, P2175; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTER AN, 1992, J BIOL CHEM, V267, P14563; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DADI HK, 1993, J CLIN INVEST, V92, P1559, DOI 10.1172/JCI116736; DAMEN JE, 1993, BLOOD, V81, P3204; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; HAVERKOS HW, 1985, NEW ENGL J MED, V312, P1518; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RUTGERS JL, 1986, AM J PATHOL, V122, P493; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; THOMPSON PA, 1992, ONCOGENE, V7, P719; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WEICH HA, 1991, AM J PATHOL, V139, P1251; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	70	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2253	2260						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036010				2022-12-28	WOS:A1994NX62900017
J	MOYRET, C; THEILLET, C; PUIG, PL; MOLES, JP; THOMAS, G; HAMELIN, R				MOYRET, C; THEILLET, C; PUIG, PL; MOLES, JP; THOMAS, G; HAMELIN, R			RELATIVE EFFICIENCY OF DENATURING GRADIENT GEL-ELECTROPHORESIS AND SINGLE-STRAND CONFORMATION POLYMORPHISM IN THE DETECTION OF MUTATIONS IN EXON-5 TO EXON-8 OF THE P53 GENE	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; LI-FRAUMENI SYNDROME; POINT MUTATIONS; DNA FRAGMENTS; BREAST-CANCER; LUNG-CANCER; OCCUR; SUBSTITUTIONS; EXPRESSION; DELETIONS	p53 is the most commonly mutated gene in a large variety of human tumors including familial cancers. Because p53 mutations have in a number of human cancer types, been related to a negative outcome of the disease and the importance of pre-symptomatic diagnosis in cancer-prone families, screening for p53 mutations is becoming more and more widely used. In order to avoid sequencing of the complete coding sequence, several prescreening methods have been developed and applied to the p53 gene. Among them, Single Strand Conformation Polymorphism (SSCP) and Denaturing Gradient Gel Electrophoresis (DGGE) appear to be highly sensitive. In this work, we used 52 different p53 variants to compare the two methods. In our conditions, DGGE is more sensitive than SSCP since 100% of the variants were detected. SSCP detected 90% of the variants, but efficiency of the method can still be improved by additional optimization experiments.	INST CURIE,GENET TUMEURS LAB,F-75231 PARIS,FRANCE; INST GENET MOLEC MONTPELLIER,CNRS,F-34033 MONTPELLIER 01,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)			Molès, Jean-Pierre/M-2286-2017; Theillet, Charles/O-7634-2018	Molès, Jean-Pierre/0000-0002-6863-6350; Theillet, Charles/0000-0001-5555-2759				BAKER SJ, 1990, CANCER RES, V50, P7717; CONDIE A, 1993, HUM MUTAT, V2, P58, DOI 10.1002/humu.1380020111; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HAMELIN R, 1993, ONCOGENE, V8, P2213; HAMELIN R, 1994, INT J CANCER, V57; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTIN HM, 1992, INT J CANCER, V50, P859, DOI 10.1002/ijc.2910500604; MAZARS GR, 1992, ONCOGENE, V7, P1015; MAZARS R, 1992, CANCER RES, V52, P3918; MAZARS R, 1991, ONCOGENE, V6, P1685; MOLES JP, 1993, ONCOGENE, V8, P583; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PORTIER M, 1992, ONCOGENE, V7, P2539; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOMINAGA O, 1993, ONCOGENE, V8, P2653	25	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1739	1743						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183571				2022-12-28	WOS:A1994NL81500028
J	VENNSTROM, B; RAYNOSCHECK, C; JANSSON, L; DOEDERLEIN, G; LHOTAK, V; JOHNSSON, A; BEUG, H				VENNSTROM, B; RAYNOSCHECK, C; JANSSON, L; DOEDERLEIN, G; LHOTAK, V; JOHNSSON, A; BEUG, H			RETROVIRAL CAPTURE OF C-ERBB PROTOONCOGENE SEQUENCES - RAPID EVOLUTION OF DISTINCT VIRAL GENOMES CARRYING MUTANT V-ERBB GENES WITH DIFFERENT TRANSFORMING CAPACITIES	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; ROUS-SARCOMA VIRUS; TISSUE-SPECIFIC TRANSFORMATION; SINGLE REPLICATION CYCLE; LARGE DELETION MUTANTS; LEUKOSIS VIRUS; EGF RECEPTOR; NUCLEOTIDE-SEQUENCE; CELL-TRANSFORMATION	The evolution of oncogene-transducing retorviruses was followed by studying the genomes of five new, erbB carrying retroviruses. These viruses, isolated from cells of one chicken infected with Rous Associated virus 1 (RAV-1), had captured c-erbB sequences as a consequence of RAV-1 integration into the host genome. Their genome structures were distinct; however, their v-erbB genes had sustained identical 5' and 3' deletions and the v-erbB-env junctions were identical at the nucleotide level. The results therefore strongly suggest that all five viruses originate from the same capture event. Sequence analyses of the v-erbB genes from three of these viruses revealed that one of them had undergone no further mutation and lacked detectable capacity to transform cells, therefore probably representing an 'early' form of transducing virus. The two other v-erbB genes contained distinct mutations and differed in their potential to induce fibroblast- and erythroblast transformation; they therefore probably represent later derivatives of the virus that captured the erbB oncogene. The data suggest that the initial retrovirus rapidly underwent many alterations after capture of c-erbB sequences, already in the RAV-1 infected bird as well as during subsequent in vitro isolation procedures. The changes involve both major rearrangements of the genome as well as point mutations that activated the erbB oncogene.	KAROLINSKA INST,DEPT MED CELL BIOL,S-10401 STOCKHOLM,SWEDEN; SQUIBB FORRESTRAL GREENS,DEPT MOLEC BIOL,PLAINSBORO,NJ 08536; EMBL,HEIDELBERG,GERMANY; MT SINAI HOSP,TORONTO M5G 1X5,ON,CANADA; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Karolinska Institutet; European Molecular Biology Laboratory (EMBL); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	VENNSTROM, B (corresponding author), KAROLINSKA INST,DEPT MOLEC BIOL,S-10401 STOCKHOLM,SWEDEN.			Sanchez-Pardo Echevarria, Jesus/0000-0002-3683-5371				BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1981, VIROLOGY, V111, P201, DOI 10.1016/0042-6822(81)90665-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOODWIN RG, 1986, MOL CELL BIOL, V6, P3128, DOI 10.1128/MCB.6.9.3128; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1980, P NATL ACAD SCI-BIOL, V77, P389, DOI 10.1073/pnas.77.1.389; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HIHARA H, 1983, J NATL CANCER I, V70, P891; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUANG CC, 1986, CELL, V44, P935, DOI 10.1016/0092-8674(86)90016-4; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KAWAI S, 1987, J VIROL, V61, P1665, DOI 10.1128/JVI.61.5.1665-1669.1987; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KILLISCH I, 1992, J CELL SCI, V103, P211; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEE EB, 1990, ONCOGENE, V5, P1165; LEE EB, 1993, ONCOGENE, V8, P1317; LEUTZ A, 1988, J BIOL CHEM, V263, P3905; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P4868, DOI 10.1128/MCB.8.11.4868; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; PRIVALSKY ML, 1984, VIROLOGY, V135, P356, DOI 10.1016/0042-6822(84)90192-2; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2127; ROBINSON HL, 1985, J VIROL, V55, P617, DOI 10.1128/JVI.55.3.617-622.1985; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SCOTTING P, 1987, ONCOGENE RES, V1, P265; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; SORGE J, 1982, Journal of Molecular and Applied Genetics, V1, P547; SWAIN A, 1992, SCIENCE, V255, P841, DOI 10.1126/science.1371365; UHL E., 1936, Acta Pathologica et Microbiologica Scandinavica, V13, P434; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VOYNOW SL, 1985, J VIROL, V55, P79, DOI 10.1128/JVI.55.1.79-85.1985; VOYNOW SL, 1985, J VIROL, V55, P67, DOI 10.1128/JVI.55.1.67-78.1985; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	62	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1307	1320						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152791				2022-12-28	WOS:A1994NH40100001
J	CHOI, KH; WALL, C; HANRATTY, R; KELLER, G				CHOI, KH; WALL, C; HANRATTY, R; KELLER, G			ISOLATION OF A GENE ENCODING A NOVEL RECEPTOR TYROSINE KINASE FROM DIFFERENTIATED EMBRYONIC STEM-CELLS	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; C-KIT; SIGNAL TRANSDUCTION; ENZYMATIC AMPLIFICATION; MESSENGER-RNAS; SEQUENCES; IDENTIFICATION; ANGIOGENESIS; EXPRESSION; MUTATIONS	A mouse gene encoding a receptor tyrosine kinase, designated Embryonic receptor kinase (EmRK2), was isolated from embryoid bodies (EBs) generated by differentiating embryonic stem (ES) cells in culture for 6 days. Sequence analysis of EmRK2 cDNA clones predicts a receptor with a 755 amino acid extracellular region with seven immunoglobulin-like domains, a transmembrane region, and a 552 amino acid cytoplasmic region containing the kinase domain. The kinase domain is interrupted by a stretch of hydrophilic amino acids, the kinase insert. EmRK2 is expressed in embryoid bodies, in whole embryos at day 10 and 12 of gestation, and in the embryonic yolk sac and the fetal liver. On the basis of sequence homology, EmRK2 is likely to be the mouse homologue of human flt, a receptor for vascular endothelial growth factor, and as such, could encode an endothelial cell specific receptor tyrosine kinase.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	CHOI, KH (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206, USA.			Keller, Gordon/0000-0001-9309-9297				BREIER G, 1992, DEVELOPMENT, V114, P521; CHOI KG, 1993, P NATL ACAD SCI USA, V90, P5747, DOI 10.1073/pnas.90.12.5747; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS M, NATURE, V292, P154; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEN Z, 1991, ONCOGENE, V6, P953; GALLAND F, 1993, ONCOGENE, V8, P1233; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OELRICHS RB, 1993, ONCOGENE, V8, P11; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; REITH AD, 1990, GENE DEV, V4, P3900; RISAU W, 1988, DEVELOPMENT, V102, P471; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SHIBUYA M, 1990, ONCOGENE, V5, P519; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WANG R, 1992, DEVELOPMENT, V114, P303; WILES MV, 1991, DEVELOPMENT, V111, P259; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1	39	9	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1261	1266						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134130				2022-12-28	WOS:A1994NC04800032
J	HERBER, B; TRUSS, M; BEATO, M; MULLER, R				HERBER, B; TRUSS, M; BEATO, M; MULLER, R			INDUCIBLE REGULATORY ELEMENTS IN THE HUMAN CYCLIN-D1 PROMOTER	ONCOGENE			English	Article							CELL-CYCLE; CANDIDATE ONCOGENE; FOS JUN; DNA; GENE; FIBROBLASTS; IDENTIFICATION; EXPRESSION; COMPLEXES; FAMILY	To be able to elucidate the function of cyclin D1 in the control of cell cycle progression and its role as an oncogene in tumourigenesis, it is of paramount importance to understand the mechanisms involved in the regulation of its expression. In the present study, we have cloned the human cyclin D1 gene and analysed the structure and function of 3kb of its 5'-flanking region. Several regulatory regions involved in both basal level and serum-induced expression were identified, two of which turned out to be of particular interest. One of these regions is involved in serum induction and is located 848-944 bp upstream of the initiation site. In agreement with this result, in vivo footprinting revealed a novel, strongly inducible protein binding site around positions -928 to -921. A second constitutively occupied binding site was mapped to a potential CRE at position -52. Cotransfection experiments showed that the cyclin D1 promoter is inducible by c-Jun, and that this induction is mediated predominantly through the protected putative CRE at -52.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, EMIL MANNKOPFF STR 2, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016; Beato, Miguel/B-5564-2015	Müller, Rolf/0000-0003-3339-4248; Beato, Miguel/0000-0002-2878-2222				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PRUNELL A, 1982, EMBO J, V1, P173, DOI 10.1002/j.1460-2075.1982.tb01143.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	46	251	257	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1295	1304						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134134				2022-12-28	WOS:A1994NC04800037
J	MERLO, GR; VENESIO, T; TAVERNA, D; MARTE, BM; CALLAHAN, R; HYNES, NE				MERLO, GR; VENESIO, T; TAVERNA, D; MARTE, BM; CALLAHAN, R; HYNES, NE			GROWTH SUPPRESSION OF NORMAL MAMMARY EPITHELIAL-CELLS BY WILD-TYPE P53	ONCOGENE			English	Article							HUMAN BREAST-CANCER; CELLULAR TUMOR-ANTIGEN; BETA-CASEIN GENE; MUTANT P53; EMBRYO FIBROBLASTS; SV40 DNA; MUTATIONS; PROTEIN; TRANSFORMATION; EXPRESSION	p53 mutations are frequent in human breast cancer. In order to understand the role of p53 in the context of the accumulation of mutations in breast cancer, a model of non transformed mammary cells was sought. The HC11 cells are immortalized, non transformed rodent mammary epithelial cells which synthesize milk proteins following stimulation with lactogenic hormones. p53 protein was readily detected in HC11 protein extracts with the PAb421 antibody. Two mutations were identified in the p53 cDNA from HC11 cells: a missense mutation at codon 138, substituting Trp for Cys, and a microdeletion, codon 123 to 130, of exon 5. The latter results from an intronic mutation of the splice acceptor site at the intron 4/exon 5 junction. The mutations affect separate p53 alleles, and no wt allele was found. Wt p53 was introduced into HC11 cells by means of a retroviral vector, under the control of a Cd++-inducible promoter. In the presence of CdSO4 a dramatic growth inhibition was observed. A temperature-sensitive mutant p53 gene was also transfected into HC11 cells. This resulted in a marked inhibition of cells growth at 32 degrees C, when the p53 is in the wt conformation, while no effect was observed at 37 degrees C, when the mutant conformation is predominant. wt p53-mediated inhibition of monolayer growth does not involve induction of programmed cell death and does not activate de novo synthesis of differentiation-specific milk proteins. We conclude that mutations in the p53 gene likely played a role in their immortalization. The HC11 cells provide a model for assessing the cooperative action of other mutations in mammary tumorigenesis.	USL 1,S GIOVANNI HOSP,I-10123 TURIN,ITALY; NCI,ONCOGENET SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MERLO, GR (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.		; taverna, daniela/J-8358-2016	Venesio, Tiziana/0000-0002-9035-056X; taverna, daniela/0000-0002-6365-527X				ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BARTEK J, 1990, INT J CANCER, V45, P1105, DOI 10.1002/ijc.2910450620; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CASEY G, 1991, ONCOGENE, V6, P1791; CEPKO CL, 1992, CURRENT PROTOCOLS MO; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG J, 1992, CANCER RES, V52, P222; CZOSNEK HH, 1984, MOL CELL BIOL, V4, P1638, DOI 10.1128/MCB.4.8.1638; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GARCIA I, 1991, CANCER RES, V51, P294; GONOS ES, 1992, INT J ONCOL, V1, P209; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HAPP B, 1993, CELL GROWTH DIFFER, V4, P9; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATOZAKI T, 1992, CANCER RES, V52, P4335; MAZARS R, 1992, CANCER RES, V52, P3918; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MERLO GR, 1993, INT J CANCER, V54, P531, DOI 10.1002/ijc.2910540402; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MONTENARH M, 1992, ONCOGENE, V7, P1673; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; REDMOND SMS, 1988, ONCOGENE, V2, P259; ROVINSKI B, 1988, ONCOGENE, V2, P445; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SATO T, 1990, CANCER RES, V50, P7184; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TAYLOR WR, 1992, ONCOGENE, V7, P1383; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VARLEY JM, 1991, ONCOGENE, V6, P413; VENESIO T, 1992, CELL GROWTH DIFFER, V3, P63; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367	65	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					443	453						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290256				2022-12-28	WOS:A1994MW24800011
J	ROUSSELOT, P; HARDAS, B; PATEL, A; GUIDEZ, F; GAKEN, J; CASTAIGNE, S; DEJEAN, A; DETHE, H; DEGOS, L; FARZANEH, F; CHOMIENNE, C				ROUSSELOT, P; HARDAS, B; PATEL, A; GUIDEZ, F; GAKEN, J; CASTAIGNE, S; DEJEAN, A; DETHE, H; DEGOS, L; FARZANEH, F; CHOMIENNE, C			THE PML-RAR-ALPHA GENE-PRODUCT OF THE T(1517) TRANSLOCATION INHIBITS RETINOIC ACID-INDUCED GRANULOCYTIC DIFFERENTIATION AND MEDIATED TRANSACTIVATION IN HUMAN MYELOID CELLS	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RECEPTOR-ALPHA; MAMMALIAN-CELLS; T(15-17) TRANSLOCATION; RESPONSIVE ELEMENT; EXPRESSION; PROTEINS; THERAPY; INVITRO; BINDING	Acute promyelocytic leukemia (APL) is characterized by an arrest of granulocytic differentiation and a reciprocal t(15;17) translocation fusing the PML gene to the retinoic acid receptor alpha (RAR alpha) gene. PML was recently identified as a potential transcription factor. In non hematopoietic cells, the transfected PML-RAR alpha product binds all trans retinoic acid and exhibits altered transactivating properties when compared with RAR alpha. A major question raised by these observations is whether PML-RAR alpha contributes to the inhibition of myeloid differentiation. We find that in myeloid cell lines responsive to retinoic acid, PML-RAR alpha blocks retinoic acid mediated transactivation and totally abrogates the retinoic acid mediated granulocytic differentiation. These findings strongly suggest that PML-RAR alpha may, by blocking normal retinoic acid dependent myeloid differentiation, participate in the leukemogenesis of APL. The fact that high doses of all-trans retinoic acid relieve the inhibitory effect of PML-RAR alpha corroborates the therapeutic effect of all-trans retinoic acid in APL patients.	KINGS COLL,SCH MED & DENT,MOLEC MED UNIT,LONDON,ENGLAND; INST PASTEUR,INSERM,U163,PARIS,FRANCE; HOP ST LOUIS,SERV CLIN MALAD SANG,PARIS,FRANCE; INST HEMATOL,UPR 43,PARIS,FRANCE; LAB BIOL CELLULAIRE HEMATOPOIET,PARIS,FRANCE	University of London; King's College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Guidez, Fabien/P-4220-2019; Dejean, Anne/L-5145-2018; Guidez, Fabien/B-3750-2009; Farzaneh, Farzin/B-4902-2009	Guidez, Fabien/0000-0003-1380-4473; Farzaneh, Farzin/0000-0002-9275-2415				ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1983, CANCER SURV, V2, P265; CASTAIGNE S, 1990, BLOOD, V76, P1704; CASTAIGNE S, 1992, BLOOD, V79, P3110; CHEN Z, 1993, EMBO J, V12, P111; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; CHOMIENNE C, 1989, LANCET, V1, P746; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DEGOS L, 1990, LANCET, V11, P1140; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRATAS C, 1993, LEUKEMIA, V7, P1156; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; ITANI T, 1987, GENE, V56, P267; JONES ME, 1978, AM J MED, V75, P673; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEFEBVRE P, 1991, LEUKEMIA, V5, P1054; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NERVI C, 1992, CANCER RES, V52, P3687; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; SAKASHITA A, 1993, BLOOD, V81, P1009; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	44	125	127	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					545	551						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290265				2022-12-28	WOS:A1994MW24800022
J	TAKADA, S; KIDO, H; FUKUTOMI, A; MORI, T; KOIKE, K				TAKADA, S; KIDO, H; FUKUTOMI, A; MORI, T; KOIKE, K			INTERACTION OF HEPATITIS-B VIRUS-X PROTEIN WITH A SERINE-PROTEASE, TRYPTASE TL(2) AS AN INHIBITOR	ONCOGENE			English	Article							EUKARYOTIC TRANSCRIPTIONAL ACTIVATORS; ERYTHROID-POTENTIATING ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS; PROMOTER TRANS-ACTIVATION; LONG TERMINAL REPEAT; RAT MAST-CELLS; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; TRANSACTIVATION FUNCTION; HUMAN LYMPHOCYTES-T4+	X protein of hepatitis B virus (HBV) transactivates transcription of various viral and cellular genes. It has been suggested that X protein plays a major role in hepatocarcinogenesis by HBV. The protein possesses amino acid sequence homology to the functionally essential domain of Kunitz-type serine protease inhibitors. This Kunitz domain-like sequence in X protein is indispensable for the transactivation function. To clarify whether X protein has a serine protease inhibitor activity, a search was made for serine proteases which interact with, but not degrade X protein. Tryptase TL,, one of serine proteases in hepatic cells, was found to directly interact with X protein without degradation. Moreover, the activities of tryptase TL, and an analogous protease were substantially inhibited by X protein. These results suggest that transactivation function of X protein is exerted by modulation of the hepatic serine protease activity, giving rise to quantitative or qualitative change of cellular transcription factor(s) through protection from proteolytic degradation and/or suppression of processing.	JFCR,INST CANC,DEPT GENE RES,TOSHIMA KU,TOKYO,TOKYO 170,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,DIV ENZYME CHEM,TOKUSHIMA 770,JAPAN	Japanese Foundation for Cancer Research; Tokushima University								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDERSON S, 1983, P NATL ACAD SCI-BIOL, V80, P6838, DOI 10.1073/pnas.80.22.6838; ARII M, 1992, ONCOGENE, V7, P397; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BERAUD C, 1991, EMBO J, V10, P3795, DOI 10.1002/j.1460-2075.1991.tb04949.x; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GILMAN M, 1993, NATURE, V361, P687, DOI 10.1038/361687a0; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KATO I, 1979, FED PROC, V38, P832; KATUNUMA N, 1975, EUR J BIOCHEM, V52, P37, DOI 10.1111/j.1432-1033.1975.tb03970.x; KIDO H, 1990, J BIOL CHEM, V265, P21979; KIDO H, 1991, FEBS LETT, V286, P233, DOI 10.1016/0014-5793(91)80981-8; KIDO H, 1988, J BIOL CHEM, V263, P18104; KIDO H, 1985, ARCH BIOCHEM BIOPHYS, V239, P436, DOI 10.1016/0003-9861(85)90709-X; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOBAYASHI M, 1984, GENE, V30, P227; KODAMA K, 1985, J VIROL, V56, P978, DOI 10.1128/JVI.56.3.978-986.1985; KOIKE K, 1989, MOL BIOL MED, V6, P151; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; OKAMOTO H, 1986, J GEN VIROL, V67, P2305, DOI 10.1099/0022-1317-67-11-2305; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PATARCA R, 1985, NATURE, V318, P390, DOI 10.1038/318390a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; TANAKA K, 1992, NEW BIOL, V4, P173; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TWU JS, 1989, J VIROL, V63, P2857, DOI 10.1128/JVI.63.6.2857-2860.1989; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAHM P, 1988, ONCOGENE, V3, P169	54	57	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					341	348						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290248				2022-12-28	WOS:A1994MW24800001
J	LOVEC, H; SEWING, A; LUCIBELLO, FC; MULLER, R; MOROY, T				LOVEC, H; SEWING, A; LUCIBELLO, FC; MULLER, R; MOROY, T			ONCOGENIC ACTIVITY OF CYCLIN D1 REVEALED THROUGH COOPERATION WITH HA-RAS - LINK BETWEEN CELL-CYCLE CONTROL AND MALIGNANT TRANSFORMATION	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; EXPRESSION; CARCINOMAS; BCL-1	Circumstantial evidence implicates the putative cell cycle regulator cyclin D1 in the process of malignant transformation. Overexpression of cyclin D1 is observed in mammary carcinomas as a result of gene amplification and in parathyroid adenomas and centrocytic B-cell lymphomas as a consequence of chromosomal rearrangements and juxtaposition of the cyclin D1 gene to strong transcriptional control elements. These findings suggest that deregulation of cyclin D1 expression may contribute to malignant transformation in these tumours. To date, however, an oncogenic potential of cyclin D1 has not been demonstrated and the mechanism of its oncogenic activation remains obscure although overexpression of the wild-type protein is likely. We report here that the overexpression of cyclin D1 induces transformation in primary rat embryo fibroblasts in cooperation with activated Ha-uas. Cyclin D1/Ha-ras transformed cells are immortalized, show anchorage independence and give rise to fibrosarcomas in nude mice. Our data directly demonstrate that cyclin D1 is a proto-oncogene that can be activated by transcriptional deregulation. Its previously demonstrated ability to interact with putative cell cycle regulators suggests that cyclin D1 defines a new class of proto-oncogenes.	PHILIPPS UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Moroy, Tarik/D-9923-2011; Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1992, CANCER RES, V52, P2980; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; ROSENBERG CL, 1993, ONCOGENE, V8, P519; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SCHUURING E, 1992, ONCOGENE, V7, P355; SEWING A, 1993, J CELL SCI, V104, P545; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	253	262	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					323	326						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302597				2022-12-28	WOS:A1994MW24700040
J	SMITH, K; HOULBROOK, S; GREENALL, M; CARMICHAEL, J; HARRIS, AL				SMITH, K; HOULBROOK, S; GREENALL, M; CARMICHAEL, J; HARRIS, AL			TOPOISOMERASE-II-ALPHA COAMPLIFICATION WITH ERBB2 IN HUMAN PRIMARY BREAST-CANCER AND BREAST-CANCER CELL-LINES - RELATIONSHIP TO M-AMSA AND MITOXANTRONE SENSITIVITY	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; DNA TOPOISOMERASES; PROTEIN OVEREXPRESSION; PROGNOSTIC-SIGNIFICANCE; CHROMOSOME BREAKAGE; DRUG-ACTION; EXPRESSION; GENE; PROLIFERATION; CARCINOMA	Topoisomerase IIalpha (topo IIalpha) is a key enzyme in DNA replication and a target for many anti-cancer drugs. High levels are associated with sensitivity to topoisomerase II inhibitors. Because its chromosome location is similar to erbB2 (17q21-22), which is frequently amplified in breast cancer, co-amplification of these genes was assessed. In 117 primary breast cancers, 25 were amplified for erbB2. Three of these cases showed co-amplification of topo IIalpha. Topo IIbeta was not amplified. Four human breast cancer cell lines were assessed for erbB2 and topo IIalpha co-amplification. They were also analysed for sensitivity to the topoisomerase inhibitors m-AMSA and mitoxantrone. The most sensitive cell line was SKBr3, which was the only one with erbB2 amplification. Topo IIalpha was co-amplified to a similar extent as in tumours. This suggests that patients whose tumours show topo IIalpha amplification should be assessed specifically for therapy with topoisomerase inhibitors.	UNIV OXFORD,JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOLEC MED,MOLEC ONCOL LABS,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT SURG,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BARNES DM, 1988, BRIT J CANCER, V58, P448, DOI 10.1038/bjc.1988.238; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; DAVIES SM, 1989, NUCLEIC ACIDS RES, V17, P1337, DOI 10.1093/nar/17.4.1337; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EPSTEIN RJ, 1989, BIOCHEM BIOPH RES CO, V160, P12, DOI 10.1016/0006-291X(89)91613-6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FREAKE HC, 1981, BIOCHEM BIOPH RES CO, V101, P1131, DOI 10.1016/0006-291X(81)91565-5; FRICHE E, 1991, CANCER RES, V51, P4213; GLIKIN GC, 1986, EMBO J, V5, P151, DOI 10.1002/j.1460-2075.1986.tb04189.x; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HARRIS AL, 1990, LANCET, V335, P186, DOI 10.1016/0140-6736(90)90277-C; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HINDS M, 1991, CANCER RES, V51, P4729; HOFKER MH, 1985, HUM GENET, V70, P148, DOI 10.1007/BF00273073; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HONG JH, 1990, BIOMED PHARMACOTHER, V44, P41, DOI 10.1016/0753-3322(90)90068-K; HORAK E, 1991, ONCOGENE, V6, P2277; HSIANG YH, 1988, CANCER RES, V48, P3230; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KEITH WN, 1992, IN PRESS GENES CHROM; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LONG BH, 1991, CANCER RES, V51, P5275; NELSON WG, 1987, CANCER RES, V47, P3246; NICHOLSON S, 1988, INT J CANCER, V42, P36, DOI 10.1002/ijc.2910420108; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PENG J, 1988, P NATL ACAD SCI USA, V85, P7177; PERREN TJ, 1991, BRIT J CANCER, V63, P328, DOI 10.1038/bjc.1991.78; PLUMB JA, 1989, CANCER RES, V49, P4435; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROWE TC, 1986, CANCER RES, V46, P2021; SAINTRUF C, 1991, ONCOGENE, V6, P403; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; SNAPKA RM, 1986, MOL CELL BIOL, V6, P4221, DOI 10.1128/MCB.6.12.4221; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SULLIVAN DM, 1986, BIOCHEMISTRY-US, V25, P2248, DOI 10.1021/bi00356a060; SULLIVAN DM, 1987, CANCER RES, V47, P3973; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WRIGHT C, 1992, BRIT J CANCER, V65, P271, DOI 10.1038/bjc.1992.54; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; 1980, EUR J CANCER, V16, P1313; 1992, LANCET, V339, P71	65	127	130	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					933	938						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8096076				2022-12-28	WOS:A1993KT22000015
J	GRIECO, M; CERRATO, A; SANTORO, M; FUSCO, A; MELILLO, RM; VECCHIO, G				GRIECO, M; CERRATO, A; SANTORO, M; FUSCO, A; MELILLO, RM; VECCHIO, G			CLONING AND CHARACTERIZATION OF H4 (D10S170), A GENE INVOLVED IN RET REARRANGEMENTS IN-VIVO	ONCOGENE			English	Article							PAPILLARY THYROID CARCINOMAS; TYROSINE KINASE; INSITU HYBRIDIZATION; ONCOGENE ACTIVATION; TRANSFORMING GENE; PROTO-ONCOGENE; MESSENGER-RNA; COILED-COIL; PROTOONCOGENE; EXPRESSION	H4(D10S170) is a gene which we isolated because of its frequent rearrangement with the RET proto-oncogene in vivo. Its fusion to RET generates the RET/PTC1 oncogene, which has been detected in about 20% of human thyroid papillary carcinomas. We have cloned and sequenced the cDNA corresponding to the H4(D10S170) gene from a human normal thyroid cDNA library. The nucleotide sequence of the H4(D10S170) 3kb transcript shows no significant homology to known genes and contains an open reading frame (ORF) of 585 amino acids. H4(D10S170) predicted protein has no transmembrane domain and shows extensive regions in the alpha helical conformation, which are 30%.homologous to the alpha-helical domains of several proteins including tropomyosin, vimentin, keratin and the tail region of myosin heavy chain. A putative SH3 binding site is present at the carboxy terminus, which suggests that H4(D10S170) might be a cytoskeletal protein.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Universita Mediterranea di Reggio Calabria	GRIECO, M (corresponding author), FAC MED & CHIRURG NAPOLI,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL,CNR,I-80131 NAPLES,ITALY.		Cerrato, Aniello/AAY-1484-2020; melillo, rosa marina/O-5255-2015	MELILLO, Rosa Marina/0000-0002-9233-5275; Fusco, Alfredo/0000-0003-3332-5197; Grieco, Michele/0000-0002-4212-7814				BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRECO A, 1992, ONCOGENE, V7, P237; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; ITO T, 1993, CANCER RES, V53, P2940; JHIANG SM, 1992, ONCOGENE, V7, P1331; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; KUNIEDA T, 1991, GENE, V107, P323, DOI 10.1016/0378-1119(91)90334-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANZI C, 1992, ONCOGENE, V7, P2189; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MITCHELL PJ, 1992, ONCOGENE, V7, P383; MITCHELL PJ, 1992, ONCOGENE, V7, P2329; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1994, ONCOGENE, V9, P509; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; WATSON CJ, 1985, DNA CLONING	39	55	57	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2531	2535						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058316				2022-12-28	WOS:A1994PC05400012
J	PHINNEY, DG; KEIPER, CL; FRANCIS, MK; RYDER, K				PHINNEY, DG; KEIPER, CL; FRANCIS, MK; RYDER, K			QUANTITATIVE-ANALYSIS OF THE CONTRIBUTION MADE BY 5'-FLANKING AND 3'-FLANKING SEQUENCES TO THE TRANSCRIPTIONAL REGULATION OF JUNB BY GROWTH-FACTORS	ONCOGENE			English	Article							C-FOS; SIGNAL TRANSDUCTION; MOUSE FIBROBLASTS; GENE; ELEMENTS; ACTIVATION; PROTEINS; COMPLEX; DNA	We have identified four DNAase I-hypersensitive regions (DHRs) at the junB locus, DHR1 is located between sequences - 100 and + 250, DHR2 is centered at - 1000, DHR3 at - 1650, and DHR4 at + 2040 relative to the junB transcriptional start site. Sequence analysis of these DHRs revealed two serum response elements at - 1452 and + 2091, two cyclic AMP response elements at + 2071 and + 2116, and a 12-O-tetradecanoylphorbol-13-acetate (TPA) response element at - 949. To study the contribution made by these cis-elements to junB transcriptional regulation, we stably transfected a recombinant mouse junB gene (JBSV4) containing the intact junB coding sequences, 6.3 kb of 5'-flanking DNA, and 2.0 kb of 3'-flanking DNA into Rat1A cells. The pattern of DHRs identified at the mouse junB locus was re-established at the JBSV4 locus. By directly comparing JBSV4 and rat junB mRNA levels, we found that these genes were induced to equivalent levels by serum, TPA, cyclic AMP, platelet-derived growth factor, epidermal growth factor, and basic fibroblastic growth factor. These results established that JBSV4 resides in a physical environment within chromatin that closely mimics that of the junB locus, and contains the necessary sequence information to recapitulate the transcriptional regulation of junB. By analysing a series of recombinant mouse junB genes containing deletion mutations in 5'-flanking and 3'-flanking sequences, we provide a quantitative assessment of the contribution these sequences make to junB induction by different regulatory agents.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Phinney, Donald G/D-2155-2014	Phinney, Donald/0000-0002-8688-2619	NATIONAL CANCER INSTITUTE [F32CA009219, P30CA006927, R01CA052752] Funding Source: NIH RePORTER; NCI NIH HHS [CA-52752, F32CA-09219, CA-06927-31] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; KITABAYASHI I, 1993, J BIOL CHEM, V268, P14482; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RENZ M, 1985, EMBO J, V4, P3711, DOI 10.1002/j.1460-2075.1985.tb04139.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1990, ONCOGENE, V5, P427; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WU C, 1979, CELL, V16, P807, DOI 10.1016/0092-8674(79)90096-5	20	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2353	2362						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036018				2022-12-28	WOS:A1994NX62900029
J	MOGHUL, A; LIN, L; BEEDLE, A; KANBOURSHAKIR, A; DEFRANCES, MC; LIU, YH; ZARNEGAR, R				MOGHUL, A; LIN, L; BEEDLE, A; KANBOURSHAKIR, A; DEFRANCES, MC; LIU, YH; ZARNEGAR, R			MODULATION OF C-MET PROTOONCOGENE (HGF RECEPTOR) MESSENGER-RNA ABUNDANCE BY CYTOKINES AND HORMONES - EVIDENCE FOR RAPID DECAY OF THE 8 KB C-MET TRANSCRIPT	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; SCATTER FACTOR; EPITHELIAL-CELLS; TYROSINE KINASE; MOLECULAR-CLONING; HEPATOPOIETIN-A; CARCINOMA-CELLS; FACTOR-ALPHA; PROTOONCOGENE	The c-MET proto-oncogene product is a transmembrane tyrosine kinase receptor which was recently shown to transmit an array of important cellular responses induced by Hepatocyte Growth Factor (HGF). These biological effects include induction of mitogenesis, motogenesis, morphogenesis, metastogenesis and anti-tumor activity on a variety of epithelial cells, All of these processes are known to be associated with normal and abnormal tissue growth and development. The 190 kDa c-MET protein is encoded by a major transcript of 8 kilobases (Kb), which is reported to be expressed predominantly in epithelial tissues. The expression pattern of c-MET mRNA and protein are drastically modified in many tumor tissues and cell lines. Currently, no information is available on the molecular mechanisms that regulate c-MET mRNA level. In the present communication, we report for the first time that the inflammatory cytokines such as IL-1 alpha, IL-6 and TNF-alpha, as well as TGF-beta 1, EGF, HGF and the steroidal hormones (estrogen, progesterone, tamoxifen and dexamethasone) markedly influence the steady-state levels of the 8 kb c-MET mRNA in human carcinoma cell lines derived from human tissues such as ovary, breast and endometrium. We demonstrate that c-MET receptor protein is present at high levels in primary tumors of human ovaries (clear cell carcinomas). We present evidence that the 8 kb c-MET mRNA undergoes rapid degradation with a half-life of less than 30 min and that this decay can be quickly inhibited by cyclohex-imide. Our results suggests that the expression of the c-met proto-oncogene resembles that of an immediate early response gene.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,DIV CELLULAR & MOLEC PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Liu, Youhua/0000-0002-4740-805X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES-06109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CAPPUCCINI F, 1991, LYMPHOKINE CYTOK RES, V10, P225; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEFRANCES MC, 1992, DEVELOPMENT, V116, P38; ERROI A, 1989, INT J CANCER, V44, P795, DOI 10.1002/ijc.2910440508; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KOMADA M, 1993, ONCOGENE, V8, P2381; LIU C, 1992, ONCOGENE, V7, P181; LIU YH, 1994, J BIOL CHEM, V269, P4152; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RODRIGUES GA, 1993, HEPATOCYTE GROWTH FA, P167; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; SEOL DW, 1994, UNPUB; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SHYU AB, 1989, GENE DEV, V3, P70; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAMURA M, 1993, J BIOL CHEM, V268, P8140; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WAY DL, 1983, IN VITRO CELL DEV B, V19, P147; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; YANG XM, 1993, DEV BIOL, V157, P308, DOI 10.1006/dbio.1993.1137; YEE CJ, 1993, BIOCHEMISTRY-US, V32, P7922, DOI 10.1021/bi00082a013; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252	44	143	144	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2045	2052						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208549				2022-12-28	WOS:A1994NR68500029
J	ROTTAPEL, R; TURCK, CW; CASTERAN, N; LIU, XG; BIRNBAUM, D; PAWSON, T; DUBREUIL, P				ROTTAPEL, R; TURCK, CW; CASTERAN, N; LIU, XG; BIRNBAUM, D; PAWSON, T; DUBREUIL, P			SUBSTRATE SPECIFICITIES AND IDENTIFICATION OF A PUTATIVE BINDING-SITE FOR PI3K IN THE CARBOXY TAIL OF THE MURINE FLT3 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-C-GAMMA; GTPASE-ACTIVATING PROTEIN; FACTOR-I RECEPTOR; VAV PROTOONCOGENE PRODUCT; GAP-ASSOCIATED PROTEINS; GRB2 ADAPTER PROTEIN; PDGF BETA-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE	Flt3 is a receptor tyrosine kinase (RTK) structurally related to the CSF-1R encoded by the c-fms locus, Kit and the PDGFR which is restricted in its expression to hematopoietic precursor populations and several distinct cell types within the central nervous system. Although the ligand for Flt3 has recently been identified, the developmental function of Flt3 within these tissues has not yet been described. In order to examine the signalling properties of this receptor, we previously constructed a chimeric molecule containing the extracellular domain of CSF-1R fused to the transmembrane and cytoplasmic domain of mouse Flt3 (FF3). The ability of the FF3 to directly associate with or tyrosine phosphorylate specific cytoplasmic signalling molecules in vivo was examined. GAP, Vav, She, and to a lessor extent PLC gamma become tyrosine-phosphorylated but no in vivo association with the receptor was detectable. FF3 associates with PI3K activity and the SH2 domains of p85 and Grb-2. Phosphopeptide competition experiments suggest that the PI3K binding site is located outside of the kinase insert in the carboxy tail of the receptor.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV TORONTO, MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA; UNIV TORONTO, DEPT MOLEC GENET, TORONTO M5G 1X5, ON, CANADA; INSERM, U119, MOLEC ONCOL LAB, F-13009 MARSEILLE, FRANCE	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm)	ROTTAPEL, R (corresponding author), INSERM, U119, MOLEC HEMATOL LAB, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE.		Dubreuil, Patrice/V-4816-2019; Pawson, Tony J/E-4578-2013; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Rottapel, Robert/0000-0002-6024-5558; Liu, X. Johne/0000-0003-3381-5030				ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DAMEN JE, 1993, BLOOD, V81, P3204; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1991, ONCOGENE, V6, P895; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLAND F, 1992, ONCOGENE, V7, P585; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Jones Gwenith, 1992, Progress in Growth Factor Research, V4, P97, DOI 10.1016/0955-2235(92)90025-D; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LYMAN S, 1993, CELL, V75; LYMAN SD, 1993, ONCOGENE, V8, P815; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRINGLE NP, 1992, DEVELOPMENT, V115, P535; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSNET O, 1991, ONCOGENE, V6, P1641; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SEGATTO O, 1993, ONCOGENE, V8, P2105; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHERR CJ, 1990, BLOOD, V75, P1; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	85	71	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1755	1765						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183574				2022-12-28	WOS:A1994NL81500031
J	KNAPP, S; DELLEKARTH, G; FRIEDL, J; PURTSCHER, B; MITTERBAUER, G; DOMER, PH; JAEGER, U				KNAPP, S; DELLEKARTH, G; FRIEDL, J; PURTSCHER, B; MITTERBAUER, G; DOMER, PH; JAEGER, U			GUANINE-RICH (GGNNGG) ELEMENTS AT CHROMOSOMAL BREAKPOINTS INTERACT WITH A LOOP-FORMING, SINGLE-STRANDED DNA-BINDING PROTEIN	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; ACUTE LEUKEMIAS; MINISATELLITE DNA; CLUSTER REGION; TRANSLOCATION; RECOMBINATION; GENE; SEQUENCES; ORGANIZATION; MECHANISM	Proto-oncogene-activation is frequently preceded by chromosomal translocations. Several models suggest that DNA single-strands and loops may serve as intermediates in the process of illegitimate recombination. Guanine-rich, repetitive elements are preferred sites of chromosomal exchange and can undergo conformational changes which result in the generation of single-stranded DNA. Here we describe a single-stranded DNA-binding protein which binds specifically to guanine-rich elements at the breakpoints of human reciprocal translocations, including the t(14;18), t(2;8), t(9;22), t(15;17) and t(4;11) in leukemia and lymphoma. The primitive binding consensus consists of two guanine-residues on either side separated by a spacer of at least two nucleotides (GGN-NGG). Binding activity is unaltered by a spacer length of up to 46 nucleotides. These data suggest that the protein has the unique ability to form or stabilize DNA-loops and may thus play a general role in recombination.	UNIV VIENNA,DEPT MED 1,DIV HEMATOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT CLIN CHEM & LAB MED,A-1090 VIENNA,AUSTRIA; NORTHWESTERN UNIV,NW MEM HOSP,MOLEC DIAGNOST LAB,CHICAGO,IL 60611	University of Vienna; University of Vienna; Northwestern Memorial Hospital; Northwestern University			Knapp, Sylvia/J-3973-2013	Knapp, Sylvia/0000-0001-9016-5244				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BELL GI, 1980, NUCLEIC ACIDS RES, V8, P4091, DOI 10.1093/nar/8.18.4091; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CHANG KS, 1992, BLOOD, V79, P554; CHEN SJ, 1989, ONCOGENE, V4, P195; COGGINS LW, 1992, GENE, V121, P279, DOI 10.1016/0378-1119(92)90132-9; COLLICK A, 1991, NUCLEIC ACIDS RES, V23, P6399; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GODISKA R, 1990, CELL, V61, P1237, DOI 10.1016/0092-8674(90)90688-B; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HANSEN SR, 1993, CELL, V73, P1403; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; JAEGER U, 1993, BLOOD, V81, P1833; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MITANI K, 1990, J BIOL CHEM, V265, P15203; NGAN BY, 1989, BLOOD, V73, P1759; OHSHIMA A, 1992, P NATL ACAD SCI USA, V89, P1016, DOI 10.1073/pnas.89.3.1016; RABBITTS PH, 1988, ONCOGENE, V3, P99; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	38	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1501	1505						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152814				2022-12-28	WOS:A1994NH40100025
J	KUNDRA, V; SOKER, S; ZETTER, BR				KUNDRA, V; SOKER, S; ZETTER, BR			EXCESS EARLY SIGNALING ACTIVITY INHIBITS CELLULAR CHEMOTAXIS TOWARD PDGF-BB	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SIMIAN SARCOMA-VIRUS; V-SIS; PHOSPHATIDYLINOSITOL-3 KINASE; TYROSINE KINASES; PROTEIN-KINASES; TRANSFORMATION; ONCOGENE; SRC; TRANSDUCTION	Chemotaxis, directed migration toward a gradient of a soluble substance, requires a cell to spatially distinguish the concentration of a chemoattractant at one end relative to its opposite end. Platelet-derived growth factor (PDGF) is a potent mitogen and chemoattractant. In the current study, we attempted to interfere with PDGF-BB mediated chemotaxis by abnormal expression of potential early components of the signaling cascade. We find that expression of the PDGF homolog v-Sis prevents cellular migration toward PDGF-BB, indicating that autocrine production of a PDGF receptor ligand will prevent the chemotactic response to exogenously added ligand. In addition, while it is known that PDGF receptor mutants incapable of activating tyrosine kinase activity cannot transduce a signal for mitogenesis or chemotaxis, the effects of excess tyrosine kinase activity on PDGF mediated chemotaxis have not been tested. We demonstrate that cells expressing constitutively active tyrosine kinase genes such as v-fms, v-fes, or v-src fail to migrate toward PDGF-BB whereas expression of the serine/threonine kinase v-mos does not block the chemotactic response. The results demonstrate that chemotaxis may be prevented by excess production of either ligand, receptor activity, or downstream signaling molecule. In addition, our results show that the signals that mediate chemotaxis are separable from those that regulate unstimulated random motility in the same cells.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, PROGRAM BIOL & BIOMED SCI, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [CA37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FUKUI Y, 1991, ONCOGENE, V6, P407; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; Kaplan D R, 1992, Cancer Treat Res, V63, P265; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE BA, 1992, J CELL BIOL, V118, P1057, DOI 10.1083/jcb.118.5.1057; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; QUI F, 1988, EMBO J, V7, P1003; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; SUDOL M, 1993, NEUROCHEM INT, V22, P369, DOI 10.1016/0197-0186(93)90019-2; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	36	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1429	1435						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152804				2022-12-28	WOS:A1994NH40100015
J	BERNARD, OA; MAUCHAUFFE, M; MECUCCI, C; VANDENBERGHE, H; BERGER, R				BERNARD, OA; MAUCHAUFFE, M; MECUCCI, C; VANDENBERGHE, H; BERGER, R			A NOVEL GENE, AF-1P, FUSED TO HRX IN T(1,11)(P32,Q23), IS NOT RELATED TO AF-4, AF-9 NOR ENL	ONCOGENE			English	Article							ACUTE LEUKEMIAS; CHROMOSOME TRANSLOCATIONS; DROSOPHILA-TRITHORAX; DIRECT CLONING; PCR PRODUCTS; 11Q23; T(11-19)(Q23-P13); BREAKPOINTS; TRANSLATION; TRANSCRIPT	Most of the translocations affecting the chromosome band 11q23, frequently seen in human acute leukemias, involve a restricted area of the HRX gene. We have characterized two t(1;11)(p32;q11) translocations which fuse the HRX gene to a novel gene, AF-1p on chromosome 1p32, in two myeloid leukemias. The der (11) chromosome expresses the 1368 N-terminal amino acids of HRX, including the AT-hook, snRNP and methyltransferase similarities, fused to almost all the AF-1p product. The predicted wild type AF-1p product is a 98 kDa acidic protein which does not exhibit similarity to the AF4, AF-9 and ENL gene products. It is highly similar to the murine eps 15 gene product, which encodes a cytoplasmic phosphoprotein. Our data indicate that AF-lp defines another class of genes fused to HRX in 11q23 abnormalities.	INST GENET MOLEC, CNRS, SDI NO 15954 I, F-75010 PARIS, FRANCE; POLICLIN MONTELUCE, INST HEMATOL, I-06100 PERUGIA, ITALY; CTR HUMAN GENET, B-3000 LOUVAIN, BELGIUM	Centre National de la Recherche Scientifique (CNRS)	BERNARD, OA (corresponding author), INST NATL SANTE & RECH MED, U301, 27 RUE JULIETTE DODU, F-75010 PARIS, FRANCE.		Bernard, Olivier A./E-5721-2016	Bernard, Olivier/0000-0002-0463-9747				CHEN CS, 1993, BLOOD, V81, P2386; CHERIF D, 1993, GENE CHROMOSOME CANC, V6, P107, DOI 10.1002/gcc.2870060207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1993, BLOOD, V82, P544; CIMINO G, 1991, CANCER RES, V51, P6712; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; KOBAYASHI H, 1993, GENE CHROMOSOME CANC, V7, P204, DOI 10.1002/gcc.2870070404; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANOTTE M, 1991, BLOOD, V77, P1080; LECONIAT M, 1993, CR ACAD SCI III-VIE, V316, P692; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATSUOKA Y, 1967, P SOC EXP BIOL MED, V125, P1246; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MITELMAN F, 1993, GENOME PRIORITY REPO, V1, P700; MORGAN GJ, 1992, BLOOD, V80, P2172; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NICHOLS J, 1992, BLOOD, V80, P2953; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SAIT SNJ, 1993, GENE CHROMOSOME CANC, V7, P28, DOI 10.1002/gcc.2870070105; Sambrook J, 1989, MOL CLONING LABORATO; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDERPOEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YOUNG BD, 1992, BAILLIERE CLIN HAEM, V5, P881, DOI 10.1016/S0950-3536(11)80050-8	37	120	126	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1039	1045						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134107				2022-12-28	WOS:A1994NC04800005
J	HU, NP; GUTSMANN, A; HERBERT, DC; BRADLEY, A; LEE, WH; LEE, EYHP				HU, NP; GUTSMANN, A; HERBERT, DC; BRADLEY, A; LEE, WH; LEE, EYHP			HETEROZYGOUS RB-1(DELTA-20)/+ MICE ARE PREDISPOSED TO TUMORS OF THE PITUITARY-GLAND WITH A NEARLY COMPLETE PENETRANCE	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; BLADDER-CARCINOMA CELLS; SV40 LARGE-T; SUSCEPTIBILITY GENE; INTERMEDIATE LOBE; CELLULAR PROTEINS; MOLECULAR-CLONING; ENCODED PROTEIN; BINDING PROTEIN; CDC2 KINASE	Humans with a germline mutation of the RB gene are predisposed to retinoblastoma with a 90% penetrance and are at higher risk for other rare tumors. We have established a mouse strain carrying a germ-line mutation of the Rh-1 gene. Here we describe a nearly 100% incidence of spontaneous pituitary tumors which arise in Rb-1 heterozygous mice from ages 2 to 11 months. Histological and immunological analysis indicate that these tumors originate from the intermediate lobe of the pituitary gland, which is a vestigial structure in adult humans. Progression of the tumors can be followed by the elevated level of a specific proteotytic product of pro-opiomelanocortin prohormone, alpha-melanocyte stimulating hormone, in the circulating blood of the tumor-bearing animals. Multiple foci are frequently seen in the tiny intermediate lobe of the pituitary gland which contains approximately 1.5 x 10(5) cells. The tumor tissues invariably lose expression of full-length Rb protein due to loss of the single wild-type Rb-1 allele. The Rb knock out mouse strain provides a unique model for addressing tissue-specific tumor predisposition by inactivation of a ubiquitously expressed tumor suppressor gene.	UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839				BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CASTRO MG, 1989, J NEUROCHEM, V52, P1619, DOI 10.1111/j.1471-4159.1989.tb09217.x; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHANG CY, 1993, CELL GROWTH DIFFER, V4, P1057; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DONOSO LA, 1985, ARCH OPHTHALMOL-CHIC, V103, P855, DOI 10.1001/archopht.1985.01050060115039; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; Eipper B A, 1980, Endocr Rev, V1, P1; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLMES RL, 1974, PITUITARY GLAND COMP, P5; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KYRITSIS AP, 1984, NATURE, V307, P471, DOI 10.1038/307471a0; LAMBERTS SWJ, 1982, J CLIN ENDOCR METAB, V54, P286, DOI 10.1210/jcem-54-2-286; LEE EYH, 1991, DIVERSE MUTATIONS LE; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1991, COLD SH Q B, V56, P211; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MATSUNAGA E, 1980, HUM GENET, V56, P127; MAYOL X, 1993, ONCOGENE, V8, P2561; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MIRSHAHI M, 1986, CANCER-AM CANCER SOC, V57, P1497, DOI 10.1002/1097-0142(19860415)57:8<1497::AID-CNCR2820570810>3.0.CO;2-H; NEVINS JR, 1992, SCIENCE, V258, P424; PENNY RJ, 1978, NEUROENDOCRINOLOGY, V25, P193, DOI 10.1159/000122741; PEREZ FM, 1990, ENDOCRINOLOGY, V127, P1877, DOI 10.1210/endo-127-4-1877; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBERTS JL, 1980, BIOCHEM, V17, P3609; RODRIGUES MM, 1987, OPHTHALMOLOGY, V94, P378; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P139; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VOGEL F, 1979, HUM GENET, V52, P1; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINGSTRAND KG, 1966, PITUITARY GLAND, P1; XU HJ, 1989, ONCOGENE, V4, P807	67	234	236	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1021	1027						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134105				2022-12-28	WOS:A1994NC04800003
J	MAZOYER, S; LALLE, P; MOYRETLALLE, C; MARCAIS, C; SCHRAUB, S; FRAPPAZ, D; SOBOL, H; OZTURK, M				MAZOYER, S; LALLE, P; MOYRETLALLE, C; MARCAIS, C; SCHRAUB, S; FRAPPAZ, D; SOBOL, H; OZTURK, M			2 GERM-LINE MUTATIONS AFFECTING THE SAME NUCLEOTIDE AT CODON-257 OF P53 GENE, A RARE SITE FOR MUTATIONS	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; BREAST-CANCER; FAMILY; NEOPLASMS; PROTEIN; PATIENT	Codon 257 of the p53 gene is an extremely rare target for somatic mutations (accounting for only two of 1600 published mutations). We report here two constitutional mutations both affecting the second nucleotide of codon 257. A thymine to adenine transversion resulting in an amino acid change from leucine to glutamine was found in one proband who developed multiple independent malignant tumors (osteosarcoma, phyllodes tumor, soft-tissue sarcoma). Her mother died of early-onset breast cancer. In the other case, a deletion resulting in a frameshift in the C-terminal coding region of p53 was found in a woman who was diagnosed with breast cancer at age 34. This woman belongs to a family with features of Li-Fraumeni syndrome. In both cases, the p53 mutations identified in the proband was found in other members of the family. Codon 257, even if rarely mutated in somatic cells, may thus be an important target for germ-line mutations.	CTR LEON BERARD,ONCOL MOLEC LAB,INSERM,CJF 9302,28 PROMENADE BULLUKIAN,F-69008 LYON,FRANCE; CTR HOSP REG BESANCON,REGISTRE TUMEURS DOUBS,F-25000 BESANCON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Universite de Franche-Comte; CHU Besancon			Mazoyer, Sylvie/N-7559-2017; Moyret-Lalle, Caroline/G-2742-2013; ozturk, mehmet/G-3330-2014; LALLE, Philippe/G-7734-2018; OZTURK, MEHMET/AAS-7241-2021	Moyret-Lalle, Caroline/0000-0002-8359-2018; OZTURK, MEHMET/0000-0002-6092-9706; Mazoyer, Sylvie/0000-0002-2135-0160				BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BRUGIERES L, 1993, CANCER RES, V53, P452; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; EELES RA, 1993, ONCOGENE, V8, P1269; FELIX CA, 1993, ONCOGENE, V8, P1203; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ICHIKAWA A, 1992, BLOOD, V79, P2701; KRESS S, 1992, CANCER RES, V52, P3220; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; SOBOL H, 1992, HUM GENET, V89, P381; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001	16	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1237	1239						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134127				2022-12-28	WOS:A1994NC04800028
J	COFFER, P; DEJONGE, M; METTOUCHI, A; BINETRUY, B; GHYSDAEL, J; KRUIJER, W				COFFER, P; DEJONGE, M; METTOUCHI, A; BINETRUY, B; GHYSDAEL, J; KRUIJER, W			JUNB PROMOTER REGULATION - RAS MEDIATED TRANSACTIVATION BY C-ETS-1 AND C-ETS-2	ONCOGENE			English	Review							GUANINE NUCLEOTIDE-BINDING; EMBRYONAL CARCINOMA-CELLS; ACTIVATED PROTEIN-KINASE; LONG TERMINAL REPEAT; MURINE SARCOMA-VIRUS; NIH 3T3 CELLS; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; DNA-BINDING; MAP KINASE	The Jun gene family encode components of the AP-1 transcription factor complex that regulate a variety of TRE-containing target promoters. Expression of family members is induced by a wide variety of extracellular stimuli and thought to be important in mediating cellular proliferation and differentiation. We have localized cis-acting; DNA sequences in the murine junB promoter capable of mediating transcriptional activation by the proto-oncogene products c-Ets-l and c-Ets-2. We show by promoter deletion analysis that multiple elements located between - 848 and - 574, and between - 196 and - 91 can mediate transactivation by ETS-family members in different cell types. In vitro DNA binding assays indicate that the elements identified can specifically interact with c-Ets-1 protein. Furthermore, we show that ETS-transactivation of a variety of reporter constructs is dramatically enhanced by introduction of oncogenic Ha-ras. The activation of Pas by extracellular stimuli invokes a phosphorylation cascade that includes the downstream mitogen-activated protein (MAP) kinase p44(ERK-1). W,further show that addition of activated p44(ERK-1) MAP kinase can also enhance ETStransactivation of junB promoter reporter constructs. Here we propose that ETS-family members play a role in the activation of junB transcription by a Ras-stimulated signal transducing pathway that includes MAP kinase(s).	CTR UNIV ORSAY,INST CURIE,F-91405 ORSAY,FRANCE; UNIV GRONINGEN,DEPT GENET,9850 AA GRONINGEN,NETHERLANDS	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; University of Groningen	COFFER, P (corresponding author), HUBRECHT LAB,UPPSALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Binetruy, Bernard/A-6465-2009; Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020; Binetruy, Bernard/AFL-7188-2022; GHYSDAEL, Jacques/F-3377-2013; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/S-2062-2019	Binetruy, Bernard/0000-0001-8012-7092				ADLER V, 1992, J BIOL CHEM, V267, P17001; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V8, P148; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMPH WW, 1988, NATURE, V334, P592; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEUNG S, 1993, ONCOGENE, V8, P989; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MEDEMA RH, 1991, MOL CELL BIOL, V12, P3245; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SETH A, 1990, ONCOGENE, V5, P1761; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TYMMS M, 1993, J CELL BIOCH A S, V17, P210; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	102	122	123	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					911	921						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108135				2022-12-28	WOS:A1994MW55100028
J	WENNSTROM, S; SIEGBAHN, A; YOKOTE, K; ARVIDSSON, AK; HELDIN, CH; MORI, S; CLAESSONWELSH, L				WENNSTROM, S; SIEGBAHN, A; YOKOTE, K; ARVIDSSON, AK; HELDIN, CH; MORI, S; CLAESSONWELSH, L			MEMBRANE RUFFLING AND CHEMOTAXIS TRANSDUCED BY THE PDGF BETA-RECEPTOR REQUIRE THE BINDING-SITE FOR PHOSPHATIDYLINOSITOL 3' KINASE	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASE; SMOOTH-MUSCLE CELLS; MIDDLE T-ANTIGEN; B-TYPE RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; SH3 DOMAINS; EXPRESSION CLONING; INDUCED ACTIVATION	Activation of the platelet-derived growth factor (PDGF) beta-receptor results in motility responses in the forms of membrane ruffling and chemotaxis. Porcine aortic endothelial cells expressing the PDGF beta-receptor or a chimeric fibroblast growth factor (FGF) receptor, in which the endogenous kinase insert was replaced with the corresponding region from the PDGF beta-receptor, migrated efficiently towards a concentration gradient of PDGF-BB and bFGF, respectively, and exhibited both pronounced edge ruffling and circular membrane ruffling in response to ligand-stimulation. The wildtype FGF receptor-1 showed weak or no response in these assays. Further analyses were conducted on mutant receptors, in which tyrosine residues that can serve as autophosphorylation sites and thereby mediate interactions with specific signal transduction molecules, were changed to phenylalanine residues. Each one of the analysed mutants were mitogenically active, however, a mutant in which Tyr740 and Tyr751 were replaced failed to mediate ruffling and chemotaxis. These two residues are implicated in the binding of phosphatidylinositol 3' kinase. The notion that this enzyme is involved in PDGF beta-receptor-induced cell motility is furthermore supported by the finding that another mutant, in which Met743 and Met754 were replaced, and which failed to interact with phosphatidylinositol 3' kinase, was also unable to mediate motility responses.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN; UNIV HOSP UPPSALA,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital				Claesson-Welsh, Lena/0000-0003-4275-2000				ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ARVIDSSON AK, 1992, CELL GROWTH DIFFER, V3, P881; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLAESSONWELSH L, 1993, BIOL PLATELET DERIVE, V5, P31; COOPER J, 1993, BIOL PLATELET DERIVE, V5, P44; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOSANG M, 1989, J CELL PHYSIOL, V140, P558, DOI 10.1002/jcp.1041400322; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; LAROSE L, 1993, ONCOGENE, V8, P2493; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCAVOY JW, 1989, DEVELOPMENT, V107, P221; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHOFIELD PN, 1992, FEBS LETT, V298, P154, DOI 10.1016/0014-5793(92)80044-H; SENIOR RM, 1983, J CELL BIOL, V96, P382, DOI 10.1083/jcb.96.2.382; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VALIUS B, 1993, CELL, V73, P321; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WESTERMARK B, 1985, J CELL PHYSIOL, V124, P43, DOI 10.1002/jcp.1041240108; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	81	307	307	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					651	660						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290276				2022-12-28	WOS:A1994MW24800034
J	CIARDIELLO, F; TORTORA, G; BIANCO, C; SELVAM, MP; BASOLO, F; FONTANINI, G; PACIFICO, F; NORMANNO, N; BRANDT, R; PERSICO, MG; SALOMON, DS; BIANCO, AR				CIARDIELLO, F; TORTORA, G; BIANCO, C; SELVAM, MP; BASOLO, F; FONTANINI, G; PACIFICO, F; NORMANNO, N; BRANDT, R; PERSICO, MG; SALOMON, DS; BIANCO, AR			INHIBITION OF CRIPTO EXPRESSION AND TUMORIGENICITY IN HUMAN COLON-CANCER CELLS BY ANTISENSE RNA AND OLIGODEOXYNUCLEOTIDES	ONCOGENE			English	Article							GROWTH-FACTOR-ALPHA; MAMMARY EPITHELIAL-CELLS; C-HA-RAS; INVITRO TRANSFORMATION; COLORECTAL TUMORS; LINES; PROLIFERATION; GENE; OLIGONUCLEOTIDES; AMPHIREGULIN	CRIPTO is an epidermal growth factor-related gene expressed in a majority of human colorectal tumors. To assess the role of CRIPTO in the growth control of human colon cancer, we have treated human colon carcinoma GEO and CBS cells, that possess high levels of CRIPTO, and WIDR colon cancer cells, that are negative for CRIPTO expression, with two antisense phosphorothioate oligodeoxynucleotides complementary to the 5' end of the human CRIPTO mRNA. Both antisense oligodeoxynucleotides significantly reduced endogenous CRIPTO protein levels and inhibited GEO and CBS cell growth in monolayer and in semisolid medium, whereas they did not affect WIDR cell growth. In addition, GEO, CBS and WIDR cells were infected with a recombinant retroviral vector containing the hygromycin-resistance gene and a 900 bp EcoRI-EcoRI coding fragment of the human CRIPTO cDNA oriented in the 3' to 5' direction. GEO and CBS CRIPTO antisense infectants exhibited a 60 to 70% reduction in CRIPTO protein expression, in monolayer growth and in soft agar cloning efficiency as compared to parental noninfected cells. In contrast, infection of WIDR cells with the CRIPTO antisense retrovirus did not alter their growth. Finally, GEO CRIPTO antisense infectants formed tumors in nude mice that were significantly smaller and had a larger latency period as compared to noninfected GEO cells.	US FDA,DIV TRANSFUS SCI,BETHESDA,MD 20892; UNIV PISA,FAC MED & CHIRURG,IST ANAT & ISTOL PATOL,I-56100 PISA,ITALY; CNR,IST INT GENET & BIOFIS,I-80125 NAPLES,ITALY; NCI,TUMOR IMMUNOL & BIOL LAB,TUMOR GROWTH FACTOR SECT,BETHESDA,MD 20892	US Food & Drug Administration (FDA); University of Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	CIARDIELLO, F (corresponding author), UNIV NAPOLI FEDERICO II,FAC MED & CHIRURG,CATTEDRA ONCOL MED,I-80131 NAPLES,ITALY.		Normanno, Nicola/AAT-1107-2021; Fontanini, Gabriella/O-7636-2015	Fontanini, Gabriella/0000-0003-1957-2052; Normanno, Nicola/0000-0002-7158-2605; Pacifico, Francesco Maria/0000-0001-9563-3596; Tortora, Giampaolo/0000-0002-1378-4962; BASOLO, FULVIO/0000-0003-1657-5020				ANZANO MA, 1989, CANCER RES, V49, P2898; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; CALABRETTA B, 1991, CANCER RES, V51, P4505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; CIARDIELLO F, 1993, INT J CANCER, V54, P952, DOI 10.1002/ijc.2910540615; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CLARKE R, 1992, J NATL CANCER I, V84, P1506, DOI 10.1093/jnci/84.19.1506; COFFEY RJ, 1987, CANCER RES, V47, P4590; DOLNICK BJ, 1991, CANCER INVEST, V9, P185, DOI 10.3109/07357909109044229; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FONTANINI G, 1992, AM J PATHOL, V141, P1285; GRAY GD, 1993, CANCER RES, V53, P577; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; LAHM H, 1992, BRIT J CANCER, V65, P341, DOI 10.1038/bjc.1992.69; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORONI MC, 1992, J BIOL CHEM, V267, P2714; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; MULDER KM, 1989, CELL MOL BIOL COLON, P46; MURPHY PR, 1992, MOL ENDOCRINOL, V6, P877, DOI 10.1210/me.6.6.877; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; RASCHELLA G, 1992, CANCER RES, V52, P4221; SAEKI T, 1992, CANCER RES, V52, P3467; SALOMON DS, 1990, CANCER CELL-MON REV, V2, P389; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; STEIN CA, 1988, CANCER RES, V48, P2659; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; Todaro G J, 1990, Semin Cancer Biol, V1, P257; TRICOLI JV, 1986, CANCER RES, V46, P6169; TROOJAN J, 1992, P NATL ACAD SCI USA, V89, P4874; VALDEZ BC, 1992, CANCER RES, V52, P5681; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P325; WATKINS LF, 1991, INT J CANCER, V47, P455, DOI 10.1002/ijc.2910470325; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	42	69	80	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					291	298						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302592				2022-12-28	WOS:A1994MW24700035
J	KODURU, PRK; GOH, JC; PERGOLIZZI, RG; LICHTMAN, SM; BROOME, JD				KODURU, PRK; GOH, JC; PERGOLIZZI, RG; LICHTMAN, SM; BROOME, JD			MOLECULAR CHARACTERIZATION OF A VARIANT PH(1) TRANSLOCATION T(92211) (Q34Q11Q13) IN CHRONIC MYELOGENOUS LEUKEMIA (CML) REVEALS THE TRANSLOCATION OF THE 3'-PART OF BCR GENE TO THE CHROMOSOME BAND 11Q13	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOCYTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TRANSFERASE-PI-GENE; B-CELL LYMPHOMAS; C-ABL ONCOGENE; PHILADELPHIA-CHROMOSOME; FRAGILE SITES; CLUSTER REGION; PROTO-ONCOGENE	We performed cloning and sequence analysis of translocation junctions at 11q- and 22q- (Ph(1)) chromosomes and the corresponding germline DNAs of a variant Ph(1)-positive CML with t(9;22;11)(q34;q11;q13). Southern blot analysis using probes for different regions of bcr mapped the translocation break near the 5'-side of bcr exon 4. Cloning, Southern blot analysis and restriction map analysis of both bcr fragments showed that the part of bcr 3'- to the translocation break moved to 11q13. Sequence analysis of the translocation junction on the Ph(1) chromosome showed that the translocation break occurred 63 bp upstream of exon 4. Compared to the germline sequence, bcr sequence from the translocated partners showed deletion of seven basepairs at the site of translocation. A probe derived from the 5'-region of the clone isolated from the 11q- chromosome identified clonal rearrangements in the leukemic DNA. Restriction map and sequence analysis showed that this clone consisted of the 3'-half of the glutathione S-transferase Pi (GST-Pi) gene and the 3'-part of bcr. We identified two point mutations in the GST-Pi allele involved in translocation. Northern blot analysis showed that the GST-Pi gene was expressed in the leukemic cells at blast crisis but not at chronic phase; however, no fusion mRNA between GST-Pi and bcr was identified. We did not find any sequence homology between 11q13 DNA and 22q11 DNA around the translocation breakpoints; however, sequences homologous to ALU repeats were identified close to the sites of translocation breaks at 22q11 and 11q13. This study supports our hypothesis that variant Ph(1) translocations may occur as primary cytogenetic changes similar to the classical Ph(1) translocations.	N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT LABS,MANHASSET,NY 11030; N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT RES,MANHASSET,NY 11030; N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT MED,DON MONTI DIV HEMATOL & ONCOL,MANHASSET,NY 11030; CORNELL UNIV,COLL MED,DEPT PATHOL,NEW YORK,NY; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY	Cornell University; Northwell Health; North Shore University Hospital; Cornell University; Northwell Health; North Shore University Hospital; Cornell University; Northwell Health; North Shore University Hospital; Cornell University; Cornell University					NCRR NIH HHS [S07 RR05924] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005924] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADELAIDE J, 1988, ONCOGENE, V2, P413; BAKSHI A, 1988, P NATL ACAD SCI USA, V84, P2396; BLENNERHASSETT GT, 1988, LEUKEMIA, V2, P648; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHAGANTI RSK, 1987, CYTOGENET CELL GENET, V45, P93, DOI 10.1159/000132436; CHEN SJ, 1989, ONCOGENE, V4, P195; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; COLLINS SJ, 1987, BLOOD, V69, P893; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEBRAEKELEER M, 1987, CYTOGENET CELL GENET, V44, P215, DOI 10.1159/000132374; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAO JZ, 1991, P NATL ACAD SCI USA, V88, P4882, DOI 10.1073/pnas.88.11.4882; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROFFEN J, 1987, ADV VIRAL ONCOL, V7, P77; HALUSKA FG, 1987, TRENDS GENET, V3, P11, DOI 10.1016/0168-9525(87)90155-7; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HOLMES J, 1990, BRIT J CANCER, V62, P209, DOI 10.1038/bjc.1990.262; ISHIHARA T, 1988, CANCER GENET CYTOGEN, V32, P75, DOI 10.1016/0165-4608(88)90314-7; ISLAM MQ, 1989, HUM GENET, V82, P338; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4774; KODURU P, 1988, CYTOGENET CELL GENET, V49, P269, DOI 10.1159/000132675; KODURU P, 1991, HEMATOL PATHOL, V5, P57; KODURU PRK, 1989, ONCOGENE, V4, P929; KORSMEYER SJ, 1992, BLOOD, V80, P879; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; LEBEAU MM, 1986, BLOOD, V67, P849; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MCKEITHAN TW, 1992, P NATL ACAD SCI USA, V89, P4923, DOI 10.1073/pnas.89.11.4923; MCQUAID S, 1989, BRIT J CANCER, V59, P540, DOI 10.1038/bjc.1989.110; MELO JV, 1993, BLOOD, V81, P158; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; PEAR WS, 1988, ONCOGENE, V2, P499; RABBITTS PH, 1988, ONCOGENE, V3, P99; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VANDERFELTZ MJM, 1989, NUCLEIC ACIDS RES, V17, P1, DOI 10.1093/nar/17.1.1; WILLIAMS BP, 1988, ONCOGENE, V3, P345; YUNIS JJ, 1987, ONCOGENE, V1, P59	53	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3239	3247						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247527				2022-12-28	WOS:A1993MG78200006
J	CUADRADO, A; BRUDER, JT; HEIDARAN, MA; APP, H; RAPP, UR; AARONSON, SA				CUADRADO, A; BRUDER, JT; HEIDARAN, MA; APP, H; RAPP, UR; AARONSON, SA			H-RAS AND RAF-1 COOPERATE IN TRANSFORMATION OF NIH3T3 FIBROBLASTS	ONCOGENE			English	Article							PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; ONCOGENE PRODUCTS; GROWTH-FACTOR; 3T3 CELLS; EXPRESSION; ACTIVATION; GENE; HETEROGENEITY	We examined the effect of overexpression of growth factor-regulated second messenger enzymes, alone and in combination, on transformation of NIH3T3 cells. Signal transducers included phospholipase C-gamma (PLC-gamma), protein kinase C-gamma (PKC-gamma), and two proto-oncogenes, c-H-ras and c-raf-1. Three of these proteins, PLC-gamma PKC-gamma and Raf-1, did not transform NIH3T3 cells alone or in combination. c-H-ras, which under its own promoter control has low transforming activity, also did not cooperate with PLC-gamma or PKC-gamma. In contrast, the combination of normal or oncogenic p21 H-Ras with the Raf-I kinase dramatically increased transformation efficiency. The level of Ras protein required for transformation was reduced in Raf-1 co-transfectants, implying that, at low levels of p21 Ras, p74 Raf-I is rate limiting. As transformation by Ras depends on jun-mediated transcriptional events, we also examined H-ras and c-raf-1 cooperation in transcriptional transactivation of TPA-responsive element (TRE)-dependent reporters. Like the H-ras/c-raf-1 cooperation in transformation, we observed this synergistic stimulation of TRE-dependent transcription. This pathway for transformation and transcriptional activation by increased levels of normal Ras and Raf may be important in tumors that show overexpression but lack mutationally activated forms of these two proto-oncogenes.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; SUGEN INC, REDWOOD CITY, CA 94063 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BOS JL, 1989, CANCER RES, V49, P4682; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUDER JT, 1992, IN PRESS J VIROL; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CUADRADO A, 1990, BIOCHEM BIOPH RES CO, V170, P526, DOI 10.1016/0006-291X(90)92123-H; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARRIS CC, 1991, IARC SCI PUBL, V105, P294; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MARSHALL CJ, 1989, INT J CANCER, P29; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRIS JDH, 1989, ONCOGENE, V4, P27; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1992, IN PRESS J BIOL CHEM; RAPP UR, 1991, ONCOGENE, V6, P495; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SITHANANDAM G, 1989, ONCOGENE, V4, P451; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; STACEY DW, 1991, ONCOGENE, V6, P2297; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, IN PRESS ONCOGENE; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIALLET J, 1990, AM J RESP CELL MOL, V2, P225, DOI 10.1165/ajrcmb/2.3.225; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	55	39	39	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2443	2448						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361757				2022-12-28	WOS:A1993LT36800015
J	ALILECHE, A; PLAISANCE, S; HAN, DS; RUBINSTEIN, E; MINGARI, C; BELLOMO, R; JASMIN, C; AZZARONE, B				ALILECHE, A; PLAISANCE, S; HAN, DS; RUBINSTEIN, E; MINGARI, C; BELLOMO, R; JASMIN, C; AZZARONE, B			HUMAN-MELANOMA CELL-LINE M14 SECRETES A FUNCTIONAL INTERLEUKIN-2	ONCOGENE			English	Article							T-CELL; LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; ACTIVE INTERLEUKIN-2; HUMAN-PLACENTA; EXPRESSION; RECEPTOR; GENE; PROLIFERATION; PROMOTER	Interleukin 2 (IL2) is an important regulator of the immune system. In this report, we have analysed five human melanoma cell lines expressing the IL2R for their ability to secrete IL2. In the M14 melanoma cell line, we observed the appearance of the 0.9 kb transcript specific for the IL2 gene, 72 h after subculture, and the secretion of a biologically active IL2 which specifically sustains the proliferation of the IL2 dependent murine lymphoid cell tine CTLL2. In M14 cells, IL2 gene activation is transient as in lymphoid cells but is not inhibited by the immunosuppressive drugs cyclosporine-A and FK506 which are effective on PHA-blasts. In M14 cells, recombinant IL2 (36 pM) induces the down modulation of ICAM-1 expression at the surface of M14 cells. Overnight incubation of these cells with polyclonal anti-IL2 antibodies leads to an increased expression of ICAM-1 and a decreased membrane detection of the IL2Ralpha, suggesting the existence of an autocrine/paracrine loop involved in the surface expression of these antigens. A decreased expression of the ICAM-1 protein could help some melanoma cells to escape from cytolytic recognition and therefore favour their metastasis.	HOP PAUL BROUSSE,INSERM,UNITE 268,14 AV PAUL VAILLANT COUTURIER,F-94800 VILLEJUIF,FRANCE; IST,GENOA,ITALY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Rubinstein, Eric/B-4650-2019; Azzarone, Bruno/AAH-9251-2019; Plaisance, Stephane/B-3488-2009; Plaisance, Stephane/ABI-6307-2020	Rubinstein, Eric/0000-0001-7623-9665; Azzarone, Bruno/0000-0002-5962-3849; Plaisance, Stephane/0000-0002-1651-241X; Plaisance, Stephane/0000-0002-1651-241X				ARYA SK, 1984, BIOCHEMISTRY-US, V23, P6686; BENVENISTE EN, 1988, J NEUROIMMUNOL, V17, P301, DOI 10.1016/0165-5728(88)90121-X; BOEHM KD, 1989, P NATL ACAD SCI USA, V86, P656, DOI 10.1073/pnas.86.2.656; CARLONI G, 1989, ONCOGENE, V4, P873; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CILLO C, 1984, INT J CANCER, V34, P11, DOI 10.1002/ijc.2910340104; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DOMZIG W, 1983, J IMMUNOL, V130, P1970; DRENO B, 1986, J INVEST DERMATOL, V86, P359, DOI 10.1111/1523-1747.ep12285581; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; EFRAT S, 1984, P NATL ACAD SCI-BIOL, V81, P2601, DOI 10.1073/pnas.81.9.2601; EFRAT S, 1982, NATURE, V297, P236, DOI 10.1038/297236a0; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; FARRAR JJ, 1982, IMMUNOL REV, V63, P129, DOI 10.1111/j.1600-065X.1982.tb00414.x; FARRAR WL, 1981, J IMMUNOL, V126, P1120; FLOMENBERG N, 1983, J IMMUNOL, V130, P2635; FRAZIERSCOTT K, 1988, J CLIN INVEST, V82, P1877; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; GRIMM EA, 1983, J EXP MED, V157, P884, DOI 10.1084/jem.157.3.884; HENNEY CS, 1982, TRANSPLANT P, V14, P565; HERLYN M, 1990, CLIN EXP METASTAS, V8, P9; Hicks C, 1991, Growth Factors, V5, P201, DOI 10.3109/08977199109000284; JANKOVIC DL, 1990, J IMMUNOL, V145, P4136; JOHNSON JP, 1981, EUR J IMMUNOL, V11, P825, DOI 10.1002/eji.1830111015; JONJIC N, 1992, EUR J IMMUNOL, V22, P2255, DOI 10.1002/eji.1830220912; LANTZ O, 1991, J IMMUNOL METHODS, V137, P121, DOI 10.1016/0022-1759(91)90401-Z; LEIBSON HJ, 1981, J EXP MED, V154, P1681, DOI 10.1084/jem.154.5.1681; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; NABEL GJ, 1988, P NATL ACAD SCI USA, V85, P2934, DOI 10.1073/pnas.85.9.2934; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PLAISANCE S, 1992, INT IMMUNOL, V4, P739, DOI 10.1093/intimm/4.7.739; PLAISANCE S, 1993, NATO ASI SERIES H, V67, P103; SANETO RP, 1986, P NATL ACAD SCI USA, V83, P9221, DOI 10.1073/pnas.83.23.9221; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SMITH KA, 1988, ADV IMMUNOL, V42, P165, DOI 10.1016/S0065-2776(08)60844-5; SOUBIRAN P, 1987, J REPROD IMMUNOL, V12, P225, DOI 10.1016/0165-0378(87)90026-X; SWAIN SL, 1981, P NATL ACAD SCI-BIOL, V78, P2517, DOI 10.1073/pnas.78.4.2517; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WALKER E, 1988, J IMMUNOL, V140, P859; WEIDMANN E, 1992, CANCER RES, V52, P5963; WILLIAMS TM, 1988, J IMMUNOL, V141, P662; YAMADA G, 1992, PROGR IMMUNOLOGY, V6, P469	45	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1791	1796						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8099724				2022-12-28	WOS:A1993LG68200010
J	SMITMCBRIDE, Z; PRIVALSKY, ML				SMITMCBRIDE, Z; PRIVALSKY, ML			FUNCTIONAL DOMAINS OF THE V-ERBA PROTEIN NECESSARY FOR ONCOGENESIS ARE REQUIRED FOR TRANSCRIPTIONAL ACTIVATION IN SACCHAROMYCES-CEREVISIAE	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; GLUCOCORTICOID RECEPTOR; BINDING DOMAIN; DNA-BINDING; C-ERBA; YEAST; PHOSPHORYLATION; TRANSFORMATION; SPECIFICITY	The v-erbA oncogene is a retrovirus-transduced and altered copy of a cellular gene (c-erbA-alpha) for a thyroid hormone receptor. In this paper we show that the v-erbA domains required for transcriptional activation in yeast and for oncogenic function in animal cells are closely congruent. We conclude that the behavior of the v-erbA protein as a transcriptional activator in yeast appears to closely reflect the same biochemical requirements that are necessary for v-erbA function in the neoplastic vertebrate cell. Intriguingly, parallel analyses of c-erbA-alpha and -beta demonstrated unexpected differences in the activities of the two thyroid hormone receptor isoforms in the yeast, perhaps reflecting different functions of these genes in vertebrates. Furthermore, results obtained by analysis of chimeric v-/c-erbA genes suggest that the basal and the hormone-induced transcriptional activity of the nuclear hormone receptors can be modulated independently by distinct structural features within the protein molecule.	UNIV CALIF DAVIS, DEPT MICROBIOL, DAVIS, CA 95616 USA	University of California System; University of California Davis				Smit-McBride, Zeljka/0000-0003-0275-8088	NCI NIH HHS [CA53394, F32 CA09050] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394, F32CA009050, R01CA053394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BONDE BG, 1990, J VIROL, V64, P1314, DOI 10.1128/JVI.64.3.1314-1320.1990; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BOUCHER P, 1990, ONCOGENE, V5, P1303; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, ONCOGENE, V6, P2129; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORREST D, 1990, ONCOGENE, V5, P309; GANDRILLON O, 1987, EUR J BIOCHEM, V166, P63; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALL BL, 1992, CELL GROWTH DIFFER, V3, P207; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MAK P, 1989, J BIOL CHEM, V264, P21613; MCDONNELL DP, 1989, MOL CELL BIOL, V9, P3517, DOI 10.1128/MCB.9.8.3517; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; PRIVALSKY ML, 1992, BIOCHIM BIOPHYS ACTA, V1114, P51, DOI 10.1016/0304-419X(92)90006-K; PRIVALSKY ML, 1991, J BIOL CHEM, V266, P1456; PRIVASLKY ML, 1988, MOL CELL BIOL, V8, P4155; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHENA M, 1990, METHOD ENZYMOL, V194, P373; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SIKORSKI RS, 1989, GENETICS, V122, P19; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	44	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1465	1475						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8099219				2022-12-28	WOS:A1993LE06400009
J	KNOWLES, MA; SHAW, ME; PROCTOR, AJ				KNOWLES, MA; SHAW, ME; PROCTOR, AJ			DELETION MAPPING OF CHROMOSOME-8 IN CANCERS OF THE URINARY-BLADDER USING RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS AND MICROSATELLITE POLYMORPHISMS	ONCOGENE			English	Article							TRANSITIONAL CELL-CARCINOMA; DINUCLEOTIDE REPEAT POLYMORPHISM; POLYMERASE CHAIN-REACTION; COLORECTAL CANCERS; CLONAL EVOLUTION; GENE; IDENTIFICATION; ADENOCARCINOMAS; LEUKEMIA; LOCUS	We have used a combination of restriction fragment length polymorphism (RFLP) markers and highly informative microsatellite polymorphisms to map a common region of deletion on chromosome 8p in cancers of the urinary bladder. Analysis of loss of heterozygosity (LOH) using microsatellite polymorphisms was shown to be at least as sensitive as detection of RFLPs by Southern blotting. A total of 110 tumours was analysed for loss of heterozygosity (LOH) on 8p and 8q; 109 patients were informative for at least one marker on each chromosome arm and 29 tumours (26%) showed LOH of chromosome 8 markers, 26 of which (25%) showed LOH on 8p. Sixteen tumours (14%) showed LOH on 8q. Thirteen of these also had LOH on 8p. Of the 29 tumours with LOH, five had LOH at all informative loci, indicating loss of an entire copy of chromosome 8. An association was found between high tumour grade and stage and chromosome 8 LOH. Fifty-three per cent of grade 3 muscle-invasive tumours showed LOH compared with 11% of grade 1 non-invasive tumours (0.01 < P < 0.025 and 0.025 < P < 0.05 for grade and stage respectively). Deletion mapping of tumours with chromosome 8 LOH suggests the presence of a suppressor gene(s) for urothelial cancer within a region defined by the loci NEFL and PLAT (8p21 - q11.2). If there is a common target for deletions in bladder and those in hepatocellular and colorectal tumours reported previously, this defines a common region of deletion at 8p21.3.			KNOWLES, MA (corresponding author), MARIE CURIE SKLODOWSKA MEM INST,EPITHELIAL CARCINOGENESIS LAB,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND.			Knowles, Margaret/0000-0002-9363-8657				ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; DEVILEE P, 1991, ONCOGENE, V6, P1705; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERTI AD, 1988, CANCER GENET CYTOGEN, V34, P101, DOI 10.1016/0165-4608(88)90174-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GIBAS Z, 1984, CANCER RES, V44, P1257; GIBAS Z, 1986, CANCER GENET CYTOGEN, V19, P229, DOI 10.1016/0165-4608(86)90051-8; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; GRANBERGOHMAN I, 1984, CANCER GENET CYTOGEN, V11, P69, DOI 10.1016/0165-4608(84)90100-6; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; JIN YS, 1988, CANCER GENET CYTOGEN, V33, P11, DOI 10.1016/0165-4608(88)90043-X; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LEVERGER G, 1988, MED PEDIATR ONCOL, V16, P227, DOI 10.1002/mpo.2950160402; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; MITELMAN F, 1981, CANCER GENET CYTOGEN, V4, P197, DOI 10.1016/0165-4608(81)90014-5; MULERIS M, 1986, INT J CANCER, V38, P167, DOI 10.1002/ijc.2910380204; OCHI H, 1986, CANCER GENET CYTOGEN, V22, P295, DOI 10.1016/0165-4608(86)90022-1; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; PROCTOR AJ, 1991, ONCOGENE, V61, P787; STOLL C, 1979, LEUKEMIA RES, V3, P61, DOI 10.1016/0145-2126(79)90063-8; TAUTZ D, 1990, BIOESSAYS, V12, P44, DOI 10.1002/bies.950120111; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P2200; WOOD S, 1991, NUCLEIC ACIDS RES, V19, P6664, DOI 10.1093/nar/19.23.6664-a; ZULIANI G, 1990, NUCLEIC ACIDS RES, V18, P4958, DOI 10.1093/nar/18.16.4958-a; 1978, TNM CLASSIFICATION M, P113; 1973, INT HISTOLOGICAL CLA; 1991, CYTOGENET CELL GENET, V58, P1	44	192	194	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1357	1364						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8097582				2022-12-28	WOS:A1993KY32800029
J	KADOHAMA, T; TSUJI, K; OGAWA, K				KADOHAMA, T; TSUJI, K; OGAWA, K			INDISTINCT CELL-CYCLE CHECKPOINT AFTER UV DAMAGE IN H-RAS-TRANSFORMED MOUSE-LIVER CELLS DESPITE NORMAL P53 GENE-EXPRESSION	ONCOGENE			English	Article							WILD-TYPE P53; ATAXIA-TELANGIECTASIA; DNA DAMAGE; HEPATOCELLULAR-CARCINOMA; MONOCLONAL-ANTIBODY; IONIZING-RADIATION; GROWTH ARREST; PROTEIN; AMPLIFICATION; INDUCTION	Growth arrest after u.v. damage was investigated in C3H mouse primary cultured hepatocytes, spontaneously immortalized liver epithelial cells and their H-ras-transformed derivatives. All cells except for one of the transformed lines had the wild type p53 gene considered necessary for the G1-S checkpoint. Growth arrest and accumulation of p53 protein with an abnormally-extended half-life were observed after 8 J/m(2) u.v. treatment in primary hepatocytes and immortalized cells, but the arrest was much less evident in H-ras-transformed cells, in spite of the presence of the wild type p53 gene and accumulation of p53. Thus, the signal transduction upstream of p53 in the p53-mediated G1-S checkpoint may be retained in these transformed cell lines, although its downstream signal transduction or a pathway totally independent of this system could be altered. The transformed cells showed a much wider distribution of chromosomal number as compared to normal and immortalized cells, indicating that progression from the immortal to transformed state is associated with chromosomal instability, together with much decrease in the cell cycle checkpoint function.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA 078,HOKKAIDO,JAPAN	Asahikawa Medical College				Kadohama, Takayuki/0000-0002-5175-748X				BAARK Y, 1993, EMBO J, V12, P461; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUKUDA I, 1993, MOL CARCINOGEN, V7, P257, DOI 10.1002/mc.2940070408; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, ONCOGENE, V8, P2457; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P926; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE GH, 1989, CANCER RES, V49, P403; LEE GH, 1991, INT J CANCER, V47, P60, DOI 10.1002/ijc.2910470112; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NISHIMORI H, IN PRESS INT J CANCE; OLSON DC, 1993, ONCOGENE, V8, P2353; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; POPESCU NC, 1972, CYTOGENETICS, V11, P500, DOI 10.1159/000130216; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; TISHLER RB, 1993, CANCER RES, V53, P2212; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; TOKUMITSU M, 1994, MOL CARCINOGEN, V10, P52, DOI 10.1002/mc.2940100109; TSUJI K, 1994, MOL CARCINOGEN, V9, P167, DOI 10.1002/mc.2940090308; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	41	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2845	2852						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084590				2022-12-28	WOS:A1994PG82200010
J	PASTOREK, J; PASTOREKOVA, S; CALLEBAUT, I; MORNON, JP; ZELNIK, V; OPAVSKY, R; ZATOVICOVA, M; LIAO, S; PORTETELLE, D; STANBRIDGE, EJ; ZAVADA, J; BURNY, A; KETTMANN, R				PASTOREK, J; PASTOREKOVA, S; CALLEBAUT, I; MORNON, JP; ZELNIK, V; OPAVSKY, R; ZATOVICOVA, M; LIAO, S; PORTETELLE, D; STANBRIDGE, EJ; ZAVADA, J; BURNY, A; KETTMANN, R			CLONING AND CHARACTERIZATION OF MN, A HUMAN TUMOR-ASSOCIATED PROTEIN WITH A DOMAIN HOMOLOGOUS TO CARBONIC-ANHYDRASE AND A PUTATIVE HELIX-LOOP-HELIX DNA-BINDING SEGMENT	ONCOGENE			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; AMINO-ACID SEQUENCES; HUMAN CELL HYBRIDS; SECONDARY STRUCTURE; NEGATIVE REGULATOR; EXPRESSION; MOTIF; TUMORIGENICITY; TRANSCRIPTION; EFFICIENT	MN is a transmembrane glycoprotein that has been detected in HeLa cells and in some human carcinomas. The expression of MN protein in HeLa cells is regulated by cell density. In HeLa x fibroblast cell. hybrids its expression correlates,vith tumorigenicity. Using a specific monoclonal antibody we have identified a cDNA clone coding for MN. Analysis of the deduced amino acid sequence revealed strong structural homology between the central region of the MN protein and carbonic anhydrases (CA). MN sequence retains the conserved zinc-binding site as well as the enzyme's active center. In accord with these findings, MN protein from HeLa cells was found to bind zinc and to have carbonic anhydrase activity. The N-terminal region of MN shares some similarity with DNA binding proteins of the helix-loop-helix (HLH) family, and the protein was found to have affinity for DNA by DNA-cellulose chromatography. The region between the CA-like domain and the putative HLH domain is rich in imperfect repeats of serine, proline, glycine and acidic residues with few hydrophobic amino acids, resembling thus an activation region of transcription factors. The fact that MN protein is detectable in several types of human carcinomas, but not in corresponding non-cancerous tissues, suggests its possible role in neoplasia. In addition, the analysis of biological consequences of MN expression of NIH3T3 cells provides the evidence in favour of MN protein involvement in control of cell proliferation and transformation.	FAC AGR SCI GEMBLOUX, DEPT MOLEC BIOL, B-5030 GEMBLOUX, BELGIUM; UNIV BRUSSELS, DEPT MOLEC BIOL, B-1640 RHODE ST GENESE, BELGIUM; UNIV CALIF IRVINE, COLL MED, DEPT MICROBIOL & MOLEC GENET, IRVINE, CA 92717 USA; UNIV PARIS 06, DEPT BIOL MACROMOLEC, MINERAL CRYSTALLO LAB, F-75252 PARIS 05, FRANCE; UNIV DENIS DIDEROT, F-75252 PARIS 05, FRANCE	University of California System; University of California Irvine; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	PASTOREK, J (corresponding author), SLOVAK ACAD SCI, INST VIROL, BRATISLAVA 84246, SLOVAKIA.		Zaťovičová, Miriam/ABA-3268-2021; Zelnik, Vladimir/AAS-4952-2020; Pastorekova, Silvia/C-6685-2018	Zaťovičová, Miriam/0000-0002-8682-4232; 				ALDRED P, 1991, BIOCHEMISTRY-US, V30, P569, DOI 10.1021/bi00216a035; AUSUBEL FM, 1989, SHORT PROTOCOLS MOL, P387; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DODGSON JS, 1991, CARBONIC ANHYDRASES, P398; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KATZ DS, 1993, PROTEIN ENG, V6, P701, DOI 10.1093/protein/6.7.701; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; LIAO SY, 1994, IN PRESS AM J PATHOL; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; STEIN CA, 1988, CANCER RES, V48, P2659; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WOODCOCK S, 1992, PROTEIN ENG, V5, P629, DOI 10.1093/protein/5.7.629; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZAVADA J, 1972, NATURE-NEW BIOL, V240, P124, DOI 10.1038/newbio240124a0; ZAVADA J, 1993, INT J CANCER, V54, P268, DOI 10.1002/ijc.2910540218	39	445	492	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2877	2888						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084592				2022-12-28	WOS:A1994PG82200013
J	PRICE, TNC; MOORWOOD, K; JAMES, MR; BURKE, JF; MAYNE, LV				PRICE, TNC; MOORWOOD, K; JAMES, MR; BURKE, JF; MAYNE, LV			CELL-CYCLE PROGRESSION, MORPHOLOGY AND CONTACT INHIBITION ARE REGULATED BY THE AMOUNT OF SV40 T-ANTIGEN IN IMMORTAL HUMAN-CELLS	ONCOGENE			English	Article							HUMAN-FIBROBLASTS	Expression of Simian Virus 40 (SV40) T antigen in human dermal fibroblasts over-rides the normal controls on cell division leading to changes in cellular proliferation and life span. These changes are accompanied by other changes in cell morphology, expression of cell specific functions, and altered cell-cell interactions. In this study, we have examined the effects of different amounts of T antigen on cell cycle progression, life span and morphology in human dermal fibroblasts and demonstrated T antigen to be a concentration dependent regulator of the cell cycle. Using a novel, metal inducible episomal expression vector (p735.6) which produces low basal levels of protein but high (greater than 100-fold) levels of induction, we have compared the effects of low and high levels of T antigen expression in a precrisis and immortalised human line (1BRMT1). The presence of inducing agent led to maximal levels of T antigen expression and resulted in cultures with a high rate of proliferation, an extended in vitro life span, a loss of contact inhibition of growth and a morphology characteristic of SV40-transformed cells. In the absence of inducing agent, read-through of the T antigen gene resulted in low but detectable levels of protein. The reduction in T antigen levels was accompanied by a 50% or greater reduction in the proliferative rate and restoration of cell morphology and contact inhibition similar to that found in non-transfected cells. The results presented here demonstrate that low amounts of T antigen are sufficient to maintain cell viability and prevent the re-expression of the senescent phenotype seen in the absence of T antigen. Similarly, the ability of T antigen to extend the in vitro life span is not dependent on high level expression of T antigen. In contrast, the rate of proliferation of human cells as well as the cell morphology and contact inhibition are dependent on the amount of T antigen present. Many of the cellular effects can be minimised or reversed by reducing T antigen expression.	UNIV SUSSEX,TRAFFORD CTR MED RES,DIV BIOL SCI,BRIGHTON BN1 9RY,E SUSSEX,ENGLAND	University of Brighton; University of Sussex								MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; OGRIS E, 1993, ONCOGENE, V8, P1277; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; Sambrook J, 1989, MOL CLONING LABORATO; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; SLADEK TL, 1992, ONCOGENE, V7, P1305; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	7	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2897	2904						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084594				2022-12-28	WOS:A1994PG82200015
J	CICCOLINI, F; DIPASQUALE, G; CARLOTTI, F; CRAWFORD, L; TOMMASINO, M				CICCOLINI, F; DIPASQUALE, G; CARLOTTI, F; CRAWFORD, L; TOMMASINO, M			FUNCTIONAL-STUDIES OF E7 PROTEINS FROM DIFFERENT HPV TYPES	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; MUTATIONAL ANALYSIS; CERVICAL-CARCINOMA; ADENOVIRUS E1A; PRIMARY-CELLS; RB PROTEIN; CYCLIN-A; TRANSFORMATION	We have performed comparative studies on the E7 proteins from malignant and non-malignant Human Papillomavirus types (HPV 1, 6, 11, 16, 18, 33). GST/E7 fusion proteins from all these HPV types associate with Rb1, p107 and the cyclin A/CDK2 complex. As has been shown for Rb1, the association with p107 and Cyclin A was weaker for the 'low risk' HPV6 and 11 E7 proteins as compared to 'high risk' HPV16, 18 and 33 E7 proteins. In contrast the E7 protein of the benign type HPV1 bound Rb1, p107 and cyclin A with the same affinity as the 'high risk' E7 proteins. The affinities of the E7/Rb1 interaction have been confirmed in vivo by the 'two hybrid' method in the yeast Saccharomyces cerevisiae. Although HPV1 E7 showed the same affinity in vitro and in vivo for Rb1 as the high risk HPV E7s, it did not have the ability to activate the E2F-1 transcription factor inhibited by Rb1, nor did it have any transforming activity when coexpressed with activated ras in primary rodent cells.	UNIV CAMBRIDGE, DEPT PATHOL, IMPERIAL CANC RES FUND, TUMOUR VIRUS GRP, CAMBRIDGE CB2 1QP, ENGLAND	University of Cambridge				Ciccolini, Francesca/0000-0002-7276-7361				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; STANDIGER M, 1993, J BIOL CHEM, V268, P4608; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TOMMASINO M, 1993, ONCOGENE, V8, P195; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993	38	78	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2633	2638						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058327				2022-12-28	WOS:A1994PC05400023
J	VOYNOYASENETSKAYA, TA; PACE, AM; BOURNE, HR				VOYNOYASENETSKAYA, TA; PACE, AM; BOURNE, HR			MUTANT ALPHA-SUBUNITS OF G12 AND G13 PROTEINS INDUCE NEOPLASTIC TRANSFORMATION OF RAT-1 FIBROBLASTS	ONCOGENE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; STIMULATES DNA-SYNTHESIS; CYCLIC-AMP ACCUMULATION; MALIGNANT TRANSFORMATION; PHOSPHOLIPASE-C; POSSIBLE INVOLVEMENT; CELL-PROLIFERATION; RECEPTOR SUBTYPES; KINASE ACTIVATION; PITUITARY-TUMORS	Mutationally activated alpha subunits of two G proteins, G(s) and G(i2,)) induce neoplastic transformation of fibroblasts and are found in human tumors. Here we report that mutationally activated alpha subunits of two other G proteins, G12 and G13, induce neoplastic transformation of Rat-1 fibroblasts and NIH3T3 fibroblasts. Constitute activation of these alpha subunits resulted from replacement by leucine of glutamine-229 and glutamine-226 in alpha 12 and alpha 13, respectively. Transient expression of mutant alpha 12 and alpha 13 cDNAs induced focus formation in Rat-1 cells and NIH3T3 cells, and stable expression of these mutant proteins in Rat-1 cells accelerated growth rate, induced growth in soft agar, and increased DNA synthesis. Mitogen-activated protein (MAP) kinase activity, stimulated by EGF, was increased in Rat-1 cells that expressed mutant alpha 12 or alpha 13. The MAP kinase cascade plays a role in mediating neoplastic transformation induced by other GTPases, including ras and the alpha subunit of G(i2). Therefore, we propose that the MAP kinase cascade is an effector pathway affected by alpha 12 and alpha 13 and may contribute to neoplastic transformation by these mutant proteins. We predict that activating somatic mutations in alpha 12 and alpha 13 genes will be found in human tumors, as is the case for mutationally activated alpha subunits of G(s) and G(i2).	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54427] Funding Source: Medline; NHLBI NIH HHS [HL 07731] Funding Source: Medline; NIGMS NIH HHS [GM 27800] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBAS J, 1993, J BIOL CHEM, V268, P22235; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOURNE HR, 1991, P NATO ADV STUDY I C, P253; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CUADRADO A, 1993, ONCOGENE, V8, P2443; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; LANDIS CA, 1990, J CLIN ENDOCR METAB, V71, P1416, DOI 10.1210/jcem-71-6-1416; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LETTORIO JJ, 1986, SCIENCE, V243, P1117; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TOBIN CJ, 1982, NATURE, V300, P143; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1992, J BIOL CHEM, V267, P1811; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1	42	136	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2559	2565						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058319				2022-12-28	WOS:A1994PC05400015
J	YAMASHIRO, S; URANO, T; SHIKU, H; FURUKAWA, K				YAMASHIRO, S; URANO, T; SHIKU, H; FURUKAWA, K			ALTERATION OF NM23 GENE-EXPRESSION DURING THE INDUCED-DIFFERENTIATION OF HUMAN LEUKEMIA-CELL LINES	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; TUMOR-METASTASIS; PROTEINS; DROSOPHILA; IDENTIFICATION; SURFACE	The nm23-H1 gene is regarded as a human homologue of the mouse nm23 gene, which was expressed in a nonmetastatic subline of mouse melanoma K-1735. The expression levels of nm23-H1 mRNA and the levels of protein during induced differentiation of human leukemia cell lines were analysed. mRNA levels of the megakaryoblastic leukemia line MEG-O1, which were induced to differentiate into megakaryocyte by TPA, decreased rapidly from 2 days after the start of treatment and became almost undetectable at day 4. Similar downregulation of nm23-H1 mRNA was also observed in the induced differentiation of the promyelocytic leukemia line HL-60 by TPA, or DMSO into monocyte-macrophage lineage or granulocytes, respectively. The amount of Nm23-H1 protein was analysed by Western immune-blot analysis using mouse antiserum raised against a recombinant fusion protein with glutathione S-transferase. The amount of Nm23-H1 protein also decreased during the induced differentiation of these leukemia cell lines. On the other hand, in the differentiation of the erythroleukemia line K562 by hemin, levels of both mRNA and protein of Nm23-H1 elevated transiently, then reduced to the original level. When MEG-01 and K562 were stably transfected with nm23-H1 cDNA, MEG-O1 transfectants showed reduced sensitivity to the induction of differentiation, whereas K562 transfectants were better induced to synthesize hemoglobin than controls. These findings suggest the possibility that Nm23-H1 protein plays an important role to maintain the proliferation of immature leukemic cells in MEG-O1 and HL-60, but it may also play a role in the early stage of K562 differentiation, possibly in the different manner.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN	Nagasaki University				Urano, Takeshi/0000-0003-3383-3554				Agarwal R P, 1978, Methods Enzymol, V51, P376; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CIOE L, 1981, CANCER RES, V41, P237; HAYASHI K, 1986, ACTA HAEMATOL-BASEL, V75, P141, DOI 10.1159/000206107; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, DECONTAMINATION DILU; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; OGURA M, 1985, BLOOD, V66, P1384; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; SORSCHER SM, 1993, BIOCHEM BIOPH RES CO, V195, P336, DOI 10.1006/bbrc.1993.2049; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, CANCER METASTASIS, P48; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; URANO T, 1993, ONCOGENE, V8, P1371; URANO T, 1992, INT J ONCOL, V1, P425; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; YAMASHIRO S, 1993, LEUKEMIA RES, V17, P129, DOI 10.1016/0145-2126(93)90057-R	26	32	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2461	2468						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058309				2022-12-28	WOS:A1994PC05400005
J	CLEVELAND, JL; TROPPMAIR, J; PACKHAM, G; ASKEW, DS; LLOYD, P; GONZALEZGARCIA, M; NUNEZ, G; IHLE, JN; RAPP, UR				CLEVELAND, JL; TROPPMAIR, J; PACKHAM, G; ASKEW, DS; LLOYD, P; GONZALEZGARCIA, M; NUNEZ, G; IHLE, JN; RAPP, UR			V-RAF SUPPRESSES APOPTOSIS AND PROMOTES GROWTH OF INTERLEUKIN-3-DEPENDENT MYELOID CELLS	ONCOGENE			English	Article							RECOMBINANT MURINE RETROVIRUS; C-MYC; HEMATOPOIETIC-CELLS; BCL-2 ONCOPROTEIN; KINASE-ACTIVITY; PROTEIN-KINASE; BONE-MARROW; B-CELLS; EXPRESSION; ACTIVATION	Interleukin-3 (IL-3) is required for the proliferation, survival and differentiation of myeloid progenitors. In the absence of IL-3, murine myeloid 32D.3 cells accumulate in the G1 phase of the cell cycle and subsequently undergo programmed cell, death, or apoptosis. Here we demonstrate that enforced expression of the v-raf oncogene suppresses apoptosis of myeloid 32D.3 cells following the withdrawal of IL-3. Surprisingly, steady state levels of Bcl-2, an oncogene known to suppress apoptosis, were not dependent upon IL-3 in 32D.3 cells and its levels were not augmented in v-raf clones. This suggests that ability of v-raf to suppress apoptosis in the absence of ligand is either Bcl-2 independent or that v-raf kinase promotes Bcl-2 function. v-raf also promoted growth of these cells in the presence of IL-3. v-raf clones proliferated at an increased rate due to a shortened G1 phase and had decreased requirements for IL-3 for growth. Therefore, transformation of myeloid cells by v-raf involves signaling pathways which promote both cell cycle progression and cell survival.	UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; NCI, FREDERICK CANC RES FACIL, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES FACIL, PROGRAM RESOURCES INC, FREDERICK, MD 21701 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Tennessee System; University of Tennessee Health Science Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan	CLEVELAND, JL (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA.		Nuñez, Gabriel/A-7160-2014	Askew, David/0000-0002-6477-2515; Troppmair, Jakob/0000-0002-0611-3837	NCI NIH HHS [P0 CA21765] Funding Source: Medline; NIDDK NIH HHS [DK44158, DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932, R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; EILES M, 1990, EMBO J, V10, P133; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P3934; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROWCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGEL JN, 1993, J IMMUNOL, V151, P4116; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	61	128	128	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2217	2226						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036007				2022-12-28	WOS:A1994NX62900013
J	HOFFMAN, B; LIEBERMANN, DA				HOFFMAN, B; LIEBERMANN, DA			MOLECULAR CONTROLS OF APOPTOSIS - DIFFERENTIATION/GROWTH ARREST PRIMARY RESPONSE GENES, PROTOONCOGENES, AND TUMOR-SUPPRESSOR GENES AS POSITIVE AND NEGATIVE MODULATORS	ONCOGENE			English	Review							PROGRAMMED CELL-DEATH; WILD-TYPE P53; TRANSFORMING GROWTH FACTOR-BETA-1; LEUKEMIA INHIBITORY FACTOR; IMMEDIATE EARLY RESPONSE; CONSTITUTIVE C-MYC; TERMINAL DIFFERENTIATION; HUMAN CANCER; BCL-2; CYCLE				HOFFMAN, B (corresponding author), TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA.							ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ASKEW DS, 1991, ONCOGENE, V6, P1915; BEALDING C, 1993, P NATL ACAD SCI USA, V90, P2719; BISHOP JM, 1991, COLD SH Q B, V56, P99; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COFFEY RJ, 1988, CANCER RES, V48, P1596; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOOPER WC, 1991, LEUKEMIA RES, V15, P179, DOI 10.1016/0145-2126(91)90118-D; JUVEN T, 1993, ONCOGENE, V8, P3411; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; Liebermann D A, 1994, Curr Opin Hematol, V1, P24; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCGEOCH DJ, 1991, NATURE, V353, P609, DOI 10.1038/353609b0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PIENTENPOL JA, 1990, CELL, V61, P777; QUESENBERRY PJ, 1990, HEMATOLOGY, P129; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; RUSCETTI FW, 1991, ANN NY ACAD SCI, V628, P31, DOI 10.1111/j.1749-6632.1991.tb17220.x; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG YS, 1993, ONCOGENE, V8, P3427; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	84	228	239	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1807	1812						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208526				2022-12-28	WOS:A1994NR68500001
J	SHIOTA, M; FUJIMOTO, J; SEMBA, T; SATOH, H; YAMAMOTO, T; MORI, S				SHIOTA, M; FUJIMOTO, J; SEMBA, T; SATOH, H; YAMAMOTO, T; MORI, S			HYPERPHOSPHORYLATION OF A NOVEL 80 KDA PROTEIN-TYROSINE KINASE SIMILAR TO LTK IN A HUMAN KI-1 LYMPHOMA CELL-LINE, AMS3	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; C-ERBB-2 ONCOGENE; HODGKINS-DISEASE; BREAST-CANCER; BLADDER-CANCER; GENE-PRODUCT; PHOSPHORYLATION; EXPRESSION; TRANSLOCATION; AMPLIFICATION	Ki-l lymphoma is a subtype of human malignant lymphoma characterized by the expression of CD30 (Ki-1) and a peculiar morphology. It is occasionally accompanied by a unique reciprocal chromosomal translocation t(2;5)(p23;q35). A Ki-l lymphoma cell line, AMS3, was established by maintaining biopsied tumor cells in SCID (severe combined immunodeficiency) mice. To investigate abnormalities of the signal transduction in Ki-l lymphomas, AMS3 lysate was immunoprecipitated with anti-phosphotyrosine monoclonal antibody, 25.2G4, and the immunoprecipitates were subjected to kinase assay and immune-blotting with 25.2G4. A unique phosphotyrosine-containing protein of MW 80 000, designated p80, was found only in AMS3 cells and not in other cell lines or mononuclear cells from healthy donors. Subsequent amino acid sequence analysis of its tryptic digests showed that p80 was a hitherto undescribed tyrosine phosphoprotein similar to Ltk (leukocyte tyrosine kinase). Furthermore, physical interaction of p80 with CD30 was suggested from immunoprecipitation experiments with AMS3 lysates.	APPL BIOSYST JAPAN,URAYASU,CHIBA 279,JAPAN	Thermo Fisher Scientific; Applied Biosystems	SHIOTA, M (corresponding author), UNIV TOKYO,INST MED SCI,DEPT PATHOL,MINATO KU,4-6-1 SHIROKAMEDAI,TOKYO 108,JAPAN.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; EBSTEIN SA, 1990, GENES CHROMOSOME CAN, V2, P27; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2276, DOI 10.1073/pnas.80.8.2276; HASSE VH, 1991, ONCOGENE, V6, P2319; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ITOH T, 1993, CANCER, V72, P2684; KADIN ME, 1986, BLOOD, V68, P1042; KANEKO Y, 1989, BLOOD, V73, P806; KANEKO Y, 1990, Current Opinion in Oncology, V2, P816, DOI 10.1097/00001622-199010000-00003; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MARU Y, 1990, ONCOGENE RES, V5, P199; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORIYAMA M, 1991, J UROLOGY, V145, P423, DOI 10.1016/S0022-5347(17)38356-8; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NEAL DE, 1985, LANCET, V1, P366; PALLAS D, 1982, CELL, V30, P407, DOI 10.1016/0092-8674(82)90238-0; PENNY RJ, 1991, CANCER, V68, P362, DOI 10.1002/1097-0142(19910715)68:2<362::AID-CNCR2820680226>3.0.CO;2-C; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINSBURY JRC, 1985, LANCET, V1, P364; SATOH H, 1993, CYTOGENET CELL GENET, V62, P49, DOI 10.1159/000133443; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; SLAMON DJ, 1989, SCIENCE, V244, P7047; STEIN H, 1985, BLOOD, V66, P848; TAKAHASHI E, 1993, GENOMICS, V17, P234, DOI 10.1006/geno.1993.1310; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMORI T, 1991, CANCER RES, V51, P5859; YOKOTA J, 1988, ONCOGENE, V2, P283; YOKOTA J, 1986, LANCET, V1, P765; ZHOU DJ, 1987, CANCER RES, V47, P6123	44	201	219	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1567	1574						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183550				2022-12-28	WOS:A1994NL81500006
J	KRATZKE, RA; OTTERSON, GA; HOGG, A; COXON, AB; GERADTS, J; COWELL, JK; KAYE, FJ				KRATZKE, RA; OTTERSON, GA; HOGG, A; COXON, AB; GERADTS, J; COWELL, JK; KAYE, FJ			PARTIAL INACTIVATION OF THE RB PRODUCT IN A FAMILY WITH INCOMPLETE PENETRANCE OF FAMILIAL RETINOBLASTOMA AND BENIGN RETINAL TUMORS	ONCOGENE			English	Article							LARGE T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELLULAR PROTEINS; MOLECULAR-CLONING; BINDING PROTEIN; EXPRESSION; MUTATIONS; IDENTIFICATION; TRANSCRIPTION	While familial retinoblastoma has served as the paradigm for the two-hit theory of tumorigenesis and for the concept of the tumor suppressor gene, the etiology of incomplete penetrance of familial retinoblastoma is poorly understood. To address the molecular basis for this phenotype we have studied the functional properties of a mutant Rb gene identified in a kindred with incomplete penetrance of familial retinoblastoma and evidence for regressed retinal lesions (retinomas). In contrast to all previously isolated RB mutant proteins, we demonstrated that the mutant product from this kindred retained the wildtype properties of nuclear localization, the ability to undergo hyperphosphorylation in vivo, and the capacity to suppress growth of RB((-)) cells. Protein binding ('pocket') activity, however, was defective defining a new class of RB mutant with partial inactivation. The presence of this unique RB mutant in the germline of obligate carriers with incomplete penetrance and regressed retinal lesions suggests a molecular basis for this phenotype and supports the hypothesis that a minimum 'RB threshold' level of protein binding activity is required to suppress tumorigenesis.	USN,NCI,MED ONCOL BRANCH,BETHESDA,MD 20889; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20889; INST CHILD HLTH,IMPERIAL CANC RES FUND,LONDON WC1N 1EH,ENGLAND; MOLEC ONCOL INC,GAITHERSBURG,MD 20878	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA; Cancer Research UK; University of London; University College London			kaye, frederic/E-2437-2011	Cowell, John/0000-0002-2079-5950				BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHAR DH, 1974, AM J OPHTHALMOL, V78, P5, DOI 10.1016/0002-9394(74)90003-8; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DESTREE OHJ, 1992, DEV BIOL, V153, P141, DOI 10.1016/0012-1606(92)90098-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YK, 1987, SCIENCE, V236, P218; Gallie B L, 1977, Prog Clin Biol Res, V16, P229; GALLIE BL, 1982, BRIT J CANCER, V45, P513, DOI 10.1038/bjc.1982.87; GALLIE BL, 1979, IMMUNOLOGY IMMUNOPAT; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HASHIMOTO T, 1991, ONCOGENE, V6, P463; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOGG A, 1992, ONCOGENE, V7, P1445; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MAYOL X, 1993, ONCOGENE, V8, P2561; MEHRA KS, 1965, BRIT J OPHTHALMOL, V49, P381, DOI 10.1136/bjo.49.7.381; MUNCASTER MM, 1992, CANCER RES, V52, P654; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1993, BRIT J CANCER, V68, P958, DOI 10.1038/bjc.1993.461; OTTERSON GA, 1993, ONCOGENE, V8, P949; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STEWARD JK, 1956, BRIT J OPHTHALMOL, V40, P449; STIRDIVANT SM, 1992, J BIOL CHEM, V267, P14846; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WUSTENBERG W, 1950, Klin Monbl Augenheilkd Augenarztl Fortbild, V117, P423; YOKOTA J, 1988, ONCOGENE, V3, P471	60	60	62	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1321	1326						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152792				2022-12-28	WOS:A1994NH40100002
J	LARSSON, LG; PETTERSSON, M; OBERG, F; NILSSON, K; LUSCHER, B				LARSSON, LG; PETTERSSON, M; OBERG, F; NILSSON, K; LUSCHER, B			EXPRESSION OF MAD, MXI1, MAX AND C-MYC DURING INDUCED-DIFFERENTIATION OF HEMATOPOIETIC-CELLS - OPPOSITE REGULATION OF MAD AND C-MYC	ONCOGENE			English	Note							DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; ONCOGENE; PROTEIN; FOS; COTRANSFORMATION; ONCOPROTEIN; INTERFERON; DOMAINS	The Myc proto-oncoprotein family is considered to play an important role in the control of cell growth and differentiation. It appears that the interaction of Myc with its heterodimeric partner Max is essential for Myc function. Recently two other partners of Max, called Mad and Mxi1, have been identified. In an effort to gain insight into the network of these four proteins we have started to analyse the expression of the c-myc, max, mad and mxi1 genes at the mRNA level during hematopoietic cell growth and differentation. In the human myeloid cell lines U-937, HL-60 and ML-1 c-myc expression was down-regulated as shown previously after induction of differentiation, whereas the expression of max was only slightly affected. In contrast to these two genes the expression of mad was induced upon differentiation in the three cell lines by TPA, retinoic acid, vitamin D3, dimethyl sulfoxide, and interferon-gamma and remained elevated for at least 3 days. A kinetic analysis showed that the induction of mad in U-937 in response to TPA was rapid (15 min) and at least in part transcriptional, reminiscent of immediate early genes. The expression of mxi1 was induced in U-937 by some inducers but not in HL-60 or ML-1. Its induction occurred slowly, peaking around 48 h. These analysis thus suggest that the expression of mad and c-myc is inversely regulated during induced hematopoietic differentiation.	UNIV UPPSALA,UNIV HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	LARSSON, LG (corresponding author), HANNOVER MED SCH,INST MOLEK BIOL,KONSTANTY GUTSCHOW STR 8,D-30623 HANNOVER,GERMANY.		Larsson, Lars-Gunnar/D-9747-2012; Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMATI B, 1993, CELL, V72, P235; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KREZNER L, 1992, NATURE, V359, P426; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LARSSON LG, 1991, LEUKEMIA LYMPHOMA, V4, P193, DOI 10.3109/10428199109068065; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; Nilsson K., 1980, INT S NEW TRENDS HUM, P271; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; REDDY CD, 1992, ONCOGENE, V7, P2085; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TODD RF, 1981, J IMMUNOL, V126, P1435; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WATT SM, 1991, BLOOD, V78, P63; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	40	170	171	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1247	1252						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134128				2022-12-28	WOS:A1994NC04800030
J	SAIKUMAR, P; GABRIEL, JL; REDDY, EP				SAIKUMAR, P; GABRIEL, JL; REDDY, EP			THE MYB ONCOGENE PRODUCT INDUCES DNA-BENDING	ONCOGENE			English	Article							GENE V-MYB; C-MYB; BINDING DOMAIN; ESCHERICHIA-COLI; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATORS; CELLULAR PROGENITOR; TRANSFORMING GENE; TRANS-ACTIVATION; RNA-POLYMERASE	The nuclear oncogene v-myb and its cellular counterpart c-myb code for proteins that bind to DNA in a sequence specific manner and act as regulators of transcription. The Myb protein contains DNA binding and transregulatory domains which are important for its function. The DNA binding domain of Myb protein has been shown to contain three imperfectly conserved repeats of 50-52 aminoacids that constitute the amino terminal end. In this communication, we show that Myb protein induces conformational change in DNA after protein-DNA complex formation. Circular permutation assays indicate that Myb protein induces DNA bending at the site of binding. Phasing analysis confirm the DNA bending and allowed the detection of relative orientation of bend. Myb proteins which comprise only DNA-binding domains either with three repeats or two repeats also bend DNA in the same orientation as the larger proteins with both DNA-binding and transactivating domains. However, the transactivating region seems to influence the magnitude of bend angle. We used molecular modeling to analyse the structure of Myb-DNA complex formation resulting in the bending of DNA. Data presented here show that Myb protein, like other transcriptional regulators, bends DNA upon binding allowing the interaction of regulatory elements.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P01CA052009, P30CA012227] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 12227, CA 52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BAUR CP, 1988, J MOL BIOL, V203, P1009, DOI 10.1016/0022-2836(88)90125-8; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GABRIEL JL, 1993, P NATL ACAD SCI USA, V90, P4186, DOI 10.1073/pnas.90.9.4186; GABRIEL JL, 1991, J THEOR BIOL, V151, P541, DOI 10.1016/S0022-5193(05)80369-8; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GROTEWOLD E, 1991, P NATL ACAD SCI USA, V88, P4587, DOI 10.1073/pnas.88.11.4587; HEUMANN H, 1988, EMBO J, V7, P4379, DOI 10.1002/j.1460-2075.1988.tb03336.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KERPPOLA T, 1991, CELL, V66, P1; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOSTREWA D, 1991, NATURE, V349, P178, DOI 10.1038/349178a0; LEPRINCE D, 1983, EMBO J, V2, P1073, DOI 10.1002/j.1460-2075.1983.tb01548.x; MAROCCO A, 1989, MOL GEN GENET, V216, P183, DOI 10.1007/BF00334354; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILLIAMS JS, 1988, MOL CELL BIOL, V8, P2763, DOI 10.1128/MCB.8.7.2763; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	69	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1279	1287						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134132				2022-12-28	WOS:A1994NC04800035
J	BARTHOLOMEW, C; CLARK, AM				BARTHOLOMEW, C; CLARK, AM			INDUCTION OF 2 ALTERNATIVELY SPLICED EVI-1 PROTOONCOGENE TRANSCRIPTS BY CAMP IN KIDNEY-CELLS	ONCOGENE			English	Note							MYELOID TRANSFORMING GENE; MOUSE MYELOBLASTIC LEUKEMIAS; ZINC FINGER PROTEIN; RETROVIRAL INSERTIONS; EXPRESSION; SITE; IDENTIFICATION; TRANSLOCATIONS; ACTIVATION; KILOBASES	The evi-1 proto-oncogene is normally predominantly expressed in the kidney. We report here that evi-1 transcripts are also abundant in foetal kidney and expression is retained in primary kidney cell cultures. However available kidney cell lines express low or no evi-1 mRNA. In the human renal cell carcinoma cell line, A704, evi-1 is inducible approximately 16-fold by elevating intra-cellular cAMP levels with either forskolin or dibutyryl cAMP. TPA down-regulates evi-1 mRNA production and blocks forskolin mediated induction. Similar effects are seen in NIH3T3 cells and primary kidney cell cultures. Induction of evi-1 gene expression by forskolin does not alter the ratio of full length and an alternatively spliced transcript which encodes a protein lacking two repeats of the zinc finger motif. Potential regulation of evi-1 expression in kidney by hormones which modulate intra-cellular cAMP levels suggest that h can respond to environmental cues which might be important to the normal physiological role of this protein in kidney differentiation, development and function.			BARTHOLOMEW, C (corresponding author), BEATSON INST CANC RES,CANC RES CAMPAIGN BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND.							BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; BORDEREAUX D, 1990, ONCOGENE, V5, P925; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; FICHELSON S, 1992, LEUKEMIA, V6, P93; HOLLAND PWH, 1988, DEVELOPMENT, V102, P159; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NGUYEN VC, 1989, HUM GENET, V81, P257; NIBBS RJB, 1993, MOL CELL BIOL, V13, P5582, DOI 10.1128/MCB.13.9.5582; PERKINS AS, 1991, DEVELOPMENT, V111, P479; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Saxen L., 1987, ORGANOGENESIS KIDNEY; TAUB M, 1979, P NATL ACAD SCI USA, V76, P3338, DOI 10.1073/pnas.76.7.3338; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	26	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					939	942						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108138				2022-12-28	WOS:A1994MW55100031
J	LANG, FF; MILLER, DC; PISHARODY, S; KOSLOW, M; NEWCOMB, EW				LANG, FF; MILLER, DC; PISHARODY, S; KOSLOW, M; NEWCOMB, EW			HIGH-FREQUENCY OF P53 PROTEIN ACCUMULATION WITHOUT P53 GENE MUTATION IN HUMAN JUVENILE PILOCYTIC, LOW-GRADE AND ANAPLASTIC ASTROCYTOMAS	ONCOGENE			English	Note							17P ALLELIC LOSS; ACTIVATING MUTATIONS; BREAST-CANCER; EXPRESSION; HETEROZYGOSITY; OVEREXPRESSION; FORMS; CHROMOSOME-17; CARCINOMA; ONCOGENE	We analysed 31 non-glioblastoma astrocytomas for alterations in p53 protein expression and for mutations in the p53 gene. Immunohistochemistry detected p53 protein accumulation in 71% (five of seven) of juvenile pilocytic astrocytomas (WHO grade I), 63% (five of eight) of astrocytomas (WHO grade II), and 63% (10 of 16) of anaplastic astrocytomas (WHO grade III). The single strand conformation polymorphism (SSCP) assay of exons 2-11 of the p53 gene and direct DNA sequencing identified p53 mutations in 14% (one of seven) of grade I, 25% (two of eight) of grade II, and 19% (three of 16) of grade III astrocytomas. This is the first report of a p53 mutation in grade I juvenile pilocytic astrocytomas. Immunohistochemistry and SSCP analyses gave concordant results in 55% (17 of the 31) of the tumors. A total of 14 tumors, 60-80% within each grade, showed p53 protein accumulation in the absence of detectable mutations of the p53 gene. No mdm-2 gene amplification was found in these tumors. The similar frequency of p53 alterations in tumors of grades I-III suggests that the p53 gene plays a significant role early in the formation of astrocytomas rather than late in tumor progression to higher grade. The data suggest that mechanisms other than p53 gene inactivation by mutation or mdm-2 complex formation result in the accumulation of P53 protein in > 70% of non-glioblastoma astrocytomas.	NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU MED CTR,DEPT NEUROSURG,NEW YORK,NY 10016; KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016	New York University; New York University					NCI NIH HHS [CA 40533] Funding Source: Medline; PHS HHS [P30-16087] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040533, R23CA040533, R29CA040533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1991, ONCOGENE, V6, P1699; BENNETT WP, 1992, CANCER RES, V52, P6092; BRUNER JM, 1991, MODERN PATHOL, V4, P671; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CAMPO E, 1991, CANCER RES, V51, P4436; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULTS D, 1992, CANCER RES, V52, P674; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KLEIHUES P, 1993, HISTOLOGIC TYPING TU; KOHLER MF, 1992, CANCER RES, V52, P1622; KORNBLITH PL, 1987, NEUROLOGIC ONCOLOGY, P35; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASSAM NJ, 1993, CANCER RES, V53, P2235; LAWS ER, 1984, J NEUROSURG, V61, P665, DOI 10.3171/jns.1984.61.4.0665; LEACH FS, 1993, CANCER RES, V53, P2231; LOUIS DN, 1993, J NEUROPATH EXP NEUR, V52, P31, DOI 10.1097/00005072-199301000-00005; MARKS JR, 1991, CANCER RES, V51, P2979; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MCCORMACK BM, 1992, NEUROSURGERY, V31, P636; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEWCOMB EW, 1993, BRAIN PATHOL, V3, P229, DOI 10.1111/j.1750-3639.1993.tb00749.x; NEWCOMB EW, 1993, GROWTH CONTROL NEOPL, P53; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; OKAZAKI H, 1989, FUNDAMENTALS NEUROPA, P205; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RUBIO MP, 1993, CANCER RES, V53, P3465; SAXENA A, 1992, CANCER RES, V52, P6716; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; STRETCH JR, 1991, CANCER RES, V51, P5976; SZENASY J, 1983, CHILD BRAIN, V10, P39; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WAGATA T, 1993, CANCER RES, V53, P846; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303	45	127	130	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					949	954						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108140				2022-12-28	WOS:A1994MW55100033
J	HIBI, K; YAMAKAWA, K; UEDA, R; HORIO, Y; MURATA, Y; TAMARI, M; UCHIDA, K; TAKAHASHI, T; NAKAMURA, Y; TAKAHASHI, T				HIBI, K; YAMAKAWA, K; UEDA, R; HORIO, Y; MURATA, Y; TAMARI, M; UCHIDA, K; TAKAHASHI, T; NAKAMURA, Y; TAKAHASHI, T			ABERRANT UP-REGULATION OF A NOVEL INTEGRIN ALPHA-SUBUNIT GENE AT 3P21.3 IN SMALL-CELL LUNG-CANCER	ONCOGENE			English	Article							ADHESION RECEPTOR; SHORT ARM; EXPRESSION; VLA-4; FIBRONECTIN; CARCINOMA; DISTINCT; DELETION; FAMILY; ABNORMALITIES	Our recent identification of homozygous deletions at 3p21.3 in lung cancer has provided further support for the presence of a tumor suppressor gene in this chromosomal region. As a part of our efforts for positional cloning of a tumor suppressor gene at 3p21.3, we have characterized a transcriptional unit within this region using genomic fragments with interspecies conservation. The identified gene was found to encode a novel integrin alpha subunit, termed alpha(RLC), which is closely related to alpha(4) in structure but clearly different from alpha(4) in its expression pattern in the physiological and pathological setting of the lung. This finding and the exact localization of the gene suggest that it is a good candidate for a tumor suppressor gene in lung cancer, but our extensive search covering one third of the gene did not reveal any somatic mutations within the coding region. Interestingly, however, alpha(RLC) was abundantly expressed in fetal lung and lung cancers, particularly small cell lung cancers (SCLC). Its aberrant upregulation in the SCLC samples, both cell lines and primary tumors, which might have been caused by a yet unidentified mutations or by deletions of other gene, and its homology to alpha which is thought to play a role in metastasis, suggest that altered alpha(RLC) expression may contribute to the acquisition of malignant phenotypes of this type of lung cancer.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN; CANC INST,DEPT BIOCHEM,TOSHIMA KU,TOKYO,TOKYO 170,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Japanese Foundation for Cancer Research			Yamakawa, Kazuhiro/N-5050-2015; Takahashi, Takashi/I-7262-2014; Tamari, Mayumi/N-5378-2015	Yamakawa, Kazuhiro/0000-0002-1478-4390; Takahashi, Takashi/0000-0003-0615-7001; Horio, Yoshitsugu/0000-0003-4661-6399				BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1991, ONCOGENE, V6, P2291; HIDA T, 1993, JPN J CLIN ONCOL, V23, P14; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KORETZ K, 1991, AM J PATHOL, V138, P741; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; MATTILA P, 1992, INT J CANCER, V52, P918, DOI 10.1002/ijc.2910520615; MINNA JD, 1991, MOL MECHANISMS THEIR, P63; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SAKAKURA T, 1983, UNDERSTANDING BREAST, P261; SUZUKI H, 1992, CANCER RES, V52, P734; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; SUZUKI S, 1993, JPN J CANCER RES, V84, P168, DOI 10.1111/j.1349-7006.1993.tb02851.x; Szebenyi DME, 1981, NATURE, V294, P327, DOI 10.1038/294327a0; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1986, CANCER RES, V46, P4770; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TSUKAMOTO T, 1992, CANCER RES, V52, P3506; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOYAMA S, 1992, CANCER RES, V52, P873; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	37	59	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					611	619						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290272				2022-12-28	WOS:A1994MW24800029
J	LALLE, P; DELATOUR, M; RIO, P; BIGNON, YJ				LALLE, P; DELATOUR, M; RIO, P; BIGNON, YJ			DETECTION OF ALLELIC LOSSES ON 17Q12-Q21 CHROMOSOMAL REGION IN BENIGN LESIONS AND MALIGNANT-TUMORS OCCURRING IN A FAMILIAL CONTEXT	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; DINUCLEOTIDE REPEAT POLYMORPHISM; HUMAN OVARIAN CARCINOMAS; ADENOMATOUS POLYPOSIS; ESTROGEN-RECEPTOR; HETEROZYGOSITY; GENE; ALLELOTYPE; DISEASE; MUTATIONS	A predisposing gene (BRCA-1) for breast and ovarian cancer has been located on chromosomal region 17q12-21. According to Knudson's hypothesis if this gene is a tumor suppressor gene, allelic losses would be found in tumors occurring in families with cancer aggregations. We studied 25 samples of both benign lesions and malignant tumors, from breast cancer site-specific families and other familial cancer aggregations. Allelic losses seem to be more frequent in tumors from breast site-specific families but also include the predisposing locus in other syndromes, suggesting a role of BRCA-1 in such families. Finding of allele losses near this locus in benign lesions suggests that such alterations may represent a first step in breast carcinogenesis. It is noteworthy that allele losses involve larger chromosome fragments in malignant tumors than in benign lesions where BRCA-1 is not lost, suggesting a similar mechanism for genomic deletion in the tumorigenesis of the colon and of the breast.	CTR JEAN PERRIN,ONCOL MOLEC LAB,F-63011 CLERMONT 1,FRANCE; CTR JEAN PERRIN,SERV ANAT PATHOL,F-63011 CLERMONT 1,FRANCE; INSERM,U71,F-63005 CLERMONT FERRAND,FRANCE	UNICANCER; Centre Jean Perrin; UNICANCER; Centre Jean Perrin; Institut National de la Sante et de la Recherche Medicale (Inserm)			LALLE, Philippe/G-7734-2018; , bignon/Y-3243-2019; Rio, Pascale/N-5237-2018					ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BOWCOCK AM, 1993, AM J HUM GENET, V52, P730; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEINARD AS, 1992, NUCLEIC ACIDS RES, V20, P1171, DOI 10.1093/nar/20.5.1171-a; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, ONCOGENE, V6, P1705; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; EASTON DF, 1993, AM J HUM GENET, V52, P679; ECCLES DM, 1992, ONCOGENE, V7, P2069; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; FOULKES W, 1991, LANCET, V338, P444, DOI 10.1016/0140-6736(91)91065-3; FUTREAL PA, 1992, CANCER RES, V52, P2624; FUTREAL PA, 1992, HUM MOL GENET, V1, P66, DOI 10.1093/hmg/1.1.66-a; GARCIA T, 1989, NUCLEIC ACIDS RES, V17, P8364; GENUARDI M, 1989, AM J HUM GENET, V45, P73; HALL JM, 1992, AM J HUM GENET, V50, P1235; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE JH, 1990, CANCER RES, V50, P2724; LEONE A, 1991, CANCER RES, V51, P2490; LINDBLOM A, 1993, HUM GENET, V91, P6; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MAZOYER S, 1993, AM J HUM GENET, V52, P754; MIYAKI M, 1990, CANCER RES, V50, P7166; NAROD SA, 1991, LANCET, V338, P82; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SATO T, 1990, CANCER RES, V50, P7184; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SKOLNICK MH, 1990, SCIENCE, V250, P1715, DOI 10.1126/science.2270486; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STEPHENSON CF, 1992, CANCER GENET CYTOGEN, V63, P32, DOI 10.1016/0165-4608(92)90060-L; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; ZIEGLER M, 1992, GENETICS MOL BIOL BR, P83; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	48	29	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					437	442						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290255				2022-12-28	WOS:A1994MW24800010
J	INUZUKA, M; ISHIKAWA, H; KUMAR, S; GELINAS, C; ITO, Y				INUZUKA, M; ISHIKAWA, H; KUMAR, S; GELINAS, C; ITO, Y			THE VIRAL AND CELLULAR REL ONCOPROTEINS INDUCE THE DIFFERENTIATION OF P19 EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							CHICKEN SPLEEN-CELLS; NF-KAPPA-B; V-REL; RETICULOENDOTHELIOSIS VIRUS; C-JUN; PROTEINS; EXPRESSION; ONCOGENE; F9; TRANSFORMATION	Rel proteins have been implicated in the differentiation and transformation of lymphoid cells. Despite their significant sequence homology to the Drosophila Dorsal morphogen, a functional role for Rel proteins in early development has yet to be established. Here we show that expression of the v- or c-rel genes in P19 embryonal carcinoma (EC) cells leads to drastic morphological changes accompanied by the expression of several differentiation-specific antigens. In contrast, v-Rel mutants defective for DNA-binding as well as those lacking the F9 cell-specific transcription activation region of v-Rel were equally unable to promote P19 cell differentiation. Our results demonstrate that transcriptional activation by Rel proteins correlates with Rel-induced differentiation of EC cells, and raise the intriguing possibility that Rel proteins may play an important role in early developmental processes.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Kyoto University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center								ADAMSON ED, 1984, DIFFERENTIATION, V27, P152, DOI 10.1111/j.1432-0436.1984.tb01421.x; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRAVO R, 1988, QUANT BIOL, P901; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Graham C.F, 1977, CONCEPTS MAMMALIAN E, P315; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ISHIKAWA H, 1993, IN PRESS ONCOGENE; KAHAN B, 1983, CELL PROLIFERAT, V10, P131; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T, 1989, DECONTAMINATION DILU; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SHIBUYA T, 1982, CANCER RES, V42, P2722; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	33	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					133	140						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302572				2022-12-28	WOS:A1994MW24700016
J	TAKAISHI, K; SASAKI, T; KATO, M; YAMOCHI, W; KURODA, S; NAKAMURA, T; TAKEICHI, M; TAKAI, Y				TAKAISHI, K; SASAKI, T; KATO, M; YAMOCHI, W; KURODA, S; NAKAMURA, T; TAKEICHI, M; TAKAI, Y			INVOLVEMENT OF RHO-P21 SMALL GTP-BINDING PROTEIN AND ITS REGULATOR IN THE HGF-INDUCED CELL MOTILITY	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; BOTULINUM ADP-RIBOSYLTRANSFERASE; BOVINE BRAIN CYTOSOL; SCATTER FACTOR; GENE-PRODUCT; CLOSTRIDIUM-BOTULINUM; FACTOR RECEPTOR; PARTIAL-PURIFICATION; MET PROTOONCOGENE; EXCHANGE PROTEINS	Hepatocyte growth factor (HGF) induced motility of cultured mouse keratinocytes (308R cells). This HGF-induced cell motility was inhibited by microinjection of either rho GDI, an inhibitory GDP/GTP exchange protein for rho p21 small GTP-binding protein, or a botulinum exoenzyme C3 which is known to selectively impair the function of who p21 by ADP-ribosylating its effector domain. The rho GDI action was prevented by comicroinjection with the guanosine 5'-(3-O-thio)triphosphate (GTP gamma S)-bound active form of rhoA p21, and the C3 action was prevented by comicroinjection with a rhoA p21 mutant (rhoA(Ile41) p21) which is resistant to the C3 action. The HGF-induced cell motility was not inhibited by microinjection of a dominant negative rac1 p21 mutant (rac1(Asn17) p21) or a dominant negative Ki-ras p21 mutant (Ki-ras(Asn17) p21). Microinjection of the GTP gamma S-bound form of rac1 p21 or a dominant active Ki-ras p21 mutant (Ki-ras(Val12) p21) did not induce cell motility. These results indicate that both rho p21 and who GDI, but neither rac p21 nor ras p21, are involved in the HGF-induced cell motility. However, microinjection of the GTP gamma S-bound form of rhoA p21 alone did not induce cell motility in the absence of HGF, suggesting that activation of who p21 is necessary but not sufficient for the HGF-induced cell motility. The HGF-induced cell motility was mimicked by 12-O-tetradecanoylphorbol-13-acetate, a protein kinase C-activating phorbol ester, but not by Ca2+ ionophore. The phorbol ester-induced cell motility was also inhibited by microinjection of rho GDI or C3. These results indicate that both rho p21 and rho GDI are also involved in the phorbol ester-induced cell motility.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,OSAKA,OSAKA 565,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO,KYOTO 606,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kobe University; Osaka University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			Takeichi, Masatoshi/G-5903-2012; KURODA, SHINYA/G-4961-2014	Takeichi, Masatoshi/0000-0002-9931-3378; 				AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; FURLONG RA, 1991, J CELL SCI, V100, P173; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KONISHI T, 1991, BIOCHEM BIOPH RES CO, V180, P765, DOI 10.1016/S0006-291X(05)81131-3; KURODA S, 1992, BIOCHEM BIOPH RES CO, V185, P473, DOI 10.1016/S0006-291X(05)81009-5; MIURA Y, 1993, J BIOL CHEM, V268, P510; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1992, J BIOL CHEM, V267, P20921; MORIISHI K, 1991, J BACTERIOL, V173, P6025, DOI 10.1128/jb.173.19.6025-6029.1991; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; OSADA S, 1992, FEBS LETT, V297, P271, DOI 10.1016/0014-5793(92)80554-T; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sambrook J, 1989, MOL CLONING LABORATO; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; UEDA T, 1990, J BIOL CHEM, V265, P9373; WATABE M, 1993, CELL STRUCT FUNCT, V18, P111; Weber K, 1972, Methods Enzymol, V26, P3; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YUSPA SH, 1981, NATURE, V293, P72, DOI 10.1038/293072a0	59	195	198	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					273	279						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302589				2022-12-28	WOS:A1994MW24700033
J	WELSH, M; MARES, J; KARLSSON, T; LAVERGNE, C; BREANT, B; CLAESSONWELSH, L				WELSH, M; MARES, J; KARLSSON, T; LAVERGNE, C; BREANT, B; CLAESSONWELSH, L			SHB IS A UBIQUITOUSLY EXPRESSED SRC HOMOLOGY-2 PROTEIN	ONCOGENE			English	Article							TYROSINE KINASE; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PDGF RECEPTOR; CDNA CLONING; ACTIVATION; ONCOGENE; INSULIN; DOMAIN; SEQUENCES	To identify serum-inducible genes in the insulin-producing cell line beta TC-1, a library subtraction screening procedure was performed on serum-deprived (G(0)) and serum-restimulated (G(1)) insulin-producing beta TC-1 cells. A cDNA containing a motif with strong homology to Src homology 2 (SH2) domains was found using this procedure and called Shb. The Shb cDNA contains two methionine codons in its N-terminus and thus may code for two proteins of 67 and 56 kDa, each with one SH2 domain in its C-terminus. No other structural similarity to proteins with catalytic activity could be detected, suggesting that Shb is a so called adaptor. Shb contains the proline-rich sequence PPPGPGR between the two proposed initiator methionines which resembles a sequence for binding to Src homology 3 (SH3) domains. A second proline-rich sequence was detected after the second methionine codon. The Shb cDNA hybridized to a similar or identical mRNA of 3.1 kb expressed in mouse brain, liver, kidney, heart, NIH3T3 fibroblasts and beta TC-1 cells. Western blot analysis of the same tissues using an antiserum directed against a synthetic peptide corresponding to a part of the SH2 domain of Shb, revealed reactivity with two proteins of 56 and 67 kDa. In addition, a third reactive component of 40 kDa was detected in most tissues. Transfection and transient expression of the Shb cDNA in COS-1 cells yielded increased expression of the 67, 56 and 40 kDa proteins. Transfection and stable expression of the Shb cDNA in pig aortic endothelial cells showed increased expression primarily of the 67 kDa protein. A fusion protein consisting of the SH2 domain of Shb linked to glutathione S-transferase showed increased binding to glycoproteins of cells stimulated with platelet-derived growth factor (PDGF-BB). Furthermore, the autophosphorylated PDGF beta-receptor but not the autophosphorylated epidermal growth factor (EGF) receptor bound specifically to immobilized fusion protein. It is concluded that Shb is a novel SH2-containing protein with proline-rich domains and therefore probably involved in the signal-transduction of some ligand-activated tyrosine kinase receptors.	CHARLES UNIV, INST BIOL & MED GENET, PRAGUE, CZECH REPUBLIC; HOP ST ANTOINE, INSERM, U55, F-75571 PARIS, FRANCE; UPPSALA UNIV, LUDWIG INST CANC RES, UPPSALA, SWEDEN	Charles University Prague; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ludwig Institute for Cancer Research; Uppsala University	WELSH, M (corresponding author), UPPSALA UNIV, DEPT MED CELL BIOL, UPPSALA, SWEDEN.		Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755; Claesson-Welsh, Lena/0000-0003-4275-2000				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BREANT B, 1990, DIABETOLOGIA, V33, P586, DOI 10.1007/BF00400201; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1993, IN PRESS PROG GROWTH; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Hellerstrom C, 1985, DIABETIC PANCREAS, P53; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; OIE HK, 1983, ENDOCRINOLOGY, V112, P1070, DOI 10.1210/endo-112-3-1070; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sambrook J, 1989, MOL CLONING LABORATO; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1984, CELL, V36, P349; WELSH M, 1993, DIABETES METAB REV, V9, P25, DOI 10.1002/dmr.5610090104; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	66	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					19	27						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302579				2022-12-28	WOS:A1994MW24700003
J	WARNER, LC; HACK, N; EGAN, SE; GOLDBERG, HJ; WEINBERG, RA; SKORECKI, KL				WARNER, LC; HACK, N; EGAN, SE; GOLDBERG, HJ; WEINBERG, RA; SKORECKI, KL			RAS IS REQUIRED FOR EPIDERMAL GROWTH FACTOR-STIMULATED ARACHIDONIC-ACID RELEASE IN RAT-1 FIBROBLASTS	ONCOGENE			English	Article							PROTEIN-KINASE-C; FACTOR RECEPTORS; MAP KINASE; CYTOSOLIC PHOSPHOLIPASE-A2; SIGNAL TRANSDUCTION; MESANGIAL CELLS; 3T3 CELLS; TYROSINE PHOSPHORYLATION; THYROID-CELLS; MESSENGER-RNA	Previous studies have provided suggestive evidence for an interaction between ras activation and signalling pathways involved in agonist-stimulated arachidonic acid release in a variety of cell systems. In order to clarify this interaction, we have measured epidermal growth factor (EGF)-stimulated arachidonic acid release in rat-1 fibroblasts transfected with the N-17 dominant negative mutation of ras. Cells transfected with the N-17 ras mutant, display a markedly attenuated arachidonic acid-release response to EGF, compared to sham-transfected and non-transfected cells. In contrast, the response to phorbol myristate acetate (PMA) was not attenuated in the N-17-mutant expressing cells. No differences were detected between sham-transfected and N-17 mutant expressing cells in levels of immunodetectable EGF receptor, cytosolic phospholipase A(2) or mitogen-activated protein (MAP) kinase. Attenuation of EGF-stimulated arachidonic acid release in the N-17 mutant expressing cells, was accompanied by a marked diminution in EGF-stimulated tyrosine phosphorylation of MAP kinase. We conclude that the signalling pathway involved in epidermal growth factor-stimulated arachidonic acid release is similar to the signalling pathway for mitogenic responses to epidermal growth factor and requires ras activation, likely followed by a downstream cascade of kinases eventuating in MAP kinase activation.	UNIV TORONTO,DEPT MED,DIV NEPHROL,MRC,MEMBRANE BIOL GRP,TORONTO M5S 1A8,ON,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO M5S 1A8,ON,CANADA; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	University of Toronto; University of Toronto; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; BOS JL, 1989, CANCER RES, V49, P4682; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P83; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gan B S, 1989, Proc West Pharmacol Soc, V32, P269; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HACK N, 1990, BIOSCIENCE REP, V10, P353, DOI 10.1007/BF01117235; HACK N, 1991, BIOCHEM J, V275, P563, DOI 10.1042/bj2750563; Hack N., 1991, Journal of Basic and Clinical Physiology and Pharmacology, V2, P161; HACK N, IN PRESS J BIOL CHEM; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HARRIS RC, 1990, FASEB J, V4, P1654, DOI 10.1096/fasebj.4.6.2138579; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS BL, 1988, BIOCHEM J, V249, P587, DOI 10.1042/bj2490587; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MENE P, 1991, AM J PHYSIOL, V260, P159; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PANAYOTOU G, 1992, MOL CELL BIOL, V12, P991; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SELVA E, 1993, J BIOL CHEM, V268, P2250; SHARMA SV, 1992, ONCOGENE, V7, P193; SHARP JD, 1991, J BIOL CHEM, V266, P14850; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZOR U, 1990, BIOCHIM BIOPHYS ACTA, V1091, P385	65	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3249	3255						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247528				2022-12-28	WOS:A1993MG78200007
J	TAMAGNONE, L; LAHTINEN, I; MUSTONEN, T; VIRTANEVA, K; FRANCIS, F; MUSCATELLI, F; ALITALO, R; SMITH, CIE; LARSSON, C; ALITALO, K				TAMAGNONE, L; LAHTINEN, I; MUSTONEN, T; VIRTANEVA, K; FRANCIS, F; MUSCATELLI, F; ALITALO, R; SMITH, CIE; LARSSON, C; ALITALO, K			BMX, A NOVEL NONRECEPTOR TYROSINE KINASE GENE OF THE BTK/ITK/TEC/TXK FAMILY LOCATED IN CHROMOSOME XP22.2	ONCOGENE			English	Note							X-LINKED AGAMMAGLOBULINEMIA; SRC FAMILY; SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; MESSENGER-RNAS; EXPRESSION; RECEPTOR; IDENTIFICATION; PP60C-SRC; SEQUENCE	The Bmx sequence was identified and cloned during our search for novel tyrosine kinase genes expressed in human bone marrow cells. Bmx cDNA comprises a long open reading frame of 675 amino acids, containing one SH3, one SH2 and one tyrosine kinase domain, which are about 70% identical with Btk, Itk and Tec and somewhat less with Txk tyrosine kinase sequences. The amino terminal sequences of these four tyrosine kinases are about 40% identical and each contains a so-called pleckstrin homology domain. The 2.7 kb Bmx mRNA was expressed in endothelial cells and several human tissues by Northern blotting and an 80 kD Bmx polypeptide was detected in human endothelial cells. Immunoprecipitates of COS cells transfected with a Bmx expression vector and NIH3T3 cells expressing a Bmx retrovirus contained a tyrosyl phosphorylated Bmx polypeptide of similar molecular weight. The BMX gene was located in chromosomal band Xp22.2 between the DXS197 and DXS207 loci. Interestingly, chromosome X also contains the closest relative of BMX, the BTK gene, implicated in X-linked agammaglobulinemia. The BMX gene thus encodes a novel nonreceptor tyrosine kinase, which may play a role;in the growth and differentiation of hematopoietic cells.	UNIV HELSINKI,TRANSPLANTAT LAB,SF-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT GENET,MOLEC CANC BIOL LAB,SF-00014 HELSINKI,FINLAND; IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,OXFORD OX3 9DU,ENGLAND; KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN; KAROLINSKA HOSP,DEPT CLIN GENET,S-17176 STOCKHOLM,SWEDEN	University of Helsinki; University of Helsinki; Cancer Research UK; University of Oxford; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital			Muscatelli, Françoise/P-4650-2016; Francis, Fiona/B-5854-2016; Alitalo, Kari K/J-5013-2014; Tamagnone, Luca/J-8948-2018	Muscatelli, Françoise/0000-0003-4001-6528; Alitalo, Kari K/0000-0002-7331-0902; Tamagnone, Luca/0000-0002-2884-7946; SMITH, C. I. Edvard/0000-0003-1907-3392; Francis, Fiona/0000-0001-8542-7537; Mustonen, Tuija/0000-0002-2429-5064				BOLEN JB, 1993, ONCOGENE, V8, P2025; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GIBSON S, 1993, BLOOD, V82, P1561; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MANO H, 1993, ONCOGENE, V8, P417; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MORGENSTERN JP, 1990, NUC ACIDS RES, V12, P6460; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; MUSTELIN T, 1994, SRC FAMILY TYROSINE; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SICILIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; ZHU QL, 1994, J EXP MED, V180, P461, DOI 10.1084/jem.180.2.461	39	167	178	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3683	3688						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970727				2022-12-28	WOS:A1994PT39200032
J	CARTER, R; YUMET, G; PENA, A; SOPRANO, DR; SOPRANO, KJ				CARTER, R; YUMET, G; PENA, A; SOPRANO, DR; SOPRANO, KJ			TRANSCRIPTIONAL REGULATION OF C-JUN EXPRESSION DURING LATE G(1)/S IN NORMAL HUMAN-CELLS IS LOST IN HUMAN TUMOR-CELLS	ONCOGENE			English	Article							PROTO-ONCOGENE; MESSENGER-RNA; G0/G1 TRANSITION; BINDING PROTEIN; DNA-REPLICATION; FACTOR AP-1; FOS; GENE; ACTIVATION; FIBROBLASTS	Previous results from our laboratory have identified a second peak in steady state levels of c-jun mRNA (in addition to the immediate early induction) which occurs at the G(1)/S border in WI-38 normal human diploid fibroblasts. The present studies were undertaken in an attempt to determine (1) the molecular mechanism responsible for the expression of c-jun in late G(1)/S, (2) the relationship between this second peak of c-jun mRNA expression and the induction of DNA synthesis and (3) whether this cell cycle specific c-jun expression is deregulated in transformed cells. Our results show that the second peak in steady state levels of c-jun mRNA is the result of new transcription during late G(1) and not altered stability of the c-jun mRNA transcribed during G(1). We also show that this second peak of expression still occurs even when DNA synthesis is inhibited by either hydroxyurea or aphidicolin. Thus, the second peak precedes and is independent of DNA synthesis. Finally, we find that while two other normal human fibroblast cell lines exhibit a second peak of c-jun mRNA during late G(1)/S, c-jun expression is not cell cycle-regulated but rather is constitutively expressed in a number of distinct transformed cell lines. Since events occuring throughout G(1) are known to regulate cell growth, our results suggest that the extent of regulation of c-jun expression during G, may affect molecular events which ultimately lead to altered growth control as a result of cellular transformation.	TEMPLE UNIV, SCH MED, DEPT IMMUNOL & MICROBIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Borghaei, Ruth/0000-0003-4206-0231	NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ANDEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CARTER R, 1991, ONCOGENE, V6, P229; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COSENZA SC, 1994, J CELL BIOCHEM, V55, P503, DOI 10.1002/jcb.240550410; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; GINSBERG D, 1990, ONCOGENE, V5, P1285; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; JOHNSON TR, 1991, P NATL ACAD SCI USA, V88, P5287, DOI 10.1073/pnas.88.12.5287; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KUNZE N, 1990, EUR J BIOCHEM, V194, P323, DOI 10.1111/j.1432-1033.1990.tb15620.x; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MELVIN WT, 1977, BIOCHEM J, V168, P595, DOI 10.1042/bj1680595; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NOMURA N, 1993, J BIOL CHEM, V268, P4259; PHILLIPS PD, 1992, J CELL PHYSIOL, V151, P206, DOI 10.1002/jcp.1041510126; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAKAI M, 1989, CANCER RES, V49, P5633; SAUVE GL, 1991, DNA SEQUENCE, V1, P13; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHARMA A, 1989, P NATL ACAD SCI USA, V86, P491, DOI 10.1073/pnas.86.2.491; SINCLAIR WK, 1967, CANCER RES, V27, P297; SOPRANO KJ, 1992, ANN NY ACAD SCI, V660, P231, DOI 10.1111/j.1749-6632.1992.tb21075.x; STEIN GS, 1984, RECOMBINANT DNA CELL, P107; TAKEISHI K, 1989, J BIOCHEM-TOKYO, V106, P575, DOI 10.1093/oxfordjournals.jbchem.a122898; TAVALI S, 1989, J BIOL CHEM, V264, P7466; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WASYLYK C, 1990, ONCOGENE, V5, P1055; WOODFORD TA, 1988, ANAL BIOCHEM, V171, P166, DOI 10.1016/0003-2697(88)90138-8; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	48	8	8	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2675	2682						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058331				2022-12-28	WOS:A1994PC05400028
J	TAM, SW; THEODORAS, AM; SHAY, JW; DRAETTA, GF; PAGANO, M				TAM, SW; THEODORAS, AM; SHAY, JW; DRAETTA, GF; PAGANO, M			DIFFERENTIAL EXPRESSION AND REGULATION OF CYCLIN D1 PROTEIN IN NORMAL AND TUMOR HUMAN-CELLS - ASSOCIATION WITH CDK4 IS REQUIRED FOR CYCLIN D1 FUNCTION IN G1 PROGRESSION	ONCOGENE			English	Review							HUMAN-DIPLOID FIBROBLASTS; HUMAN BREAST-CANCER; DNA POLYMERASE-DELTA; RETINOBLASTOMA PROTEIN; NUCLEAR ANTIGEN; GENE-EXPRESSION; P53 GENE; SUBUNIT REARRANGEMENT; AUXILIARY PROTEIN; DEPENDENT KINASES	In this study we have surveyed by immunoblotting the protein levels of Cyclin D1, D2, D3 and their catalytic partners, Cdk4 and Cdk6 in normal and transformed human cells. We found that all these proteins were differentially expressed in diploid cells derived from different tissues, in contrast to Cyclin E, Cyclin A and Cdk2 which are ubiquitously expressed. D-type Cyclins were never dramatically overexpressed and often very poorly expressed in tumor cell lines when compared to the levels in their normal counterparts. In contrast, Cdk4 was expressed at high levels in several tumor cell lines and Cdk6 was ectopically expressed in two sarcoma lines, suggesting a possible involvement of these two Cdks in oncogenesis. Interestingly, low levels of Cyclin D1 and D3 proteins always correlated with functional inactivation of the retinoblastoma gene product (pRb). In cells displaying active pRb, Cyclin D1 was found associated with Cdk4 regardless of whether the p53 gene was wild-type or mutant. Microinjection during G1 of Cyclin D1 anti-sense cDNA or anti-Cyclin D1 antibody in these cells arrested the cell cycle in G1. In cells lacking pRb function, Cyclin D1 was dissociated from Cdk4. Microinjection during G1 of Cyclin D1 antisense cDNA or anti-Cyclin D1 antibody in these cells did not affect G1 progression. These results show that (i) in the absence of pRb, Cyclin D1 is expressed at low levels, is dissociated from Cdk4 and becomes dispensable in G1; (ii) Cyclin D1 needs to be associated with its catalytic subunit, Cdk4, to function as a positive regulator of G1 progression.	MITOTIX INC, CAMBRIDGE, MA 02139 USA; UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011	pagano, michele/0000-0003-3210-2442	NCI NIH HHS [CA50195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTEK J, 1992, ONCOGENE, V7, P101; BARTEK J, 1990, ONCOGENE, V5, P893; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BUCHOU T, 1993, ONCOGENE, V8, P1765; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GLOTZE RM, 1990, NATURE, V349, P132; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL FL, 1993, ONCOGENE, V8, P1377; HANNA Z, 1993, ONCOGENE, V8, P1661; HARPER JW, 1993, CELL, V75, P805; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KHATIB ZA, 1993, CANCER RES, V53, P5535; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEW J, 1992, J BIOL CHEM, V267, P25922; LOVEC H, 1994, ONCOGENE, V9, P323; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; LUKAS J, 1994, ONCOGENE, V9, P707; Maniatis T., 1982, MOL CLONING; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MATSUSHIME H, 1991, COLD SPRING HARBOR S, V56; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAGANO M, 1994, IN PRESS GENES DEV; PALMERO I, 1993, ONCOGENE, V8, P1049; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; SHAY JW, 1993, ONCOGENE, V8, P1407; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; STRATTON MR, 1990, ONCOGENE, V5, P1297; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOMINAGA O, 1993, ONCOGENE, V8, P2653; TSAI LH, 1993, DEVELOPMENT, V119, P1029; WASEEM NH, 1990, J CELL SCI, V96, P121; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	103	313	329	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2663	2674						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058330				2022-12-28	WOS:A1994PC05400027
J	WANG, HG; MIYASHITA, T; TAKAYAMA, S; SATO, T; TORIGOE, T; KRAJEWSKI, S; TANAKA, S; HOVEY, L; TROPPMAIR, J; RAPP, UR; REED, JC				WANG, HG; MIYASHITA, T; TAKAYAMA, S; SATO, T; TORIGOE, T; KRAJEWSKI, S; TANAKA, S; HOVEY, L; TROPPMAIR, J; RAPP, UR; REED, JC			APOPTOSIS REGULATION BY INTERACTION OF BCL-2 PROTEIN AND RAF-1 KINASE	ONCOGENE			English	Note							EPSTEIN-BARR-VIRUS; CELL-DEATH; PROTOONCOGENE EXPRESSION; RAS; ONCOPROTEIN; ACTIVATION; LINE; PHOSPHORYLATION; ONCOGENES; PROSTATE	The Bcl-2 protein is over-produced in many types of human tumors and suppresses apoptosis induced by a wide-variety of stimuli, including chemotherapeutic drugs and gamma-irradiation. The biochemical mechanism of action of the Bcl-2 protein however remains enigmatic. Here we show that Bcl-2 can be co-immunoprecipitated with the serine/ threonine-specific Raf-1 kinase both in a mammalian hemopoietic cell 32D.3 and when the two proteins are produced in Sf9 insect cells using recombinant baculoviruses. Though analysis of-Raf-1 deletion mutants suggested that the C-terminal half of the protein which contains the catalytic domain is sufficient for co-immunoprecipitation with Bcl-2, Raf-1 does not appear to induce phosphorylation of Bcl-2 protein in 32D.3 and Sf9 cells. Furthermore, a mutant form of Raf-1 that lacks kinase activity could still be co-immunoprecipitated with Bcl-2 in Sf9 cells, suggesting that the interaction of these proteins does not reflect a kinase-substrate relation, Gene transfer experiments using 32D.3 hemopoietic cells demonstrated functional synergy between Bcl-2 and Raf-1 with regards to suppression of apoptosis induced by growth factor withdrawal. Taken together, these observations for the first time functionally link Bcl-2 to a signal transducing protein and suggest that the interaction of the Bcl-2 and Raf-1 proteins may be responsible for their ability to cooperate in the suppression of apoptosis.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037; NCI,FREDERICK CANC RES FACIL,TUMOR VIROL LAB,FREDERICK,MD 21702	Sanford Burnham Prebys Medical Discovery Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Troppmair, Jakob/0000-0002-0611-3837	NCI NIH HHS [CA-54957] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054957] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; CAMPOS I, 1993, BLOOD, V18, P3091; CLEVELAND J, IN PRESS ONCOGENE; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DEJONG D, 1994, CANCER RES, V54, P256; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; HANADA M, 1993, BLOOD, V82, P1820; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IKEGAKI B, 1994, CANCER RES, V54, P6; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KOCACHE MM, 1990, INTERVIROLOGY, V31, P1; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MARILIO F, 1989, ONCOGENE, V4, P301; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NGAN BY, 1988, NEW ENGL J MED, V318, P1638, DOI 10.1056/NEJM198806233182502; PEZELLA F, 1993, NEW ENGL J MED, V329, P690; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; REED JC, 1994, ANN ONCOL, V5, pS61, DOI 10.1093/annonc/5.suppl_1.S61; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REY I, 1994, ONCOGENE, V9, P686; SATO T, IN PRESS P NATL ACAD; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	236	245	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2751	2756						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058342				2022-12-28	WOS:A1994PC05400040
J	RAO, VN; REDDY, ESP				RAO, VN; REDDY, ESP			ELK-1 PROTEINS INTERACT WITH MAP KINASES	ONCOGENE			English	Article							ETS-RELATED PROTEIN; SERUM RESPONSE FACTOR; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; C-FOS; DNA-BINDING; C-ETS-1 PROTOONCOGENE; FACTOR P62TCF; PHOSPHORYLATION; SEQUENCE	Mitogen activated protein kinases (MAP) or extracellular signal regulated protein kinases (ERK) are a family of protein serine/threonine kinases that are activated very rapidly in response to many extracellular stimuli. elk-1, an ets related gene codes for two transcriptional factors elk-1, which regulates c-fos transcription and Delta elk-1, both of which are substrates for MAP kinases. A part of the C-terminal transcriptional activation domain (ETA-2) which is common to both the proteins was previously shown to function as an activator of MAP kinases. In this report, in an attempt to investigate the mechanism of activation of MAP kinases, purified preparations of recombinant elk-1 and P44(mpk)/ERK-1/ERK-2 proteins were used to show the association of elk-1 proteins with MAP kinases, The specific interactions of elk-1 proteins with MAP kinases were confirmed by co-immunoprecipitation studies. Thus elk-1 proteins appear to regulate the activity of MAP kinases by interacting with them ensuring a conformational change and stimulating their autophosphorylation and activation property. The activation was dependent on the presence of ATP and Mg2+. In vitro phosphorylation of elk-1 protein was not regulatory for autonomous DNA binding activity of elk-1 protein. Cells which were exposed to EGF showed a rapid stimulation of an elk-1 specific kinase activity, probably MAP kinase which phosphorylated MBP and was found to be associated with immobilized GST-elk-1. Furthermore, dephosphorylation studies indicate that elk-1 proteins can activate only tyrosine phosphorylated MAP kinase. These results demonstrate the presence of an alternative pathway/mechanism (other than MAP kinase kinase, MAPKK/Mek) for the activation of MAP kinases with tyrosine phosphorylation occurring before serine/threonine autophosphorylation and activation by elk-1 proteins.			RAO, VN (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.				NATIONAL CANCER INSTITUTE [P01CA050507] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CHENG HC, 1991, J BIOL CHEM, V266, P17919; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEWIS IC, 1991, J BIOL CHEM, V266, P15180; MARIAS R, 1993, CELL, V73, P381; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1993, CANCER RES, V53, P3449; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1991, ONCOGENE, V6, P2285; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	36	80	81	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1855	1860						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208531				2022-12-28	WOS:A1994NR68500007
J	SIYANOVA, EY; SERFAS, MS; MAZO, IA; TYNER, AL				SIYANOVA, EY; SERFAS, MS; MAZO, IA; TYNER, AL			TYROSINE KINASE GENE-EXPRESSION IN THE MOUSE SMALL-INTESTINE	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; HEMATOPOIETIC-CELLS; PROTEIN-KINASE; DIFFERENTIATED ENTEROCYTES; CATALYTIC DOMAIN; CARCINOMA-CELLS; STEM-CELLS; RECEPTOR; FAMILY; CRYPT	To identify tyrosine kinases that may regulate regeneration of the mammalian intestinal epithelium, we amplified portions of the catalytic domains of protein kinases expressed in intestinal crypt cells, using the polymerase chain reaction technique with primers directed against two invariant amino acid sequence motifs found in all kinases. These fragments were cloned and a library of kinase catalytic domains was generated, Sequence analysis of unique clones resulted in the identification of the catalytic domains of several characterized tyrosine kinases, including lyn, hck, c-fgr, tec, JAK2, itk, and the putative receptor kinase ryk, and expression of these kinases has not previously been described in the intestine. We compared the levels of mRNA encoding these kinases in multiple tissues using RNase protection assays, and we localized the expression of hck, lyn, and JAK2 in the intestine using in situ hybridization. In addition, we identified two novel putative catalytic domain sequences. One of these, which we have named sik (src-related intestinal kinase), is expressed at high levels in the gastrointestinal tract and may play a specific role in signal transduction in epithelial tissues.	UNIV ILLINOIS, COLL MED, DEPT GENET, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Mazo, Ilya A/G-6549-2014	Mazo, Ilya A/0000-0002-8587-4895; Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044525, R01DK044525] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK044525, DK44525, R01 DK044525-06] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BJERKNES M, 1981, ANAT REC, V199, P565, DOI 10.1002/ar.1091990412; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; BURGESS DR, 1989, J CELL BIOL, V109, P2139, DOI 10.1083/jcb.109.5.2139; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CERFBENSUSSAN N, 1991, GASTROENTEROL CLIN N, V20, P549; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FOSS FM, 1989, ONCOGENE RES, V5, P13; GILMAN M, 1987, CURRENT PROTOCOLS MO; GORDON JI, 1993, GASTROENTEROLOGY, V104, P315; GUYGRAND D, 1993, CURR OPIN IMMUNOL, V5, P247, DOI 10.1016/0952-7915(93)90012-H; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPUR AG, 1992, ONCOGENE, V7, P1347; HOEKSTRA MF, 1991, TRENDS GENET, V7, P256, DOI 10.1016/0168-9525(91)90161-I; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; KLEMSZ MJ, 1987, NUCLEIC ACIDS RES, V15, P9600, DOI 10.1093/nar/15.22.9600; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; LEGUEN L, 1992, GENE, V120, P249, DOI 10.1016/0378-1119(92)90100-4; MAHER PA, 1988, J CELL BIOL, V106, P1747, DOI 10.1083/jcb.106.5.1747; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; NEUTRA MR, 1988, CELL TISSUE BIOL, P642; OTTILIE S, 1992, ONCOGENE, V7, P1625; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TRIER JS, 1991, GASTROENTEROL CLIN N, V20, P531; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	38	65	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2053	2057						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208550				2022-12-28	WOS:A1994NR68500030
J	WU, LT; YEE, A; LIU, L; CARBONAROHALL, D; VENKATESAN, N; TOLO, VT; HALL, FL				WU, LT; YEE, A; LIU, L; CARBONAROHALL, D; VENKATESAN, N; TOLO, VT; HALL, FL			MOLECULAR-CLONING OF THE HUMAN CAK1 GENE ENCODING A CYCLIN-DEPENDENT KINASE-ACTIVATING KINASE	ONCOGENE			English	Article							HUMAN OSTEOSARCOMA CELLS; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHATASE; CATALYTIC SUBUNIT; PHOSPHORYLATION; P34CDC2; IDENTIFICATION; INHIBITOR; P34(CDC2)	Cyclin-dependent, proline-directed protein kinases normally function to execute critical cell cycle transitions; abnormal expression and/or viral subversion of the positive (cyclins) and negative (Pic1) regulatory subunits may contribute to neoplastic transformation and tumorigenesis. In addition to the binding of regulatory subunits, the enzymatic activities of the cyclin-dependent kinases, Cdc2 and Cdk2, are tightly regulated by site-specific protein phosphorylation events, Recent studies have identified a critical phosphorylation site (Thr-161) located within kinase Subdomain VIII that is necessary for Cdc2 activation, and enzymatic activities capable of carrying out this heterologous phosphorylation event have been detected in both Xenopus oocytes and human somatic cells. In this report, we characterize by molecular cloning a human homologue of the Xenopus Cdk-activating kinase (Cak, encoded by MO15); the novel human gene is designated (HS)CAK1. While only 75% identity is observed at the nucleotide level, the deduced amino acid sequence encoded by (HS)CAK1 is approximately 87% identical to that of the Xenopus MO15 gene in corresponding regions. The catalytic domain of (HS)Cak1, defined by conserved kinase Subdomains I through XI, exhibits considerable homology with (HS)Cdc2, suggesting that this kinase cascade involves closely related enzymes. Immunological studies with anti-Cak antibodies confirm the presence of specific immunoreactivity in highly purified preparations of the human Cdc2-activating kinase. The molecular characterization of (HS)CAK1 should facilitate studies of its physiological regulation, as well as its potential utility as a target for therapeutic intervention in the treatment of proliferative disorders.	CHILDRENS HOSP LOS ANGELES, RES INST, DIV ORTHOPAED SURG, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90033 USA	Children's Hospital Los Angeles; University of Southern California					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049715] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01GM49715-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; DOU QP, 1993, CANCER RES, V53, P1493; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERSHLER MA, 1993, GENE, V124, P305, DOI 10.1016/0378-1119(93)90411-U; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUERRUCCI M-A, 1991, Protein Sequences and Data Analysis, V4, P337; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PINES J, 1990, New Biologist, V2, P389; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; WHITE BA, 1982, J BIOL CHEM, V257, P8569; Williams R. T., 1993, Molecular Biology of the Cell, V4, p239A; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WU LT, 1993, INT J ONCOL, V3, P859; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	45	47	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2089	2096						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208556				2022-12-28	WOS:A1994NR68500036
J	MAROULAKOU, IG; PAPAS, TS; GREEN, JE				MAROULAKOU, IG; PAPAS, TS; GREEN, JE			DIFFERENTIAL EXPRESSION OF ETS-1 AND ETS-2 PROTOONCOGENES DURING MURINE EMBRYOGENESIS	ONCOGENE			English	Article							LONG TERMINAL REPEAT; DNA-BINDING MOTIF; C-FOS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; PROMOTER SEQUENCES; TRANSFORMING GENE; CELLS; DOMAIN; PROTEINS	ets-l and ets-2 genes have previously been identified by their sequence homology to the v-ets oncogene of the avian erythroblastosis virus, E26. These cellular genes have been shown to function as transcription factors important in lymphoid differentiation and activation and cellular proliferation. In this study, we have broadly analysed the differential expression of ets-l and ets-2 during murine development using in situ hybridization. Our results indicate that these transcription factors are expressed in multiple tissues during critical stages of embryo formation and organogenesis, suggesting that these genes may serve multiple functions during mouse development. The patterns of expression of both genes are quite different as early as day 8.0 of gestation. ets-l expression is clearly observed during a narrow developmental stage in the developing nervous system, including the presumptive hindbrain regions, the neural tube, as well as neural crest and the first and second branchial arches. ets-2 expression is limited to the developing limb buds and distal tail. At later times, ets-l expression is observed in developing vascular structures, including the heart, arteries, capillaries and meninges, whereas ets-2 is highly expressed in developing bone, tooth buds, epithelial layers of the gut, nasal sinus and uterus, and several regions of the developing brain. Both ets-l and ets-2 are expressed in developing lung, gut and skin. High levels of expression in both genes is observed in adult lymphoid tissues, but in different tissue subsets. ets-l is expressed in the adult lung, gut mesenchyme and bone marrow. ets-2 continues to be expressed at low levels in several adult tissues, except in the differentiated brain, where substantial levels of expression are found in particular regions of the mature brain. These results demonstrate that ets-l and ets-2 are differentially regulated, are widely expressed in many tissues during murine embryogenesis and may play important roles in cellular proliferation and differentiation during mouse development.	NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								Ascione R., 1993, Genome research in molecular medicine and virology., P199; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAVAL JL, 1989, J NEUROCHEM, V52, P1954, DOI 10.1111/j.1471-4159.1989.tb07285.x; FISHER CL, 1991, J IMMUNOL, V146, P1743; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; PAPAS TS, 1989, CURR TOP MICROBIOL, P143; PARMA DL, 1991, INT J DEV NEUROSCI, V9, P613, DOI 10.1016/0736-5748(91)90023-F; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; QUEVA C, 1993, ONCOGENE, V8, P2511; ROWE A, 1992, EXP CELL RES, V202, P199, DOI 10.1016/0014-4827(92)90420-D; SACCHI N, 1991, ONCOGENE, V6, P2149; Sambrook J, 1989, MOL CLONING LABORATO; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WERNERT N, 1992, AM J PATHOL, V140, P119; YOUNG WS, 1990, METHODS ANAL NEURONA, P481	48	191	194	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1551	1565						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183549				2022-12-28	WOS:A1994NL81500005
J	BELLUSCI, S; MOENS, G; GAUDINO, G; COMOGLIO, P; NAKAMURA, T; THIERY, JP; JOUANNEAU, J				BELLUSCI, S; MOENS, G; GAUDINO, G; COMOGLIO, P; NAKAMURA, T; THIERY, JP; JOUANNEAU, J			CREATION OF AN HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR AUTOCRINE LOOP IN CARCINOMA-CELLS INDUCES INVASIVE PROPERTIES ASSOCIATED WITH INCREASED TUMORIGENICITY	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; TYROSINE KINASE-ACTIVITY; EPITHELIAL-CELLS; MET PROTOONCOGENE; C-MET; EXTRACELLULAR-MATRIX; FACTOR RECEPTOR; RAT; IDENTIFICATION; EXPRESSION	Exogenous HGF/SF converts subconfluent cultures of NBT-II epithelial carcinoma cells into mobile fibroblast-like cells while being only mitogenic for cells maintained at high density. To investigate the potential rote of such factor in tumor progression, we generated HGF/SF-producing NBT-II cells by transfection with an expression plasmid containing human HGF/SF cDNA. HGF/SF-producing cells also exhibit a fibroblastic phenotype. Media conditioned by these cells are potent inducers of in vitro tubulogenesis which can be inhibited with specific anti-HGF/SF antibodies; these antibodies are also able to reverse the scattered phenotype of the HGF/SF-producing cells. In addition spheroids of HGF/SF-producing cells are dispersed into 3D collagen gels suggesting an increase of invasive properties of these cells. When injected in nude mice, these HGF/SF-producing cells induce tumors appearing more rapidly than did those obtained with untransfected cells. These results show that HGF/SF can promote motility and invasive properties of NBT-II bladder carcinoma cells and also confers a tumorigenic advantage when acting as an autocrine factor.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY; OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV BIOCHEM,SUITA,OSAKA 565,JAPAN	University of Turin; Osaka University	BELLUSCI, S (corresponding author), ECOLE NORMALE SUPER,PHYSIOPATHOL DEV LAB,CNRS,URA 1337,46 RUE ULM,F-75231 PARIS 05,FRANCE.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Comoglio, Paolo/0000-0002-7056-5328; Thiery, Jean Paul/0000-0003-0478-5020	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA 49417-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ADAMS JC, 1991, J CELL SCI, V98, P385; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; COLBEREGARAPIN F, 1981, J MOL BIOL, V105, P1; Cowin P, 1985, CELL CONTACT, P427; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GAVRILOVIC J, 1990, CELL REGUL, V1, P1003, DOI 10.1091/mbc.1.13.1003; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; JIANG WG, 1993, CLIN EXP METASTAS, V11, P235, DOI 10.1007/BF00121166; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KENWORTHY P, 1992, BRIT J CANCER, V66, P243, DOI 10.1038/bjc.1992.251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SPORN MB, 1985, NATURE, V327, P239; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; TUCKER GC, 1991, INVAS METAST, V11, P297; TUCKER GC, 1991, J CELL SCI, V100, P371; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001	54	192	201	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1091	1099						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134112				2022-12-28	WOS:A1994NC04800011
J	REY, I; TAYLORHARRIS, P; VANERP, H; HALL, A				REY, I; TAYLORHARRIS, P; VANERP, H; HALL, A			R-RAS INTERACTS WITH RASGAP, NEUROFIBROMIN AND C-RAF BUT DOES NOT REGULATE CELL-GROWTH OR DIFFERENTIATION	ONCOGENE			English	Article							TYPE-1 GENE TRANSCRIPTS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; PROTEIN GAP; P21; IDENTIFICATION; EXPRESSION; PRODUCT; DOMAIN; GTPASE	Within the superfamily of ras-related GTP-binding proteins, only ras itself has been shown to act as an oncogene. Seven other proteins, however, have greater than 50% amino acid identity to ras and one of them, rap1A, has been shown to interact with the ras GTPase activating protein, ras-GAP, and to inhibit ras function when overexpressed. In this paper, we have examined the biological and biochemical activities of another close relative of ras, R-ras. We show that in vitro, R-ras shares a number of activities with ras; it interacts with the catalytic domain of ras-GAP, with the GAP-related domain of neurofibromin and with the ser/thr kinase, c-raf. Furthermore, R-ras stimulates the expression of c-fos when microinjected into Swiss 3T3 cells. However, unlike ras, R-ras does not include DNA synthesis or membrane ruining in quiescent fibroblasts, nor does it induce maturation of Xenopus oocytes or differentiation of PC12 cells. In addition, we show that unlike rap1A, R-ras does not interfere with ras-stimulated gene transcription. We conclude from these experiments that although R-ras and ras share some biochemical activities, they control distinct biological processes.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOLLAG G, 1992, CANCER BIOL, V3, P199; BOS JL, 1989, CANCER RES, V49, P4682; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1986, J BIOL CHEM, V261, P963; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHI T, 1991, ONCOGENE, V6, P1555; PIZON V, 1988, ONCOGENE, V3, P201; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAKODA T, 1992, ONCOGENE, V7, P1705; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SELF AJ, 1993, ONCOGENE, V8, P655; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P955, DOI 10.1016/0006-291X(91)92029-J; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UCHIDA T, 1992, BIOCHEM BIOPH RES CO, V187, P332, DOI 10.1016/S0006-291X(05)81497-4; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	52	64	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					685	692						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108110				2022-12-28	WOS:A1994MW55100002
J	YOON, HY; BOETTIGER, D				YOON, HY; BOETTIGER, D			EXPRESSION OF V-SRC ALTERS THE EXPRESSION OF MYOGENIC REGULATORY FACTOR GENES	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; CONTRACTILE PROTEIN-SYNTHESIS; MUSCLE-SPECIFIC GENES; DIFFERENTIATION PROGRAM; MYOBLAST DIFFERENTIATION; SKELETAL-MUSCLE; CELLS; MYOD1; FIBROBLASTS; ACTIVATION	Inactivation of v-src in transformed chicken myoblasts induced changes in expression of the myogenic regulatory factors (MRF's), MyoD, myogenin and Myf5. Both MyoD and Myf5 were expressed in the transformed cells. The inactivation of v-src by a temperature up-shift resulted in the loss of Myf5 expression, a transient increase in MyoD, followed by a rise in myogenin mRNA levels. The increase in transcripts for the later muscle proteins, myosin heavy and light chains, alpha-actin and troponin T followed the sequence of changes in MRF expression suggesting that their induction was the result of altered MRF expression. Thus, v-src appears to operate through effects on MRF's and not directly on the expression of the late muscle-specific proteins. When v-src was reactivated in mature myotubes by a temperature down-shift, the pattern of expression was quite different, the late muscle-specific transcripts decreased before the loss of myogenin transcripts and before the rise of Myf5 transcripts.	UNIV PENN,DEPT MICROBIOL,PHILADELPHIA,PA 19104	University of Pennsylvania					NCI NIH HHS [CA 49866, CA 16502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049866, R01CA016502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ANESKIEVICH BJ, 1991, ONCOGENE, V6, P1381; BILLETER R, 1988, MOL CELL BIOL, V8, P1361, DOI 10.1128/MCB.8.3.1361; BISCHOFF R, 1968, J CELL BIOL, V36, P111, DOI 10.1083/jcb.36.1.111; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BRAN T, 1989, EMBO J, V8, P2617; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; DEVLIN RB, 1978, CELL, V13, P599, DOI 10.1016/0092-8674(78)90211-8; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELDRIDGE J, 1985, GENE, V36, P55, DOI 10.1016/0378-1119(85)90069-1; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1984, EMBO J, V3, P1327, DOI 10.1002/j.1460-2075.1984.tb01971.x; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; GROSSI M, 1991, ONCOGENE, V6, P1767; HASTINGS KEM, 1985, J BIOL CHEM, V260, P3699; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; HUMPHRIES EH, 1972, J VIROL, V10, P82, DOI 10.1128/JVI.10.1.82-87.1972; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MANGIACAPRA FJ, 1992, MOL ENDOCRINOL, V6, P2038, DOI 10.1210/me.6.12.2038; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; OTT MO, 1991, DEVELOPMENT, V111, P1097; PAYETTE RF, 1988, DEV BIOL, V125, P341, DOI 10.1016/0012-1606(88)90217-5; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SU HY, 1991, ONCOGENE, V6, P1759; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEST CM, 1983, CANCER RES, V43, P2042; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WYKE JA, 1973, VIROLOGY, V54, P152; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	46	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					801	807						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108122				2022-12-28	WOS:A1994MW55100015
J	PULVERER, BJ; FISHER, C; VOUSDEN, K; LITTLEWOOD, T; EVAN, G; WOODGETT, JR				PULVERER, BJ; FISHER, C; VOUSDEN, K; LITTLEWOOD, T; EVAN, G; WOODGETT, JR			SITE-SPECIFIC MODULATION OF C-MYC COTRANSFORMATION BY RESIDUES PHOSPHORYLATED IN-VIVO	ONCOGENE			English	Article							CASEIN KINASE-II; GLYCOGEN-SYNTHASE KINASE-3-BETA; HUMAN NEUROBLASTOMA-CELLS; CELLULAR GENE-EXPRESSION; DNA-BINDING ACTIVITY; PROTEIN-KINASE; ACTIVATES TRANSCRIPTION; NUCLEAR-LOCALIZATION; NUCLEOTIDE-SEQUENCE; RAPID INDUCTION	c-Myc is a nuclear phosphoprotein which binds DNA as a heterodimer with Max. We have identified two in vivo phosphorylation sites, Thr58 and Ser62, within a domain highly conserved among all Myc family members. Thr58 is mutated in several viral forms of the protein and constitutes a mutational hot-spot in Burkitt's lymphoma. Members of the GSK-3 and MAP kinase families, but not CKII, specifically phosphorylated these sites in vitro. The effect of these phosphorylation sites on Myc function was assessed by cotransformation of primary rat embryo fibroblasts with Pas. Mutagenesis of Thr58 to alanine potentiated focus formation, whereas substitution of Ser62 severely inhibited transformation. Mutation of both residues restored wild-type activity. These data suggest acute, post-translational modulation of Myc via phosphorylation of a conserved region previously implicated in transactivation, transformation and autorepression.	ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA; ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Imperial College London; Ludwig Institute for Cancer Research; Cancer Research UK			Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				AHN NG, 1991, J BIOL CHEM, V266, P4220; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BISTER K, 1980, J VIROL, V36, P617, DOI 10.1128/JVI.36.2.617-621.1980; BISTER K, 1987, ONCOGENE, V1, P97; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CROUCH DH, 1990, ONCOGENE, V5, P683; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOODE N, 1992, J BIOL CHEM, V267, P16878; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HAMANN U, 1991, ONCOGENE, V6, P1745; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Ingvarsson S, 1990, Semin Cancer Biol, V1, P359; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUO K, 1990, ONCOGENE, V5, P921; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MEEK DW, 1992, BIOCHEM J, V287, P1; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOORE JP, 1987, ONCOGENE RES, V2, P65; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAMAKRISHNA S, 1989, BIOCHEMISTRY-US, V28, P856, DOI 10.1021/bi00428a067; RAMAKRISHNA S, 1988, J BIOL CHEM, V263, P12677; RAMSAY GM, 1982, J VIROL, V41, P745, DOI 10.1128/JVI.41.3.745-753.1982; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SAKSELA K, 1992, ONCOGENE, V7, P347; SCHWEINFEST CW, 1988, MOL CELL BIOL, V8, P3080, DOI 10.1128/MCB.8.8.3080; SETH A, 1991, J BIOL CHEM, V266, P23521; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SYMONDS G, 1989, ONCOGENE, V4, P285; WATERS CM, 1991, ONCOGENE, V6, P797; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WOODGETT JR, 1989, ANAL BIOCHEM, V180, P237, DOI 10.1016/0003-2697(89)90423-5; WOODGETT JR, 1992, NEURONAL CELL LINES, P133; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	83	207	210	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					59	70						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302604				2022-12-28	WOS:A1994MW24700008
J	SACHSE, R; MURAKAMI, Y; SHIRAISHI, M; HAYASHI, K; SEKIYA, T				SACHSE, R; MURAKAMI, Y; SHIRAISHI, M; HAYASHI, K; SEKIYA, T			DNA ABERRATIONS AT THE RETINOBLASTOMA GENE LOCUS IN HUMAN SQUAMOUS-CELL CARCINOMAS OF THE LUNG	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; SUSCEPTIBILITY GENE; OSTEO-SARCOMA; SEQUENCE POLYMORPHISMS; PROTEIN EXPRESSION; POINT MUTATIONS; HUMAN GENOME; SHORT ARM; RB GENE; HETEROZYGOSITY	We detected DNA aberrations at the RB locus in surgical specimens of human primary non-small cell lung carcinoma by single-strand conformation polymorphism analysis of polymerase chain reaction products amplified from regions of exons 2 to 27 including parts of the flanking intron sequences. Detection of nucleotide sequence polymorphism revealed loss of heterozygosity in six of eight informative cases among 13 squamous cell carcinomas analysed. In two of the six cases, mutations in the remaining allele were detected. In 25 adenocarcinomas analysed, no loss of heterozygosity was observed in 16 informative cases and a point mutation was detected in one of the uniformative cases. In one of three adenosquamous carcinomas analysed, a point mutation was detected and one adenoid cystic carcinoma analysed showed allelic loss of the RB gene. Our results indicated that loss of heterozygosity at the RB locus is frequent in squamous cell carcinomas of the lung,:but not in adenocarcinomas. In the squamous cell carcinomas with allelic loss, mutations of the RB gene in the remaining alleles were found in one third of the tumors.	NATL CANC CTR,RES INST,DIV ONCOGENE,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								BARKER D, 1982, CYTOGENET CELL GENET, V32, P253; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORG A, 1992, CANCER RES, V52, P2991; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CAIRNS P, 1991, ONCOGENE, V6, P2305; COOPER DN, 1984, HUM GENET, V66, P1, DOI 10.1007/BF00275182; COOPER DN, 1985, HUM GENET, V69, P201, DOI 10.1007/BF00293024; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HAYASHI K, 1992, GENET ANAL-BIOMOL E, V9, P73, DOI 10.1016/1050-3862(92)90001-L; HENSEL CH, 1990, CANCER RES, V50, P3067; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ISHIKAWA J, 1991, CANCER RES, V51, P5736; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KISHIMOTO Y, 1992, HUM GENET, V88, P487, DOI 10.1007/BF00219333; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MASHIYAMA S, 1991, TECHNIQUE, V2, P304; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MORI N, 1990, ONCOGENE, V5, P1713; MORI N, 1989, CANCER RES, V49, P5130; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Nei M., 1987, MOL EVOLUTIONARY GEN; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; REISSMANN PT, 1993, ONCOGENE, V8, P1913; REISSMANN PT, 1989, ONCOGENE, V4, P839; SACHSE R, 1992, JPN J CANCER RES, V83, P1299, DOI 10.1111/j.1349-7006.1992.tb02762.x; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VARLEY JM, 1989, ONCOGENE, V4, P725; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; XU HJ, 1991, CANCER RES, V51, P2735; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471; YOKOYAMA S, 1992, CANCER RES, V52, P873	52	31	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					39	47						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302602				2022-12-28	WOS:A1994MW24700006
J	HENRIKSSON, M; BAKARDJIEV, A; KLEIN, G; LUSCHER, B				HENRIKSSON, M; BAKARDJIEV, A; KLEIN, G; LUSCHER, B			PHOSPHORYLATION SITES MAPPING IN THE N-TERMINAL DOMAIN OF C-MYC MODULATE ITS TRANSFORMING POTENTIAL	ONCOGENE			English	Article							CASEIN KINASE-II; GLYCOGEN-SYNTHASE KINASE-3; HIERARCHICAL PROTEIN-PHOSPHORYLATION; NUCLEOTIDE-SEQUENCE ANALYSIS; MYELOCYTOMATOSIS VIRUS MC29; E-MU-MYC; V-MYC; TRANSGENIC MICE; CELL-LINES; NEOPLASTIC TRANSFORMATION	The nuclear proto-oncoprotein c-Myc is involved in the regulation of cell growth and differentiation. c-Myc is phosphorylated at multiple sites in vivo, two of which we have identified near the amino terminus. In chicken Thr-61/Ser-65 are phosphorylated, as are the comparable positions, Thr-58/Ser-62 in human c-Myc. These residues are located within a domain that is implicated in transactivation and is important for the transforming potential of the protein. Furthermore, these phosphorylation sites or nearby amino acids are frequently mutated in v-myc and in several c-myc genes from Burkitt's lymphoma cells. In vitro these two phosphorylation sites can be modified by glycogen synthase kinase 3 and mitogen activated protein kinase. To address their biological importance we mutated these amino terminal phosphorylation sites separately and together. Stably transfected Rat1A cells expressing the mutated proteins have an increased growth potential in soft agar Compared to wt-c-myc transfectants. These altered transformation characteristics indicate that Myc function may be negatively regulated by the amino terminal phosphorylation.	HANNOVER MED SCH, INST MOLEC BIOL, D-30623 HANNOVER, GERMANY; KAROLINSKA INST, DEPT TUMOR BIOL, S-10401 STOCKHOLM, SWEDEN	Hannover Medical School; Karolinska Institutet			Henriksson, Marie Arsenian/F-5010-2015; Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BIEGALKE BJ, 1987, J VIROL, V61, P2138, DOI 10.1128/JVI.61.7.2138-2142.1987; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FIRZLAFF J M, 1989, New Biologist, V1, P44; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FRYKBERG L, 1987, ONCOGENE, V1, P415; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HIHARA H, 1974, NATL I ANIM HEALTH Q, V14, P163; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lenoir GM, 1987, ADV VIRAL ONCOL, V7, P173; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; OVERELL RW, 1989, ONCOGENE, V4, P1425; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAKSELA K, 1992, ONCOGENE, V7, P347; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SYMONDS G, 1989, ONCOGENE, V4, P285; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WALKER CW, 1992, ONCOGENE, V7, P2007; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P3642, DOI 10.1073/pnas.80.12.3642; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	74	161	162	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3199	3209						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247524				2022-12-28	WOS:A1993MG78200002
J	PUPA, SM; MENARD, S; MORELLI, D; POZZI, B; DEPALO, G; COLNAGHI, MI				PUPA, SM; MENARD, S; MORELLI, D; POZZI, B; DEPALO, G; COLNAGHI, MI			THE EXTRACELLULAR DOMAIN OF THE C-ERBB-2 ONCOPROTEIN IS RELEASED FROM TUMOR-CELLS BY PROTEOLYTIC CLEAVAGE	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; HUMAN-BREAST-CARCINOMA; PLASMINOGEN-ACTIVATOR ACTIVITY; EGF RECEPTOR; MONOCLONAL-ANTIBODIES; PROTO-ONCOGENE; TRUNCATED RECEPTOR; MAMMARY-TUMOR; CATHEPSIN-B	A molecule that is immunologically related to the c-erbB-2 oncogene product (p185HER2/neu) was detected in the conditioned culture medium from neu-overexpressing tumor cell lines and in sera of advanced-stage breast carcinoma patients. Using a sensitive (in the range of 0.5 ng ml-1) double-determinant radioimmunoassay (DDIRMA) with two monoclonal antibodies (MAbs) directed against the neu extracellular domain (ECD), soluble oncoproteins were detected in supernatants from several neu-positive tumor cell lines, independent of the levels of membrane p185HER2 expression. The molecule detected did not react with a MAb directed against an intracytoplasmic epitope of the p185HER2. Western blot analysis of the concentrated supernatant revealed a protein of approximately 110 kDa molecular mass, which closely matches the predicted size of the glycosylated p185HER2 ECD. Immunoprecipitation of culture supernatant from cell surface-radioiodinated cells confirmed the 110 kDa molecular mass of the glycosylated shed protein, which migrated to 86 kDa after deglycosylation. Proteolytic cleavage of the p185HER2 molecule was demonstrated in release assays carried out with protease inhibitors. The combined use of leupeptin and EDTA completely inhibited release of the molecule. Analysis of sera from breast carcinoma patients and healthy donors by DDIRMA revealed the presence of soluble neu in 15% of pathologic sera but none of the normal sera. A good correlation was found between neu-overexpression in the primary tumor and the soluble marker in serum of patients with advanced disease; sera of early-stage patients were always negative, independent of neu-overexpression in the tumor. These results suggest the usefulness of soluble neu as an indicator of tumor aggressiveness but not as a diagnostic marker of breast cancer.	IST NAZL TUMORI,DIV DIAGNOST SURG,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	PUPA, SM (corresponding author), IST NAZL TUMORI,DIV EXPTL ONCOL E,VIA G VENEZIAN 1,I-20133 MILAN,ITALY.		Pupa, Serenella/K-6388-2016; Morelli, Daniele/I-4113-2017; menard, sylvie mm/C-7940-2011	Pupa, Serenella/0000-0002-4592-6830; Morelli, Daniele/0000-0002-1823-3764; 				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ALPER O, 1990, CELL GROWTH DIFFER, V1, P591; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; CARNEY W P, 1991, Journal of Tumor Marker Oncology, V6, P53; CENTIS F, 1992, HYBRIDOMA, V11, P267, DOI 10.1089/hyb.1992.11.267; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Diotti A, 1987, Int J Biol Markers, V2, P161; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EISEMANN A, 1991, ONCOGENE, V6, P1195; ETO I, 1992, BIOCHEM J, V283, P209, DOI 10.1042/bj2830209; EVERS JL, 1982, CANCER RES, V42, P219; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; KAMITANI H, 1992, Neurological Research, V14, P236; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGTON BC, 1991, CANCER RES, V51, P2593; LEITZEL K, 1992, J CLIN ONCOL, V10, P1436, DOI 10.1200/JCO.1992.10.9.1436; LIN YZJ, 1991, ONCOGENE, V6, P639; MAIER LA, 1991, CANCER RES, V51, P5361; MARIANICOSTANTINI R, 1984, VIRCHOWS ARCH A, V402, P389, DOI 10.1007/BF00734636; MENARD S, 1983, CANCER RES, V43, P1295; MORI S, 1990, JPN J CANCER RES, V81, P489, DOI 10.1111/j.1349-7006.1990.tb02596.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NYGREN PA, 1988, J MOL RECOG, V1, P540; PARK JB, 1989, CANCER RES, V49, P6605; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; POOLE AR, 1978, NATURE, V273, P545, DOI 10.1038/273545a0; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RECKLIES AD, 1982, BIOCHEM J, V207, P633, DOI 10.1042/bj2070633; RECKLIES AD, 1980, CANCER RES, V40, P550; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SAINSBURY JRC, 1987, LANCET, V1, P1398; SHI ZR, 1983, CANCER RES, V43, P4045; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUTHERLAND DJA, 1980, JNCI-J NATL CANCER I, V64, P3; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; THORSEN T, 1982, EUR J CANCER CLIN ON, V18, P129, DOI 10.1016/0277-5379(82)90055-4; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WALDMANN TA, 1985, CANCER RES, V45, P4559; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	53	138	147	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2917	2923						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8105438				2022-12-28	WOS:A1993MC09300004
J	PASLEAU, F; GROOTECLAES, M; GOLWINKLER, R				PASLEAU, F; GROOTECLAES, M; GOLWINKLER, R			EXPRESSION OF THE C-ERBB2 GENE IN THE BT474 HUMAN MAMMARY-TUMOR CELL-LINE - MEASUREMENT OF C-ERBB2 MESSENGER-RNA HALF-LIFE	ONCOGENE			English	Article							HUMAN BREAST-CANCER; PROTO-ONCOGENE; GROWTH-FACTOR; EGF-RECEPTOR; C-MYC; HER-2/NEU PROTOONCOGENE; OVARIAN-CANCER; OVEREXPRESSION; LIGAND; ACTIVATION	BT474 and SK-BR-3 mammary adenocarcinoma cells contain eight copies of the c-erbB2 gene but overexpress the mRNA 80 times over the levels measured in normal breast or in the HBL-100 cell line. Using Northern blot analysis and molecular titration based on RNAase protection assay, the decrease in the c-erbB2 mRNA level was monitored in BT474 cells treated with actinomycin D from 1 up to 24 h. The c-erbB2 degradation rate during the first 12 h corresponds to a calculated c-erbB2 mRNA half-life of approximately 7 h. Forty percent of the mRNA present in the cells before treatment remains undegraded after transcription has been blocked for 24 h. Pretreatment with cycloheximide results in complete mRNA degradation in 24 h, suggesting that labile proteins stabilize part of the c-erbB2 mRNA population. Comparison with the c-erbB2 mRNA turnover in HBL100 'normal' cells indicated that the accumulation of the c-erbB2 gene product in the tumor cells is not the result of stabilization of the messenger. Rather, it is correlated with an increased rate of c-erbB2 mRNA transcription as indicated by run-on transcription assays. Both BT474 and SK-BR-3 tumor cell lines were found to synthesize 20-40 times more c-erbB2 mRNA than HBL-100 cells.			PASLEAU, F (corresponding author), UNIV LIEGE,DEPT RADIOIMMUNOL,MOLEC ONCOL LAB,TOUR PATHOL B23,B-4000 SART,BELGIUM.							AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BERCHUCK A, 1990, CANCER RES, V50, P4087; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DATI C, 1990, ONCOGENE, V5, P1001; DELVENNE CG, 1992, EUR J CANCER, V28A, P700; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; JINNO Y, 1988, NUCLEIC ACIDS RES, V16, P4957, DOI 10.1093/nar/16.11.4957; KERN JA, 1990, CANCER RES, V50, P5184; KESAVAN P, 1990, ONCOGENE, V5, P483; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LACY J, 1989, EMBO J, V8, P1973, DOI 10.1002/j.1460-2075.1989.tb03603.x; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LEMOINE NR, 1990, ONCOGENE, V5, P237; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PASLEAU F, 1990, ARCH INT PHYSL BIOCH, V98, P40; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PERREN TJ, 1991, BRIT J CANCER, V63, P328, DOI 10.1038/bjc.1991.78; PRESS MF, 1990, ONCOGENE, V5, P953; RAYMOND V, 1989, ONCOGENE RES, V5, P1; READ LD, 1990, CANCER RES, V50, P3947; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2179; THOMPSON KL, 1989, J BIOL CHEM, V264, P3230; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WEINER DB, 1990, CANCER RES, V50, P421; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	35	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					849	854						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8096075				2022-12-28	WOS:A1993KT22000005
J	LARSON, RC; FISCH, P; LARSON, TA; LAVENIR, I; LANGFORD, T; KING, G; RABBITTS, TH				LARSON, RC; FISCH, P; LARSON, TA; LAVENIR, I; LANGFORD, T; KING, G; RABBITTS, TH			T-CELL TUMORS OF DISPARATE PHENOTYPE IN MICE TRANSGENIC FOR RBTN-2	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOMAL TRANSLOCATION; ANTIGEN RECEPTOR; HOMEOBOX GENE; PROTEIN; LYMPHOMA; FUSION; FAMILY; HOX11; ONCOGENES	RBTN2 is a LIM domain protein which can be activated by the translocation t(11;14)(p13;q11) in childhood T cell acute leukaemia. Transgenic mice were examined in which rbtn2 protein is expressed in the T cell lineage. An average of 72% of these mice developed T cell tumours before 18 months of age, compared with 9% in transgenic mice expressing the related gene Rbtn-1. Rbtn2-induced tumours first appeared at 5 months of age and were clonal. They displayed a range of phenotypes, the most notable being CD3/CD45R double-positive cells. Tumours expressing either T cell receptor alpha/beta or gamma/delta heterodimers were found. Thus rbtn2 can promote tumours within a range of T cell types and maturities. The latency period before tumour development indicates that secondary events must occur before the onset of overt malignancy.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology			Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				ASENSI V, 1990, CLIN EXP IMMUNOL, V80, P268; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLARK SS, 1993, J VIROL, V67, P6033, DOI 10.1128/JVI.67.10.6033-6046.1993; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUBE ID, 1991, BLOOD, V78, P2996; FISCH P, 1992, ONCOGENE, V7, P2389; FIZZOTTI M, 1994, LEUKEMIA, V8, P1124; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; KAPFF CT, 1991, ACUTE LYMPHATIC LEUK; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RIBEIRO RC, 1991, BLOOD, V78, P466; RIBEIRO RC, 1992, LEUKEMIA LYMPHOMA, V7, P351, DOI 10.3109/10428199209049790; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Sperling A I, 1989, Int Immunol, V1, P434, DOI 10.1093/intimm/1.4.434; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, IN PRESS EMBO J, V13; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Yagita H, 1989, INT IMMUNOL, V1, P94, DOI 10.1093/intimm/1.1.94	34	89	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3675	3681						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970726				2022-12-28	WOS:A1994PT39200031
J	MARTELLI, F; CENCIARELLI, C; SANTARELLI, G; POLIKAR, B; FELSANI, A; CARUSO, M				MARTELLI, F; CENCIARELLI, C; SANTARELLI, G; POLIKAR, B; FELSANI, A; CARUSO, M			MYOD INDUCES RETINOBLASTOMA GENE-EXPRESSION DURING MYOGENIC DIFFERENTIATION	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; LOOP-HELIX PROTEINS; DNA-BINDING; CELL-CYCLE; SUSCEPTIBILITY GENE; MOUSE MUSCLE; RB1 GENE; PRODUCT; DOMAIN; PHOSPHORYLATION	In skeletal muscle cells permanent withdrawal from the cell cycle is a prerequisite for terminal differentiation. The muscle-specific transcription factor MyoD can activate downstream muscle structural genes and myogenic conversion in many different cell types. It has been demonstrated that the product of the retinoblastoma susceptibility gene, with its growth-suppressive activity, is involved in the myogenic function of MyoD (Caruso et al., 1993; Gu et al., 1993). The present study characterises the modulation of retinoblastoma (Rb1) mRNA levels during myogenic differentiation of the murine C2 cell line and provides evidence that the muscle-specific regulatory factor MyoD enhances Rb1 gene transcription. We demonstrate that MyoD mediates the transactivation of a CAT construct whose expression is driven by the human Rbl gene promoter, and that this is not a consequence of direct binding of MyoD to an E-box DNA sequence motif present in the Rb1 promoter sequences. In addition we have tested the capability of several MyoD mutant proteins of inducing the Rb1 promoter CAT construct. Our results indicate that the MyoD function required for induction of Rb1 promoter activity is distinct from its myogenic function.	CNR,IST TECNOL BIOMED,I-00161 ROME,ITALY; IST REGINA ELENA STUDIO & CURA TUMORI,I-00158 ROME,ITALY; CNR,IST BIOL CELLULARE,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR)			Felsani, Armando/D-1784-2010; Martelli, Fabio/AAL-3788-2020; Caruso, Maurizia/G-8895-2013	Felsani, Armando/0000-0001-8851-6295; Martelli, Fabio/0000-0002-8624-7738; Caruso, Maurizia/0000-0001-5445-6343; Cenciarelli, Carlo/0000-0001-7480-4608	Telethon [298] Funding Source: Medline	Telethon(Fondazione Telethon)		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; CARUSO M, 1993, ONCOGENE, V8, P267; CARUSO M, 1990, EMBO J, V9, P947, DOI 10.1002/j.1460-2075.1990.tb08193.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAUBAS P, 1985, NUCLEIC ACIDS RES, V13, P4623, DOI 10.1093/nar/13.13.4623; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LARSON DE, 1989, BIOCHIM BIOPHYS ACTA, V1009, P177, DOI 10.1016/0167-4781(89)90098-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PAGANO M, 1992, ONCOGENE, V7, P1681; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SLACK RS, 1993, ONCOGENE, V8, P1585; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; STEIN G S, 1992, Current Opinion in Cell Biology, V4, P166, DOI 10.1016/0955-0674(92)90028-B; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TANG A, 1989, ONCOGENE, V4, P401; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343	69	104	104	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3579	3590						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970718				2022-12-28	WOS:A1994PT39200021
J	WADMAN, IA; HSU, HL; COBB, MH; BAER, R				WADMAN, IA; HSU, HL; COBB, MH; BAER, R			THE MAP KINASE PHOSPHORYLATION SITE OF TAL1 OCCURS WITHIN A TRANSCRIPTIONAL ACTIVATION DOMAIN	ONCOGENE			English	Note							LOOP-HELIX PROTEINS; T-CELL LEUKEMIA; DNA-BINDING; ENHANCER-BINDING; MAMMALIAN-CELLS; GENE; TRANSLOCATION; MOTIF; EXPRESSION; YEAST	Alteration of the TAL1 gene is the most common genetic lesion found in patients with T cell acute lymphoblastic leukemia. TAL1 encodes a basic helix-loop-helix transcription factor that is phosphorylated on serine residue 122 by the mitogen-activated protein (MAP) kinase ERK1. Here we show that the amino-terminal sequences of TAL1 (residues 1-166) function in vivo as a transcriptional activation domain. Mutation of serine residue 122 reduces the potency of the transactivation domain by more than half. The data suggest that the amino-terminal transactivation domain of TAL1 is positively regulated by S122 phosphorylation and that the functional properties of TAL1 can be influenced by signal transduction pathways that involve the MAP kinases.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473	NATIONAL CANCER INSTITUTE [R01CA063191] Funding Source: NIH RePORTER; NCI NIH HHS [CA63191] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BERNARD O, 1991, ONCOGENE, V6, P1477; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODWIN G, 1991, NUCLEIC ACIDS RES, V20, P368; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOUTHON MA, 1993, BLOOD, V81, P647; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SADOWSKI I, 1988, NATURE, V335, P559; SETH A, 1991, J BIOL CHEM, V266, P23521; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	36	36	37	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3713	3716						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970731				2022-12-28	WOS:A1994PT39200037
J	ZHOU, XL; TARMIN, L; YIN, J; JIANG, HY; SUZUKI, H; RHYU, MG; ABRAHAM, JM; MELTZER, SJ				ZHOU, XL; TARMIN, L; YIN, J; JIANG, HY; SUZUKI, H; RHYU, MG; ABRAHAM, JM; MELTZER, SJ			THE MTS1 GENE IS FREQUENTLY MUTATED IN PRIMARY HUMAN ESOPHAGEAL TUMORS	ONCOGENE			English	Article							P53; CANCERS; HETEROZYGOSITY; MUTATIONS	Homozygous and heterozygous deletions involving chromosome 9p21 have been reported in a variety of primary human tumors in vivo, and point mutations have been reported in melanoma cell lines in vitro within a probable tumor suppressor gene, MTS1, located at chromosome 9p21. We describe six sequence alterations occurring among twenty-four primary esophageal squamous carcinomas and nineteen primary esophageal adenocarcinomas analyzed by DNA sequencing of MTS1 exon 2. Nucleotide substitutions were observed in five squamous cell carcinomas and in one adenocarcinoma. Two occurred in the germline, while four were somatic alterations. All six nucleotide changes resulted in marked alterations in amino acid sequence. Four were nonsense mutations leading to premature termination codons; nucleotide substitutions identical to two of these stop codons were previously reported in other tumor types. Loss of heterozygosity occurred in all five informative (constitutionally heterozygous) cases in which a sequence alteration was present. Esophageal cancer is one primary human tumor in which MTS1 constitutes an apparent target of heterozygous or homozygous deletions occurring at chromosome 9p21.	UNIV MARYLAND,SCH MED,DEPT MED,DIV GI,BALTIMORE,MD 21201; VET AFFAIRS HOSP,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NIDDK NIH HHS [R01 DK47717] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT WP, 1991, ONCOGENE, V6, P1779; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; BRISEBOIS JJ, 1993, MUTAT RES, V287, P191, DOI 10.1016/0027-5107(93)90012-5; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1994, CANCER RES, V54, P1422; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; HARRIS CC, 1991, ONCOGENE, V6, P1779; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HUANG Y, 1993, CANCER RES, V53, P1889; HUANG Y, 1992, CANCER RES, V52, P6525; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MARX J, 1994, SCIENCE, V264, P344, DOI 10.1126/science.8153613; MEAD LJ, 1994, CANCER RES, V54, P2307; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2322; MERLO A, 1994, CANCER RES, V54, P640; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; ORLOW I, 1994, CANCER RES, V54, P2848; POWELL SM, 1994, IN PRESS GASTROENTER; RHYU MG, 1994, ONCOGENE, V9, P29; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; ZHANG LH, 1992, J MOL BIOL, V223, P627, DOI 10.1016/0022-2836(92)90979-T	29	143	151	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3737	3741						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970734				2022-12-28	WOS:A1994PT39200040
J	LANDERS, JE; HAINES, DS; STRAUSS, JF; GEORGE, DL				LANDERS, JE; HAINES, DS; STRAUSS, JF; GEORGE, DL			ENHANCED TRANSLATION - A NOVEL MECHANISM OF MDM2 ONCOGENE OVEREXPRESSION IDENTIFIED IN HUMAN TUMOR-CELLS	ONCOGENE			English	Note							WILD-TYPE P53; MONOCLONAL-ANTIBODY; TRANSFORMED-CELLS; SIMIAN VIRUS-40; GENE-EXPRESSION; MUTATIONS; AMPLIFICATION; ANTIGEN; PROTEIN; SARCOMAS	The cellular mdm2 gene, which has potential transforming activity that can be activated by overexpression, is amplified in a significant percentage of human sarcomas and in other mammalian tumors. Proteins encoded by the mdm2 gene can bind to, and inhibit the function of, the protein product of the p53 tumor suppressor gene. As reported here, we have identified human choriocarcinoma cell lines that express high levels of mdm2 proteins as well as the p53 protein. Several lines of evidence demonstrate that the p53 in these tumor cells has a wild-type nucleotide sequence, although the protein exhibits an extended half-life. Further, the more than 100-fold overexpression of mdm2 proteins in these cells cannot be explained by gene amplification, elevated RNA expression, or altered protein stability; rather our data indicate that elevated mdm2 protein levels in these choriocarcinoma cell lines result from enhanced translation. This mechanism has not previously been implicated in the regulation of mdm2 gene expression, and it represents a novel means by which the potential transforming,activity of the mdm2 oncogene could be activated.	UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Landers, John/0000-0001-8084-5043	NATIONAL CANCER INSTITUTE [F32CA060390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050786] Funding Source: NIH RePORTER; NCI NIH HHS [NCI 1F32CA60390] Funding Source: Medline; NHLBI NIH HHS [HL50786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDONCARDO C, 1994, CANCER RES, V54, P794; DVIDOFF AM, 1992, ONCOGENE, V7, P127; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FELIX CA, 1992, J CLIN INVEST, V90, P653, DOI 10.1172/JCI115907; FELIX CA, 1992, CANCER RES, V52, P2243; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LADANYI M, 1993, CANCER RES, V53, P16; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1993, ONCOGENE, V8, P2001; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; MURPHY M, 1991, J NEUROSCI RES, V30, P475, DOI 10.1002/jnr.490300304; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIFENBERGER G, 1993, CANCER RES, V53, P2736; REIHSAUS E, 1990, ONCOGENE, V5, P137; RUBIO MP, 1993, CANCER RES, V53, P3465; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	44	160	160	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2745	2750						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058341				2022-12-28	WOS:A1994PC05400039
J	MAFUNE, Y; ASAKURA, H; KOMINAMI, R				MAFUNE, Y; ASAKURA, H; KOMINAMI, R			ALLELIC LOSSES AND METASTATIC ABILITY OF MOUSE-TUMOR CELL CLONES DERIVED FROM A HETEROZYGOUS MOUSE	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; DNA POLYMORPHISMS; SUPPRESSOR GENES; PROSTATIC-CANCER; ALLELOTYPE; MUTATIONS; CARCINOMA; GENOME; P53; MAP	Some chromosomal or subchromosomal deletions observed in a variety of cancer cells may be related with metastatic properties of the tumor cells. Thus, relationship between allelic losses and metastatic ability is here investigated of ten in vitro clones obtained from 505 cells that are derived from a fibrosarcoma induced in a F-1 mouse between C3H and C57BL strains. Allelic loss was examined using 61 microsatellite markers spanning all autosomes and deletions of various loci were observed in all of the clones. One clone showed a metastatic ability higher than the parental 505 cells and the other clones. This particular clone specifically lost a chromosome 16 derived from C57BL, suggesting an association of this chromosome deletion with the metastatic ability. Consistently, examination of metastatic nodules derived from 505 cells and one in vitro clone showed that the cells with deletion of the C57BL chromosome increased in number during metastasis. These results suggest that mouse chromosome 16 may harbor a gene(s) involved in metastasis.	NIIGATA UNIV,SCH MED,DEPT BIOCHEM 1,NIIGATA 951,JAPAN; NIIGATA UNIV,SCH MED,DEPT INTERNAL MED 3,NIIGATA 951,JAPAN	Niigata University; Niigata University								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BACKER JM, 1993, ONCOGENE, V8, P497; BRATHWAITE O, 1992, CANCER RES, V52, P3791; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CORNALL RJ, 1991, GENOMICS, V10, P874, DOI 10.1016/0888-7543(91)90175-E; DIETRICH W, 1992, GENETICS, V131, P423; EMANUEL BS, 1991, CYTOGENET CELL GENET, V58, P827, DOI 10.1159/000133182; ENOKI Y, 1990, JPN J CANCER RES, V81, P141, DOI 10.1111/j.1349-7006.1990.tb02540.x; FUJIMORI M, 1991, CANCER RES, V51, P89; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAYASHI H, 1993, JPN J CANCER RES, V84, P1292; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; Hirohashi S, 1991, Princess Takamatsu Symp, V22, P87; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; ICHIKAWA T, 1991, CANCER RES, V51, P3788; ICHIKAWA T, 1992, CANCER RES, V52, P3486; ICHIKAWA T, 1992, P NATL ACAD SCI USA, V89, P1607, DOI 10.1073/pnas.89.5.1607; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KODAMA Y, 1982, J NATL CANCER I, V69, P595; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1986, CANCER RES, V46, P1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MIYAKI M, 1990, CANCER RES, V50, P7166; MOHLER JL, 1988, CANCER RES, V48, P4312; MORITA R, 1991, CANCER RES, V51, P820; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSHIMURA M, 1986, ENVIRON MUTAGEN, V8, P129, DOI 10.1002/em.2860080112; RAMSHAW IA, 1983, INT J CANCER, V32, P471, DOI 10.1002/ijc.2910320414; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TAKADA T, 1992, JPN J CANCER RES, V83, P165, DOI 10.1111/j.1349-7006.1992.tb00082.x; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WANG LM, 1993, CANCER RES, V53, P717; WEBER JL, 1989, AM J HUM GENET, V44, P388; YAMAGUCHI T, 1992, CANCER RES, V52, P2419	40	7	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2191	2196						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036005				2022-12-28	WOS:A1994NX62900010
J	PORCU, P; GRANA, X; LI, S; SWANTEK, J; DELUCA, A; GIORDANO, A; BASERGA, R				PORCU, P; GRANA, X; LI, S; SWANTEK, J; DELUCA, A; GIORDANO, A; BASERGA, R			AN E2F BINDING SEQUENCE NEGATIVELY REGULATES THE RESPONSE OF THE INSULIN-LIKE GROWTH-FACTOR-1 (IGF-I) PROMOTER TO SIMIAN-VIRUS-40T ANTIGEN AND TO SERUM	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; LARGE T-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; CYCLIN-A; HUMAN-FIBROBLASTS; CELL-CYCLE; VIRAL ONCOPROTEINS; RAT GLIOBLASTOMA; NUCLEAR FACTOR; TUMOR-ANTIGEN	The promoter of the Insulin-like growth factor I (IGF-I) gene is activated by the Simian Virus 40 large T antigen (SVLT), and one of the elements responding to SVLT activation has been localized to a short 124 bp immediately upstream of the first initiation of transcription site. This short promoter contains an E2F binding site, that, in gel shifts, binds a protein complex, but only when the promoter activity is reduced or absent. A mutation in the E2F binding site deregulates the activity of the promoter, which becomes active even in those conditions in which the wild type promoter is inactive. By using antibodies in gel retardation analyses, we can show that the different protein complexes include, at least, the following proteins: E2F, cyclin A and p107. We conclude that the short IGF-I promoter is negatively regulated by an E2F binding site that complexes with several proteins. Our data suggest that disaggregation of these complexes by the action of SVLT (or other activators) increases expression from the promoter, thus establishing a link between the regulation of cell proliferation by growth factors and the E2F-associated proteins.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,PHILADELPHIA,PA 19107; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Grana, Xavier/0000-0001-7134-0473	NATIONAL CANCER INSTITUTE [P01CA056309, T32CA009678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56309, 5-T32-CA 09678-02] Funding Source: Medline; NIGMS NIH HHS [GM33694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO ML, 1993, ENDOCRINOLOGY, V132, P935, DOI 10.1210/en.132.2.935; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P7873, DOI 10.1093/nar/14.20.7873; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMMONS DR, 1983, J CELL PHYSIOL, V115, P137, DOI 10.1002/jcp.1041150206; CLEMMONS DR, 1981, TISSUE GROWTH FACTOR, P161; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEPPERT W, 1991, ONCOGENE, V6, P1931; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERBER A, 1993, J BIOL CHEM, V268, P17883; FLOROS J, 1981, EXP CELL RES, V132, P215, DOI 10.1016/0014-4827(81)90097-5; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOLIFF K, 1993, NUCLEIC ACIDS RES, V19, P2267; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LAM EWF, 1993, EMBO J, V12, P2706; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MAYOL X, 1993, ONCOGENE, V8, P2561; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PONTEN J, 1971, SPONTANEOUS VIRUS IN; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TOPP CW, 1980, DNA TUMOR VIRUSES; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WERNER H, 1991, INSULIN LIKE GROWTH, P17	63	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2125	2134						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8035997				2022-12-28	WOS:A1994NX62900002
J	MAYO, MW; STEELMAN, LS; MCCUBREY, JA				MAYO, MW; STEELMAN, LS; MCCUBREY, JA			PHORBOL ESTERS SUPPORT THE PROLIFERATION OF A HEMATOPOIETIC-CELL LINE BY UP-REGULATING C-JUN EXPRESSION	ONCOGENE			English	Article							PROTEIN-KINASE-C; TRANSCRIPTION FACTOR AP-1; EARLY GENE-EXPRESSION; MESSENGER-RNA; METALLOTHIONEIN GENE; GROWTH-FACTORS; FOS; ONCOGENE; INDUCTION; DNA	FD/PMA, a derivative of the interleukin-3 (IL-3) dependent FDC-P1 cell line, proliferates in response to either phorbol esters (phorbol 12-myristate 13-acetate, PMA) or IL-3. Analysis of immediate-early gene expression revealed that FD/PMA cells contained elevated levels of c-jun transcripts when grown in the presence of phorbol esters. Upregulation of c-jun mRNA was specific since other jun family members (namely jun-B and jun-D) displayed similar patterns of gene expression as observed in the parental cell line. The accumulation of c-jun RNA was due to increased c-jun transcription and not the result of altered message stability, Furthermore, elevated c-jun expression resulted in increased AP-1 binding activity in FD/PMA cells, Antisense c-jun oligonucleotides suppressed proliferation of FD/PMA cells by 80% and resulted in a significant reduction in both AP-1 binding activity and c-jun message levels. Collectively, these results demonstrate that FD/PMA cells require elevated levels of c-jun expression for PMA-responsive proliferation and indicate that tumor promoters have the ability to abrogate IL-3 dependency by elevating AP-1 activity.	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858	University of North Carolina; East Carolina University				McCubrey, James/0000-0001-6027-3156	NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER; NCI NIH HHS [NCI RO1CA51025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CARTER TH, 1987, MECHANISMS ENV CARCI, V1, P47; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVOLORO J, 1980, METHOD ENZYMOL, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HERRMANN F, 1992, CYTOKINES HEMATOLOGY, V2; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY JA, 1991, ONCOGENE RES, V6, P1; MCCUBREY JA, 1990, BLOOD, V76, P63; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; WAYS DK, 1991, BLOOD, V78, P2633; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YANG-YEN H-F, 1990, New Biologist, V2, P351	46	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1999	2008						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208545				2022-12-28	WOS:A1994NR68500024
J	ZHANG, JD; CHANG, CC; LOMBARDI, L; DALLAFAVERA, R				ZHANG, JD; CHANG, CC; LOMBARDI, L; DALLAFAVERA, R			REARRANGED NFKB2 GENE IN THE HUT78 T-LYMPHOMA CELL-LINE CODES FOR A CONSTITUTIVELY NUCLEAR FACTOR LACKING TRANSCRIPTIONAL REPRESSOR FUNCTIONS	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING; RETICULOENDOTHELIOSIS VIRUS; ONCOPROTEIN BCL-3; REL; SUBUNIT; P50; ONCOGENE; CLONING; INHIBITION	Rearrangements of the NFKB2 gene are associated with lymphoid malignancies, but the functional significance of these alterations is not known. Here we characterize structurally and functionally a rearranged NFKB2 gene identified at the T cell lymphoma line, HUT78. The rearrangement has truncated NFKB2 sequences within the 3' ankyrin domain, leading to the production of truncated mRNA species and proteins as detected by Northern blot and immunoprecipitation analysis, respectively. Cloning and sequencing of the corresponding cDNAs indicates that, via alternative splicing, the rearranged gene codes for two proteins of 84 and 85 kD (p84/85) which retain the DNA-binding rel domain and the first five ankyrin repeats, but have lost their carboxy-terminus including the seventh ankyrin repeat. Immunofluorescence and immunoprecipitation analysis of HUT78 cells indicate that p84/85 are abnormally located in the nucleus in an unprocessed form, suggesting that these proteins can escape the cytoplasmic retention typical of the normal NFKB2 p100 protein before it is processed into p52. Electrophoretic mobility shift assays performed on HUT78 nuclear extracts indicate that the abnormal NFKB2 proteins bind kappa B sites specifically and alter the composition of NF-kappa B complexes in HUT78 cells. Transient co-transfection assays involving NFKB2 expression vectors and kappa B-driven reporter plasmids indicate that NFKB2 p85 has lost the transcriptional repressor functions typical of normal NFKB2 p52. These data indicate that the NFKB2 gene rearrangement detected in HUT78 cells leads to the production of abnormal NFKB2 proteins capable of altering the function of the NF-kappa B transcription system. Since analogous rearrangements are found in lymphoid malignancies, these findings further support a role of NFKB2 alterations in tumorigenesis.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; UNIV MILAN,OSPED MAGGIORE,IRCCS,IST SCI MED,EMATOL LAB,MILAN,ITALY	Columbia University; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan					NCI NIH HHS [CA 44029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1989, ONCOGENE, V4, P935; CHANG CC, 1994, ONCOGENE, V9, P923; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GAZDAR AF, 1980, BLOOD, V55, P409; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1992, INT REV CYTOL, V48, P1; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OFFIT K, 1991, BLOOD, V77, P1508; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAGLIO G, 1986, CANCER RES, V46, P1413; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; YANO T, 1993, BLOOD, V82, P1813, DOI 10.1182/blood.V82.6.1813.bloodjournal8261813	38	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1931	1937						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208540				2022-12-28	WOS:A1994NR68500017
J	WINKLER, C; WITTBRODT, J; LAMMERS, R; ULLRICH, A; SCHARTL, M				WINKLER, C; WITTBRODT, J; LAMMERS, R; ULLRICH, A; SCHARTL, M			LIGAND-DEPENDENT TUMOR-INDUCTION IN MEDAKAFISH EMBRYOS BY A XMRK RECEPTOR TYROSINE KINASE TRANSGENE	ONCOGENE			English	Article							TRANSIENT EXPRESSION; ORYZIAS-LATIPES; XIPHOPHORUS; MICE; MELANOMA; ONCOGENE; PROMOTER; GENE; OVEREXPRESSION; NEOPLASIA	Xmrk encodes a subclass I receptor tyrosine kinase (RTK) which has been cloned from the melanoma-inducing locus Tn of the poeciliid fish Xiphophorus. To demonstrate a high oncogenic potential in vivo we transferred the gene into early embryos of the closely related medakafish. Ectopic expression of the Xmrk oncogene under the control of a strong, constitutive promoter (CMVTk) led to the induction of embryonic tumors with high incidence, after short latency periods, and with a specific pattern of affected tissues. We demonstrate ligand-dependent transformation in vivo using a chimeric receptor consisting of the extracellular and transmembrane domains of the human EGF receptor (HER) and the cytoplasmatic domain of Xmrk. Expression of the chimeric receptor alone does not lead to kinase activation or induction of tumors. Coexpression of the chimera with its corresponding ligand, human transforming growth factor alpha (hTGF alpha), however, results in the activation of the chimeric RTK. In injected fish embryos the induction of the neoplastic growth is observed with similar incidence and tissue distribution as in embryos carrying the native Xmrk oncogene suggesting that the ligand as well as factors downstream of the RTK are required for tumor formation. In this study we show single-step induction of tumors by ectopic expression of RTKs in vivo substantiating the significance of autocrine stimulation in RTK induced tumors in vertebrates.	UNIV WURZBURG,BIOCTR,DEPT PHYSIOL CHEM 1,D-97074 WURZBURG,GERMANY; UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	University of Wurzburg; University of Basel; Max Planck Society			Wittbrodt, Joachim/D-4735-2014; Winkler, Christoph/G-4822-2012	Wittbrodt, Joachim/0000-0001-8550-7377; Schartl, Manfred/0000-0001-9882-5948; Winkler, Christoph/0000-0003-4688-6241				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; CHONG SSC, 1989, THEOR APPL GENET, V78, P369, DOI 10.1007/BF00265299; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; FRIEDENREICH H, 1990, NUCLEIC ACIDS RES, V18, P3299, DOI 10.1093/nar/18.11.3299; FRIEND SH, 1993, SCIENCE, V259, P774, DOI 10.1126/science.8430329; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kirchen R. V, 1976, JAPANESE MEDAKA ITS; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; MARCEY D, 1986, NATURE, V321, P380, DOI 10.1038/321380a0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MICHIELS F, 1989, EMBO J, V8, P1559, DOI 10.1002/j.1460-2075.1989.tb03540.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; TAKAGI H, 1992, CANCER RES, V52, P5171; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WEINBERG RA, 1989, CANCER RES, V49, P3713; WINKLER C, 1991, MOL GEN GENET, V226, P129, DOI 10.1007/BF00273596; Winkler Christoph, 1992, Molecular Marine Biology and Biotechnology, V1, P326; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YAMAMOTO TO, 1961, INT REV CYTOL, V12, P361	27	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1517	1525						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183545				2022-12-28	WOS:A1994NL81500001
J	CARNERO, A; CUADRADO, A; DELPESO, L; LACAL, JC				CARNERO, A; CUADRADO, A; DELPESO, L; LACAL, JC			ACTIVATION OF TYPE-D PHOSPHOLIPASE BY SERUM STIMULATION AND RAS-INDUCED TRANSFORMATION IN NIH3T3 CELLS	ONCOGENE			English	Article							PROTEIN-KINASE-C; SWISS 3T3 CELLS; PHOSPHATIDYLCHOLINE BREAKDOWN; PHOSPHATIDATE PHOSPHOHYDROLASE; 2ND MESSENGERS; POINT MUTATION; HYDROLYSIS; CHOLINE; DIACYLGLYCEROL; ONCOGENE	Mitogenic stimulation of NIH3T3 fibroblasts with growth factors or ras oncogenes is associated with an increase in the levels of phosphorylcholine and diacylglycerol. Both metabolites could be generated as a result of direct activation of a phosphatidylcholine-specific phospholipase C (PC-PLC) or by a more complex pathway, involving activation of phospholipase D followed by choline kinase and phosphatidic acid-hydrolase. We show evidence indicating that the generation of phosphorylcholine and diacylglycerol follow independent mechanisms in both serum-treated and in ras-transformed NIH3T3 cells. No significant activation of a PC-PLC enzyme was observed. Instead, activation of a phosphatidylcholine-specific phospholipase D (PC-PLD) was detected. Moreover, while a fivefold constitutive activation of the endogenous PLD activity and a twofold increase on the levels of phosphatidic acid were observed in uas-transformed cells, very small alterations on these parameters were detected at late times after serum stimulation of quiescent cells. Thus, cell proliferation induced by uas oncogenes in fibroblasts cells may be functionally linked to activation of a PC-PLD enzyme. The differences found in the activation of this enzyme between ras-transformed and normal cells may constitute an important difference in mitogenic signalling between normal and transformed cells.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			del Peso, Luis/K-9391-2014; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979; Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; BLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; CANNON JG, 1988, PHARMACEUT RES, V5, P359, DOI 10.1023/A:1015955527100; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; COOK SJ, 1991, BIOCHEM J, V280, P431, DOI 10.1042/bj2800431; CORVEN EJ, 1989, CELL, V59, P45; CUADRADO A, 1993, ONCOGENE, V8, P2959; DALY PF, 1987, J BIOL CHEM, V262, P14875; DUGAN LL, 1986, J CHROMATOGR, V378, P317, DOI 10.1016/S0378-4347(00)80728-8; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; KOUL O, 1987, ARCH BIOCHEM BIOPHYS, V253, P453, DOI 10.1016/0003-9861(87)90199-8; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MURRAY JJ, 1990, BIOCHEM J, V270, P63, DOI 10.1042/bj2700063; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; PREISS J, 1986, J BIOL CHEM, V261, P8597; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	38	94	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1387	1395						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152799				2022-12-28	WOS:A1994NH40100010
J	MONTE, D; BAERT, JL; DEFOSSEZ, PA; DELAUNOIT, Y; STEHELIN, D				MONTE, D; BAERT, JL; DEFOSSEZ, PA; DELAUNOIT, Y; STEHELIN, D			MOLECULAR-CLONING AND CHARACTERIZATION OF HUMAN ERM, A NEW MEMBER OF THE ETS FAMILY CLOSELY-RELATED TO MOUSE PEA3 AND ER81 TRANSCRIPTION FACTORS	ONCOGENE			English	Article							DNA-BINDING MOTIF; GENE FAMILY; C-FOS; MESSENGER-RNAS; ACTIVATION; PROTEIN; ONCOGENE; DOMAIN; EXPRESSION; SEQUENCES	The ets-related transcription factors PEA3 and ER81 have recently been isolated and characterized in the mouse. They share 95% identity in a 85 amino acid (AA) domain termed the ETS domain which is responsible for DNA binding, and therefore they form an Ets family group. By screening a human testis cDNA library with a probe containing the mouse PEA3 ETS domain, we isolated a 2.2 kb clone containing a 510 AA open reading frame. Since the ETS domain, which is localized in the carboxy terminal region of the encoded protein, is 95% and 96% identical to that of PEA3 and ER81, respectively, we named this new member 'Ets Related Molecule PEA3-like' (ERM). Although the first 120 AA in the amino-terminal region of ERM share 47% identity with PEA3 and 66% with ER81, ERM contains a central region of approximate to 35 AA not found in the two mouse proteins. Gel shift analysis indicates that the full-length ERM protein is able to bind specifically to an oligonucleotide containing the consensus nucleotide core sequence GGAA recognized by the Ets proteins. Moreover, in vitro translation of 83 AA of the ERM ETS domain led to the production of a truncated protein which also binds to DNA. Though differential expression is observed in primary tumors and normal lymphocytes do not express ERM, this gene is almost ubiquitously expressed in human normal tissues. ERM mRNA is highly expressed in brain as well as in placenta and, to a lesser degree, in lung, pancreas, and heart. Moreover, almost all human cell lines tested express it at varying levels. In mouse tissues, we showed that PEA3 and ER81 mRNAs display restricted expression, whereas ERM is almost ubiquitously expressed as observed for human tissues. Altogether these results indicate that ERM is clearly a new ets family member and not the human equivalent of PEA3 or ER81.	INST PASTEUR,UNITE ONCOL MOLEC,CNRS,URA 1160,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Defossez, Pierre-Antoine/0000-0002-6463-9263; monte, didier/0000-0002-0613-6203				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GEGONNE A, 1992, NEW BIOL, V4, P512; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAGET MP, 1993, NUCLEIC ACIDS RES, V21, P5987, DOI 10.1093/nar/21.25.5987; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1992, ONCOGENE, V7, P9; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MONTE D, 1992, BLOOD, V79, P2670; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZHAO HF, 1991, J BIOL CHEM, V266, P583	36	117	119	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1397	1406						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152800				2022-12-28	WOS:A1994NH40100011
J	BURKS, RT; KESSIS, TD; CHO, KR; HEDRICK, L				BURKS, RT; KESSIS, TD; CHO, KR; HEDRICK, L			MICROSATELLITE INSTABILITY IN ENDOMETRIAL CARCINOMA	ONCOGENE			English	Article							GENE-MUTATIONS; P53	Microsatellite instability (MI), detected as electrophoretic shifts in allele sizes of microsatellite DNA sequences, has been identified in some colorectal carcinomas. Investigators have previously attributed such microsatellite instability to replication errors (RER). The colorectal carcinomas with RER have been found to arise either sporadically or in association with the hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Because endometrial carcinoma is also commonly associated with HNPCC, we studied 30 cases of endometrial carcinoma to characterize the presence of MI in these neoplasms. Seven cases (23%) showed MI. Four cases showed both Type I (large shifts) and Type II (small shifts) mutation patterns and the remaining three cases showed Type I mutations only. We conclude that MI frequently occurs in endometrial cancers and that this type of genetic alteration may be an important pathogenetic feature of this tumor type.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205	Johns Hopkins University				Cho, Kathleen/0000-0003-0500-9998				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; ENOMOTO T, 1990, CANCER RES, V50, P6139; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; IGNARTROWBRIDGE D, 1992, AM J OBSTET GYNECOL, V167, P227, DOI 10.1016/S0002-9378(11)91663-9; IMAMURA T, 1992, INT J CANCER, V51, P47, DOI 10.1002/ijc.2910510110; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; OKAMOTO A, 1991, CANCER RES, V51, P5632; PELOYPELTOMAKI P, 1993, SCIENCE, V260, P810; RISINGER JI, 1992, MOL CARCINOGEN, V5, P250, DOI 10.1002/mc.2940050403; Rousseau Francois, 1992, Human Mutation, V1, P91, DOI 10.1002/humu.1380010202; SASAKI H, 1993, CANCER RES, V53, P1906; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122	19	214	219	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1163	1166						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134118				2022-12-28	WOS:A1994NC04800019
J	SAVATIER, P; HUANG, S; SZEKELY, L; WIMAN, KG; SAMARUT, J				SAVATIER, P; HUANG, S; SZEKELY, L; WIMAN, KG; SAMARUT, J			CONTRASTING PATTERNS OF RETINOBLASTOMA PROTEIN EXPRESSION IN MOUSE EMBRYONIC STEM-CELLS AND EMBRYONIC FIBROBLASTS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; SV40 LARGE-T; GENE-PRODUCT; SUSCEPTIBILITY GENE; MOLECULAR-CLONING; RB GENE; E1A-LIKE ACTIVITY; CARCINOMA-CELLS; BINDING PROTEIN; CELLULAR GENES	The expression of the retinoblastoma susceptibility (RB-1) gene was investigated in highly proliferating mouse embryonic stem (ES) cells and in slowly proliferating mouse embryonic fibroblasts. The RIB protein was expressed at the same level in these two cell types. Mainly hyperphosphorylated RB was detected in exponentially-growing ES cells. Embryonic fibroblasts and embryonic stem cells were synchronized by colcemid block followed by mitotic shake-off. In embryonic fibroblasts, DNA replication started 10-15 h after exit from mitosis and RB was transiently dephosphorylated during the G1 phase as previously described. In ES cells, DNA replication started 2h after release from the colcemid block but virtually no hypophosphorylated RB was observed after the release. Instead, there was a dramatic decrease in the total RB protein level between exit from mitosis and entry into S phase, These observations were made by using two different monoclonal antibodies, both in immunoblotting and immunoprecipitation experiments. Absence of hypophosphorylated RB and cell cycle-dependent change in total RB protein level may be relevant to the high proliferation rate and to the tumorigenic nature of mouse embryonic stem tells.	KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet	SAVATIER, P (corresponding author), ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.		Szekely, Laszlo/B-1268-2009; Wiman, Klas/AAB-8399-2021; SAVATIER, Pierre/J-4663-2014; Samarut, Jacques/AAD-2587-2019	Wiman, Klas/0000-0002-7113-524X; 				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BEDDINGTON RSP, 1983, J EMBRYOL EXP MORPH, V75, P189; BERG RW, 1990, DEV BIOL, V138, P123, DOI 10.1016/0012-1606(90)90182-I; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DAMJANOV I, 1971, ROUX ARCH DEV BIOL, V167, P288, DOI 10.1007/BF00584254; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLINGSWORTH RE, 1993, CURRENT OPINION CELL, V5, P1194; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; ILES SA, 1977, J EMBRYOL EXP MORPH, V38, P63; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MACAULEY A, 1993, DEVELOPMENT, V117, P873; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MCCORMICK PJ, 1990, EXP CELL RES, V189, P183, DOI 10.1016/0014-4827(90)90234-2; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MURRAY EJ, 1991, MOL CELL BIOL, V11, P5534, DOI 10.1128/MCB.11.11.5534; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENSTRAUS MJ, 1982, DEV BIOL, V89, P516, DOI 10.1016/0012-1606(82)90340-2; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SLACK RS, 1993, ONCOGENE, V8, P1585; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; STOKKE T, 1993, EXP CELL RES, V204, P147, DOI 10.1006/excr.1993.1019; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	63	212	215	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					809	818						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108123				2022-12-28	WOS:A1994MW55100016
J	VALENTINIS, B; PORCU, P; QUINN, K; BASERGA, R				VALENTINIS, B; PORCU, P; QUINN, K; BASERGA, R			THE ROLE OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR IN THE TRANSFORMATION BY SIMIAN-VIRUS-40 T-ANTIGEN	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; CELLULAR DNA-SYNTHESIS; MESSENGER-RNA LEVELS; SV40-TRANSFORMED CELLS; PERMISSIVE CELLS; SOMATOMEDIN-C; A REGULATION; PROTEIN; BINDING; PHOSPHORYLATION	Balb/c 3T3 cells transformed by the tsA58 temperature-sensitive (ts) mutant of SV40 large T antigen, BalbA58 cells, grow in 1% serum at the permissive temperature of 34 degrees C but fail to grow at the restrictive temperature of 39.6 degrees C. Although incapable of growing, BalbA58 cells, in low serum at 39.6 degrees C, stilt synthesize DNA and tend to accumulate in the G(2) phase of the cell cycle. Growth in 1% serum at 39.6 degrees C resumes if BalbA58 cells are treated with insulin-like growth factor I (IGF-I). By using cells overexpressing the IGF-I receptor, and cells with a targeted disruption of the IGF-I receptor genes, we show that: 1) the activation of the IGP-I receptor by its ligand(s) plays a major role in the ability of the SV40 large T antigen to promote growth in low serum; and 2) the IGF-I receptor plays a role in the progression of cells not only through G(1), but also through the S and G(2) phases of the cell cycle. These findings, together with other recent findings from the literature, suggest that one of the mechanisms by which oncogenes and tumor suppresser genes regulate cell growth is through the modulation of growth factors and their receptors.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107; NCI,DCPC,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NCI NIH HHS [CA56309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; CAMPISI J, 1984, MOL CELL BIOL, V4, P1807, DOI 10.1128/MCB.4.9.1807; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CRISTOFALO VJ, 1989, J GERONTOL, V44, P55, DOI 10.1093/geronj/44.6.55; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1991, ONCOGENE, V6, P1931; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FERBER A, 1993, J BIOL CHEM, V268, P17883; FOYT HL, 1991, INSULIN LIKE GROWTH, P1; Gai X X, 1988, Oncogene Res, V3, P377; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HISCOTT JB, 1979, J VIROL, V30, P590, DOI 10.1128/JVI.30.2.590-599.1979; HISCOTT JB, 1981, J VIROL, V37, P802, DOI 10.1128/JVI.37.2.802-812.1981; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251; NIELSEN FC, 1993, MOL CELL ENDOCRINOL, V93, P87, DOI 10.1016/0303-7207(93)90143-8; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; OTTAVIO L, 1990, MOL CELL BIOL, V10, P303, DOI 10.1128/MCB.10.1.303; PERDUE JF, 1991, ENDOCRINOLOGY, V129, P3101, DOI 10.1210/endo-129-6-3101; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RUSSELL WE, 1984, P NATL ACAD SCI-BIOL, V81, P2389, DOI 10.1073/pnas.81.8.2389; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, IN PRESS P NATL ACAD; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TRAVALI S, 1991, ONCOGENE, V6, P887; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WERNER H, 1991, INSULIN LIKE GROWTH, P17; YAMORI T, 1991, CANCER RES, V51, P5859; YOSHINOUCHI M, 1993, CELL PROLIFERAT, V26, P139, DOI 10.1111/j.1365-2184.1993.tb00014.x	49	55	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					825	831						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108125				2022-12-28	WOS:A1994MW55100018
J	BERGELSON, S; PINKUS, R; DANIEL, V				BERGELSON, S; PINKUS, R; DANIEL, V			INDUCTION OF AP-1 (FOS/JUN) BY CHEMICAL-AGENTS MEDIATES ACTIVATION OF GLUTATHIONE-S-TRANSFERASE AND QUINONE REDUCTASE GENE-EXPRESSION	ONCOGENE			English	Article							YA-SUBUNIT GENE; ELECTROPHILE-RESPONSIVE ELEMENT; INDUCIBLE EXPRESSION; REGULATORY ELEMENTS; C-JUN; PROTO-ONCOGENE; PROTEINS; STRESS; CELLS; FOS	A regulatory element, EpRE, was found to be responsible for the induction of mouse glutathione S-transferase (GST) Ya gene expression by a variety of chemical agents such as planar aromatic hydrocarbons, diphenols, phorbol ester, phenobarbital and electrophilic compounds. The EpRE is composed of two adjacent AP-1-like binding sites and was recently found to be activated by Fos/Jun heterodimeric complex (AP-1). In this report we show that regulatory elements ARE, previously demonstrated to mediate the chemical induction of rat GST Ya and quinone reductase genes, have a similar structure with EpRE and are activated by Fos/Jun complex. The activation of GST Ya and quinone reductase genes by a variety of chemical inducers is found to be associated with an increase in AP-1 binding activity. We present evidence that chemical agents induce expression of c-fos and c-jun proto-oncogenes and an enhanced synthesis of protein components of AP-1 complex. We suggest that the increased synthesis of AP-1 complex followed by an AP-l-mediated transcriptional activation of GST Ya and quinone reductase genes may provide a molecular mechanism for the induction of these drug-metabolizing enzymes by chemical agents.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DANIEL V, 1989, DNA-J MOLEC CELL BIO, V8, P399, DOI 10.1089/dna.1.1989.8.399; DANIEL V, 1993, STRUCTURE FUNCTION G, P129; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KIM YJ, 1983, J CELL BIOL, V96, P393, DOI 10.1083/jcb.96.2.393; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LI Y, 1992, J BIOL CHEM, V267, P15097; MACKENZIE PI, 1990, J BIOL CHEM, V265, P11328; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PINKUS R, 1993, BIOCHEM J, V290, P637, DOI 10.1042/bj2900637; PROCHASKA HJ, 1988, CANCER RES, V48, P4776; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHELTON KR, 1986, J BIOL CHEM, V261, P1935; Talalay P, 1987, CANCER BIOL THERAPEU, P187	29	99	99	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					565	571						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290267				2022-12-28	WOS:A1994MW24800024
J	LONGATI, P; BARDELLI, A; PONZETTO, C; NALDINI, L; COMOGLIO, PM				LONGATI, P; BARDELLI, A; PONZETTO, C; NALDINI, L; COMOGLIO, PM			TYROSINES(1234-1235) ARE CRITICAL FOR ACTIVATION OF THE TYROSINE KINASE ENCODED BY THE MET PROTOONCOGENE (HGF RECEPTOR)	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; C-MET; PHOSPHATIDYLINOSITOL 3-KINASE; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; SIGNAL TRANSDUCTION; SCATTER FACTOR; SH2 DOMAINS; CELL-LINE; AUTOPHOSPHORYLATION	The tyrosine kinase encoded by the MET proto-oncogene (p190(MET)) is the receptor for Hepatocyte Growth Factor/Scatter Factor (HGF/SF). Previous work has shown that autophosphorylation of p190(MET) enhances its enzymatic activity and that the major phosphorylation site is Tyr(1235), located in the catalytic domain. This residue is part of a 'three tyrosine' motif, including Tyr(1230), Tyr(1234), and Tyr(1235), conserved in several other receptor kinases. We studied the role of these tyrosines in the positive regulation of the p190(MET) kinase by site-directed mutagenesis. Substitution of either Tyr(1235) Or Tyr(1234) with phenylalanine severely reduced the in vitro kinase activity toward exogenous substrates. Kinetic experiments showed that the residual activity of these mutants could still be enhanced by autophosphorylation. Phosphopeptide mapping indicated that, in the absence of Tyr(1235), Tyr(1234) is phosphorylated. Only the replacement of both Tyr(1234) and Tyr(1235) yielded a mutant which completely lost the ability to be activated by autophosphorylation. In stable transfectants expressing the HGF/SF receptor with single substitution of either Tyr(1234) Or Tyr(1235) the response to HGF/SF was impaired. The ligand did not induce tyrosine phosphorylation of the receptor nor stimulated chemotaxis. These data show that Tyr(1234) and Tyr(1235) are critical for the activation of the HGF/SF receptor kinase both in vitro and in response to the ligand in intact cells.	UNIV TORINO,SCH MED,DEPT BIOMED SCI & OCOL,I-10126 TURIN,ITALY	University of Turin			Naldini, Luigi/E-9083-2012; BARDELLI, Alberto/J-9721-2018	BARDELLI, Alberto/0000-0003-1647-5070				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1992, ONCOGENE, V7, P3; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAYNE DM, EMBO J, V4, P885; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE FM, 1988, J BIOL CHEM, V263, P2629	44	203	206	1	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					49	57						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302603				2022-12-28	WOS:A1994MW24700007
J	KHANNA, KK; LAVIN, MF				KHANNA, KK; LAVIN, MF			IONIZING-RADIATION AND UV INDUCTION OF P53 PROTEIN BY DIFFERENT PATHWAYS IN ATAXIA-TELANGIECTASIA CELLS	ONCOGENE			English	Article							RADIORESISTANT DNA-SYNTHESIS; FLOW CYTOMETRIC ANALYSIS; WILD-TYPE P53; LATE G1 PHASE; CYCLE CHECKPOINT; TOPOISOMERASE-II; KINASE-C; CANCER; PERTURBATIONS; IRRADIATION	Cell cycle anomalies have been described in ataxia-telangiectasia cells after exposure to ionizing radiation. A recent report demonstrates that cells from these patients lack the ionizing radiation-induced increase in p53 protein seen in controls. We report here that an ionizing radiation-induced p53 response is reduced and/or delayed in cells from four ataxia-telangiectasia complementation groups. On the other hand, p53 induction is normal in all A-T complementation groups after exposure to UV-B light, an agent to which these cells are not hypersensitive. Specific inhibitors of protein kinase C and serine/threonine phosphatases prevented the radiation induction of p53 protein. Agents that produced double-strand breaks in DNA and/or inhibition of transcription caused an induction of p53 in the absence of radiation in control cells but not in ataxia-telangiectasia, but inhibitors of cell cycle progression such as mimosine and aphidicolin led to an increase in p53 in both cell types in the absence of radiation. These results suggest that there is more than one signal transduction pathway responsible for activation of p53, one of which is less efficient in ataxia-telangiectasia cells.	QUEENSLAND INST MED RES, BANCROFT CTR, QUEENSLAND CANC FUND RES UNIT, BRISBANE, QLD 4029, AUSTRALIA	QIMR Berghofer Medical Research Institute			Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381				ABDELLA BR, 1984, ENV HLTH PERSPECT, V64, P3; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; BATES P, 1985, MUTAT RES, V218, P165; BAXTER G, 1988, IMMUNOL CELL BIOL, V67, P57; BEAMISH H, IN PRESS RAD RES; BODER E, 1985, ATAXIA TELANGIECTASI, V19, P1; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN P, 1984, MUTAT RES, V129, P165, DOI 10.1016/0027-5107(84)90149-0; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DAVIES SM, 1989, NUCLEIC ACIDS RES, V17, P1337, DOI 10.1093/nar/17.4.1337; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDWARDS MJ, 1980, NATURE, V287, P745, DOI 10.1038/287745a0; FORD MD, 1981, NUCLEIC ACIDS RES, V9, P1395, DOI 10.1093/nar/9.6.1395; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJIKI H, 1990, ADV SEC MESS PHOSPH, V24, P340; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; IMRAY FP, 1983, MUTAT RES, V112, P369; JASPERS NGJ, 1982, MUTAT RES, V92, P439, DOI 10.1016/0027-5107(82)90242-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAVIN MF, 1987, MOL CELL BIOCHEM, V73, P45; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEHMANN AR, 1982, CELLULAR MOL LINK CA, P347; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MCFARLIN DE, 1972, MEDICINE, V51, P281, DOI 10.1097/00005792-197207000-00002; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MIRZAYANS R, 1989, CANCER RES, V49, P5523; MOHAMED R, 1989, BIOCHEM BIOPH RES CO, V158, P749, DOI 10.1016/0006-291X(89)92785-X; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; PATERSON MC, 1979, CANCER RES, V39, P3225; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; PETERSON RD, 1964, LANCET, V1, P1193; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SINGH SP, 1988, NUCLEIC ACIDS RES, V16, P3919, DOI 10.1093/nar/16.9.3919; SONG Q, 1993, BIOCHEM BIOPH RES CO, V190, P45; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TEALE B, IN PRESS J BIOL CHEM; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651	58	282	288	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3307	3312						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247533				2022-12-28	WOS:A1993MG78200014
J	BARLAT, I; SCHWEIGHOFFER, F; CHEVALLIERMULTON, MC; DUCHESNE, M; FATH, I; LANDAIS, D; JACQUET, M; TOCQUE, B				BARLAT, I; SCHWEIGHOFFER, F; CHEVALLIERMULTON, MC; DUCHESNE, M; FATH, I; LANDAIS, D; JACQUET, M; TOCQUE, B			THE SACCHAROMYCES-CEREVISIAE GENE-PRODUCT SDC25 C-DOMAIN FUNCTIONS AS AN ONCOPROTEIN IN NIH3T3 CELLS	ONCOGENE			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; GDP-GTP EXCHANGE; RAS PROTEINS; P21RAS; ACTIVATION; STIMULATION; SCD25	Ras proteins in mammalian cells cycle between a GTP-bound 'on' state and a GDP-bound 'off' state. Activation of Ras p21 results from the dissociation of tightly bound GDP and the exchange of bound GDP for GTP. A guanine nucleotide exchange factor is required for this activation. Activation promotes interaction with effector molecules and allows the signal to be transduced. In Saccharomyces cerevisiae, the function of guanine nucleotide exchange has been ascribed to the product of the CDC25 gene. The C-terminus domain of SDC25, a homologue of CDC25, can substitute for the CDC25 protein in yeast. We have demonstrated that the SDC25 C-terminus domain promotes GTP binding to Ras p21 in CHO cells. In the present study, we found that the stable expression of the SDC25 C-terminus domain induced transformation of NIH3T3 cells. Ras proteins in these tumorigenic cells were GTP bound. In addition, the coexpression of wild-type Ha-Ras protein with the SDC25 C-terminus was found to enhance the tumorigenic properties of the NIH3T3 cells. These results imply that, in subsets of human tumours, cellular Ras p21 might be found in its GTP-bound active form as a consequence of an oncogenic activation of a mammalian Ras guanine nucleotide exchange factor.	RHONE POULENC RORER,13 QUAI JULES GUESDE,BP 14,F-94403 VITRY,FRANCE; UNIV PARIS 11,INFORMAT GENET & DEV GRP CNRS,URA 1354,F-91405 ORSAY,FRANCE	Sanofi-Aventis; UDICE-French Research Universities; Universite Paris Saclay								BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; REY I, 1991, ONCOGENE, V6, P347; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	16	16	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					215	218						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	7999142				2022-12-28	WOS:A1993KN00500027
J	MCCRACKEN, S; LEUNG, S; BOSSELUT, R; GHYSDAEL, J; MIYAMOTO, NG				MCCRACKEN, S; LEUNG, S; BOSSELUT, R; GHYSDAEL, J; MIYAMOTO, NG			MYB AND ETS RELATED TRANSCRIPTION FACTORS ARE REQUIRED FOR ACTIVITY OF THE HUMAN LCK TYPE-I PROMOTER	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; T-CELL DEVELOPMENT; LONG TERMINAL REPEAT; DIFFERENTIAL EXPRESSION; THYMOCYTE DEVELOPMENT; GENE; PROTEIN; ACTIVATION; PRODUCT; P56LCK	The lck gene, which encodes a lymphoid-specific Src family tyrosine kinase, is transcribed from two promoters that are differentially utilized during T cell development. We have shown previously that the human lck type I promoter, which is preferentially expressed in immature thymocytes, requires a binding site (-97 to -90) for the Ets family of transcription factors for its activity in Jurkat T leukemia cells. Three putative Myb binding sites (-86 to -82, -77 to -72 and -59 to -54) were analysed for their ability to activate the lck type I promoter. In vitro assays demonstrated specific binding of purified, bacterially expressed c-Myb DNA binding domain to the Myb (-59 to -54) site. Transient transfection assays using the site-directed mutants of the lck type I promoter in Jurkat cells revealed that mutation of the Myb (-59 to -54) site abolished transcriptional activity. In transiently transfected HeLa cells, the lck type I promoter was activated by cotransfection with a vector that expresses c-Myb. This c-Myb dependent activation required the presence of intact Myb and Ets binding sites, indicating that the expressed c-Myb functions with endogenous Ets related transcription factors to activate the lck type I promoter. This effect was further enhanced by co-transfection with vectors that express either Ets1 or Ets2. These results demonstrate that Myb and Ets related transcription factors synergistically activate the human lck type I promoter.	INST CURIE,BIOL SECT,CNRS,U1443,F-91405 ORSAY,FRANCE; PRINCESS MARGARET HOSP,ONTARIO CANC INST,DIV CELLULAR & MOLEC BIOL,TORONTO M4X 1K9,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ON,CANADA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto			GHYSDAEL, Jacques/F-3377-2013					ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; ASCIONE R, 1992, INT J ONCOL, V1, P631; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOSSELUT R, 1992, VIROLOGY, V186, P764, DOI 10.1016/0042-6822(92)90044-P; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CASSEL DL, 1983, CANCER RES, V43, P4582; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LEUNG S, 1993, ONCOGENE, V8, P989; LEUNG S, 1991, J CELL PHYSIOL, V148, P344, DOI 10.1002/jcp.1041480304; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	37	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3609	3615						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970721				2022-12-28	WOS:A1994PT39200024
J	CHEDID, M; MICHIELI, P; LENGEL, C; HUPPI, K; GIVOL, D				CHEDID, M; MICHIELI, P; LENGEL, C; HUPPI, K; GIVOL, D			A SINGLE NUCLEOTIDE SUBSTITUTION AT CODON-31 (SER/ARG) DEFINES A POLYMORPHISM IN A HIGHLY CONSERVED REGION OF THE P53-INDUCIBLE GENE WAF1/CIP1	ONCOGENE			English	Note							CYCLIN-DEPENDENT KINASES; EXPRESSION; INHIBITOR; GROWTH; CELLS; P21	The recently discovered WAF1/CTP1 gene is a mediator of p53 tumor suppressor activity. To analyse WAF1/ CIP1 for possible mutations, polymerase chain reaction (PCR) amplified cDNAs from several tumor cell lines were cloned and sequenced. A single point mutation which changes codon 31 from AGC to AGA (Ser to Arg) was found. This change resulted in the loss of a Bpu1102I and gain of an Esp3I restriction site, allowing for rapid screening of this mutation in human DNAs. Analysis of genomic DNAs from 50 randomly selected individuals revealed that this base pair substitution represents a polymorphism with an allelic frequency of 0.14. Transfection studies demonstrated that the expression of the Arg allele of WAF1/CIP1 was not associated with loss of tumor suppressor activity. Moreover, screening of 22 tumor DNA samples revealed no association between the tumor phenotype and the Arg allele of WAF1/CIP1 (two out of 22 tumor DNAs contained the Arg31 allele). This polymorphism will be a useful molecular marker in the analysis of loss of heterozygosity in human cancers, and further studies using a larger panel of tumors may reveal an association between this polymorphism and specific types of cancer.	NCI,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	CHEDID, M (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,BETHESDA,MD 20892, USA.		Michieli, Paolo/A-2588-2011	Michieli, Paolo/0000-0002-3093-8871				BODNER SM, 1992, ONCOGENE, V7, P743; CHEDID M, 1994, J BIOL CHEM, V269, P10753; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUPPI K, 1994, IN PRESS ONCOGENE; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; MICHIELI P, 1994, CANCER RES, V54, P3391; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; NAZARSTEWART V, 1993, CANCER RES, V53, P2313; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TAKAHASHI T, 1992, CANCER RES, V52, P2340; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	17	110	115	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3021	3024						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084608				2022-12-28	WOS:A1994PG82200031
J	OHNO, T; OUCHIDA, M; LEE, L; GATALICA, Z; RAO, VN; REDDY, ESP				OHNO, T; OUCHIDA, M; LEE, L; GATALICA, Z; RAO, VN; REDDY, ESP			THE EWS GENE, INVOLVED IN EWING FAMILY OF TUMORS, MALIGNANT-MELANOMA OF SOFT PARTS AND DESMOPLASTIC SMALL ROUND-CELL TUMORS, CODES FOR AN RNA-BINDING PROTEIN WITH NOVEL REGULATORY DOMAINS	ONCOGENE			English	Article							ETS-RELATED PROTEIN; TRANSCRIPTIONAL ACTIVATION DOMAINS; PUTATIVE ONCOGENE SPI-1; SERUM RESPONSE FACTOR; LONG TERMINAL REPEAT; DNA-BINDING; C-FOS; C-ETS-1 PROTOONCOGENE; LEUKEMIA-VIRUS; FLI-1 GENE	The EWS gene, which maps to band q12 of human chromosome 22, is involved in a wide variety of human solid tumors including Ewing sarcoma, related primitive neuroectodermal tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors. In these tumors, the EWS is fused to genes encoding transcriptional activators/repressors, like Fli-1 or erg or ATF 1 or wt1. To better understand the function of the EWS protein, we cloned the EWS cDNA. Sequence analysis of this cDNA revealed differential splicing invoving two exons encoding 72 amino acids. Both alternatively spliced transcripts, EWS and EWS-b, are expressed in a variety of cells. Because EWS proteins contain putative conserved RNA binding motifs, we studied the RNA binding properties of the EWS protein. The EWS-b protein binds to RNA in vitro and, specifically, to poly G and poly U. The RNA binding activity was localized to the carboxy terminal 86 amino acids, which constitute RGG box. Thus the amino terminal domain of EWS (NTD-EWS), which is involved in chromosome translocation may regulate the specificity of RNA binding activity of EWS. An EWS-erg chimeric protein, which is found in Ewing's sarcoma cells, functions as a transcriptional activator. Mutational analysis of EWS-erg chimeric protein revealed that NTD-EWS functions as a regulatory domain for the transcriptional activation properties of EWS-erg chimeric protein.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; PROGRAM RESOURCES INC,FREDERICK,MD 21702; THOMAS JEFFERSON UNIV,DEPT PATHOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NCI NIH HHS [CA 58642, CA 57157, CA 51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R01CA058642, R01CA057157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAYNES SR, 1992, NEW BIOL, V4, P421; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; ICHIKAWAH, 1994, CANCER RES, V54, P2865; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KLEMSZ M, 1994, GENOMICS, V20, P291, DOI 10.1006/geno.1994.1169; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LADANYI M, 1994, CANCER RES, V54, P2837; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; OHNO T, 1993, CANCER RES, V53, P5859; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1990, CANCER RES, V50, P5013; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; [No title captured]	66	168	173	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3087	3097						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084618				2022-12-28	WOS:A1994PG82200042
J	ROLLEY, N; MILNER, J				ROLLEY, N; MILNER, J			SPECIFIC DNA-BINDING BY P53 IS INDEPENDENT OF MUTATION AT SERINE-389, THE CASEIN KINASE-II SITE	ONCOGENE			English	Note							TUMOR SUPPRESSOR PROTEIN; WILD-TYPE; ACTIVATION DOMAIN; MUTANT FORMS; CONFORMATION; TRANSCRIPTION; VARIANTS; OLIGOMERIZATION; TRANSFORMATION; COMPLEXES	The best understood function of p53 is that of cell growth suppression and this is likely to involve sequence-specific DNA binding and modulation of gene expression. Casein kinase II phosphorylates the C-terminal serine of p53 (residue 389 for murine p53) and mutation of this site abolishes p53 growth suppressor function. DNA binding by purified p53 is 'activated' by casein kinase II, suggesting that the carboxyl terminus of p53 represents a critical regulatory domain for sequence-specific DNA binding and hence for growth suppressor function. In the present study we have substituted serine 389 with either aspartic acid (mimics phosphoserine and partially conserves p53 suppressor function) or with alanine, a non-phosphorylable residue which abolishes suppressor function (Milne et al., 1992; Nucleic Acids Research 20, 5565-5570). When expressed in vitro p53(ala389) and p53(asp389) were both indistinguishable from wild type p53 on the basis of size fractionation and immunoreactivity with PAb421, PAb246 and PAb1620. Both mutants also exhibited specific binding for the DNA consensus p53-CON. Since p53(ala389) retains the ability to bind DNA and yet is known to lack growth suppressor function we conclude that phosphorylation by casein kinase II is important for p53 growth suppressor function via a mechanism which is ancilliary to p53 sequence-specific DNA binding.	UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V8, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEDCALF EA, 1993, ONCOGENE, V8, P2001; MEEK DW, 1994, IN PRESS SEMINARS CA; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1994, IN PRESS SEMINARS CA, V5; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	41	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3067	3070						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084615				2022-12-28	WOS:A1994PG82200039
J	LECOINTE, N; BERNARD, O; NAERT, K; JOULIN, V; LARSEN, CJ; ROMEO, PH; MATHIEUMAHUL, D				LECOINTE, N; BERNARD, O; NAERT, K; JOULIN, V; LARSEN, CJ; ROMEO, PH; MATHIEUMAHUL, D			GATA-BINDING AND SP1-BINDING SITES ARE REQUIRED FOR THE FULL ACTIVITY OF THE TISSUE-SPECIFIC PROMOTER OF THE TAL-1 GENE	ONCOGENE			English	Article							T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; DNA-BINDING PROTEIN; LOOP-HELIX GENE; SCL GENE; CHROMOSOMAL LOCALIZATION; HEMATOPOIETIC-CELLS; MAMMALIAN-CELLS; CONTROL REGION	The tal-1 gene, which is frequently activated in human T cell acute leukemias (T-ALLs), codes for a protein of the basic helix-loop-helix family (b-HLH) and potentially a transcription factor. In human and murine hematopoiesis tal-1 is expressed during the differentiation of the erythroid, megakaryocytic and mastocytic cell lineages. The expression of tal-1 appears to be comodulated with that of the transcription factor GATA-1 gene, suggesting that the GATA-1 protein may regulate the tal-1 gene activity in these hematopoietic lineages. To get further insights into the molecular mechanisms that control tal-1 expression, we have isolated 5' sequences of the murine gene and compared them to their human counterparts. The 5' flanking sequences from the two genes show several regions of high homology. The alignment of both sequences enabled us to predict that similarly, to the human, the mouse gene contains two alternative first exons (Ia and Ib). Remarkably, in both species, the proximal region of the tissue-specific exon Ia (i.e. gene segment -122 to +1) contains two GATA-motifs (at -65 and -33) and one SP-1 consensus binding site (-59). Mobility shift assays demonstrate that GATA proteins are able to interact with both GATA-motifs in a sequence specific fashion, but with different efficiencies. Moreover transfection studies show that the GATA-1 protein directly mediates tal-1 transcription by interacting with the -122/+1 fragment, defined as a minimal promoter in erythroid cells. Mutagenesis of the promoter establishes that the -33 GATA-binding site present in this fragment is critical for tal-1 expression in erythroid cells, but by itself does not lead to full promoter activity. Indeed, further mutations show that the second -65 GATA-binding site and the binding motif for SP1 (-59) significantly contribute to the overall activity of the proximal tal-1 promoter. Altogether, our data provide evidence that GATA-1 cooperates with the transcription factor SP1 to mediate the erythroid-specific expression of the tal-1 gene.	INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,F-34033 MONTPELLIER 1,FRANCE; INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Mathieu, Daniele/G-6092-2012; Bernard, Olivier A./E-5721-2016; Romeo, Paul-Henri/L-5989-2017	Romeo, Paul-Henri/0000-0002-8294-0367; JOULIN, Virginie/0000-0003-1091-7819; Bernard, Olivier/0000-0002-0463-9747				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BERNARD O, 1991, ONCOGENE, V6, P1477; BORIES JC, 1990, J EXP MED, V171, P75, DOI 10.1084/jem.171.1.75; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; HWANG LY, 1993, ONCOGENE, V8, P3043; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KNEZETIC JA, 1993, MOL CELL BIOL, V13, P4632, DOI 10.1128/MCB.13.8.4632; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KOLJ, 1993, MOL CELL BIOL, V13, P4011; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1990, NATURE, V344, P1777; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOUHTON MA, 1993, BLOOD, V81, P647; MURRE C, 1989, CELL, V58, P777; ORKIN SH, 1992, BLOOD, V80, P575; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER J, 1991, ONCOGENE, V6, P187; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; XIA Y, 1992, GENE CHROMOSOME CANC, V4, P211, DOI 10.1002/gcc.2870040304; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	52	63	64	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2623	2632						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058326				2022-12-28	WOS:A1994PC05400022
J	JALAVA, A; MAI, S				JALAVA, A; MAI, S			FOS AND JUN FORM CELL-SPECIFIC PROTEIN COMPLEXES AT THE NEUROPEPTIDE TYROSINE PROMOTER	ONCOGENE			English	Note							NEURO-BLASTOMA CELLS; HUMAN NEUROBLASTOMA-CELLS; TRANSCRIPTION FACTOR AP-1; DNA-BINDING; C-JUN; Y GENE; KINASE; EXPRESSION; TPA; DIFFERENTIATION	In this study we have investigated DNA-protein interactions at an AP1-like motif of the neuropeptide tyrosine (NPY) promoter during in vitro differentiation of human neuroblastoma cells SH-SY5Y to mature liferative sympathetic neuron-like cells. neuroblast-like cells originate from the parental cell line SK-N-SH from which two phenotypically distinct major cell types have been subcloned: the neuroblast-like SH-SY5Y cells and the epithelial-like SH-EP cells. SH-SY5Y cells can be induced to differentiate towards mature noradrenergic ganglion-like cells by the protein kinase C activator TPA (12-O-tetradecanoyl phorbol 13-acetate). Interestingly, the effects of TPA are mimicked by the protein kinase inhibitor, staurosporine, which induces the expression of TPA target genes such as the neuronal differentiation-associated gene NPY in SH-SY5Y cells. Following activation of PKC, the effects of TPA are known to act through the transcription factor AP-1. To study transcriptional regulation during sympathetic differentiation of human neuroblastoma cells by TPA as well as by staurosporine, we focussed on protein complexes at an evolutionarily conserved AP-1 like motif located at nucleotide positions -70 to -65 within the 5'-flanking region of the NPY gene. We show that both c-Jun and c-Fos are part of the protein complexes that bind to this sequence in SH-SY5Y cells. Both staurosporine and TPA enhanced and modulated the binding of these DNA-protein complexes concomitant with the NPY mRNA expression. On the other hand, the absence of these complexes in the SH-EP subclone was associated with the absence of NPY mRNA expression and a lack of differentiation-associated morphological changes. The data suggest that Fos and Jun heterodimers are part of the protein complexes that bind to the AP-1 regulatory element of the NPY promoter in the neuroblast-like SH-SY5Y cells. These protein complexes appear to contribute to the cell specific expression of the NPY gene and seem to be required during differentiation of SH-SY5Y human neuroblastoma cells further along the sympathetic neuronal lineage induced by either TPA or staurosporine.	ABO AKAD UNIV,DEPT BIOCHEM & PHARM,SF-20521 TURKU,FINLAND; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Abo Akademi University			Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201				ANDERSSON G, 1994, CELL GROWTH DIFFER, V57, P27; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIARDINA SL, 1987, ANAL BIOCHEM, V161, P109, DOI 10.1016/0003-2697(87)90659-2; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAMMERLING U, 1987, ONCOGENE, V2, P73; HEIKKILA JE, 1989, J CELL PHYSIOL, V140, P593, DOI 10.1002/jcp.1041400326; JALAVA A, 1993, J CELL PHYSIOL, V155, P301, DOI 10.1002/jcp.1041550211; JALAVA A, 1992, FEBS LETT, V300, P114, DOI 10.1016/0014-5793(92)80176-H; JALAVA AM, 1988, EXP CELL RES, V179, P10, DOI 10.1016/0014-4827(88)90343-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Maniatis T., 1982, MOL CLONING; MINTH CD, 1990, J BIOL CHEM, V265, P12933; MINTH CD, 1986, J BIOL CHEM, V261, P1974; PAHLMAN S, 1981, INT J CANCER, V28, P583, DOI 10.1002/ijc.2910280509; PARROW V, 1992, J CELL PHYSIOL, V152, P536, DOI 10.1002/jcp.1041520313; ROSS RA, 1983, J NATL CANCER I, V71, P741	27	25	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2369	2375						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036020				2022-12-28	WOS:A1994NX62900031
J	SHIROUZU, M; KOIDE, H; FUJITAYOSHIGAKI, J; OSHIO, H; TOYAMA, Y; YAMASAKI, K; FUHRMAN, SA; VILLAFRANCA, E; YOKOYAMA, S; KAZIRO, Y				SHIROUZU, M; KOIDE, H; FUJITAYOSHIGAKI, J; OSHIO, H; TOYAMA, Y; YAMASAKI, K; FUHRMAN, SA; VILLAFRANCA, E; YOKOYAMA, S; KAZIRO, Y			MUTATIONS THAT ABOLISH THE ABILITY OF HA-RAS TO ASSOCIATE WITH RAF-1	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; AMINO-ACID-RESIDUES; PC12 CELLS; SIGNAL TRANSDUCTION; MOLECULAR SWITCH; EFFECTOR DOMAIN; IDENTIFICATION; P21; DIFFERENTIATION; RESOLUTION	Recent studies have revealed that Ras can associate physically with Raf. In the present study, we tested 34 mutants of Ha-Ras carrying substitution(s) in the region of residues 23- 71 for their ability to associate with Raf-1. Mouse Ba/F3 cell lysates were incubated w ith each mutant Ras protein, in either the guanosine 5'-[gamma-thio]triphosphate (GTP gamma S)- or the guanosine 5'-[beta-thio]diphosphate (GDP beta S)-bound form, and the anti-Ras antibody Y13-238. The immunoprecipitates were analysed for the presence of Raf-1 by Western blotting with an anti-Raf-1 antibody. Six mutants of Ras, E31K, P34G, T35S, D38N, D57A and A59T, failed to bind Raf-1. Mutations N26G, V29A, S39A, Y40W, R41A, V44A, V45E, L56A and T58A partially reduced the ability to bind Raf-1. All the other mutants could associate with Raf-1 with nearly the same efficiency as that of wild-type Ras. Thus, the Raf-1-binding ability of Ras appears to be affected by mutations in the N-terminal region, and in particular, by those in and neighboring the effector region (residues 32-40) and in the region (residues 56-59) banking the N-terminal of Switch II. The abilities to bind Raf-1 and to induce neurite outgrowth of pheochromocytoma (PC) 12 cells correlate to each other for 22 Ras mutants. However, mutation A59T, which does not reduce the neurite-inducing or transforming activities, abolishes the ability to bind Raf-1. In contrast, mutations Y32F, K42A and L53A, which impair the neurite-inducing activity of Ras, have no effect on the Ras.Raf-1 association. Partially reduced Raf-1-binding ability was observed for mutants V29A, S39A, Y40W, R31A, V44A, L56A and T58A, which exhibit full neurite-inducing activity, and also for mutant V45E, which has no activity of neurite induction.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; AGOURON PHARMACEUT INC,SAN DIEGO,CA 92121	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Pfizer			Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016; Koide, Hiroshi/E-9000-2011; Yoshigaki, Junko/AAE-6702-2020; Yamasaki, Kazuhiko/L-7108-2018	Yokoyama, Shigeyuki/0000-0003-3133-7338; Yamasaki, Kazuhiko/0000-0003-0320-9697; Koide, Hiroshi/0000-0001-5916-3179				ANDREASON GL, 1989, ANAL BIOCHEM, V180, P269, DOI 10.1016/0003-2697(89)90429-6; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FUJITAYOSHIGAKI J, 1991, FEBS LETT, V294, P187, DOI 10.1016/0014-5793(91)80665-P; JOHN J, 1988, J BIOL CHEM, V263, P11792; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SHIROUZU M, 1992, ONCOGENE, V7, P475; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; STONE JC, 1991, MOL CELL BIOL, V11, P6158, DOI 10.1128/MCB.11.12.6158; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; YAMASAKI K, 1994, BIOCHEMISTRY-US, V33, P65, DOI 10.1021/bi00167a009; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	35	64	64	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2153	2157						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036000				2022-12-28	WOS:A1994NX62900005
J	GANJU, P; SHIGEMOTO, K; BRENNAN, J; ENTWISTLE, A; REITH, AD				GANJU, P; SHIGEMOTO, K; BRENNAN, J; ENTWISTLE, A; REITH, AD			THE ECK RECEPTOR TYROSINE KINASE IS IMPLICATED IN PATTERN-FORMATION DURING GASTRULATION, HINDBRAIN SEGMENTATION AND LIMB DEVELOPMENT	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; MOUSE MUTANT EMBRYOS; GERM-CELL SURVIVAL; NEURAL CREST; REPEATED EPILATION; PROTEIN-KINASE; CHICK-EMBRYO; SCATTER FACTOR; MET RECEPTOR; KIT RECEPTOR	Members of the protein superfamily of transmembrane receptor tyrosine kinases are key components of intercellular signal transduction pathways that elicit appropriate cellular responses to environmental cues during development of multicellular organisms. In a search for additional receptor tyrosine kinases expressed during mouse embryogenesis we cloned the murine homolog of Eck, a member of the Eph subfamily, that maps to the distal region of mouse chromosome 4. Specific antisera defined Eck in murine embryonic cells as a glycoprotein of 130 kDa with an intrinsic autophosphorylation activity. Immunohistochemical staining and laser scanning microscopy revealed a dynamic and tightly regulated distribution of Eck receptor protein in the developing mouse embryo. During gastrulation, a high transient distribution of Eck was seen in mesodermal cells aggregating in the midline as notochordal plate. A similar restriction of Eck receptor protein was apparent along the rostrocaudal axis of the developing neural tube. In hindbrain neuroepithelia, Eck protein localised specifically to cells of rhombomere 4 and was also seen transiently in cells populating second and third branchial arches and neurogenic facial crest VII-VIII and IX-X. Receptor distribution also implicated Eck in development of the proximodistal axis of the limb, expression being restricted to distal regions of limb bud mesenchyme. At later stages, additional sites of Eck protein expression were seen in the cartilaginous model of the skeleton, tooth primordia, infundibular component of the pituitary and various fetal tissue epithelia. Taken together, our data suggest pleiotropic functions for the Eck receptor, initially in distinctive aspects of pattern formation and subsequently in development of several fetal tissues, and reveal possible allelism with known mouse developmental mutant loci.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research				Brennan, Jane/0000-0003-3222-5485				BEDDINGTON RSP, 1992, DEVELOPMENT, P157; BEDDINGTON RSP, 1993, CURR OPIN GENET DEV, V3, P655, DOI 10.1016/0959-437X(93)90103-V; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BOHME B, 1993, ONCOGENE, V8, P2857; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAKRAVARTI S, 1991, MAMM GENOME, V1, P270, DOI 10.1007/BF00352338; CHAN J, 1991, ONCOGENE, V6, P1057; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; END P, 1992, EUR J BIOCHEM, V209, P1041, DOI 10.1111/j.1432-1033.1992.tb17380.x; ENTWISTLE A, 1992, J MICROSC-OXFORD, V168, P219, DOI 10.1111/j.1365-2818.1992.tb03265.x; ENTWISTLE A, 1992, J MICROSC-OXFORD, V165, P347, DOI 10.1111/j.1365-2818.1992.tb01492.x; ENTWISTLE A, 1990, T ROY MICR, V1, P405; ENTWISTLE A, 1990, T ROY MICR, V1, P361; FAUST C, 1993, CURR OPIN GENET DEV, V3, P491, DOI 10.1016/0959-437X(93)90125-9; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUENET JL, 1979, J HERED, V70, P90, DOI 10.1093/oxfordjournals.jhered.a109223; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASIMOTO K, 1987, DEVELOPMENT, V100, P587; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HERRMANN BG, 1992, CIBA F SYMP, V165, P78; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; JURAND A, 1974, J EMBRYOL EXP MORPH, V32, P1; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KOMADA M, 1993, ONCOGENE, V8, P2381; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MEISLER MH, 1992, TRENDS GENET, V8, P341, DOI 10.1016/0168-9525(92)90278-C; MEREDITH R, 1964, MOUSE NEWS LETT, V31, P25; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MORGAN BA, 1993, CURR OPIN GENET DEV, V3, P668, DOI 10.1016/0959-437X(93)90105-X; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NICHOLS DH, 1981, J EMBRYOL EXP MORPH, V64, P105; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NODEN DM, 1988, DEVELOPMENT, V103, P121; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PESCE M, 1993, DEVELOPMENT, V118, P1089; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1993, ONCOGENE, V8, P45; REITH AD, 1991, GENOME ANAL, V3, P105; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SALZGEBER B, 1984, J CRAN GENET DEV BIO, V4, P95; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SELLECK MAJ, 1992, DEVELOPMENT, V114, P403; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TASSIN MT, 1983, J CRAN GENET DEV BIO, V3, P289; TAYLOR BA, 1977, J VIROL, V23, P106, DOI 10.1128/JVI.23.1.106-109.1977; VERWOERD CDA, 1979, ADV ANATOMY EMBRYOLO, V58; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILCOX FH, 1981, J HERED, V72, P387, DOI 10.1093/oxfordjournals.jhered.a109537; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; ZAKUT R, 1993, ONCOGENE, V8, P2221	80	91	98	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1613	1624						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183555				2022-12-28	WOS:A1994NL81500012
J	OHTANIFUJITA, N; FUJITA, T; TAKAHASHI, R; ROBBINS, PD; DRYJA, TP; SAKAI, T				OHTANIFUJITA, N; FUJITA, T; TAKAHASHI, R; ROBBINS, PD; DRYJA, TP; SAKAI, T			A SILENCER ELEMENT IN THE RETINOBLASTOMA TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; LARGE T-ANTIGEN; CELL-CYCLE; SUSCEPTIBILITY GENE; E2F-BINDING SITE; BINDING PROTEIN; CARCINOMA-CELLS; REPORTER GENE	We have previously identified two positive regulatory elements in the retinoblastoma gene (RB) promoter. One is an ATF site and the other we have called a retinoblastoma binding factor 1 site. In addition, a consensus E2F site is located directly 3' to the ATF site. Here we demonstrate with gel shift assays that E2F and E2F-dependent complexes can bind in vitro to the E2F site of the RB promoter (RB-E2F site). Moreover, we demonstrate that deletion of the RB-E2F site results in stimulation of RB promoter activity in transient transfection assays in several cell lines. Specific point mutations in the E2F site that inhibit the binding of E2F and its complexes also stimulate the RB promoter activity, suggesting that a factor(s) that can bind to the RB-E2F site could be a silencer. RB promoter activity was also stimulated two- to four-fold by mutation of the E2F site in the RB-negative cell lines, J82 and HTB9. Taken together, our results show that the E2F site in the promoter of the RB tumor-suppressor gene acts as a silencer element and that the silencer effect of the E2F site is not necessarily dependent on the presence of the RB protein.	KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; KYOTO UNIV,FAC MED,DEPT PATHOL 2,KYOTO 606,JAPAN; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261; HARVARD UNIV,SCH MED,MASSACHUSETTS EYE & EAR INFIRM,DEPT OPHTHALMOL,BOSTON,MA 02114	Kyoto Prefectural University of Medicine; Kyoto University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary								BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISTCHENKO AS, 1993, INT J CANCER, V53, P87, DOI 10.1002/ijc.2910530117; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SLACK RS, 1993, ONCOGENE, V8, P1585; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YOKOTA J, 1988, ONCOGENE, V3, P471; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	55	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1703	1711						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183566				2022-12-28	WOS:A1994NL81500023
J	NAMCIU, S; LIEBERMAN, MA; STAVNEZER, E				NAMCIU, S; LIEBERMAN, MA; STAVNEZER, E			INDUCTION OF THE C-SKI PROTOONCOGENE BY PHORBOL ESTER CORRELATES WITH INDUCTION OF MEGAKARYOCYTE DIFFERENTIATION	ONCOGENE			English	Article							LEUKEMIA-CELL-LINE; HEL CELLS; EXPRESSION; PHENOTYPE; SEQUENCE; PRODUCT; CULTURE; GROWTH; MUSCLE; GENE	Overexpression of v-ski blocks the terminal differentiation of chicken erythroblasts, and in cooperation with v-sea causes transformation of these cells, indicating that c-ski may play a role in regulating either proliferation or differentiation in hematopoietic cells. We examined c-ski expression in four different myeloid cell lines which can be induced to differentiate by exposure to phorbol 12-myristate 13-acetate (PMA). Two of the cell lines are multipotent and have the ability to differentiate into either erythrocytes or megakaryocytes (K562 and HEL cells), one cell line differentiates exclusively into megakaryocytes (CHRF-288-11), and the fourth cell line differentiates into either monocytes or granulocytes (HL-60). Our findings indicate that c-ski mRNA is up regulated by PMA only in those cell lines which respond by differentiating along the megakaryocyte lineage. The extent of differentiation and the observed increase in c-ski mRNA levels are positively correlated with the PMA concentration used to induce differentiation. Experiments in which CHRF-288-11 cells were treated with the protein kinase C (PKC) activator bryostatin 1 indicate that c-ski mRNA induction is not a general effect of PKC activation. The results strongly suggest that c-ski expression is correlated with megakaryocyte maturation.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT BIOCHEM,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati; University of Cincinnati; University of Cincinnati					NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER; NCI NIH HHS [CA43600] Funding Source: Medline; NIEHS NIH HHS [T32-ES07250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRENCH BT, 1990, CANCER CHEMOTH PHARM, V27, P171, DOI 10.1007/BF00685709; FUGMAN DA, 1990, BLOOD, V75, P1252; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOFFMAN R, 1989, BLOOD, V74, P1196; KABNOUDIAS A, 1992, EXP HEMATOL, V20, P43; LARSEN J, 1992, ONCOGENE, V7, P1903; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCKINNON RD, 1987, MOL CELL BIOL, V7, P2148, DOI 10.1128/MCB.7.6.2148; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MILNER RM, 1983, NUCLEIC ACIDS RES, V11, P4597; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PAPAYANNOPOULOU T, 1987, BLOOD, V70, P1764; PRASAD VS, 1991, J IMMUNOL, V147, P4200; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; STAEHELI P, 1989, MOL CELL BIOL, V9, P4038; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TAKAHASHI T, 1991, BRIT J HAEMATOL, V78, P480, DOI 10.1111/j.1365-2141.1991.tb04476.x; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7	36	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1407	1416						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152801				2022-12-28	WOS:A1994NH40100012
J	MYMRYK, JS; SHIRE, K; BAYLEY, ST				MYMRYK, JS; SHIRE, K; BAYLEY, ST			INDUCTION OF APOPTOSIS BY ADENOVIRUS TYPE-5 E1A IN RAT-CELLS REQUIRES A PROLIFERATION BLOCK	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR PROTEIN; HOST-CELL; DNA; DEGRADATION; SUPPRESSOR; BINDING; ANTIGEN; 19-KDA; GENE	Infection with Ad5dl520EIB-, an adenovirus producing only the 243 residue EIA protein and lacking the EIB region, caused apoptosis in normal rat kidney (NRK) cells as judged by the production of nucleosomal DNA fragments. Apoptosis occurred only when the celts were growth-inhibited by cell-cell contacts in confluent cultures or by serum starvation and not when they were actively growing. In uninfected cultures, apoptosis also occurred at confluency, but more slowly than after infection. Studies with EIA deletion mutants of dl520E1B- showed that the regions of the EIA protein essential for induction of apoptosis were those in exon 1 required for binding to the cellular proteins p300 and pRb. Mutants defective at inducing apoptosis were previously found to be defective at inducing baby rat kidney cells to synthesize cellular DNA. In our experiments, cells underwent apoptosis when stimulated by E1A to proliferate under conditions where proliferation was blocked. It is possible that it was the proliferation block opposing the induction of proliferation that led directly to apoptosis. Circumstances leading to induction of apoptosis by c-myc (Evan et al., 1992) are similar and can be interpreted in a similar way.	MCMASTER UNIV,DEPT BIOL,HAMILTON L8S 4K1,ONTARIO,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8S 4K1,ONTARIO,CANADA	McMaster University; McMaster University								BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DHALLUIN JC, 1979, J VIROL, V32, P61, DOI 10.1128/JVI.32.1.61-71.1979; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EZOE H, 1981, J VIROL, V40, P20, DOI 10.1128/JVI.40.1.20-27.1981; FATT RBL, 1982, J VIROL, V42, P969, DOI 10.1128/JVI.42.3.969-977.1982; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MYMRYK JS, 1993, J GEN VIROL, V74, P2131, DOI 10.1099/0022-1317-74-10-2131; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	102	105	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1187	1193						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134121				2022-12-28	WOS:A1994NC04800022
J	KURATA, WE; LAU, AF				KURATA, WE; LAU, AF			P130(GAG-FPS) DISRUPTS GAP JUNCTIONAL COMMUNICATION AND INDUCES PHOSPHORYLATION OF CONNEXIN43 IN A MANNER SIMILAR TO THAT OF PP60(V-SRC)	ONCOGENE			English	Note							FUJINAMI SARCOMA-VIRUS; TYROSINE PROTEIN-KINASES; TO-CELL COMMUNICATION; SRC GENE-PRODUCT; PHORBOL ESTER; MAP KINASE; V-SRC; GROWTH; INHIBITION; PHOSPHOTYROSINE	The pp60v-src tyrosine kinase disrupts gap junctional communication in transformed fibroblasts and induces the phosphorylation of the gap junction protein, connexin43, on tyrosine. We report here that the p130(gag-fps) tyrosine kinase also profoundly disrupted gap junctional communication and markedly increased the phosphorylation of connexin43 which appeared to result from an accumulation of phosphotyrosine and phosphoserine. The disruption of gap junctional communication by pp60(v-src) and p130(gag-fps) did not appear to result from the gross alteration of gap junction plaques. Furthermore, two-dimensional phosphotryptic peptide mapping showed that the v-Src and V-Fps kinases stimulated the phosphorylation of multiple connexin43 peptides which contained phosphotyrosine and/or phosphoserine. Phosphotyrosine was detected in two connexin43 phosphotryptic peptides from v-src-transformed cells which suggested that more than one connexin43 tyrosine site may be recognized by pp60(v-src) in fibroblasts. The apparent higher levels of phosphoserine-containing connexin43 peptides in the oncogene-transformed cells pointed to the possibility that pp60(v-src) and p130(gag-fps) may also modulate connexin43 function through mechanism(s) involving the activation of signaling serine kinases. Taken together, these results suggested that connexin43 is a common target of the v-Src and v-Fps tyrosine kinase oncoproteins.	UNIV HAWAII, CANC RES CTR, MOLEC CARCINOGENESIS PROGRAM, HONOLULU, HI 96813 USA	Cancer Research Center of Hawaii; University of Hawaii System					NCI NIH HHS [CA-52098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P207, DOI 10.1007/BF01871630; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; CAVENEY S, 1985, ANNU REV PHYSIOL, V47, P319; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; CROW DS, 1992, ONCOGENE, V7, P999; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; GARFIELD RE, 1988, OXFORD REV REPROD B, V10, P436; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KUFFLER SW, 1976, NEURON BRAIN CELLULA, P154; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAU AF, 1986, VIROLOGY, V151, P86, DOI 10.1016/0042-6822(86)90106-6; LAU AF, 1992, MOL BIOL CELL, V3, P865, DOI 10.1091/mbc.3.8.865; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; LOEWENSTEIN WR, 1987, CELL, V48, P725, DOI 10.1016/0092-8674(87)90067-5; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; OH SY, 1991, BIOCHIM BIOPHYS ACTA, V1094, P243, DOI 10.1016/0167-4889(91)90016-Q; PAGE E, 1986, HEART CARDIOVASCULAR, P573; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1980, CELL, V22, P767, DOI 10.1016/0092-8674(80)90553-X; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; YOUNG JDE, 1987, CELL, V48, P733, DOI 10.1016/0092-8674(87)90071-7	41	60	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					329	335						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302599				2022-12-28	WOS:A1994MW24700042
J	RHYU, MG; PARK, WS; MELTZER, SJ				RHYU, MG; PARK, WS; MELTZER, SJ			MICROSATELLITE INSTABILITY OCCURS FREQUENTLY IN HUMAN GASTRIC-CARCINOMA	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; APC GENE; COLORECTAL TUMORIGENESIS; MUTATIONS OCCUR; CANCER; DELETIONS; REPEAT	Microsatellites are short repeated oligonucleotide sequences found throughout the human genome. Microsatellite instability has been reported in hereditary and sporadic colorectal carcinomas. Since gastric carcinoma shares numerous molecular abnormalities with colon cancer, we evaluated 52 gastric adenocarcinomas and adjacent dysplastic tissues for microsatellite instability at five chromosomal loci. Instability at one or more loci was observed in 16 (31%) of the 52 tumors, but in only two dysplastic tissues adjacent to their respective tumors. These results demonstrate that microsatellite instability is not limited to colorectal carcinoma, but also occurs frequently in another cancer, that of the stomach. It is probably a late event, developing only rarely in premalignant dysplastic lesions.	DEPT VET AFFAIRS,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21201; UNIV MARYLAND HOSP,BALTIMORE,MD 21201; CATHOLIC UNIV SEOUL,COLL MED,DEPT PATHOL,SEOUL,SOUTH KOREA	University System of Maryland; University of Maryland Baltimore; Catholic University of Korea								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SJ, 1990, CANCER RES, V50, P7717; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; GUSELLA JF, 1993, NEW ENGL J MED, V329, P571, DOI 10.1056/NEJM199308193290811; HORII A, 1992, CANCER RES, V52, P3231; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAERVI O, 1951, ACTA PATHOL MIC SC, V29, P26; JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEISTER I, 1990, CANCER RES, V50, P7232; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MELTZER SJ, 1990, CANCER RES, V50, P3627; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RENAULT B, 1993, CANCER RES, V53, P2614; SANO T, 1991, CANCER RES, V51, P2926; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEBER JL, 1989, AM J HUM GENET, V44, P388	23	221	227	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					29	32						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302591				2022-12-28	WOS:A1994MW24700004
J	SORKIN, A; DIFIORE, PP; CARPENTER, G				SORKIN, A; DIFIORE, PP; CARPENTER, G			THE CARBOXYL-TERMINUS OF EPIDERMAL GROWTH-FACTOR RECEPTOR/ERBB-2 CHIMERAE IS INTERNALIZATION IMPAIRED	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; EGF RECEPTOR; DOWN-REGULATION; A431 CELLS; HUMAN-FIBROBLASTS; ENDOCYTIC SYSTEM; CARCINOMA-CELLS; NEU ONCOGENE; GENE; PROTEIN	The endocytosis of gp185erbB-2 was studied using chimeric receptors in which the intracellular domain of erbB-2, or subdomains thereof, was substituted for the corresponding regions of the epidermal growth factor (EGF) receptor. Chimeric and wild-type EGF or erbB-2 receptors were expressed in mouse NIH3T3 or NR6 fibroblasts and in a human mammary adenocarcinoma cell line, MDAMB-134. The rate of EGF-induced internalization for the chimera consisting of the extracellular EGF receptor domain and intracellular erbB-2 domain was reduced three- to fourfold compared with the wild-type EGF receptor. The low rate of internalization of the chimeric receptor resulted in impaired down-regulation and degradation of the receptor. Substitution of the carboxyl terminus of erhB-2 for the corresponding region of the EGF receptor caused a similar decrease of receptor endocytosis, whereas substitution of the erhB-2 tyrosine kinase domain did not affect internalization and down-regulation. Since the tyrosine kinase of the internalization-defective chimeric receptors could be activated by EGF, kinase activity and autophosphorylation of erhB-2 do not appear to be sufficient for a maximum rapid internalization of the chimeric receptors. These results suggest that the carboxyl terminus of erhB-2 either does not possess all the signals required for the rapid internalization or contains an inhibitory signal for rapid internalization.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SORKIN, A (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA.		Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Sorkin, Alexander/0000-0002-4446-1920	NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER; NCI NIH HHS [CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIFIORE PP, 1992, GENES ONCOGENES HORM, P139; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HELIN K, 1991, J BIOL CHEM, V266, P8363; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LONARDO F, 1990, New Biologist, V2, P992; LOTTI LV, 1990, NEW BIOL, V2, P992; LUND KA, 1990, J BIOL CHEM, V265, P15713; MAIER LA, 1991, CANCER RES, V51, P5361; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEGATTO O, 1992, ONCOGENE, V7, P1339; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; STOSCHECK CM, 1984, J CELL PHYSIOL, V120, P296, DOI 10.1002/jcp.1041200306; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	47	95	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3021	3028						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8105439				2022-12-28	WOS:A1993MC09300016
J	GUPTA, K; COPELAND, NG; GILBERT, DJ; JENKINS, NA; GRAY, DA				GUPTA, K; COPELAND, NG; GILBERT, DJ; JENKINS, NA; GRAY, DA			UNP, A MOUSE GENE-RELATED TO THE TRE ONCOGENE	ONCOGENE			English	Note							LINKAGE MAP; CLONING; SEQUENCES; REGION; CDNA; ADENOVIRUS-E1A; TRANSLATION; CARCINOMA; DELETION; PROTEIN	We have cloned cDNAs from a novel gene designated Unp. Unp cDNAs contain a large open reading frame that would encode a protein of 89 kDa. The predicted protein contains a putative nuclear localization signal, as well as consensus sequences for binding to the retinoblastoma gene product. The latter elements are contained within a region having strong similarity to the human tre oncogene. We have localized the Unp gene to mouse chromosome 9 in a region of homology with human chromosome 3p. This region has been implicated in a number of human malignancies.	UNIV OTTAWA,DEPT BIOCHEM,451 SMYTH RD,OTTAWA K1H 8M5,ONTARIO,CANADA; NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702; UNIV OTTAWA,DEPT MED,OTTAWA K1H 8M5,ONTARIO,CANADA	University of Ottawa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Ottawa			/U-3554-2018	/0000-0002-8634-4984	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; COLLINS T, 1985, NATURE, V316, P748, DOI 10.1038/316748a0; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; Green EL, 1981, GENETICS PROBABILITY, P77; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUEBNER K, 1988, ONCOGENE, V3, P449; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KINGSLEY DM, 1989, GENETICS, V123, P165; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	24	66	71	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2307	2310						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336951				2022-12-28	WOS:A1993LP17100035
